


Consolidated List of Products

Whose Consumption and/or Sale
Have Been Banned, Withdrawn, Severely Restricted
or Not Approved by Governments

Twelfth Issue

Pharmaceuticals



United Nations

DESA

The Department of Economic and Social Affairs of the United Nations Secretariat is a vital interface between global and policies in the economic, social and environmental spheres and national action. The Department works in three main interlinked areas: (i) it compiles, generates and analyses a wide range of economic, social and environmental data and information on which States Members of the United Nations draw to review common problems and to take stock of policy options; (ii) it facilitates the negotiations of Member States in many intergovernmental bodies on joint courses of action to address ongoing or emerging global challenges; and (iii) it advises interested Governments on the ways and means of translating policy frameworks developed in United Nations conferences and summits into programmes at the country level and, through technical assistance, helps build national capacities.

Note

Symbols of United Nations documents are composed of the capital letters combined with figures. Mention of such a symbol indicates a reference to a United Nations document.

Applications for the right to reproduce this work or parts thereof are welcomed and should be sent to the Secretary, United Nations Publications Board, United Nations Headquarters, New York, NY 10017, United States of America. Governments and governmental institutions may reproduce this work or parts thereof without permission, but are requested to inform the United Nations of such reproduction.

UNITED NATIONS PUBLICATION

TABLE OF CONTENTS

Introduction	4
Alphabetical Listing of products	8
Classified Listing of products	20
List of codes for countries, territories and areas	30

PART I. REGULATORY INFORMATION

Pharmaceuticals (monocomponent products)	31
Pharmaceuticals (combination and group products)	284

PART II. COMMERCIAL INFORMATION

Pharmaceuticals (trade names)	319
-------------------------------------	-----

INDEXES

A. Index by Chemical Abstract Service (CAS) Registry numbers	415
B. Index to Pharmaceuticals by scientific and common names, and synonyms....	432
C. Index to Pharmaceuticals by available trade names	465

ANNEXES

I. Relevant resolutions of the General Assembly and Economic and Social Council	559
II. Criteria for the inclusion of pharmaceutical and chemical products in the Consolidated List	573
III. List of references cited in the regulatory text.....	574
IV. Questionnaire	595

INTRODUCTION

1. The Consolidated List of Products whose Consumption and/or Sale have been Banned, Withdrawn, Severely Restricted or Not Approved by Governments is part of a continuing effort in the United Nations system aimed at disseminating information widely on products harmful to health and the environment. It constitutes a tool which helps Governments to keep current with regulatory decisions taken by other Governments and assists them in considering the scope for their own eventual regulatory action. It enables government agencies, which review applications for product registration to ascertain easily restrictive regulatory decisions made in other countries. It complements and consolidates other information on the subject produced within the United Nations system, including data received from United Nations Environment Programme (UNEP) and Food and Agriculture Organization of the United Nations (FAO) on chemicals and from World Health Organization (WHO) on pharmaceuticals.

2. The main source of information on chemicals is the Prior Informed Consent (PIC) circulars issued by the Secretariat, which is maintained jointly by UNEP and FAO, of the Rotterdam Convention on the Prior Informed Consent Procedure for Certain Hazardous Chemicals and Pesticides in International Trade, but the List also contains information previously received under the original PIC procedure as well as the Notification Scheme for Banned and Severely Restricted Chemicals. The source on pharmaceuticals is WHO Drug Information circulars and Pharmaceuticals Newsletters, which contain information received from Member States on the safety and efficacy of drugs including information gathered through drug monitoring programmes as well as certification scheme on the quality of pharmaceutical products moving in international commerce.

3. The question of the exchange of information on banned hazardous chemicals and unsafe pharmaceutical products was first considered by the General Assembly at its thirty-fourth session in 1979. By its resolution 37/137 (Annex I) of 17 December 1982, the General Assembly requested the Secretary-General to prepare the Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely restricted or Not Approved by Governments on the basis of the work already being undertaken within the United Nations system.

4. By its resolution 39/229 (annex I) of 18 December 1984, the Assembly decided, inter alia, that an updated List should be issued annually, and that the data should be made available to Governments and other users through direct computer access to it. In accordance with the resolution, the format of the List has been kept under continued review in cooperation with the relevant organs, organizations and bodies of the United Nations system, with a view to its improvement, taking into account its complementary nature, the experience obtained and the views expressed by Governments. Also, in accordance with GA resolution 39/229, the Secretary-General

informed the General Assembly at its forty-first session and every third year thereafter, through the Economic and Social Council (ECOSOC), on the implementation of the above resolutions.

5. The 1992 United Nations Conference on Environment and Development (UNCED) provided impetus to the ongoing work of the United Nations system in the area of chemical safety. In Chapter 19 of Agenda 21, entitled "Environmentally Sound Management of Toxic Chemicals", six programme areas were approved for action. One of them, "Information exchange on toxic chemicals and chemical risks", corresponds directly to the purposes for which the List was established. In this regard, decisions of intergovernmental bodies and the entry into force of the relevant Conventions have direct bearing on the composition and future direction of the List. Any developments in this area are carefully reviewed in order to make appropriate changes in the future issues of the List.

6. The Economic and Social Council in its resolution 2001/33, of 26 July 2001, requested the Secretary-General, within existing resources, to continue to disseminate the list as widely as possible and to look at the possibility of using online dissemination in collaboration with the World Trade Organization (WTO), FAO, WHO and UNEP. In its most recent resolution 2004/55 of 23 July 2004, the Council requested the Secretary-General to continue to update the electronic version of the Consolidated List, alternating between chemicals and pharmaceuticals every year, while printing only new data to complement previously printed issues for the benefit of those, particularly in developing countries, who may not have easy access to the electronic version.

BACKGROUND

7. In 1985, the United Nations Secretariat, in close cooperation with the World Health Organization (WHO) and the then United Nations Environment Programme (UNEP) - International Register of Potentially Toxic Chemicals (IRPTC) - now named UNEP Chemicals, met at their first inter-agency coordinating meeting, and carried out the first review of the List. The review focused on arrangements for the preparation of future issues, the need for criteria for determining the inclusion of products, the question of the legal and public health context of regulatory actions that had not been included in the first issue of the List, and the treatment of commercial data. As a result of the review, a memorandum of collaboration, outlining the division of responsibilities among WHO, UNEP Chemicals and the United Nations Secretariat was agreed upon. Since the first triennial review, the arrangements for the production of the List have remained essentially the same.

8. In 1995, at an inter-agency coordinating meeting, it was decided to divide the List into two separate issues, each to be

published in alternate years, one focusing on pharmaceuticals and the other on chemicals. The sixth issue of the List, the first under the new arrangement, was entirely devoted to pharmaceuticals and the seventh to chemicals, with subsequent issues following the same pattern. Dividing the List into two categories, pharmaceuticals and chemicals, has made it more accessible to a greater number of users, and has made the various databases more manageable.

Important recent Developments

9. Chapter 19 of Agenda 21 emanating from the United Nations Conference on Environment and Development (UNCED) reflects the preoccupation and the work of the organizations of the United Nations system in the area of environmentally sound management of toxic chemicals. The current work on the issue of products harmful to health and the environment is based on the principles indicated in Chapter 19, which encourage increased national and international efforts for intensive international work and improved coordination of international activities. Furthermore, chapter 19 states the need for increased coordination of United Nations bodies and other international organizations involved in chemical assessment and management.

10. As a result of continuous collaboration between FAO and UNEP on the principle of prior informed consent, the Conference of Plenipotentiaries in Rotterdam, Netherlands adopted the Rotterdam Convention on the Prior Informed Consent Procedure for Certain Hazardous Chemicals and Pesticides in International Trade on 10 September 1998. It was signed by 72 States and one regional economic integration organization, and entered into force on 24 February 2004.

11. Another major development was the adoption of the Stockholm Convention on Persistent Organic Pollutants. The convention was adopted and opened for signature in Stockholm on 22-23 May 2001. 91 Countries and the European Union signed the treaty. The prompt entry into force of the Stockholm Convention on 17 May 2004 is an important step towards achieving progress in the implementation of the recommendations contained therein.

12. The World Trade Organization (WTO) addresses the issue of the export of domestically prohibited goods (DPGs). More specifically the WTO Committee on Trade and Environment (CTE) has been examining this issue since 1995 when the mandate of the General Agreement on Tariff and Trade (GATT) Working Group on Export of Domestically Prohibited Goods and other Hazardous Substances was incorporated in the work programme of the Committee. The CTE has identified a number of international instruments relevant to the export of DPGs, but much progress remains to be achieved. However, since 1997 there has been a positive exchange of information and experience on trade related issues between the Committee and the Secretariats of relevant multilateral environmental agreements (MEAs), including the Rotterdam and Stockholm Conventions.

Dissemination and utilization

13. The List continues to present, in a unified manner, information on restrictive regulatory decisions taken by Governments on a range of pharmaceutical products and agricultural and industrial chemicals. As such, it is a recognized source of valuable information for Governments in ensuring access to information that may be useful in taking appropriate regulatory measures on chemical and pharmaceutical products in the light of their particular national circumstances. Furthermore, the provision of information on trade names, under which these products are marketed, adds value to the Consolidated List and makes it easier for national authorities and others monitoring such activities, to identify a restricted product available in the local market. The identification of the chemical products with its manufacturers also provides access to safety data sheets and other information available from the manufacturers. Additionally, commercial data provides an easy method to cross-reference trade names with recognized common scientific names under which most regulatory information is available.

14. In addition to Governments, other users of the List include intergovernmental organizations, academic institutions, concerned non-governmental organizations, the media, and other members of civil society. The List has proved to be an important tool for public interest and consumer groups in bringing to the attention of Governments and manufacturers the need to remove hazardous products from the marketplace, and to raise awareness among public officials and non-governmental organizations on health-related effects of using certain products.

15. There is a continuous increase in the promotion of the dissemination and utilization of the List. In particular, a number of concerned non-governmental organizations make requests to have access to the List and also provide feedback on the positive use of the List. Starting with the second issue of the List, a questionnaire has been included in the List for purposes of assisting the Secretariat to determine the best way to disseminate the information in the List and the use to which it is being put. The List continues to play an important role in facilitating information on products, which are severely restricted or banned in some countries but are still available in others. The Secretariat considers feedback from users very valuable in exploring the possibility of making the List available online and if feasible to provide free of charge internet access to its databases. The Secretariat continues to make efforts to produce List data on diskettes/CDs with search facilities and to make them available as sales items in addition to the printed text.

Format, contents and scope

16. Continuous review of the format and content of the List have made it possible to expand its coverage and scope. While the List, in line with General Assembly resolution 37/137 has remained easy to read and understand, the number of products listed and the number of Governments reporting has regularly increased with each new issue of the Consolidated List. Thus, the first issue of the List covered less than 500

products regulated by 60 Governments, the fifth issue covering both pharmaceuticals and chemicals included more than 700 products with regulatory actions taken by 94 Governments. At present, the two most recently updated issues, eleventh containing chemicals and twelfth containing pharmaceuticals, both of which are available on the web, contain information on over 1100 products regulated by 115 states and non-state entities.

17. Information included in the List on pharmaceutical products is provided by WHO, which collects and disseminates it through various exchange mechanisms, among them: (i) the international drug monitoring programme, which collaborates in monitoring suspected adverse drug reactions with the aim of identifying, at the earliest possible moment, the liability of a drug to produce undesirable effects which were not detected during its clinical trials; (ii) the WHO certification scheme on the quality of pharmaceutical products moving in international commerce, through which the exporting country is required to certify, on request, the quality control standard of the drugs. In the case of products not authorized for sales or distribution in the exporting country, the reasons are explicitly stated and, when relevant, grounds for refusal are disclosed; (iii) WHO drug information circulars contain information received from Member States on the safety and efficacy of drugs, which include any decision to prohibit or limit the availability of a drug already in use, any decision to refuse the approval of a new drug and any approval when accompanied by restrictive provisions.

18. As with previous issues, the scope of information contained in the List will remain essentially the same. The List is divided in two parts. Part I, compiled by the United Nations and WHO, contains text of restrictive regulatory decisions taken by competent national authorities on pharmaceutical products. Part II of the List presents commercial information (trade/brand names) and is compiled by the United Nations Secretariat from publicly available sources. In addition, the List includes an alphabetical and classified listing of products and three indexes: scientific and common names, trade/brand names and Chemical Abstract Service (CAS) Registry numbers.

Part I

19. Part one, prepared jointly by the United Nations and WHO, presents in unified manner information on restrictive regulatory decisions taken by Governments on pharmaceutical products. While the information cannot be regarded as exhaustive, either in terms of products or regulatory measures, it covers regulatory actions taken by a total of 90 Governments on some 500 products. In this context it should be noted that decisions taken by a limited number of Governments on a specific product may not be representative of the position of other Governments, particularly in view of differing risk-benefit considerations. It is also important to realize that all pharmaceutical products are potentially harmful if not correctly used. In addition, the fact that a given product is not listed as regulated by a country does not necessarily mean that it is permitted in that country. Rather it could mean that the relevant regulatory decision has not been communicated to

the United Nations or its agencies. It is also important to note that the issue of the efficacy of products in the regulatory text is not addressed, but is an aspect that may be crucial when a Government is considering a product for regulatory action of its own.

20. To ensure that the list focuses on products harmful to health and the environment, criteria for the inclusion of pharmaceutical and chemical products was developed in 1985 and transmitted to Governments for their comments. The criteria, revised in light of the comments received, is contained in annex II. The application of the criteria significantly facilitated the screening of information for the list. However, the interpretation by the Governments of the criterion "severely restricted", in particular, continues to vary widely, leading to considerable inconsistency in reporting on national restrictive regulatory measures. When necessary, additional information and/or clarifications are requested from Governments; products, which clearly do not meet the criteria, have been omitted after consultation with Governments. Information received from non-governmental organizations is also verified with Governments. When there is evidence that a listed product is no longer available or the safety issue has been resolved, the need for retaining the entry in subsequent issues of the list is routinely reviewed.

21. The List does not include information on widely used food additives, which fall outside the scope of the List. They are considered by the Codex Alimentarius Commission, which is jointly managed by FAO and WHO. Psychotropic and narcotic substances scheduled under one of the international conventions are included only where a Government is controlling a substance more rigorously than required under the relevant international convention.

22. WHO regularly provides explanatory comments regarding information on related national regulatory actions taken on most pharmaceutical products. These comments contain useful information reflecting the position of Governments on their regulatory actions in the light of different national priorities, thus providing a context for these actions. The regulatory information also includes references to the relevant legal and statutory documents in order to enable the user to ascertain the legal context and scope of the regulations. Such references cannot be given for some products since product licenses are often made or amended by an administrative decision, which is not published. There are also bibliographical references to scientific and technical studies by international organizations relating to some products.

23. Part one is further sub-divided into two sections, i.e. monocomponent products and Combination & group products. Products are listed alphabetically within each section. International Non-Proprietary Names (INN) have been used, whenever possible, to identify pharmaceutical products. Each product entry includes, where available, the Chemical Abstracts Service Registry Number (CAS number); other scientific names, common names and synonyms; the effective date on which the regulation came into force; a summary of regulatory measures taken by Governments; brief explanatory comments where available and legal and bibliographical references. Entries within each product are listed by country,

and sorted by effective date. A listing of the references cited at the end of the regulatory text, and if available, the addresses where copies of the documents can be obtained, are given in annex III.

Part II

24. Part Two, compiled by the United Nations Secretariat, presents commercial information, including data on trade names, relating to a large proportion of the products covered in Part One. It provides an easy way to cross-reference commercial names with recognized common scientific names, under which the regulatory data is presented. Trade name data is included for most of the monocomponent and some group products. It should be noted that manufacturers and distributors might maintain a proprietary trade name while

changing the ingredients or the formulation. Therefore it is important to check the contents of a specific product using an identified trade name in order to ensure the accuracy of the reference to the given product.

25. The first step in compiling the commercial data is to review various on-line databases and commercial directories for alternative nomenclature for the regulated products. Commercial names are then separated from alternate Scientific names. Trade names are collected irrespective of the manufacturer's form of ownership and include transnational and national enterprises from all regions.

26. The commercial information is organized under the same headings as the regulatory data in order to facilitate easy reference. Each product entry includes the product name and CAS number, and a listing of known trade names.

Users' Guide

If you are interested in finding out what restrictive regulatory action has been taken on a certain product or what commercial information is available - for example, on chloroform - you would look up the page reference in the alphabetical listing of products (pages 8 - 19). But if you only know one of the trade names, such as "Eludril", and not the product name Chloroform, you would consult index C for the page reference (pages 465 - 558). On the other hand if you are familiar with Chloroform by one of its scientific names, for example, "TRICHLOROMETHANE", you would consult index B for the appropriate page reference (pages 432 - 464). Also, if only a C.A.S. number of a product is known, you would look into index A (pages 415 - 431) for product name and the page reference. In addition to three indices described above, a classified listing of products (pages 20 - 29) is also included, grouping the products according to their usage. Furthermore, a list of codes, used throughout the publication to denote countries and territories, is provided on page 30.

Data verification was carried out to the best of our capabilities within the given time constraints. However, there may still be inaccuracies, which have not been identified and corrected when checking and proofreading the text. Comments on the contents and suggestions for the improvement of the Consolidated List are most welcome. They should be sent to: The Director, OESC/DESA, United Nations Secretariat, New York, NY 10017, U.S.A.

ALPHABETICAL LISTING OF PRODUCTS

Product name	Page
Acarbose.....	31
ACE-Inhibitors.....	284
Acetanilide.....	31, 319
Acetarsol.....	31, 319
Acetylfuratrizine.....	32, 319
Acetylleucine.....	32
Acetylsalicylic acid (paediatric).....	32, 319
Acetylsalicylic acid/antacid.....	285
Acetylsalicylic acid/codeine.....	285
Acetylsalicylic acid/phenacetin/caffeine (APC).....	285
Acitretin.....	35, 319
Acridine derivatives.....	36, 320
Alatrofloxacin mesilate.....	37
Albumin.....	37
Alclofenac.....	38, 320
Aldesleukin.....	39
Allergen extracts.....	39, 320
Allopurinol and benzbromarone.....	286
Almitrine.....	39
Aloxiprin.....	40, 320
Alpidem.....	40
Alprostadil.....	40, 320, 321
Amaranth.....	41
Amfepramone hydrochloride.....	42
Amfepramone.....	42, 321
Amfetamine.....	42, 321
Amineptine.....	43
Aminoglutethimide.....	44, 322
Aminophenazone.....	44, 322, 323
Aminophylline.....	47, 323
Aminorex.....	47, 323
Amiprilose.....	48
Amitriptyline.....	48, 324
Amobarbital.....	49, 324, 325
Amodiaquine.....	49, 325
Amoxicillin/clavulanic acid.....	286
Ampicillin/cloxacillin.....	286, 325
Amyl nitrite.....	50
Anabolic steroids.....	50
Anagestone acetate.....	50
Analgesics in combination.....	286
Androgens.....	51
Anorectic drugs.....	287
Anorectic dugs in combinations.....	288
Antidiarrhoeal combinations.....	289
Antihistamine (topical).....	51
Antirheumatic combinations with glucocorticosteroids.....	289
Aphrodisiac drugs.....	52

ALPHABETICAL LISTING OF PRODUCTS

Product name	Page
Aprobarbital.....	52, 325
Aristolochia.....	52
Aristolochic acid.....	52, 325
Arsenic-based compounds.....	53
Astemizole.....	54, 325
Atropine in combination.....	290
Azapropazone.....	56, 326
Azaribine.....	56, 326
Azatadine maleate/pseudoephedrine sulfate.....	290, 326
Barbital.....	57, 326
Barbiturates in asthma preparations.....	290
Barbiturates in combination.....	291
Beclobrate.....	57
Bencyclane.....	58, 326
Benorilate.....	58, 327
Benoxaprofen.....	58, 327
Benzarone.....	59, 327
Benzbromarone and Benziodarone.....	292
Benzbromarone.....	59, 327
Benzoylperoxide.....	59, 327
Benzyl alcohol.....	60, 327, 328
Benzylpenicillin sodium (topical preparations).....	61, 328
Berberine.....	62, 328
Beta ethoxyacetanilide.....	62
Bicalutamide.....	63
Bismuth salts.....	63
Bismuth subsalicylate.....	64
Bithionol.....	65, 328
Boric acid and borates.....	65, 292, 329
Bovine tissue derived medicines.....	66
Bromfenac.....	67
Bromisoval.....	67
Bromocriptine.....	68, 329, 330
Broxyquinoline (see also halogenated hydroxyquinoline derivatives).....	68, 330
Bucetin.....	69, 330
Bufexamac.....	69, 330
Buformin.....	69, 330, 331
Bumadizone.....	70, 331
Bunamiodyl.....	71, 331
Buprenorphine.....	71, 331
Buspirone hydrochloride.....	72
Cadralazine.....	72, 331
Calamus.....	73, 331
Calcium bromidum and chloral hydrate.....	292
Calcium channel blockers.....	293
Camelia sinensis.....	73, 331
Camphor.....	73, 332
Canrenone.....	74, 332

ALPHABETICAL LISTING OF PRODUCTS

Product name	Page
Canthaxanthin.....	74, 332
Cartilage extract.....	75
Cathine.....	76, 332
Cefaloridine.....	76
Cefalosporins (topical preparations).....	76, 332
Cell preparations.....	77
Cerivastatin.....	77, 332
Chenodeoxycholic acid.....	78, 332, 333
Chloramphenicol in combination.....	293
Chloramphenicol.....	78, 333, 334, 335
Chlormadinone acetate.....	79, 335
Chlormadinone acetate/mestranol (in oral contraceptives).....	294
Chlormezanone.....	80
Chlornaphazine.....	81, 336
Chloroform.....	81, 336
Chloroquine.....	83, 336
Chlorphentermine.....	84, 336, 337
Cianidanol.....	84, 337
Cinchophen.....	85, 337
Cinepazide.....	85
Cinnarizine.....	86, 337
Ciprofibrate.....	86
Cisapride.....	86, 337
Clemastine.....	89, 337, 338
Clioquinol (see also halogenated hydroxyquinoline derivatives).....	89, 338, 339
Clobenzorex.....	91, 339
Clofenotane.....	91
Clofibrate.....	92, 339, 340
Cloforex.....	94, 340
Clometacin.....	94
Clomethiazole.....	95, 340
Cloпамide, reserpine and dihydroergocristine mesilate.....	294
Clozapine.....	95, 341
Cobalt (non-radioactive forms).....	96, 341
Codeine.....	97, 341
Contrast media (ionic and non-ionic).....	294
Coumarin (synthetic).....	97
Cyclamates in drugs.....	98, 341
Cyclandelate.....	98
Cyclopentiazide.....	99
Cycloserine/isoniazid.....	295
Cyproheptadine.....	99, 341, 342
Cyproterone acetate.....	100
Dalkon shield.....	100
Danazol.....	101, 342
Dantron.....	101, 342
Depot medroxyprogesterone acetate (DMPA).....	102, 342
Dequalinium chloride.....	103, 342, 343

ALPHABETICAL LISTING OF PRODUCTS

Product name	Page
Dequalinium.....	103
Desensitizing vaccines.....	295
Dexamfetamine.....	104, 343
Dexfenfluramine hydrochloride.....	104
Dexfenfluramine.....	104, 343
Dextromethorphan.....	105, 343
Dibenzepin hydrochloride.....	105, 343
Diclofenac sodium.....	105, 343, 344
Dicycloverine(dicyclomine)/doxylamine/pyridoxine).....	296
Dicycloverine.....	106, 344
Dienestrol.....	107, 344, 345
Diethylaminoethoxyhexestrol.....	107, 345
Diethylstilbestrol.....	107, 345
Difemerine.....	108
Difenoxin.....	109, 345
Difurazone.....	109, 345
Dihydroergotamine/heparin.....	296
Dihydrostreptomycin sulfate/streptomycin sulfate.....	296
Dihydrostreptomycin.....	109, 345, 346
Dihydroxymethylfuratrizine.....	110, 346
Dilevalol.....	110
Dimazole.....	111, 346
Dinoprostone.....	111, 346
Dionaea muscipula (extract).....	112
Diphenazine.....	112
Diphenoxylate.....	112, 346
Dipotassium clorazepate/acepromazine/aceprometazine.....	297
Dithiazanine iodide.....	113, 346, 347
Domperidone(injectable).....	114, 347
Doxepin.....	114, 347
Doxycycline hyclate(injectable).....	115, 347, 348
Dronabinol.....	116
Droperidol.....	116, 348
Droxicam.....	116
Ebrotidine.....	117
Emetine.....	117, 348
Encainide.....	117
Ephedra.....	118, 348
Epinephrine.....	118, 348, 349
Epoetin alfa.....	119
Epoetin beta.....	119
Erythrityl tetranitrate.....	119
Erythromycin estolate.....	120, 349, 350
Estrogen-progestogen preparations for secondary amenorrhea.....	297
Estrogens (in oral contraceptives).....	298
Estrogens.....	297
Estrogens/testosterone.....	298
Etamivan in combination.....	298

ALPHABETICAL LISTING OF PRODUCTS

Product name	Page
Etanercept.....	121, 350
Ethambutol.....	121, 350
Ethanol.....	121, 350, 351
Ethinylestradiol/methyltestosterone.....	299
Ethyl nitrite (spirit).....	122
Ethylene dichloride.....	123
Ethylestrenol.....	123, 351
Etidocaine hydrochloride/epinephrine tartrate.....	299
Etomidate.....	124, 351
Etretinate.....	124, 351
Factor IX.....	125, 351
Factor VIII.....	126, 351
Famotidine.....	126, 351, 352
Fenclofenac.....	126, 352
Fenetylline.....	127, 352
Fenfluramine.....	127
Fenoterol.....	128, 352
Feprazone.....	128, 352
Fipexide.....	129, 352
Flecainide.....	129, 352, 353
Floctafenine.....	131, 353
Flosequinan.....	131
Flunarizine.....	131
Flunitrazepam.....	132, 353
Fluoxetine.....	133
Fluphenazine and nortriptyline.....	299
Fluvoxamine.....	133, 353
Furazolidone.....	133, 353, 354
Gallopamil.....	134, 354
Gamelonic acid.....	135, 354
Gangliosides.....	135, 299
Gemfibrozil.....	135, 354
Gentamicin (topical preparations).....	136
Germander.....	136
Ginkgo biloba.....	137, 354
Glafenine.....	137, 354, 355
Glucosamine sulfate.....	138, 355
Glutethimide.....	139, 355
Glutoxim.....	139
Grepafloxacin hydrochloride.....	139
Griseofulvin.....	140, 355
Guaifenesin/camphor/ether.....	300
Guanofuracin.....	141
H1-Antihistamines.....	141
Halofantrine.....	142
Halogenated hydroxyquinoline derivatives.....	142, 356
Halogenated salicylanilides.....	143, 356
Heptabarb.....	144, 356

ALPHABETICAL LISTING OF PRODUCTS

Product name	Page
Herbal dietary supplements.....	300
Herpes simplex vaccines.....	144, 356
Hexachlorophene.....	145, 356, 357
Hexestrol.....	145, 357
Hexobarbital.....	146, 357, 358
Hormonal pregnancy tests.....	300
Human dura mater.....	146
Hyaluronidase.....	147, 358
Hydrochlorothiazide/potassium.....	301
Hydroquinidine.....	147
Hydroquinone.....	147, 358
Hydroxyquinolines in combination.....	301
Hyoscine methonitrate.....	148, 358
Ibopamine.....	148
Ibuprofen.....	148, 358, 359, 360
Indalpine.....	149, 360
Indometacin and indometacin farnesil.....	149, 360
Indoprofen.....	150, 360
Iodinated casein strophanthin (neo-barine).....	150, 361
Iproniazid.....	151, 361
Iron preparations.....	302
Isaxonine phosphate.....	151, 361
Isocarboxazid.....	151, 361
Isoprenaline.....	152, 361, 362
Isotretinoin.....	152, 362
Isoxicam.....	154, 362
Kaolin and pectin.....	302
Kaolin.....	154, 362
Kava products.....	302
Kebuzone.....	155, 362, 363
Ketamine hydrochloride.....	155
Ketoconazole.....	156, 363
Ketorolac.....	156
Laetrile.....	157
Lamivudine.....	157
Lamotrigine.....	158
Latamoxef.....	158, 363
Lead oxide and lead salts.....	159, 363
Levacetylmethadol.....	159, 363
Levamphetamine.....	159, 363
Levamisole hydrochloride.....	160, 364
Levarterenol.....	160, 364
Lexipafant.....	161
Lidocaine, salicylic acid and chloral hydrate.....	303
Lindane.....	161, 364
Lipoic acid.....	162, 364
Lobelia.....	162
Loperamide.....	162, 364

ALPHABETICAL LISTING OF PRODUCTS

Product name	Page
Loratadine and pseudoephedrine.....	303
Loxoprofen sodium.....	164
L-Tryptophan.....	164, 364
Lynestrenol.....	166, 365
Mazindol.....	166, 365
Meclozine.....	167, 365, 366
Medifoxamine.....	167
Medroxyprogesterone acetate/ethinylestradiol.....	303
Mefloquine.....	167
Megestrol acetate.....	168, 366
Melatonin.....	169
Mepacrine.....	169
Mephesisin.....	170, 366
Meprobamate.....	170, 367, 368
Meprobamate/diazepines.....	304
Mepyramine maleate/pamabrom.....	304
Mercuric derivatives (topical).....	304, 368
Mesna.....	170, 368
Metamfetamine.....	171, 368, 369
Metamizole sodium, fempiverinium bromide and pitofenone hcl.....	305
Metamizole sodium.....	171, 369, 370, 371
Metformin.....	175
Methanol.....	175
Methapyrilene.....	175, 371
Methaqualone.....	176, 372
Methiodal sodium.....	177, 372, 373
Methylphenidate.....	177, 373
Methylrosanilinium chloride.....	178
Methyprylon.....	178, 373
Metoclopramide (paediatric).....	179
Metoclopramide/polidocanol.....	305
Metofoline.....	179, 373
Metrodin HP.....	179
Mianserin.....	180, 373
Mibefradil.....	180
Mifepristone.....	181, 373
Miglustat.....	181, 373
Minocycline.....	182, 374
Misoprostol.....	182, 374
Mofebutazone.....	182, 374
Moxisylyte.....	183
Mucopolysaccharide polysulfuric acid ester.....	183
Muzolimine.....	184
Nabilone.....	185, 374
Naftidrofuryl (parenteral formulations).....	185
Nandrolone decanoate (injectable).....	186, 374
Nandrolone phenylpropionate (injectable).....	186, 375
Nebacumab.....	187

ALPHABETICAL LISTING OF PRODUCTS

Product name	Page
Nefazodone.....	187, 375
Neomycin sulfate.....	187, 375, 376, 377
Neomycin sulfate/polymyxin bisulfate/nystatin/acetarsol.....	305
Nevirapine.....	188, 377
Nialamide.....	188, 377
Nifedipine.....	189
Nimesulide.....	189, 377
Nitrates.....	306
Nitrefazole.....	190, 377, 378
Nitrendipine.....	190
Nitrofural.....	190, 378
Nitrofurantoin.....	191, 378
Nitroxoline.....	191, 379
Nomifensine.....	192, 379
Nonsteroidal anti-inflammatory agents.....	306
Norethisterone enantate (injectable).....	192, 379
Noscapine.....	193, 379, 380
Novobiocin.....	194, 380
Omeprazole.....	194
Opium in antitussive preparations.....	195, 380
Oral contraceptives (third generation).....	306
Oral rehydration salts.....	195
Oral sodium phosphate bowel preparations.....	307
Orgotein.....	195
Oxeladin citrate.....	196
Oxeladin.....	196
Oxyphenbutazone.....	197, 380
Oxyphenisatine acetate.....	199, 381
Oxytocin.....	201, 381, 382
Pancreatic enzymes.....	308
Pangamic acid.....	201
Paracetamol.....	201, 382
Paracetamol/methionine.....	308
Paromomycin.....	202, 382
Paroxetine.....	202
Pectin.....	203, 382
Pemoline.....	203
Penicillin/streptomycin.....	308
Penicillin/tetracycline.....	309
Pentazocine.....	204, 382, 383
Pentobarbital.....	204, 383
Pentosan polysulfate sodium.....	204
Pexiganan.....	205
Phenacetin.....	205, 383, 384, 385
Phenazone.....	207, 385
Phenazopyridine.....	208, 385, 386
Phendimetrazine.....	208, 386
Phenformin.....	209, 386, 387

ALPHABETICAL LISTING OF PRODUCTS

Product name	Page
Phenformin/chlorpropamide.....	309
Phenicarbazine.....	211, 387
Phenmetrazine.....	211, 387
Phenobarbital, difebarbamate and febarbamate (Tetrabamate).....	309
Phenobarbital.....	211, 387, 388, 389
Phenol.....	212, 389
Phenolphthalein.....	213, 389, 390
Phenoxybenzamine.....	214, 390
Phentermine.....	214, 390
Phentolamine mesilate.....	215
Phenylbutazone.....	215, 390, 391, 392
Phenylephrine.....	218, 392
Phenylpropanolamine.....	218, 392, 393
Phlebotonics.....	310
Phthalylsulfathiazole.....	220, 393
Pipamazine.....	221, 394
Pipenzolate.....	221, 394
Piperazine.....	221, 394, 395
Pipradol/hesperidin.....	310
Pipradrol.....	222, 395, 396
Pirprofen.....	223
Pituitary-chorionic gonadotropin (injectable).....	223, 396
Placental tissue derived medicine.....	223
Podophyllum resin.....	224, 396
Polidexide sulfate.....	224
Polyoxyethylated castor oil.....	225, 396
Polyvidone.....	225, 396, 397
Potassium canrenoate.....	226, 397
Potassium chloride.....	226, 397, 398
Potassium nitrate.....	227, 398
Practolol.....	227, 398
Prasterone.....	228, 398
Prednisolone/phenobarbital.....	310
Prenylamine.....	229
Progabide.....	229, 398
Promethazine in combination.....	310
Promethazine.....	229
Propafenone.....	230, 399
Propionic acid.....	230
Propofol.....	231, 399
Propylhexedrine.....	231, 399
Propyphenazone.....	232, 399
Proxibarbal.....	232
Pseudoephedrine and phenylpropanolamine.....	311
Pumactant.....	233
Pyrazolones in combination (see also aminophenazone, metamizole sodium).....	311
Pyrethroids.....	312
Pyridoxine (Vitamin B6).....	233

ALPHABETICAL LISTING OF PRODUCTS

Product name	Page
Pyrithione zinc.....	233
Pyritinol.....	234, 400
Pyrrolizidine.....	234
Quinidine/verapamil.....	313
Quinine sulfate.....	235
Quinolone antimicrobial agents.....	313
Remifentanil.....	235
Remoxipride.....	236
Repaglinide and gemfibrozil.....	314
Retinol.....	236, 400
Rituximab.....	237
Rubiae tinctorum radix.....	237
Santonin.....	237, 400
Scopolamine.....	238, 400
Secobabital.....	238, 400
Selegiline.....	239
Sertindole.....	239
Sibutramine.....	240
Sildenafil.....	240, 400, 401
Silver acetate.....	240, 401
Sodium dibunate.....	241, 401
Sodium hydrogen bicarbonate (paediatric).....	241
Somatropin (pituitary-derived).....	241, 401
Sotalol.....	242
Sparfloxacin.....	243
Spirolactone.....	243, 401, 402
Streptomycin.....	244, 402
Strychnine and salts.....	244
Sulfacarbamide.....	245
Sulfadiazine.....	245, 402, 403
Sulfadimidine.....	246, 403
Sulfaguanidine.....	246, 403
Sulfamerazine sodium.....	248, 403
Sulfamethizole.....	248, 403, 404
Sulfamethoxyipyridazine.....	248, 404, 405
Sulfanilamide.....	249, 405
Sulfathiazole sodium with sodium lactate or sodium bicarbonate.....	314
Sulfathiazole.....	250, 405, 406
Sulfisomidine.....	250, 406
Sulfonamides (topical preparations).....	251
Suloctidil.....	251, 406
Sulprostone.....	252, 406
Sultopride.....	252, 406
Sumatriptan.....	252
Superheporin.....	314
Suprofen.....	254, 406
Suxamethonium chloride.....	254
Suxibuzone.....	255, 407

ALPHABETICAL LISTING OF PRODUCTS

Product name	Page
Tamoxifen.....	255
Tartrazine.....	256, 407
Temafloxacin.....	257, 407, 408
Temazepam.....	257
Terbinafine.....	257
Terconazole.....	258, 408
Terfenadine.....	258, 408
Terodiline.....	260, 408
Testosterone propionate (injectable).....	260, 408, 409
Tetracycline (paediatric).....	261, 409
Tetracycline in combination.....	314
Thalidomide.....	262, 409
Thenalidine.....	263, 410
Theophylline/meprobamate/barbiturates.....	315
Thiazides/potassium chloride.....	315
Thiomersal.....	264, 410
Tianeptine sodium.....	264, 410
Tiaprofenic acid.....	265
Ticlopidine.....	265, 410
Tienilic acid.....	266, 410
Tilbroquinol.....	267
Tilbroquinol/tiliquinol.....	315
Tiratricol/cyclovalone/retinol.....	316
Tocainide.....	267, 410
Tolcapone.....	268
Tolrestat.....	269
Tramadol.....	269, 410, 411
Trancylopramine and trifluoperazine.....	316
Tranylcypramine.....	269, 411
Trazodone.....	270, 411
Tretinoin.....	270, 411
Triacetyldiphenolisatin.....	271, 411, 412
Triazolam.....	271, 412
Trimethoprim/sulfamethoxazole.....	316
Trimipramine.....	274, 412
Troglitazone.....	274, 412
Trolamine.....	275, 412
Trovafloxacin mesilate.....	276
Trypsin.....	276, 412
Tyrothricin/fomocaine/diphenhydramine.....	317
Urethane.....	277
Vaccines for mumps, measles, and rubella.....	277
Valproic acid.....	278, 412
Vigabatrin.....	278, 413
Vinarol and viga (dietary supplements).....	279
Vinbarbital.....	279, 413
Vincamine.....	279, 413
Voglibose.....	280

ALPHABETICAL LISTING OF PRODUCTS

Product name	Page
Warfarin.....	280, 413
Xenazoic acid.....	281, 413
Xibornol and lidocaine.....	317
Zimeldine.....	281, 413
Zipeprol.....	281, 413, 414
Ziperol.....	282
Zomepirac.....	282, 414
Zopiclone.....	282, 414

CLASSIFIED LISTING OF PRODUCTS

PHARMACEUTICALS (MONOCOMPONENT PRODUCTS)

ANALGESICS, ANTIPYRETICS, AND NONSTEROIDAL ANTIINFLAMMATORY DRUGS

Acetanilide.....	31, 319
Acetylsalicylic acid (paediatric).....	32, 319
Alclofenac.....	38, 320
Aloxiprin.....	40, 320
Aminophenazone.....	44, 322, 323
Azapropazone.....	56, 326
Benorilate.....	58, 327
Benoxaprofen.....	58, 327
Beta ethoxylacetanilide.....	62
Bucetin.....	69, 330
Bumadizone.....	70, 331
Cinchophen.....	85, 337
Clometacin.....	94
Dequalinium chloride.....	103, 342, 343
Diclofenac sodium.....	105, 343, 344
Fenclofenac.....	126, 352
Feprazone.....	128, 352
Floctafenine.....	131, 353
Germander.....	136
Glafenine.....	137, 354, 355
Ibuprofen.....	148, 358, 359, 360
Indometacin and indometacin farnesil.....	149, 360
Indoprofen.....	150, 360
Isoxicam.....	154, 362
Kebuzone.....	155, 362, 363
Ketorolac.....	156
Metamizole sodium.....	171, 369, 370, 371
Metofoline.....	179, 373
Mofebutazone.....	182, 374
Orgotein.....	195
Oxyphenbutazone.....	197, 380
Paracetamol.....	201, 382
Phenacetin.....	205, 383, 384, 385
Phenazone.....	207, 385
Phenazopyridine.....	208, 385, 386
Phenicarbazide.....	211, 387
Phenylbutazone.....	215, 390, 391, 392
Pirprofen.....	223
Propyphenazone.....	232, 399
Suprofen.....	254, 406
Suxibuzone.....	255, 407
Tiaprofenic acid.....	265
Tramadol.....	269, 410, 411
Zomepirac.....	282, 414

ANESTHETICS

Ketamine hydrochloride.....	155
Promethazine.....	229
Propofol.....	231, 399

ANTIALLERGICS

Allergen extracts.....	39, 320
Antihistamine (topical).....	51
Astemizole.....	54, 325
Cinnarizine.....	86, 337
Clemastine.....	89, 337, 338

CLASSIFIED LISTING OF PRODUCTS

ANTIALLERGENICS	
H1-Antihistamines.....	141
Methapyrilene.....	175, 371
Nitrendipine.....	190
Terfenadine.....	258, 408
Thenalidine.....	263, 410
ANTICOAGULANTS	
Ticlopidine.....	265, 410
Warfarin.....	280, 413
ANTIDOTES AND OTHER SUBSTANCES USED IN POISONINGS	
Mesna.....	170, 368
ANTIINFECTIVE DRUGS	
Acetarsol.....	31, 319
Acetylfuratrizine.....	32, 319
Acridine derivatives.....	36, 320
Amodiaquine.....	49, 325
Amyl nitrite.....	50
Benzylpenicillin sodium (topical preparations).....	61, 328
Bithionol.....	65, 328
Boric acid and borates.....	65, 329
Cefaloridine.....	76
Cefalosporins (topical preparations).....	76, 332
Chloramphenicol.....	78, 333, 334, 335
Chloroquine.....	83, 336
Dequalinium chloride.....	103, 342, 343
Difenoxin.....	109, 345
Difurazone.....	109, 345
Dihydrostreptomycin.....	109, 345, 346
Dihydroxymethylfuratrizine.....	110, 346
Dimazole.....	111, 346
Diphenoxylate.....	112, 346
Dithiazanine iodide.....	113, 346, 347
Doxycycline hyclate(injectable).....	115, 347, 348
Emetine.....	117, 348
Erythromycin estolate.....	120, 349, 350
Furazolidone.....	133, 353, 354
Gentamicin (topical preparations).....	136
Griseofulvin.....	140, 355
Guanofuracin.....	141
Halogenated hydroxyquinoline derivatives.....	142, 356
Halogenated salicylanilides.....	143, 356
Hexachlorophene.....	145, 356, 357
Ketoconazole.....	156, 363
Latamoxef.....	158, 363
Levamisole hydrochloride.....	160, 364
Mefloquine.....	167
Minocycline.....	182, 374
Neomycin sulfate.....	187, 375, 376, 377
Nitrofurantoin.....	190, 378
Nitrofurantoin.....	191, 378
Nitroxoline.....	191, 379
Novobiocin.....	194, 380
Paromomycin.....	202, 382
Pexiganan.....	205
Phenol.....	212, 389
Phthalylsulfathiazole.....	220, 393

CLASSIFIED LISTING OF PRODUCTS

ANTIINFECTIVE DRUGS

Piperazine.....	221, 394, 395
Propionic acid.....	230
Quinine sulfate.....	235
Santonin.....	237, 400
Silver acetate.....	240, 401
Sparfloxacin.....	243
Streptomycin.....	244, 402
Sulfacarbamide.....	245
Sulfadiazine.....	245, 402, 403
Sulfadimidine.....	246, 403
Sulfaguanidine.....	246, 403
Sulfamerazine sodium.....	248, 403
Sulfamethizole.....	248, 403, 404
Sulfamethoxyipyridazine.....	248, 404, 405
Sulfanilamide.....	249, 405
Sulfathiazole.....	250, 405, 406
Sulfisomidine.....	250, 406
Sulfonamides (topical preparations).....	251
Temafloxacin.....	257, 407, 408
Terconazole.....	258, 408
Tetracycline (paediatric).....	261, 409
Tilbroquinol.....	267
Trovafloxacin mesilate.....	276
Xenazoic acid.....	281, 413

ANTINEOPLASTIC AND IMMUNOSUPPRESSIVE DRUGS

Aminoglutethimide.....	44, 322
Chlornaphazine.....	81, 336
Progabide.....	229, 398
Tamoxifen.....	255
Urethane.....	277

CARDIOVASCULAR DRUGS

Alprostadil.....	40, 320, 321
Beclobrate.....	57
Bencyclane.....	58, 326
Benzarone.....	59, 327
Cadralazine.....	72, 331
Cinepazide.....	85
Clofibrate.....	92, 339, 340
Diethylaminoethoxyhexestrol.....	107, 345
Encainide.....	117
Epinephrine.....	118, 348, 349
Flecainide.....	129, 352, 353
Flunarizine.....	131
Levarterenol.....	160, 364
Moxisylyte.....	183
Naftidrofuryl (parenteral formulations).....	185
Nifedipine.....	189
Phenoxybenzamine.....	214, 390
Polidexide sulfate.....	224
Practolol.....	227, 398
Prenylamine.....	229
Propafenone.....	230, 399
Sotalol.....	242
Suloctidil.....	251, 406
Terodiline.....	260, 408
Tocainide.....	267, 410

CLASSIFIED LISTING OF PRODUCTS

CARDIOVASCULAR DRUGS

Vincamine..... 279, 413

DERMATOLOGICAL DRUGS

Acitretin..... 35, 319
 Azaribine..... 56, 326
 Benzoylperoxide..... 59, 327
 Bufexamac..... 69, 330
 Clofenotane..... 91
 Etretinate..... 124, 351
 Hydroquinone..... 147, 358
 Isotretinoin..... 152, 362
 Lead oxide and lead salts..... 159, 363
 Lindane..... 161, 364
 Methylrosanilinium chloride..... 178
 Podophyllum resin..... 224, 396
 Pyrithione zinc..... 233
 Thalidomide..... 262, 409
 Tretinoin..... 270, 411

DIURETICS

Benzbromarone..... 59, 327
 Canrenone..... 74, 332
 Ethyl nitrite (spirit)..... 122
 Muzolimine..... 184
 Potassium canrenoate..... 226, 397
 Potassium nitrate..... 227, 398
 Spironolactone..... 243, 401, 402
 Tienilic acid..... 266, 410

DRUGS NOT SCHEDULED INTERNATIONALLY

Aminorex..... 47, 323
 Amitriptyline..... 48, 324
 Cathine..... 76, 332
 Chlorphentermine..... 84, 336, 337
 Cloforex..... 94, 340
 Clozapine..... 95, 341
 Cyproheptadine..... 99, 341, 342
 Dibenzepin hydrochloride..... 105, 343
 Dilevalol..... 110
 Doxepin..... 114, 347
 Fipexide..... 129, 352
 Fluvoxamine..... 133, 353
 Indalpine..... 149, 360
 Iodinated casein strophanthin (neo-barine)..... 150, 361
 Iproniazid..... 151, 361
 Isaxonine phosphate..... 151, 361
 Isocarboxazid..... 151, 361
 Lamotrigine..... 158
 Levamfetamine..... 159, 363
 L-Tryptophan..... 164, 364
 Medifoxamine..... 167
 Mephesisin..... 170, 366
 Mianserin..... 180, 373
 Nialamide..... 188, 377
 Nomifensine..... 192, 379
 Pemoline..... 203
 Propylhexedrine..... 231, 399
 Pyritinol..... 234, 400

CLASSIFIED LISTING OF PRODUCTS

DRUGS NOT SCHEDULED INTERNATIONALLY

Remifentanyl.....	235
Sertindole.....	239
Sodium dibunate.....	241, 401
Sultopride.....	252, 406
Suxamethonium chloride.....	254
Temazepam.....	257
Tianeptine sodium.....	264, 410
Tranlycypromine.....	269, 411
Trazodone.....	270, 411
Trimipramine.....	274, 412
Vigabatrin.....	278, 413
Zimeldine.....	281, 413
Zopiclone.....	282, 414

ENDOCRINE SYSTEM, DRUGS ACTING ON THE

Anabolic steroids.....	50
Anagestone acetate.....	50
Androgens.....	51
Aphrodisiac drugs.....	52
Bromocriptine.....	68, 329, 330
Buformin.....	69, 330, 331
Chlormadinone acetate.....	79, 335
Depot medroxyprogesterone acetate (DMPA).....	102, 342
Dienestrol.....	107, 344, 345
Diethylstilbestrol.....	107, 345
Dinoprostone.....	111, 346
Ethylestrenol.....	123, 351
Gemfibrozil.....	135, 354
Hexestrol.....	145, 357
Lynestrenol.....	166, 365
Megestrol acetate.....	168, 366
Mepacrine.....	169
Metformin.....	175
Mifepristone.....	181, 373
Nandrolone decanoate (injectable).....	186, 374
Nandrolone phenylpropionate (injectable).....	186, 375
Norethisterone enantate (injectable).....	192, 379
Phenformin.....	209, 386, 387
Pituitary-chorionic gonadotropin (injectable).....	223, 396
Prasterone.....	228, 398
Somatropin (pituitary-derived).....	241, 401
Testosterone propionate (injectable).....	260, 408, 409

GASTROINTESTINAL DRUGS

Berberine.....	62, 328
Bismuth salts.....	63
Broxyquinoline (see also halogenated hydroxyquinoline derivatives).....	68, 330
Chenodeoxycholic acid.....	78, 332, 333
Clioquinol (see also halogenated hydroxyquinoline derivatives).....	89, 338, 339
Dantron.....	101, 342
Dicycloverine.....	106, 344
Difemerine.....	108
Domperidone (injectable).....	114, 347
Hyoscine methonitrate.....	148, 358
Loperamide.....	162, 364
Meclozine.....	167, 365, 366
Metoclopramide (paediatric).....	179
Omeprazole.....	194

CLASSIFIED LISTING OF PRODUCTS

GASTROINTESTINAL DRUGS

Oral rehydration salts.....	195
Oxyphenisatine acetate.....	199, 381
Phenolphthalein.....	213, 389, 390
Pipamazine.....	221, 394
Pipenzolate.....	221, 394
Scopolamine.....	238, 400
Strychnine and salts.....	244
Triacetyldiphenolisatin.....	271, 411, 412

IMMUNOLOGICALS

Herpes simplex vaccines.....	144, 356
Vaccines for mumps, measles, and rubella.....	277

LIVER, DRUGS ACTING ON THE

Cianidanol.....	84, 337
Nitrefazole.....	190, 377, 378

MEDICAL DEVICES

Dalkon shield.....	100
--------------------	-----

MUSCULOSKELETAL DRUGS

Cartilage extract.....	75
Mucopolysaccharide polysulfuric acid ester.....	183

NARCOTICS SCHEDULED UNDER SINGLE CONVENTION ON NARCOTIC DRUGS

Buprenorphine.....	71, 331
Codeine.....	97, 341
Noscapine.....	193, 379, 380
Opium in antitussive preparations.....	195, 380
Pentazocine.....	204, 382, 383
Zipeprol.....	281, 413, 414

NERVOUS SYSTEM, DRUGS ACTING ON THE

Zopiclone.....	282, 414
----------------	----------

NOT CLASSIFIED

Acarbose.....	31
Acetylleucine.....	32
Alatrofloxacin mesilate.....	37
Albumin.....	37
Aldesleukin.....	39
Alpidem.....	40
Amfepramone hydrochloride.....	42
Amineptine.....	43
Amiprilose.....	48
Aristolochia.....	52
Bismuth subsalicylate.....	64
Bromfenac.....	67
Buspirone hydrochloride.....	72
Chlormezanone.....	80
Ciprofibrate.....	86
Cisapride.....	86, 337
Coumarin (synthetic).....	97
Cyclandelate.....	98
Cyclopenthiazide.....	99
Cyproterone acetate.....	100
Dequalinium.....	103
Dexfenfluramine hydrochloride.....	104
Dexfenfluramine.....	104, 343
Dronabinol.....	116
Droperidol.....	116, 348

CLASSIFIED LISTING OF PRODUCTS

NOT CLASSIFIED

Droxicam.....	116
Ebrotidine.....	117
Epoetin alfa.....	119
Epoetin beta.....	119
Erythrityl tetranitrate.....	119
Fenfluramine.....	127
Flosequinan.....	131
Fluoxetine.....	133
Ginkgo biloba.....	137, 354
Grepafloxacin hydrochloride.....	139
Halofantrine.....	142
Human dura mater.....	146
Hydroquinidine.....	147
Ibopamine.....	148
Lamivudine.....	157
Levacetylmethadol.....	159, 363
Lexipafant.....	161
Loxoprofen sodium.....	164
Melatonin.....	169
Mibefradil.....	180
Misoprostol.....	182, 374
Nimesulide.....	189, 377
Oxeladin citrate.....	196
Oxeladin.....	196
Oxytocin.....	201, 381, 382
Pentosan polysulfate sodium.....	204
Phentolamine mesilate.....	215
Proxibarbal.....	232
Pumactant.....	233
Rituximab.....	237
Selegiline.....	239
Sibutramine.....	240
Sodium hydrogen bicarbonate (paediatric).....	241
Sumatriptan.....	252
Terbinafine.....	257
Tolcapone.....	268
Tolrestat.....	269
Troglitazone.....	274, 412
Voglibose.....	280

OPHTHALMOLOGICAL PREPARATIONS

Phenylephrine.....	218, 392
Thiomersal.....	264, 410

OTHER PHARMACEUTICAL PRODUCTS

Aristolochic acid.....	52, 325
Arsenic-based compounds.....	53
Berberine.....	62, 328
Bovine tissue derived medicines.....	66
Calamus.....	73, 331
Canthaxanthin.....	74, 332
Cell preparations.....	77
Dionaea muscipula (extract).....	112
Diphenazine.....	112
Factor IX.....	125, 351
Factor VIII.....	126, 351
Gangliosides.....	135
Iodinated casein strophanthin (neo-barine).....	150, 361

CLASSIFIED LISTING OF PRODUCTS

OTHER PHARMACEUTICAL PRODUCTS

Laetrile.....	157
Nebacumab.....	187
Placental tissue derived medicine.....	223
Pyrrrolizidine.....	234
Rubiae tinctorum radix.....	237

PHARMACEUTIC AIDS (SOLVENTS, etc)

Amaranth.....	41
Benzyl alcohol.....	60, 327, 328
Canthaxanthin.....	74, 332
Chloroform.....	81, 336
Cyclamates in drugs.....	98, 341
Ethanol.....	121, 350, 351
Ethylene dichloride.....	123
Glucosamine sulfate.....	138, 355
Kaolin.....	154, 362
Methanol.....	175
Pectin.....	203, 382
Polyoxyethylated castor oil.....	225, 396
Polyvidone.....	225, 396, 397
Tartrazine.....	256, 407
Trolamine.....	275, 412

PLASMA FRACTIONS

Factor IX.....	125, 351
Factor VIII.....	126, 351

PSYCHOTROPICS SCHEDULED UNDER CONVENTION ON PSYCHOTROPIC SUBSTANCES

Amfepramone.....	42, 321
Amfetamine.....	42, 321
Amobarbital.....	49, 324, 325
Aprobarbital.....	52, 325
Barbital.....	57, 326
Bromisoval.....	67
Clomethiazole.....	95, 340
Dexamfetamine.....	104, 343
Etomidate.....	124, 351
Fenetylline.....	127, 352
Flunitrazepam.....	132, 353
Glutethimide.....	139, 355
Heptabarb.....	144, 356
Hexobarbital.....	146, 357, 358
Levamphetamine.....	159, 363
Mazindol.....	166, 365
Meprobamate.....	170, 367, 368
Metamphetamine.....	171, 368, 369
Methaqualone.....	176, 372
Methylphenidate.....	177, 373
Methyprylon.....	178, 373
Nabilone.....	185, 374
Pentobarbital.....	204, 383
Phendimetrazine.....	208, 386
Phenmetrazine.....	211, 387
Phenobarbital.....	211, 387, 388, 389
Phentermine.....	214, 390
Pipradrol.....	222, 395, 396
Propylhexedrine.....	231, 399
Remoxipride.....	236

CLASSIFIED LISTING OF PRODUCTS

PSYCHOTROPICS SCHEDULED UNDER CONVENTION ON PSYCHOTROPIC SUBSTANCES

Secobabital.....	238, 400
Triazolam.....	271, 412
Vinbarbital.....	279, 413

RADIOCONTRAST MEDIA

Bunamiodyl.....	71, 331
Methiodal sodium.....	177, 372, 373

RESPIRATORY TRACT, DRUGS ACTING ON THE

Almitrine.....	39
Aminophylline.....	47, 323
Camphor.....	73, 332
Fenoterol.....	128, 352
Isoprenaline.....	152, 361, 362
Lobelia.....	162
Phenylpropanolamine.....	218, 392, 393
Ziperol.....	282

VITAMINS, MINERALS, ENZYMES

Cobalt (non-radioactive forms).....	96, 341
Pangamic acid.....	201
Potassium chloride.....	226, 397, 398
Pyridoxine (Vitamin B6).....	233
Retinol.....	236, 400

PHARMACEUTICALS (COMBINATION AND GROUP PRODUCTS)

ACE-Inhibitors.....	284
Acetylsalicylic acid/antacid.....	285
Acetylsalicylic acid/codeine.....	285
Acetylsalicylic acid/phenacetin/caffeine (APC).....	285
Amoxicillin/clavulanic acid.....	286
Ampicillin/cloxacillin.....	286, 325
Analgesics in combination.....	286
Anorectic drugs.....	287
Anorectic drugs in combinations.....	288
Antidiarrhoeal combinations.....	289
Antirheumatic combinations with glucocorticosteroids.....	289
Atropine in combination.....	290
Azatadine maleate/pseudoephedrine sulfate.....	290, 326
Barbiturates in asthma preparations.....	290
Barbiturates in combination.....	291
Calcium channel blockers.....	293
Chloramphenicol in combination.....	293
Chlormadinone acetate/mestranol (in oral contraceptives).....	294
Clopamide, reserpine and dihydroergocristine mesilate.....	294
Contrast media (ionic and non-ionic).....	294
Cycloserine/isoniazid.....	295
Desensitizing vaccines.....	295
Dicycloverine(dicyclomine)/doxylamine/pyridoxine).....	296
Dihydroergotamine/heparin.....	296
Dihydrostreptomycin sulfate/streptomycin sulfate.....	296
Dipotassium clorazepate/acepromazine/aceprometazine.....	297
Estrogen-progestogen preparations for secondary amenorrhea.....	297
Estrogens (in oral contraceptives).....	298
Estrogens.....	297
Estrogens/testosterone.....	298
Etamivan in combination.....	298

CLASSIFIED LISTING OF PRODUCTS

Ethinylestradiol/methyltestosterone.....	299
Etidocaine hydrochloride/epinephrine tartrate.....	299
Guaifenesin/camphor/ether.....	300
Hormonal pregnancy tests.....	300
Hydrochlorothiazide/potassium.....	301
Hydroxyquinolines in combination.....	301
Iron preparations.....	302
Kaolin and pectin.....	302
Loratadine and pseudoephedrine.....	303
Medroxyprogesterone acetate/ethinylestradiol.....	303
Meprobamate/diazepines.....	304
Mepyramine maleate/pamabrom.....	304
Mercuric derivatives (topical).....	304
Metamizole sodium, fempiverinium bromide and pitofenone hcl.....	305
Metoclopramide/polidocanol.....	305
Neomycin sulfate/polymyxin bisulfate/nystatin/acetarsol.....	305
Nitrates.....	306
Nonsteroidal anti-inflammatory agents.....	306
Oral contraceptives (third generation).....	306
Oral sodium phosphate bowel preparations.....	307
Pancreatic enzymes.....	308
Paracetamol/methionine.....	308
Penicillin/streptomycin.....	308
Penicillin/tetracycline.....	309
Phenformin/chlorpropamide.....	309
Pipradol/hesperidin.....	310
Prednisolone/phenobarbital.....	310
Promethazine in combination.....	310
Pseudoephedrine and phenylpropanolamine.....	311
Pyrazolones in combination (see also aminophenazone, metamizole sodium).....	311
Pyrethroids.....	312
Quinidine/verapamil.....	313
Quinolone antimicrobial agents.....	313
Sulfathiazole sodium with sodium lactate or sodium bicarbonate.....	314
Superheporin.....	314
Tetracycline in combination.....	314
Theophylline/meprobamate/barbiturates.....	315
Thiazides/potassium chloride.....	315
Tilbroquinol/tiliquinol.....	315
Tiratricol/cyclovalone/retinol.....	316
Trancylopramine and trifluoperazine.....	316
Trimethoprim/sulfamethoxazole.....	316
Tyrothricin/fomocaine/diphenhydramine.....	317

LIST OF CODES USED FOR COUNTRIES, TERRITORIES AND AREAS

@EC	European Union	ITA	Italy
@WD	World	JAM	Jamaica
ARE	United Arab Emirates	JOR	Jordan
ARG	Argentina	JPN	Japan
ARM	Armenia	KOR	Republic of Korea
AUS	Australia	KWT	Kuwait
AUT	Austria	LBN	Lebanon
BDS	Brunei Darussalam	LIY	Libyan Arab Jamahiriya
BEL	Belgium	LKA	Sri Lanka
BGD	Bangladesh	LTH	Lithuania
BGR	Bulgaria	MAR	Morocco
BHR	Bahrain	MEX	Mexico
BLZ	Belize	MUS	Mauritius
BRA	Brazil	MYS	Malaysia
BRB	Barbados	NGA	Nigeria
CAN	Canada	NLD	Netherlands
CHE	Switzerland	NOR	Norway
CHL	Chile	NPL	Nepal
COE	Council of Europe	NZL	New Zealand
COG	Congo	OMN	Oman
COL	Colombia	PAK	Pakistan
CRI	Costa Rica	PAN	Panama
CUB	Cuba	PER	Peru
CYP	Cyprus	PHL	Philippines
DEU	Germany	PRT	Portugal
DNK	Denmark	ROM	Romania
DOM	Dominican Republic	RWA	Rwanda
EGY	Egypt	SAU	Saudi Arabia
EME	European Agency	SDN	Sudan
ESP	Spain	SGP	Singapore
ETH	Ethiopia	SLV	Slovak Republic
FIN	Finland	SUN	Union of Soviet Socialist Republics
FRA	France	SUR	Suriname
GBR	United Kingdom	SWE	Sweden
GHA	Ghana	SYR	Syria
GRC	Greece	TCO	Chad
HKG	Hong Kong	THA	Thailand
HND	Honduras	TUN	Tunisia
HUN	Hungary	TUR	Turkey
IDN	Indonesia	URT	United Republic of Tanzania
IND	India	USA	United States
IRL	Ireland	VEN	Venezuela
IRN	Iran	VTN	Viet Nam
IRQ	Iraq	YEM	Yemen
ISL	Iceland	ZAF	South Africa
ISR	Israel	ZMB	Zambia
		ZWE	Zimbabwe

The designations employed and the presentations of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area or its authorities, or concerning the delimitation of its frontiers or boundaries.

Pharmaceuticals(Monocomponent Products)

Twelfth Issue

PHARMACEUTICALS (MONOCOMPONENT PRODUCTS)

31

Product Name **Acarbose**

C.A.S. number **56180-94-0**

Scientific and common names, and synonyms

D-GLUCOSE, O-4,6-DIDEOXY-4-[[[1S-(1?,4?, 5?, 6?)]-4,5,6-TRIHYDROXY-3-(HYDROXYMETHYL)-2-CYCLOHEXEN-1-YL]-AMINO]-?-D-GLUCOPYRANOSYL-(1?4)-O-?-D-GLUCOPYRANOSYL-(1?4)

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
JPN	Dec 1994	The product information has been revised to state that acarbose drug may cause ileus-like symptoms and that the drug should be discontinued should such symptoms appear. Concomitant use of acarbose and oral hypo- glycaemics or insulin is contraindicated as this may lead to hypoglycaemia. (Reference: (JPNARD) Information on Adverse Reactions to Drugs, No.129, , Dec 1994)
JPN	Dec 1996	The product information has been revised to state that hypoglycaemia and hypoglycaemic symptoms developed in elderly debilitated patients when no other antidiabetics were administered. [See also voglibose]. (Reference: (JPNARD) Information on Adverse Reactions to Drugs, No.140, , Dec 1996)

WHO Comment : Acarbose, ana-glucosidase inhibitor, is used as an adjunctive therapy in the control of postprandial hyperglycaemia in non-insulin-dependent diabetes mellitus. Use of two or more hypoglycaemic drugs is not recommended.

Product Name **Acetanilide**

C.A.S. number **103-84-4**

Scientific and common names, and synonyms

ANTIFEBRIN
N-PHENYLACETAMIDE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
JPN	Jul 1971	This analgesic and antipyretic has been banned for use in over-the-counter preparations due to the risk of aplastic anaemia. It was subsequently voluntarily withdrawn from prescription products. WHO Comment : Acetanilide, a para-aminophenol derivative with analgesic, antipyretic and weak antiinflammatory activity, was introduced into medicine in 1886. It subsequently proved to be excessively myelosuppressive and has been superseded by safer alternatives.

Product Name **Acetarsole**

C.A.S. number **97-44-9**

Scientific and common names, and synonyms

ACETARSONE
N-ACETYL-4-HYDROXY-M-ARSANILIC ACID

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
MUS	9 Mar 1982	Under the Pharmacy and Poisons (Prohibitions of Harmful Drugs) Regulations, this drug is deemed "harmful" by the Ministry of Health and is prohibited for import, manufacture, storage, distribution, sale, possession, use, export or other transaction.

Legislative or regulation action

Product Name	Acetarsol	
C.A.S. number	97-44-9	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		(Reference: (MPPHD) Pharmacy & Poisons (Prohibitions of Harmful Drugs) Regulations, , , Mar 1982) WHO Comment : Acetarsol, which has antiprotozoal and antitrichomonal activity, has largely been discarded for systemic use because of its potential to cause systemic poisoning. However, topical preparations for vaginal trichomoniasis are still available and it is included in low concentrations (equal to or less than 0.45%) in some medicated toothpastes.
Product Name	Acetylfuratrizine	
C.A.S. number	1789-26-0	
Scientific and common names, and synonyms	N-(6-(2-(5-NITRO-2-FURYL)VINYL)-1,2,4-TRIAZIN-3-YL) ACETAMIDE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
JPN	Jul 1977	Withdrawn from all marketed preparations on the grounds that it has been superseded by safer and more effective preparations.
SAU		The withdrawal of nitrofurans compounds is under consideration since they have been superseded by safer and more effective preparations.
VEN		Not approved for use and/or sale. WHO Comment : Acetylfuratrizine, a nitrofurans derivative, was formerly used as an anti-infective agent. It has, however, been superseded by safer compounds and WHO has no information to suggest that it remains commercially available.
Product Name	Acetylleucine	
C.A.S. number	149-80-6	
Scientific and common names, and synonyms	N-ACETYL-DL-LEUCINE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
NLD	1995	The Committee for the Evaluation of Medicines has decided that products containing acetylleucine may no longer be dispensed because the manufacturer has not provided any evidence of efficacy. (Reference: (NPHWB) Pharmaceutisch Weekblad, 28(5):128, , 1994) WHO Comment : The products were indicated for the treatment of vertigo and had been authorized for marketing under the "grandfather" clause, which waives full registration requirements for products marketed before 1963.
Product Name	Acetylsalicylic acid (paediatric)	
C.A.S. number	50-78-2	
Scientific and common names, and synonyms	ASPIRIN	

Legislative or regulation action

Product Name **Acetylsalicylic acid (paediatric)**

C.A.S. number **50-78-2**

Scientific and common names, and synonyms

BENZOIC ACID, 2-(ACETYLOXY)-

SALICYLIC ACID ACETATE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
CHE	1986	The Intercantonal Office for Drug Control has decided that products containing salicylates should bear on the package a warning against use by children under twelve years of age, except on medical advice. The package leaflets directed to both physicians and patients should additionally include warnings concerning Reye's syndrome in both the sections "Limitations of use" and "Undesirable effects". (Reference: (CHBCM) Bulletin Mensuel, 8, , 1986)
IRQ	1986	The National Board for the Selection of Drugs has decided to prohibit the sale of products containing acetylsalicylic acid without a medical prescription. The product information should contain a warning that acetylsalicylic acid should be avoided in children suffering from influenza or chickenpox and that children under 12 years of age should receive acetylsalicylic acid only on medical advice.
ISR	Feb 1986	The Ministry of Health has ordered that preparations of acetylsalicylic acid intended specifically for children be subjected to prescription control and that all preparations should contain a warning referring to the reported risk of Reye's syndrome in children and young adults with fever due to viral infections.
ITA	Jun 1986	The Italian Health Council has decided that all products containing acetylsalicylic acid should bear the following warning: "Consult your physician before administering this product to children and teenagers with viral diseases such as influenza or chicken pox. Discontinue use immediately if persistent vomiting or undue sleepiness occurs."
IRL	9 Jun 1986	The National Drugs Advisory Board, in agreement with manufacturers, requires that all paediatric dosage forms be available on prescription only. All preparations should carry the warning "This product should not be given to children, particularly those under 12 years of age, without medical advice."
GBR	10 Jun 1986	The Committee on Safety of Medicines has advised that acetylsalicylic acid should not be administered to children under 12 years of age except on medical advice. Leading manufacturers have declared their intention to stop supplying paediatric preparations.
AUS	11 Jun 1986	The Adverse Drug Reactions Advisory Committee has warned that acetylsalicylic acid should not be given to children and teenagers with fever. The warning does not relate to use for disorders in children and teenagers who do not have fever.
ESP	7 Aug 1986	The Director General for Pharmacy and Health Products of the Ministry of Health has issued guidelines for package inserts for preparations containing acetylsalicylic acid. A warning should be included stating that the preparation should be administered to children and adolescents with febrile conditions such as influenza or varicella only on medical advice.
HKG	1 Sep 1986	The Medical and Health Department requires that the product information for all preparations containing acetylsalicylic acid must warn against its use in children under 12 years of age, except on medical advice. Manufacturers are urged to withdraw all paediatric preparations.
DEU	Oct 1986	The Federal Health Office requires pharmaceutical preparations containing acetylsalicylic acid to bear a warning against use for feverish conditions in children and young people unless on medical advice and only if other measures have failed.
OMN	Dec 1986	The Central Drug Committee has informed doctors and pharmacists that no products containing acetylsalicylic acid (aspirin) should be given to children under 12 years of age who have chicken pox, influenza or any other febrile illness. Paediatric aspirin preparations will be available only from pharmacies. Products for export containing acetylsalicylic acid should bear the following statutory warning on new packs: "This product should not be given to children, particularly those under 12 years of age, without

Legislative or regulation action

Product Name		Acetylsalicylic acid (paediatric)
C.A.S. number		50-78-2
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		medical advice."
EGY	1987	The Technical Committee for Drug Control has decided that the product information of all paediatric pharmaceutical products containing acetylsalicylic acid should bear the following warning: "Consult a physician before giving aspirin to children aged less than 12 years, especially in cases of influenza and chickenpox, to avoid risk of Reye's Syndrome." (Reference: (EGYDC) Decision of the Egyptian Technical Committee for Drug control, Vol.5(2), 1, 1987)
NGA	Jan 1987	Because of the suspected link between the use of acetylsalicylic acid in children below the age of 12 years and Reye's syndrome, importation, manufacture, sale and distribution of paediatric products containing acetylsalicylic acid or other salicylates have been prohibited. The labels of non-paediatric products must bear the warning: "Not for use in children below 12 years of age". (Reference: (NGAPN) Pharmanews, 10(11), 15, 1988)
CHL	2 Feb 1987	The Institute of Public Health of Chile has decided that all pharmaceutical products containing acetylsalicylic acid should carry a warning on the label that the drug should not be given to children under 12 years of age with febrile viral diseases without consulting a doctor. (Reference: (CHLRS) Resolution of the Minister of Health, No.01042, , Feb 1987)
DNK	1 Jul 1987	The National Board of Health has decided that pharmaceutical preparations containing acetylsalicylic acid in paediatric dosages (less than 200mg/tablet) should bear the following warning: "Not to be given to feverish children without consulting a doctor."
SGP	1 Dec 1987	The Ministry of Health has made it mandatory for all aspirin products to bear the cautionary label: "Caution: not to be given to persons below the age of 16 years except under the direction of a doctor" before the products can be sold in the market. The public is advised not to give their children any medicine containing aspirin unless otherwise advised by the doctor. (Reference: (SGPMA) Medicines Act (Chapter 176), No.S 230/87, 1078, Aug 1987)
SWE	1988	The National Board of Health and Welfare has revised the product information for preparations containing acetylsalicylic acid to recommend that they should not be taken by febrile children under 18 years of age and to indicate that paracetamol is the drug of choice in these circumstances. (Reference: (SSLMS) Information från Socialstyrelsens Läkemedelsavdelning, Vol.12(6), 145, 1987)
BEL	1 Jan 1988	The Ministry of Public Health and the Environment requires pharmaceutical products containing acetylsalicylic acid to bear the following warning: "This medicine contains acetylsalicylic acid. Do not use in feverish children without medical advice.". (Reference: (BELMD) Ministerial Decree, , , June 1987)
USA	Jun 1988	The United States Food and Drug Administration has revised the labelling of products containing acetylsalicylic acid to read: "Children and teenagers should not use this medicine for chickenpox or flu symptoms before a doctor is consulted about Reye's syndrome, a rare but serious illness, reported to be associated with aspirin." (Reference: (FEREAC) Federal Register, 53(111), 21633, 1988)
USA	Apr 1994	The FDA proposed to revise the labelling of products containing acetylsalicylic acid (including buffered acetylsalicylic) alone or in combination with an antacid to include the following statement: "IMPORTANT: See your doctor before taking this product for your heart or for other new uses of aspirin [acetylsalicylic acid], because serious side effects could occur with self- treatment?. [See also Combinations] (Reference: (FEREAC) Federal Register, 58(201) , p. 54224, 1993)
USA	Apr 1994	The Food and Drug Administration proposed to extend to products containing bismuth subsalicylate and all oral and rectal over-the- counter products that contain acetylsalicylic

Legislative or regulation action

Product Name		Acetylsalicylic acid (paediatric)	
C.A.S. number		50-78-2	
Legislative or regulatory action			
Country	Effective Date	Description of action taken Grounds for decision	
		acid (aspirin) or other salicylates the following warning: "Children and teenagers who have or are recovering from chicken pox, flu symptoms or flu should not use this product. If nausea or fever occur, consult a doctor because these symptoms could be an early sign of Reye syndrome, a rare but serious illness." [See also Bismuth subsalicylate] (Reference: (FEREAC) Federal Register, 58(201) , p. 54228, 1993)	
LKA	9 Jul 1996	Registration of a particular product was rejected because the picture of children on the label was considered inappropriate. (Reference: (LKADES) Drug Evaluation Sub-Committee, , ,)	
FRA	May 1997	A special form of 100 mg tablets to chew or suck was withdrawn because of risk of aspiration in small children. The manufacturer stopped marketing of this medicinal product. (Reference: (FRAAMP) Press Release, , , 14 May 1997)	
BRA	Jun 2001	The National Health Surveillance Agency requires all pharmaceutical products containing acetylsalicylic acid to bear a warning against using such products in children with chicken pox or flu symptoms without consulting a physician about Reye's syndrome. (Reference: (BRARES) Resolucao n., 529/ANVISA, , 06 Aug 2001)	
GBR	Oct 2002	The Medicines Control Agency (MCA) has restricted the use of acetylsalicylic acid products in 16 year old and younger children since the risk of aspirin associated Reye's syndrome exists in all children up to this age group. All acetylsalicylic acid containing products are required to include this restriction in the product monograph. (Reference: (GBRSTE) Statement, 2002/0436, , 22 Oct 2002)	
ESP	20 Jun 2003	All paediatric OTC medicinal preparations containing salicylates/acetylsalicylic acid (Aspirin) are being withdrawn from the market. This measure has been undertaken to prevent the use of these products in children with viral fever and thereby reduce the risk of Reye's syndrome in these children. For non-paediatric OTC products containing salicylates/acetylsalicylic acid the Summary of Product Characteristics (SPC) will have to be modified to include that OTC products for adult use are contraindicated in children below the age of 16 years and prescription products are contraindicated for the treatment of fever, chickenpox and viral fevers in patients below 16 years of age. (Reference: (ESPSPS) Communication to WHO, , , 08 July 2003)	
NLD		The Board for the Evaluation of Medicines requires information for patients on products containing acetylsalicylic acid to contain the statement: "To be used in children with chickenpox or influenza only on the advice of a doctor." WHO Comment : Acetylsalicylic acid, a nonsteroidal anti-inflammatory, analgesic and antipyretic agent, was introduced into medicine in 1899 and has since been widely available in over-the-counter preparations. Recent studies carried out in the USA have shown an association between acetylsalicylic acid consumption in children and the development of Reye's syndrome (a rare condition characterized by a combination of encephalopathy and liver disorder and usually preceded by an acute viral illness, such as influenza, diarrhoea, or chickenpox). Many drug regulatory authorities have acted to caution against the use of the drug in children and young adults with febrile conditions. Even within this group the risk of exposure is remote and has been estimated to be of the order of 1.5 per million. This warning also concerns products containing other salicylates. The new indication of acetylsalicylic acid - prophylaxis of myocardial infarction due to its antithrombotic effect - requires long-term use and may lead to serious adverse reactions, including cerebral haemorrhage. Acetylsalicylic acid retains a valuable place in medicine and remains in the WHO Model List of Essential Drugs. (Reference: (WHODI) WHO Drug Information, 1:5, , 1985)	

Product Name **Acitretin**

Legislative or regulation action

C.A.S. number 55079-83-9

Scientific and common names, and synonyms

2,4,6,8-NONATRAENOIC ACID, 9-(4-METHOXY-2,3,6-TRIMETHYLPHENYL)-3,7-DIMETHYL-2,4,6,8-NONATETRAENOIC ACID, (ALL-E)

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
@EC	14 Dec 1990	The Committee for Proprietary Medicinal Products recommended that the product information for preparations containing acitretin should state that contraception should be maintained for 2 years after cessation of treatment and that patients should not donate blood for 1 year after the end of therapy. (Reference: (CPMPPO) Pharmacovigilance Opinion, 9, , 14 Dec 1990)
FRA	Jun 1991	The marketing authorization for products containing acitretin was suspended, on the grounds that the analysis of blood samples from patients receiving the drug had indicated etretinate to be a possible metabolite. Acitretin was reintroduced in April 1991 with an amended product information stating that contraceptive measures must be taken for a minimum of one year after discontinuation of treatment and preferably for two years and that patients should not donate blood either during treatment or for one year thereafter. (Reference: (FRAMS) Ministry of Social Affairs and Integration, , , June 1991) (Reference: (FRAMHS) Ministry of Health and Social Affairs, , , 27 Oct 1990)

WHO Comment : Acitretin, a retinol derivative, was introduced in 1989 for the treatment of severe psoriasis. By the end of 1990, acitretin was confirmed to be metabolized in part to etretinate. Marketing authorization was suspended temporarily in France while the product information was modified to conform to the recommendations issued by the Committee for Proprietary Medicinal Products of the European Communities. Acitretin remains registered in several countries. See also WHO comment for etretinate.

Product Name Acridine derivatives

C.A.S. number 260-94-6

Scientific and common names, and synonyms

AMINACRINE
ACRIFLAVINE
EUFLAVINE
ETHACRIDINE
PROFLAVINE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
ITA	1973	These products are only available as topical disinfectants in concentrations not higher than 1%.
DNK	Sep 1979	Proflavine was withdrawn from all dental-care products in May 1978, following demonstration of mutagenic activity in vitro. Euflavine was similarly withdrawn as of September 1979. No direct evidence exists of any risk to man and the extent to which these substances penetrate mammalian cells is uncertain. Nevertheless, the Registration Board has recommended that the restriction should apply to all acridine disinfectants "that many regard as obsolete and whose safety is questionable".
VEN		Not approved for use and/or sale. WHO Comment : Acridine derivatives with antiseptic and disinfectant activity, including acriflavine, proflavine and euflavine, were formerly used in the treatment of infected wounds and burns. Such use has largely been discontinued on the grounds that safer and more effective alternatives are now available. Following demonstration of the mutagenic activity of proflavine in 1978 it was withdrawn from

Legislative or regulation action

Product Name	Acridine derivatives	
C.A.S. number	260-94-6	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		dental products in Denmark. Subsequently, euflavine was similarly withdrawn.
Product Name	Alatrofloxacin mesilate	
C.A.S. number	157605-25-9	
Scientific and common names, and synonyms		
7-((1R,5S,6S)-6-((S)-2-AMINOPROPIONAMIDO)PROPIONAMIDO)-3-AZABICYCLO[3.1.0]HEX-3-YL)-1-(2,4-DIFLUOROPHENYL)-6-FLUORO-1,4-DIHYDRO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID MONOMETHANESULPHONATE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
ARM	Jul 2000	The Drug and Medical Technology Agency have rejected registration of alatrofloxacin because recent studies have shown serious and unpredictable liver injuries after administration of the drug. (Reference: (ARMCW) Communication to WHO, , , 09 Aug 2000)
SGP		The National Pharmaceutical Administration in the Ministry of Health has not approved alatrofloxacin since it is associated with hepatic adverse reactions. (Reference: (SGPCW) Communication to WHO, , , 02 Aug 2000)
Product Name	Albumin	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
FRA	5 Dec 1993	The Ministry of Health decided that all blood and every placenta used for the manufacture of albumin must be shown to be derived from a donor who has never received an extract of human growth hormone and has no family history of neurodegenerative disease. (Reference: (FRAAMC) Communiqué de Presse, , , 01 Dec 1993)
DEU	Nov 1994	Following plans of the Federal Health Office to suspend marketing authorization of a product containing albumin manufactured from human placenta, the manufacturer has voluntarily withdrawn the licence. (Reference: (DAZ) Deutsche Apotheker Zeitung, 134(2), , 1994)
GBR	Nov 1997	Acting on advice from the Medicines Control Agency, the UK supplier has recalled 3 batches of human serum albumin (Amerscan Pulmonate II Technetium Lung Agent®: Nycomed Amersham), as a precautionary measure after post-donation information revealed that a blood donor was subsequently diagnosed with New Variant Creutzfeldt-Jakob disease. (Reference: (GBRNBA) Communication, , , 20 Nov 1997) (Reference: (GBRDPR) EU/EEA Rapid Alert - Defective Product Recall, , , 17 Nov 1997)
WHO Comment : Although there is no proven or even probable instance of transmission of Creutzfeldt-Jakob Disease (CJD), also known as Trans-missible Spongiform Encephalopathy, by blood, blood components or plasma derivatives, increased awareness has raised concern about such a possibility. While published epidemiological studies give some reassurances that transmission of CJD has not occurred through blood, they are limited in scope, and improved surveillance for CJD is essential. In addition to routine internationally recognized donor selection		

Legislative or regulation action

Product Name **Albumin**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
		criteria the following donors should be excluded: donors who have been treated with extracts from human pituitary glands, donors who have familial history of CJD, Gerstmann- Strüssler-Scheinker syndrome (GSS) or Fatal Familial Insomnia (FFI), and donors who have received a human dura mater graft. (Report of a WHO Consultation on Medicinal and other Products in Relation to Human and Animal Transmissible Spongiform Encephalopathies. (WHO/EMC/ZOO/97.3; WHO/BLG/97.2, WHO, Geneva, 24-26 March 1997.)) (Reference: (WHOCON) See also Placental tissue derived medication in full edition, , ,)

Product Name **Alclofenac**

C.A.S. number **22131-79-9**

Scientific and common names, and synonyms

BENZENEACETIC ACID, 3-CHLRO-4-(2-PROPENYLOXY)-
(4-ALLYLOXY-3-CHLOROPHENYL) ACETIC ACID

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
IRL	1977	Products containing alclofenac were rejected following evidence of metabolite mutagenicity.
CYP	1979	Withdrawn following reports that an epoxide urinary metabolite has mutagenic activity.
DEU	1979	Registration has been suspended following the voluntary withdrawal of alclofenac in the United Kingdom.
GBR	1979	Alclofenac was voluntarily withdrawn by the manufacturer following reports of skin rashes associated with its use.
ITA	1979	Withdrawn following reports that an epoxide urinary metabolite has mutagenic activity.
NZL	1979	Voluntarily withdrawn from the market.
EGY	Mar 1984	Pharmaceutical preparations containing this antiinflammatory agent no longer qualify for registration to avoid the potential risk associated with a urinary metabolite having mutagenic activity.
GRC	1985	Withdrawn from the market.
DNK		Voluntarily withdrawn by the manufacturer.
IDN		Registration has been refused following reports that an epoxide urinary metabolite has mutagenic activity.
IND		Not approved for marketing following reports that an epoxide urinary metabolite has mutagenic activity.
JOR		Registration has been refused following reports that an epoxide urinary metabolite has mutagenic activity.
MAR		Registration has been refused following reports that an epoxide urinary metabolite has mutagenic activity.
		WHO Comment : Alclofenac, a phenylacetic acid derivative with analgesic, antipyretic and antiinflammatory activity, was introduced in 1972 for the treatment of rheumatic disorders. In the late 1970s its use was associated with a high incidence of adverse effects, mainly skin rashes, and a urinary metabolite was

Legislative or regulation action

Product Name	Alclofenac	
C.A.S. number	22131-79-9	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		reported to have mutagenic activity (positive Ames test). This resulted in the withdrawal of the drug, in some cases voluntarily, from several countries. In others registration has been refused. The reported mutagenic potential has been questioned by some investigators and the drug remains on the market in at least three countries with highly evolved regulatory authorities.

Product Name	Aldesleukin	
Scientific and common names, and synonyms		
EPIDERMAL THYMOCYTE ACTIVATING FACTOR		
INTERLEUKIN-2		
T-CELL GROWTH FACTOR		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
SGP		The National Pharmaceutical Administration in the Ministry of Health has restricted the use of aldesleukin to medical oncologists in view of life-threatening toxicities, which have been reported with the drug. (Reference: (SGPCW) Communication to WHO, , , 02 Aug 2000)

Product Name	Allergen extracts	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
SWE	1 Apr 1986	The National Board of Health and Welfare required producers of all marketed allergen extracts to file registration applications before 1 April 1986. Extracts currently available were allowed to remain on the market pending a final decision. However, having regard to recently reported adverse reactions, existing preparations derived from mites, moulds and certain domestic animals were withdrawn with immediate effect. Provision was, however, made for further clinical trial of such formulations.

Product Name	Almitrine	
C.A.S. number	27469-53-0	
Scientific and common names, and synonyms		
2,4-BIS(ALLYLAMINO)-6-(4-(BIS-(P-FLUOROPHENYL)METHYL)-1-PIPERAZINYL)-S- TRIAZINE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU		The indications for use of almitrine have been restricted to chronic obstructive pulmonary disease with respiratory insufficiency. WHO Comment : Peripheral neuropathy has been reported in a few patients receiving almitrine for long periods. The indications for treatment have

Legislative or regulation action

Product Name Almitrine

C.A.S. number 27469-53-0

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
		consequently been restricted in the Federal Republic of Germany. Some other countries have advised doctors to maintain patients under close supervision throughout treatment and to restrict dosage to two out of every three months.

Product Name Aloxiprin

C.A.S. number 9014-67-9

Scientific and common names, and synonyms

POLYMERIC CONDENSATION PRODUCT OF ALUMINIUM OXIDE AND O- ACETYLSALICYLIC ACID

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
GBR	Dec 1986	The Committee on Safety of Medicines has advised that preparations containing the acetylsalicylic acid pro-drug aloxiprin should not be administered to children under 12 years of age except on medical advice. (Reference: (GBMIL) Medicines Act Information Letter, No.48, , Oct 1986) WHO Comment : Aloxiprin is a pro-drug of acetylsalicylic acid. See WHO comment for acetylsalicylic acid.

Product Name Alpidem

C.A.S. number 82626-01-5

Scientific and common names, and synonyms

IMIDAZOL[1,2-?]PYRIDINE-3-ACETAMIDE, 6-CHLORO-2-(4-CHLOROPHENYL)-N,N-DIPROPYL

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
FRA	Jan 1994	The marketing authorization of the anxiolytic agent alpidem has been withdrawn because of several reports of hepatotoxicity, some of them fatal. (Reference: (FRAAMC) Communiqué de Presse, , , 06 Jan 1994)

Product Name Alprostadi

C.A.S. number 745-65-3

Scientific and common names, and synonyms

PROST-13-EN-1-OIC ACID, 11,15,-DIGYDROXY-9-OXO, (11ALPHA, 13E, 15S)-

PGE1, PROSTAGLANDIN E1

(1R,2R,3R)-3-HYDROXY-2-[(E)-(3S)-HYDROXY-1-OCTENYL]-5-OXOCYCLOPENTANEHEPTANOIC ACID

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
DEU	1991	Products for intravenous administration containing alprostadi were contraindicated in patients with cardiac disease, including inadequately treated coronary atherosclerosis, cardiac insufficiency and arrhythmia, cardiac infarction within the last six months, clinical or radiological suspicion of pulmonary oedema or infiltration, severe chronic airway obstruction, acute liver damage with elevation of transaminases or gamma-GT and an

Legislative or regulation action

Product Name Alprostadiil

C.A.S. number 745-65-3

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
		<p>increased bleeding tendency. (Reference: (BGHBL) Bundesgesundheitsblatt, 3/91, 139, 1991)</p> <p>WHO Comment : Alprostadiil, a prostaglandin with vasodilating and platelet anti-aggregatory activity, was introduced in 1984 for the treatment of chronic arterial obstruction. Intravenous administration of the drug has been associated with adverse effects that have sometimes been severe. These include allergic reactions, pulmonary oedema and cardiac insufficiency. Interactions with antihypertensive agents, vasodilators, anticoagulants and inhibitors of platelet aggregation have also occurred. This has led the German agency to modify the approved product information of alprostadiil preparations to warn against these adverse effects.</p>

Product Name Amaranth

C.A.S. number 915-67-3

Scientific and common names, and synonyms

BORDEAUX-S
COLOUR INDEX NO.16185
CI FOOD RED 9
CI ACID RED 27
E123
FD&C RED NO.2

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
USA	1976	The provisional approval for use of amaranth as a colour additive has been withdrawn since no study is available to resolve the uncertainty over its safety.
EGY	1981	Having regard to the potential carcinogenicity of amaranth, no new preparations containing this substance will henceforth be considered for registration and manufacturers are to replace amaranth with alternative substances within a period of three years. (Reference: (EGYDC) Decision of the Egyptian Technical Committee for Drug control, , 1981)
KWT	Apr 1984	Amaranth is no longer approved for use in pharmaceutical preparations and food products. (Reference: (KTMD) Ministerial Decree, 156/84, , 1984)
OMN	1 Apr 1986	Import of pharmaceutical products containing the colouring agent amaranth is prohibited.
LKA		The Drug Evaluation Sub-Committee (Ministry of Health and Highways and Social Affairs) decided not to accept new applications for registration of pharmaceutical products containing the colouring agent, amaranth, because of its potential carcinogenicity. (Reference: (LKADES) Drug Evaluation Sub-Committee, , ,) WHO Comment : Approval of amaranth as a permitted colouring agent in foods and pharmaceutical products was withdrawn by the United States FDA in 1976, on the basis of positive findings in carcinogenicity tests which were later disputed on technical grounds and which have not been confirmed in subsequent tests. It has since been withdrawn by some other national regulatory authorities because of uncertainty regarding its safety, but elsewhere it remains widely used.

Legislative or regulation action

Product Name **Amfepramone**
C.A.S. number **90-84-6**
Scientific and common names, and synonyms
 DIETHYLPROPION
 1-PROPANONE, 2-(DIETHYLAMINO)-1-PHENYL-,
 2-(DIETHYLAMINO)PROPIOPHENONE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
TUR	1975	Amfepramone is prohibited for import, export, production, sale and distribution for reasons of harmful health effects; the lack of evidence of value in the long-term management of obesity; and the risk of dependency.
SWE	Jan 1981	Amfepramone containing appetite suppressants have been withdrawn from the market. There is a lack of evidence of their value in long-term management of obesity, they have the potential for abuse and despite warnings they are frequently used over unacceptably prolonged periods.
OMN	11 Jan 1987	Import and marketing of products containing amfepramone were prohibited. (Reference: (OMNCR) Circular, 2/87, , Jan 1987)
ARE		Pharmaceutical preparations containing amfepramone are banned.
NOR		As a centrally acting appetite-reducing preparation, amfepramone is considered harmful and is not approved in Norway.
VEN		Amfepramone is not approved for use and/or sale. WHO Comment : Amfepramone, a phenethylamine derivative introduced in 1957, is controlled under Schedule IV of the 1971 Convention on Psychotropic Substances. It remains available in many other countries with highly evolved drug regulatory authorities as an aid to weight reduction. (Reference: (UNCPS4) United Nations Convention on Psychotropic Substances (IV), , , 1971)

Product Name **Amfepramone hydrochloride**
C.A.S. number **134-80-5**
Scientific and common names, and synonyms
 DETHYLPROPION HYDROCHLORIDE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
GBR	Apr 2000	The Medicines Control Agency has banned the anorectic agent, amfepramone hydrochloride on the basis of a European Commission decision stating that risks outweigh the benefits. (Reference: (GBRMCA) Communication to WHO, , , 30 Aug 2000)

Product Name **Amfetamine**
C.A.S. number **300-62-9**
Scientific and common names, and synonyms
 AMPHETAMINE
 BENZENEETHANAMINE, ALPHA-METHYL-, (+/-)
 (+/-)-ALPHA-METHYLPHENETHYLAMINE

Legislative or regulative action

Legislative or regulation action

Product Name		Amfetamine
C.A.S. number		300-62-9
Country	Effective Date	Description of action taken Grounds for decision
USA	1973	Anorectic drugs containing amfetamine were withdrawn from the market by the Food and Drug Administration due to evidence of abuse and a high risk of dependence.
ARE	9 Jun 1981	Pharmaceutical preparations containing amfetamine are banned. (Reference: (UAEMD) Ministry of Health Decree, No.694, , 1981)
TUR	6 Sep 1982	Banned for production, import, export, sale and use.
OMN	10 May 1982	Import and marketing of products containing amfetamine were prohibited. (Reference: (OMNCR) Circular, 11/82, , May 1982)
MYS	Jul 1987	All products containing amfetamine or derivatives indicated as appetite suppressants have been withdrawn. (Reference: (MYSDC) Malaysian Drug Control Authority, No.10, , Apr 1987)
NGA	1988	All products containing amfetamine have been banned. (Reference: (NGAPN) Pharmanews, 10(11), 15, 1988)
SAU		Centrally-acting appetite suppressants are severely restricted since they have been found to be ineffective in the management of obesity and they are subject to misuse. WHO Comment : Amfetamine and its derivatives are potent central stimulants. Use of amfetamines has widely been discouraged due to abuse of their euphoric effect and their limited field of usefulness. Amfetamines have a place in the treatment of narcolepsy and in hyperkinetic syndrome in children. However, they are no longer recommended for use in obesity or depressive illness. Amfetamine is controlled under Schedule II of the 1971 Convention on Psychotropic Substances. (Reference: (UNCPS2) United Nations Convention on Psychotropic Substances (II), , , 1971)

Product Name		Amineptine
C.A.S. number		57574-09-1
Scientific and common names, and synonyms		
7-[(10,11-DIHYDRO-5H-DIBENZO(A,D)CYCLOHEPTEN-5-YL)AMINO]HEPATANOIC ACID HYDROCHLORIDE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
FRA	Jan 1999	The Medicines Agency has announced that the marketing authorization for the antidepressant, amineptine (SurvectorR: Servier) has been suspended and withdrawn in France. These actions have been taken after an evaluation of amineptine revealed a potential for abuse and risk of dependence. (Reference: (FRAAMI) Infobox - Pharmacovigilance, , , 22 Jan 1999)
THA	Jan 1999	The Ministry of Health has withdrawn preparations of amineptine following action taken in France. (Reference: (THAFDA) Communication to WHO, , , 28 Jan 1999)
ARE	12 Jan 1999	The Ministry of Health has banned the sale of amineptine on account of a potential for abuse and risk of dependence. (Reference: (UAECW) Communication to WHO, , , 10 July 2000)
BDS	Jun 1999	The Medical Health Services Headquarters in the Ministry of Health has withdrawn all tablets of amineptine (Survector) from the market with effect from 30 June 1999. (Reference: (BDSOL) Official letter to Regulatory Agencies, , , Feb 1999)
MAR	Jun 1999	The National Advisory Commission for Pharmacovigilance has decided to suspend the marketing authorization for amineptine. This action is based on international data

Legislative or regulation action

Product Name	Amineptine	
C.A.S. number	57574-09-1	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		concerning the potential abuse and risk of dependence associated with the intake of this product. (Reference: (MARDMP) Letter to WHO, , , 24 Aug 1999)
VTN	Aug 1999	The Drug Administration of Viet Nam in the Ministry of Health has withdrawn approval for the antidepressant, amineptine (Survector). This follows the decision taken by France to suspend amineptine on the basis of abuse and dependency potential. (Reference: (VTNMHD) Directive, 41(1999), QD-QLD, 05 Aug 1999)
OMN	Apr 2000	The Directorate General of Pharmaceutical Affairs & Drug Control has rescheduled amineptine as a non-psychotropic restricted controlled item because of international data concerning its potential abuse and risk of dependence. (Reference: (OMNCR) Circular, No. 25/2000, , 25 Apr 2000)

Product Name	Aminoglutethimide	
C.A.S. number	125-84-8	
Scientific and common names, and synonyms		
2,6-PIPERIDINEDIONE, 3-(4-AMINOPHENYL)-3-ETHYL- 2-(4-AMINOPHENYL)-2-ETHYLGLUTARIMIDE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
USA	1966	Withdrawn from the market following demonstration of serious toxic effects to thyroids, ovaries, adrenals and uteri of female rats, as well as atrophy and mottling of the adrenals of some male rats. Clinical experience showed that in some children it caused sexual precocity, masculinization of young females and other untoward effects including goitre with thyroid hypofunction.
SAU		Withdrawn from the market due to reported serious side effects. WHO Comment : Aminoglutethimide, a weak anticonvulsant, was introduced in 1960 for use in the treatment of epilepsy. However, its adrenocortical suppressant activity gave rise to serious adverse effects. The FDA decision in 1966 was taken in respect of a preparation indicated in epilepsy. In 1980 preparations containing aminoglutethimide were reintroduced in the USA exclusively for the treatment of Cushing's disease. In 1986 they were also registered in Saudi Arabia for use in Cushing's syndrome and for the treatment of breast cancer. In some other countries these preparations are additionally approved for carcinoma of the prostate.

Product Name	Aminophenazone	
C.A.S. number	58-15-1	
Scientific and common names, and synonyms		
ANTIPYRINE AMINOPYRINE AMIDOPYRINE-PYRAMIDON AMIDOPYRINE AMIDAZOFEN DIMETHYLAMINOPHENAZONE DIMETHYLAMINOANTIPYRINE		

Legislative or regulation action

Product Name **Aminophenazone**

C.A.S. number **58-15-1**

Scientific and common names, and synonyms

4-DIMETHYLAMINO-2,3-DIMETHYL-1-PHENYL-3-PYRAZOLIN-5-ONE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
AUS	1965	Importation has been prohibited because of the potential hazard of bone marrow depression and fatal agranulocytosis. (Reference: (AUDEC) Report of the Australian Drug Evaluation Committee, No. 90, ,)
FIN	1976	This ingredient was removed from non-prescription drugs owing to the potential hazard of bone marrow depression and agranulocytosis.
CHE	1977	Because of the potential to produce carcinogenic nitrosamines, this substance has been withdrawn from all analgesic/antipyretic preparations. Two major international manufacturers of such preparations voluntarily decided to remove this substance from their products.
DEU	1977	Because of the potential to produce carcinogenic nitrosamines, this substance has been withdrawn from all analgesic/antipyretic preparations. Two major international manufacturers of such preparations voluntarily decided to remove this substance from their products.
USA	Nov 1977	The regulation providing for marketing of aminophenazone was revoked. However this drug is not known to have been marketed in the United States. (Reference: (FEREAC) Federal Register, 42, 53954, Oct 1977)
JPN	Dec 1977	Because of the potential to produce carcinogenic nitrosamines, this substance has been withdrawn from all oral preparations and subsequently from all other preparations.
ITA	1978	Products for oral use were withdrawn from the market due to the risk of formation of carcinogenic nitrosocompounds. Injectable products require warnings about the risk of hypersensitivity reactions.
KOR	1978	In view of its propensity to form a potentially carcinogenic n-nitroso compound, this product has been withdrawn from use.
AUT	Mar 1978	In view of its propensity to form a potentially carcinogenic n-nitroso compound, pharmaceutical products containing aminophenazone and intended for oral use have been withdrawn.
THA	Nov 1978	Registration permit has been revoked for pharmaceutical preparations containing this ingredient.
IRL	1979	Products containing aminophenazone have been withdrawn.
DNK	Apr 1979	At the recommendation of the Registration Board in Denmark, preparations containing aminophenazone and noramidopyrine for systemic use were withdrawn. This decision was based on the potential danger of bone-marrow depression and fatal agranulocytosis, suspected carcinogenic hazards and the availability of alternative products. (Reference: (UGLAAD) Ugeskrift for Laeger, 141, 873, Mar 1979)
KWT	Dec 1979	Banned for use and/or sale because of its dangerous side effects, mainly agranulocytosis. (Reference: (KTMD) Ministerial Decree, 556, , 1978)
YEM	Jan 1980	The Supreme Board of Drugs has called for the withdrawal of all preparations containing aminophenazone.
GRC	Oct 1980	The Ministry of Health and Welfare has withdrawn this product from domestic use. (Reference: (GRAGA) Ministry of Health Decision, 12946, , Dec 1980)
ARE	9 Jun 1981	Pharmaceutical preparations containing aminophenazone are banned. (Reference: (UAEMD) Ministry of Health Decree, No.694, , 1981)
ROM	1982	The Minister of Health has recommended the gradual reduction in the use of this product until it has been phased out of use completely.

Legislative or regulation action

Product Name		Aminophenazone
C.A.S. number		58-15-1
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
SDN	1982	The Ministry of Health no longer allows registration of preparations containing aminophenazone.
FRA	25 Jan 1982	The Committee for Registration of Medicines has recommended that all preparations containing aminophenazone be withdrawn from the market by 1 January 1982.
TUR	Feb 1982	After review of published information about this product, the Ministry of Health has decided on its withdrawal and recommends changing the composition of all products containing aminophenazone for systemic use, due to the potential danger of bone marrow depression and fatal agranulocytosis and the availability of alternative products. Export of this product is prohibited.
MUS	9 Mar 1982	Under the Pharmacy and Poisons (Prohibitions of Harmful Drugs) Regulations, this drug is deemed "harmful" by the Ministry of Health and is prohibited for import, manufacture, storage, distribution, sale, possession, use, export or other transaction. (Reference: (MPPHD) Pharmacy & Poisons (Prohibitions of Harmful Drugs) Regulations, , , Mar 1982)
IND	1983	Prohibited for manufacture, sale and import due to questionable therapeutic value; evidence of adverse effects on bone marrow as well as suspected carcinogenic hazards; and the availability of safer analgesic drugs. (Reference: (GAZIE) The Gazette of India: Extraordinary, II-3i, , 23 July 1986)
NPL	1983	All preparations containing aminophenazone have been banned from use.
PHL	Oct 1983	Preparations containing aminophenazone are no longer allowed for use/sale due to serious side effects such as bone marrow depression and agranulocytosis.
RWA	1 Oct 1983	Preparations containing aminophenazone have been banned following established evidence of the adverse effects of these preparations.
CHL	1984	Products containing aminophenazone have been withdrawn from the market in view of its carcinogenic potential.
ETH	1984	Withdrawn due to the potential to produce carcinogenic nitrosamines.
HKG	1 Jan 1984	The Pharmacy and Poisons Committee no longer allows the registration, sale or distribution of products containing aminophenazone.
BRA	23 May 1986	Registration of pharmaceutical products containing aminophenazone has been withdrawn and further production prohibited. (Reference: (BRAPT) Portaria do Servico Publico Federal, 9, , May 1986)
MYS	Nov 1986	All products containing aminophenazone have been withdrawn. (Reference: (MYSDC) Malaysian Drug Control Authority, No.4, , Nov 1986)
OMN	Mar 1987	Import and marketing of products containing aminophenazone were prohibited. (Reference: (OMNCR) Circular, 11/87, , Mar 1987)
BEL	1 Jan 1988	Preparations containing aminophenazone have been placed in List IV of the Arr [^] t, du R,gent of 2 June 1946 and as such can be administered only on prescription. They must be kept in a poisons cabinet and carry the skull and cross-bones label. (Reference: (BELAR) Arr [^] t ^e Royal, , , June 1987)
GHA	01 Sep 1989	Products containing aminophenazone or its derivatives have been banned. (Reference: (GHAPDR) Pharmacy and Drugs (Banned Drugs) Regulations, Legislative Instruments, 1484, , 1989)
BHR		Preparations containing aminophenazone have been withdrawn.
GBR		Products containing aminophenazone have been withdrawn from the market due to the risk of agranulocytosis.

Legislative or regulation action

Product Name	Aminophenazone	
C.A.S. number	58-15-1	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
SGP		Aminophenazone and related salts have been banned for importation.
SWE		Products containing aminophenazone have been withdrawn from the market due to the risk of agranulocytosis.
VEN		Withdrawn from the market due to its carcinogenic potential.
<p>WHO Comment : Aminophenazone, a pyrazolone derivative, has been used as an antiinflammatory and analgesic agent for over a century. Its use has been associated with cases of bone marrow depression and agranulocytosis and more recently it has been claimed to have a carcinogenic potential. Products containing aminophenazone have been formally withdrawn in many countries and marketing has been voluntarily suspended in others. Elsewhere, however, proprietary preparations containing this ingredient may remain available.</p> <p>(Reference: (WHODI) WHO Drug Information, 3, 9, 1977)</p>		

Product Name	Aminophylline	
C.A.S. number	317-34-0	
Scientific and common names, and synonyms	AMINOPHYLLINUM EUPHYLLINUM ETHYLENEDIAMINE METAPHYLLIN THEOPHYLLINE THEOPHYLLAMINUM	

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
NLD	May 1992	<p>The Medicines Evaluation Board in The Netherlands has decided that tablet and suppository formulations of pharmaceutical products containing aminophylline should no longer be marketed. Absorption rate from these formulations is slow and unpredictable, bioavailability of the suppository varies widely and the therapeutic range is narrow.</p> <p>(Reference: (GENMB) Geneesmiddelenbulletin, 25(5), 27, May 1992)</p> <p>WHO Comment : Aminophylline, the ethylenediamine salt of theophylline, was introduced many years ago as a treatment for asthma and is listed in the 8th WHO Model List of Essential Drugs. It has been recognized for some 10 years that aminophylline preparations are not interchangeable because bioavailability can vary considerably. The resulting variability in drug absorption can lead to adverse effects including irritation of the mucosa. Allergic reaction can also be an adverse effect of aminophylline. Theophylline functions similarly but is considered less of an irritant.</p>

Product Name	Aminorex	
C.A.S. number	2207-50-3	
Scientific and common names, and synonyms	AMINOXAPHEN 2-OXAZOLAMINE, 4,5-DIHYDRO-5-PHENYL- 2-AMINO-5-PHENYL-2-OXAZOLINE	

Legislative or regulation action

Product Name	Aminorex	
C.A.S. number	2207-50-3	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	1967	The Ministry of Health withdrew preparations containing aminorex, cloforex and chlorphentermine as a precautionary measure pending scientific evidence of a relationship between their use and the development of pulmonary hypertension.
VEN		Banned for use and/or sale.
WHO Comment : Aminorex, an anorexic agent, was introduced over twenty years ago for the treatment of obesity. Between 1967 and 1971 its use was associated with cases of pulmonary hypertension which led to its withdrawal in the Federal Republic of Germany. WHO has no information to suggest that this drug remains commercially available.		

Product Name	Amiprilose	
C.A.S. number	56824-20-5	
Scientific and common names, and synonyms		
?-D-GLUCOFURANOSE, 3-0-[3-(DIMETHYLAMINO)PROPYL]-1,2-0-(1-METHYLETHYLIDENE)-, HYDROCHLORIDE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
USA	27 Jan 1994	The Arthritis Advisory Committee of the FDA has recommended against approval of the anti-inflammatory agent, amiprilose, for the treatment of rheumatoid arthritis because adequate evidence of effectiveness and safety had not been provided. (Reference: (FDATP) Food and Drug Administration Talk Paper, T94-7, , 27 Jan 1994)

Product Name	Amitriptyline	
C.A.S. number	50-48-6	
Scientific and common names, and synonyms		
3-(10,11-DIHYDRO-5H-DIBENZO[A,D]CYCLOHEPTEN-5-YLIDENE)PROPYLDIMETHYLAMINE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
NOR	1992	The Medicines Control Authority has decided that the 50 mg tablet formulation of amitriptyline may be prescribed only in hospitals and specialized clinics because of the toxic potential of these products and the risk of overdosage and suicide with the high dose formula. (Reference: (NNSLM) Nytt fra Statens Legemiddelkontroll, 1, 9, 1992)
WHO Comment : Amitriptyline, a tricyclic antidepressant was introduced in 1961 for the management of endogenous depression and is listed in the 8th WHO Model List of Essential Drugs. Much of the adverse effects are caused by its antimuscarinic actions. These include dry mouth, cardiac arrhythmias, central nervous system disturbances, blood disorders and risk of suicide. The risk of suicide and dangers related to overdosage led the Norwegian Medicines Control Authority to put the higher strength formulation under prescribing restriction in 1992. The risk of death following overdosage is apparently higher for products containing tricyclic compounds as compared with nontricyclic products.		

Product Name	Amobarbital	
Legislative or regulation action		

C.A.S. number	57-43-2	
Scientific and common names, and synonyms	5-ETHYL-5-ISOPENTYLBARBITURIC ACID AMYLBARBITONE 2,4,6-(1H,3H,5H)-PYRIMIDINETRIONE, 5-ETHYL-5-(3-METHYL-BUTYL)-	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
SWE	Jul 1985	Withdrawn following discussions between the manufacturer and the National Board of Health and Welfare. Fatal intoxications and abuse are associated with use of preparations containing amobarbital.
NZL	1990	In agreement with the Department of Health, products containing amobarbital and amobarbital sodium have been withdrawn by the manufacturer. (Reference: (NZCSL) Clinical Services Letter, Department of Health, 258, , 16 July 1990) WHO Comment : Amobarbital is an intermediate-acting barbiturate which is controlled under Schedule III of the 1971 Convention on Psychotropic Substances. See WHO comment for barbiturates. (Reference: (UNCPS3) United Nations Convention on Psychotropic Substances (III), , , 1971)
Product Name		
	Amodiaquine	
C.A.S. number	86-42-0	
Scientific and common names, and synonyms	PHENOL, 4-((7-CHLORO-4-QUINOLINYL)AMINO)-2-((DIETHYLAMINO)METHYL)- 4-((7-CHLORO-4-QUINOLYL)AMINO)-ALPHA-(DIETHYLAMINO)-O-CRESOL	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
@WD	Jul 1986	Having regard to cases of agranulocytosis associated with prophylactic use of amodiaquine, the major manufacturer has removed malaria prophylaxis from the data sheet worldwide. WHO Comment : Amodiaquine, an antimalarial agent related to chloroquine, was introduced over 40 years ago for the treatment and prophylaxis of malaria. The drug was voluntarily withdrawn in the United Kingdom in 1975 for commercial reasons but was subsequently reintroduced in 1985 to meet the medical demand for an antimalarial drug to deal with the rapid spread of chloroquine-resistant falciparum malaria in Asia and Africa. By 1986 a significant number of cases of agranulocytosis associated with prophylactic use, some of which were fatal, had been reported there and it has been estimated that the frequency of this risk is of the order of 1:2,000. Although most cases occurred when amodiaquine had been used in combination with other antimalarials, the major manufacturer decided to withdraw the prophylactic indication worldwide following discussions with experts. Preparations remain available for the treatment of acute attacks of malaria which involves only a short period of exposure to the drug. (Reference: (WHODI) WHO Drug Information, 1, 5, 1987)
Product Name		
	Amyl nitrite	
Scientific and common names, and synonyms	MIXTURE OF NITROUS ACID, 2-METHYLBUTYL ESTER AND NITROUS ACID, 3-METHYLBUTYL ESTER	
Legislative or regulative action		

Legislative or regulation action

Product Name	Amyl nitrite	
Country	Effective Date	Description of action taken Grounds for decision
GBR	Aug 1996	The Medicines Control Agency has proposed that amyl nitrite should become a prescription-only medicine in view of its misuse as a stimulant. (Reference: (GBRPHJ) The Pharmaceutical Journal, Vol.257, p.785, 10 Aug 1996)

Product Name	Anabolic steroids	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
THA	Oct 1989	Products containing anabolic steroids indicated for increasing appetite in children have been withdrawn, due to the risks of undesirable androgenic effects. All products containing anabolic steroids have been subjected to prescription control. (Reference: (THAMH) Ministry of Public Health, , , 15 Apr 1991)
CAN	26 Jun 1992	Products containing androgenic-anabolic steroids are classified in Schedule G of the Food and Drugs Act and the Schedule to the Food and Drugs Regulations with regard to the high prevalence of their abuse by athletes and high school children. They are now subject to import/export permits, licensing and prescription control. (Reference: (CANHW) Canada Health and Welfare, , , 13 Oct 1992)
<p>WHO Comment : Anabolic steroids were formerly used to increase weight in patients suffering from emaciation or debilitating diseases but have not proved totally successful. They are also used in the treatment of certain aplastic anaemias, breast cancer and in the prevention of osteoporosis. They have been subject to much abuse in athletes and malnourished children to increase body weight. Misuse in prepubertal children has been associated with undesirable effects, including precocious sexual development in males and virilization in females, which have led the Thai agency to withdraw products containing anabolic steroids indicated for increasing appetite in children.</p>		

Product Name	Anagestone acetate	
C.A.S. number	3137-73-3	
Scientific and common names, and synonyms	PREGN-4-EN-20-ONE, 17-(ACETYLOXY)-6-METHYL-, (6ALPHA) 17-HYDROXY-6ALPHA-METHYL-PREGN-4EN-20-ONE-ACETATE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	1969	Following reports of breast tumours in dogs receiving anagestone acetate in combination with mestranol, the manufacturer withdrew preparations containing these drugs.
AUT	23 May 1969	Following reports of breast tumours in dogs receiving anagestone acetate in combination with mestranol, the manufacturer withdrew preparations containing these drugs.
KWT	1 Apr 1970	Importation and marketing of preparations containing anagestone acetate is prohibited.
<p>WHO Comment : Anagestone acetate, a synthetic progestogen, was introduced in 1968 as a component in oral contraceptive preparations. In 1969, it was shown to be associated with an increased risk of mammary tumours in dogs which led the United States Food and Drug Administration to order the termination of its use in all clinical trials. Subsequently the manufacturer withdrew preparations containing anagestone acetate, ultimately on a worldwide basis.</p>		

Legislative or regulation action

Product Name Anagestone acetate

C.A.S. number 3137-73-3

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
---------	----------------	---

Product Name Androgens

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
---------	----------------	---

USA	Sep 1989	<p>Products containing androgens may no longer be indicated for suppression of lactation and prevention of breast engorgement in mothers who elect not to breastfeed. (Reference: (FDATP) Food and Drug Administration Talk Paper, T89-56, , 27 Sep 1989)</p> <p>WHO Comment : Androgens have been used for the prevention of postpartum breast pain and engorgement. However, because of the risk of rebound effect and since only 10% of women benefit therapeutically from such intervention, the United States Food and Drug Administration has requested manufacturers to stop labeling preparations containing androgens for this indication. The World Health Organization is not aware of similar action having been taken elsewhere.</p>
------------	-----------------	--

Product Name Antihistamine (topical)

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
---------	----------------	---

MYS	Nov 1986	<p>Antihistamines intended for local use were not approved. (Reference: (MYSDC) Malaysian Drug Control Authority, 1985-1987, ,)</p>
LKA	1 Jan 1992	<p>The Ministry of Health withdrew from sale cream formulations of antihistamines. It considers that antihistamine cream is of no value in hypersensitive skin rashes and that the preparations can themselves induce such rashes. (Reference: (LKADIB) Drug Information Bulletin, University of Peradeniya and Ministry of Health, 4(1), , 1992)</p> <p>WHO Comment : Antihistamines have been used for many years as a treatment for hypersensitive reactions. The topical application of antihistamines is, however, associated with an unacceptable incidence of skin irritation and hypersensitivity reactions.</p>

Product Name Aphrodisiac drugs

Scientific and common names, and synonyms

CANTHARIDES
ESTROGENS
METHYLTESTOSTERONE
NUX VOMICA
STRYCHNINE
TESTOSTERONE
YOHIMBINE

Legislative or regulation action

Product Name **Aphrodisiac drugs**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
USA	8 Jan 1990	All nonprescription products claiming to have aphrodisiac effects have been banned, on the grounds that they are unsafe and of doubtful effectiveness. Among the ingredients contained in these products are: cantharides, estrogens, methyltestosterone, nux vomica, strychnine, testosterone and yohimbine. (Reference: (FEREAC) Federal Register, 54(129), 28780, 1989) (Reference: (FDATP) Food and Drug Administration Talk Paper, T89-42, , 07 July 1989)

Product Name **Aprobarbital**

C.A.S. number **77-02-1**

Scientific and common names, and synonyms

5-ALLYL-5-ISOPROPYLBARBITURIC ACID
APROBARBITONE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
SWE	Jul 1985	Withdrawn following discussions between the manufacturer and the National Board of Health and Welfare. Fatal intoxications and abuse are associated with use of preparations containing aprobarbital. WHO Comment : Aprobarbital is an intermediate-acting barbiturate. See WHO comment for barbiturates.

Product Name **Aristolochia**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
GBR	Jul 1999	The Medicines Control Agency has banned the import, sale and supply of medicinal products containing the Chinese herbal medicine Aristolochia. This was on account of end-stage renal failure associated with the use of this product. (Reference: (GBRSIN) Statutory Instrument, The Medicines (Aristolochia) (Temporary Prohibition) Order 1999, , , 28 Oct 1999)

Product Name **Aristolochic acid**

C.A.S. number **313-67-7**

Scientific and common names, and synonyms

8-METHOXY-6-NITROPHENANTHRO(3,4-D)-1,3-DIOXOLE-5-CARBOXYLIC ACID
ARISTOLOCHINE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
DEU	1981	The Federal Health Office withdrew all preparations containing aristolochic acid from the national market following demonstration of a carcinogenic potential in a three-month toxicity study in rats. The Federal Health Office considers that aristolochic acid is a

Legislative or regulation action

Country	Effective Date	Description of action taken Grounds for decision
<p>Product Name Aristolochic acid</p> <p>C.A.S. number 313-67-7</p> <p>Legislative or regulative action</p>		
		<p>particularly potent carcinogen having regard to the unusually short period of exposure required for induction; the variety of tissues involved; the marked dose-effect relationship and the rapid progression of malignant changes after suspension of dosage. The regulatory decision relates not only to branded drugs containing aristolochic acid but to the sale of herbal preparations or extracts prepared from plants of the aristolochiaceae family. Only homeopathic preparations prepared to a dilution of at least 1:100,000,000,000 were exempted.</p>
AUT	Aug 1981	The Federal Ministry of Health and Environmental Protection has instructed pharmacists that, having regard to their apparent risks, preparations containing aristolochic acid have no justifiable use.
EGY	1982	Products containing aristolochic acid were withdrawn following demonstration of carcinogenicity in rats.
USA	Apr 2001	The FDA has cautioned consumers against consuming any dietary supplement or traditional medicine containing aristolochic acid. (Reference: (USAMDR) Media Release, , , 11 Apr 2001)
FRA	Jul 2001	All homeopathic preparations containing Aristolochia brasiliensis and homeopathic preparations containing products belonging to Aristolochiaceae or related plant families have been withdrawn due to risks of nephrotoxicity and carcinogenicity associated with aristolochic acid. (Reference: (FRACW) Communication to WHO, , , 05 Oct 2001)
OMN	Jul 2001	Prohibition of import and marketing in view of kidney toxicity and urinary tract cancer associated with aristolochic acid. (Reference: (OMNCR) Circular, 25/2001, , 02 Oct 2001)
CAN	Oct 2001	Health Canada has issued a Customs Alert to prevent the sale and import of products containing aristolochic acid. Manufacturers, retailers and importers have been requested to withdraw from the market all existing products containing aristolochia and aristolochic acid. (Reference: (CANWHC) Warnings/Advisories, 20011005, 20020516, 24 Aug 2001)
AUS	Dec 2001	A traditional product named Longdan Qiegan Wan (Wetness Heat Pill) has been removed from the Australian Register of Therapeutic Goods since it contains aristolochic known to cause kidney damage and urinary tract cancer. (Reference: (AUSMDR) Media Release, , , 07 Dec 2001)
VEN		Not approved for use and/or sale.
<p>WHO Comment : Extracts of aristolochiaceae have traditionally been used as a bitter for which a broad range of therapeutic effects has been claimed. Aristolochic acid is claimed to promote phagocytosis and to have immunostimulant activity. However, in 1981, a three-month toxicity study in rats revealed the carcinogenic potential of aristolochic acid and preparations containing this substance have since been withdrawn in several countries.</p>		

Country	Effective Date	Description of action taken Grounds for decision
<p>Product Name Arsenic-based compounds</p> <p>Legislative or regulative action</p>		
AUT	Oct 1969	All tonics, parenteral preparations, oral asthma remedies and vaginal tablets containing arsenic have been withdrawn in the light of the carcinogenic potential of arsenic-

Legislative or regulation action

Product Name		Arsenic-based compounds	
Legislative or regulative action			
Country	Effective Date	Description of action taken Grounds for decision	
		containing compounds.	
PHL	Mar 1976	Banned in any form for use in pharmaceuticals.	
ESP	1 Oct 1983	Preparations containing inorganic arsenicals have been withdrawn. (Reference: (ESPMC) Programa Selectivo de Revisión de Medicamentos, (1), , Sep 1983)	
ITA		These substances in tonics and reconstituents have been removed from the market owing to an unfavourable risk/benefit ratio. WHO Comment : Arsenic-based compounds, which were used over 2000 years ago as both therapeutic agents and poisons, became the mainstay of chemotherapy earlier this century. Although such compounds have been largely superseded by safer and more effective alternatives, they remain important in the treatment of certain tropical diseases.	
Product Name		Astemizole	
C.A.S. number		68844-77-9	
Scientific and common names, and synonyms			
1H-BENZIMIDAZOL-2-AMINE, 1[[4-FLUOROPHENYL]METHYL]-N-[1-[2-(4-METHOXYPHENYL)ETHYL]-4-PIPERIDINYL]-1[[4-FLUOROPHENYL]METHYL]-N-[1-[2-(4-METHOXYPHENYL)ETHYL]-4-PIPERIDINYL]-1H-BENZIMIDAZOL-2-AMINE 1-(P-FLUOROBENZYL)-2-[[1-(P-METHOXYPHENETHYL)-4-PIPERIDYL]AMINO]BENZIMIDAZOLE			
Legislative or regulative action			
Country	Effective Date	Description of action taken Grounds for decision	
NOR	1987	The medicines control authority has refused registration of astemizole because its prolonged half-life renders appropriate dosage difficult and the possibility of hepatic toxicity and adverse immunologically-mediated effects have not been adequately excluded. (Reference: (NNSLM) Nytt fra Statens Legemiddelkontroll, 4, 4, 1987)	
NZL	Oct 1996	Astemizole has been reclassified to Restricted Medicine (an OTC classification, but may only be sold personally by a pharmacist). (Reference: (NZLPU) Prescriber Update, No.13, , Oct 1996)	
ARG	1997	Product information and labelling of pharmaceutical products containing the histamine H-antagonists astemizole and terfenadine have to include a warning ¹ concerning prolongation of the QT interval and ventricular arrhythmias. (Reference: (ARGBO) Boletín oficial, No.28.616, 1535/97,)	
GBR	1998	Astemizole has been reclassified to Prescription only Medicine as a result of new data on interactions from postmarketing surveillance studies. These data highlight an increased risk of QT prolongation with concomitant administration of oral or parenteral formulations of azole antifungals, macrolide antibiotics except azithromycin, selective serotonin reuptake inhibitors, HIV protease inhibitors and mibefradil (now withdrawn worldwide). In addition, astemizole is contraindicated for use in patients with hepatic dysfunction. (Reference: (GBRPHJ) The Pharmaceutical Journal, 261, p.9, 04 July 1998)	
PHL	1998	The Department of Health Bureau of Food and Drugs have noted the voluntary withdrawal by the sponsoring company of the antihistamine, astemizole due to its association with severe cardiac adverse events when used inappropriately with contraindicated drugs. (Reference: (PHLCTW) Communication to WHO, , , 15 Aug 2000)	

Legislative or regulation action

Product Name		Astemizole	
C.A.S. number		68844-77-9	
Legislative or regulatory action			
Country	Effective Date	Description of action taken Grounds for decision	
USA	1999	Janssen, the manufacturer of the histamine H1-receptor antagonist, astemizole, (HismanalR) has announced that it is voluntarily withdrawing the 10-mg formulation from the market. Since the drug's approval in 1988, new adverse reaction data has necessitated a series of labelling changes and warnings. In the light of the choices of other prescription antihistamines now available and the overall risk benefit profile of this drug, the Food and Drug Administration supports the decision of the company to withdraw the product. (Reference: (FDATP) Food and Drug Administration Talk Paper, T99-29, , 21 June 1999)	
ZAF	1999	The South African Medicines Control Council has withdrawn products containing astemizole because of the potential for serious drug interactions. (Reference: (ZAFPS) Information from the Pharmaceutical Services, , ,)	
ARE	Jun 1999	The Ministry of Health has banned the sale of astemizole with effect from 23 June 1999 on account of increased risk of QT prolongation with concomitant administration of oral or parenteral formulations of azole antifungals, macrolide antibiotics except azithromycin, selective serotonin reuptake inhibitors and HIV protease inhibitors. (Reference: (UAECW) Communication to WHO, , , 10 July 2000)	
MUS	Jun 1999	Astemizole was withdrawn from the market following reports of adverse drug reactions published by the FDA and the decision of Janssen Pharmaceutica to remove the drug in the USA. (Reference: (MUSMHQ) Letter to WHO, , , 27 Dec 2000)	
BDS	Jul 1999	The manufacturer withdrew astemizole worldwide because of serious adverse cardiovascular reactions. (Reference: (BDSOL) Official letter to Regulatory Agencies, , , 01 July 1999)	
URT	2 Jul 1999	The Pharmacy Board of the Ministry of Health, in the United Republic of Tanzania has withdrawn astemizole from the market. (Reference: (URTMH) Communication to WHO, , , 20 Nov 2000)	
ARM	Jul 2000	Astemizole has been voluntarily withdrawn on the basis of prolongation of the QT-interval and ventricular arrhythmias. (Reference: (ARMCW) Communication to WHO, , , 09 Aug 2000)	
BRA	Jun 2001	Registration cancelled due to several adverse reactions. (Reference: (BRARES) Resolucao n., 526/ANVISA, , 06 Aug 2001)	
ESP	08 Apr 2003	The Spanish Medicines Agency has withdrawn the marketing authorization for 10 medicinal products containing astemizole due to the potential of these products to produce life-threatening ventricular ar-rhythmias. (Reference: (ESPSMA) Communication to WHO, , , 08 Apr 2003)	
ARG	19 Aug 2003	The Food, Drug and Medical Devices agency in Argentina, ANMAT, has withdrawn all medicinal products containing astemizole since these products have the potential to cause life-threatening ventricular arrhythmias. (Reference: (ARGFDM) Communication from ANMAT, , , 19 Aug 2003)	
SGP		The National Pharmaceutical Administration in the Ministry of Health has banned astemizole since it has been associated with adverse drug reactions including irregular heart rhythms and severe allergic reactions if taken at higher than recommended doses or in conjunction with some other drugs including antihypertensives and anti-asthmatics. (Reference: (SGPCW) Communication to WHO, , , 02 Aug 2000)	
WHO Comment : The first clinically interesting histamine H-antagonists were1 introduced in the late forties and early fifties. Several histamine H-antagonists1 have a similar cardiac effect to that seen with astemizole and terfenadine. Serious cardiovascular adverse reactions have been reported when used concomitantly with imidazole antifungals and macrolide antibiotics. See also under terfenadine.			

Legislative or regulation action

Product Name	Astemizole	
C.A.S. number	68844-77-9	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
<hr/>		
Product Name	Azapropazone	
C.A.S. number	13539-59-8	
Scientific and common names, and synonyms		
5-DIMETHYLAMINO-9-METHYL-2-PROPYL-1H-PYRAZOLO(1,2-A)(1,2,4)BENZOTRIAZINE-1, 3(2H)-DIONE APAZONE 1H-PYRAZOLO(1,2-A)(1,2,4)BENZOTRIAZINE-1,3(2H)-DIONE, 5-(DIMETHYLAMINO) -9-METHYL-2-PROPYL-		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
<hr/>		
DEU	1985	Indications are restricted to exacerbations of inflammatory degenerative rheumatism, soft tissue rheumatism and pain, post-traumatic swelling or inflammation. Preparations are contraindicated in children under six years of age.
OMN	Sep 1986	The Ministry of Health has prohibited the import of preparations containing azapropazone except those intended for topical use.
BEL	1 Jan 1988	Preparations containing azapropazone have been placed in List IV of the 'Arrêt, du R,gent' of 2 June 1946 and as such can be administered only on prescription. They must be kept in a poisons cabinet and carry the skull and cross-bones label. (Reference: (BELAR) Arrêté Royal, , , June 1987)
AUT		Indications restricted to exacerbations of gout and other arthritic conditions. Treatment should not exceed seven days and doctors are advised not to prescribe this drug to children under 14 years of age or elderly patients. (Reference: (WIMAM) Wichtige Mitteilung ueber Arzneimittel, (1), , 1984)
WHO Comment : Azapropazone, which has anti-inflammatory, analgesic and antipyretic activity, was introduced in 1970 for the treatment of rheumatic disorders. Although sometimes classified as a pyrazolone derivative, the relationship with this group of compounds has been disputed and classification as a benzotriazine derivative might be preferable. Although, to date, it has not been associated with blood dyscrasias, some regulatory authorities have applied the same rigorous restrictions to its indications as they have applied to pyrazolone derivatives. The World Health Organization was informed that as of December 1987 azapropazone was available in some 27 countries.		
<hr/>		
Product Name	Azaribine	
C.A.S. number	2169-64-6	
Scientific and common names, and synonyms		
AS-TRIAZINE-3,5-(2H,4H)-DIONE, 2-(2',3',5'-TRIACETYL-BETA-D- RIBOFURANOSYL)- TRIACTYL AZAURIDINE 1,2,4-TRIAZINE-3,5(2H,4H)-DIONE, 2-(2,3,5-TRI-O-ACETYL-BETA- RIBOFURANOSYL)- 2-BETA-D-RIBOFURANOSYL-AS-TRIAZINE-3, -5(2H,4H)-DIONE 2',3',5',- TRIACETATE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
<hr/>		
USA	Aug 1976	This antineoplastic agent, which was indicated only for severe, recalcitrant, disabling arthritis, was withdrawn from the market following reports of several serious

Legislative or regulation action

Product Name	Azaribine	
C.A.S. number	2169-64-6	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
THA	Feb 1977	thromboembolic and thrombotic reactions. Several of these lesions occurred in relatively unusual arterial sites (including the radial, ulnar, femoral and popliteal arteries) and one death resulted from pulmonary embolism.
MUS	9 Mar 1982	Products containing this ingredient have been banned. Under the Pharmacy and Poisons (Prohibitions of Harmful Drugs) Regulations, this drug is deemed "harmful" by the Ministry of Health and is prohibited for import, manufacture, storage, distribution, sale, possession, use, export or other transaction. (Reference: (MPPHD) Pharmacy & Poisons (Prohibitions of Harmful Drugs) Regulations, , , Mar 1982)
SAU		Withdrawn from the market following reports of adverse effects.
VEN		Not approved for use and/or sale.
WHO Comment : Azaribine, an antineoplastic agent, was introduced in 1975 for the treatment of severe, recalcitrant, disabling arthritis. Following reports of thromboembolic and thrombotic reactions, the drug was withdrawn in the USA in 1976. The causal relationship between azaribine and these events has been questioned and the drug remains available in the USA for investigational purposes.		

Product Name	Barbital	
C.A.S. number	57-44-3	
Scientific and common names, and synonyms		
5,5-DIETHYLBARBITURIC ACID		
BARBITONE		
DIETHYLMALONYLUREA		
DIEMALUM		
MALONAL		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
ITA		This substance for use as a sedative has been removed from the market owing to an unfavourable risk-benefit ratio and the lack of substantial evidence of efficacy. WHO Comment : Barbital is a long-acting barbiturate which is controlled under Schedule IV of the 1971 Convention on Psychotropic Substances. See WHO comment for barbiturates. (Reference: (UNCPS4) United Nations Convention on Psychotropic Substances (IV), , , 1971)

Product Name	Beclobrate	
C.A.S. number	55937-99-0	
Scientific and common names, and synonyms		
ETHYL(+)-2-[[ALPHA-(P-CHLOROPHENYL)-P-TOLYL]OXY]-2-METHYLBUTYRATE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision

Legislative or regulation action

Product Name	Beclobrate	
C.A.S. number	55937-99-0	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
CHE	1990	Having regard to two reports of fatal hepatitis, the marketing authorization of products containing beclobrate has been withdrawn. (Reference: (CHBCM) Bulletin Mensuel, 8, , 24 Sep 1990) WHO Comment : Beclobrate, an antihyperlipidaemic agent, was introduced into medicine in 1985. Although a causal relationship between the use of the drug and hepatic toxicity has not been established, the Intercantonal Office for the Control of Medicines has withdrawn marketing authorization since safer therapeutic alternatives are available. Beclobrate is not registered elsewhere.
Product Name	Bencyclane	
C.A.S. number	2179-37-5	
Scientific and common names, and synonyms		
3-[(1/BENZYL CYCLOHEPTYL)OXY]-N,N-DIMETHYLPROPYLAMINE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	Feb 1991	In collaboration with the Federal Health Office, the manufacturer amended the approved product information of preparations containing bencyclane to contraindicate their use in epileptic patients; in patients who had sustained head injury within the previous 12 months; and in patients receiving treatment with pentoxifylline, naftidrofuryl, flunarizine or buflomedil. (Reference: (DEUFHO) Communication from Federal Health Office, , , 29 June 1992) WHO Comment : Bencyclane, a vasodilator, was introduced in 1970 for the treatment of peripheral and cerebral vascular disorders. In 1991, its use was contraindicated by the German authorities in patients at risk of epilepsy following reports of convulsions in patients under treatment. Bencyclane is widely registered and the World Health Organization is not aware of restrictive action having been taken elsewhere.
Product Name	Benorilate	
C.A.S. number	5003-48-5	
Scientific and common names, and synonyms		
BENORYLATE 4-ACETAMIDOPHENYL SALICYLATE ACETATE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GBR	Dec 1986	The Committee on Safety of Medicines has advised that preparations containing benorilate should not be administered to children under 12 years of age except on medical advice. (Reference: (GBMIL) Medicines Act Information Letter, No.48, , Oct 1986) WHO Comment : Benorilate is the acetylsalicylic ester of paracetamol. See WHO comment for acetylsalicylic acid.
Product Name	Benoxaprofen	

Legislative or regulation action

C.A.S. number 51234-28-7

Scientific and common names, and synonyms

5-BENZOXAZOLEACETIC ACID, 2-(4-CHLOROPHENYL)-ALPHA-METHYL, (+/-)
(+/-)-2-(P-CHLOROPHENYL)-ALPHA-METHYL-5-BENZOXAZOLEACETIC ACID

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
@WD	Aug 1982	<p>Following action in Denmark and reports from other countries, in particular of hepatic reactions in elderly patients from the United Kingdom, the drug was withdrawn worldwide by the manufacturer. Benoxaprofen had previously been withdrawn in several countries because of serious toxic effects on various organ systems, particularly the gastro-intestinal tract, the liver and bone marrow, in addition to previously known effects on the skin, eyes and nails. Subsequent to this decision, limited clinical trials were abandoned following demonstration of positive findings in carcinogenicity studies in mice.</p> <p>WHO Comment : Benoxaprofen, a nonsteroidal antiinflammatory agent, was introduced in 1980 for the treatment of rheumatic disorders. Following reports of serious adverse effects, some of which were fatal, it was withdrawn in several countries prior to worldwide withdrawal by the manufacturer in 1982.</p>

Product Name Benzarone

C.A.S. number 1477-19-6

Scientific and common names, and synonyms

2-ETHYLBENZOFURAN-3-YL 4-HYDROXYPHENYL KETONE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
DEU	19 Oct 1992	<p>The Federal Health Office suspended the marketing authorization for pharmaceutical products containing benzarone. (Reference: (DEUPD) BGA Pressedienst, , , 20 Oct 1992) (Reference: (DEUFHO) Communication from Federal Health Office, , , 19 Oct 1992)</p> <p>WHO Comment : Benzarone is given by mouth and applied topically for treatment of various vascular peripheral disorders. The decision to suspend the marketing authorization results from several reports of toxic hepatitis, including one fatal case from within Germany. The product remains registered in Italy and France.</p>

Product Name Benzbromarone

C.A.S. number 2004-0-0001

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
PRT	Apr 2003	<p>Suspended due to unfavourable benefit-risk evaluation. (Reference: (PRTRAC) Communication to WHO, , , Apr 2003)</p>
FRA	22 Apr 2003	<p>The hyperuricaemic product benzbromarone (Desuric) has been withdrawn following reports of serious liver damage associated with the product's use. (Reference: (FRAAMP) Press Release, , , 22 Apr 2003)</p>

Product Name Benzoylperoxide

C.A.S. number 94-36-0

Scientific and common names, and synonyms

BENZOYL PEROXIDE

Legislative or regulation action

Product Name	Benzoylperoxide	
C.A.S. number	94-36-0	
Scientific and common names, and synonyms	BENZOIC ACID, PEROXIDE DIBENZOYL PEROXIDE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
USA	Aug 1995	The FDA has proposed additional labelling (warning and directions) for topically applied acne treatment drug products containing benzoyl peroxide. It advises consumers to avoid unnecessary exposure to the sun and to apply a sunscreen when using benzoyl peroxide to treat acne. (Reference: (FEREAC) Federal Register, 60(33) , p. 9545, 1995) WHO Comment : Benzoyl peroxide slowly releases oxygen and hence is bactericidal. It is also keratolytic, antiseborrheic and irritant. It is used in the treatment of acne. Benzoyl peroxide is listed in the WHO Model List of Essential Drugs.
Bibliographical references		
IARC MONOGRAPH, 36, 267, 1985		

Product Name	Benzyl alcohol	
C.A.S. number	100-51-6	
Scientific and common names, and synonyms	ALPHA-TOLUENOL ALPHA-HYDROXYTOLUENE BENZENEMETHANOL BENZENECARBINOL PHENYLMETHYL ALCOHOL PHENYLMETHANOL PHENYLCARBINOL (HYDROXYMETHYL)BENZENE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
ISR	1982	The Ministry of Health has ordered that this preservative be excluded from solutions intended for parenteral infusions (in large volumes). In other parenteral preparations containing this preservative, the following warning should be added to the label: "Caution - not to be used in newly-born or premature infants".
OMN	1982	Prohibited for import or sale as a preservative in water and normal saline intended for injection.
USA	1982	The Food and Drug Administration has advised that benzyl alcohol should not be used as a preservative in drugs or fluids intended for parenteral administration in neonates, following reports of 16 deaths in neonates attributed to the use of 0.9% benzyl alcohol in water and saline used to clear intravascular catheters and to reconstitute drugs. Death followed signs of metabolic acidosis and convulsions. Both blood and urine contained high concentrations of benzoic and hippuric acid.
ITA	1983	The label for products containing this compound advises "Owing to benzyl alcohol presence, do not administer to children less than two years old".
GRC	1984	All preparations containing benzyl alcohol must carry the warning "Its use should be avoided in children under two years of age. Not to be used at all in neonates."

Legislative or regulation action

Product Name	Benzyl alcohol	
C.A.S. number	100-51-6	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU		The contraindications have been extended to include "Not to be used in neonates, particularly in the premature". (Reference: (AFS) Arbetarskyddsstyrelsens Foerfattningssamling, 32, 3, 4332)
THA		The use of pharmaceutical preparations containing benzyl alcohol is severely restricted.
VEN		Subject to restricted use and/or sale.
WHO Comment : Benzyl alcohol has been used as an antimicrobial agent in pharmaceutical preparations for many years. Parenteral administration of preparations containing 0.9% benzyl alcohol resulted in the death of 16 neonates in the USA in the early 1980s. Many countries subsequently warned against using such preparations in neonates. This decision is not applicable to the use of benzyl alcohol as a preservative in other circumstances or to its use in topical preparations and no country has placed a total ban on the compound.		
Product Name	Benzylpenicillin sodium (topical preparations)	
C.A.S. number	69-57-8	
Scientific and common names, and synonyms		
BENZYPENICILLIN		
CRYSTALLINE PENICILLIN G SODIUM		
MONOSODIUM (2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-(2-PHENYLACETAMIDO)-4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLATE		
PENICILLIN G		
PENICILLIN		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
USA	Feb 1972	Topical preparations have been withdrawn from the market and are prohibited for export by the Food and Drug Administration due to the lack of effectiveness of these products and an unfavourable benefit-to-risk ratio. (Reference: (FEREAC) Federal Register, 37, 438, Feb 1972)
ITA	1976	Preparations for rectal and topical use, including those intended for use in the mouth, have been withdrawn from the market owing to the risk of sensitization.
PHL	1976	Penicillin ointment and other penicillin-containing products for topical application have been banned for use/sale due to the risk of sensitization. (Reference: (PHADO) Administrative Order, 238, , 1976)
ETH	1978	Preparations for topical use have been withdrawn following reports of hypersensitivity.
BGD	Jun 1982	Use of all topical preparations was discontinued due to lack of effectiveness and risk of hypersensitivity reactions.
IND	1983	Skin and eye ointments have been prohibited for manufacture and sale for reasons of health risks associated with use and/or questionable therapeutic value. (Reference: (GAZIE) The Gazette of India: Extraordinary, II-3i, , 23 July 1986)
CHL		Pharmaceutical preparations intended for topical use containing penicillin and its derivatives were prohibited. (Reference: (CHLRS) Resolution of the Minister of Health, No. 10154, , Oct 1986)
CYP		All products containing penicillin intended for topical use were withdrawn following a review of published information on hypersensitivity in treated patients.

Legislative or regulation action

Product Name	Benzylpenicillin sodium (topical preparations)	
C.A.S. number	69-57-8	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
ESP		Combination products containing penicillin for topical or rectal use will no longer be considered for registration since topically applied penicillin may evoke serious dermatitis and rectal absorption is insecure, irregular and inadequate.
THA		Ointment containing benzylpenicillin is not approved for use.
VEN		Not approved for use and/or sale.
<p>WHO Comment : Benzylpenicillin sodium, one of the first penicillin derivatives to be used in medicine, was introduced in the early 1940s. Topical preparations intended for use on the skin have been associated with allergic rashes and are in general no longer acceptable. However, topical preparations for specialized use, in particular in the eye and on open wounds, are available in many countries. Injectable preparations of benzylpenicillin are included in the WHO Model List of Essential Drugs.</p> <p>(Reference: (WHTAC1) The Use of Essential Drugs, 2nd Report of the WHO Expert Committee, 722, , 1985)</p>		

Bibliographical references

WHO FOOD ADD., 27, 105, 1991

Product Name	Berberine	
C.A.S. number	2086-83-1	
Scientific and common names, and synonyms		
5,6-DIHYDRO-9,10-DIMETHOXY-BENZO(G)-1,3-BENZODIAXOLO(5,6-A) QUINOLIZINIUM		
7,8,13,13A-TETRAHYDRO-9,10-DIMETHOXY-2,3-METHYLENEDIOXY-BERBERINIUM		
BERBERIN		
BERBERICINE		
UMBELLATIN		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
SGP	Oct 1978	The Ministry of Health announced a prohibition on the importation and sale of preparations containing berberine following reports of jaundice, haemolytic anaemia and kernicterus with brain damage in infants with glucose 6-phosphate dehydrogenase deficiency who were exposed either in utero or post-natally.
VEN		Not approved for use and/or sale.
<p>WHO Comment : Berberine, an alkaloid contained in many plants including Berberis species, remains available in many tropical countries. Both traditional herbal remedies and tablet formulations containing this substance have been used in the treatment of gastrointestinal disease, and injectable preparations have been claimed to be of value in the treatment of cutaneous leishmaniasis. The action taken in Singapore relates to reports of jaundice, haemolytic anaemia and kernicterus with brain damage in infants with G6PD deficiency who were exposed either in utero or post-natally. Preparations for topical application are also available in some countries. These have not been associated with reports of systemic toxicity.</p>		

Product Name	Beta ethoxylacetanilide
C.A.S. number	539-08-2

Legislative or regulation action

Product Name **Beta ethoxylacetanilide**

C.A.S. number **539-08-2**

Scientific and common names, and synonyms

LACTYLPHENETIDINE
LACTIC ACID-P-PHENETIDINE
N-(PARA-ETHOXYPHENYL) LACTAMIDE
N-(4-ETHOXYPHENYL)-2-HYDROXYPROPANAMIDE
P-LACTOPHENETIDINE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
DEU	Mar 1986	Preparations containing beta-ethoxylacetanilide have been withdrawn and will no longer be considered for registration. WHO Comment : Beta-ethoxylacetanilide is an analogue of phenacetin. See WHO comment for phenacetin.

Product Name **Bicalutamide**

C.A.S. number **2004-0-0002**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
CAN	18 Aug 2003	Withdrawn due to reports of accelerated deaths of patients with localized prostate cancer. (Reference: (CANWHC) Warnings/Advisories, , , 18 Aug 2003)
GBR	28 Oct 2003	Withdrawn due to reports of accelerated deaths of patients with localized prostate cancer. (Reference: (GBRCW) Communication, , , 28 Oct 2003)

Product Name **Bismuth salts**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
EGY	1975	Products containing bismuth subgallate were withdrawn due to a possible association with encephalopathy.
JPN	Jun 1975	Bismuth was banned in over-the-counter drugs due to psychoneurotic disorders found with use. In 1981 the indication for bismuth in preparations available only on prescription was restricted to diarrhoea.
GRC	1976	Bismuth subgallate was withdrawn in 1976 and bismuth subnitrate was withdrawn in 1980.
FRA	Sep 1978	All oral proprietary medicinal products containing insoluble bismuth salts were removed provisionally from the market for a period of one year and have subsequently remained suspended on grounds of apparent neuropsychiatric toxicity. Relevant entries have not, however, been deleted from the French Pharmacopoeia and pharmacists remain entitled to compound prescriptions on the order of a doctor.
AUT	31 Dec 1980	Pharmaceutical preparations containing salts or esters of bismuth were withdrawn following reports of encephalopathy associated with their use. Some eye ointments were exempted from this decision.
BGD	1982	Under the provisions of the Drugs (Control) Ordinance, products with bismuth have been banned. This substance is cited as a cause of encephalopathy. (Reference: (BGDCO) The Drugs (Control) Ordinance, , , 1982)

Legislative or regulation action

Product Name		Bismuth salts
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
TUR	1982	After review of published information about this product, the Ministry of Health required manufacturers to remove insoluble bismuth salts from pharmaceutical products intended for oral use, with the exception of colloidal bismuth potassium citrate complex. Export of these products is prohibited.
MUS	9 Mar 1982	Under the Pharmacy and Poisons (Prohibitions of Harmful Drugs) Regulations, this drug is deemed "harmful" by the Ministry of Health and is prohibited for import, manufacture, storage, distribution, sale, possession, use, export or other transaction. (Reference: (MPPHD) Pharmacy & Poisons (Prohibitions of Harmful Drugs) Regulations, , , Mar 1982)
SWE	Sep 1983	Preparations containing bismuth salts are now available on prescription only.
OMN	Apr 1989	Import and marketing of antidiarrhoeal preparations intended for paediatric use containing bismuth salts were prohibited. (Reference: (OMNCR) Circular, 9/89, , Apr 1989)
CUB		The use of bismuth subnitrate in paediatric preparations is prohibited on the recommendation of the National Paediatricians Group.
IND		Prohibited for manufacture and sale for reasons of health risks associated with use and/or questionable therapeutic value. (Reference: (GAZIE) The Gazette of India: Extraordinary, II-3i, , 23 July 1986)
ITA		Insoluble bismuth salts for oral administration carry a label with a warning concerning the advisability of avoiding prolonged use and high dosages. Products with other chemotherapeutic activity (other than anti-luetic) have been withdrawn from the market.
SAU		Bismuth subgallate remains available only for use in suppositories. WHO Comment : Bismuth salts were first introduced into medicine over two centuries ago and have since been used in over-the-counter preparations for the treatment of dyspepsia. In 1972 prolonged intake of high doses of bismuth subgallate was associated with cases of encephalopathy in Australia. Subsequently a similar association involving the subnitrate salt became evident in France. Preparations containing bismuth salts have since either been withdrawn or subjected to restrictive regulatory action in many countries. However, in some countries preparations containing bismuth subsalicylate, which retains a place in the management of dyspepsia, have been exempted from this restriction. Additionally, colloidal bismuth subcitrate is widely used in the treatment of gastritis and peptic ulcer disease. (Reference: (WHODI) WHO Drug Information, 2, 8, 1977)

Product Name		Bismuth subsalicylate
C.A.S. number		14882-27-4
Scientific and common names, and synonyms		(2-HYDROXY-BENZOATO-O)-OXOBISMUTH 2-HYDROXYBENZOIC ACID BISMUTH (3+) SALT1
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
USA	Apr 1994	The Food and Drug Administration proposed to extend to products containing bismuth subsalicylate and all oral and rectal over-the-counter products that contain acetylsalicylic acid (aspirin) or other salicylates the following warning: "Children and teenagers who have or are recovering from chicken pox, flu symptoms or flu should not use this

Legislative or regulation action

Product Name	Bismuth subsalicylate	
C.A.S. number	14882-27-4	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		product. If nausea or fever occur, consult a doctor because these symptoms could be an early sign of Reye's syndrome, a rare but serious illness." (Reference: (FEREAC) Federal Register, 58(201) , p. 54228, 1993)
		WHO Comment : See under Acetylsalicylic acid.
Product Name	Bithionol	
C.A.S. number	97-18-7	
Scientific and common names, and synonyms		
	BIS(2-HYDROXY-3,5-DICHLOROPHENYL)SULFIDE 2,2'-THIOBIS(4,6-DICHLOROPHENOL)	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
USA	Oct 1967	Withdrawn from the market and prohibited for export by the Food and Drug Administration due to photosensitivity and cross-photosensitivity with other chemicals.
JPN	Jul 1971	Banned as an ingredient in cosmetics due to photosensitivity reactions.
		WHO Comment : Bithionol, which has bactericidal and anthelmintic activity, was formerly available in soaps. By the late 1960s use of such preparations had been associated with a risk of photosensitivity reactions and cross-sensitivity with other halogenated disinfectants. This resulted in their withdrawal in the USA. Oral preparations of bithionol remain available for the treatment of paragonimiasis and fascioliasis.
Product Name	Boric acid and borates	
C.A.S. number	10043-35-3	
Scientific and common names, and synonyms		
	BORIC ACID (H3BO3)	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
KWT	30 Mar 1970	Any drug preparation intended for external use and containing boric acid should be labelled with the following warnings: "Only for external use." and "Do not apply to extensive areas of abraded or damaged skin."
ISR	1973	Use of boric acid is prohibited except as a preservative in eyedrops and in dermal preparations in concentrations not higher than 1%.
KOR	1973	The Ministry of Health and Social Affairs has prohibited the manufacture of any baby powder which contains boric acid and sodium borate.
PHL	1973	By Administrative Order No. 195, all products for oral use and products for use in infants and children under three years of age have been prohibited. Products for external use must carry a special warning. These products have been reported to cause certain toxic reactions (disturbances in circulation, profound shock, convulsion) and fatalities with systemic absorption. (Reference: (PHADO) Administrative Order, 195, , 1973)
THA	Oct 1973	Boric acid and borax are prohibited for use in baby powders.

Legislative or regulation action

Product Name **Boric acid and borates**

C.A.S. number **10043-35-3**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
IRL	1981	The Drugs Advisory Board has withdrawn all oral preparations. Some preparations for topical administration remain available but must bear a warning that they should not be administered to infants. (Reference: (IRDAB) National Drugs Advisory Board Annual Report, 12, , 1981)
DNK	1983	Subject to maximum concentration limits of 0.5% for peroral use, 1% for vaginal use and 3% for use in ear, eye or nose.
DEU	Jul 1983	The Federal Health Office has withdrawn the registration of the last remaining preparations containing either boric acid or its salts and esters. Exceptions to this order are made for ophthalmic preparations, mineral waters in which the boron content does not surpass that of ordinary drinking water, and some previously registered products containing phenylmercury dihydrogen borate.
JPN	Jul 1985	The Ministry of Health and Welfare banned boric acid and its salts except for eye application because of the toxicity of boric acid.
MYS	31 Dec 1990	Products containing boric acid or borax for use in the oral cavity, rectum, vagina or on the skin and wounds have been withdrawn, having regard to reports of fatalities among infants and young children following accidental ingestion of these products or as a result of absorption from abraded skin. (Reference: (MYSR) Ministry of Health Press Release, 15, , 28 Feb 1990)
CRI		The Ministry of Public Health has prohibited the production, importation and sale of all products containing sodium borate (borax, sodium tetraborate) and boric acid in their composition, as well as their use as separate ingredients.
GBR		Following evidence that boric acid absorbed from topical preparations was responsible for the death of many healthy infants, the use of boric acid in topical preparations intended for use in infants has been prohibited. (Reference: (CFRUS) Code of Federal Regulations, 21-369.20, 204, 1985)
IND		Preparations for children under three years of age prohibited for manufacture and sale for reasons of health risks associated with use and/or questionable therapeutic value.
ITA		Products for topical use are marketed with the following concentration limitations: not higher than 0.5% for stomatological use and not higher than 3% for any other use.
PER		Prohibited from use in cosmetic powders, due to their serious effects on the liver and kidney; and on the cardiovascular, digestive and nervous systems. Some fatalities have been connected to the use of these substances.
SAU		Use is restricted to ophthalmic preparations only.
USA		Following evidence that boric acid absorbed from topical preparations was responsible for the death of many healthy infants, the use of boric acid in topical preparations intended for use in infants has been prohibited. (Reference: (CFRUS) Code of Federal Regulations, 21-369.20, 204, 1985)
VEN		Subject to restricted use and/or sale.

WHO Comment : Boric acid and some borates were formerly extensively used as disinfectants and antiinflammatory agents. By the late 1960s an association between the death of many infants and application of high concentrations of boric acid contained in topical preparations used in the treatment of napkin rash had been established. This led to the restriction of the use of boric acid in pharmaceutical preparations by many regulatory authorities. In some countries it is now permitted only as an ingredient in ophthalmological preparations.

Product Name **Bovine tissue derived medicines**

Legislative or regulation action

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
IRL	1989	The National Drugs Advisory Board has decided that products containing bovine-derived components will not be approved for marketing unless adequate evidence is provided that there is no potential for infectivity. (Reference: (IRDAB) National Drugs Advisory Board Annual Report, 1989, 28, Dec 1990)
CHE	26 Mar 1991	The Intercantonal Office for the Control of Medicines has prohibited as a part of the precautionary measures, the use of tissue from the high risk organs from cattle for the manufacture of medicines unless the tissues are derived from animals that are younger than six months, come from a country where no cases of bovine spongiform encephalopathy (BSE) have been reported and have not been fed animal material such as meat, bone flour or fat. In addition, the manufacturing process should be capable of removing or reducing any potential for infection with BSE. Products containing only lactose of those that have the bovine material largely removed during manufacture procedure and those that cannot be withdrawn at short notice due to therapeutic importance are excluded from these measures, the latter only for a limited time. (Reference: (CHBCM) Bulletin Mensuel, , , 26 Mar 1991)
FRA	23 Jul 1992	The Directorate of Pharmacy and Medicines of the Ministry of Health and Humanitarian Action has suspended the marketing authorization for medicinal products derived from bovine tissues. (Reference: (FRAMHH) Ministry of Health and Humanitarian Action, , , 23 July 1992) WHO Comment : Bovine tissues are used to make important medicinal products such as heparin, glucagon, insulin and blood factors. In 1986, bovine spongiform encephalopathy (transmitted from scrapie) was diagnosed in the United Kingdom. Restrictions on use of bovine material took into consideration the fact that the prion (sub-viral agent) causing the spongiform encephalopathy appears to be transmissible orally between species. As yet, there is no evidence of any direct causal relationship between scrapie and Creutzfeldt-Jacob disease or any other spongiform encephalopathy of man. Nonetheless, a substantial array of research projects have been funded and in the interim precautionary measures were taken by the regulatory agencies.

Product Name	Bromfenac
C.A.S. number	91714-94-2
Scientific and common names, and synonyms	AHR-10282 SODIUM[2-AMINO-3-(P-BROMOBENZOYL)PHENYL]ACETATE SESQUIHYDRATE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
USA	Jun 1998	Wyeth Ayerst Laboratories have voluntarily withdrawn from the market capsules of bromfenac sodium, a nonsteroidal anti-inflammatory analgesic indicated for the short-term management of acute pain. This action was taken on the basis of reports of severe hepatic failure resulting in four deaths and 8 liver transplants. (Reference: (FEREAC) Federal Register, 64 (44) , p. 10944, 1999)
SAU	Jun 1999	The Ministry of Health has withdrawn from the market products containing bromfenac because of reports of liver failure, sometimes fatal. (Reference: (SAUCW) Notification, , , 20 June 1999)

Product Name	Bromisoval
C.A.S. number	496-67-3

Legislative or regulation action

Product Name **Bromisoval**
C.A.S. number **496-67-3**
Scientific and common names, and synonyms
 BROMYLUM
 BROMVALETONE
 BROMVALERYLUREA
 BROMISOVALERYLUREA
 2-BROMO-3-METHYLBUTYRYLUREA

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
NLD	Jan 1987	On request of the Board for the Evaluation of Medicines the manufacturers have withdrawn all products containing bromisoval having regard to their dependence potential and the risk of subsequent chronic intoxication. WHO Comment : Bromisoval is a monureide sedative of long standing. It remains available in several countries. However, it releases the bromide ion and prolonged usage can result in chronic bromide accumulation and intoxication.

Product Name **Bromocriptine**
C.A.S. number **25614-03-3**
Scientific and common names, and synonyms
 ERGOTAMAN-3',6',18'-TRIONE,2-BROMO-12'-HYDROXY-2'-(1-METHYLETHYL)-5-(2-METHYLPROPYL)-,(5'ALPHA)-2-BROMO-ALPHA-ERGOCRYPTINE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
USA	Sep 1989	Products containing bromocriptine may no longer be indicated for suppression of breast engorgement in mothers who elect not to breastfeed. (Reference: (FDATP) Food and Drug Administration Talk Paper, T89-56, , 27 Sep 1989) WHO Comment : Bromocriptine, a semisynthetic ergot alkaloid derivative and prolactin inhibitor was introduced into medicine in 1976. It is used in the prevention of lactation, but because of the risk of rebound effect and since only 10% of women benefit therapeutically from such intervention, the United States Food and Drug Administration has requested manufacturers to no longer indicate preparations containing bromocriptine for this purpose. The World Health Organization is not aware of similar action having been taken elsewhere.

Product Name **Broxyquinoline (see also halogenated hydroxyquinoline derivatives)**
C.A.S. number **521-74-4**
Scientific and common names, and synonyms
 5,7-DIBROMO-8-QUINOLINOL

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
JPN	Sep 1970	The Ministry of Health and Welfare has prohibited the sale of cloiquinol and broxyquinoline, and preparations containing them. These decisions were taken following reports that cloiquinol might be one of the causes of subacute myelo-optic neuropathy (SMON).

Legislative or regulation action

Product Name Broxyquinoline (see also halogenated hydroxyquinoline derivatives)
C.A.S. number 521-74-4

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
ARE	9 Jun 1981	Pharmaceutical preparations containing broxyquinoline are banned. (Reference: (UAEMD) Ministry of Health Decree, No.694, , 1981)
SAU		Import of this product is prohibited.
VEN		Subject to restricted use and/or sale.

WHO Comment : Broxyquinoline is a halogenated hydroxyquinoline. See entry for halogenated hydroxyquinoline derivatives and WHO comment for clioquinol.

Product Name Bucetin

C.A.S. number 1083-57-4

Scientific and common names, and synonyms
 3-HYDROXY-P-BUTYROPHENETIDIDE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
DEU	1986	Preparations containing bucetin have been withdrawn from the market and will no longer be considered for registration. WHO Comment : Bucetin is an analogue of phenacetin. See WHO comment for phenacetin.

Product Name Bufexamac

C.A.S. number 2438-72-4

Scientific and common names, and synonyms
 2-(P-BUTOXYPHEYL)ACETOHYDROXAMIC ACID

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
FRA	Dec 1990	Because of reports of eczematous reactions, the indications for preparations containing bufexamac intended for topical application were restricted to the relief of pruritus in inflammatory dermatological conditions. These preparations could no longer be used for the treatment of eczema. (Reference: (FRARP) La Revue Prescrire, 11(106), 182, 1991)
DEU	Aug 1991	The approved product information for preparations containing bufexamac was amended to warn against hypersensitivity reactions, including allergic contact dermatitis, generalized skin sensitization, urticaria, and contact eczema. (Reference: (DAZ) Deutsche Apotheker Zeitung, 131(31), VI, 1991) WHO Comment : Bufexamac, an analgesic and anti-inflammatory agent, was introduced in 1974 for the topical treatment of a wide range of dermatoses. The drug is widely marketed and the World Health Organization is not aware of restrictive action having been taken elsewhere.

Product Name Buformin

C.A.S. number 692-13-7

Legislative or regulation action

Product Name	Buformin
C.A.S. number	692-13-7
Scientific and common names, and synonyms	BUTYLFORMIN BUTYLDIGUANIDE BUTYLBIGUANIDE BUTFORMIN BUFORMINE GLYBIGIDUM N-BUTYL-IMIDODICARBONIMIDIC DIAMIDE N-BUTYLDIGUANIDE 1-BUTYLBIGUANIDE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
ITA	1978	Warnings and contraindications have been added to currently marketed products with this ingredient. It has been recommended that dosages lower than 100 mg/day be followed due to the risk of lactic acidosis.
DEU	Mar 1978	Withdrawn from the market because of occurrence of lactic acidosis.
AUT	Sep 1978	In conformity with decisions taken in several other countries, and following reports of occasional fatal cases of lactic acidosis, all products containing phenformin and buformin will be withdrawn. Metformin will remain available for use for limited indications.
BEL	1979	Voluntarily withdrawn from the market by the manufacturer.
IRL	1979	The biguanide hypoglycaemics, phenformin and buformin, were withdrawn from the market in Ireland in 1979 as a result of concern regarding lactic acidosis. Metformin will remain available but doctors are urged to ensure that patients receiving it are kept under regular surveillance. (Reference: (IRDAB) National Drugs Advisory Board Annual Report, 14, , 1979)
VEN		Subject to restricted use and/or sale. WHO Comment : Buformin is an analogue of phenformin. See WHO comment for phenformin. (Reference: (WHODI) WHO Drug Information, 2, 4, 1977)

Product Name	Bumadizone
C.A.S. number	3583-64-0
Scientific and common names, and synonyms	BUTYLMALONIC ACID MONO(1,2-DIPHENYLHYDRAZIDE)

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
DEU	1985	Indications restricted to severe exacerbations of rheumatism and acute gout. Duration of oral treatment should not exceed one week. Parenteral preparations are indicated exclusively for initiating therapy. A single injection only is recommended because local tissue damage may occur. Preparations are contraindicated in children under 14 years of age.
OMN	Sep 1986	The Ministry of Health has prohibited the import of preparations containing bumadizone except those intended for topical use.
AUT		Indications restricted to exacerbations of gout and other arthritic conditions. Treatment should not exceed seven days and doctors are advised not to prescribe this drug to

Legislative or regulation action

Product Name	Bumadizone	
C.A.S. number	3583-64-0	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		children under 14 years of age or elderly patients. (Reference: (WIMAM) Wichtige Mitteilung ueber Arzneimittel, (1), , 1984) WHO Comment : Bumadizone, a pyrazolone derivative with antiinflammatory, analgesic and antipyretic activity, was introduced in 1972 for the treatment of rheumatic disorders. As it is structurally related to phenylbutazone it is subjected to rigorously restricted indications by some national regulatory authorities. See WHO comment for phenylbutazone.
Product Name	Bunamiodyl	
C.A.S. number	1233-53-0	
Scientific and common names, and synonyms		
CINNAMIC ACID, 3-BUTYRAMIDO-ALPHA-ETHYL-2,4,6-TRIIODO-, 2-(3-BUTYRAMIDO-3,4,6-TRIIODOPHENYL-METHYLENE)-BUTYRIC ACID		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
SWE	1964	The National Board of Health refused the approval of bunamiodyl on the grounds that its use is associated with adverse reactions.
USA	1964	The Food and Drug Administration withdrew bunamiodyl for oral cholecystography since repeat doses may be associated with oliguria, renal tubular necrosis, and death; the use of other cholecystographic agents within one week after bunamiodyl ingestion may be dangerous. It is contraindicated in patients with a history of renal disease. Evaluation of renal function should be performed before use of the drug. (Reference: (FEREAC) Federal Register, 36, 14493, Aug 1971)
VEN		Not approved for use and/or sale. WHO Comment : Bunamiodyl, an orally administered radio-opaque medium, was introduced in 1958 for use in the examination of the biliary tract. By 1964 its use had been associated with cases of renal failure, in some cases fatal, which resulted in its withdrawal by the United States Food and Drug Administration. Buniamiodyl was withdrawn worldwide by the manufacturer in 1984.
Product Name	Buprenorphine	
C.A.S. number	52485-79-7	
Scientific and common names, and synonyms		
6,14-ETHENOMORPHINAN-7-METHANOL, 17-(CYCLOPROPYLMETHYL)-ALPHA-(1,1-DIMETHYLETHYL)-4,5-EPOXY-18,19-DIHYDRO-3-HYDROXY-6-METHOXY-ALPHA-METHYL-[5ALPHA, 7ALPHA, (S)]- 21-CYCLOPROPYL-7ALPHA-((S)-1-HYDROXY-1,2,2-TRIMETHYLPROPYL)-6,14-ENDO-ETHANO-6,7,8,14-TETRAHYDRO-ORIPAVINE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
NZL	22 Sep 1983	Buprenorphine was included in Part IV of the Third Schedule of the Misuse of Drugs Act 1975. This implies that this substance is now subjected to the same controls as amobarbital, butobarbital and cyclobarbital. These include a requirement that prescriptions be written in triplicate on forms provided by the Department of Health.

Legislative or regulation action

Product Name	Buprenorphine	
C.A.S. number	52485-79-7	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
AUT	1 Jun 1984	Subjected to control at national level analogous to that provided by Schedule I of the 1961 Single Convention on Narcotic Drugs.
DEU	1 Sep 1984	Subjected to control at national level analogous to that applied to substances included in the 1961 Single Convention on Narcotic Drugs.
EGY	26 Nov 1986	Withdrawn from the market.
MUS	2000	The Ministry of Health and Quality of Life has listed buprenorphine as a Schedule II medicine under the new Dangerous Drugs Act 2000. This is because abuse of the drug by intravenous as opposed to oral use has been reported to cause a number of deaths. (Reference: (MUSMHQ) Letter to WHO, , , 27 Dec 2000)
<p>WHO Comment : Buprenorphine, an opioid analgesic with both morphine agonist and antagonist activity, was introduced in 1978. It was originally considered to possess low dependence potential. However, it has latterly been identified as causing a socially significant abuse problem in several countries which have consequently subjected it to control in 1989 under Schedule III of the 1971 Convention of Psychotropic Substances.</p> <p>(Reference: (UNCPS3) United Nations Convention on Psychotropic Substances (III), , , 1971)</p>		

Product Name	Buspirone hydrochloride	
C.A.S. number	33386-08-2	
Scientific and common names, and synonyms		
8-[4-(4-PYRIMIDIN-2-YLPIPERAZIN-L-YL)BUTYL]-8-AZASPIRO[4,5]DECANE-7,9-DIONE HYDROCHLORIDE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
MUS	May 2000	The Ministry of Health and Quality of Life has rescheduled the antipsychotic agent buspirone into Schedule III of the consolidated Dangerous Drugs Act 2000 following observations of irrational use and emerging abuse. (Reference: (MUSMHQ) Letter to WHO, , , 27 Dec 2000)

Product Name	Cadralazine	
C.A.S. number	64241-34-5	
Scientific and common names, and synonyms		
ETHYL 6-[2-(2-HYDROXYPROPYL)AMINO]-3-PYRIDAZINYL]HYDRAZINECARBOXYLIC ACID ETHYL ESTER		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
NOR	1992	The Medicines Control Authority refused an application for registration of the peripheral vasodilator, cadralazine on the grounds that the pharmacological and clinical documentation was inadequate. (Reference: (NNSLM) Nytt fra Statens Legemiddelkontroll, 1, 25, 1992)
<p>WHO Comment : Cadralazine, a peripheral vasodilator, was introduced in 1989 for the treatment of arterial hypertension. In 1992, its association with serious side effects led to the refusal of registration in Norway. Animal experiments have demonstrated drug-related impairment of thyroid function as well as potential</p>		

Legislative or regulation action

Product Name	Cadralazine	
C.A.S. number	64241-34-5	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		carcinogenicity and genotoxicity. It remains available for treatment of hypertension in Italy.
Product Name	Calamus	
C.A.S. number	8015-79-0	
Scientific and common names, and synonyms		
OIL OF CALAMUS		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
USA	Nov 1968	Withdrawn from the market and prohibited for export by the Food and Drug Administration on the basis of findings of animal carcinogenicity. (Reference: (FEREAC) Federal Register, 33, 17204, Nov 1968) WHO Comment : Calamus, the dried rhizome of acorus calamus, has been used as a bitter and carminative. The World Health Organization has no information further to the above regarding preparations containing calamus or to indicate that they are still commercially manufactured.
Product Name	Camelia sinensis	
C.A.S. number	2004-0-0003	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
FRA		The French and Spanish Advisory Board have suspended the marketing authorization of a green tea (camelia sinensis) product (exolise), prepared from the ethanolic extract of green tea, due to several reports of hepatic disorders.
ESP	11 Apr 2003	The French and Spanish Advisory Board have suspended the marketing authorization of a green tea (camelia sinensis) product (exolise), prepared for the ethanolic extract of green tea, due to several reports of hepatic disorders. (Reference: (ESPSPS) Communication to WHO, , , 11 Apr 2003)
Product Name	Camphor	
C.A.S. number	76-22-2	
Scientific and common names, and synonyms		
ALCANFOR		
CAMPHORA		
ROOT BARK OIL		
1,7,7-TRIMETHYLBICYCLO(2,2,1)HEPTANE-2-ONE		
2-CAMPHANONE		
2-BORNANONE		
Legislative or regulative action		

Legislative or regulation action

Product Name		Camphor
C.A.S. number		76-22-2
Country	Effective Date	Description of action taken Grounds for decision
FRA	17 Nov 1983	The National Commission of Pharmacovigilance has recommended that preparations containing camphor be contraindicated in infants under 30 months and that they be used with caution in older children. This action results from reports of convulsions associated with topical application or inhalation.
ZAF	1999	The South African Medicines Control Council has removed camphor from all medicines unless efficacy data is submitted. (Reference: (ZAFPS) Information from the Pharmaceutical Services, , ,)
EGY		The Technical Committee for Drug Control has published a warning that products containing camphor be contraindicated in infants under 30 months and that they be used with caution in older children. This action results from reports of convulsions associated with topical application or inhalation.
ITA		All pharmaceutical products containing camphor must bear the following warning: "This product is contraindicated in children under two years of age with a history of laryngospasm or convulsions. Caution must be exercised when older children are treated." (Reference: (BIFTI) Bolletino d'Informazione sui Farmaci, (12), , 1984) WHO Comment : Camphor, an aromatic crystalline substance with mild local anaesthetic activity, is available in preparations for both external application and inhalation. The use of such preparations has precipitated convulsions in susceptible infants. This has led several regulatory authorities to require the inclusion of appropriate warnings on labelling.

Product Name		Canrenone
C.A.S. number		976-71-6
Scientific and common names, and synonyms		
ALDADIENE		
PREGNA-4,6-DIENE-21-CARBOXYLIC ACID, 17-HYDROXY-3-OXO-, GAMMA-LACTONE (17ALPHA)-		
17-HYDROXY-3-OXO-17ALPHA-PREGNA-4,6-DIENE-21-CARBOXYLIC ACID GAMMA- LACTONE		
17ALPHA-(2-CARBOXYETHYL)-17BETA-HYDROXYANDROSTA-4,6-DIEN-3-ONE LACTONE		

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
DEU	1986	Preparations containing canrenone have been withdrawn having regard to the possible carcinogenic risk associated with long-term use. WHO Comment : Canrenone, which has aldosterone antagonist activity, is a major metabolite of spironolactone and the major metabolite of potassium canrenoate. See WHO comments for potassium canrenoate and spironolactone.

Product Name		Canthaxanthin
C.A.S. number		514-78-3
Scientific and common names, and synonyms		
BETA,BETA-CAROTENE-4,4'-DIONE		
COLOUR INDEX NO.40850		
CI FOOD ORANGE 8		
E.161.G		

Legislative or regulative action

Legislative or regulation action

Product Name		Canthaxanthin
C.A.S. number		514-78-3
Country	Effective Date	Description of action taken Grounds for decision
DEU	May 1985	The Federal Health Office has prohibited the use of canthaxanthin which is used in the treatment of certain photodermatoses and is contained in orally administered bronzing agents following reports of crystalline deposits in the retina.
AUT	31 Dec 1985	The Federal Ministry of Health and Environmental Protection has agreed with the manufacturer to withdraw pharmaceutical preparations containing canthaxanthin following reports of crystalline deposits in the retina.
IRL	1986	Having regard to reported ocular toxicity associated with long-term use of the tanning agent canthaxanthin, the National Drugs Advisory Board has informed manufacturers that it will no longer be permitted as a constituent of medicinal products. In 1989 the Board was additionally advised that the compound be excluded from tanning preparations. (Reference: (IRDAB) National Drugs Advisory Board Annual Report, , , 1986)
EGY	1987	The Technical Committee for Drug Control has decided that canthaxanthin will no longer be accepted as a bronzing agent to avoid ophthalmic problems. (Reference: (EGYDI) Drug Information, 5(2), 1, 1987)
OMN	Sep 1987	Import and marketing of products containing canthaxanthin were prohibited. (Reference: (OMNDI) Drug Information, 5(2):1, , 1987)
<p>WHO Comment : Canthaxanthin, a naturally-occurring carotenoid with a deep red-orange colour, is widely used as a food colouring agent. Since the mid-1970s it has been included in oral 'artificial suntan' preparations. It is also available in preparations used in the treatment of certain photodermatoses. By the mid-1980s its use in such preparations had been associated with the accumulation of crystalline deposits in the retina. Reported functional changes relating to dark adaptation have been of marginal clinical significance and largely reversible. Nevertheless, this has led to the withdrawal of artificial suntan preparations containing canthaxanthin by several regulatory authorities. Preparations for treatment of photodermatoses remain available in some but not all of these countries.</p>		

Product Name		Cartilage extract
Scientific and common names, and synonyms		AQUEOUS CALF CARTILAGE & BONE MARROW EXTRACT
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	Jun 1992	The marketing authorization of injectable preparations containing calf cartilage and bone marrow extract was suspended, in the first instance, until 31 December 1992. The decision resulted from an apparent association with serious adverse effects including local intolerance and anaphylactoid reactions, renal insufficiency, pulmonary fibrosis and autoimmune diseases of the skin and muscles. (Reference: (DEUPD) BGA Pressedienst, 24, , 1992)
<p>WHO Comment : A preparation containing calf cartilage and bone marrow extract was introduced in 1960 for the treatment of degenerative joint disease, and it is currently registered in several countries. In 1987, a risk-benefit assessment of the product was commissioned in Germany. This resulted initially in its use being contraindicated in patients with altered immune responses. Subsequently, the marketing authorization was suspended in Germany in 1992 when the product was associated with serious adverse effects.</p>		

Product Name	Cathine	
C.A.S. number	492-39-7	
Scientific and common names, and synonyms	(+)-THREO-2-AMINO-1-HYDROXY-1-PHENYLPROPYLPROPANE (+)-NORPSEUDOEPHEDRINE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	Jul 1981	Administration of centrally active appetite inhibiting preparations containing cathine has been restricted to four weeks. A warning concerning the risk of dependence has been included in the package leaflet.
PHL	Oct 1983	Disapproved for use in appetite control due to the risk of drug dependency and other adverse effects such as apathy, depression, chronic gastroduodenitis, dyspeptic disorders and dreamy euphoria with loquacity.
GRC	1985	Not accepted as an appetite suppressant having regard to its low benefit-to-risk ratio (systemic side-effects). WHO Comment : Cathine, a sympathomimetic amine, was formerly widely available in proprietary anorexic preparations. As dependence can occur and abuse has been reported, cathine has recently (1986) been subjected to control under Schedule III of the 1971 Convention on Psychotropic Substances. (Reference: (UNCPS3) United Nations Convention on Psychotropic Substances (III), , , 1971)

Product Name	Cefaloridine	
C.A.S. number	50-59-9	
Scientific and common names, and synonyms	CEPHALORIDINE PYRIDIUM,1-[[[2-CARBOXY-8-OXO-7-[(2-THIENYLACETYL)AMINO]-5-THIA-1-AZABICYCLO[4.2.0]-OCT-2-EN-3-YL]METHYL]-,HYDROXIDE, INNER SALT, (6R-TRANS)-	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
ESP	1989	The marketing authorization of products containing cefaloridine has been withdrawn, having regard to their nephrotoxicity. (Reference: (ESPINS) Información Terapéutica de la Seguridad Social, 13(1), 7, 1989) WHO Comment : Cefaloridine, a semi-synthetic cephalosporin antibiotic, was introduced into medicine in 1964 for the treatment of bacterial infections. It is considered to be the most toxic of the cephalosporins, and for this reason is now seldom used. Nevertheless, it still remains available in certain countries and the World Health Organization is not aware of restrictive actions taken elsewhere.

Product Name	Cefalosporins (topical preparations)	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
CHL		Pharmaceutical preparations for topical use containing cephalosporin and its derivatives are prohibited. (Reference: (CHLRS) Resolution of the Minister of Health, No.10154, , Oct 1986)

Legislative or regulation action

Product Name		Cell preparations
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
AUT	Aug 1987	Deep-frozen cell preparations used in the practice of cell therapy have been banned, on the grounds that fatalities associated with these products have been reported in the Federal Republic of Germany and that marketing authorization has been suspended in this country. (Reference: (DAZ) Deutsche Apotheker Zeitung, 127(34), 1720, 1987)
DEU	30 Jun 1988	The marketing authorization for injectable preparations used in the practice of cell therapy has been withdrawn, having regard to the serious and sometimes fatal reactions associated with these products, which have not been demonstrated to possess any therapeutic effect. (Reference: (DEUPD) BGA Pressedienst, 22, , 1988)
CHE	Jul 1988	All products prepared from fresh animal cells have been banned, on the grounds that fatalities associated with their use had been reported in the Federal Republic of Germany and that efficacy had not been demonstrated. (Reference: (CHBCM) Bulletin Mensuel, , , 31 Aug 1988)
<p>WHO Comment : Injectable preparations used in the practice of cell therapy were introduced into medicine many years ago. They contain cells from organs or tissues of fetal or juvenile animals of species such as sheep, cattle, swine and rabbits. A variety of indications were claimed by the manufacturers of these products, including adjuvant tumour therapy, Down's syndrome, ageing, immune defects, endocrine disturbances, diseases of the motor system, the central nervous system, the heart and vascular system and chronic liver disease. Whilst proof of efficacy in these indications has never been established, the use of cell preparations has been associated with severe, sometimes fatal adverse immunological reactions, particularly with anaphylactic shock and serum sickness. This has led to their withdrawal by regulatory authorities in the countries listed above.</p>		

Product Name		Cerivastatin
C.A.S. number		145599-86-6
Scientific and common names, and synonyms		
(3R,5S,6E)-7-[4-(4-FLUOROPHENYL)-2,6-DIISOPROPYL-5-(METHOXYMETHYL)-3-PYRIDYL]-3,5-DIHYDROXY-6-HEPTENOIC ACID		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
USA	Nov 1999	Prescribing information was changed to include a contraindication for the combined use of cerivastatin and gemfibrozil.
AUS	Feb 2001	Prescribing information was changed to include a contraindication for the combined use of cerivastatin and gemfibrozil and warning issued to alert prescribers to the possibility of rhabdomyolysis with all statins. (Reference: (AUSADR) Australian Adverse Drug Reactions Bulletin, Vol. 20(1), , Feb 2001)
CAN	Mar 2001	Prescribing information was changed to include a contraindication for the combined use of cerivastatin and gemfibrozil.
USA	May 2001	The Dosage and Administration section was revised to highlight that 0.4 mg is the starting dose for cerivastatin. (Reference: (USADHP) "Dear Healthcare Professional " letter, , ,)
@EC	Jun 2001	Europe-wide regulatory action was taken to reduce the risk of rhabdomyolysis, when the concomitant use of cerivastatin and gemfibrozil was contraindicated and the maximum

Legislative or regulation action

Product Name	Cerivastatin	
C.A.S. number	145599-86-6	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
CAN	Jul 2001	daily dose of cerivastatin was reduced to 0.4 mg. (Reference: (GBRDSI) Drug Safety Information, , , 08 Aug 2001)
@WD	Aug 2001	The prescribing information was revised to recommend a starting dose of 0.2 mg. (Reference: (CANDHP) "Dear Healthcare Professional" letter, , ,) Cerivastatin was voluntarily withdrawn from the world market by the parent company (Bayer) on account of the increased risk of rhabdomyolysis associated with its use, particularly when used in combination with gemfibrozil. (Reference: (FDATP) Food and Drug Administration Talk Paper, TOI-34, , 08 Aug 2001)

Product Name	Chenodeoxycholic acid	
C.A.S. number	474-25-9	
Scientific and common names, and synonyms		
CHOLAN-24-OIC ACID, 3,7-DIHYDROXY-, (3ALPHA,5BETA,7ALPHA)-		
CHENODIOL		
3ALPHA,7ALPHA-DIHYDROXY-5BETA-CHOLAN-24-OIC ACID		

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
NOR	1987	Chenodeoxycholic acid is not approved for registration on grounds of animal studies indicating a carcinogenic effect and because the risk of a cancer-promoting effect in man is considered significant. WHO Comment : Chenodeoxycholic acid was introduced in 1975 for the treatment of cholelithiasis. It is available in several countries and the World Health Organization is not aware that registration has been refused in any other country.

Product Name	Chloramphenicol	
C.A.S. number	56-75-7	
Scientific and common names, and synonyms		
ACETAMIDE, 2,2-DICHLORO-N-(2-HYDROXY-1-(HYDROXYMETHYL)-2-(4- NITROPHENYL)ETHYL)-, (R-(R*,R*))		
D-THREO(-)-2,2-DICHLORO-N-(BETA-HYDROXY-ALPHA-(HYDROXYMETHYL)-P-NITROPHENETHYL)ACETAMIDE		
LAEVOMYCETINUM		

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
DEU	1975	Use should be limited to treatment of acute attacks of typhoid and paratyphoid fever, purulent meningitis and life-threatening infections caused by sensitive organisms in which less dangerous antibiotics are ineffective or contraindicated.
JPN	Oct 1975	Indications have been restricted.
DNK	1978	Doctors have been advised that systemic chloramphenicol should be used only in patients requiring admission to hospital. It is contraindicated in uncomplicated urinary tract infections. (Reference: (UGLAAD) Ugeskrift for Laeger, 140, 1165, 1978)
FRA	22 Sep 1978	Products for topical application containing chloramphenicol have been withdrawn from

Legislative or regulation action

Product Name	Chloramphenicol	
C.A.S. number	56-75-7	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		the market, with the exception of eyedrops and ophthalmic ointments. Indications for products intended for internal use are restricted to serious infections caused by organisms sensitive to chloramphenicol when other potentially less dangerous products are ineffective.
PHL	Jul 1982	Severely restricted in use due to the risk of developing agranulocytosis. Limited to indications of typhoid fever, meningitis and brain abscess.
EGY	Jul 1983	All pharmaceutical preparations containing chloramphenicol should bear the following warning: "Not to be used for long periods or repeatedly, even in small doses, to avoid the risk of toxic effects such as bone marrow aplasia and acute leukaemia. Use should be restricted to cases not responding to other antibiotics".
NLD	1984	Doctors have been reminded that, even when applied topically in the eye, chloramphenicol may induce blood dyscrasias. When chloramphenicol appears to be the drug of choice, the susceptibility of the pathogenic organism should always be confirmed bacteriologically.
CAN	1985	Prohibited for administration to animals that may be consumed as food due to persistent residues in food products.
ESP	1 Mar 1985	Registration of combination products containing chloramphenicol will no longer be considered because of the propensity of this drug to cause aplastic anaemia.
HUN	1987	Chloramphenicol has been banned for therapeutic purposes in milk- and egg-producing animals, having regard to its potential to induce aplastic anaemia in man, and the prolonged period during which residues remain demonstrable after withdrawal. (Reference: (HUNIH) National Institute of Occupational Health Notification, , 25 May 1988)
IRL	Oct 1989	The administration of chloramphenicol to all food-bearing animals (including horses) has been prohibited, on the grounds that the drug enters the food chain and may therefore cause adverse effects and transferable drug resistance in man. (Reference: (IRDAP) Animal Pharm, 187, 4, Sep 1989) (Reference: (IRDAB) National Drugs Advisory Board Annual Report, , 312, 1987)
<p>WHO Comment : Chloramphenicol, an antibiotic isolated from <i>Streptomyces venezuelae</i> in 1947, first became available for general clinical use in 1948. By 1950 it was evident that its use could cause serious, sometimes fatal, blood dyscrasias. However, it remains one of the most effective antibiotics for treating invasive typhoid fever and salmonellosis, some rickettsioses and serious infections caused by <i>Haemophilus influenzae</i> or anaerobic organisms. This is considered to justify its retention in the WHO Model List of Essential Drugs.</p> <p>(Reference: (WHTAC1) The Use of Essential Drugs, 2nd Report of the WHO Expert Committee, 722, , 1985)</p>		

Product Name	Chlormadinone acetate	
C.A.S. number	302-22-7	
Scientific and common names, and synonyms		
6-CHLORO-17-HYDROXYPREGNA-4,6-DIENE-3,20-DIONE ACETATE PREGNA-4,6-DIENE-3,20-DIONE, 17-(ACETYLOXY)-6-CHLORO		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
USA	Mar 1972	Application for approval of oral contraceptives containing chlormadinone acetate

Legislative or regulation action

Product Name	Chlormadinone acetate	
C.A.S. number	302-22-7	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		withdrawn by the manufacturer on recommendation by the Food and Drug Administration after findings in beagle bitches showing an increased incidence of mammary tumours resulting from this component. (Reference: (FEREAC) Federal Register, 37(52), 5516, 1972)
GBR	1977	The product licence for an oral contraceptive containing this substance has been cancelled due to the risk of carcinogenicity.
ITA	1979	Withdrawn from the market because of an increased incidence of breast tumours in beagle dogs during the course of long-term toxicity tests.
EGY	1980	Chlormadinone was not approved having regard to its potential to cause breast tumours in dogs.
VEN		Not approved for use and/or sale.
WHO Comment : Chlormadinone acetate, a synthetic progestogen, was introduced in 1965 as a component in oral contraceptive preparations. In 1967, as a result of new regulations required by the United States Food and Drug Administration, chlormadinone acetate was submitted to long-term toxicity studies and by the early 1970s it was shown to be associated with an increased incidence of mammary tumours in beagle bitches which led to its withdrawal by several regulatory authorities. Subsequently the validity of the beagle bitch model as a predictor of carcinogenicity of steroid contraceptives has been contested by many national regulatory authorities and chlormadinone remains available in some countries for contraceptive purposes. In some instances it is indicated for treatment of progesterone deficiency and endometriosis, and of irregular uterine bleeding due to fibroids. (Reference: (WHODI) WHO Drug Information, 84.1, 5, 1984)		

Product Name	Chlormezanone	
C.A.S. number	80-77-3	
Scientific and common names, and synonyms	CHLORMETHAZANONE 2-(P-CHLOROPHENYL)-TETRAHYDRO-3-METHYL-4H-1,3-THIAZIN-4-ONE 1,1-DIOXIDE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
@WD	15 Nov 1996	Because of severe cutaneous reactions including life-threatening toxic epidermal necrolysis, Stevens-Johnson syndrome, and fixed drug eruptions, the manufacturer of chlormezanone withdrew the drug worldwide. This coincided with local action undertaken in several countries. The withdrawal concerns chlormezanone used alone or in combination. (Reference: (SANOFI) Letter to Regulatory Agencies, Sanofi, , , 09 Oct 1996)
ARE	1997	The Ministry of Health has withdrawn marketing approval for pharmaceutical products containing chlormezanone because it has been associated with an unacceptable incidence of Stevens-Johnson syndrome. (Reference: (UAEDIB) Drug Information Bulletin, No. 3, p.2, 1997)
ZAF	1998	The South African Medicines Control Council has withdrawn products containing chlormezanone because of the unacceptable risk-benefit profile which is not in the interest of public health. (Reference: (ZAFPS) Information from the Pharmaceutical Services, , ,)

Legislative or regulation action

Product Name	Chlormezanone	
C.A.S. number	80-77-3	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
ZWE	1998	The Medicines Control Authority has cancelled the registration of all chlormezanone-containing products in the light of international actions taken on the basis of a safety evaluation of chlormezanone. This drug has been associated with an unacceptable incidence of Stevens-Johnson syndrome. (Reference: (ZWEDIB) Drug Information Bulletin, Vol.2 No.1, , Mar 1998)
SAU	Jun 1999	The Ministry of Health has withdrawn from the market products containing chlormezanone because of an unacceptable incidence of Stevens-Johnson syndrome. (Reference: (SAUCW) Notification, , , 20 June 1999)
SGP		The National Pharmaceutical Administration in the Ministry of Health has banned chlormezanone since it has been associated with reports of life-threatening toxic epidermal necrolysis and borderline major bullous forms. (Reference: (SGPCW) Communication to WHO, , , 02 Aug 2000)
WHO Comment : Chlormezanone is a sedative with antianxiety properties and a central skeletal muscle relaxant effect. It had already been falling into obsolescence for several years.		

Product Name	Chlornaphazine	
C.A.S. number	494-03-1	
Scientific and common names, and synonyms		
BETA-NAPHTHYLBIS(BETA-CHLOROETHYL)AMINE		
NAPHTHYLAMINE MUSTARD		
N,N-BIS(2-CHLOROETHYL)- 2-NAPHTHYLAMINE		
2-NAPHTHALENAMINE, N,N-BIS(2-CHLOROETHYL)-		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DNK	1964	The National Health Service withdrew chlornaphazine, a drug used against lympho-granulomatosis, polycythaemia and chronic leukaemia, as it appeared to be carcinogenic especially in the bladder.
VEN		Not approved for use and/or sale.
WHO Comment : The World Health Organization has no information further to the above regarding preparations containing chlornaphazine or to indicate that they are still commercially manufactured.		

Product Name	Chloroform	
C.A.S. number	67-66-3	
Scientific and common names, and synonyms		
METHANE, TRICHLORO-		
TRICHLOROMETHANE		
TRICHLOROFORM		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision

Legislative or regulation action

Product Name		Chloroform
C.A.S. number		67-66-3
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GRC	1976	Not accepted in pharmaceuticals or cosmetics.
TUR	1976	Removed from all cough syrups after a decision by the Ministry of Health based on a review of published information regarding carcinogenicity in rats. Export of this product is prohibited.
JPN	May 1976	Banned by the Pharmaceutical Affairs Bureau in Drugs and Cosmetics for reasons of carcinogenicity.
USA	Jul 1976	Withdrawn from the market and prohibited for export in drugs and cosmetics by the Food and Drug Administration on the basis of findings of liver cancer in experimental mice and rats by the National Cancer Institute. (Reference: (FEREAC) Federal Register, 41, 26842, July 1976)
PAN	30 Nov 1976	The Ministry of Health has banned the sale of pharmaceuticals containing chloroform. (Reference: (PANMR) Ministry of Health Resolution, 1843, , Aug 1976)
SAU	1977	Sale or supply of any medicinal product containing chloroform has been prohibited by the Drug Committee.
BRA	25 May 1977	Products containing chloroform are prohibited. (Reference: (BRAPT) Portaria do Servico Publico Federal, No.15, , May 1977)
ITA	1978	Withdrawn from the market owing to suspected carcinogenicity.
CAN	Jan 1978	National legislation has provided that no manufacturer or importer shall sell a drug for human use that contains chloroform as an ingredient. The Health Protection Branch has reviewed evidence from the National Cancer Institute in the US which suggests that chloroform may be carcinogenic in rats and mice when administered in high doses over prolonged periods. Export of this product is allowed with no requirement of foreign notification regarding domestic restrictions on its use. (Reference: (CANGZ) Canada Gazette, , , Nov 1977)
NOR	Apr 1978	Prohibited for use in pure form or as an additive to pharmaceutical preparations.
PHL	Apr 1978	Prohibited for use as an ingredient in human drugs and cosmetics on the grounds of results of a study by the National Cancer Institute in the United States, suggesting that the substance may be carcinogenic in rats and mice when administered over prolonged periods. (Reference: (PHADO) Administrative Order, 341S, , 1978)
GBR	1979	The Chloroform Prohibition Order has prohibited the sale or supply of any medicinal product containing chloroform. Certain exemptions apply. (Reference: (GBCHL) Chloroform Prohibition Order, , , 1979)
NZL	1980	Toothpaste formulations containing chloroform have been voluntarily withdrawn from the market.
DNK	1981	Registered for veterinary use only. (Reference: (DENBH) Danish National Board of Health, Circular Letter, , , Sep 1981)
ETH	1981	Prohibited because of its carcinogenic effects.
ZWE	May 1981	Medicinal products containing more than 0.5% chloroform are prohibited because of the toxicity of the drug. Certain exemptions apply. (Reference: (ZWDCC) Drugs Control Council, News Bulletin, 1, , 1983)
DEU	1982	Prohibited for use and/or sale.
BGD	Jun 1982	Use of chloroform as an excipient in pharmaceutical preparations has been banned due to reported adverse effects.
DOM	1983	Domestic manufacturers and importers have been requested to eliminate this ingredient

Legislative or regulation action

Product Name	Chloroform	
C.A.S. number	67-66-3	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
BEL	12 Feb 1983	from their marketed products since pharmacological studies have shown it to be toxic to the liver and the heart, and to be carcinogenic. Prohibited for sale. (Reference: (BELAR) Arrêté Royal, , , Feb 1983)
NGA	1 Feb 1985	Chloroform is not allowed in cosmetic and drug products since 1 Feb. 1985. From that date, import, export and sale of products containing chloroform became illegal. The decision was based on reports from literature of the carcinogenic effects of chloroform on animals and possible hepatotoxic and nephrotoxic effects after prolonged use by humans. (Reference: (AARNO) Administrative Action, MH.1856/S.3T, 112, 15 Sep 1983)
IRL	1989	Having regard to their toxicity, approval for marketing of all preparations containing chloroform was withdrawn. (Reference: (IRDAB) National Drugs Advisory Board Annual Report, , 29, 1989)
OMN	27 Jul 1992	Sale and marketing of products containing chloroform were prohibited, having regard to reported adverse effects and toxicity. (Reference: (OMNCR) Circular, 27/92, , July 1992)
CUB		Following the action taken by the US Food and Drug Administration, the National Formulary Commission requested removal of chloroform from pharmaceutical preparations.
THA		The use of pharmaceutical preparations containing chloroform is severely restricted.
VEN		Subject to restricted use and/or sale.
<p>WHO Comment : Chloroform was formerly widely used in pharmaceutical preparations as a solvent and preservative as well as for its anaesthetic and flavouring properties. By the late 1970s reservations concerning its safety, including positive results in a carcinogenicity screening programme sponsored by the National Cancer Institute in the USA, had led to considerable restrictions in its use in pharmaceutical preparations. While many pharmaceutical products containing chloroform have been withdrawn or reformulated to exclude this substance, it may still be incorporated in toothpastes and other specified products in some countries, subject to statutorily-imposed concentration limits. (Reference: (IARCCD) Chloroform: IARC Monograph, 20(20), 401-427, 1979)</p>		

Product Name	Chloroquine	
C.A.S. number	54-05-7	
Scientific and common names, and synonyms	7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)-QUINOLINE 1,4-PENTANEDIAMINE, N4-(7-CHLORO-4-QUINOLINYL)-N1,N1-DIETHYL-	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
JPN	1975	Chloroquine was voluntarily withdrawn from production and sale by the manufacturer due to the risk of retinopathy associated with its use at high doses in the treatment of rheumatoid arthritis and related diseases. WHO Comment : Chloroquine, a 4-aminoquinoline derivative, was introduced in the 1940s for the treatment and prophylaxis of malaria. It was subsequently found to be effective in higher and prolonged dosage in the treatment of lupus erythematosus, rheumatoid arthritis and nephritis. In the early 1970s its use in these latter

Legislative or regulation action

Product Name	Chloroquine	
C.A.S. number	54-05-7	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		conditions was largely discontinued when it was found that prolonged daily administration at high dosage was associated with cases of retinopathy resulting from local deposition of the compound. Chloroquine however remains a valuable drug. It can be used continuously at the dosages required for malaria prophylaxis for as long as five years without risk of undue accumulation and it is included in the WHO Model List of Essential Drugs for both its antimalarial and antiamoebic activity. (Reference: (WHTAC1) The Use of Essential Drugs, 2nd Report of the WHO Expert Committee, 722, , 1985)

Product Name	Chlorphentermine	
C.A.S. number	461-78-9	
Scientific and common names, and synonyms	P-CHLORO-ALPHA,ALPHA-DIMETHYLPHENETHYLAMINE 1-(P-CHLOROPHENYL)-2-METHYL-2-AMINOPROPANE 4-CHLORO-ALPHA,ALPHA-DIMETHYL-BENZENEETHANAMINE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	1969	The Ministry of Health withdrew preparations containing aminorex, cloforex and chlorphentermine as a precautionary measure pending scientific evidence of a relationship between their use and the development of pulmonary hypertension.
BEL	1 Jan 1988	Preparations containing chlorphentermine have been placed in List IV of the 'Arrêt, du R.gent' of 2 June 1946 and as such can be administered only on prescription. They must be kept in a poisons cabinet and carry the skull and cross-bones label. (Reference: (BELAR) Arrêté Royal, , , June 1987)
VEN		Banned for use and/or sale. WHO Comment : Chlorphentermine, a sympathomimetic phenethylamine derivative, was introduced over twenty years ago for the treatment of obesity. Concern that its use was associated with cases of pulmonary hypertension led to its withdrawal in several countries. However, it remains available in some other countries.

Product Name	Cianidanol	
C.A.S. number	154-23-4	
Scientific and common names, and synonyms	CIANIDOL (+)-CATECHOL	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
ITA	5 Sep 1985	Provisionally withdrawn by the Pharmaceutical Division of the Ministry of Health.
@WD	6 Sep 1985	Marketing of cianidanol was temporarily suspended worldwide by the manufacturer.
EGY	22 Oct 1985	Cianidanol has been withdrawn from the market and importation temporarily prohibited.

Legislative or regulation action

Product Name	Cianidanol	
C.A.S. number	154-23-4	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	26 Jun 1987	Subsequent to its decision to suspend the marketing authorization of products containing cianidanol, the Federal Health Office has definitively withdrawn registration of these products. (Reference: (FRGGH) Bundesgesundheitsamt Pressedienst, , , June 1987)
CHE	Jun 1988	The Intercantonal Office for Drug Control has withdrawn the marketing license for cianidanol.
@WD	Jun 1988	Cianidanol was definitively withdrawn worldwide by the manufacturer.
AUT		Use of preparations containing cianidanol has been prohibited until further notice.
WHO Comment : Cianidanol, which is extracted from the tropical plant Uncaria gambir, was introduced in 1976 as an adjunct in the treatment of liver disorders. Following a cluster of cases of haemolytic anaemia reported in 1985 from Naples, Italy, four of which were fatal, the company suspended sales worldwide. Although subsequently reintroduced in Switzerland and France for the treatment of acute and chronic hepatitis-B, it was later definitively withdrawn in Switzerland on detailed reassessment and the manufacturer has now withdrawn the product worldwide.		

Product Name	Cinchophen	
C.A.S. number	132-60-5	
Scientific and common names, and synonyms		
CINCHONINIC ACID, 2-PHENYL-		
2-PHENYLQUINOLINE-4-CARBOXYLIC ACID.		
2-PHENYLCINCHONINIC ACID		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	Jun 1991	Products containing cinchophen were withdrawn, because of the associated risks of hepatic toxicity, including jaundice, hepatitis and cirrhosis and a greater incidence of gastric ulceration than is associated with other nonsteroidal antiinflammatory agents. (Reference: (FRGGH) Bundesgesundheitsamt Pressedienst, , , June 1991)
ITA		Withdrawn from the market owing to an unfavourable risk-benefit ratio and the lack of substantial evidence of efficacy.
WHO Comment : Cinchophen, an analgesic and antipyretic, was formerly available in preparations for the treatment of gout. Its use was associated with adverse effects including hepatitis, cirrhosis, skin lesions and angioneurotic oedema. WHO has no information to suggest that preparations containing cinchophen remains commercially available.		

Product Name	Cinepazide	
C.A.S. number	23887-46-9	
Scientific and common names, and synonyms		
1-[(1-PYRROLIDINYL)CARBONYL]METHYL-4-(3,4,5-TRIMETHOXYCINNAMOYL) PIPERAZINE		
Legislative or regulative action		

Legislative or regulation action

Product Name	Cinepazide	
C.A.S. number	23887-46-9	
Country	Effective Date	Description of action taken Grounds for decision
EGY	1988	Registration of products containing cinepazide was refused, having regard to international reports of blood dyscrasias associated with their use. (Reference: (EGYDI) Drug Information, 6(4), 1, 1988)
ESP	1988	In agreement with the Ministry of Health, products containing cinepazide have been withdrawn by the manufacturers. (Reference: (ESPOR) Ministerio de Sanidad y Consumo, , , 13 Feb 1991) WHO Comment : Cinepazide, a vasodilating agent, was first introduced into medicine in 1974. It is used in the treatment of peripheral and cerebral vascular disorders. Following reports of blood dyscrasias, including agranulocytosis and thrombocytopenia, associated with the use of the drug, the Spanish Committee on Drug Surveillance has recommended its withdrawal. In other countries, the approved product information of preparations containing cinepazide has been amended to include a relevant warning on these adverse effects.

Product Name	Cinnarizine	
C.A.S. number	298-57-7	
Scientific and common names, and synonyms		
PIPERAZINE,1-(DIPHENYLMETHYL)-4-(3-PHENYL-2-PROPENYL) 1-CINNAMYL-4-(DIPHENYLMETHYL) PIPERAZINE		

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
ESP	Aug 1989	Having regard to their potential to induce extrapyramidal symptoms, products containing cinnarizine may no longer be indicated for cerebral and peripheral arterial insufficiency, including loss of memory, insomnia, intermittent claudication, rest pain or vasospastic disturbances. The approved indications are restricted to vestibular disturbances, vertigo, prophylaxis of vascular headache and prevention of motion sickness. (Reference: (ESPINS) Información Terapéutica de la Seguridad Social, 13(8), 176, 1989) WHO Comment : Cinnarizine, an antihistaminic and vasodilator agent, was introduced into medicine in 1962. It is indicated for the treatment of labyrinthine disturbances and vascular disorders, although its effectiveness in the latter indication has not been convincingly demonstrated.

Product Name	Ciprofibrate	
C.A.S. number	52214-84-3	
Scientific and common names, and synonyms		
PROPANOIC ACID, 2-[4-(2,2-DICHLOROCYCLOPROPYL)PHENOXYL]-2-METHYL		

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
FRA	Jun 1995	The use of ciprofibrate has been restricted because of dose-dependent rhabdomyolysis. The distribution of the 200 mg dose formulation has been stopped. (Reference: (FRAAMC) Communiqué de Presse, , , 14 June 1995) WHO Comment : The safety profile of ciprofibrate is similar to that of clofibrate. See also under clofibrate in full edition.

Legislative or regulation action

Product Name **Cisapride**

C.A.S. number **810968-60-4**

Scientific and common names, and synonyms

CISAPRIDUM

CIS-4-AMINO-5-CHLORO-N-[1-[3-(P-FLUOROPHENOXY)PROPYL]-3-METHOXY-4-PIPERIDYL]-O-ANISAMIDE;

R-51619

Legislative or regulatory action

Country	Effective Date	Description of action taken Grounds for decision
IRL	Sep 1999	The Irish Medicines Board has restricted the indications for cisapride following reports of cardiac arrhythmia, cardiac arrest and sudden death. (Reference: (IRDDS) Drug Safety Newsletter, , , Sep 1999)
PHL	2000	The Department of Health Bureau of Food and Drugs has banned the use of cisapride because of documented reports on adverse events including deaths associated with its use. (Reference: (PHADO) Administrative Order, (97) s. 2000, , 09 Aug 2000)
OMN	Apr 2000	The Directorate General of Pharmaceutical Affairs & Drug Control has suspended the marketing of cisapride because of the possibility of rare but serious heart complications including arrhythmias and sudden death. (Reference: (OMNCR) Circular, No. 28/2000, , 30 Apr 2000)
USA	Apr 2000	Cisapride has been voluntarily withdrawn from the market because of the risk of rare but serious cardiac events associated with the drug. These include heart rhythm disorders associated with the drug. These include heart rhythm disorders and deaths associated mostly with the use of the drug in people who are either taking certain other medications or who have certain underlying conditions that are known risk factors. (Reference: (FDAWWW) www.fda.gov/medwatch/safety/2000/propull.htm, , ,)
ARE	15 Apr 2000	Indications for use of cisapride have been severely restricted because of the risk of rare but serious cardiac events associated with the drug. (Reference: (UAECW) Communication to WHO, , , 10 July 2000)
COL	May 2000	The Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) in Colombia, Colombian Ministry of Health has restricted the use of cisapride. It should be made available only if other therapeutic management is insufficient. (Reference: (COLVMA) Letter from INVIMA to WHO, , , 21 Aug 2000)
DEU	Jun 2000	The Federal Institute for Drugs and Medical Devices has suspended the marketing authorization of cisapride because of the association with cardiac arrhythmias and a number of deaths. (Reference: (DEUCFI) Communication, , , 03 July 2000)
GBR	Jul 2000	The Medicines Control Agency has withdrawn cisapride from the market because of rare but serious cardiac adverse effects. (Reference: (GBRMCA) Communication to WHO, , , 21 July 2000)
MUS	Jul 2000	Cisapride was withdrawn from the market following reports of adverse cardiac events published by the FDA. (Reference: (MUSMHQ) Letter to WHO, , , 27 Dec 2000)
CAN	7 Aug 2000	Health Canada has withdrawn cisapride because of the possibility of rare but serious heart complications including arrhythmias and sudden death. (Reference: (CANWHC) Warnings/Advisories, , , 31 May 2000)
BDS	Sep 2000	The Drug Advisory Committee of the Ministry of Health has withdrawn cisapride (Prepulsid) from the market because of reports of serious cardiovascular adverse effects. (Reference: (BDSMHS) Official letter to WHO, , , 30 Sep 2000)
TUR	May 2000	General Directorate of Pharmaceuticals and Pharmacy of the Ministry of Health has withdrawn cisapride from the market because of serious cardiovascular adverse effects seen in the world. (Reference: (TURCW) Communication to WHO, , , 20 Sep 2001)

Legislative or regulation action

Product Name **Cisapride**

C.A.S. number **810968-60-4**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
IDN	30 Jun 2000	The Directorate General of Drug and Food Control has suspended the marketing authorization for cisapride and has withdrawn it from the market until the risk/benefit ratio is further reviewed because of the possibility of rare but serious heart complications including arrhythmias and sudden death. (Reference: (IDNCW) Communication to WHO, , , 13 Sep 2001)
SGP	Sep 2000	The product licences for all cisapride containing preparations were suspended by the National Pharmaceutical Administration, Ministry of Health, Singapore in September 2000 following reports of increased risk of serious cardiac arrhythmia. Cisapride may still be made available on an individual basis.
IDN	Oct 2000	The Directorate General of Drug and Food Control has allowed the marketing authorization for 5 mg cisapride with restrictions on indication, dosage, access and distribution. Availability has been restricted to only a few hospitals, with close monitoring for adverse reactions. (Reference: (SGPCW) Communication to WHO, , , 19 Sep 2001) (Reference: (IDNCW) Communication to WHO, , , 13 Sep 2001)
JPN	Oct 2000	The Ministry of Health and Welfare, Tokyo has decided to suspend marketing authorization of cisapride until its risk/benefit ratio is further reviewed. (Reference: (JPNMHC) Communication to WHO, , , 18 Oct 2000)
CUB	Jan 2001	The Centre for State Control of Drug Quality in Cuba (CECMED) has banned the use of cisapride until its risk/benefit ratio is further reviewed. (Reference: (CUBCDQ) CECMED Resolution, No. 1/2001, , 08 Jan 2001)
BRA	Apr 2001	The National Health Surveillance Agency severely restricted the use of cisapride through prescription and suspended the marketing authorization with the exception of manufacturers with their own Pharmacovigilance System. (Reference: (BRARES) Resolucao n., 530/ANVISA, , 18 Apr 2001)
BHR	May 2001	Cisapride was withdrawn from the local market in May 2001. The action was based on reports of serious cardiac events. (Reference: (BHRCW) Communication with WHO, , , 20 Aug 2001)
THA	Jun 2001	Severely restricted for prescription use by gastrointestinal physicians and limited use in gastro-esophageal-reflux-disease patients only. (Reference: (THACW) Communication to WHO, , , 28 Sep 2001)
CHL	Jul 2001	The Public Health Institute of Chile has restricted the indications for cisapride because of the risk of serious cardiac adverse effects. The use in children is contraindicated. (Reference: (CHLCW) Communication to WHO, , , 26 Sep 2001)
AUS	Dec 2002	Highest strength tablets of cisapride have been withdrawn and product information has been revised. All patients now require measurements of renal function and ECGs before and during treatment. Follow up measures should be undertaken every three months. Concerns about cardiac arrhythmias led to restrictions being placed on the prescription of cisapride. (Reference: (AUSPRE) Australian Prescriber, 25, No.6, Dec 2002)
ARM		Cisapride has been voluntarily withdrawn because of the increased risk of cardiac arrhythmias in patients taking other medications or suffering from underlying conditions known to increase risk of cardiac arrhythmias. (Reference: (ARMCW) Communication to WHO, , , 09 Aug 2000)
NZL		The Therapeutics section of the Ministry of Health, Wellington has severely restricted the use of cisapride in view of reports of cardiac arrhythmias associated with its use particularly in conjunction with erythromycin, clarithromycin, fluconazole, itraconazole or miconazole. (Reference: (NZLPU) Prescriber Update, No.14, , Feb 1997)

Legislative or regulation action

Product Name	Cisapride	
C.A.S. number	810968-60-4	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
<hr/>		
Product Name	Clemastine	
C.A.S. number	15686-51-8	
Scientific and common names, and synonyms		
PYRROLIDINE, 2-[[1-(4-CHLOROPHENYL)-1-PHENYLETHOXY]ETHYL]-1-METHYL-, [R-(R*,R*)]-		
(+)-(2R)-2-[1-[(R)-P-CHLORO-ALPHA-METHYL-ALPHA-PHENYLBENZYL]OXY]ETHYL]-1-METHYLPYRROL		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
<hr/>		
GBR	1991	Products containing clemastine were disallowed in children under one year of age, because of their possible association with sleep apnoea. (Reference: (GBRPHJ) The Pharmaceutical Journal, , , 24 Aug 1991) WHO Comment : See WHO comment for H1-antihistamines.
<hr/>		
Product Name	Clioquinol (see also halogenated hydroxyquinoline derivatives)	
C.A.S. number	130-26-7	
Scientific and common names, and synonyms		
5-CHLORO-7-iodoquinolinol		
5-CHLORO-7-iodo-8-quinolinol		
chloroiodoquin		
chinoxin		
iodochlorhydroxyquinoline		
iodochlorhydroxyquin		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
<hr/>		
JPN	Sep 1970	The Ministry of Health and Welfare prohibited the sale of clioquinol and broxyquinoline, and preparations containing them, following reports that clioquinol might be one of the causes of subacute myelo-optic neuropathy (SMON).
NOR	Jan 1974	Withdrawn from the market.
SWE	Jun 1975	Withdrawn by the manufacturer after mutual discussions due to neurological adverse reactions. It remains on the market for external use.
BEL	1976	Following cases of subacute myelo-optic neuropathy (SMON) in Japan, manufacturers of clioquinol in Belgium have limited the indications for use and duration of treatment. Since 1975 clioquinol has been available only on prescription.
DEU	1 Jan 1977	Preparations containing clioquinol intended for internal use have been placed under prescription control because of a propensity to cause neurological disorders.
DNK	1978	Products have been withdrawn from the market. (Reference: (UGLAAD) Ugeskrift for Laeger, 140, 1181, 1978)
FRA	3 Nov 1978	Clioquinol has been placed under Schedule A of the Poisonous Substances Regulations.
ARE	9 Jun 1981	Pharmaceutical preparations containing clioquinol are banned. (Reference: (UAEMD) Ministry of Health Decree, No.694, , 1981)

Legislative or regulation action

Product Name **Clioquinol (see also halogenated hydroxyquinoline derivatives)**

C.A.S. number **130-26-7**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
NGA	1982	Importation, sale and manufacture of clioquinol and clioquinol-containing products for oral administration have been prohibited, because of evidence of neurological disorders, including SMON, associated with their use. (Reference: (NGAPN) Pharmanews, 10(11), 15, 1988)
BGD	Jun 1982	Banned as a single ingredient or in combination due to its implication in subacute myelo-optic neuropathy.
PHL	Aug 1982	This drug, used to treat infectious diarrhea, has been withdrawn from the domestic market due to reports of neurological disorders (SMON) associated with its use in Japan.
ITA	1983	Withdrawn from the market.
NPL	1983	All preparations containing this substance have been banned.
DOM	Feb 1983	Prohibited for use and/or sale after authorities were informed of the manufacturer's intent to gradually replace this ingredient in all preparations currently marketed worldwide.
ZWE	Feb 1983	Use of clioquinol is prohibited because of its propensity to cause neurological disorders. (Reference: (ZWDCC) Drugs Control Council, News Bulletin, 1, , 1983)
ESP	29 Jul 1983	The Ministry of Health and Consumer Protection has withdrawn approval for clioquinol. (Reference: (ESPMC) Programa Selectivo de Revisión de Medicamentos, (I), , Sep 1983)
ZMB	7 Dec 1983	Preparations of clioquinol for internal use may only be imported or exported on a licence issued by the Director of Medical Services. (Reference: (ZMBSI) Statutory Instrument, 166-167, , Dec 1983)
HKG	1 Jan 1984	The Pharmacy and Poisons Committee no longer allows the registration, sale or distribution of products containing clioquinol.
ETH	7 Sep 1984	Prohibited due to its association with sub-acute myelo-optic neuropathy.
HND	24 Oct 1985	The importation, manufacture and sale of products containing clioquinol have been prohibited having regard to the drug's potential to cause SMON. (Reference: (HNDSP) Circular, 10-85, , 1985)
OMN	Mar 1987	Import and marketing of oral and parenteral preparations containing clioquinol and related substances intended for the treatment of diarrhoea in children were prohibited. Topical preparations remain on the market. (Reference: (OMNCR) Circular, 11/87, , Mar 1987)
PAK	1988	Oral preparations containing clioquinol were withdrawn. (Reference: (PAKMH) Ministry of Health, Special Education and Social Welfare, , , Aug 1988)
GHA	1 Sep 1989	Products containing clioquinol have been banned. (Reference: (GHAPDR) Pharmacy and Drugs (Banned Drugs) Regulations, Legislative Instruments, 1484, , 1989)
LIY	21 May 1990	The General People's Health Committee banned the use of clioquinol in children. (Reference: (LIYRL) Resolution of the General People's Health Committee, 141, , May 1990)
BHR		Preparations containing clioquinol have been withdrawn.
CHE		Oral preparations of clioquinol have been subjected to prescription control and the approved indications restricted to intestinal amoebiasis and diarrhoea caused by sensitive organisms following cases of subacute myelo-optic neuropathy (SMON) in Switzerland.

Legislative or regulation action

Product Name Clioquinol (see also halogenated hydroxyquinoline derivatives)

C.A.S. number 130-26-7

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
CUB		Use restricted to treatment of parasitic infections.
NLD		Preparations containing clioquinol have been withdrawn from the market.
SAU		Following reports of subacute myelo-optic neuropathy (SMON) in patients treated with this drug, the Drug Committee has prohibited its import.
THA		The use of pharmaceutical preparations containing clioquinol is severely restricted.
VEN		Subject to restricted use and/or sale.

WHO Comment : Clioquinol, a halogenated hydroxyquinoline derivative, was introduced into medicine around 1900 as a topical antiseptic and in 1934 oral preparations for the treatment of amoebic dysentery and simple diarrhoea became available. By 1964 its use in Japan had been associated with cases of sub-acute myelo-optic neuropathy (SMON) which reached epidemic proportions resulting in its withdrawal there in 1970. Although relatively few cases of SMON were documented elsewhere, clioquinol was subsequently withdrawn from use in many countries and placed under prescription control in others. It was phased out worldwide by the major manufacturer between 1983 and 1985 on grounds of obsolescence. No adequately controlled evidence was ever generated to demonstrate that clioquinol is effective in bacterial or viral diarrhoea. However, products containing clioquinol and related halogenated hydroxyquinolines continue to be used in some tropical and subtropical countries where amoebiasis remains endemic. Other amoebocides are preferred in the WHO Model List of Essential Drugs.

(Reference: (WHODI) WHO Drug Information, 77.1, 9, 1977)

Product Name Clobenzorex

C.A.S. number 13364-32-4

Scientific and common names, and synonyms

(+)-N-(O-CHLOROBENZYL)-ALPHA-METHYLPHENETHYLAMINE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
MUS	Aug 2000	Removed from the market following a similar decision of the Agence Francaise de Securite Sanitaire des Produits de Sante in respect of appetite suppressants in September 1999. (Reference: (MUSCW) Communication to WHO, , , 27 Aug 2001)

Product Name Clofenotane

C.A.S. number 50-29-3A

Scientific and common names, and synonyms

ALPHA,ALPHA-BIS(P-CHLOROPHENYL)-BETA,BETA,BETA-TRICHLOROETHANE

CHLOROPHENOTHANE

DICHLORODIPHENYLTRICHLOROETHANE (USA)

DDT

ETHANE, 1,1,1-TRICHLORO-2,2-BIS(P-CHLOROPHENYL)

P,P'-DICHLORODIPHENYLTRICHLOROETHANE

TRICHLOROBIS(4-CHLOROPHENYL)ETHANE

Legislative or regulation action

Product Name Clofenotane

C.A.S. number 50-29-3A

Scientific and common names, and synonyms

1,1,1-TRICLORO-2,2-BIS(4-CLORO-FENIL)-ETANO (ITA)
 1,1,1-TRICHLORO-2,2-DI(4-CHLOROPHENYL)-ETHANE
 1,1,1-TRICHLORO-2,2-BIS(P-CHLOROPHENYL)ETHANE
 1,1,1-TRICHLORO-2,2-BIS(4-CHLOROPHENYL)ETHANE
 1,1,1-TRICHLOR-2,2-BIS(4-CHLOR-PHENYL)-AETHAN (DEU)
 1,1,1-TRICHLOR-2,2-BIS(4-CHLOOR FENYL)-ETHAAN (NLD)
 2,2-BIS(P-CHLOROPHENYL)-1,1,1-TRICHLOROETHANE
 4,4'-DICHLORODIPHENYLTRICHLOROETHANE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
USA	Jul 1972	The Environmental Protection Agency has cancelled all DDT products, except the following list of uses: the U.S. Public Health Service and other health service officials for control of vector diseases; the USDA or military for health quarantine; in drugs, for controlling body lice. (To be dispensed only by a physician). These compounds have been found to pose carcinogenic risk to humans and to be toxic to the ecosystem. (Reference: (FEREAC) Federal Register, 37, 13369, 1972)
LKA	1 Jan 1976	DDT is banned for use as a pesticide. It was prohibited for crop use prior to 1970. It was phased out of vector control in 1976. No remaining uses allowed. The substance was banned on grounds of long persistent residues and bioaccumulation. (Reference: (LKAPFC) Meeting of the Pesticide Formulary Committee, , , 1988)
BLZ	28 Dec 1985	Severely restricted. Vector control for use only by public health officials. Residue persistency and bio-accumulation. (Reference: (EP1) UNEP/FAO - PIC Circular X - 12/1999, , ,)

Bibliographical references

IARC MONOGRAPH, 5, 83, 1974
 IPCS ENVIRONMENTAL HEALTH CRITERIA, 9, , 1979
 IARC MONOGRAPH, SUPPL.4, 105, 1982
 WHO GUIDELINES FOR DRINKING WATER QUALITY, 2, , 1984
 FAO PLANT PRODUCTION & PROTECTION PAPER, 62, , 1984

Product Name Clofibrate

C.A.S. number 637-07-0

Scientific and common names, and synonyms

ETHYL CLOFIBRATE
 ETHYL ALPHA-(4-CHLOROPHENOXY)-ALPHA-METHYLPROPIONATE
 ETHYL 2-(P-CHLOROPHENOXY)ISOBUTYRATE
 ETHYL 2-(PARA-CHLOROPHENOXY)-2-METHYLPROPIONATE
 PROPANOIC ACID, 2-(P-CHLOROPHENOXY)-2-METHYL, ETHYL ESTER
 PROPANOIC ACID, 2-(4-CHLOROPHENOXY)-2-METHYL, ETHYL ESTER

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
DEU	1978	Although withdrawn following reports of increased mortality associated with its use, clofibrate was subsequently reinstated for treatment of high-risk patients in whom diet, weight reduction, exercise and control of diabetes had failed to elicit adequate control.
DNK	1979	Indications for use have been restricted.

Legislative or regulation action

Product Name Clofibrate

C.A.S. number 637-07-0

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
ISR	1979	Withdrawn from the market following reports of increased mortality associated with use.
NOR	1979	Withdrawn from the market following reports of increased mortality associated with use.
FRA	2 Feb 1979	The indications have been restricted, as for every hypolipidaemic drug, to the treatment of endogenous hypercholesterolaemia and hypertriglyceridaemia a) when a suitable and assiduously followed diet has proved inadequate; and b) when cholesterolaemia is still raised after dieting and/or there are associated risk factors present. (Reference: (FRAPC) Press Communiqué, , , Feb 1979)
USA	Aug 1979	Indications are restricted to treatment of patients with hyperlipidaemia refractory to dietary measures. (Reference: (FDADB) FDA Drug Bulletin, 9(3), 14, 1979)
PHL	1980	Severely restricted in use to certain patients only. This compound has been shown to cause hepatic tumours in rodents. There is an increased risk of malignancy and cholelithiasis with use in humans. A warning statement is required to be placed on the labels of all products.
ITA	1981	Currently marketed in Italy with limited therapeutic indications (certain hyperproteinaemias with ascertained diagnoses; diabetic exudative retinopathy; xanthomes).
SWE	Jan 1981	Used only in cases of severe hyperlipoproteinaemia due to increased mortality connected with long-term treatment.
BGD	1982	Under the provisions of the Drugs (Control) Ordinance, this drug has been banned since it increases the incidence of gallstones and cholecystitis, drug-induced cardiac arrhythmias, cardiomegaly, angina, claudication and thromboembolic phenomena. It also enhances the effects and toxicity of other acidic drugs and it is implicated in the incidence of various tumours. (Reference: (BGDCO) The Drugs (Control) Ordinance, , , 1982)
CHL	16 Dec 1982	Indications are restricted to treatment of patients with high plasma lipid levels, resistant to dietary control. (Reference: (CHLRS) Resolution of the Minister of Health, 3261, , Dec 1982)
CHE		Indications are restricted to treatment of patients with hyperlipidaemia refractory to dietary measures. (Reference: (FDADB) FDA Drug Bulletin, 9(3), 14, 1979)
CUB		Indications are restricted to treatment of patients with hyperlipidaemia.
GBR		Indications are restricted to treatment of patients with hyperlipidaemia refractory to dietary measures. (Reference: (FDADB) FDA Drug Bulletin, 9(3), 14, 1979)
GRC		Indications are restricted to treatment of patients with severe hyperlipidaemia.
IND		Currently available on the market. Precautionary information is required to be given with this drug.
SAU		Severely restricted for use and/or sale.
VEN		Subject to restricted use and/or sale.

WHO Comment : Clofibrate, an antihyperlipidaemic agent, was introduced in 1967 and was subsequently extensively studied in the primary and secondary prevention of ischaemic heart disease. Following reports, published in 1978, of increased mortality among patients receiving clofibrate in a WHO-sponsored cooperative trial concerned with the primary prevention of ischaemic heart disease, the drug was withdrawn in some countries and its approved indications were severely restricted

Legislative or regulation action

Product Name	Clofibrate	
C.A.S. number	637-07-0	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		in many others. These restrictions have become the norm for more recently developed analogues of clofibrate. (Reference: (WHODI) WHO Drug Information, 2, 6, 1979)
Product Name	Cloforex	
C.A.S. number	14261-75-7	
Scientific and common names, and synonyms		
	CLOPHOREX ETHYL(P-CHLORO-ALPHA,ALPHA-DIMETHYLPHENETHYL)-CARBAMATE (P-CHLORO-ALPHA,ALPHA-DIMETHYLPHENETHYL)-CARBAMIC ACID (2-(4-CHLOROPHENYL)-1,1-DIMETHYLETHYL)-CARBAMIC ACID	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	1969	The Ministry of Health withdrew preparations containing aminorex, cloforex and chlorphentermine as a precautionary measure pending scientific evidence of a relationship between their use and the development of pulmonary hypertension.
SWE	14 Feb 1969	All antiobesity preparations containing cloforex were withdrawn from the market following several reports of pulmonary hypertension in patients treated with the related drug chlorphentermine in West Germany, and pre-existing knowledge of a relationship between pulmonary hypertension and the antiobesity drug aminorex.
VEN		Not approved for use and/or sale. WHO Comment : Cloforex, a sympathomimetic phenethylamine derivative, was introduced over twenty years ago for the treatment of obesity. Concern that its use was associated with cases of pulmonary hypertension led to its withdrawal in several countries. WHO has no information to suggest that this drug remains commercially available.
Product Name	Clometacin	
C.A.S. number	25803-14-9	
Scientific and common names, and synonyms		
	3-(P-CHLOROBENZOYL)-6-METHOXY-2-METHYLINDOLE-1-ACETIC ACID	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
FRA	1990	All preparations containing clometacin were withdrawn, having regard to severe cases of hepatitis associated with their use. (Reference: (FRARP) La Revue Prescrire, 10(95), 148, 1990) WHO Comment : Clometacin, an analogue of indometacin, was introduced on the market in 1971. Subsequently several cases of severe - in some cases fatal - hepatitis were reported, which led in 1987 to the withdrawal of a high-dosage tablet formulation, while the indications for a lower dosage tablet were restricted and duration of the treatment was limited. Eventually all tablet formulations were removed from the market. Clometacin is not widely registered in other countries.

Legislative or regulation action

Product Name	Clomethiazole	
C.A.S. number	533-45-9	
Scientific and common names, and synonyms	5-(2-CHLOROETHYL)-4-METHYLTHIAZOLE CHLORETHIAZOLE CHLORETHIAZOL	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		WHO Comment : Clomethiazole, which has sedative, anxiolytic and anticonvulsant activity, was introduced in 1960 for the treatment of acute alcohol withdrawal, delirium tremens, status epilepticus, eclamptic toxæmia, sleep disturbances in the elderly and agitation in psychogeriatric patients. It is also used as a sedative in certain anaesthetic procedures. There is little evidence of primary dependence in man but secondary dependence can occur in patients with a history of abuse of other substances, particularly alcohol. Dependence of this type has been reported as a result of inappropriate, long-term prescribing to outpatient alcoholics. Clomethiazole should not be prescribed to alcoholics who continue to drink. Adverse interactions with alcohol have been fatal. Although not controlled under the 1971 Convention on Psychotropic Substances, clomethiazole is subject to analogous controls in some countries.

Product Name	Clozapine	
C.A.S. number	5786-21-0	
Scientific and common names, and synonyms	5H-DIBENZO(B,E),(1,4)DIAZEPINE, 8-CHLORO-11-(4-METHYL-1-PIPERAZINYL)- 8-CHLORO-11-(4-METHYL-1-PIPERAZINYL)-5H-DIBENZO(B,E)(1,4)DIAZEPINE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
FIN	1975	Withdrawn from general use and restricted to named patients subject to permission of the competent authority.
SGP	Aug 1977	Importation prohibited.
DEU	1978	Clozapine, a tricyclic neuroleptic, was introduced in 1972 for the treatment of psychosis. In 1975 its use was associated with cases of agranulocytosis, particularly in Finland. These cases, which included several fatalities, resulted in the withdrawal of the drug in some countries. However, clozapine remains available in at least 30 countries, in some cases only on special request, for the treatment of severe psychotic disorders unresponsive to other neuroleptics provided that close monitoring of the blood count is feasible. In 1989, it was introduced in the United States for the treatment of severe schizophrenia. Lately, the use of clozapine in the United Kingdom has been associated with convulsions. (Reference: (WHODI) WHO Drug Information, 2, 10, 1977)
NOR	1986	Registration refused since the balance of safety and efficacy does not justify registration. (Reference: (NNSLM) Nytt fra Statens Legemiddelkontroll, 2, 15, 1986)
ESP	Oct 1993	The Directorate General of Pharmacy and Health Products of the Ministry of Health and Consumer Affairs has restricted the use of the neuroleptic agent, clozapine (Leponex®: Sandoz) because incorrect use of this product could result in serious adverse reactions. The package will state that clozapine is subject to medical prescription and supervision and the outside container will bear the words "SPECIAL MEDICAL CONTROL". The product information will also state immediately after the name "SPECIALITY SUBJECT TO SPECIAL MEDICAL CONTROL". Clozapine should be prescribed only by a psychiatrist, who must ensure at the onset that the patient's leukocyte count is within

Legislative or regulation action

Product Name	Clozapine	
C.A.S. number	5786-21-0	
Legislative or regulatory action		
Country	Effective Date	Description of action taken Grounds for decision
		normal limits, and arrange for subsequent counts to be performed at weekly intervals for 18 weeks, and at monthly intervals thereafter for as long as treatment is continued. (Reference: (ESPCR) Circular, No. 10/93, ,)
GBR	1 Jan 1994	The manufacturer of the neuroleptic agent, clozapine (Clozaril) has modified® the instructions regarding dosage and administration. A section on drug interactions has been added, and the section on adverse effects has been expanded. (Reference: (GBRPHJ) The Pharmaceutical Journal, 252: 37, , 1994)
NZL	May 1994	Because of the risk of agranulocytosis, patients taking clozapine should have weekly blood count checks during the first 18 weeks of therapy and monthly thereafter. Patients taking clozapine and presenting with symptoms of infection should be checked immediately for neutropenia. (Reference: (NZLPU) Prescriber Update, No.5, , May 1994)
FRA	Feb 1995	The French Commission of Pharmacovigilance has agreed with the manufacturer of the antipsychotic agent, clozapine (Leponex®: Sandoz), to revise the product information to include detailed instructions on use and to warn against the risk of neutropenia, agranulocytosis and neurologic disorders. (Reference: (FRAAMC) Communiqué de Presse, , , 14 June 1995)
<p>WHO Comment : Clozapine, a tricyclic neuroleptic, was introduced in 1972 for the treatment of psychosis. In 1975 its use was associated with cases of agranulocytosis, particularly in Finland. These cases, which included several fatalities, resulted in the withdrawal of the drug in some countries. However, clozapine remains available in at least 30 countries, in some cases only on special request, for the treatment of severe psychotic disorders unresponsive to other neuroleptics provided that close monitoring of the blood count is feasible. In 1989, it was introduced in the United States for the treatment of severe schizophrenia. Lately, the use of clozapine in the United Kingdom has been associated with convulsions.</p> <p>(Reference: (WHODIB) WHO Drug Information Bulletin, 2: 10, , 1977)</p>		
Product Name	Cobalt (non-radioactive forms)	
C.A.S. number	7440-48-4	
Legislative or regulatory action		
Country	Effective Date	Description of action taken Grounds for decision
USA	Jul 1967	Withdrawn from the market and prohibited for export (non-radioactive forms only) by the Food and Drug Administration due to the lack of evidence of effectiveness in treating iron-deficiency anemia and on the basis of toxic effects in humans including liver damage, claudication, myocardial damage, thyroid hyperplasia, hypothyroidism, dermatitis, nausea and anorexia. (Reference: (FEREAC) Federal Register, 32, 7945, 1967)
KWT	26 Oct 1967	Importation and marketing of preparations containing inorganic cobalt salts are prohibited.
<p>WHO Comment : The World Health Organization has no information further to the above regarding preparations containing cobalt or to indicate that they are still commercially manufactured.</p>		
Product Name	Codeine	
C.A.S. number	6095-47-8	
Legislative or regulation action		

Product Name Codeine

C.A.S. number 6095-47-8

Scientific and common names, and synonyms

6-HYDROXY-3-METHOXY-N-METHYL-4,5 EPOXYMORHIN-7-ENE
7,8-DIDEHYDRO-4,5-ALPHA-EPOXY-3-METHOXY-17-METHYLMORPHINAN-6-ALPHA-OL MONOHYDRATE
MORPHINAN-6-OL, 7,8-DIDEHYDRO-4,5-EPOXY-3-METHOXY-17-METHYL-, MONOHYDRATE, (5ALPHA,6ALPHA)

Legislative or regulatory action

Country	Effective Date	Description of action taken Grounds for decision
BGD	Sep 1985	Use of codeine in any dosage form has been banned due to liability for addiction and misuse.
MYS	1 Jan 1996	The Drug Control Authority has banned the import of all cough preparations containing codeine with effect on 1 January 1996 and all imported products have been recalled. Local manufacture of all combination products containing codeine with ephedrine or pseudoephedrine has also been banned and product registrations have been withdrawn. The products can be reformulated and new applications for registration submitted. The agency has not registered any new product containing codeine since 1992, when a decision was made to stop registration of new codeine-containing products. (Reference: (MYS DI) Berita Ubat-Ubatan (Drug Information), 9(4): 2, , Dec 1995)
MUS	Aug 2001	All codeine based products have been moved to the prescription-only status, import of these products require authorization from the Ministry of Health, Importers and distributors are required to submit monthly returns of sales. (Reference: (MUSCW) Communication to WHO, , , 27 Aug 2001)
MYS	31 Dec 2002	The Drug Control Authority in Malaysia has announced that liquid codeine-containing preparations will not be available after 31 December 2002. This announcement follows its decision to cancel the registration of these products due to the growing problem of codeine misuse and abuse in Malaysia. (Reference: (MYS DN) Berita Ubat-Ubatan (Drug Newsletter), 19:5, , Aug 2002)

**WHO Comment : Codeine, which has antitussive, opioid analgesic and antidiarrhoeal activity, was first extracted from opium in 1832 and has since been widely used in medicine. The development of dependence and its potential for abuse resulted in the control of the substance under Schedule II of the 1961 Single Convention on Narcotic Drugs. Preparations containing codeine remain widely available and are included in the WHO Model List of Essential Drugs.
(Reference: (WHTAC1) The Use of Essential Drugs, 2nd Report of the WHO Expert Committee, 722, , 1985)**

Product Name Coumarin (synthetic)

C.A.S. number 91-64-5

Scientific and common names, and synonyms

2H-1-BENZOPYRAN-2-ONE

Legislative or regulatory action

Country	Effective Date	Description of action taken Grounds for decision
AUS	15 Aug 1996	The Department of Health and Family Services cancelled the registration of 200 mg coumarin tablets (Lodema®) on the grounds that the safety and quality of the product are unacceptable, after reports of death in women who developed hepatotoxicity associated with its use. (Reference: (AUSTGA) Therapeutic Goods Administration, Department of Community Services and Health, , , 23 Aug 1996)
FRA	Dec 1996	The manufacturer, with the agreement of the Agence du Médicament, has decided to suspend the marketing authorization of coumarin (Lysedem®) because of its

Legislative or regulation action

Product Name	Coumarin (synthetic)	
C.A.S. number	91-64-5	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		unfavourable risk/benefit profile, and particularly because of several reports of hepatic adverse effects. (Reference: (FRAAMR) Rapid Alert - Pharmacovigilance, , , 23 Dec 1996)

Product Name	Cyclamates in drugs	
C.A.S. number	139-05-9	
Scientific and common names, and synonyms		
	CYCLOHEXANESULFAMIC ACID SULFAMIC ACID, CYCLOHEXYL-	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
PER	Oct 1969	Banned in pharmaceuticals due to its carcinogenic effects in experimental animals.
PHL	Jan 1971	Cyclamic acid (or its salts) used as a sweetening agent in drugs has been withdrawn due to evidence of its carcinogenicity in animals.
PAN	23 Nov 1971	Cyclamates are no longer allowed in pharmaceutical preparations. (Reference: (PANMR) Ministry of Health Resolution, 534, , Nov 1971)
THA	Dec 1974	As pharmaceutical ingredients, cyclamate and its salts are restricted to dosages of 3.5 g/day in adults and 1.2 g/day in children.
BGD	Jun 1982	Use of cyclamate as a sweetening agent has been banned due to reported adverse effects.
GRC	1986	Registration not approved.
NGA	1988	Sodium cyclamate has been banned, because its use has been associated with carcinogenicity in experimental animals. (Reference: (NGAPN) Pharmanews, 10(11), 15, 1988)
		WHO Comment : Cyclamates, non-nutritive sweetening agents, have been used as additives in food and drugs since 1950. They have been demonstrated to have a carcinogenic potential at very high and long-sustained dosage in experimental animals. Some countries have consequently banned their use as food additives, whereas in others they remain available for this purpose. Most countries, however, continue to allow their use in small quantities in pharmaceutical preparations. (Reference: (WHODI) WHO Drug Information, 77.2, 12, , 1977)

Product Name	Cyclandelate	
C.A.S. number	456-59-7	
Scientific and common names, and synonyms		
	3,3,5-TRIMETHYLCYCLOHEXYL MANDELATE 3,3,5-TRIMETHYLCYCLOHEXANOL ?-PHENYL-?-HYDROXYACETATE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
USA	Dec 1996	The Food and Drug Administration withdrew the marketing approval for the peripheral vasodilator cyclandelate on the grounds that this product has not been shown to be

Legislative or regulation action

Product Name	Cyclandelate	
C.A.S. number	456-59-7	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		effective for such use. (Reference: (FEREAC) Federal Register, 61(233) , p. 64099, 1996) WHO Comment : Cyclandelate is a papaverine type spasmolytic and vasodilating drug intended for symptomatic treatment of various peripheral vascular disorders, such as intermittent claudication in arteriosclerosis obliterans as well as a treatment for cognitive dysfunction in patients suffering from senile dementia of the multi-infarct or Alzheimer's type. Cyclandelate remains registered in several countries.
Product Name	Cyclopenthiazide	
C.A.S. number	742-20-1	
Scientific and common names, and synonyms		
2H-1,2,4-BENZOTHIADIAZINE-7-SULFONAMIDE, 6-CHLORO-3-(CYCLOPENTYLMETHYL)-3,4-DIHYDRO-,1,1-DIOXIDE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
NZL	Feb 1997	The Therapeutics Section has restricted the indications for the thiazide diuretic, cyclopenthiazide, by deleting the indications for idiopathic hypercalciuria and oedema due to heart failure. (Reference: (NZLPU) Prescriber Update, No.14, , Feb 1997) WHO Comment : Cyclopenthiazide, a thiazide diuretic, was introduced in 1968. It continues to be used mainly in combination drugs.
Product Name	Cyproheptadine	
C.A.S. number	129-03-3	
Scientific and common names, and synonyms		
PIPERIDINE,4-(5H-DIBENZO(A,D)CYCLOHEPTEN-5-YLIDENE)-1-METHYL- PIPERIDINE, 4-(5H-DIBENZO[A,D]-CYCLOHEPTEN-5-YLIDENE)-1-METHYL-, HYDROCHLORIDE, SESQUIHYDRATE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GHA	1979	Sale and use of preparations containing cyproheptadine have been severely restricted due to abuse of its appetite stimulant effect.
BGD	1982	Under the provisions of the Drugs (Control) Ordinance, cyproheptadine was banned following unacceptable promotion encouraging its use as an appetite stimulant. (Reference: (BGDCO) The Drugs (Control) Ordinance, , , 1982)
MYS	Nov 1986	All products containing cyproheptadine marketed as an appetite stimulant have been withdrawn. (Reference: (MYSDC) Malaysian Drug Control Authority, No.4, , Nov 1986)
GBR	Jan 1994	The manufacturer of the antihistamine, cyproheptadine, has announced that it is no longer indicated as an appetite stimulant. The syrup formulation as the most often used in children will no longer be available in the United Kingdom. Use of the product as an antihistamine is not affected. (Reference: (GBRPHJ) The Pharmaceutical Journal, 252:136, , 1994)

Legislative or regulation action

Product Name	Cyproheptadine	
C.A.S. number	129-03-3	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		WHO Comment : Cyproheptadine, an antihistamine with anticholinergic and serotonin-antagonist properties, was introduced in 1961 for the symptomatic relief of allergy and was subsequently used as an appetite stimulant. In 1982 the drug was prohibited in Bangladesh because of its misuse as an appetite stimulant due to inappropriate promotion. Cyproheptadine remains widely available and the current marketing policy of the major manufacturer requires that it should be used as an appetite stimulant only under the supervision of a physician who should be assured that adequate food is available.
Product Name	Cyproterone acetate	
C.A.S. number	2098-66-0	
Scientific and common names, and synonyms		
3H-CYCLOPROPA[1,2]PREGNA-1,4,6-TRIENE-3,20-DIONE, 17-(ACETYLOXY)-6-CHLORO-1,2-DIHYDRO-, (1?,2?)-		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GBR	Feb 1995	The Committee on Safety of Medicines decided that in view of the hepatotoxicity associated with long-term daily use of cyproterone in prostatic cancer, it should be restricted to short courses to cover flare associated with testosterone agonists, to treatment of hot flushes after orchidectomy or LHRH agonists and to patients who have not responded to, or are intolerant of other treatments. (Reference: (GBRCP) Current Problems in Pharmacovigilance, vol.21, , Feb 1995)
		WHO Comment : Cyproterone was introduced in the late sixties. It is an orally-active anti-androgen with competitive inhibitory effects on androgen-sensitive target organs. It also has anti-gonadotropic and progestative properties. In 1995 the drug was found to have a hepatotoxic effect.
Product Name	Dalkon shield	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
USA	1974	The Dalkon shield has not been marketed since 1974, when the manufacturer withdrew the product from distribution following reports of mid-trimester septic abortions. In September 1980 the manufacturer issued a letter to all doctors recommending removal of all Dalkon shields due to an increased risk of pelvic inflammatory disease caused by actinomyces israeli. The Food and Drug Administration has recently stated that due to an increased risk of pelvic inflammatory disease, the Dalkon shield intrauterine device should be removed from any woman still using one. Women using the Dalkon shield were shown to have a fivefold increased risk of pelvic inflammatory disease compared with women using other types of IUD. (Reference: (FDADB) FDA Drug Bulletin, 13(2), , 1983)
GBR	1985	The manufacturer of the device has written to all doctors reminding them that women still wearing the Dalkon shield should have the device removed. Marketing was discontinued in 1975 and a similar letter was distributed in 1980.
NZL	1985	The New Zealand Health Authorities have instituted a programme to ensure that all women still wearing a Dalkon shield IUD have their device removed.
Legislative or regulation action		

Product Name **Dalkon shield**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
		(Reference: (NZCSL) Clinical Services Letter, Department of Health, 234, , July 1985)

Product Name **Danazol**

C.A.S. number **2004-0-0004**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
GBR	10 Sep 2003	The use of danazol (Danol) has been restricted to second-line therapy in endometriosis and benign fibrocystic breast disease, as a result of safety and risk-benefit assessments suggesting that it may increase the baseline risk of ovarian cancer in patients being treated for endometriosis. (Reference: (GBRMI) News and updates, , , 10 Sep 2003)

Product Name **Dantron**

C.A.S. number **117-10-2**

Scientific and common names, and synonyms

9,10-ANTHRACENEDIONE,1,8-DIHYDROXY,1,8-DIHYDROXYANTHRAQUINONE
9,10-ANTHRACENEDIONE,1,8-DIHYDROXY-
ANTRAPUROL
CHRYSAZIN
DIANTHON
DANTHRON
1,8-DIHYDROXYANTHRAQUINONE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
NOR	1987	The major manufacturer has discontinued production of products containing dantron. All other manufacturers in Norway have subsequently withdrawn such preparations. (Reference: (NNSLM) Nytt fra Statens Legemiddelkontroll, 3(6), , 1987)
DEU	31 Jan 1987	The Federal Health Office no longer permits the use of dantron in pharmaceutical preparations.
JPN	Feb 1987	The Ministry of Health and Welfare has requested manufacturers to discontinue production and marketing of laxatives containing dantron.
USA	30 Mar 1987	The United States Food and Drug Administration advised manufacturers to discontinue production of laxatives containing dantron and to recall all such products from retail stores.
GBR	Apr 1987	The Committee on Safety of Medicines advised that the licensed indications for those products containing dantron that remain on the market should be limited to: (1) constipation in geriatric practice and analgesic-induced constipation in the terminally ill and (2) constipation in cardiac failure and coronary thrombosis (conditions in which defaecation must be free of strain). The Committee also advised that these products should be subjected to prescription control as quickly as possible.
SGP	15 Jan 1988	The Ministry of Health has prohibited the import and sale of dantron on the basis of potential carcinogenicity.

Legislative or regulation action

Product Name	Dantron	
C.A.S. number	117-10-2	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		(Reference: (SGPRD) The Sale of Drugs (Prohibited Drugs) Regulations, S9, 7, Jan 1988)
CAN	Nov 1997	After reviewing the benefits and risks associated with the use of dantron-containing stimulant laxatives, Health Canada has concluded that dantron is a genotoxic animal carcinogen and that the risks of using these products outweigh the therapeutic benefits. Dantron is a synthetic anthraquinone and, although there is no direct evidence that it has caused cancer in humans, it may have a carcinogenic potential. Manufacturers have voluntarily ceased sale of their products. (Reference: (CANPR) Press Release, 1997-64, , 25 Nov 1997)
CAN	25 Nov 1997	After reviewing the benefits and risks associated with the use of dantron-containing stimulant laxatives, Health Canada has concluded that dantron is a genotoxic animal carcinogen and that the risks of using these products outweigh the therapeutic benefits. Dantron is a sythetic anthraquinone and, although there is no direct evidence that it has caused cancer in humans, it may have a carcinogenic potential. Manufacturers have voluntarily ceased sale of their products. (Reference: (CANPR) Press Release, 1997-64, , 25 Nov 1997)
GBR	May 2000	The Medicines Control Agency has severely restricted the use of the laxative, dantron following studies showing genotoxicity. It is now restricted to use in terminally ill adult patients only. (Reference: (GBRMCA) Communication to WHO, , , 30 Aug 2000)
WHO Comment : Dantron, an anthroquinone derivative, has been available for over twenty years and is widely used as a laxative. The results of two chronic toxicity studies in rodents, published in 1985 and 1986, have shown that administration of high doses is associated with the development of intestinal and liver tumours.		

Bibliographical references

IARC MONOGRAPH, 50, 265, 1990

Product Name	Depot medroxyprogesterone acetate (DMPA)	
C.A.S. number	71-58-9	
Scientific and common names, and synonyms	DMPA PREGN-4-ENE,3,20-DIONE, 17-(ACETYLOXY)-6-METHYL-,(6ALPHA) 17-HYDROXY-6ALPHA-METHYLPREGN-4-ENE-3,20-DIONE ACETATE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	1983	The use of injectable steroid preparations for contraceptive purposes has been restricted to use by women with a normal menstrual cycle who do not tolerate other forms of contraception. Pregnancy must be excluded before treatment is started and it is contraindicated during lactation. The label must bear a warning about adverse effects including menstrual disturbances and headaches.
GBR	1983	Approved for long-term contraception when other methods are unacceptable or inappropriate.
SWE	1983	Approved for long-term contraception when other methods have given rise to adverse reactions or otherwise been judged as inappropriate. Patients must accept that after conclusion of treatment return of fertility may be slow.
ZMB	7 Dec 1983	The use of medroxyprogesterone acetate in injectable form as a contraceptive is

Legislative or regulation action

Product Name	Depot medroxyprogesterone acetate (DMPA)	
C.A.S. number	71-58-9	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		prohibited. The drug may only be imported or exported on a licence issued by the Director of Medical Services. (Reference: (ZMBSI) Statutory Instrument, No.166-167, , Dec 1983)
EGY	1984	Use of this drug was restricted to contraception in women with a normal menstrual cycle who do not tolerate other forms of contraception.
USA	1984	Approval for this product was not granted on the grounds that the available evidence did not provide a sufficient basis for determining that depot medroxyprogesterone acetate is safe for general marketing in the USA. However, multinational studies subsequently indicated that the risk of cancer associated with its use was minimal or absent and the drug was registered in 1992. (Reference: (HHSNS) HHS News: US Department of Health and Human Services, , , 29 Oct 1992) (Reference: (FEREAC) Federal Register, 49, 43507, Oct 1984)
		WHO Comment : A depot preparation containing 150 mg medroxyprogesterone acetate was introduced over 20 years ago for use as a long-acting injectable contraceptive. Subsequently, positive results of carcinogenicity studies carried out in beagle bitches led to refusal of registration in the United States. These findings were later considered irrelevant to contraceptive use in women and the drug was approved by the Food and Drug Administration. Menstrual irregularities are the most common adverse effect associated with depot medroxyprogesterone acetate. Risk-benefit judgements differ significantly from country to country, having regard to differing national circumstances. The preparation is, however, widely available and is included in the WHO Model List of Essential Drugs. (Reference: (WHTAC4) The Use of Essential Drugs, 4th Report of the WHO Expert Committee, 796, , 1990) (Reference: (WHTAC1) The Use of Essential Drugs, 2nd Report of the WHO Expert Committee, 722, , 1985) (Reference: (WHODI) WHO Drug Information, 2(1), 31, 1988)
Product Name	Dequalinium	
C.A.S. number	6707-58-0	
Scientific and common names, and synonyms		
	DECAMINIUM DECALINIUM CHLORIDE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
BGR	Aug 1998	The Bulgarian Drug Agency in the Ministry of Health withdrew the vaginal tablet of dequalinium (Efisol) because of serious adverse reactions reported in the country. (Reference: (BGRBDA) Communication to WHO, , ,)
Product Name	Dequalinium chloride	
C.A.S. number	522-51-0	
Scientific and common names, and synonyms		
	1,1'-DECAMETHYLENEBIS (4-AMINOQUINALDINIUM CHLORIDE)	
Legislative or regulative action		

Legislative or regulation action

Product Name	Dequalinium chloride	
C.A.S. number	522-51-0	
Country	Effective Date	Description of action taken Grounds for decision
GRC	1984	Withdrawn from the market due to an unacceptable benefit to risk ratio (low efficacy/skin reactions). WHO Comment : Skin reactions to dequalinium chloride, including necrotic lesions, have been reported. It remains available as a mouth and throat disinfectant in many countries.

Product Name	Dexamfetamine	
C.A.S. number	51-64-9	
Scientific and common names, and synonyms		
BENZENEETHANAMINE, ALPHA-METHYL-, (S)- DEXTROAMPHETAMINE DEXAMPHETAMINE (+)-ALPHA-METHYLPHENETHYLAMINE		

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
USA	1973	Anorectic drugs containing dexamfetamine were withdrawn from the market by the Food and Drug Administration due to evidence of abuse and a high risk of dependence.
TUR	6 Sep 1982	Banned for production, import, export, sale and use.
OMN	10 May 1982	Import and marketing of products containing dexamfetamine were prohibited. (Reference: (OMNCR) Circular, 11/82, , May 1982)
NGA	1988	All products containing dexamfetamine have been banned. (Reference: (NGAPN) Pharmanews, 10(11), 15, 1988) WHO Comment : Dexamfetamine, an amphetamine derivative, is controlled under Schedule II of the 1971 Convention on Psychotropic Substances. See WHO comment for amphetamine. (Reference: (UNCPS2) United Nations Convention on Psychotropic Substances (II), , 1971)

Product Name	Dexfenfluramine	
C.A.S. number	3239-44-9	
Scientific and common names, and synonyms		
(S)-N-ETHYL-ALPHA-METHYL-3-(TRIFLUOROMETHYL)BENZENEETHANAMINE		

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
BRA	Aug 2001	Registration has been cancelled due to risks of heart valve disorders. (Reference: (BRARES) Resolucao n., 147/ANVISA, , 14 Aug 2001)

Product Name	Dexfenfluramine hydrochloride	
C.A.S. number	3239-45-0	
Scientific and common names, and synonyms		
(S)-N-ETHYL-A-METHYL-3-TRIFLUOROMETHYLPHENETHYLAMINE HYDROCHLORIDE		

Legislative or regulation action

Product Name	Dexfenfluramine hydrochloride	
C.A.S. number	3239-45-0	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
MAR	Sep 1997	The manufacturer of dexfenfluramine removed the product dexfenfluramine from the market because of the risk of rare, but potentially fatal pulmonary artery hypertension. (Reference: (MARDMP) Letter to WHO, , , 08 Sep 2000)
PHL	Sep 1998	The Department of Health Bureau of Food and Drugs has noted the voluntary withdrawal by the sponsoring company of the anorectic drugs fenfluramine and dexfenfluramine. (Reference: (PHLCTW) Communication to WHO, , , 15 Aug 2000)
LTH	May 2000	The State medicines Control Agency has withdrawn for the market capsules of dexfenfluramine for reasons of safety. (Reference: (LTHMCA) Order of State Medicines Control Agency, No. 8, , 10 Jan 2000)
Product Name	Dextromethorphan	
C.A.S. number	125-71-3	
Scientific and common names, and synonyms		
(9ALPHA,13ALPHA,14ALPHA)-3-METHOXY-17-METHYLMORPHINAN		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
OMN	Jun 2001	All preparations containing dexamethorphan, either alone or in combination, have been classified as controlled non-psychotropic drugs. This action was taken to ensure that the drug is not misused, in view of a huge increase in its consumption in the form of cough preparations etc. (Reference: (OMNCR) Circular, 22/2001, , 22 July 2002)
Product Name	Dibenzepin hydrochloride	
C.A.S. number	315-80-0	
Scientific and common names, and synonyms		
11H-DIBENZO(B,E)(1,4)-DIAZEPIN-11-ONE, 10-(2-DIMETHYLAMINO)-ETHYL)-5, 10-DIHYDRO-5-METHYL-, MONOHYDROCHLORIDE		
10-(2-DIMETHYLAMINO)ETHYL)-5,10-DIHYDRO-5-METHYL-11H-DIBENZO(B,E),(1,4)-DIAZEPIN-11-ONE MONOHYDROCHLORIDE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
SWE	1 Jan 1983	Dibenzepin hydrochloride was associated with an unexpectedly high number of fatal suicidal attempts. The drug was withdrawn following discussions between the company and the National Board of Health and Welfare. WHO Comment : Dibenzepin hydrochloride, a tricyclic antidepressant, was introduced in 1968 for the treatment of depressive illness. By 1973 its use in Sweden had been associated with an unexpectedly high number of suicide attempts which led to its withdrawal in that country. Although its use has lapsed in several countries, it remains available in at least eight European countries.
Product Name	Diclofenac sodium	
C.A.S. number	15307-79-6	

Legislative or regulation action

Product Name **Diclofenac sodium**

C.A.S. number **15307-79-6**

Scientific and common names, and synonyms

ACETIC ACID, O-(2,6-DICHLOROANILINO)PHENYL-, MONOSODIUM SALT
 BENZENEACETIC ACID, 2-((2,6-DICHLOROPHENYL)AMINO)-, MONOSODIUM SALT
 SODIUM (O-(2,6-DICHLOROANILINO)PHENYL) ACETATE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
PHL	Sep 1983	Disapproved for use due to fear of exposure of young children to risks of agranulocytosis, leucopenia and thrombocytopenia.
NOR	1987	Diclofenac acid is not approved for registration because the results of carcinogenicity testing in rats were not clearly negative and testing in another species is required. WHO Comment : The World Health Organization currently has no information to suggest that diclofenac is less safe than other widely available non-steroidal antiinflammatory substances of this type, or that children are particularly liable to react adversely. It is registered in many countries in several dosage forms, including a 12.5 mg suppository indicated for juvenile arthritis.

Product Name **Dicycloverine**

C.A.S. number **77-19-0**

Scientific and common names, and synonyms

DICYCLOMINE
 (BICYCLOHEXYL)-1-CARBOXYLIC ACID, 2-(DIETHYLAMINO)ETHYL ESTER
 2-(DIETHYLAMINO)ETHYL (BICYCLOHEXYL)-1-CARBOXYLATE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
SWE	1985	The Swedish Board of Drugs has recommended that dicycloverine be used only by specialists for the treatment of very severe cases of infantile colic. (Reference: (SSLMS) Information från Socialstyrelsens Läkemedelsavdelning, No.6, , Oct 1985)
AUS	20 Feb 1985	The manufacturer has warned against administration of dicycloverine to infants under six months of age and deleted colic from the indications.
NZL	18 Mar 1986	The Department of Health has issued a statement that liquid dicycloverine preparations for the treatment of colic are no longer recommended for infants under six months of age. (Reference: (NZCSL) Clinical Services Letter, Department of Health, 242, , 1986)
BGD	Dec 1986	Syrup and drop forms are being withdrawn to avoid possible misuse and adverse reactions in children.
GBR		The manufacturer has warned against administration of dicycloverine to infants under six months of age and deleted colic from the indications.
NOR		In view of its propensity to cause serious adverse reactions in infants under six months of age, the Drug Control Board has prohibited the import of dicycloverine. WHO Comment : Dicycloverine, an anticholinergic agent with antispasmodic and local anaesthetic activity, was introduced in 1952 for treatment of functional conditions involving smooth muscle of the gastrointestinal tract. Its use in the treatment of colic in infants under six months of age has been associated with irritability and restlessness, convulsions and apnoea which has led the major manufacturer to issue revised global prescribing information in 1985 contraindicating the use of dicycloverine in this age group. Subsequently restrictive regulatory action directed to other available brands of this drug was

Legislative or regulation action

Product Name	Dicycloverine	
C.A.S. number	77-19-0	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
taken in several countries. Preparations containing dicycloverine remain available in at least ten major markets.		

Product Name	Dienestrol	
C.A.S. number	84-17-3	
Scientific and common names, and synonyms		
DINOEX		
DIENOL		
PHENOL, 4,4'-(DIETHYLIDENEETHYLENE)DI-		
4,4'-(1,2-DIETHYLIDENE-1,2-ETHANEDIYL)BIS-PHENOL,(E,E)-		

Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
AUT	Feb 1977	Pharmaceutical specialities containing dienestrol, diethylstilbestrol, hexestrol and their derivatives have been withdrawn following reports indicating an association between prenatal exposure to diethylstilbestrol and the subsequent development of adenocarcinoma in post pubertal girls and young women. The use of stilbene derivatives is only authorized for the treatment of cancer of the prostate.
ITA	1979	Withdrawn from the market due to suspected carcinogenicity in newborns following prenatal exposure.
KWT	Apr 1980	Prohibited for import.
SAU		Following reports indicating the development of adenocarcinoma in post-pubertal girls and young women exposed prenatally to preparations containing diethylstilbestrol, dienestrol and their derivatives, the Drug Committee prohibited the use of these products during pregnancy.
VEN		Subject to restricted use and/or sale.
WHO Comment : Dienestrol is a stilbene derivative. See WHO comment for diethylstilbestrol. Vaginal forms of dienestrol, which were introduced in 1947, are currently available in over 35 countries for the management of hypoestrogenic vaginal atrophy. (Reference: (WHODI) WHO Drug Information, 77.1, 16, 1977)		

Product Name	Diethylaminoethoxyhexestrol	
C.A.S. number	2691-45-4	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
JPN	Dec 1970	This product for the treatment of angina pectoris was voluntarily withdrawn from production by the manufacturer due its effects on the liver.
WHO Comment : The World Health Organization has no information further to the above regarding preparations containing diethylaminoethoxyhexestrol, a coronary vasodilator, or to indicate that they are still commercially manufactured.		

Product Name	Diethylstilbestrol	
Legislative or regulation action		

C.A.S. number 56-53-1

Scientific and common names, and synonyms

ALPHA,ALPHA'-DIETHYL-(E)-4,4'-STILBENEDIOL
DIETHYLSTILBOESTROL
PHENOL, 4,4'-(1,2-DIETHYL-1,2-ETHENEDIYL)BIS-(E)-
STILBOESTROL

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
PAN	15 Jul 1973	Sale and use of diethylstilbestrol or its derivatives in subcutaneous implants is prohibited. (Reference: (PANMR) Ministry of Health Resolution, No.1A, , Jan 1973)
USA	4 Aug 1975	Because of a statistically significant association between maternal ingestion during pregnancy of diethylstilbestrol (and close congeners) and the occurrence of vaginal carcinoma in the offspring, the labelling of all such products has previously been required to state that their use in pregnancy is contraindicated. An additional warning is now required concerning the possible development of vaginal adenosis in postpubertal girls whose mothers received diethylstilbestrol during pregnancy. (Reference: (FEREAC) Federal Register, 40, 32773, Aug 1975)
AUT	Feb 1977	Pharmaceutical specialities containing diethylstilbestrol, dienestrol, hexestrol and their derivatives have been withdrawn following reports indicating an association between prenatal exposure to diethylstilbestrol and the subsequent development of adenocarcinoma in postpubertal girls and young women. The use of stilbene derivatives is only authorized for the treatment of cancer of the prostate.
DEU	Feb 1977	Indications for use restricted to the treatment of carcinoma of the prostate.
GRC	1980	Diethylstilbestrol is registered solely for the treatment of cancer of the prostate.
KWT	Jan 1980	Importation of pharmaceutical preparations containing diethylstilbestrol and diethylstilbestrol diphosphate is prohibited.
TUN	May 1983	Prohibited for pregnancy-related uses in women; restricted to urological use only.
ITA		Withdrawn from the market owing to an unfavourable risk-benefit ratio and the lack of substantial evidence of efficacy.
SAU		Following reports indicating the development of adenocarcinoma in post-pubertal girls and young women exposed prenatally to preparations containing diethylstilbestrol, dienestrol and their derivatives, the Drug Committee prohibited the use of these products during pregnancy. WHO Comment : Diethylstilbestrol, a synthetic estrogen which is a stilbene derivative, was introduced into obstetric practice in the late 1940s and subsequently widely used for the treatment of threatened abortion. This use was later shown to be associated with an increased risk of vaginal cancer in the offspring which resulted in restrictive regulatory action in several countries. Diethylstilbestrol and other stilbenes remain available in many countries, however, for the treatment of certain hormone-dependent neoplasms including carcinoma of the prostate and postmenopausal breast cancer. (Reference: (WHODI) WHO Drug Information, 77.1, 16, 1977)

Bibliographical references

IARC MONOGRAPH, 6, 55, 1974
IARC MONOGRAPH, 21, 173, 1979
IARC MONOGRAPH, SUPPL.4, 184, 1982

Product Name

Difemerine

C.A.S. number

80387-96-8

Scientific and common names, and synonyms

2-(DIMETHYLAMINO)-1,1-DIMETHYLETHYL BENZILATE

Legislative or regulation action

Product Name **Difemerine**

C.A.S. number **80387-96-8**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
DEU	Mar 1986	Oral preparations of difemerine were withdrawn by the manufacturer on the grounds of exceptionally frequent adverse effects.

Product Name **Difenoxin**

C.A.S. number **28782-42-5**

Scientific and common names, and synonyms

DIFENOXYLIC ACID

1-(3-CYANO-3,3-DIPHENYLPROPYL)-4-PHENYL-ISONIPECOTIC ACID

4-PIPERIDINECARBOXYLIC ACID, 1-(3-CYANO-3,3-DIPHENYLPROPYL)-4-PHENYL-

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
PAK	Jun 1990	Drop and syrup formulations of products containing difenoxin intended for the treatment of diarrhoea in children were banned.
OMN	Sep 1990	Import and marketing of oral preparations intended for paediatric use containing difenoxin were prohibited. (Reference: (OMNMH) Ministry of Health, , , 29 Sep 1990)
KOR	May 1991	Antidiarrhoeal products containing difenoxin were not accepted for registration. (Reference: (KRMHSA) Ministry of Health and Social Affairs - Communication to WHO, , , 13 Dec 1991)
LBN	Aug 1991	Use of products containing difenoxin in children under 5 years of age was discontinued and preparations for paediatric use were withdrawn. (Reference: (LBNMHD) Ministry of Health and Social Affairs Decree, 150/1, , Aug 1991) WHO Comment : Difenoxin is the principal metabolite of diphenoxylate. See WHO comment for diphenoxylate.

Product Name **Difurazone**

C.A.S. number **804-36-4**

Scientific and common names, and synonyms

1,3-BIS(5-NITROFURFURYLIDEN)ACETONEGUANYLHYDRAZONE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
JPN	Jul 1977	Withdrawn from all marketed preparations on the grounds that it has been superseded by safer and more effective preparations.
SAU		The withdrawal of nitrofurans is under consideration since they have been superseded by safer and more effective preparations.
VEN		Not approved for use and/or sale. WHO Comment : Difurazone, a nitrofurans derivative, was formerly used as an anti-infective agent. It has, however, been superseded by safer compounds and WHO has no information to suggest that it remains commercially available.

Product Name **Dihydrostreptomycin**

Legislative or regulation action

C.A.S. number 128-46-1

Scientific and common names, and synonyms
DST
DHSM

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
USA	Sep 1970	Withdrawn from the market (injectable form) and prohibited for export by the Food and Drug Administration on the grounds of an unfavourable benefit/risk ratio. This antibiotic is considered unsafe due to its ototoxic hazards.
PHL	1972	Dihydrostreptomycin and its salts, singly or in combination, were withdrawn from sale for human use. The drug can cause severe vestibular damage.
ESP	1 Oct 1983	The Ministry of Health and Consumer Protection has withdrawn approval for dihydrostreptomycin except in oral preparations. (Reference: (ESPMC) Programa Selectivo de Revisión de Medicamentos, , , Sep 1983)
DOM		Prohibited for use and/or sale since scientific studies have shown that it can cause deafness.
ITA		Withdrawn from the market owing to an unfavourable risk-benefit ratio and the lack of substantial evidence of efficacy.
PER		Prohibited for use in its injectable form. It has been found to cause permanent deafness.

WHO Comment : Dihydrostreptomycin, a derivative of the aminoglycoside antibiotic streptomycin with similar antibacterial activity, was first synthesized in 1947 and subsequently used in the treatment of tuberculosis and gram-negative infections. Preparations for systemic use have been widely withdrawn as a result of concern regarding their severe ototoxicity. Dihydrostreptomycin is poorly absorbed from the gastrointestinal tract. It remains available in oral preparations in some countries.

Product Name Dihydroxymethylfuratrizine

C.A.S. number 794-93-4

Scientific and common names, and synonyms
BIS(HYDROXYMETHYL)FURATRIZINE
(((6-(2-(5-NITRO-2-FURYL)VINYL)-AS-TRIAZIN-3-YL)IMIDO)DI-METHANOL

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
JPN	Jul 1977	Withdrawn from all marketed preparations on the grounds that it has been superseded by safer and more effective preparations.
SAU		The withdrawal of nitrofurans is under consideration since they have been superseded by safer and more effective preparations.
VEN		Not approved for use and/or sale.

WHO Comment : Dihydroxymethylfuratrizine, a nitrofurans derivative, was formerly used as an anti-infective agent. It has, however, been superseded by safer compounds and WHO has no information to suggest that it remains commercially available.

Product Name Dilevalol

C.A.S. number 75659-07-3

Scientific and common names, and synonyms
BENZAMIDE,2-HYDROXY-5-[1-HYDROXY-2-[(1-METHYL-3-PHENYLPROPYL)AMINO]ETHYL]-,-[R*(R*)]-

Legislative or regulation action

Product Name	Dilevalol	
C.A.S. number	75659-07-3	
Scientific and common names, and synonyms	(-)-5-[(1R)-1-HYDROXY-2-[(1R)-1-METHYL-3-PHENYLPROPYL]AMINO]ETHYL] SALICYLAMIDE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
@WD	9 Aug 1990	<p>Products containing dilevalol hydrochloride have been voluntarily discontinued by the manufacturer, having regard to evolving evidence of isolated cases of liver toxicity. (Reference: (SPCNR) Schering-Plough Corporation news release, , , 09 Aug 1990)</p> <p>WHO Comment : Dilevalol, a beta-adrenoreceptor antagonist, was introduced into medicine in 1989 for the treatment of hypertension. Shortly afterwards, its use became associated with isolated cases of hepatic toxicity. Although few cases were reported, the manufacturer discontinued sales in Japan and Portugal, the only countries where the drug was marketed, and withdrew applications for registration elsewhere.</p>

Product Name	Dimazole	
C.A.S. number	95-27-2	
Scientific and common names, and synonyms	AMYCAZOL BENZOTHIAZOL,6-(2-DIETHYLAMINOETHOXY)-2-DIMETHYLAMINO- DIAMTHAZOLE DIHYDROCHLORIDE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
USA	Jul 1977	<p>Withdrawn from the market and prohibited for export by the Food and Drug Administration on the grounds that the drug was not shown to be safe for its indicated uses. Neurotoxic effects had been found in humans. Products containing this ingredient had been used for the prophylaxis and treatment of athletes' foot. (Reference: (FEREAC) Federal Register, 42, 37057, July 1977)</p> <p>WHO Comment : Dimazole, an antifungal agent, was introduced in 1951 for the treatment of tinea infections. Although the major manufacturer subsequently discontinued marketing preparations in the United States, the US Food and Drug Administration formally withdrew marketing approval for such preparations in 1977 on the grounds of their association with severe neurotoxic reactions, their potential for misuse and the availability of safer alternative products. Topical preparations of dimazole remain available in some 40 countries.</p>

Product Name	Dinoprostone	
C.A.S. number	363-24-6	
Scientific and common names, and synonyms	PROSTAGLANDIN E2 PROSTA-5,13-DIEN-1-OIC ACID,11,15-DIHYDROXY-9-OXO-,(5Z,11ALPHA,13E,15S)- (E,Z)-(1R,2R,3R)-7-[3-HYDROXY-2-[(3S)-(3-HYDROXY-1-OCTENYL)]-5-OXOCYCLOPENTYL]-5-HEPTENOIC ACID (5Z, 11ALPHA, 13E, 15S)-11, 15-DIHYROXY-9-OXOPROSTA-5, 13-DIEN-1-OIC ACID	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision

Legislative or regulation action

Product Name	Dinoprostone	
C.A.S. number	363-24-6	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GBR	19 Jul 1990	In consultation with the Department of Health, a controlled-release pessary containing dinoprostone has been withdrawn by the manufacturer, having regard to reports of an unacceptable incidence of uterine hypertonia and foetal distress. (Reference: (CRDDL) Communication from Roussel enclosing "Dear Doctor" letter, , , 19 July 1990)
THA	Apr 2001	Severely restricted for use as a prescription drug in hospitals only. (Reference: (THACW) Communication to WHO, , , 28 Sep 2001) WHO Comment : Dinoprostone, prostaglandin E2, was introduced into medicine in 1971 and is primarily used for cervical ripening during the induction of labour. It is available in various formulations for oral, parenteral and vaginal administration. Tablets, ampoules and vaginal dosage forms (tablets, pessaries, gel) remain registered in many countries.

Product Name	Dionaea muscipula (extract)	
Scientific and common names, and synonyms VENUS FLY TRAP		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	Jan 1986	The Federal Health Office has suspended the sale of an injectable herbal anticancer drug prepared from the carnivorous plant <i>Dionaea muscipula</i> following hypersensitivity reactions in almost two-thirds of patients. WHO Comment : The World Health Organization has no information further to the above regarding preparations containing <i>Dionaea muscipula</i> or to indicate that they are still commercially manufactured.

Product Name	Diphenazine	
C.A.S. number	13838-14-7	
Scientific and common names, and synonyms 1,4-BIS(ALPHA-METHYLPHENETHYL)PIPERAZINE 1,4-BIS(1-PHENYLISOPROPYL)PIPERAZINE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
HUN	1967	Withdrawn from the market on account of photosensitivity, and possibly cataract, associated with its use.
VEN		Not approved for use and/or sale. WHO Comment : The World Health Organization has no further information regarding preparations containing diphenazine and is not aware that they are still commercially manufactured.

Product Name	Diphenoxylate	
---------------------	----------------------	--

Legislative or regulation action

C.A.S. number 915-30-0

Scientific and common names, and synonyms

DIPHENOXYLATE HYDROCHLORIDIUM
 ETHYL 1-(3-CYANO-3,3-DIPHENYLPROPYL-4-PHENYLISONIPECOTATE
 R-1132
 4-PIPERIDINECARBOXYLIC ACID, 1-(3-CYANO-3,3-DIPHENYLPROPYL)-4-PHENYL-,ETHYL

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
LIY	21 May 1990	Use of products containing diphenoxylate in children was banned. (Reference: (LIYRL) Resolution of the General People's Health Committee, 141, , May 1990)
PAK	Jun 1990	Drop and syrup formulations of products containing diphenoxylate intended for the treatment of diarrhoea in children were banned.
MEX	Dec 1990	Elixir formulations of products containing diphenoxylate intended for the treatment of diarrhoea in children were withdrawn. (Reference: (MEXMH) Communication from the Ministry of Health, , , 28 Nov 1990)
NPL	1991	Liquid formulations of products containing diphenoxylate either alone or in combination, and intended for the treatment of diarrhoea in children, were banned (Reference: (NPLDDA) Communication from the Department of Drug Administration, , , 27 Feb 1992)
PHL	1991	Paediatric formulations of products containing diphenoxylate were withdrawn.
KOR	May 1991	Antidiarrhoeal products containing diphenoxylate were not accepted for registration. (Reference: (KRMHSA) Ministry of Health and Social Affairs - Communication to WHO, , , 13 Dec 1991)
LBN	03 Aug 1991	Use of products containing diphenoxylate in children under 5 years of age was discontinued and preparations for paediatric use were withdrawn. (Reference: (LBNMHD) Ministry of Health and Social Affairs Decree, 150/1, , Aug 1991)
THA	27 May 1992	The Ministry of Public Health, withdrew the registration of products containing diphenoxylate formulated as either syrup or drop formulation. (Reference: (THAMH) Ministry of Public Health, , , 27 May 1992)
BHR	2000	The Ministry of Health has restricted the prescription of medicines containing diphenoxylate as controlled medicines that should be dispensed only on special prescriptions issued by the Directorate of Pharmacy and Drug Control at the Ministry of Health with effect from 2 May 2000. (Reference: (BHRCW) Communication with WHO, , , 27 June 2000)

WHO Comment : Diphenoxylate, a derivative of pethidine without analgesic activity, is used in the symptomatic treatment of acute and chronic diarrhoea to reduce intestinal motility. There is no clear evidence that it has any beneficial effect in diminishing fluid losses and it has been associated with central nervous system toxicity, particularly in children, which results in anorexia, nausea and vomiting, headache, drowsiness, confusion, insomnia, dizziness, restlessness, euphoria and depression. The World Health Organization recommends that diphenoxylate should not be used for the management of diarrhoea in children and many countries have since withdrawn products containing this compound indicated for paediatric use. (Reference: (WHORUD) The Rational Use of Drugs, , , 1990)

Product Name Dithiazanine iodide

C.A.S. number 514-73-8

Scientific and common names, and synonyms

3-ETHYL-2-(5-(3-ETHYL-2-BENZOTHIAZOLINYLIDENE)-1,3-PENTADIENYL) BENZOTHIAZOLIUM IODIDE
 3-ETHYL-2-(5-(3-ETHYL-2(3H)-BENZOTHIAZOLYLIDENE)-1,3-PENTADIENYL)- BENZOTHIAZOLIUM IODIDE

Legislative or regulation action

Product Name	Dithiazanine iodide	
C.A.S. number	514-73-8	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
USA	1964	Reports of death associated with the use of dithiazanine iodide led the Food and Drug Administration to limit the indications for its use to trichuris trichuria and strongyloides stercoralis infestations of a clinically severe nature.
FRA	Nov 1964	Withdrawn from the market in agreement with the manufacturer following reports of death associated with its use.
TCO	1965	Following reports of fatal incidents associated with the use of dithiazanine iodide, the Ministry of Foreign Affairs prohibited importation and marketing of this drug.
ITA	1979	Withdrawn from the market owing to an unfavourable risk/benefit balance.
CUB		Withdrawn from use on grounds of adverse effects on the gastrointestinal tract. This drug has been superseded by more effective and less toxic products.
WHO Comment : Dithiazanine iodide, an anthelmintic, was introduced in 1959 for the treatment of strongyloid worms and whipworms. Between 1961 and 1964 its use was associated with eight fatal cases of severe acidosis and shock. Although the drug is not significantly absorbed from the gut, in normal circumstances it was assumed that these fatalities were due to atypically high uptake from inflamed intestinal mucosa. Dithiazanine iodide has been superseded by safer and more effective drugs; however, it may remain available in some countries.		

Product Name	Domperidone(injectable)	
C.A.S. number	57808-66-9	
Scientific and common names, and synonyms		
5-CHLORO-1-(1-(3-(2-OXO-1-BENZIMIDAZOLINYL)PROPYL)-4-PIPERIDYL)-2- BENZIMIDAZOLINONE 2H-BENZIMIDAZOL-2-ONE, 5-CHLORO-1-(1-(3-(2,3-DIHYDRO-2-OXO-1H- BENZIMIDAZOL-1-YL)PROPYL)-4-PIPERIDINYL),3-DIHYDRO-		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
@WD	31 Jan 1985	The manufacturer has informed the World Health Organization that injectable dosage forms of the antiemetic domperidone have been voluntarily withdrawn from all markets following reports of cases of cardiotoxicity associated with intravenous administration. Suppositories remain available and injectable forms will continue to be supplied for a named patient at the written request of a doctor.
WHO Comment : Domperidone, a peripheral dopaminergic antagonist, was introduced in 1979 for the symptomatic relief of acute nausea and vomiting. The major manufacturer became aware that the injectable formulation was being used in some countries in much higher doses than those recommended to combat nausea and vomiting in cancer patients treated with cytostatic agents. Such use - which was not in conformity with the approved indications - was associated with cardiotoxicity, which in some cases was fatal, and the manufacturer decided to withdraw the injectable dosage form from the market worldwide in January 1985. Suppositories, tablets and a suspension remain available and the manufacturer continues to supply the injection for the treatment of a named patient at the written request of a doctor on the understanding that the appropriate dosage recommendations will be followed.		

Product Name	Doxepin	
C.A.S. number	1668-19-5	
Legislative or regulation action		

Product Name	Doxepin	
C.A.S. number	1668-19-5	
Scientific and common names, and synonyms	3-(DIBENZ[B,E]OXEPIN-11-YLIDENE)PROPYL-DIMETHYLAMINE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
NOR	1992	The Medicines Control Authority has decided that the 50 mg tablet formulation of doxepin may be prescribed only in hospitals and specialized clinics because of the toxic potential of this product and the risk of overdosage and suicide with the high dose formula. (Reference: (NNSLM) Nytt fra Statens Legemiddelkontroll, 1, 9, 1992) WHO Comment : Doxepin, a tricyclic antidepressant was introduced in 1964 for the management of endogenous depression. Much of the adverse effects are caused by its antimuscarinic actions. These include dry mouth, cardiac arrhythmias, central nervous system disturbances, blood disorders and risk of suicide. The risk of suicide and dangers related to overdosage led the Norwegian Medicines Control Authority to put the higher strength formulation under prescribing restriction in 1992. The risk of death following overdosage is apparently higher for products containing tricyclic compounds as compared with nontricyclic products.
Product Name	Doxycycline hyclate(injectable)	
C.A.S. number	24390-14-5	
Scientific and common names, and synonyms	6-DEOXY-5BETA-HYDROXYTETRACYCLINE HYDROCHLORIDE 2-NAPHTACENECARBOXAMIDE, 4-(DIMETHYLAMINO)-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-3,5,10,12,12A-PENTAHYDROXY-6-METHYL-1,11-DIOXO-, MONOHYDROCHLORIDE, COMPD. WITH ETHANOL(2:1), MONOHYDRATE, [4S-(4ALPHA,4AALPHA,5ALPHA,5AALPHA,6ALPHA,12AALPHA)]-	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
FRA	1989	The use of injectable preparations containing doxycycline hyclate has been restricted exclusively to hospitals, on the grounds that cases of anaphylactic shock and bronchospasm, some of which have been fatal, have occurred during intravenous administration of the product. Furthermore, these preparations should only be prescribed to patients unable to take medicines orally and should always be administered by slow intravenous infusion and under close supervision. (Reference: (FRAMH) Ministry of Solidarity, Health and Social Protection, , , 17 Feb 1989)
MAR	May 2000	The National Advisory Commission for Pharmacovigilance has suspended marketing authorization for all pharmaceutical products containing doxycycline in capsule form. There is evidence of a high risk of oesophageal damage with the administration of capsules of doxycycline. (Reference: (MARDMP) Letter to WHO, , , 08 Sep 2000)
FRA	Feb 2001	The gel form of doxycycline preparations remain suspended in France due to frequent associations of adverse effects on the oesophagus. (Reference: (FRACW) Communication to WHO, , , 05 Oct 2001) WHO Comment : Doxycycline, a semi-synthetic tetracycline derivative, was first introduced into medicine in 1960 for the treatment of bacterial, rickettsial and amoebic infections. Although allergic manifestations are uncommon, injectable preparations have occasionally resulted in severe anaphylactoid reactions. Clinical features and the fact that asthmatic patients seemed to be particularly at risk lead to suspect a sulfite preservative in the formulation more than doxycycline itself. Rapid administration may also be a factor. Injectable preparations of doxycycline hyclate are included in the WHO Model List of Essential Drugs.

Legislative or regulation action

Product Name	Doxycycline hyclate(injectable)	
C.A.S. number	24390-14-5	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
(Reference: (WHTAC4) The Use of Essential Drugs, 4th Report of the WHO Expert Committee, 796, , 1990)		
Product Name	Dronabinol	
C.A.S. number	1972-08-3	
Scientific and common names, and synonyms		
NSC-134454		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
USA	1998	Dronabinol is reclassified from Schedule II to Schedule III of the US Controlled Substances Act. Dronabinol is internationally controlled in Schedule II of the 1971 Convention on Pyschotropic Substances. (Reference: (FEREAC) Federal Register, 63(214) , p. 59751, 1998)
Product Name	Droperidol	
C.A.S. number	548-73-2	
Scientific and common names, and synonyms		
1-[1-[4-(FLUOROPHENYL)-4-OXOBUTYL]-1,2,3,6-TETRAHYDRO-4-PYRIDINYL]-1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GBR	Mar 2001	Droperidol has been withdrawn in the UK following concerns about serious cardiac adverse effects. (Reference: (GBRISM) Information Safety Message, , , 11 Jan 2001)
IDN	Jun 2001	The National Agency for Drug and Food Control (NADFC) has suspended the marketing authorization of droperidol because of serious cardiac adverse effects. (Reference: (IDNCW) Communication to WHO, , , 13 Sep 2001)
Product Name	Droxicam	
C.A.S. number	90101-16-9	
Scientific and common names, and synonyms		
5-METHYL-3-(2-PYRIDYL)-2H,5H-1,3-OXAZINO[5,6-C]-[1,2]BENZOTHIAZINE-2,4(3H)-DIONE 6,6-DIOXIDE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
@EC	14 Dec 1994	The Committee on Proprietary Medicinal Products has advised that the marketing authorization of droxicam should be suspended pending receipt of further data on epidemiological and pharmacokinetic studies. (Reference: (CPMPPO) Pharmacovigilance Opinion, No.18, , 14 Dec 1994)
WHO Comment : Droxicam is authorized to be marketed in many European countries. Although droxicam is metabolized to piroxicam, it is considered that the		

Legislative or regulation action

Product Name	Droxicam	
C.A.S. number	90101-16-9	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		risk of hepatic damage differs from that shown by other NSAIDs products, including piroxicam.
Product Name	Ebrotidine	
C.A.S. number	100981-43-9	
Scientific and common names, and synonyms		
P-BROMO-N-[(E)-{(2-[(2-DIAMINOMETHYLENE)AMINO]-4-THIAZOYL)METHYL}THIO]ETHYL)AMINO]METHYLENE]BENZENESULFONAMIDE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
PER		La Direcció General de Medicamentos, Insumos y Drogas (DIGEMID) of the Ministry of Health withdrew marketing authorization for the histamine H2 receptor antagonist ebrotidine (Ebrocit) because of reports of serious liver dysfunction particularly on long-term treatment and when the drug was administered with anti-inflammatory agents and corticosteroids. (Reference: (PERDGM) Alerta DIGEMID, No. 07-98, , 12 Oct 1998)
Product Name	Emetine	
C.A.S. number	483-18-1	
Scientific and common names, and synonyms		
EMETAN, 6',7',10,11-TETRAMETHOXY		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
MUS	9 Mar 1982	Under the Pharmacy and Poisons (Prohibitions of Harmful Drugs) Regulations, this drug is deemed "harmful" by the Ministry of Health and is prohibited for import, manufacture, storage, distribution, sale, possession, use, export or other transaction. (Reference: (MPPHD) Pharmacy & Poisons (Prohibitions of Harmful Drugs) Regulations, , , Mar 1982) WHO Comment : Emetine, an alkaloid obtained from ipecacuanha, was first used rationally as an amoebocide in 1912. It was subsequently widely used and was included in earlier editions of the WHO Model List of Essential Drugs but has now been replaced by the less cardiotoxic synthetic derivative dehydroemetine. Although it is valuable in the treatment of systemic amoebic hepatitis it has now been largely superseded by considerably less toxic drugs, and in particular by metronidazole.
Product Name	Encainide	
C.A.S. number	37612-13-8	
Scientific and common names, and synonyms		
BENZAMIDE,4-METHOXY-N-[2-[2-(1-METHYL-2-PIPERIDINYL)ETHYL]-PHENYL]-,(N)- (N)-2'-[2-(1-METHYL-2-PIPERIDYL)ETHYL]-P-ANISANILIDE		
Legislative or regulative action		

Legislative or regulation action

Product Name	Encainide	
C.A.S. number	37612-13-8	
Country	Effective Date	Description of action taken Grounds for decision
MYS	Jul 1980	Products containing encainide will only be considered for registration if the indications are restricted to the treatment of life-threatening arrhythmias only. (Reference: (MYSDN) Berita Ubat-Ubat (Drug Newsletter), 3(3), 3, 1989)
SWE	26 Oct 1990	The indications for products containing encainide are restricted to prophylaxis and treatment of life-threatening ventricular tachyarrhythmia such as ventricular tachycardia in patients unresponsive to conventional treatment. (Reference: (SWEILS) Information från Läkemiddelsverket, 1(3), , 1990)
WHO Comment : The membrane-stabilizing antiarrhythmic agent encainide was introduced into medicine in the mid-1980's. The decision to delete the indications for patients with asymptomatic and less severe symptomatic ventricular arrhythmias was taken on the basis of the results of a trial (CAST study) that showed a two-fold increase in deaths in post-myocardial patients taking encainide compared with the placebo group. (See also WHO comment for flecainide).		

Product Name	Ephedra	
C.A.S. number	2004-0-0005	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
USA	02 Jan 2004	The FDA has banned the weight-loss aid ephedra due to safety concerns that the product can cause heart attacks and stroke. (Reference: (USADIZ) News and updates, , , 02 Jan 2004)
JOR	19 Jan 2004	The Jordan Food and Drug Administration has withdrawn a herbal product (Magic Herb), used to promote weight loss, on the grounds that it contain ephedra. This decision was based on the US FDA's website information about the unreasonable risk in using food supplements containing ephedra or ephedrine. (Reference: (JORPCC) Communication to WHO, , , 19 Jan 2004)
NLD	18 Feb 2004	According to the Ministry of Health in the Netherlands, ephedra herbal products may only be sold as medicinal products in the Netherlands. (Reference: (NLDMEB) News and Publications, , , 18 Feb 2004)

Product Name	Epinephrine	
C.A.S. number	51-43-4	
Scientific and common names, and synonyms		
ADRENALINE		
(-)-3,4-DIHYDROXY-ALPHA-((METHYLAMINO)METHYL)BENZYL ALCOHOL		
2-BENZENEDIOL, 4-(1-HYDROXY-2-(METHYLAMINO)ETHYL)-,(R)-		
3,4-DIHYDROXY-ALPHA-((METHYLAMINO)METHYL)-BENZYL ALCOHOL		
4-(1-HYDROXY-2-(METHYLAMINO)-ETHYL)-1,2-BENZENEDIOL		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
IRL	1973	The National Drugs Advisory Board has withdrawn from the market all local anesthetic preparations intended for infiltration anesthesia containing epinephrine 1:50,000 and norepinephrine 1:50,000 alone or in combination. This decision, reached in agreement with the Irish Dental Association, followed reports of serious cardiovascular and

Legislative or regulation action

Product Name	Epinephrine	
C.A.S. number	51-43-4	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
VEN		<p>cerebrovascular reactions.</p> <p>Epinephrine is not approved for use for infiltration anaesthesia, either alone or in combination.</p> <p>WHO Comment : Epinephrine, first isolated in 1899, is the main hormone secreted by the adrenal medulla. It is widely used as a vasoconstrictor substance and in the treatment of anaphylactic shock. Its use in combination with local anaesthetics to prolong infiltration anaesthesia has been associated with systemic reactions including serious cardiovascular and cerebrovascular incidents. Regulations restricting the concentrations permitted in such preparations have been introduced in many countries but combination products containing epinephrine or levarterenol in concentrations of 1:80,000 or less remain widely available. Representative preparations are included in the WHO Model List of Essential Drugs. (Reference: (WHTAC1) The Use of Essential Drugs, 2nd Report of the WHO Expert Committee, 722, , 1985)</p>
Product Name	Epoetin alfa	
C.A.S. number	113427-24-0	
Scientific and common names, and synonyms		
ERYTHROPOEITIN		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
MUS		<p>The Ministry of Health and Quality of Life has restricted the use of injections of epoetin alfa and beta, recombinant erythropoietins, used in the management of anaemia associates with chronic renal failure in patients requiring renal dialysis to use in hospitals and renal dialysis centres. This is in order to minimize the risk of abuse of the drug by athletes and for horse racing.</p> <p>(Reference: (MUSMHQ) Letter to WHO, , , 27 Dec 2000)</p>
Product Name	Epoetin beta	
C.A.S. number	122312-54-3	
Scientific and common names, and synonyms		
ERYTHROPOEITIN		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
MUS		<p>The Ministry of Health and Quality of Life has restricted the use of injections of epoetin alfa and beta, recombinant erythropoietins, used in the management of anaemia associates with chronic renal failure in patients requiring renal dialysis to use in hospitals and renal dialysis centres. This is in order to minimize the risk of abuse of the drug by athletes and for horse racing.</p> <p>(Reference: (MUSMHQ) Letter to WHO, , , 27 Dec 2000)</p>
Product Name	Erythrityl tetranitrate	
C.A.S. number	7297-25-8	

Legislative or regulation action

Product Name Erythrityl tetranitrate

C.A.S. number 7297-25-8

Scientific and common names, and synonyms

ERYTHROL NITRATE

NITROERYTHROL

NITROERYTHRITE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
USA	1998	The Food and Drug Administration has withdrawn conditional approval of abbreviated new drug applications for single-entity drug products containing erythrityl tetranitrate because there is a lack of substantial evidence that these drugs are effective for indications relating to the management, prophylaxis or treatment of anginal attacks. (Reference: (FEREAC) Federal Register, 63(200) , p. 55616, 1998)

Product Name Erythromycin estolate

C.A.S. number 3521-62-8

Scientific and common names, and synonyms

ERYTHROMYCIN, 2'PROPIONATE, DODECYL SULPHATE

ERYTHROMYCIN PROPIONATE LAURYL SULPHATE

ERYTHROMYCIN 2'-PROPANOATE DODECYL SULPHATE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
SGP	Nov 1976	Banned for importation.
GRC	1977	Withdrawn from the market.
SDN	1982	The Ministry of Health no longer allows registration of preparations containing erythromycin estolate.
MUS	9 Mar 1982	Under the Pharmacy and Poisons (Prohibitions of Harmful Drugs) Regulations, this drug is deemed "harmful" by the Ministry of Health and is prohibited for import, manufacture, storage, distribution, sale, possession, use, export or other transaction. (Reference: (MPPHD) Pharmacy & Poisons (Prohibitions of Harmful Drugs) Regulations, , , Mar 1982)
BGD	1983	Banned due to its reported hepatotoxicity.
BHR		Preparations containing erythromycin estolate are not approved for registration.
DNK		Registration has been cancelled. (Reference: (UGLAAD) Ugeskrift for Laeger, 136, 2093, Sep 1974)
PER		The package and/or label for this product requires a warning regarding the possibility of liver damage with this drug; and, in cases of repeated use, possible side effects including fever, nausea, vomiting, jaundice, and eosinophilia. It also warns pregnant women that no safe level for administration during pregnancy has yet been determined.
SWE		This product has been banned for use and/or sale for domestic purposes due to cases of severe cholestatic hepatitis and jaundice. WHO Comment : Erythromycin estolate, a macrolide antibiotic, was introduced in 1958 for the treatment of gram-positive infections. By the early 1970s its use had been associated with a higher incidence of hepatic toxicity than that seen with other salts and esters of erythromycin. This led to its withdrawal by some regulatory authorities whereas others required the addition of a warning in the product information. Evidence that the estolate ester is more hepatotoxic than other salts or esters has subsequently been disputed. It has been claimed to be the

Legislative or regulation action

Product Name	Erythromycin estolate	
C.A.S. number	3521-62-8	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		most effective ester for treatment of Legionnaire's disease and preparations remain widely available. (Reference: (BMJOAE) British Medical Journal, 286, 1954, 1983)

Product Name	Etanercept	
C.A.S. number	185243-69-0	
Scientific and common names, and synonyms		
	1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN GAMMA1-CHAIN FC FRAGMENT) DIMER	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
CHL	Oct 2001	The Public Health Institute of Child has modified the labels to include warnings about the adverse reactions that affect the central nervous system and the haematological system. (Reference: (CHLCW) Communication to WHO, , , 26 Sep 2001)

Product Name	Ethambutol	
C.A.S. number	74-55-5	
Scientific and common names, and synonyms		
	[S-(R*, R*)]-2,2 1-(1,2-ETHANEDIYLDIIMINO)BIS(1-BUTANOL);	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
THA	Oct 2000	Warning about the risk of loss of eyesight. (Reference: (THACW) Communication to WHO, , , 28 Sep 2001)

Product Name	Ethanol	
C.A.S. number	64-17-5	
Scientific and common names, and synonyms		
	ALCOHOL ETHYL ALCOHOL	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
KWT	1966	The permissible limit of ethanol in liquid oral dosage forms should not exceed 10%. (Reference: (KTMD) Ministerial Decree, 71/66, , 1966)
CHL	1 Sep 1985	The Institute of Public Health has prohibited the use of ethanol in oral pharmaceutical products. Exemptions from this decision will be allowed when use of ethanol is essential for galenic reasons, provided that it is used for this purpose at the lowest effective concentration. (Reference: (CHLRS) Resolution of the Minister of Health, No.3102, , Apr 1985)
IRQ	1989	The Ministry of Health has approved the restriction of the inclusion of ethanol in

Legislative or regulation action

Product Name Ethanol

C.A.S. number 64-17-5

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
		pharmaceutical preparations. (Reference: (IRQMH) Resolution of the Arab Ministers of Health 13th Meeting, 9-13, , 1986)
LKA	1 Jan 1992	The Ministry of Health withdrew from sale, all paediatric oral liquid formulations of pharmaceutical products containing ethanol, and all formulations for adults containing more than 5% of ethanol. (Reference: (LKADIB) Drug Information Bulletin, University of Peradeniya and Ministry of Health, 4(1), , 1992)
USA	1995	The maximum permissible concentration limits for alcohol (ethanol, ethyl alcohol) as an inactive ingredient in over-the-counter drug products intended for oral ingestion have been established as 0.5% alcohol for children under six years of age; 5% for children between six and twelve years of age and 10% for children over twelve years of age and adults. The alcohol content should be stated prominently in a display panel on the front page of all product labelling. (Reference: (FEREAC) Federal Register, 60(48) , p. 13590, 1995)
BRA	Apr 2001	The National Health Surveillance Agency has prohibited the inclusion of ethanol in pharmaceutical preparations. (Reference: (BRARES) Resolucao n., 543/ANVISA, , 19 Apr 2001)
ARE		Pharmaceutical preparations containing high concentrations of ethanol are banned.

WHO Comment : Ethanol has been used throughout recorded history both in a medicinal and a social context. It is currently included in pharmaceutical preparations either as an active or inactive ingredient. At pharmacologically active doses ethanol is both a powerful cerebral depressant and a drug of addiction. Its use in pharmaceutical preparations has been severely restricted in several countries and in 1986 the 39th World Health Assembly adopted a resolution to prohibit such use except when ethanol is an essential ingredient which cannot be replaced by an appropriate alternative.

Product Name Ethyl nitrite (spirit)

C.A.S. number 109-95-5

Scientific and common names, and synonyms

NITROUS ETHER SPIRIT

SWEET NITRE SPIRIT

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
USA	26 Jun 1980	Withdrawn from the market and prohibited for export by the Food and Drug Administration (FDA) due to the lack of scientific evidence for its effectiveness for any use. This drug was used in infants and children as a diuretic, a diaphoretic and an intestinal antispasmodic. The FDA has found evidence of a risk of fatal methaemoglobinaemia and poisoning in some infants. (Reference: (FEREAC) Federal Register, 45(126), 43400, 1980)

WHO Comment : Ethyl nitrite was formerly available in over-the-counter preparations for use as a diaphoretic, a diuretic and an intestinal antispasmodic. In the 1970s its use was associated with cases of methaemoglobinaemia, some of which were fatal. This led to its withdrawal in 1980 by the United States Food and Drug Administration. WHO has no information regarding its current availability in pharmaceutical preparations.

Legislative or regulation action

Product Name	Ethyl nitrite (spirit)	
C.A.S. number	109-95-5	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
<hr/>		
Product Name	Ethylene dichloride	
C.A.S. number	107-06-2	
Scientific and common names, and synonyms		
BROCID		
DUTCH LIQUID		
ETHANE, 1,2-DICHLORO-		
1,2-DICHLOROETHANE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
<hr/>		
DEU	1978	Two topical prescription preparations for rheumatic complaints containing ethylene dichloride were withdrawn. These preparations were implicated in a number of cases of acute poisoning following accidental ingestion and investigations by the National Cancer Institute in the USA demonstrated a possible carcinogenic effect.
SAU		Prohibited due to reports demonstrating carcinogenic effects in experimental animals. WHO Comment : Ethylene dichloride was formerly used as an excipient in some pharmaceutical preparations. It has been reported to be carcinogenic in experimental animals and its accidental ingestion has resulted in liver and kidney damage. Although ethylene dichloride continues to be used as an industrial solvent, WHO has no information to suggest that it remains commercially available in pharmaceutical products or as a food additive. (Reference: (WHTAC3) 23rd Report of Joint FAO/WHO Expert Committee on Food Additives, 648, , 1980)
Bibliographical references		
IARC MONOGRAPH, 20, 429, 1979		
WHO GUIDELINES FOR DRINKING WATER QUALITY, 2, , 1984		
FAO PLANT PRODUCTION & PROTECTION PAPER, 72/1, , 1985		
IPCS ENVIRONMENTAL HEALTH CRITERIA, 62, , 1986		
<hr/>		
Product Name	Ethylestrenol	
C.A.S. number	965-90-2	
Scientific and common names, and synonyms		
ETHYLOESTRENOL		
19-NORPREGN-4-EN-17-OL,(17-ALPHA)		
19-NOR-17-ALPHA-PREGN-4-EN-17-BETA-OL		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
<hr/>		
BGD	1982	Under the provisions of the Drugs (Control) Ordinance, low-strength preparations were banned following unacceptable promotion encouraging their use in children suffering from malnutrition. (Reference: (BGDCO) The Drugs (Control) Ordinance, , , 1982) WHO Comment : Ethylestrenol, an anabolic steroid, was introduced in 1964. In
Legislative or regulation action		

Product Name	Ethylestrenol	
C.A.S. number	965-90-2	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		1982, low dosage preparations were prohibited in Bangladesh due to inadmissible promotion of products containing anabolic steroids for malnourished children. Higher dosage preparations of ethylestrenol remain available in many countries, including Bangladesh, for several highly specific but limited indications that apply to patients with chronic debilitating and emaciating diseases, particularly associated with neoplasia and some types of aplastic anaemia. Ethylestrenol is additionally used for its fibrinolytic activity.
Product Name	Etomidate	
C.A.S. number	33125-97-2	
Scientific and common names, and synonyms		
(+)-ETHYL 1-(ALPHA-METHYLBENZYL)IMIDAZOLE-5-CARBOXYLATE 1H-IMIDAZOLE-5-CARBOXYLIC ACID, 1-(1-PHENYLETHYL)-, ETHYL ESTER(+)		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GBR	1985	Use of etomidate is restricted to induction of anaesthesia having regard to reports of reduced serum cortisol levels unresponsive to adrenocorticotrophic hormone (ACTH) injections. WHO Comment : Etomidate, a potent hypnotic agent, was introduced in 1977 for use as an intravenous anaesthetic. Its prolonged use can inhibit adrenal steroidogenesis and, following reports of reduced serum cortisol levels unresponsive to ACTH injection, the manufacturer suspended promotion of etomidate for sedation in intensive care in 1983. In 1985 regulatory action taken only in the United Kingdom further restricted use of the drug to induction of anaesthesia. Etomidate remains widely available and is currently registered for induction of anaesthesia in 34 countries and for maintenance of anaesthesia in 17 countries. It has never been registered for sedation.
Product Name	Etretinate	
C.A.S. number	54350-48-0	
Scientific and common names, and synonyms		
ETHYL (ALL-E)-9-(4-METHOXY-2,3,6-TRIMETHYLPHENYL)-3,7-DIMETHYL-2,4,6,8- NONATETRAENOATE 2,4,6,8-NONATETRAENOIC ACID, 9-(4-METHOXY-2,3,6-TRIMETHYLPHENYL)-, ETHYL ESTER, (ALL-E)-		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
OMN	24 Dec 1985	Having regard to its teratogenicity, etretinate may only be used under the supervision and control of a hospital dermatologist. (Reference: (OMNMH) Ministry of Health, 5, , 1985)
SWE	1987	The National Board of Health and Welfare has decided that contraception is essential during treatment of women of child-bearing age and that contraceptive measures must be continued for at least two years after discontinuation of treatment.
MYS	1988	The Drug Control Authority has decided that the labelling of preparations containing etretinate should contain a distinct warning regarding teratogenicity, emphasizing that contraceptive measures must be instituted throughout treatment and for at least twelve
Legislative or regulation action		

Product Name	Etretinate	
C.A.S. number	54350-48-0	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		months thereafter, and additional reference is also required to the following adverse effects: symptoms of hypervitaminosis-A; transient and reversible elevation of transaminases and alkaline phosphatases; bone changes after long-term high dosage; benign intracranial hypertension. (Reference: (MYSND) Berita Ubat-Ubat (Drug Newsletter), 2(1), 3, Feb 1988)
BEL	1 Jan 1988	Preparations containing etretinate have been placed in List IV of the 'Arrêt, du R,gent' of 2 June 1946 and as such can be administered only on prescription. They must be kept in a poisons cabinet and carry the skull and cross-bones label. They must bear a warning regarding the embryotoxicity and teratogenicity of the drug which contraindicates its use during pregnancy. (Reference: (BELAR) Arrêté Royal, , , June 1987)
NOR	Dec 1992	The Medicines Control Authority has withdrawn etretinate from the market. (Reference: (NORMCA) Norwegian Medicines Control Authority, , , 02 May 1995)
BRA	Feb 2001	Use and sale banned because of dangerous side effects, mainly myopathy. (Reference: (BRACW) , , , 13 Sep 2001)
ESP		Contraindications to etretinate must include a boxed paragraph stating that the drug may be used in women of child-bearing age only when an effective method of contraception assures protection during and for at least one year after discontinuation of treatment. Pregnancy must be excluded before initiation of treatment.
ITA		Having received reports of two deaths among patients taking etretinate, the Ministry of Health has decided to restrict the product to hospital use only for the treatment of particularly serious and/or diffuse forms of psoriasis causing evident psychological stress. WHO Comment : Etretinate, a retinol derivative, was introduced in 1981 for the treatment of psoriasis. Its use in pregnant women has resulted in major foetal abnormalities. The manufacturer's information emphasizes that the drug is teratogenic and must not be given to women who are pregnant, and that contraceptive measures must be maintained for at least two years after discontinuation of treatment. In some countries, blood banks are advised not to accept as donors persons who have taken etretinate within the previous year.

Product Name	Factor IX	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
SWE		A manufacturer of Factor IX concentrate has withdrawn the product from the market following reports of infections with HIV (the AIDS virus) in three patients known to have been treated with the product. (Reference: (SSLMS) Information från Socialstyrelsens Läkemedelsavdelning, 3, 8, 1986) WHO Comment : Factor IX, a naturally occurring plasma protein fraction, is a vital component of the normal blood clotting mechanism which is deficient in haemophiliacs who require replacement therapy for both the treatment and prevention of bleeding. Factor IX is extracted from the pooled plasma of a large number of donors and is presented as a concentrate. It has been recognized since 1984 that some viruses, and particularly the HIV (AIDS virus) could be transmitted to haemophiliacs from such preparations. As a result many regulatory authorities have issued new directives for the manufacture of blood products that avert this

Legislative or regulation action

Product Name	Factor IX	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		danger, by requiring the introduction of specific antiviral treatment measures during the manufacturing process. Manufacturers have withdrawn pre-existing preparations.
Product Name	Factor VIII	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	Jun 1984	Having regard to the transfer of AIDS and other viral diseases, changes in the manufacturing process of Factor VIII preparations are required. These include selection of donors, monitoring for viral contamination, limiting the donor-pool as well as the inclusion of warnings in the product information.
GBR	Oct 1986	A manufacturer of Factor VIII products has agreed voluntarily to surrender product licences for these products following concern about the ability of the heat treatment procedure used to inactivate HIV (the AIDS virus). WHO Comment : Factor VIII, a naturally occurring plasma protein fraction, is a vital component of the normal blood clotting mechanism which is deficient in haemophiliacs who require replacement therapy for both the treatment and prevention of bleeding. Factor VIII is extracted from the pooled plasma of a large number of donors and is presented as a concentrate. It has been recognized since 1984 that some viruses, and particularly the HIV (AIDS virus) could be transmitted to haemophiliacs from such preparations. As a result many regulatory authorities have issued new directives for the manufacture of blood products that avert this danger, by requiring the introduction of specific antiviral treatment measures during the manufacturing process. Manufacturers have withdrawn pre-existing preparations.
Product Name	Famotidine	
C.A.S. number	76824-35-6	
Scientific and common names, and synonyms	3-[[[2-[(AMINOIMINOMETHYL)AMINO]-4-THIAZOLYL]METHYL]THIO-N-(AMINOSULFONYL)PROPANIMIDAMIDE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
THA	Apr 2001	To be used with precaution, especially in renal patients. (Reference: (THACW) Communication to WHO, , , 28 Sep 2001)
Product Name	Fenclofenac	
C.A.S. number	34645-84-6	
Scientific and common names, and synonyms	BENZENEACETIC ACID, 2-(2,4-DICHLOROPHENOXY)- (O-(2,4-DICHLOROPHENOXY)PHENYL)ACETIC ACID	
Legislative or regulative action		

Legislative or regulation action

Product Name	Fenclofenac	
C.A.S. number	34645-84-6	
Country	Effective Date	Description of action taken Grounds for decision
GBR	1985	Withdrawn from the market.
NOR	1985	Not approved for registration having regard to its propensity to cause skin reactions which are not considered to be counter-balanced by any apparent advantage over other nonsteroidal anti-inflammatory drugs. (Reference: (NNSLM) Nytt fra Statens Legemiddelkontroll, 1, , 1985) WHO Comment : Fenclofenac, a nonsteroidal anti-inflammatory agent, was introduced in 1978 for the treatment of rheumatic disorders. By 1984 its use in the United Kingdom was associated with serious adverse effects, predominantly skin rashes, some of which were fatal. This led to the UK Committee on Safety of Medicine's refusal to renew the product licence and to the subsequent withdrawal of the drug by the manufacturer in all countries in which it was marketed.

Product Name	Fenetylline	
C.A.S. number	3736-08-1	
Scientific and common names, and synonyms		
7-[2-[ALPHA-METHYLPHENETHYL)AMINO]ETHYL]THEOPHYLLINE AMFETYLLINE FENETHYLLINE 1H-PURINE-2,6-DIONE,3,7-DIHYDRO-1,3-DIMETHYL-7-[2-[(1-METHYL-2-PHENYLETHYL)AMINO]ETHYL]-		

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
OMN	May 1991	Import and marketing of products containing fenetylline were prohibited. (Reference: (OMNCR) Circular, 16/91, , May 1991)
BGR	09 Apr 1992	Manufacture, use, storage, trade, import, and export of the central stimulant fenetylline were no longer permitted. (Reference: (BGRNDI) Communication from National Drug Institute, , , 09 Apr 1992) WHO Comment : Fenetylline, a theophylline derivative of amphetamine, was introduced in 1966 as a central nervous stimulant. It is subject to abuse and is therefore controlled under Schedule II of the 1971 Convention on Psychotropic Substances. Fenetylline is not widely marketed. (Reference: (UNCPS2) United Nations Convention on Psychotropic Substances (II), , , 1971)

Product Name	Fenfluramine	
C.A.S. number	458-24-2	
Scientific and common names, and synonyms		
BENZENEETHANAMINE, N-ETHYL-?-METHYL-3-(TRIFLUOROMETHYL)-, HYDROCHLORIDE BENZENEETHANAMINE, N-ETHYL- -METHYL-3-(TRIFLUOROMETHYL)-, HYDROCHLORIDE		

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
ARE	1997	The Ministry of Health has withdrawn the marketing approval for fenfluramine the only anorectic drug approved in the UAE. (Reference: (UAEDIB) Drug Information Bulletin, No. 3, p.2, 1997)

Legislative or regulation action

Product Name	Fenfluramine	
C.A.S. number	458-24-2	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
USA	Aug 1997	The Food and Drug Administration alerted physicians to reports of valvular heart disease in women treated for obesity with a combination of fenfluramine and phentermine which were approved in the USA for single-drug, short-term obesity therapy but have more recently been widely used "off-label" in combination for long-term management of obesity. The FDA agreed labelling changes with the manufacturers, including a boxed warning describing valvular heart disease and advising patients to consult a physician if these symptoms develop.
@WD	Sep 1997	The anti-obesity agents fenfluramine and its stereoisomer dexfenfluramine were withdrawn worldwide following the association of valvular heart disease with these drugs.
PHL	Sep 1998	The Department of Health Bureau of Food and Drugs has noted the voluntary withdrawal by the sponsoring company of the anorectic drugs fenfluramine and dexfenfluramine. (Reference: (PHLCTW) Communication to WHO, , , 15 Aug 2000) WHO Comment : Fenfluramine, dexfenfluramine and phentermine were approved individually more than 20 years ago in the USA for single-drug, short-term treatment of obesity. The manufacturers of fenfluramine and dexfenfluramine have since voluntarily withdrawn both products from the market worldwide. Phentermine remains available.

Product Name	Fenoterol	
C.A.S. number	13392-18-2	
Scientific and common names, and synonyms		
1,3-BENZENEDIOL,5-[(1-HYDROXY-2-[[2-(4-HYDROXYPHENYL-1-METHYLETHYL)AMINO]ETHYL]-3,5-DIHYDROXY-ALPHA-[(P-HYDROXY-ALPHA-METHYLPHENYLETHYL)AMINO]METHYL]BENZYL ALCOHOL		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
AUS	27 Mar 1990	The indications of products containing fenoterol have been restricted to the treatment of mild to moderate asthma, having regard to reports from New Zeland of an increased risk of death when fenoterol is used in patients with severe asthma. (Reference: (AUSTGA) Therapeutic Goods Administration, Department of Community Services and Health, , , 27 Mar 1990) WHO Comment : Fenoterol, a beta 2-adrenoreceptor agonist with bronchodilator activity, was introduced in 1971 for the management of asthma. In the 1960's, the use of other sympathomimetics in pressurised aerosols had already been associated with an increase in mortality due to asthma. However, it was not clear whether patients died from the severity of the asthma attack or from its treatment.

Product Name	Feprazone	
C.A.S. number	30748-29-9	
Scientific and common names, and synonyms		
PRENAZONE PHENYLPRENAZONE 4-(3-METHYLBUT-2-ENYL)-1,2-DIPHENYLPYRAZOLIDONE-3,5-DIONE 4-(3-METHYL-2-BUTENYL)-1,2-DIPHENYL-3,5-PYRAZOLIDINEDIONE		
Legislative or regulative action		

Legislative or regulation action

Product Name		Feprazone	
C.A.S. number		30748-29-9	
Country	Effective Date	Description of action taken Grounds for decision	
GBR	30 Mar 1984	Voluntarily withdrawn from the market after concern was expressed over its risk-benefit ratio by the Committee on Safety of Medicines.	
DEU	Nov 1984	Marketing authorization for the sale of feprazone was withdrawn at the request of the manufacturer having regard to the frequency of reported adverse reactions, particularly involving the skin, and demonstration of a carcinogenic potential in rats. The manufacturer had never exercised its option to market feprazone in the Federal Republic of Germany.	
GRC	1985	Withdrawn from the market.	
EGY	26 Feb 1985	Preparations containing feprazone are not approved for registration.	
OMN	May 1987	Products intended for internal use containing feprazone were subjected to prescription control and a certificate from the Ministry of Health was required for their importation. (Reference: (OMNCR) Circular, 26/87, , May 1987)	
AUT		Indications restricted to exacerbations of gout and other arthritic conditions. Treatment should not exceed seven days and doctors are advised not to prescribe this drug to children under 14 years of age or elderly patients. (Reference: (WIMAM) Wichtige Mitteilung ueber Arzneimittel, (1), , 1984) WHO Comment : Feprazone, a pyrazolone derivative with antiinflammatory, analgesic and antipyretic activity, was introduced in 1978 for the treatment of rheumatic disorders. As it is structurally related to phenylbutazone it is subjected to rigorously restricted indications by some national regulatory authorities. See WHO comment for phenylbutazone. WHO has been informed that to date feprazone is only available in some 7 countries.	

Product Name		Fipexide	
C.A.S. number		34161-24-5	
Scientific and common names, and synonyms			
1-[(P-CHLOROPHENOXY)ACETYL]-4-PIPERONYLPYPERAZINE			
Legislative or regulative action			
Country	Effective Date	Description of action taken Grounds for decision	
FRA	1990	Products containing fipexide were contraindicated in children, because their use had been associated with pneumopathy, neuropsychological disorders and rare cases of agranulocytosis. In 1991, the manufacturer decided to withdraw all preparations from the market. (Reference: (FRAMHH) Ministry of Health and Humanitarian Action, , , 11 Dec 1992) WHO Comment : Fipexide, a stimulant of the central nervous system, was introduced in 1973 for the treatment of depression and memory defects. Following its association with hepatic and hemopoietic disorders, particularly in children, the drug was withdrawn in France. Although not widely marketed, it may still remain registered elsewhere.	

Product Name		Flecainide	
C.A.S. number		54143-55-4	
Scientific and common names, and synonyms			
BENZAMIDE, N-(2-PIPERIDINYLMETHYL)-2,5-BIS(2,2,2-TRIFLUOROETHOXY)- N-(2-PIPERIDYLMETHYL)-2,5-BIS(2,2,2-TRIFLUOROETHOXY)BENZAMIDE			

Legislative or regulation action

Product Name		Flecainide	
C.A.S. number		54143-55-4	
Legislative or regulatory action			
Country	Effective Date	Description of action taken Grounds for decision	
SWE	31 May 1989	The indications for products containing flecainide are restricted to prophylaxis and treatment of life-threatening tachyarrhythmia, supraventricular tachyarrhythmia unresponsive to conventional treatment and Wolf-Parkinson-White syndrome. (Reference: (SSLMS) Information från Socialstyrelsens Läkemedelsavdelning, 14(3), 60, 1989)	
FRA	Jul 1989	The indications for flecainide have been restricted to the treatment of potentially life-threatening ventricular arrhythmias, particularly ventricular tachycardia, and symptomatic arrhythmias (except those resulting from myocardial infarction) with unchanged left ventricular function. Flecainide is now contraindicated in non-persistent ventricular arrhythmia after myocardial infarction. (Reference: (FRARP) La Revue Prescrire, 9(87), 292, 1989)	
MYS	Jul 1989	The indications of products containing flecainide have been restricted to the treatment of life-threatening arrhythmias only. (Reference: (MYSDN) Berita Ubat-Ubatan (Drug Newsletter), 3(3), 3, 1989)	
@EC	Nov 1989	Having regard to the CAST (Cardiac Arrhythmia Suppression Trial) study carried out in the USA, the Committee for Proprietary Medicinal Products has issued the following statement on products containing flecainide: 1) myocardial infarction as a precondition must be a contraindication for use except for life-threatening ventricular arrhythmias 2) asymptomatic and non severe symptomatic ventricular arrhythmias are contraindications 3) life-threatening ventricular arrhythmias may be treated provided that treatment is started in hospital under specific monitoring; 4) supraventricular arrhythmias may be treated provided that there is a definite need for treatment and in the absence of left ventricular function impairment. Patients on safe and effective long-term treatment with flecainide already before publication of the results of the CAST study may continue to take the drug. (Reference: (CECC) Communication from CEC, , , 21 June 1990)	
ITA	1990	The indications for products containing flecainide are restricted to some forms of supraventricular tachycardias and to persistent life-threatening hyperkinetic ventricular arrhythmia. In the latter indication, patients should be hospitalized when treatment is commenced and remain under specialized medical supervision throughout therapy. Use is contraindicated in cases of cardiac block, cardiogenic shock, cardiac insufficiency, known hypersensitivity and in patients with a history of myocardial infarction, except for the treatment of life-threatening ventricular arrhythmias. (Reference: (BIFTI) Bolletino d'Informazione sui Farmaci, 14(1), 2, 1990)	
NOR	1990	The indications for products containing flecainide were restricted to life-threatening ventricular tachycardia and to treatment and prophylaxis of severe incapacitating supraventricular arrhythmia. Treatment was required to be instituted in a hospital after full cardiological assessment of the patient. (Reference: (NNSLM) Nytt fra Statens Legemiddelkontroll, 4, 7, 1990)	
DEU	Jan 1990	The approved indications of flecainide are restricted to supraventricular and severe ventricular arrhythmias. It is contraindicated in recent myocardial infarction and impaired ventricular function, except in patients with life-threatening arrhythmias. (Reference: (DAZ) Deutsche Apotheker Zeitung, 130(5), 10, 1990)	
<p>WHO Comment : The membrane-stabilizing antiarrhythmic agent flecainide was introduced into medicine in 1982. The decision to delete the indications for patients with asymptomatic and less severe symptomatic ventricular arrhythmias was taken on the basis of the results of a trial (CAST study) that showed a two-fold increase in deaths in post-myocardial patients taking flecainide compared with the placebo group.</p>			

Product Name **Floctafenine**

Legislative or regulation action

C.A.S. number	23779-99-9	
Scientific and common names, and synonyms	BENZOIC ACID, 2-[[8-(TRIFLUOROMETHYL)-4-QUINOLINYL]AMINO]-,2,3-DIHYDROXYPROPYL ESTER 2,3-DIHYDROXYPROPYL-N-(8-TRIFLUOROMETHYL-4-)QUINOLYL)ANTHRANILATE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
BEL	26 Jun 1987	Having regard to the potential of floctafenine to cause severe anaphylactic shock, products containing floctafenine may now only be obtained on medical prescription. (Reference: (BELAR) Arrêté Royal, , , June 1987) WHO Comment : See WHO comment for glafenine.
Product Name		
Flosequinan		
C.A.S. number	76568-02-0	
Scientific and common names, and synonyms	4(1H)-QUINOLINONE, 7-FLUORO-1-METHYL-3-(METHYLSULFINYL)-	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GBR	Jul 1993	Subsequent to its withdrawal of the 100 mg tablet formulation of the vasodilator, flosequinan (Manoplax: Boots), the manufacturer has now also withdrawn the remaining 50 mg tablet. The company took this decision after further analysis of interim results of a trial (100 mg and 75 mg) showed an increase in hospital admissions among patients taking doses of 75 mg daily (the only available dosage formulation the trial conducted in the United States). The initial analysis had shown increased risk of death in patients taking the 100 mg dosage. In view of these data the company considered the continued use of flosequinan could not be recommended. (Reference: (GBRPHJ) The Pharmaceutical Journal, p.114, , 24 July 1993)
Product Name		
Flunarizine		
C.A.S. number	52468-60-7	
Scientific and common names, and synonyms	PIPERAZINE, 1-[BIS(4-FLUOROPHENYL)METHYL]-4-(3-PHENYL-2-PROPENYL)-(E)- (E)-1-[BIS-(P-FLUOROPHENYL)METHYL]-4-CINNAMYLPIPERAZINE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
ESP	Aug 1989	Having regard to their potential to induce extrapyramidal symptoms, products containing flunarizine may no longer be indicated for cerebral and peripheral arterial insufficiency, including loss of memory, insomnia, intermittent claudication, rest pain or vasospastic disturbances. The approved indications are restricted to vestibular disturbances, vertigo, prophylaxis of vascular headache and prevention of motion sickness. (Reference: (ESPINS) Información Terapéutica de la Seguridad Social, 13(8), 176, 1989)
DEU	Jan 1991	The indications for products containing flunarizine were restricted to the treatment of vestibular dysfunction, having regard to association of the compound with Parkinsonism, extrapyramidal symptoms and depression and to insufficient proof of efficacy in other indications. Doctors were advised not to continue treatment for longer than is necessary to obtain an effective response, and in no circumstances for longer than 3 months. (Reference: (BGHBL) Bundesgesundheitsblatt, 2/91, 81, Feb 1991)
@EC	12 Mar 1991	The Committee for Proprietary Medicinal Products advised that the indications for

Legislative or regulation action

Product Name	Flunarizine	
C.A.S. number	52468-60-7	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		products containing flunarizine should be restricted to the prophylaxis of severe refractory migraine and to the treatment of functional vestibular vertigo, having regard to the risks associated with their use. In 1989 the Committee had recommended that the approved product information should: 1) state that the product is contraindicated in patients with a history of extrapyramidal symptoms, Parkinsonism, Alzheimer's disease and depression; 2) warn that it may induce extrapyramidal signs and depression and unmask Parkinsonism, particularly in the elderly; 3) provide a description of the signs of extrapyramidal and depressive reactions. (Reference: (CPMPPO) Pharmacovigilance Opinion, 6, , 13 Sep 1989)
JPN	Jul 1991	The approved labelling of products containing flunarizine was amended to indicate that reversible extrapyramidal disturbances and, less frequently, depression have been associated with their use, particularly in the elderly. (Reference: (JPNARD) Information on Adverse Reactions to Drugs, 109, , July 1991) WHO Comment : Flunarizine, an antihistaminic and vasodilator agent, was introduced into medicine in 1970. It is indicated for the treatment of central and peripheral vascular disorders. However, its effectiveness in these conditions has not been convincingly demonstrated, and its use has been associated with adverse reactions involving the central nervous system, including extrapyramidal disturbances and depression. This has led several regulatory authorities to restrict the approved indications for products containing flunarizine.
Product Name		
Flunitrazepam		
C.A.S. number		
1622-62-4		
Scientific and common names, and synonyms		
5-(O-FLUOROPHENYL)-1,3-DIHYDRO-1-METHYL-7-NITRO-2H-1,4-BENZODIAZEPIN-2- ONE 2H-1,4-BENZODIAZEPIN-2-ONE, 5-(2-FLUOROPHENYL)-1,3-DIHYDRO-1-METHYL-7- NITRO-		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
TUR	1986	The Ministry of Health and Social Assistance has subjected flunitrazepam to controls equivalent to those applied to drugs in Schedule II of the 1971 Convention on Psychotropic Drugs in view of its frequent abuse by drug addicts.
DEU	1 Apr 1994	As from 1 April 1994, pharmaceutical products containing more than 1-mg flunitrazepam per delivery unit will be scheduled under Narcotic Drugs Regulations. Pharmacists are now required to maintain records indicating the quantity of stock held and their destination. The major manufacturers have been requested to comply with relevant provisions. (Reference: (DAZ) Deutsche Apotheker Zeitung, 134(13):1130, , 31 Mar 1994)
ZAF		The South African Medicines Control Council has withdrawn registration of all 2 mg formulations of flunitrazepam and has scheduled 1 mg tablets in Schedule 6 of the Narcotic Drugs Regulations. It has also decreed that all flunitrazepam- containing products be reformulated to include a bitter taste and colorant in order to minimize risk of illegal use in facilitating crimes. (Reference: (ZAFPS) Information from the Pharmaceutical Services, , ,) WHO Comment : Flunitrazepam, a benzodiazepine derivative with sedative and hypnotic activity, was introduced in 1974 for the management of anxiety. Although it is subject to international control under Schedule IV of the 1971 Convention on Psychotropic Substances, its potential for abuse by drug addicts has led at least two countries (Germany and Turkey) to apply controls equivalent to those of

Legislative or regulation action

Product Name	Flunitrazepam	
C.A.S. number	1622-62-4	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		Schedule II. (Reference: (UNCPS4) United Nations Convention on Psychotropic Substances (IV), , , 1971)
Product Name	Fluoxetine	
C.A.S. number	54910-89-3	
Scientific and common names, and synonyms		
BENZENEPROPANAMINE, N-METHYL-G-[4-(TRIFLUOROMETHYL)- PHENOXYL]-, (±)-		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
NZL	Dec 1994	Hyponatraemia which may be life-threatening may occur with fluoxetine and other selective serotonin reuptake inhibitors particularly in elderly women. Patients in the ?at risk? category should have electrolyte monitoring during the first month of therapy. (Reference: (NZLPU) Prescriber Update, No.7, , Dec 1994)
Product Name	Fluvoxamine	
C.A.S. number	54739-18-3	
Scientific and common names, and synonyms		
5-METHOXY-4'-(TRIFLUOROMETHYL)VALEROPHENONE (E)-0-(2-AMINOETHYL)OXIME		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
ISL		The Committee on Pharmaceuticals has refused to approve fluvoxamine for registration because animal experiments have shown teratogenicity and a potential to cause renal damage. (Reference: (ISLCP) Notification, , , Feb 1987)
Product Name	Furazolidone	
C.A.S. number	67-45-8	
Scientific and common names, and synonyms		
NITROFURAZOLIDONUM		
NIFURAZOLIDONUM		
2-OXAZOLIDINONE, 3-(((5-NITRO-2-FURANYL)METHYLENE)AMINO)-		
3-((5-NITROFURFURYLIDENE)AMINO)-2-OXAZOLIDONE		
3-((5-NITROFURFURYLIDENE)AMINO)-2-OXAZOLIDINONE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
JPN	Jul 1977	Withdrawn from all marketed preparations on the grounds that it has been superseded by safer and more effective preparations.
PHL	1980	Approved for restricted use only. Animal tests have shown that this drug has

Legislative or regulation action

Product Name	Furazolidone	
C.A.S. number	67-45-8	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		carcinogenic potential. A warning statement is required to be placed on the labels of all products.
ITA	1982	The following warning has been inserted on the label taking into account experimental data on animals: "To be used systemically only for short periods and under the physician's guidance".
IRQ	1986	The National Board for the Selection of Drugs has withdrawn furazolidone from the market.
MYS	Mar 1987	All products containing furazolidone have been withdrawn. (Reference: (MYSDC) Malaysian Drug Control Authority, No.8, , Dec 1986)
KOR	Dec 1988	All products containing furazolidone were banned, because there are many preparations which are safer and more effective. (Reference: (KRMHSA) Ministry of Health and Social Affairs - Communication to WHO, , 13 Dec 1991)
LBN	Aug 1991	Products containing furazolidone intended for the treatment of diarrhoea in children were withdrawn. (Reference: (LBNMHD) Ministry of Health and Social Affairs Decree, 150/1, , Aug 1991)
YEM	1998	The Supreme Board of Drugs and Medical Devices has withdrawn all formulations of the nitrofurantoin derivative, furazolidone, because many other safer and more effective alternatives are available. (Reference: (YEMCW) Communications to WHO, , 10 Oct 1998)
<p>WHO Comment : Furazolidone, a nitrofurantoin derivative with antibacterial and antiprotozoal activity, was introduced in 1954. In the 1970s it was shown to have a carcinogenic potential following long-term administration to experimental animals. However, the relevance of this to short-term therapy in man has not been established. The risk-benefit assessment varies and furazolidone remains widely available in many countries for the treatment of diarrhoea and enteritis.</p>		

Bibliographical references

WHO FOOD ADD., 31, 85, 1993

Product Name	Gallopamil	
C.A.S. number	1662-47-8	
Scientific and common names, and synonyms		
ALPHA[3-[2-(3,4-DIMETHOXYPHENYL)ETHYL]METHYLAMINO]PROPYL]-3,4,5-TRIMETHOXY-ALPHA-(1-METHYLETHYL) BENZENEACETONITRILE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
TUR	May 2001	The General Directorate of Pharmaceuticals and Pharmacy of the Ministry of Health suspended the marketing authorization of gallopamil because of the decision of the Registration Committee. (Reference: (TURCW) Communication to WHO, , 20 Sep 2001)
Product Name	Gamelonic acid	
C.A.S. number	2003-0-1001	
Scientific and common names, and synonyms		
PRIMROSE OIL DERIVATIVE		

Legislative or regulation action

Product Name	Gamelonic acid	
C.A.S. number	2003-0-1001	
Scientific and common names, and synonyms		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GBR	Oct 2002	The Medicines Control Agency has withdrawn the marketing authorizations for two gamelonic acid containing derivatives (Epogam, Efamast) of primrose oil, originally licensed for the symptomatic relief of eczema in children, due to inadequate standards of efficacy with these products. However, since no safety issues are involved, these products will continue to be available in health food shops as dietary supplements. (Reference: (GBRNUP) News Update, , ,)
Product Name	Gangliosides	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	31 Aug 1992	The Federal Health Office extended the suspension period for the injectable preparation of mixed bovine brain gangliosides at least until 30 September 1994. The product was first suspended in 1989 because of a possible association with Guillain-Barr, syndrome. (Reference: (DEUFHO) Communication from Federal Health Office, , , 31 Aug 1992) WHO Comment : Gangliosides are a glycolipid extract of bovine cerebral cortex claimed to ameliorate peripheral neuropathies of various types, including post-herpetic neuropathy, tobacco-alcohol amblyopia, toxic acoustic injuries, and traumatic facial paralysis. Its use has been associated with cases of Guillain-Barr, syndrome characterized by mixed polyneuropathy and in some instances, flaccid paralysis.
Product Name	Gemfibrozil	
C.A.S. number	25812-30-0	
Scientific and common names, and synonyms	PENTANOIC ACID, 5-(2,5-DIMETHYLPHENOXY)-2,2-DIMETHYL 2,2-DIMETHY-5-(2,5-XYLLOXY)VALERIC ACID	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
NOR	1987	The Medicines Control Authority has refused registration of gemfibrozil on the grounds that the risk of adverse effects is not balanced by therapeutic benefit. (Reference: (NNSLM) Nytt fra Statens Legemiddelkontroll, 4, 10, 1987) WHO Comment : Gemfibrozil, an antihyperlipidaemic derivative of clofibrate, was introduced in the early 1980's. It is registered in several countries for the treatment of hyperlipidaemia unresponsive to dietary measures. (See also the WHO comment for clofibrate).
Product Name	Gentamicin (topical preparations)	
C.A.S. number	1403-66-3	
Scientific and common names, and synonyms	O-3-DEOXY-4-C-METHYL-3-(METHYLAMINO-?-L-ARABINO-PYRANOSYL-(1?)-O-[2,6-DIAMINO-2,3,4,6-TETRADEOXY-?-D-ERYTHRO-HEXOPYRANOSYL-(1?)]-2-DEOXY-D-STREPTAMINE (GENTAMICIN C)1A	
Legislative or regulation action		

Product Name **Gentamicin (topical preparations)**

C.A.S. number **1403-66-3**

Scientific and common names, and synonyms

O-3-DEOXY-4-C-METHYL-3-(METHYLAMINO- -L-ARABINO-PYRANOSYL-(1 6)-O-[2,6,DIAMINO-2,3,4,6-TETRADEOXY- -D-ERYTHRO-HEXOPYRANOSYL-(1 4)]-2-DEOXY-D-STREPTAMINE (GENTAMICIN C1A)

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
NLD	1994	The Committee for the Evaluation of Medicines has withdrawn the marketing authorization for dermal products containing gentamicin. The Committee considers that the local use of antibiotics that are also available for systemic administration is no longer acceptable because of the risk of development of resistance (including cross-resistance with other aminoglycoside antibiotics). (Reference: (NPHWB) Pharmaceutisch Weekblad, 28(5):126, , 1994)
MYS	May 1997	The Drug Control Agency has decided to lift the ban on topical preparations containing gentamicin. However, the indications will be restricted to community-based skin infections only, i.e. treatment of impetigo, erythema and other localized primary bacterial skin infections with a Gram-negative component and also for secondary bacterial infections complicating other pre-existing dermatoses. In addition, a boxed warning will be included in the product information and package insert stating : "Use of topical gentamicin preparations in closed hospital settings is actively discouraged". (Reference: (MYS DI) Berita Ubat-Ubat (Drug Information), 11(2): 8, , May 1997)
ARM		The Drug and Medical Technology Agency withdrew registration of gentamicin ointment for ?in situ? treatment of minor infections because antibiotics that are also available for systemic use are not considered acceptable for topical use because of resistance development. (Reference: (ARM CW) Communication to WHO, , , 09 Aug 2000) WHO Comment : Gentamicin has been used in situ preparations for the treatment of minor infections. Antibiotics that are also available for systemic use are not considered acceptable for topical use because of the risk of development of resistance. Neomycin is the topical aminoglycoside listed in the WHO Model List of Essential Drugs.

Product Name **Germander**

Scientific and common names, and synonyms

TEUCRIUM CHAMAEDRYIS

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
DEU	1992	The Federal Health Office withdrew the marketing authorization for herbal medicines containing germander based on reports of hepatotoxicity generated within France by the drug regulatory agency. (Reference: (DAZ) Deutsche Apotheker Zeitung, 132(12):20, , 1992)
FRA	1992	The Ministry of Health and Humanitarian Action suspended the marketing authorization for medicinal products containing the plant germander having regard to 26 cases of liver necrosis associated with the use of these products. (Reference: (FRARP) La Revue Prescrire, 12(114):17, , 1992)
BEL	04 Aug 1992	The Minister of Social Integration, Public Health and the Environment decided to suspend for a period of one year all medicines containing germander having regard to concerns relating to hepatotoxicity generated within France. This suspension has been prolonged for another year from 20 July 1993 by order of the Ministry. (Reference: (BELMD) Ministerial Decree, , , 04 Aug 1992)

Legislative or regulation action

Product Name **Germander**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
		(Reference: (BELMB) Moniteur Belge, , 20542, 25 Sep 1992) WHO Comment : Germander has been traditionally used as a diet aid, a treatment for light diarrhoea, or locally as an analgesic for oral pain. In 1991, the first cases of hepatitis associated with the use of these products were reported to the National System of Pharmacovigilance in France. It is yet uncertain whether contamination possible by pesticides or fungi, may be implicated or whether these cases result from toxic or immuno-allergic reactions to constituents of Germander.

Product Name **Ginkgo biloba**

Scientific and common names, and synonyms

FOSSIL TREE
GBE-761
KEW TREE
MAIDENHAIR TREE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
DEU	1998	The Federal Institute for Drugs and Medical Devices has extended the suspension of parenteral infusion formulations after having received several reports of adverse reactions associated with its use, most of which described anaphylactic symptoms (shock, fever, leukocytosis, and cardiac arrhythmia), in some cases life-threatening. (Reference: (DEUCFI) Communication, , , 19 June 1998)

Product Name **Glafenine**

C.A.S. number **3820-67-5**

Scientific and common names, and synonyms

GLAPHENINE
2,3-DIHYDROXYPROPYL-N-(7-CHLORO-4-QUINOLYL) ANTHRANILATE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
DEU	1984	Following reports of frequent severe allergic reactions, this analgesic was withdrawn from the market by the manufacturer.
ITA	Oct 1987	Having regard to adverse reactions reported in Italy and other countries, the General Directorate of the Pharmaceutical Service of the Ministry of Health has revoked the marketing authorization for suppositories containing 1 mg of glafenine. This preparation contained a higher dosage of the active principle than others available on the market. (Reference: (BIFTI) Bolletino d'Informazione sui Farmaci, 10(10), 2, 1987)
BEL	1 Jan 1991	In agreement with the manufacturers, the Ministry of Health suspended the marketing authorization for all products containing glafenine, including extemporaneous preparations, following reports of anaphylactic shock, acute tubulo-interstitial renal insufficiency and immuno-allergic hepatitis. In 1992, glafenine was withdrawn by the major manufacturer. (Reference: (BELGPI) General Pharmaceutical Inspectorate, , , 12 Dec 1991)

Legislative or regulation action

Product Name	Glafenine	
C.A.S. number	3820-67-5	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
@EC	14 Jan 1992	The Committee for Proprietary Medicinal Products of the European Communities recommended the withdrawal of products containing glafenine, because the risk of serious anaphylactic reactions associated with their use is greater than with other analgesics. (Reference: (CPMPPO) Pharmacovigilance Opinion, 8/2, , 14 Jan 1992)
CHE	Mar 1992	The marketing authorization for products containing glafenine was suspended and later withdrawn by the company. (Reference: (CHBCM) Bulletin Mensuel, , , Mar 1992)
FRA	Mar 1992	In agreement with the manufacturer, the Ministry of Health withdrew the marketing authorization for products containing glafenine, having regard to the risk of anaphylactic reactions. (Reference: (FRAMS) Ministry of Social Affairs and Integration, , , Apr 1992)
PRT	Mar 1992	The marketing authorization for monocomponent and combination products containing glafenine was suspended. (Reference: (PRTMH) Ministry of Health, , , Mar 1992)
OMN	Mar 1992	Import and marketing of products containing glafenine were prohibited, and they will not be considered for registration. (Reference: (OMNCR) Circular, 5/92, , Mar 1992)
@WD	May 1992	Upon agreement of regulatory authorities, products containing glafenine were withdrawn worldwide by the major manufacturer. (Reference: (CRU) Communication to WHO from Roussel Uclaf, , , 21 May 1992)
WHO Comment : Glafenine, a quinolylanthranilate derivative, was introduced in 1965 for use as an analgesic. By the late 1970s its use had been associated with severe allergic responses, including anaphylactoid reactions, which led to its withdrawal in one country whereas in others a warning to this effect is required in the product information. In 1992, on the advice of the Committee for Proprietary Medicinal Products of the European Communities, glafenine was eventually withdrawn worldwide by the major manufacturer.		

Product Name	Glucosamine sulfate	
C.A.S. number	3416-24-8	
Scientific and common names, and synonyms		
CHITOSAMINE SULFATE		
D-GLUCOSE, 2-AMINO-2-DEOXY-, SULFATE		
2-AMINO-2-DEOXY-BETA-D-GLUCOPYRANOSE SULFATE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	1986	Following reports of local hypersensitivity reactions, preparations containing glucosamine sulfate are no longer approved for intra-articular administration.
EGY	1987	Preparations of glucosamine sulfate for intra-articular injection will not be considered for registration because of an unacceptable potential to cause allergic reactions. (Reference: (EGYDI) Drug Information, 5(3), 1, 1987)
WHO Comment : Glucosamine is found in chitin, mucoproteins and mucopolysaccharides. It is used as a pharmaceutical aid. Glucosamine sulfate has been used in the treatment of rheumatic disorders though it is not widely marketed		

Legislative or regulation action

Product Name	Glucosamine sulfate	
C.A.S. number	3416-24-8	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
for this purpose.		
Product Name	Glutethimide	
C.A.S. number	77-21-4	
Scientific and common names, and synonyms		
GLUTEMIDE		
2-ETHYL-2-PHENYLGLUTARIMIDE		
2,6-PIPERIDINEDIONE, 3-ETHYL-3-PHENYL-		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
NOR	1980	Withdrawn from the market.
ZWE	Nov 1984	Prohibited for use. (Reference: (ZWESI) Statutory Instrument, 366, , Nov 1984)
PAK	1988	Products containing glutethimide were withdrawn. (Reference: (PAKMH) Ministry of Health, Special Education and Social Welfare, , , Aug 1988)
WHO Comment : Glutethimide, a piperidine derivative, was introduced in 1955 for use as a sedative-hypnotic drug. Its addiction liability and severity of withdrawal symptoms are equal to those of the barbiturates and it is controlled under Schedule III of the 1971 Convention on Psychotropic Substances. (Reference: (UNCPS3) United Nations Convention on Psychotropic Substances (III), , , 1971)		
Product Name	Glutoxim	
C.A.S. number	2003-0-1002	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
ARM	Sep 2000	The Armenian Drug and Medical Technology Agency did not approve the marketing of the new immunomodulating agency on grounds of doubtful safety and incomplete clinical trial. (Reference: (ARMCW) Communication to WHO, , , 31 Aug 2001)
Product Name	Grepafloxacin hydrochloride	
C.A.S. number	161967-81-3	
Scientific and common names, and synonyms		
OPC-17116		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision

Legislative or regulation action

Product Name	Grepafloxacin hydrochloride	
C.A.S. number	161967-81-3	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GBR	Oct 1999	Grepafloxacin (Raxar) was voluntarily withdrawn from the market by the licence holder from the market because of a small number of severe cardiac arrhythmias among patients in post-marketing surveillance. (Reference: (GBRMCA) Communication to WHO, , , 30 Aug 2000)
LTH	Nov 1999	Marketing authorization for grepafloxacin was suspended by the State Medicines Control Agency. (Reference: (LTHMCA) Order of State Medicines Control Agency, No. 96, , 15 Nov 1999)
PER	Dec 1999	La Direcció General de Medicamentos, Insumos y Drogas (DIGEMID) of the Ministry of Health has communicated to health professionals that Glaxo Wellcome has voluntarily withdrawn the fluoroquinolone grepafloxacin from the market because of prolongation of the QT interval giving rise to ventricular arrhythmias known as torsades de pointes. (Reference: (PERDGM) Alerta DIGEMID, No. 12-99, , 15 Dec 1999)
ARM	Jul 2000	Grepafloxacin has been voluntarily withdrawn after the observation of severe cardiovascular events among patients. (Reference: (ARMCW) Communication to WHO, , , 09 Aug 2000)
SGP		Grepafloxacin has been voluntarily withdrawn due to an effect of the drug on cardiac repolarization, manifested as QT interval prolongation. Some patients may be at risk of the very rare but serious ventricular arrhythmia known as torsades de pointes. (Reference: (SGPCW) Communication to WHO, , , 02 Aug 2000)

Product Name	Griseofulvin	
C.A.S. number	126-07-8	
Scientific and common names, and synonyms	7-CHLORO-2',4,6-TRIMETHOXY-6'BETA-METHYLSPIRO(BENZOFURAN-2(3H),1'-(2) CYCLOHEXENE)-3,4'-DIONE SPIRO(BENZOFURAN-2(3H), 1'-(2)CYCLOHEXENE)-3,4'-DIONE, 7-CHLORO-2',4,6- TRIMETHOXY-6'-METHYL-,(1'S-TRANS)-	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GBR	1986	Having regard to recently evaluated reports of carcinogenicity, fetotoxicity and teratogenicity in rodents administered very high doses of griseofulvin, the Committee on the Review of Medicines has recommended that all products containing griseofulvin should be restricted in their use to the treatment of dermatophyte infections of the skin, scalp, hair and nails when topical therapy has failed or is considered inappropriate. It also recommends that such products should not be used during pregnancy or for prophylactic treatment.
DEU	1992	Following reports of teratogenicity in experimental animals, the approved product information for products containing griseofulvin was amended to contraindicate their use during pregnancy, except in life-threatening conditions, and lactation. The need for contraceptive measures to be maintained throughout treatment and, for men, for 6 months thereafter was emphasized. (Reference: (DAZ) Deutsche Apotheker Zeitung, 32(12):XII, , 1992) WHO Comment : Griseofulvin, isolated from a penicillin producing mould, has been widely used as a systemically administered antifungal agent in man for over 20 years. It is effective in dermatophyte infections (including tinea barbae and tinea capitis) but it is inactive against yeasts and bacteria. Evidence that very high doses of griseofulvin are carcinogenic, teratogenic and fetotoxic in laboratory animals has led to an acceptance that it should not be used to treat trivial infections that

Legislative or regulation action

Product Name	Griseofulvin	
C.A.S. number	126-07-8	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		respond to topical therapy. Oral formulations of griseofulvin are included in the WHO Model List of Essential Drugs. (Reference: (WHTAC1) The Use of Essential Drugs, 2nd Report of the WHO Expert Committee, 722, , 1985)
Product Name	Guanofuracin	
C.A.S. number	300-25-4	
Scientific and common names, and synonyms		
	5-NITROFURFURYLIDENAMINO GUANIDINE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
JPN	Jul 1977	Withdrawn from all marketed preparations on the grounds that it has been superseded by safer and more effective preparations.
VEN		Not approved for use and/or sale. WHO Comment : Guanofuracin, a nitrofur derivative, was formerly used as an anti-infective agent. It has, however, been superseded by safer compounds and WHO has no information that it remains commercially available.
Product Name	H1-Antihistamines	
Scientific and common names, and synonyms		
	HISTAMINE H1 RECEPTOR ANTAGONISTS	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	1987	Products containing histamine H1 receptor antagonists indicated for vomiting during pregnancy may only be dispensed on medical prescription, because they have been associated with an increased risk of neonatal pyloric stenosis. H1-antihistamines labelled for other indications should mention pregnancy as a contraindication. (Reference: (BGHBL) Bundesgesundheitsblatt, 30, 186, 1987)
CHE	28 Mar 1990	Over-the-counter preparations containing phenothiazine antihistamines indicated for children under one year of age may only be dispensed on medical prescription. The product information directed to physicians must carry a warning stating that caution is recommended in treating children of less than one year of age and that the use of the preparation is clearly contra-indicated under the following circumstances: neonates (particularly premature births), history of apnoeic crises (near-miss-SIDS), SIDS in brothers and sisters and cardiorespiratory problems. The information intended for patients must carry a warning that a doctor is to be consulted before children of less than one year of age are treated. (Reference: (CHEAZ) Schweizer Apotheker Zeitung, 128(11), 311, 1990)
@EC	13 May 1991	The Committee for Proprietary Medicinal Products advised that products containing phenothiazines, including alimemazine, mequitazine, oxomemazine and promethazine indicated for the treatment of cough, allergic reactions, motion sickness and for sedation, should not be used in children below the age of one year, having regard to their possible
Legislative or regulation action		

Product Name **H1-Antihistamines**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
BEL		<p>association with sudden infant death syndrome. (Reference: (CPMPDP) Draft Position Statement on Phenothiazines and sudden infant death syndrome, , , 13 May 1991)</p> <p>The approved information of products containing histamine H1 receptor antagonists must warn in the section "Precautions" against their administration to children aged less than one year without medical advice, because their sedative effect may be associated with episodes of sleep apnoea. The package leaflets of preparations containing of phenothiazine antihistamine must bear an identical warning in the section "Contra-indications". (Reference: (BELGPI) General Pharmaceutical Inspectorate, , , 18 June 1987)</p> <p>WHO Comment : Histamine H1 receptor antagonists were introduced in 1937 as over-the-counter medicines for the treatment of allergies of the upper respiratory tract and skin. They are also widely used to reduce the symptoms of the common cold, although there is little evidence of their effectiveness in this condition. The sedative and antiemetic effects of antihistamines are of value in the treatment of sleep disorders, motion sickness and vomiting. In 1979, the possibility was raised that the use of phenothiazine antihistamines, particularly promethazine, could be associated with sleep apnoea in young children and with sudden infant death syndrome (SIDS). Studies carried out subsequently, although they have not established a causal relationship, have led some drug regulatory authorities to subject products containing phenothiazine antihistamines to prescription control and/or to caution against their use in young children. In some countries, similar warnings have also been included in the package leaflets of other H1-antihistamines.</p>

Product Name **Halofantrine**

C.A.S. number **69756-53-2**

Scientific and common names, and synonyms

9-PHENANTHRENE METHANOL, 1,3-DICHLORO-?-[2-(DIBUTYLAMINO)ETHYL]-6-(TRIFLUOROMETHYL)-, HYDROCHLORIDE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
FRA	Jan 1994	<p>The National Commission for Pharmacovigilance has contraindicated the use of the antimalarial agent, halofantrine, in patients with congenital or acquired QT prolongation, in those with a family history of congenital QT prolongation, and in patients taking antiarrhythmic medicines or hypokalaemic substances. (Reference: (FRAAMC) Communiqué de Presse, , , 14 Jan 1994)</p> <p>WHO Comment : Halofantrine is an antimalarial introduced to medicine in 1982. It should be reserved for use in areas where multiple drug-resistant falciparum malaria is prevalent. Cases of serious cardiotoxicity have been reported.</p>

Product Name **Halogenated hydroxyquinoline derivatives**

C.A.S. number **148-24-3**

Scientific and common names, and synonyms

8-QUINOLINOL
OXYQUINOLINE
OXYQUINOL

Legislative or regulation action

Product Name	Halogenated hydroxyquinoline derivatives	
C.A.S. number	148-24-3	
Scientific and common names, and synonyms	OXINE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DNK	1978	All halogenated hydroxyquinoline derivatives intended for oral administration have been withdrawn from use. (Reference: (UGLAAD) Ugeskrift for Laeger, 140, 1181, 1978)
CYP	1980	The Drug Council withdrew all products containing halogenated hydroxyquinoline derivatives intended for internal use due to the possible risk of occurrence of sub-acute myelo-optic neuropathy (SMON) in treated patients.
PHL	Aug 1980	Withdrawn from the domestic market due to reports of neurological disorders (SMON) with their use in Japan.
BGD	1982	Under the provisions of the Drugs (Control) Ordinance, these preparations have been banned. Clioquinol is implicated in sub-acute myelo-optic neuropathy (SMON), manifested by pain and persistent diarrhoea and proceeding to bilateral sensory disturbances, paraesthesias and dysaesthesias. Similar toxic effects have been observed with other halogenated hydroxyquinolines. (Reference: (BGDCO) The Drugs (Control) Ordinance, , , 1982)
GHA	1982	All preparations containing halogenated hydroxyquinoline derivatives for oral administration have been withdrawn from use.
TUR	20 Dec 1982	Banned for production and sale having regard to severe adverse reactions.
ITA	1983	Withdrawn from the market.
GRC	Mar 1984	Pharmaceutical products containing halogenated hydroxyquinolines have been withdrawn having regard to experimental and clinical evidence of toxicity.
OMN	Mar 1987	Import and marketing of oral and parenteral preparations containing oxyquinoline and its halogenated derivatives intended for the treatment of diarrhoea in children were prohibited. Topical preparations remained on the market. (Reference: (OMNCR) Circular, 11/87, , Mar 1987)
ARE		The following halogenated hydroxyquinoline derivatives used for intestinal amoebiasis are banned: broxyquinoline, clioquinol and diiodohydroxyquinoline.
IND		Currently available on the market. Precautionary information is required to be given with this drug.
VEN		Subject to restricted use and/or sale.
		WHO Comment : Halogenated hydroxyquinoline is structurally related to clioquinol. See WHO comment for clioquinol. (Reference: (WHODI) WHO Drug Information, 77.1, 9, 1977)

Product Name	Halogenated salicylanilides
Scientific and common names, and synonyms	DIBROMSALAN METABROMSALAN TRIBROMSALAN TETRACHLOROSALICYLANILIDE
Legislative or regulative action	

Legislative or regulation action

Product Name		Halogenated salicylanilides	
Country	Effective Date	Description of action taken Grounds for decision	
USA	1 Dec 1975	Withdrawn from the market and prohibited for export in drugs and cosmetic products by the Food and Drug Administration due to the risks of disabling skin disorders and photosensitivity in humans. (Reference: (FEREAC) Federal Register, 40(210), 50527, 1975)	
JPN	Jan 1976	Banned by the Pharmaceutical Affairs Bureau due to potential for photosensitivity reactions. WHO Comment : Halogenated salicylanilides, including dibromsalan, metabromsalan, tribromsalan and tetrachlorosalicylanilide, which have antibacterial and antifungal activity, have been used both as active ingredients for antimicrobial purposes and as inactive ingredients (preservatives) in drug and cosmetic products. Their use has been associated with photosensitive eruptions and disabling skin disorders which has resulted in their withdrawal by some national drug regulatory authorities.	
Product Name		Heptabarb	
C.A.S. number		509-86-4	
Scientific and common names, and synonyms			
5-(CYCLOHEPT-1-ENYL)-5-ETHYLBARBITURIC ACID			
HEPTAMALUM			
HEPTABARBITONE			
Legislative or regulative action			
Country	Effective Date	Description of action taken Grounds for decision	
SWE	Jul 1984	Withdrawn following discussions between the manufacturer and the National Board of Health and Welfare. Fatal intoxications and abuse are associated with use of preparations containing heptabarb. WHO Comment : Heptabarb is an intermediate-acting barbiturate. See WHO comment for barbiturates.	
Product Name		Herpes simplex vaccines	
Legislative or regulative action			
Country	Effective Date	Description of action taken Grounds for decision	
DEU	Aug 1984	Sale of Herpes simplex vaccines has not been approved by the National Control Authority having regard to their potential hazards.	
SAU		Preparations containing Herpes simplex vaccines have been withdrawn from the market.	
VEN		Not approved for use and/or sale. WHO Comment : Preparations containing Herpes simplex vaccine have been available for at least 15 years. As a result of a review of unlicensed products marketed in the Federal Republic of Germany in 1984 the National Control Authority banned the use of such preparations having regard to their potential harmfulness. Preparations remain available elsewhere, however.	
Product Name		Hexachlorophene	

Legislative or regulation action

C.A.S. number	70-30-4	
Scientific and common names, and synonyms	HEXACHLOROPHANE PHENOL, 2,2'-METHYLENEBIS[3,4,6-TRICHLORO- 2,2'-METHYLENEBIS(3,4,6-TRICHLOROPHENOL)]	
Legislative or regulatory action		
Country	Effective Date	Description of action taken Grounds for decision
PHL	1972	All talcum powders for infant use containing more than 0.75% hexachlorophene were withdrawn. All other products with a greater concentration shall be available on prescription basis only.
JPN	Mar 1972	Banned by the Pharmaceutical Affairs Bureau in preparations such as nursing powder, since edema of the brain is observed with test animals. Export is prohibited.
TUR	1981	Withdrawn from all toothpaste formulations by the Ministry of Health due to published evidence of its harmful effects. Export of this product is prohibited.
COE	1984	The Committee of Experts on Cosmetics of the Council of Europe has reclassified hexachlorophene in the list of preservatives published in the second edition 1984 of "Cosmetic Products and their Ingredients" from class A (recommended) to class D (not recommended). Hexachlorophene is now considered an ingredient which, on the basis of information provided, presents a health hazard and which therefore is not recommended for use in cosmetic products. (Reference: (COECI) Cosmetic products and their ingredients 2nd edition, , , 1984)
SUN	25 Aug 1988	Pharmaceutical products containing hexachlorophene are prohibited for production and use on grounds of teratogenicity, embryotoxicity, neurotoxicity, photosensitizing and allergic potential.
PER		Prohibited for use in hygienic preparations with the exception of deodorants, which may contain as much as 0.1%, and antiseptic soaps, which may contain 0.2% of hexachlorophene.
THA		The use of pharmaceutical preparations containing hexachlorophene is severely restricted. WHO Comment : Hexachlorophene, an antimicrobial agent, was introduced in 1948 in proprietary liquid preparations and powders and was subsequently used extensively as a topical antiseptic. By the early 1970s its use in infants had been conclusively demonstrated to cause encephalopathy as a result of transdermal absorption. More recently it has been suggested that the drug has a teratogenic potential. Many regulatory authorities have placed rigorous restrictions on the medicinal use of hexachlorophene, particularly in preparations intended for infants. However, its use still commonly remains permissible at low concentrations as a preservative in toiletries and cosmetics. (Reference: (WHODI) WHO Drug Information, 3, 6, 1978)
Bibliographical references		
IARC MONOGRAPH, 20, 241, 1979		

Product Name	Hexestrol
C.A.S. number	5635-50-7
Scientific and common names, and synonyms	DIHYDROSTILBOESTROL HEXOESTROL SYNESTROL 4,4'-(1,2-DIETHYLETHYLENE)DIPHENOL 4-4 1-(1,2-DIETHYL-1,2-ETHANEDIYL)BIS[PHENOL]
Legislative or regulatory action	

Legislative or regulation action

Product Name	Hexestrol	
C.A.S. number	5635-50-7	
Country	Effective Date	Description of action taken Grounds for decision
AUT	Feb 1977	Pharmaceutical specialities containing diethylstilbestrol, dienestrol, hexestrol and their derivatives have been withdrawn following reports indicating an association between prenatal exposure to diethylstilbestrol and the subsequent development of adenocarcinoma in postpubertal girls and young women. The use of stilbene derivatives is only authorized for the treatment of cancer of the prostate.
ITA	1979	This product has been withdrawn from the market due to suspected carcinogenicity in newborns following prenatal exposure.
KWT	Jan 1980	Prohibited for import.
ARM	Sep 2000	The Armenian Drug and Medical Technology Agency did not approve the marketing of this product on grounds of risk of carcinogenicity and withdrew the product from the entire market. (Reference: (ARMCW) Communication to WHO, , , 31 Aug 2001)
SAU		Following reports indicating the development of adenocarcinoma in post-pubertal girls and young women exposed prenatally to preparations containing diethylstilbestrol, dienestrol and their derivatives, the Drug Committee prohibited the use of these products during pregnancy.
VEN		Not approved for use and/or sale. WHO Comment : Hexestrol is a stilbene derivative. See WHO comment for diethylstilbestrol. (Reference: (WHODI) WHO Drug Information, 77.1, 16, 1977)

Product Name	Hexobarbital	
C.A.S. number	56-29-1	
Scientific and common names, and synonyms		
5-(CYCLOHEX-1-ENYL)-1,5-DIMETHYLBARBITURIC ACID		
5-(1-CYCLOHEXEN-1-YL)-1,5-DIMETHYLBARBITURIC ACID		
HEXOBARBITONE		
2,4,6(1H,3H,5H)-PYRIMIDINETRIONE, 5-(1-CYCLOHEXEN-1-YL)-1,5-DIMETHYL-		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
SWE	Oct 1984	Withdrawn following discussions between the manufacturer and the National Board of Health and Welfare. Fatal intoxications and abuse are associated with use of preparations containing hexobarbital. WHO Comment : Hexobarbital is a short-acting barbiturate. See WHO comment for barbiturates.

Product Name	Human dura mater	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	30 Dec 1997	In order to minimize the risk of transmission of pathogens of spongiform encephalopathies (e.g. Creutzfeldt-Jakob disease), the Federal Institute for Drugs and Medical Devices has restricted the indications for medicinal products containing freeze-dried human dura mater "soft" to : use in neuro- surgery if autologous tissue is not

Legislative or regulation action

Product Name	Human dura mater	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		available in sufficient quantities or not sufficiently stable, and when synthetic materials are not indicated; use in paediatric surgery for omphalocele/gastroschisis or in tracheal stenosis when autologous tissue is not available in sufficient quantities, and when synthetic materials are not indicated. At the same time, strict criteria for the selection of donors have been implemented. (Reference: (DEUCFI) Communication, , , 30 Dec 1997)
Product Name	Hyaluronidase	
C.A.S. number	9001-54-1	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
SLV	Jun 2001	Injections for intramuscular or subcutaneous use were withdrawn from sale nationally because of incomplete data on BSE risk. (Reference: (SLVCW) Communication to WHO, , , 24 Aug 2001)
Product Name	Hydroquinidine	
Scientific and common names, and synonyms		
DIHYDROQUINIDINE (ETHYL-5 QUINUCLIDINYL-2(2)) (METHOXY-6' QUINOLYL-(4))		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
FRA	14 Jan 1994	The Ministry of Health has issued a decree reclassifying the antiarrhythmic, hydroquinidine (Serecor®: Houde), as a prescription medicine available only on non-renewable prescription unless otherwise indicated by the prescriber. This action brings hydroquinidine in line with other antiarrhythmics which are all subject to prescription control, with the exception of the related product, quinidine. The need for reclassifying the latter drug remains under consideration. (Reference: (FRARP) La Revue Prescrire, 14(141):338, , 1994) (Reference: (FRAAM) Arrêté ministériel of 14 January 1994, , , 02 Feb 1994)
Product Name	Hydroquinone	
C.A.S. number	123-31-9A	
Scientific and common names, and synonyms		
HYDROCHINONUM, BENZENE-1,4-DIOL		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
NGA	1 Feb 1982	The manufacture, import, export, distribution and sale of any cosmetic products containing hydroquinone in amounts exceeding 5% (w/w) are prohibited. Reasons for the decisions: There has been gross misuse for skin bleaching purposes of hydroquinone-containing cosmetic products, many of which contain over 5% hydroquinone.

Legislative or regulation action

Product Name	Hydroquinone	
C.A.S. number	123-31-9A	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	1991	(Reference: (AARNO) Administrative Action, FDA/RU/242-2, 171, Dec 1982) The Federal Health Office has restricted the use of products containing hydroquinone to pathological hyperpigmentation. Children under 12 years of age should not be treated. (Reference: (DAZ) Deutsche Apotheker Zeitung, 132(42), , 1991) WHO Comment : Hydroquinone was introduced in 1965 as a topical depigmenting agent for hyperpigmentation. At high concentrations hydroquinone is corrosive and in most countries has been restricted to the level of approximately 2% and limited to the period of less than 2 months. Additional consideration for restrictive action is that animal experiments have also demonstrated carcinogenic and mutagenic potential of hydroquinone.
Product Name	Hyoscine methonitrate	
C.A.S. number	6106-46-3	
Scientific and common names, and synonyms		
HYOSCINE METHYLNITRATE METHYLSCOPOLAMINE NITRATE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
SWE	Jun 1981	Hyoscine methonitrate, an antimuscarinic agent, has been withdrawn from appetite suppressant preparations. WHO Comment : Hyoscine methonitrate, a quaternary ammonium anticholinergic agent, was introduced in 1947 for use as a gastrointestinal antispasmodic. The action taken in Sweden relates to the use of this compound in preparations for suppressing the appetite. Preparations may remain available elsewhere.
Product Name	Ibopamine	
C.A.S. number	66195-31-1	
Scientific and common names, and synonyms		
PROPANOIC ACID, 2-METHYL-, 4-[2-(METHYLAMINO)ETHYL]-1,2-PHENYLENE ESTER		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
NLD	Sep 1995	The Committee for the Evaluation of Medicines has restricted the indications for ibopamine to mild cardiac insufficiency in combination with diuretics. Treatment must be withdrawn gradually if the symptoms worsen. (Reference: (NPHWB) Pharmaceutisch Weekblad, 130(37/38) , p. 999, 1995) WHO Comment : Ibopamine belongs to the group of dopaminergic drugs, i.e., agents stimulating the dopaminergic system and potentiating the effects of the neurotransmitter dopamine.
Product Name	Ibuprofen	
C.A.S. number	15687-27-1	

Legislative or regulation action

Product Name	Ibuprofen	
C.A.S. number	15687-27-1	
Scientific and common names, and synonyms	2-(4-ISOBUTYLPHENYL)PROPIONIC ACID	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	Feb 1992	The Federal Health Office has amended the approved product information for a tropical formation of the non-steroidal anti-inflammatory agent, ibuprofen. The contraindications were extended to include patients with a history of allergy and children under 6 years of age. (Reference: (BGHBL) Bundesgesundheitsblatt, 2/92, 109, Feb 1992) WHO Comment : Ibuprofen, a non-steroidal anti-inflammatory agent, was introduced in 1969. It was approved for sale without prescription in packages containing no more than 400 mg, in the United Kingdom in 1983. This action was followed by the USA, Canada and several European countries. Since this time reports of suspected adverse effects have increased. Most of these relate to gastrointestinal disturbances, hypersensitivity reactions but aseptic meningitis, skin rashes and renal damage have been recorded.
Product Name	Indalpine	
C.A.S. number	63758-79-2	
Scientific and common names, and synonyms	2-(3-(4-PIPERIDYL)ETHYL)INDOLE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
FRA	13 Jul 1985	Following reports of agranulocytosis and severe neutropenia associated with the use of indalpine, the major manufacturer in consultation with the French health authorities decided to suspend the marketing of this drug. (Reference: (FMOPL) Le Moniteur des Pharmacies et des Laboratoires, 1666, , June 1985) WHO Comment : Indalpine, an antidepressant with serotonergic action, was introduced in 1983 and marketed exclusively in France. In 1984 its use was associated with cases of leucopenia and agranulocytosis which led to the voluntary suspension of clinical trials in the USA. In 1985 the major manufacturer voluntarily withdrew the drug from the market.
Product Name	Indometacin and indometacin farnesil	
C.A.S. number	53-86-1	
Scientific and common names, and synonyms	1H-INDOLE-3-ACETIC ACID, 1-(4-CHLOROBENZOYL)-5-METHOXY-2-METHYL-	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
JPN	May 1994	The Pharmaceutical Affairs Bureau has amended the approved product information for indometacin to include convulsions in the list of adverse reactions. (Reference: (JPNARD) Information on Adverse Reactions to Drugs, No.126, , May 1994)
JPN	Oct 1996	The data sheet for indometacin farnesil has been revised to include in the section on serious adverse effects haemorrhagic colitis as well as perforation of pre-existing sigmoid

Legislative or regulation action

Product Name Indometacin and indometacin farnesil

C.A.S. number 53-86-1

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
		lesions. (Reference: (JPNARD) Information on Adverse Reactions to Drugs, No.139, , Oct 1996) WHO Comment : Indometacin was introduced in 1963 and it is one of the first NSAIDs. Convulsions are rarely reported in relation with the use of this group of agents. Indometacin farnesil is a pro-drug of indometacin, and the occurrence of gastro-intestinal adverse effects could be expected. See also under nonsteroidal antiinflammatory agents.

Product Name Indoprofen

C.A.S. number 31842-01-0

Scientific and common names, and synonyms

BENZENEACETIC ACID, 4-(1,3-DIHYDRO-1-OXO-2H-ISOINDOL-2-YL)-ALPHA-METHYL

P-(1-OXO-2-ISOINDOLINYL)HYDRATROPIC ACID

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
CYP	Dec 1983	Withdrawn from the market following reports of serious adverse gastrointestinal reactions.
GBR	Dec 1983	Withdrawn from the market following reports of serious adverse gastrointestinal reactions.
@WD	1984	The nonsteroidal anti-inflammatory drug, indoprofen, was voluntarily withdrawn worldwide by the manufacturer following the demonstration of tumours in a carcinogenicity study undertaken in rats.
CHL	Jul 1984	Voluntarily withdrawn by the manufacturer.
DEU	Jul 1984	The Federal Health Office, in agreement with the manufacturer, withdrew products containing indoprofen on an interim basis pending an evaluation of the results of a recently undertaken carcinogenicity study.
ITA	Jul 1984	The manufacturer withdrew all formulations of indoprofen following decisions by the Ministry of Health to suspend promotion and disallow repeat prescriptions pending further evaluation of the safety of the drug. WHO Comment : Indoprofen, a nonsteroidal anti-inflammatory agent, was introduced in 1976 for the treatment of rheumatic disorders. By 1983 its use had been associated with serious adverse effects, some of which were fatal. This led to its withdrawal in the United Kingdom and Cyprus. In 1984 reports of intestinal tumours in rats led to the drug's temporary withdrawal in Germany and Italy. This was followed immediately by the suspension of marketing worldwide by the major manufacturer.

Product Name Iodinated casein strophanthin (neo-barine)

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
USA	Oct 1964	Withdrawn from the market and prohibited for export by the Food and Drug Administration due to the risk of thyrotoxic side effects. This drug was marketed as an appetite suppressant.

Legislative or regulation action

Product Name **Iodinated casein strophanthin (neo-barine)**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
		WHO Comment : The World Health Organization has no information further to the above regarding preparations containing iodinated casein strophanthin or to indicate that they are still commercially manufactured.

Product Name **Iproniazid**

C.A.S. number **54-92-2**

Scientific and common names, and synonyms

ISONICOTINIC ACID 2-ISOPROPYLHYDRAZIDE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
ITA		Withdrawn from the market owing to an unfavourable risk-benefit ratio and the lack of substantial evidence of efficacy. WHO Comment : Iproniazid, a monoamine oxidase inhibitor (MAOI), was introduced in 1952 for the treatment of depressive illness. Subsequently concern regarding potentially serious interactions between MAOIs and foods containing tyramine inspired much restrictive regulatory action. However, MAOIs still retain a place in the treatment of serious depressive illness although there is no international consensus on which compounds should be preferred. Thus iproniazid remains available in several countries.

Product Name **Isaxonine phosphate**

C.A.S. number **4214-72-6**

Scientific and common names, and synonyms

2-(ISOPROPYLAMINO)PYRIMIDINE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
FRA	25 Jun 1983	Isaxonine phosphate has been withdrawn following the occurrence of toxic hepatitis associated with its use.
TUN		Not approved for registration on grounds of safety. WHO Comment : Isaxonine phosphate was introduced in 1981 and marketed exclusively in France for the treatment of peripheral neuropathy. In January 1983 indications for use were restricted following its association with cases of toxic hepatitis. It was subsequently withdrawn in June 1983.

Product Name **Isocarboxazid**

C.A.S. number **59-63-2**

Scientific and common names, and synonyms

5-METHYL-3-ISOXAZOLECARBOXYLIC ACID 2-BENZYLHYDRAZIDE

3-ISOXAZOLECARBOXYLIC ACID, 5-METHYL-, 2-(PHENYLMETHYL)HYDRAZIDE

Legislative or regulative action

Legislative or regulation action

Product Name	Isocarboxazid	
C.A.S. number	59-63-2	
Country	Effective Date	Description of action taken Grounds for decision
JPN	Nov 1974	The Ministry of Health and Welfare has withdrawn all products containing isocarboxazid and nialamide on the grounds that they lack substantial evidence of efficacy and safety.
CUB		Prohibited from use by the National Formulary Commission (1982) on grounds of reported toxicity and in view of the availability of other less toxic drugs.
SAU		Products now controlled by the authorities.
VEN		Not approved for use and/or sale.
<p>WHO Comment : Isocarboxazid, a monoamine oxidase inhibitor (MAOI), was introduced in 1959 for the treatment of depressive illness. Subsequently concern regarding potentially serious interactions between MAOIs and foods containing tyramine inspired much restrictive regulatory action. However, MAOIs still retain a place in the treatment of serious depressive illness although there is no international consensus on which compounds should be preferred. Thus isocarboxazid remains available in several countries and is cited in the British National Formulary as a relatively safe example of this class of compound.</p>		

Product Name	Isoprenaline	
C.A.S. number	7683-59-2	
Scientific and common names, and synonyms		
ISOPROTERENOL		
ISOPROPYLNORADRENALINE		
ISOPROPYLARTERENOL		
1-(3,4-DIHYDROXYPHENYL)-2-ISOPROPYLAMINOETHANOL		

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
LKA	1 Jan 1992	The Ministry of Health withdrew from sale inhalers containing the beta-adrenoreceptor agonist, isoprenaline, because of its potential to induce serious cardiovascular adverse effects. (Reference: (LKADIB) Drug Information Bulletin, University of Peradeniya and Ministry of Health, 4(1), , 1992)
<p>WHO Comment : Isoprenaline, a beta-adrenoreceptor agonist, was introduced in 1949 as treatment for a number of cardiac disorders and as a bronchial dilator for the symptomatic treatment of asthma. There is evidence that regular inhalation of bronchodilator drugs is associated, in some cases with exacerbation of the disease and with increased fatality rates. The underlying causes are disputed, but an increasing body of opinion now advocates regular maintenance therapy with inhaled, corticosteroids coupled with supplementary use as required of bronchial drugs to suppress exacerbations.</p>		

Product Name	Isotretinoin	
C.A.S. number	4759-48-2	
Scientific and common names, and synonyms		
RETINOIC ACID, 13-CIS		
3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)2-CIS-4-TRANS-6- TRANS-8-TRANS-NONATETRAENOIC ACID		

Legislative or regulative action

Legislative or regulation action

Product Name	Isotretinoin	
C.A.S. number	4759-48-2	
Country	Effective Date	Description of action taken Grounds for decision
AUS	1984	Isotretinoin is approved only for the treatment of severe cystic acne unresponsive to conventional therapy. In most states the availability of products is restricted to prescription by specialist physicians. Labels and product literature carry a warning that "This product causes birth defects". Warning letters have been circulated to doctors and pharmacists concerning necessary precautions. Government approved patient information leaflets and patient consent forms have been issued. (Reference: (AUDEC) Report of the Australian Drug Evaluation Committee, No.116, , Nov 1984)
USA	Aug 1985	Having regard to its teratogenicity, isotretinoin should be used only for severe cystic acne refractory to conventional therapies. (Reference: (FDADB) FDA Drug Bulletin, (2), , 1985)
OMN	24 Dec 1985	Having regard to its teratogenicity, isotretinoin may only be used under the supervision and control of a hospital dermatologist. (Reference: (OMNMH) Ministry of Health, 5, , 1985)
MYS	1988	The Drug Control Authority has decided that the labelling of preparations containing isotretinoin should bear a distinct warning regarding teratogenicity, emphasizing that effective contraceptive measures must be instituted throughout treatment and for at least four weeks thereafter, and additional reference is also required to the following adverse effects: symptoms of hypervitaminosis-A; transient and reversible elevation of transaminases and alkaline phosphatases; bone changes after long-term high dosage; benign intracranial hypertension. (Reference: (MYSPR) Ministry of Health Press Release, 2, 3, 1988)
BEL	1 Jan 1988	Preparations containing isotretinoin have been placed in List IV of the 'Arrêt, du R,gent' of 2 June 1946 and as such can be administered only on prescription. They must be kept in a poisons cabinet and carry the skull and crossbones label. They must bear a warning regarding the embryotoxicity and teratogenicity of the drug which contraindicates its use during pregnancy. (Reference: (BELAR) Arrêté Royal, , , June 1987)
FRA	Apr 1997	Having regard to the known teratogenic risks of isotretinoin, the Ministry of Health and the Medicines Agency have decided to reinforce the prescription requirements to ensure that patients are informed of the teratogenic risk and of the necessity for contraceptive measure before, during and after treatment. The physician must ensure that pregnancy tests are performed at indicated intervals. (Reference: (FRAAMC) Communiqué de Presse, , , 11 Apr 1997)
EGY		The Technical Committee for Drug Controls has issued a statement that preparations containing isotretinoin should not be used during pregnancy. Product information must include a warning that paronychia can develop during treatment.
ESP		Contraindications to isotretinoin must include a boxed paragraph stating that the drug may only be used in women of child-bearing age when an effective method of contraception assures protection during and for at least four weeks after discontinuation of treatment. Pregnancy must be excluded before initiation of treatment.
NLD		The Ministry of Welfare, Public Health and Culture has stressed that isotretinoin should be prescribed only for serious forms of acne resistant to other treatment. Pregnancy should be excluded prior to treatment and conception prevented during treatment. (Reference: (GENMB) Geneesmiddelenbulletin, 18(9), , 1984)
NZL		Having regard to its teratogenicity, isotretinoin is indicated only in severe nodulo-cystic acne resistant to other forms of therapy. (Reference: (NZCSL) Clinical Services Letter, Department of Health, 232, , Feb 1985)
TUN		Having regard to its teratogenicity, isotretinoin should be used only for its recommended indications under the strict supervision of the prescribing doctor.

WHO Comment : Isotretinoin, a retinol derivative, was introduced in 1982

Legislative or regulation action

Product Name	Isotretinoin	
C.A.S. number	4759-48-2	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		exclusively for the treatment of severe acne. Its use in pregnant women has resulted in major fetal abnormalities. The manufacturer's information emphasizes that the drug is teratogenic and must not be given to women who are pregnant, and that contraceptive measures must be maintained for at least four weeks after discontinuation of treatment. In some countries, blood banks are advised not to accept as donors persons who have taken isotretinoin within the previous four weeks. See also under retinol (vitamin A).

Product Name	Isoxicam	
C.A.S. number	34552-84-6	
Scientific and common names, and synonyms		
	2H-1,2-BENZOTHAZINE-3-CARBOXIMIDE, 4-HYDROXY-2-METHYL-N-(5-METHYL-3- ISOXAZOLYL)-, 1,1-DIOXIDE 4-HYDROXY-2-METHYL-N-(5-METHYL-3-ISOXAZOLYL)-2H-1,2-BENZOTHAZINE-3- CARBOXAMIDE 1,1-DIOXIDE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	Oct 1985	The Federal Health Office has suspended approval of preparations containing isoxicam pending further evaluation of reported adverse reactions.
ITA	Oct 1985	Following discussions with the National Health Council, the manufacturer has withdrawn all preparations containing isoxicam pending further evaluation of the reported adverse reactions.
FRA	11 Oct 1985	The French Health Authorities have suspended marketing of products containing isoxicam following reports of rare but severe dermatological reactions.
@WD	31 Oct 1985	Marketing of the nonsteroidal antiinflammatory drug isoxicam was suspended worldwide by the major manufacturer in October 1985 after it had been withdrawn in France on 11 October 1985 following reports of severe skin reactions, some of which were fatal.
OMN	8 Jan 1986	Import and sale of isoxicam have been prohibited. (Reference: (OMNMH) Ministry of Health, 1, , 1986)
		WHO Comment : Isoxicam, a nonsteroidal anti-inflammatory agent, was introduced in 1983 for the treatment of rheumatic disorders. By 1985 its use had been associated with serious adverse effects, including four deaths from rare skin reactions. This led to its withdrawal in France followed immediately by the voluntary suspension of marketing worldwide by the major manufacturer.

Product Name	Kaolin	
C.A.S. number	1332-58-7	
Scientific and common names, and synonyms		
	ALBA BOLUS	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
IND	11 Feb 1991	The Central Government banned the manufacture and sale of combinations of fixed doses of kaolin with any other drug.

Legislative or regulation action

Product Name	Kaolin	
C.A.S. number	1332-58-7	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
LKA	1 Jan 1992	(Reference: (INDC) Drugs Controller, , , Mar 1992) The Ministry of Health withdrew from sale all liquid preparations containing kaolin. Kaolin has doubtful efficacy and its use may lead to increased salt and water loss. (Reference: (LKADIB) Drug Information Bulletin, University of Peradeniya and Ministry of Health, 4(1), , 1992) WHO Comment : Kaolin, a hydrated aluminium silicate, is an absorbent and has been used to treat diarrhoea because of its ability to bind and inactivate bacterial toxins. However, it has been shown to induce only a slight change in stool consistency and there is no evidence that it can reduce the duration or the severity of diarrhoeal disease. It does not reduce fluid and electrolyte losses. It cannot be recommended in the treatment of diarrhoea.

Product Name	Kebuzone	
C.A.S. number	853-34-9	
Scientific and common names, and synonyms		
4-(3-OXOBUTYL)-1,2-DIPHENYL-3,5-PYRAZOLIDINEDIONE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	1985	Indications are restricted to inflammatory degenerative rheumatism, chronic polyarthritis, ankylosing spondylitis, arthroses, neuritis and neuralgia such as lumbago and sciatica, acute gout, soft tissue rheumatism, painful bruising or post-traumatic inflammation and thrombophlebitis. A single course of treatment should not exceed three months. Preparations are contraindicated in children under six years of age.
OMN	Sep 1986	The Ministry of Health has prohibited the import of preparations containing kebuzone except those intended for topical use.
AUT		Indications restricted to exacerbations of gout and other arthritic conditions. Treatment should not exceed seven days and doctors are advised not to prescribe this drug to children under 14 years of age or elderly patients. (Reference: (WIMAM) Wichtige Mitteilung ueber Arzneimittel, (1), , 1984) WHO Comment : Kebuzone, a pyrazolone derivative with anti-inflammatory, analgesic and antipyretic activity, was introduced in 1973 for the treatment of rheumatic disorders. As it is structurally related to phenylbutazone it is subjected to rigorously restricted indications by some national regulatory authorities. See WHO comment for phenylbutazone.

Product Name	Ketamine hydrochloride	
C.A.S. number	1867-66-9	
Scientific and common names, and synonyms		
CN-52372-2		
CL-581		
KETAMINI HYDROCHLORIDUM		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision

Legislative or regulation action

Product Name	Ketamine hydrochloride	
C.A.S. number	1867-66-9	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
SGP		The National Pharmaceutical Administration in the Ministry of Health has rescheduled ketamine as a narcotic drug because of its high abuse potential. (Reference: (SGPCW) Communication to WHO, , , 02 Aug 2000)
Product Name	Ketoconazole	
C.A.S. number	65277-42-1	
Scientific and common names, and synonyms		
(±)-CIS-1-ACETYL-4-IP-[[2-(2,4-DICHLORPHENYL)-2-(IMIDAZOL-1-YLMETHYL)-1,3-DIOX-OLAN-4-YL]METHOXYLPHENYL]PIPERAZINE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
OMN	04 Apr 1988	Products containing ketoconazole were allowed to be used only under the supervision of a hospital physician. (Reference: (OMNCR) Circular, 11/88, , Apr 1988)
WHO Comment : Ketoconazole, an imidazole antifungal agent, was introduced in 1978 for the topical and systemic treatment of a wide variety of fungal infections. Its use by mouth has been associated with hepatotoxicity, including cases of hepatitis, which have usually been reversible on discontinuation of the drug, but some fatalities have also occurred. Ketoconazole is widely marketed.		
Product Name	Ketorolac	
C.A.S. number	74103-06-3	
Scientific and common names, and synonyms		
H-PYRROLIZINE-1-CARBOXYLIC ACID, 5-BENZOYL-2,3-DIHYDRO, (±)-, COMPOUND WITH 2-AMINO-2-(HYDROXYMETHYL)-1,3-PROPANEDIOL (1:1)		
KETOROLAC TROMETHAMINE		
KETOROLAC TROMETAMOL		
1H-PYRROLIZINE-1-CARBOXYLIC ACID, 5-BENZOYL-2,3-DIHYDRO, (±)-, COMPOUND WITH 2-AMINO-2-(HYDROXYMETHYL)-1,3-PROPANEDIOL (1:1)		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
@EC	Jun 1993	The Committee on Proprietary Medicinal Products recommended restrictions in dosage and use pending further analysis of data concerning some 80 fatalities associated with its use. (Reference: (CPMPPO) Pharmacovigilance Opinion, No.15, , 16 June 1993)
DEU	Jun 1993	The Federal Health Office in Germany withdrew the marketing authorization for the nonsteroidal anti-inflammatory agent, ketorolac, on the basis of a high number of reports of severe adverse reactions including renal failure, some of which were fatal. (Reference: (DEUFHO) Communication from Federal Health Office, , , 17 June 1993)
GBR	Jun 1993	The Committee on Safety of Medicines has revised the labelling for ketorolac to reduce the recommended dose and duration of treatment, in accordance with the CPMP. (Reference: (GBRCP) Current Problems in Pharmacovigilance, Vol. 19, , June 1993)
MYS	Sep 1993	Following regulatory actions restricting the approved uses of ketorolac trometamol in
Legislative or regulation action		

Product Name	Ketorolac	
C.A.S. number	74103-06-3	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
FRA	Dec 1993	Canada, the United States and some other countries within the European Union, the Drug Control Authority has decided to restrict the indications for the intramuscular 30mg/ml injectable formulation of this product and to revise the labelling for all products. (Reference: (MYS DI) Berita Ubat-Ubat (Drug Information), 7(3): 3, , Sep 1993)
NZL	Dec 1994	The Ministry of Health in France suspended the marketing authorization for the nonsteroidal anti-inflammatory agent, ketorolac, in view of the high frequency and seriousness of adverse drug reactions reported from the National Commission for Pharmacovigilance. (Reference: (FRAAMC) Communiqué de Presse, , , 14 Jan 1994)
JAM	1998	A parenteral dose of 120mg in 24 hours should not be exceeded in any patient, and this dose should be halved in the mildly renally impaired and the elderly. Ketorolac is contraindicated in patients with more severe renal impairment (serum creatinine > 180 µmol/L). The duration of use should be limited to two days for parenteral administration or a total of seven days if a switch is made to oral use. (Reference: (NZLPU) Prescriber Update, No.7, , Dec 1994)
		The Ministry of Health, Standards and Regulation did not approve registration of the non-steroidal anti-inflammatory drug, ketorolac due to adverse effects. (Reference: (JAMMHS) Communication to WHO, , , 26 Sep 2000)
WHO Comment : Ketorolac is a nonsteroidal anti-inflammatory agent used in the management of moderate to severe acute post-operative pain. It remains on the market in many countries with restrictions on its use.		

Product Name	Laetrile	
C.A.S. number	29883-15-6	
Scientific and common names, and synonyms	AMYGDALIN VITAMIN B17 (O-(6-O-BETA-D-GLUCOPYRANOSYL-BETA-D-GLUCOPYRANOSIDE)-D-MANDELONITRILE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
AUS	20 Feb 1986	The Australian Drug Evaluation Committee has recommended that import of preparations containing laetrile for use in cancer therapy be prohibited due to lack of efficacy, definite serious toxicity and absence of knowledge of metabolism, excretion and serum levels. Its use on an individual basis is under review. (Reference: (AUDEC) Report of the Australian Drug Evaluation Committee, 122, 13, 1986)
USA	24 Mar 1987	Preparations containing laetrile have the same status as other unapproved drugs and as such importation is prohibited.
WHO Comment : Laetrile, which consists mainly of amygdalin, a glycoside extracted from the kernels of apricots, peaches and other fruits, has been available for over 30 years in preparations purporting to be beneficial in the treatment of cancer. Although there is no evidence that these are efficacious, preparations continued to be widely used and, until the late 1970s, they were considered to be harmless. However, oral dosage forms, which may be broken down in the gut to hydrogen cyanide, have subsequently been shown to be potentially lethal. This has resulted in restrictive regulatory measures in several countries.		

Product Name **Lamivudine**

C.A.S. number **134678-17-4**

Scientific and common names, and synonyms

(-)-2'-DEOXY-3'-THIACYTIDINE

3TC

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
SGP		The National Pharmaceutical Administration in the Ministry of Health has restricted the use of lamivudine for the treatment of chronic hepatitis B to gastroenterologists only. This decision has been taken because prolonged treatment may result in the emergence of resistant strains. Furthermore post-treatment hepatitis that can be fatal in patients with poor hepatic function or cirrhosis has been observed in patients after withdrawal of therapy. (Reference: (SGPCW) Communication to WHO, , , 02 Aug 2000)

Product Name **Lamotrigine**

C.A.S. number **84057-84-1**

Scientific and common names, and synonyms

1,2,4-TRIAZINE-3,5-DIAMINE, 6-(2,3-DICHLOROPHENYL)-

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
GBR	Oct 1996	The Committee on Safety of Medicines issued a warning concerning serious skin reactions, particularly in young children, associated with lamotrigine. (Reference: (GBRCP) Current Problems in Pharmacovigilance, Vol.22, p.10, Oct 1996)
AUS	24 Oct 1997	The Adverse Drug Evaluation Committee has recommended that a boxed warning be included in the labelling for the anticonvulsant, lamotrigine, stating that severe, potentially life-threatening rashes have been reported in association with this product, particularly in children, and that lamotrigine should be discontinued at the first sign of rash unless the rash is clearly not drug related. (Reference: (AUDEC) Report of the Australian Drug Evaluation Committee, Res No. 7255, , 24 Oct 1997)

WHO Comment : Lamotrigine is a relatively new antiepilepsy agent acting through stabilization of neuronal membranes and preventing liberation of neurotransmitters.

Product Name **Latamoxef**

C.A.S. number **64952-97-2**

Scientific and common names, and synonyms

5-OXA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID,7-((CARBOXY(4-HYDROXYPHENYL)ACETYL)AMINO)-7-METHOXY-3-((1-METHYL-1H-TETRAZOL-5-YL)THIO)METHYL)-8-OXO-

LAMOXACTAM

MOXALACTAM

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
DEU	1 Jul 1984	Following reports of spontaneous bleeding and death in patients receiving preparations containing latamoxef, indications will be restricted to serious and life threatening infections such as sepsis and meningitis. WHO Comment : Latamoxef, a cefamycin antibiotic, was introduced in 1982 for the

Legislative or regulation action

Product Name	Latamoxef	
C.A.S. number	64952-97-2	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		treatment of serious infections. Its use has subsequently been associated with reports of clinically important haemorrhage, sometimes fatal, and in some countries routine co-administration of vitamin K is advised to minimize this risk.
Product Name	Lead oxide and lead salts	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
FRA	21 Feb 1980	Lead oxide and lead salts have been withdrawn from cosmetics and topically administered medicinal products having regard to the danger of percutaneous absorption and their possible contribution to encephalopathy.
DNK	30 Jun 1983	As a result of recorded cases of lead poisoning caused by excessive topical application, all pharmaceutical products containing lead compounds have been withdrawn.
SAU		Prohibited for use in cosmetics and other topical uses, having regard for the danger of percutaneous absorption.
VEN		Not approved for use and/or sale in topical pharmaceutical products.
		WHO Comment : Lead oxides and other lead salts were formerly available in topical preparations which had soothing astringent properties. The toxicity of lead salts by inhalation, ingestion and percutaneous absorption is now conclusively established and the medicinal use of preparations containing lead salts is no longer permitted in many countries.
Product Name	Levacetylmethadol	
C.A.S. number	34433-66-4	
Scientific and common names, and synonyms		
(-)-6-(DIMETHYLAMINO)-4,4-DIPHENYL-3-HEPTANOL ACETATE (ESTER)		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
@EC	2001	The European Medicines Evaluation Agency (EMA) has recommended the suspension of the marketing authorization of levacetylmethadol (Orlaam) in view of its pro-arrhythmic potential and the fact that a re-assessment of the risk-benefit profile showed no special advantage for levacetylmethadol over existing alternatives. (Reference: (EMEAPS) Public statement, EMA/8776/01, , 19 Apr 2001)
USA	23 Aug 2003	Product to be withdrawn due to adverse cardiac events; safer alternatives to be adopted. (Reference: (USARL) "Dear Healthcare Professional " letter, , , 23 Aug 2003)
Product Name	Levamphetamine	
C.A.S. number	156-34-3	
Scientific and common names, and synonyms		
LEVAMPHETAMINE		
(-)-ALPHA-METHYLPHENETHYLAMINE		

Legislative or regulation action

Product Name	Levamisole hydrochloride	
C.A.S. number	16595-80-5	
Scientific and common names, and synonyms	L-TETRAMISOLE HYDROCHLORIDE LEVAMISOLI HYDROCHLORIDUM	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
USA	1973	Anorectic drugs containing levamisole were withdrawn from the market by the Food and Drug Administration due to evidence of abuse and high risk of dependence.
OMN	May 1991	Import and marketing of products containing levamisole were prohibited. (Reference: (OMNCR) Circular, 16/91, , May 1991)
ARE		Pharmaceutical preparations containing levamisole are banned. WHO Comment : Levamisole, an amphetamine derivative, is controlled under Schedule II of the 1971 Convention on Psychotropic Substances. See WHO comment for amphetamine. (Reference: (UNCPS2) United Nations Convention on Psychotropic Substances (II), , , 1971)
Product Name	Levamisole hydrochloride	
C.A.S. number	16595-80-5	
Scientific and common names, and synonyms	L-TETRAMISOLE HYDROCHLORIDE LEVAMISOLI HYDROCHLORIDUM	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
VTN	Apr 2000	The Drug Administration of Viet Nam in the Ministry of Health has withdrawn the registration of products with the anthelmintic, levamisole as the active ingredient. The reason for withdrawal is that these products have adverse effects that cause encephalitis and mortality. (Reference: (VTNMHD) Directive, 13(2000), QD-QLD, 27 Apr 2000)
Product Name	Levarterenol	
C.A.S. number	51-41-2	
Scientific and common names, and synonyms	NOREPINEPHRINE NORADRENALINE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
IRL	1973	The National Drugs Advisory Board has withdrawn from the market all local anesthetic preparations intended for infiltration anesthesia containing epinephrine 1:50,000 and norepinephrine 1:50,000 alone or in combination. This decision, reached in agreement with the Irish Dental Association, followed reports of serious cardiovascular and cerebrovascular reactions.
SAU		Following published reports of serious cardiovascular and cerebrovascular adverse reactions, preparations for infiltration anaesthesia which contain epinephrine and levarterenol, alone or in combination, are now under review.

Legislative or regulation action

Product Name	Levarterenol	
C.A.S. number	51-41-2	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
VEN		Not approved for use and/or sale for infiltration anesthesia, alone or in combination. WHO Comment : Vasoconstrictor agents have been in use for many years to prolong duration of action of local anaesthetics, particularly in dentistry. Combination products containing epinephrine or levarterenol in concentrations of 1:80,000 or less remain widely available. See also WHO comment for epinephrine.
Product Name	Lexipafant	
C.A.S. number	139133-26-9	
Scientific and common names, and synonyms		
ETHYL-N-METHYL-N-[A-(2-METHYLIMIDAZOLE[4,5-C]PYRIDIN-1-YL)TOSYL]-L-LEUCINATE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
EME	May 1998	The European Agency for the Evaluation of Medicinal Products (EMA) has refused marketing authorization for lexipafant. The Committee for Proprietary Medicinal Products reviewed the data submitted by the company and considered that lexipafant was not approvable for the treatment of severe acute pancreatitis on the basis of the submitted data. (Reference: (EMEAPR) EMA Press Release, , , 05 May 1998)
Product Name	Lindane	
C.A.S. number	58-89-9A	
Scientific and common names, and synonyms		
BENZENE HEXACHLORIDE, GAMMA CYCLOHEXANE, 1,2,3,4,5,6-HEXACHLORO-,(1ALPHA,2ALPHA,3BETA,4ALPHA,5ALPHA,6BETA)- GAMMA-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE (1 ALPHA,2 ALPHA,3 BETA,4 ALPHA,5 ALPHA,6 BETA)-HEXACHLOROCYCLOHEXANE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
NLD	17 Jan 1984	Products containing lindane are no longer accepted for the treatment of head-lice infestation because of widespread development of resistant strains. They remain available for the treatment of scabies and body or pubic lice.
DEU	18 Jul 1986	Use is limited to 0.3% with the exception of shampoo, which may contain up to 1% since exposure time is limited to 4 minutes.
EGY	1987	The Technical Committee for Drug Control has restricted the use of lindane to topical treatment of lice and scabies. Products should not contain concentrations greater than 0.3%. (Reference: (EGYDI) Drug Information, 5(2), , 1987)
OMN	May 1991	Import and marketing of external preparations containing lindane in concentrations greater than 0.3% were prohibited. Use of more concentrated preparations is considered to be less safe and no more effective. (Reference: (OMNCR) Circular, 9, , Mar 1991)
BRA	Feb 2001	The marketing authorization for products containing lindane was withdrawn because of

Legislative or regulation action

Product Name	Lindane	
C.A.S. number	58-89-9A	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		unacceptable potential to cause toxic effects. (Reference: (BRARES) Resolucao n., 147/ANVISA, , 14 Aug 2001) WHO Comment : Lindane has been available for more than 25 years and is widely used as an agricultural and household pesticide.
Product Name	Lipoic acid	
C.A.S. number	1077-28-7	
Scientific and common names, and synonyms	1,2-DITHIOLANE-3-PENTANOIC ACID	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
ARM	Feb 2001	The Armenian Drug and Medical Technology Agency has not approved marketing of the new immunomodulating agent on the grounds of unacceptable risk benefit ratio resulting from serious adverse effects. (Reference: (ARMCW) Communication to WHO, , , 31 Aug 2001)
Product Name	Lobelia	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
BGD	1982	Under the provisions of the Drugs (Control) Ordinance, this drug has been prohibited for use. All prescription chemicals and galenical preparations not included in the latest edition of the British Pharmacopeia or British Pharmaceutical Codex have been prohibited for use. (Reference: (BGDCO) The Drugs (Control) Ordinance, , , 1982)
ITA		Withdrawn from the market owing to an unfavourable risk-benefit ratio and the lack of substantial evidence of efficacy. WHO Comment : Lobelia comprises the dried aerial parts of lobelia species, the activity of which is due chiefly to the alkaloid lobeline. Although preparations containing lobelia were formerly available for use in the symptomatic treatment of asthma, they are now largely obsolescent as a result of their irritant properties and the availability of more effective preparations.
Product Name	Loperamide	
C.A.S. number	53179-11-6	
Scientific and common names, and synonyms	1-PIPERIDINEBUTANAMIDE, 4-(4-CHLOROPHENYL)-4-HYDROXY-N,N-DIMETHYL-ALPHA, ALPHA-DIPHENYL 4-(P-CHLOROPHENYL)-4-HYDROXY-N,N-DIMETHYL-ALPHA,ALPHA-DIPHENYL-1- PIPERIDINEBUTYRAMIDE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision

Legislative or regulation action

Product Name	Loperamide	
C.A.S. number	53179-11-6	
PHL	Nov 1982	Restricted for use as an antidiarrhoeal drug. Contraindicated in children below two years of age due to the risk of central nervous system damage.
@WD	1990	Drop formulations containing loperamide have been voluntarily withdrawn by the major manufacturer. (Reference: (LJJ) Letter to WHO from Johnson & Johnson, , , 21 June 1990)
LIY	May 1990	Use of products containing loperamide in children was banned. (Reference: (LIYRL) Resolution of the General People's Health Committee, 141, , May 1990)
PAK	Jun 1990	Drop and syrup formulations of products containing loperamide were banned. (Reference: (TURMH) Communication from the Ministry of Health, , , Nov 1991)
OMN	Jul 1990	Drop and syrup formulations of products intended for paediatric use containing loperamide were voluntarily withdrawn by the manufacturer. (Reference: (OMNCR) Circular, 13/90, , July 1990)
PER	Oct 1990	Registration of drop formulations of loperamide intended for paediatric use was withdrawn. Syrup formulations of loperamide were required to carry a warning stating that they should not be administered to children under 5 years of age. (Reference: (PERMH) Ministry of Health, , , 27 Oct 1990)
IDN	Nov 1990	Syrup and liquid formulations of products containing loperamide intended for the treatment of diarrhoea in children were banned. (Reference: (IDMH) Ministry of Health, , , 19 Nov 1990)
MEX	Dec 1990	Registration of products containing loperamide intended for paediatric use was withdrawn. (Reference: (MEXMH) Communication from the Ministry of Health, , , 28 Nov 1990)
FRA	18 Dec 1990	The approved information for paediatric formulations of the antidiarrhoeal substance loperamide was amended to indicate that these products should not be administered, on grounds of safety, to children less than two years of age. (Reference: (FRARP) La Revue Prescrire, 11(108), 293, 1991)
NPL	1991	Liquid formulations of products containing loperamide either alone or in combination, and intended for the treatment of diarrhoea in children, were banned. (Reference: (NPLDDA) Communication from the Department of Drug Administration, , , 27 Feb 1992)
PHL	1991	Registration of products containing loperamide intended for paediatric use was withdrawn. (Reference: (MEXMH) Communication from the Ministry of Health, , , 28 Nov 1990)
KOR	May 1991	Solid oral dosage forms of products containing loperamide were disallowed for use in children under 7 years of age and syrup formulations were prohibited in infants under 24 months due to the severe toxic effects on the central nervous system. (Reference: (KRMHSA) Ministry of Health and Social Affairs - Communication to WHO, , , 13 Dec 1991)
LBN	Aug 1991	Use of products containing loperamide in children under 5 years of age was discontinued and registration of paediatric preparations was withdrawn. (Reference: (LBNMHD) Ministry of Health and Social Affairs Decree, 150/1, , Aug 1991)
TUR	Sep 1991	Drop and syrup formulations of products containing loperamide were banned. (Reference: (TURMH) Communication from the Ministry of Health, , , Nov 1991)
LKA	Nov 1991	Manufacture, import or sale of drop and syrup formulations of loperamide were prohibited. (Reference: (LKAGAZ) The Gazette of the Democratic Socialist Republic of Sri Lanka (Extraordinary), 688/29, Part I-1, 15 Nov 1991)

WHO Comment : Loperamide, an inhibitor of intestinal peristalsis, was introduced in 1975 for the treatment of acute and chronic diarrhoea. In many countries its use was discouraged in young children. In late 1989, treatment of infants in Pakistan was associated with 19 cases of paralytic ileus, 6 of which have been fatal. This has subsequently led the major manufacturer to withdraw all drop formulations of

Legislative or regulation action

Product Name	Loperamide	
C.A.S. number	53179-11-6	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		the drug worldwide as well as the lower dose syrup forms from countries where there is a programme for the control of diarrhoeal diseases. The WHO Control of Diarrhoeal Diseases Programme recommends that loperamide should not be used in children below five year of age. (Reference: (LJJ) Letter to WHO from Johnson & Johnson, , , 21 June 1990)
Product Name	Loxoprofen sodium	
C.A.S. number	68767-14-6	
Scientific and common names, and synonyms		
P-[(2-OXOCYCLOPENTYL)METHYL]HYDRATROPATE DIHYDRATE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
SGP		The National Pharmaceutical Administration in the Ministry of Health has not approved loxoprofen sodium because of reports of colonic ulceration and death associated with its use. (Reference: (SGPCW) Communication to WHO, , , 02 Aug 2000)
Product Name	L-Tryptophan	
C.A.S. number	73-22-3	
Scientific and common names, and synonyms		
L-2-AMINO-3-(INDOL-3-YL) PROPIONIC ACID		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
USA	17 Nov 1989	The marketing authorization for over-the-counter dietary supplements containing L-tryptophan as the sole or major ingredient has been withdrawn. (Reference: (HHSNS) HHS News: US Department of Health and Human Services, P89-49, , 17 Nov 1989)
CHE	Dec 1989	The marketing authorization for all pharmaceuticals containing L-tryptophan has been suspended. (Reference: (CHBCM) Bulletin Mensuel, , , 27 Dec 1989)
GBR	Dec 1989	Non-prescription dietary supplements containing L-tryptophan as the sole or major ingredient and medicines indicated for the treatment of depression have been withdrawn. Multivitamin and multi-aminoacid supplements where tryptophan is a minor ingredient, parenteral nutrition fluids and preparations for the treatment of phenylketonuria remain on the market. (Reference: (GBRPHJ) The Pharmaceutical Journal, 244, 486, 1990) (Reference: (GBRCSM) Committee on Safety of Medicines, Current problems, 27, , Dec 1989)
SWE	6 Dec 1989	Products containing L-tryptophan have been prohibited. An exemption has been granted for parenteral nutrition preparations and oral low dose combinations. (Reference: (SSLMS) Information från Socialstyrelsens Läkemedelsavdelning, 14(6), 181, 1989)
AUT	1990	The marketing authorization for all products containing L-tryptophan, including high and
Legislative or regulation action		

Product Name		L-Tryptophan	
C.A.S. number		73-22-3	
Legislative or regulatory action			
Country	Effective Date	Description of action taken Grounds for decision	
		low-dose formulations for oral administration, combination products and solutions for infusion has been suspended. (Reference: (AUTGB) Bundesgesetzblatt für die Republik Oesterreich, , , 18 Oct 1990)	
BEL	1990	Food supplements containing L-tryptophan as the major ingredient have been withdrawn from sale. All other products containing L-tryptophan, including extemporaneous preparations, have been subjected to prescription control. (Reference: (BELAP) Annales Pharmaceutiques belges, 2, 31, 1990) (Reference: (BELAP) Annales Pharmaceutiques belges, 11, 64, 1990)	
DEU	1990	The marketing authorization for all products intended for oral use containing L-tryptophan has been suspended until 30 September 1991. An exemption has been granted for nutritional preparations intended for patients either severely impaired digestion and absorption or who are unresponsive to other therapy. (Reference: (DEUPZ) Pharmazeutische Zeitung, 145(44), 2951, 1990) (Reference: (DEUPZ) Pharmazeutische Zeitung, 145(41), 2735, 1990) (Reference: (DEUPZ) Pharmazeutische Zeitung, 145(40), 2629, 1990)	
ESP	1990	Products containing L-tryptophan intended for oral use were withdrawn, following their association with cases of eosinophilia-myalgia syndrome. Products intended for parenteral use were allowed to remain on the market. (Reference: (ESPITS) Información de la Terapeutica del Sistema Nacional de Salud, 14(12), 349, 1990)	
NOR	1990	Products containing L-tryptophan as the therapeutic ingredient may only be prescribed for patients already under treatment and at the special request of a psychiatrist. Preparations containing tryptophan at natural levels, such as products for parenteral nutrition, are exempted from this restriction. (Reference: (NNSLM) Nytt fra Statens Legemiddelkontroll, 3, 7, 1990)	
NZL	Feb 1990	Capsules and tablets which result in a daily intake of 100 mg or more of L-tryptophan have been recalled from retail outlets. Companies may continue to provide preparations containing L-tryptophan to patients. (Reference: (NZCSL) Clinical Services Letter, Department of Health, 257, , 15 Mar 1990)	
FRA	11 Mar 1990	The manufacture, import, sale and distribution of all dietary supplements and extemporaneous medicinal preparations containing L-tryptophan has been suspended. This measure does not refer to other medicines or to special dietary preparations, including dietary products for nursing infants and for young children with metabolic and nutritional problems, hypoallergenic dietary products for infants and nutritive mixtures for special liquid nourishment. (Reference: (JORF) Journal Officiel de la Republique Francaise, , , 13 May 1990) (Reference: (FMOPL) Le Moniteur des Pharmacies et des Laboratoires, 1892, 18, 1990)	
OMN	May 1990	Following reports of cases of eosinophilia-myalgia syndrome in the United States, import and marketing of monocomponent and multi-ingredient medicinal preparations containing L-tryptophan were prohibited. A certificate from the Ministry of Health was required for the importation of dietary supplements. (Reference: (OMNCR) Circular, 9/90, , May 1990)	
JPN	14 May 1990	As a result of the epidemic of eosinophilia-myalgia syndrome reported from the USA, L-tryptophan and all drugs and food products in which it is a constituent have been withdrawn. (Reference: (JPNPH) Pharma Japan, 1204, 1, 14 May 1990)	
MYS	Jul 1990	The marketing authorization for dietary supplements and medicines containing L-tryptophan has been withdrawn. The decision does not apply to preparations intended for parenteral nutrition or to enteral feed preparations used under medical supervision in patients with specific conditions.	

Legislative or regulation action

Product Name	L-Tryptophan	
C.A.S. number	73-22-3	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		(Reference: (MYSDC) Malaysian Drug Control Authority, , , 26 July 1990) WHO Comment : L-tryptophan, an essential aminoacid and precursor of serotonin, was introduced into medicine in 1963 for the treatment of depression and sleep disorders. Its effectiveness in these conditions has, however, never been convincingly demonstrated. It is also widely used in dietary supplements, parenteral nutrition preparations and dietary products for children with phenylketonuria. In 1989, reports from the USA showed an association between the consumption of L-tryptophan containing preparations and the development of eosiniphilia-myalgia syndrome (EMS), a condition characterized by intense eosinophilia, severe muscle and joint pain, swelling of the arms and legs, skin rashes and possible fever. Some of the reported cases have been fatal. Since it is not yet clear whether L-tryptophan itself or an unidentified contaminant is the cause of the EMS, many drug regulatory authorities have suspended the marketing authorization of products containing tryptophan pending further investigation, whereas others have withdrawn these products or restricted their use.
Product Name	Lynestrenol	
C.A.S. number	52-76-6	
Scientific and common names, and synonyms		
LYNOESTRENOL		
LYNENOL		
19-NOR-17-ALPHA-PREGN-4-EN-20-YN-17-OL		
19 NORPREGN-4-EN-20-YN-17-OL, (17ALPHA)-		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
AUS	1980	High dosage (2.5mg) lynestrenol products were withdrawn following demonstration of a dose-related incidence of mammary tumours in the beagle bitch. It is acknowledged, however, that this species may not offer a reliable model for predicting possible carcinogenicity of progestogens in humans. (Reference: (AUDEC) Report of the Australian Drug Evaluation Committee, No.90, ,)
SAU		Products now controlled by the authorities. WHO Comment : Lynestrenol, a synthetic progestogen, was introduced in the early 1960s as a component in oral contraceptive preparations. In 1967, as a result of new regulations required by the United States Food and Drug Administration, lynestrenol was submitted to long-term toxicity studies and by the early 1970s it was shown to be associated with an increased incidence of mammary tumours in beagle bitches which led to its withdrawal by at least one regulatory authority. Subsequently the validity of the beagle bitch model as a predictor of carcinogenicity of steroid contraceptives has been contested by many national regulatory authorities and lynestrenol remains available in some countries for contraceptive and other purposes. (Reference: (WHODI) WHO Drug Information, 1-3, 5-7, 1984)
Product Name	Mazindol	
C.A.S. number	22232-71-9	
Scientific and common names, and synonyms		
Legislative or regulation action		

Product Name	Mazindol	
C.A.S. number	22232-71-9	
Scientific and common names, and synonyms	5-(P-CHLOROPHENYL)-2,5-DIHYDRO-3H-IMIDAZOL[2,1-A]ISOINDOL-5-OL	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
OMN	11 Jan 1987	Import and marketing of products containing mazindol were prohibited. (Reference: (OMNCR) Circular, 2/87, , Jan 1987) WHO Comment : Mazindol, an anorectic agent, was introduced into medicine in 1970 as an aid to weight reduction. It is controlled under Schedule IV of the 1971 Convention on Psychotropic Substances. It remains available in many countries with highly evolved drug regulatory authorities. (Reference: (UNCPS4) United Nations Convention on Psychotropic Substances (IV), , 1971)
Product Name	Meclozine	
C.A.S. number	569-65-3	
Scientific and common names, and synonyms	MECLIZINE PIPERAZINE, 1-((4-CHLOROPHENYL)PHENYLMETHYL)-4-((3-METHYLPHENYL)METHYL)-1-(P-CHLORO-ALPHA-PHENYLBENZYL)-4-(M-METHYLBENZYL)PIPERAZINE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
IDN	1 Jan 1963	The Ministry of Health has prohibited the importation, production, sale and distribution of this drug. (Reference: (IDMHD) Ministerial Decree, 682-PH-63B, , June 1963) WHO Comment : Meclozine, an antihistamine with antiemetic activity, was introduced in 1953 for the treatment of nausea. The action taken in Indonesia in 1963 resulted from concern regarding its possible teratogenic potential. Subsequent epidemiological studies have been widely accepted, however, as dispelling this suspicion. Meclozine remains widely available in both prescription only and over-the-counter preparations and in some countries the licensed indications include management of nausea of pregnancy.
Product Name	Medifoxamine	
C.A.S. number	32359-34-5	
Scientific and common names, and synonyms	NN-DIMETHYL-2,2-DIPHENOXYETHYLAMINE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
MAR	Jun 1999	The manufacturer has withdrawn medifoxamine from the market because of evidence of hepatic injury. (Reference: (MARDMP) Letter to WHO, , , 08 Sep 2000)
FRA	Mar 2000	The Medicines Agency has announced the withdrawal of the antidepressant, medifoxamine from the market after a pharmacovigilance enquiry performed in France revealed evidence of hepatic injury associated with the use of medifoxamine.

Legislative or regulation action

Product Name	Medifoxamine	
C.A.S. number	32359-34-5	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
(Reference: (FRAAMI) Infofax - Pharmacovigilance, , , 30 June 1999)		
Product Name	Mefloquine	
C.A.S. number	53230-10-7	
Scientific and common names, and synonyms		
4-QUINOLINEMETHANOL, 7-2-PIPERIDINYL-2,8-BIS(TRIFLUOROMETHYL)-, (R*, S*)-(±)-		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
IRL	May 1996	The Irish Medicines Board has contraindicated the use of mefloquine for prophylaxis in patients with renal insufficiency or severe impairment of liver function; for prophylaxis in patients with a history of psychoses and epilepsy; in patients with hypersensitivity to mefloquine or related compounds; in concomitant use with halofantrine. (Reference: (IRDDS) Drug Safety Newsletter, No.2, , May 1996)
GBR	Jul 1996	The Committee on Safety of Medicines recommends that prophylactic use of mefloquine is contraindicated in patients with a history of neuropsychiatric disturbance, and that patients should be informed about adverse reactions that may occur in association with mefloquine. (Reference: (GBRCP) Current Problems in Pharmacovigilance, Vol.22, p. 6, 1996) WHO Comment : Mefloquine was developed in response to proliferation of multi-drug resistant strains of Plasmodium falciparum, and has been widely used since the early 1980s. Provided the drug is used appropriately, the risks associated with its prophylactic use are clearly outweighed by the benefits. Mefloquine is listed in the WHO Model List of Essential Drugs.
Product Name	Megestrol acetate	
C.A.S. number	3562-63-8	
Scientific and common names, and synonyms		
PREGNA-4,6-DIENE-3,20-DIONE, 17-(ACETYLOXY)-6-METHYL 17-HYDROXY-6-METHYLPREGNA-4,6-DIENE-3,20-DIONE ACETATE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GRC	1976	Preparations for oral use have been withdrawn from the market.
NOR	1 Jan 1976	Oral contraceptives containing this substance have been withdrawn from the market and use is now restricted to anti-cancer treatment.
DEU	1977	Following the discovery of increased incidence of breast tumours in beagle bitches during long-term toxicity studies, contraceptive preparations containing megestrol acetate were voluntarily withdrawn by the manufacturer. The drug remains available for treatment of endometrial carcinoma.
GBR	1982	This substance is licensed only for the treatment of certain hormone-dependent neoplasms but not for use in contraceptive preparations. This restriction was applied because of reports of dose dependent mammary tumours in beagles. Such lesions have not been reported in rats and monkeys.

Legislative or regulation action

Product Name	Megestrol acetate	
C.A.S. number	3562-63-8	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
NZL		Voluntarily withdrawn from the market. WHO Comment : Megestrol acetate, a synthetic progestogen, was introduced in the early 1960s as a component in oral contraceptive preparations. In 1967, as a result of new regulations required by the United States Food and Drug Administration, megestrol acetate was submitted to long-term toxicity studies and by the early 1970s it was shown to be associated with an increased incidence of mammary tumours in beagle bitches which led to its withdrawal by several regulatory authorities. Subsequently the validity of the beagle bitch model as a predictor of carcinogenicity of steroid contraceptives has been contested by many national regulatory authorities and megestrol remains available in some countries for contraceptive purposes. In other countries its use is restricted to anticancer treatment. (Reference: (WHODI) WHO Drug Information, 1-3, 5-7, 1984)
Product Name	Melatonin	
C.A.S. number	73-31-4	
Scientific and common names, and synonyms		
5-METHOXY-N-ACETYL TRYPTAMINE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GBR	Sep 1995	The Medicines Control Agency has ordered suppliers to stop selling the hormone, melatonin, until they have obtained a product licence. The MCA has now decided that melatonin is "medicinal by function" and requires a licence. (Reference: (GBRPHJ) The Pharmaceutical Journal, Vol.255, p.245, 16 Sep 1995)
NOR	May 1996	The Medicines Control Authority has reclassified melatonin as a prescription medicine. (Reference: (NORNL) Nytt om legemidler, 19(3): 56, , 1996)
DEU	Jun 1996	The Federal Institute for Drugs and Medical Devices has decided that melatonin is a medicinal product and therefore requires a marketing authorization. (Reference: (DEUPM) Pressemitteilung, 5/96, , 14 June 1996)
NZL	Aug 1997	Melatonin has been classified as a Prescription Medicine because the information on its safety and efficacy is insufficient. Previously, melatonin was unclassified. (Reference: (NZLPU) Prescriber Update, No.15, , Aug 1997) WHO Comment : Melatonin is promoted as a cure for travel sickness, jet-lag and insomnia and has recently been claimed in the United States to reverse the ageing process. A synthetic version has been freely available from health food shops and pharmacies as a "nutritional supplement" since 1993.

Product Name	Mepacrine
C.A.S. number	83-89-6
Scientific and common names, and synonyms	
ARRITHINUM	
ANTIMALARINAE CHLORHYDRAS	
CHINACRINA MEPACRINI HYDROCHLORIDIUM	
QUINACRINE HYDROCHLORIDE	

Legislative or regulation action

Product Name	Mepacrine	
C.A.S. number	83-89-6	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
IND	Aug 1998	The Government has issued a notification banning the import, manufacture, sale and distribution of mepacrine (quinacrine) for use as a contraceptive or sterilisation agent. Penalties include up to three years imprisonment and fines of up to Rs. 5,000. This action has been taken following clinical trials undertaken by the Indian Council of Medical Research that raised questions about the safety of the drug. (Reference: (HINDU) Use of quinacrine as contraceptive banned, , , 18 Aug 1998)
Product Name	Mephesisin	
C.A.S. number	59-47-2	
Scientific and common names, and synonyms		
3-(O-METHYLPHENOXY)-1,2-PROPANEDIOL		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
JPN	Jul 1976	This compound, promoted as a muscle relaxant, has been withdrawn because of lack of substantial evidence of efficacy and safety.
SAU		Registration of this drug has been postponed, and its distribution is prohibited. WHO Comment : Mephesisin, a centrally acting muscle relaxant and sedative, was introduced in 1948 and its use has subsequently been associated with some of the undesirable features of barbiturate use. It is of limited efficacy since it is short-acting and does not relieve the spasticity associated with chronic neurological disorders. It has therefore been largely superseded by benzodiazepines but it remains available in some countries.
Product Name	Meproamate	
C.A.S. number	57-53-4	
Scientific and common names, and synonyms		
1,3-PROPANEDIOL, 2-METHYL-2-PROPYL-, DICARBAMATE 2-METHYL-2-PROPYL-1,3-PROPANEDIOL DICARBAMATE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
SWE	Jan 1981	Meproamate-containing appetite suppressants have been withdrawn from the market. There is a lack of evidence of their value in long-term management of obesity, they have the potential for abuse and despite warnings they are frequently used over unacceptably prolonged periods. WHO Comment : Meproamate, a bis-carbamate ester, was introduced in 1955 for the treatment of anxiety and was subsequently used as a sedative-hypnotic drug. Psychological and physical dependence can occur and abuse has been reported. Meproamate is controlled under Schedule IV of the 1971 Convention on Psychotropic Substances. (Reference: (UNCPS4) United Nations Convention on Psychotropic Substances (IV), , , 1971)
Product Name	Mesna	

Legislative or regulation action

C.A.S. number 19767-45-4

Scientific and common names, and synonyms

ETHANESULFONIC ACID, 2-MERCAPTO-, MONOSODIUM SALT
SODIUM 2-MERCAPTOETHANESULFONATE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
DEU	Apr 1991	<p>Oral liquid dosage forms of preparations containing mesna were voluntarily withdrawn by the manufacturer because their use had been associated with hypersensitivity reactions of different degrees, including slight skin eruptions up to more serious anaphylactic reactions, in patients with autoimmune conditions.</p> <p>(Reference: (DAZ) Deutsche Apotheker Zeitung, 131(17), VI, 1991)</p> <p>WHO Comment : Mesna, an antidote used to protect patients treated with cyclophosphamide or ifosfamide from haemorrhagic vesiculitis, was introduced on the market in 1984. Shortly afterwards, its use became associated with allergic reactions, which occurred mainly in patients treated with the oral solution. This led to the withdrawal of this formulation in Germany, the only country where it was marketed. An oral liquid dosage form is still registered, but not marketed, in the Netherlands and products for intravenous injection remain available elsewhere.</p>

Product Name Metamfetamine

C.A.S. number 537-46-2

Scientific and common names, and synonyms

METHYLAMPHETAMINE
METAMPHETAMINE
(+)-2-METHYLAMINO-1-PHENYLPROPANE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
TUR	6 Sep 1982	Banned for production, import, export, sale and use.
OMN	10 May 1982	<p>Import and marketing of products containing metamfetamine and its racemic form were prohibited.</p> <p>(Reference: (OMNCR) Circular, 11/82, , May 1982)</p>
NGA	1988	<p>All products containing metamfetamine have been banned.</p> <p>(Reference: (NGAPN) Pharmanews, 10(11), 15, 1988)</p> <p>WHO Comment : Metamfetamine, an amfetamine derivative, is controlled under Schedule II of the 1971 Convention on Psychotropic Substances. See WHO comment for amfetamine.</p> <p>(Reference: (UNCPS2) United Nations Convention on Psychotropic Substances (II), , , 1971)</p>

Product Name Metamizole sodium

C.A.S. number 68-89-3

Scientific and common names, and synonyms

ANALGIN
DIPYRONE
DIPYRON
METHANESULFONIC ACID, ((2,3-DIHYDRO-1,5-DIMETHYL-3-OXO-2-PHENYL-1H-PYRAZOL-4-YL)METHYLAMINO)-, SODIUM SALT
METHANESULFONIC ACID

Legislative or regulation action

Product Name	Metamizole sodium
C.A.S. number	68-89-3
Scientific and common names, and synonyms	METHAMPYRONE NORAMIDOPYRINE METHANESULFONATE SODIUM SULPYRINE SULPYRIN

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
AUS	1965	The Department of Health has prohibited the importation of noramidopyrine methanesulfonate sodium (metamizole sodium). (Reference: (AUDEC) Report of the Australian Drug Evaluation Committee, No.9, ,)
NOR	Jul 1976	Withdrawn from the market.
PHL	1977	Used only as a last resort in serious and life-threatening situations when other less toxic antipyretic drugs and other measures have failed and are not tolerated, and only with proper supervision and monitoring. The package inserts are required to carry extensive warning information, especially regarding the risk of fatal agranulocytosis with the usage of this drug. The drug is available only on prescription. (Reference: (PHADO) Administrative Order, 330, , 1977)
USA	27 Jun 1977	An analgesic, antipyretic drug, found to be effective at reducing fever but withdrawn from the market and prohibited for export by the Food and Drug Administration on the basis of reports of agranulocytosis, a sometimes fatal blood condition, associated with its use. The Director of the Bureau of Drugs found that agranulocytosis cannot be effectively prevented by frequent examination of treated patients since this condition can occur within a few hours following administration of the drug to a sensitive individual. In its decision, the FDA cited the availability of effective orally administered drug products (e.g. acetylsalicylic acid or paracetamol) and concluded that the risks associated with this drug far outweigh any benefit derived from its use, including use in Hodgkin's disease and similar malignant diseases. (Reference: (FEREAC) Federal Register, 42(117), 30893, 1977)
KWT	Dec 1978	All dosage forms are no longer allowed with the exception of injectable preparations which may be used only in an emergency. (Reference: (KTMD) Ministerial Decree, 556/78, , 1978)
ITA	1979	Injectable preparations with dosages higher than 1 gram and intravenous preparations in combination with other compounds have been withdrawn. The label for currently marketed preparations now carries a warning regarding fatal accidents due to hypersensitivity.
DNK	Apr 1979	Preparations containing metamizole were banned for systemic use due to the potential risk of fatal agranulocytosis. (Reference: (UGLAAD) Ugeskrift for Laeger, 873, , Mar 1979)
SAU	1980	All preparations containing metamizole were prohibited due to several reports of anaphylactic shock.
ARE	9 Jun 1981	Pharmaceutical preparations containing metamizole sodium are banned. (Reference: (UAEMD) Ministry of Health Decree, No.694, , 1981)
SDN	1982	The Ministry of Health no longer allows registration of metamizole sodium with the exception of parenteral preparations for limited use.
BGD	Jun 1982	Banned in oral drops and tablet form due to high incidence of adverse effects and availability of safer alternatives. A single ingredient injection remains available for terminal care as a restricted drug for specialized use.
EGY	Jul 1983	Following reports of anaphylactic shock, no registration licence is to be granted for injectable preparations containing more than 1 gram of this compound.

Legislative or regulation action

Product Name **Metamizole sodium**

C.A.S. number **68-89-3**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
ISR	1 Dec 1985	Fixed dose combinations of metamizole sodium are not approved for registration. Parenteral preparations of metamizole sodium (single-dose product) may be administered only in hospitals and clinics where there are suitable facilities for resuscitation (in cases of anaphylactic shock). Enteral preparations of metamizole sodium (single-dose product) may be dispensed without prescription.
BEL	1987	Preparations containing metamizole sodium have been placed in List IV of the 'Arrêt, du R.gent' of 2 June 1946 and as such can be administered only on prescription. They must be kept in a poisons cabinet and carry the skull and crossbones label. Metamizole in combination with a spasmolytic may be dispensed a maximum of five times against a renewable prescription for a period of six months. (Reference: (BELAR) Arrêté Royal, , , June 1987)
MYS	Jan 1987	All products containing metamizole sodium have been withdrawn. (Reference: (MYSDC) Malaysian Drug Control Authority, No.6, , Oct 1986)
DEU	27 Apr 1987	Subsequent to the regulatory action taken in January 1983 (see Pyrazolones) the Federal Health Office has further restricted the use of preparations containing metamizole sodium. As from 1 January 1987 all preparations have been subjected to prescription control and combination products have been withdrawn. (Reference: (FRGGH) Bundesgesundheitsamt Pressedienst, 18, , Apr 1987)
PAK	1988	All combination products containing metamizole sodium were withdrawn. (Reference: (PAKMH) Ministry of Health, Special Education and Social Welfare, , , Aug 1988)
ESP	1989	The indications of products containing metamizole sodium have been restricted to acute post-traumatic or post-surgical pain, abdominal colic and high fever unresponsive to other antipyretics. All fixed combination products containing metamizole have been withdrawn, except those in which it is associated with a spasmolytic. (Reference: (ESPINS) Información Terapéutica de la Seguridad Social, 13(1), 6, 1989)
GHA	1 Sep 1989	Products containing metamizole sodium of its salts have been banned. (Reference: (GHAPDR) Pharmacy and Drugs (Banned Drugs) Regulations, Legislative Instruments, 1484, , 1989)
NLD	1990	Having regard to reports of agranulocytosis, the manufacturers have agreed to the voluntary withdrawal of metamizole sodium from combination preparations. (Reference: (NPHWB) Pharmaceutisch Weekblad, 125(3), 82, 1990)
CHE	1 Jan 1992	Products containing metamizole sodium were subjected to prescription control. (Reference: (CHBCM) Bulletin Mensuel, 10, 686, 1991)
LKA	1 Jan 1992	The Ministry of Health withdrew from sale pharmaceutical products containing metamizole sodium (injectable formulation). This action was based on the potential of these products to induce suppression of the bone marrow. (Reference: (LKADIB) Drug Information Bulletin, University of Peradeniya and Ministry of Health, 4(1), , 1992)
THA	Feb 1994	The Ministry of Public Health has revised the product information for pharmaceutical products containing the pyrazalone analgesic, metamizole sodium (dipyrone) to include a warning on possible agranulocytosis and impairment of the immune system and to restrict its use to severe pain and lack of response to aspirin or paracetamol. The drug has been rescheduled and may now be obtained only on prescription. It has also been prohibited for use in combination products, i.e. antispasmodic and cold remedy preparations. (Reference: (THAFDA) Communication to WHO, , , 08 Feb 1994)
NPL	21 Jul 1997	The health authorities have banned the importation, manufacture, sale, distribution and storage of metamizole sodium alone or in combination. This action has been taken on

Legislative or regulation action

Product Name **Metamizole sodium**

C.A.S. number **68-89-3**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
		the basis of safety concerns relating to this product. (Reference: (NPLGZ) Nepal Gazette, Part 47(15), Notice 2, 21 July 1997)
SYR	1998	The Suprim Technical Committee and the Ministry of Health has instructed all local drug factories to stop manufacturing metamizole sodium (dipyron) ampoules with immediate effect. (Reference: (SYRAFD) Announcement from the Directorate, No: 1784, , 02 Feb 1998)
YEM	1998	The Supreme Board of Drugs and Medical Appliances has withdrawn all formulations of metamizole sodium because of its potential to cause anaphylactic shock and agranulocytosis. (Reference: (YEMCW) Communications to WHO, , , 10 Oct 1998)
ZWE	1998	The Medicines Control Authority has cancelled the registration of all metamizole sodium (dipyron)- containing products due to the potential risk of metamizole sodium causing fatal agranulocytosis. (Reference: (ZWEDIB) Drug Information Bulletin, Vol.2 No.1, , Mar 1998)
SWE	1999	The Medical Products Agency has suspended the marketing authorization for metamizole sodium with effect from 28 April 1999. The decision is based on a larger than expected number of reports of agranulocytosis in Sweden since 1996 (1 in 1,700). (Reference: (SWEMPA) EU/EEA Rapid Alert, , , 28 Apr 1999)
MAR	May 2000	The Minister of Public Health has decided to suspend the marketing authorization for products containing metamizole sodium on the recommendation of the National Advisory Commission for Pharmacovigilance. This recommendation followed an official survey which showed severe adverse reactions associated with this product. (Reference: (MARDMP) Letter to WHO, , , 08 Sep 2000)
COL	Jun 2000	The Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) in Colombia, Colombian Ministry of Health has restricted the use of metamizole either alone or in combination. These products should be available only if other combination. These products should be available only if other therapeutic management is insufficient. (Reference: (COLVMA) Letter from INVIMA to WHO, Res. 259048, , 22 June 2000)
LTH	Sep 2000	The marketing authorization for tablets was not renewed for safety reasons. (Reference: (LTHCW) Communication to WHO, , , 24 Aug 2001)
ARM		The Drug and Medical Technology Agency has suspended the marketing authorization of metamizole sodium (tablets and solution). The decision is based on a large number of reports on agranulocytosis in Sweden since 1996 and other dangerous adverse effects. (Reference: (ARMCW) Communication to WHO, , , 09 Aug 2000)
BHR		Preparations containing metamizole sodium have been withdrawn.
GRC		Preparations containing metamizole have been withdrawn from the market, with the exception of injectable preparations containing up to 1 gram, because of concern about agranulocytosis associated with the drug's use.
IRL		Products containing metamizole have been withdrawn.
MEX		Due to toxicity, not accepted for use in pediatric preparations (elixir, solution, suspension, suppositories). Alternatives must be sought.
PER		The package and/or label for this product advises that the drug is intended for prescription use only and may cause agranulocytosis.
SGP		Metamizole sodium and related salts have been banned for importation.
SWE		Preparations containing metamizole sodium were withdrawn from the market by the manufacturers after mutual discussions due to adverse reactions such as agranulocytosis.

Legislative or regulation action

Product Name	Metamizole sodium	
C.A.S. number	68-89-3	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
VEN		Not approved for use and/or sale. WHO Comment : Metamizole sodium, a pyrazolone derivative with analgesic, antipyretic and anti-inflammatory activity, was introduced in 1921 and has since been widely available in over-the-counter products. By the early 1970s its use had been associated, as with some other pyrazolones, with serious and sometimes fatal adverse reactions, notably cases of blood dyscrasias including agranulocytosis, which led to its withdrawal by some regulatory authorities (see full list). Although preparations of metamizole sodium are prohibited in certain countries, they remain widely available in others and, in some cases, in over-the-counter products.
Product Name	Metformin	
C.A.S. number	657-24-9	
Scientific and common names, and synonyms		
IMIDODICARBONIMIDIC DIAMIDE-, N,N-DIMETHYL-		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
NZL	Apr 1998	Metformin is contraindicated in chronic hepatic disease, hypoxia (e.g., recent myocardial infarction, cardiac failure, pulmonary disease), dehydration and in the period from immediately prior to surgery until the patient is again eating and drinking normally. (Reference: (NZLPU) Prescriber Update, No.16, , Apr 1998)
Product Name	Methanol	
C.A.S. number	67-56-1	
Scientific and common names, and synonyms		
METHYL ALCOHOL METHANOL		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
THA		Products containing this ingredient may not be registered. WHO Comment : Methanol has been subjected to abuse by consumption as a substitute for ethanol. Its toxic metabolites cause irreversible blindness and severe metabolic acidosis, and are ultimately fatal. Methanol continues to be used as an industrial solvent.
Product Name	Methapyrilene	
C.A.S. number	91-80-5	
Scientific and common names, and synonyms		
1,2-ETHANEDIAMINE, N,N-DIMETHYL-N'-2-PYRIDINYL-N'-(2-THIENYLMETHYL) 2((2-(DIMETHYLAMINO)ETHYL)-2-THENYLAMINO)PYRIDINE		
Legislative or regulative action		

Legislative or regulation action

Product Name		Methapyrilene	
C.A.S. number		91-80-5	
Country	Effective Date	Description of action taken Grounds for decision	
DEU	1979	Withdrawn following experimental evidence of carcinogenicity in rodents.	
DOM	1979	Withdrawn following experimental evidence of carcinogenicity in rodents.	
GBR	1979	Withdrawn following experimental evidence of carcinogenicity in rodents.	
ITA	1979	Withdrawn from the market owing to suspected carcinogenicity.	
CAN	28 Jun 1979	Approval for registration of products containing methapyrilene, or any of its salts was withdrawn. Action was based on data received by the Health Protection Branch identifying methapyrilene as a potent carcinogen in rats. (Reference: (CANGZ) Canada Gazette, 113/II(13), 2530, 1979)	
SGP	Oct 1979	Medicinal products containing methapyrilene and/or its salts have been banned for importation.	
HKG	17 Dec 1979	The Pharmacy and Poisons Committee no longer allows the registration, sale or distribution of products containing methapyrilene.	
AUS	1980	All preparations withdrawn following demonstration of carcinogenic potential in rats.	
EGY	1980	Products containing methapyrilene were withdrawn having regard to its carcinogenic potential.	
PAN	9 May 1980	The Ministry of Health has banned the sale of pharmaceuticals and cosmetics containing methapyrilene. (Reference: (PANMR) Ministry of Health Resolution, 882, , May 1980)	
BRA	30 Jun 1980	Products containing methapyrilene are prohibited. (Reference: (BRAPT) Portaria do Servico Publico Federal, No.08, , 1980)	
PHL	Sep 1980	This compound has been banned in antihistamines. It has been found to be carcinogenic in animals.	
ARE	9 Jun 1981	Pharmaceutical preparations containing methapyrilene hydrochloride are banned. (Reference: (UAEMD) Ministry of Health Decree, No.694, , 1981)	
IND	1983	Prohibited for manufacture and sale for reasons of health risks associated with use and/or questionable therapeutic value. (Reference: (GAZIE) The Gazette of India: Extraordinary, II-3i, , 23 July 1986)	
OMN	27 Jul 1992	Marketing of products containing methapyrilene was prohibited. (Reference: (OMNCR) Circular, 28/92, , July 1992)	
CHL		Withdrawn following experimental evidence of carcinogenicity in rodents.	
NZL		Voluntarily withdrawn from the market.	
USA		This antihistamine was withdrawn in the United States of America, and subsequently in several other countries, following experimental evidence of carcinogenicity in rodents.	
VEN		Withdrawn from market.	
<p>WHO Comment : Methapyrilene, an antihistamine with moderate sedative activity, was introduced in 1947 for the treatment of various allergic conditions and was subsequently incorporated in many over-the-counter sleeping aids. In the early 1970s it was identified as a carcinogen in rats and, although there was no direct evidence that it constitutes a health hazard to man, it was withdrawn in many countries. (Reference: (WHODI) WHO Drug Information, 2, 4, 1979)</p>			

Product Name		Methaqualone	
C.A.S. number		72-44-6	

Legislative or regulation action

Product Name **Methaqualone**

C.A.S. number **72-44-6**

Scientific and common names, and synonyms
 2-METHYL-3-O-TOLYL-4(3H)-QUINAZOLINONE
 4(3H)-QUINAZOLINONE, 2-METHYL-3-(2-METHYLPHENYL)-

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
GRC	1979	Withdrawn from the market.
TUR	6 Sep 1982	Banned for production, import, export, sale and use.
OMN	10 May 1982	Import and marketing of products containing methaqualone were prohibited. (Reference: (OMNCR) Circular, 11/82, , May 1982)
ZWE	Nov 1984	Prohibited for use. (Reference: (ZWESI) Statutory Instrument, 366, , Nov 1984)
PAK	1988	Products containing methaqualone were withdrawn. (Reference: (PAKMH) Ministry of Health, Special Education and Social Welfare, , , Aug 1988)
GHA	1 Sep 1989	Products containing methaqualone or its salts have been banned. (Reference: (GHAPDR) Pharmacy and Drugs (Banned Drugs) Regulations, Legislative Instruments, 1484, , 1989)
ARE		Pharmaceutical preparations containing methaqualone are banned. WHO Comment : Methaqualone, a quinazolone derivative, was introduced in 1965 for use as a sedative-hypnotic drug. It is widely abused and is associated with severe withdrawal symptoms. Methaqualone is controlled under Schedule IV of the 1971 Convention of Psychotropic Substances. (Reference: (UNCPS4) United Nations Convention on Psychotropic Substances (IV), , , 1971)

Product Name **Methiodal sodium**

C.A.S. number **126-31-8**

Scientific and common names, and synonyms
 METHANESULFONIC ACID, IODO-, SODIUM SALT
 SODIUM IODOMETHANESULFONATE
 SODIUM IODOMETHANE SULPHONATE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
SWE	1 Jan 1975	Methiodal sodium was reported to have induced muscle spasms in some patients subjected to myelography, presumably because of an irritant action on motor nerve roots. Registration was withdrawn when a safer X-ray contrast medium was introduced on the market. WHO Comment : Methiodal sodium, a radio-opaque medium, was formerly used for the examination of the urinary tract. Its use was associated with muscle spasms presumed to result from irritation of motor nerve roots in the spinal canal. This led to its withdrawal in Sweden in 1975 when a safer alternative became available. Preparations containing methiodal sodium were subsequently withdrawn worldwide by the manufacturer.

Product Name **Methylphenidate**

Legislative or regulation action

C.A.S. number	113-45-1	
Scientific and common names, and synonyms	METHYL ALPHA-PHENYL-2-PIPERIDINEACETATE 2-PIPERIDINEACETIC ACID, ALPHA-PHENYL-, METHYL ESTER, (R*,R*)-(+/-) 2-PHENYL-2-(2-PIPERIDYL)ACETIC ACID, METHYL ESTER	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
TUR	6 Sep 1982	Banned for production, import, export, sale and use.
OMN	10 May 1982	Import and marketing of products containing methylphenidate were prohibited. (Reference: (OMNCR) Circular, 11/82, , May 1982)
NGA	1988	All products containing methylphenidate have been banned. (Reference: (NGAPN) Pharmanews, 10(11), 15, 1988)
<p>WHO Comment : Methylphenidate, a piperidine derivative with mild central stimulant activity, was introduced in 1956. Its pharmacological properties resemble those of amfetamines and it shares their abuse potential. Methylphenidate retains a place as an adjunct in the treatment of hyperkinetic syndromes in both children and adults. It is controlled under Schedule II of the 1971 Convention on Psychotropic Substances. (Reference: (UNCPS2) United Nations Convention on Psychotropic Substances (II), , 1971)</p>		

Product Name	Methylrosanilinium chloride	
C.A.S. number	548-62-9	
Scientific and common names, and synonyms	CRYSTAL VIOLET CL BASIC VIOLET GENTIAN VIOLET METHYLOSANILINE CHLORIDE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
MYS	Apr 1998	The Drug Control Authority decided to cancel the registration of all existing products containing methylrosanilinium chloride following reports of adverse reactions and toxicity such as buccal ulceration, stomatitis, kerato-conjunctivitis, irritation and sensitivity reactions encountered with the use of products containing this dye. Studies have shown methylrosanilinium chloride to be a carcinogen in mice and it has been labelled as a mutagen, a mitotic poison and a clastogen. (Reference: (MYS DI) Berita Ubat-Ubatan (Drug Information), Vol.12 No.2, , Aug 1998)

Product Name	Methyprylon	
C.A.S. number	125-64-4	
Scientific and common names, and synonyms	PIPERIDINEDIONE 2,4-PIPERIDINEDIONE, 3,3-DIETHYL-5-METHYL- 3,3-DIETHYL-5-METHYL-2,4-PIPERIDINEDIONE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision

Legislative or regulation action

Product Name	Methyprylon	
C.A.S. number	125-64-4	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
ZWE	Nov 1984	Prohibited for use. (Reference: (ZWESI) Statutory Instrument, 366, , Nov 1984) WHO Comment : Methyprylon, a piperidine derivative, was introduced in 1955 for use as a sedative-hypnotic drug. Habituation, tolerance, physical dependence and addiction can occur and methyprylon is controlled under Schedule IV of the 1971 Convention on Psychotropic Substances. (Reference: (UNCPS4) United Nations Convention on Psychotropic Substances (IV), , , 1971)
Product Name	Metoclopramide (paediatric)	
C.A.S. number	364-62-5	
Scientific and common names, and synonyms		
AHR-3070-C METOCLOPRAMIDI HYDROCHLORIDIUM		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
SYR	1999	The Suprim Technical Committee and the Ministry of Health has prohibited the use of metoclopramide in children less than 20 kg of weight because of reports of sensitivity reactions. . (Reference: (SYRAFD) Announcement from the Directorate, No. 5615/3/15, , 1999)
Product Name	Metofoline	
C.A.S. number	2154-02-1	
Scientific and common names, and synonyms		
ISOQUINOLINE,1-(2-(4-CHLOROPHENYL)ETHYL)-1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-2-METHYL- METHOPHOLINE 1-(P-CHLOROPHENETHYL)-1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-2- METHYLISOQUINOLINE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
USA	Mar 1965	Withdrawn from the market and prohibited for export by the Food and Drug Administration on the basis of findings of eye changes and corneal opacities in chronic-toxicity studies in dogs. WHO Comment : Metofoline, an analgesic, was introduced in the early 1960s for the treatment of mild to moderate acute and chronic pain. It was never available outside the USA.
Product Name	Metrodin HP	
C.A.S. number	2004-0-0007	
Legislative or regulative action		

Legislative or regulation action

Product Name	Metrodin HP	
C.A.S. number	2004-0-0007	
Country	Effective Date	Description of action taken Grounds for decision
GBR	10 Feb 2003	Metrodin High Purity (HP), a product used in the treatment of infertility and manufactured from urine sourced from Italy, is being withdrawn in the UK by the Committee on Safety of Medicines (CSM), following confirmation of a case of variant Creutzfeldt-Jakob Disease (vCJD) in Italy. (Reference: (GBRMRS) Media Release, , , 10 Feb 2003)

Product Name	Mianserin	
C.A.S. number	24219-97-4	
Scientific and common names, and synonyms		
DIBENZO(C,F)-PYRAZINO(1,2-A)AZEPINE, 1,2,3,4,10,14B-HEXAHYDRO-2- METHYL 1,2,3,4,10,14B-HEXAHYDRO-2-METHYLDIBENZO(C,F)-PYRAZINO(1,2-A)AZEPINE		

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
OMN	27 Nov 1986	Having regard to reported adverse effects, the Central Drug Committee has prohibited import and marketing of pharmaceutical products containing mianserin. WHO Comment : Mianserin, a serotonin antagonist with antidepressant and antihistaminic activity, was introduced in 1975 for the treatment of depressive illness. Its use has since been associated with cases of severe blood dyscrasias, particularly in elderly patients, including agranulocytosis, leucopenia and granulocytopenia. Several drug regulatory authorities have reacted by stipulating that blood counts should be monitored regularly during the first few months of treatment and that administration should be discontinued immediately should any signs possibly indicative of dyscrasia develop.

Product Name	Mibefradil	
C.A.S. number	116644-53-2	
Scientific and common names, and synonyms		
(1S,2S)-2-([3-(2-BENZINIDAZOYL)YL]PROPYL)METHYLAMINE)-ETHYL-6-FLUORO-1,2,3,4-TETRAHYDRO-1-ISOPROPYL-2-NAPHTHYL METHOXYACETATE DIHYDROCHLORIDE		

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
PER	1998	La Direcció General de Medicamentos, Insumos y Drogas (DIGEMID) of the Ministry of Health withdrew marketing authorization for mibefradil (Posicor) following reports of serious adverse effects caused by the interaction with other medicines. (Reference: (PERDGM) Alerta DIGEMID, No. 04-98, , 1998)
USA	1998	Roche laboratories announced the voluntary market withdrawal of the antihypertensive and antianginal medication mibefradil (Posicor). This action was taken because of information on a number of drug interactions, some of them serious that occur when mibefradil is taken together with other medications. (Reference: (USADDL) Dear Doctor letter, , , 08 June 1998)
ZAF	1998	The South African Medicines Control Council has withdrawn products containing mibefradil because of safety concerns in relation to potential for serious drug interactions. (Reference: (ZAFPS) Information from the Pharmaceutical Services, , ,)
JAM	Feb 1998	The calcium channel blocking agent, mibefradil was voluntarily withdrawn from the market by Hoffman La Roche.

Legislative or regulation action

Product Name	Mibefradil	
C.A.S. number	116644-53-2	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		(Reference: (JAMMHS) Communication to WHO, , , 26 Sep 2000)
GBR	Jul 1998	Mibefradil was voluntarily withdrawn from the market by the manufacturer worldwide due to an increasing number of reports of serious interactions with a wide range of drugs. . (Reference: (GBRMCA) Communication to WHO, , , 30 Aug 2000)
DEU	Aug 1998	The Federal Institute for Drugs and Medical Devices has suspended the marketing authorization for mibefradil because it considers that mibefradil has a negative benefit/risk ratio. In particular, it has a life-threatening potential to induce cardiac arrhythmias (including torsades de pointes) especially when taken concomitantly with other medications. (Reference: (DEUCFI) Communication, , , 21 Aug 1998)
BGR	Apr 1999	The Bulgarian Drug Agency in the Ministry of Health withdrew the calcium channel blocking agent, mibefradil (Posicor) because of serious adverse reactions worldwide. (Reference: (BGRBDA) Communication to WHO, , ,)
ARM	Jul 2000	Mibefradil has been voluntarily withdrawn on the basis of a large number of reports of life-threatening interactions of the drug: extremely low heart rates and a risk of muscle injury. (Reference: (ARMCW) Communication to WHO, , , 09 Aug 2000)

Product Name	Mifepristone	
C.A.S. number	84371-65-3	
Scientific and common names, and synonyms	11BETA-[P-(DIMETHYLAMINO)PHENYL]-17BETA-HYDROXY-17-(1-PROPYNYL)ESTRA-4,9-DIEN-3-ONE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
FRA	Apr 1991	Following reports of cardiovascular adverse effects, the approved product information for mifepristone was amended to contraindicate its use, in conjunction with a prostaglandin, as an abortifacient in women who have smoked regularly for more than 2 years and in all women over 35 years of age. (Reference: (FRAMSS) Ministry of Social Affairs and Solidarity, , , 19 Apr 1991) WHO Comment : Mifepristone, an antiprogesterone used in combination with a prostaglandin for the termination of early pregnancy, was introduced in 1990. Use of the combination has been associated with episodes of coronary spasm that are attributed to administration of the prostaglandin and which have resulted in several cases of cardiac infarction and ventricular fibrillation. At least one of these incidents has been fatal.

Product Name	Miglustat	
C.A.S. number	72599-27-0	
Scientific and common names, and synonyms	1,5-(BUTYLIMINO)-1,5-DIDEOXY-D-GLUCITOL	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
ISR	2002	Miglustat has been temporarily withdrawn in Israel as a precaution pending investigation of an unexplained cognitive dysfunction in a patient previously treated with the drug.

Legislative or regulation action

Product Name	Miglustat	
C.A.S. number	72599-27-0	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		(Reference: (ISRMDR) Media Release, , , 24 Apr 2002)
Product Name	Minocycline	
C.A.S. number	10118-90-8	
Scientific and common names, and synonyms		
2-NAPHTACENECABOXAMIDE,4,7-BIS(DIMETHYLAMINO)-1,-4,4A,5,5A,6,11,12A-OCTAHYDRO-3,10,12,12A-TETRAHYDROXY-1,-11-DIOXO,[4S-(4ALPHA,4AALPHA,5AALPHA,12AALPHA)]-		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
NOR	1989	Products containing minocycline have been refused for registration, on the grounds that the associated adverse reactions tend to be more severe than those resulting from other tetracycline antibiotics. (Reference: (NNSLM) Nytt fra Statens Legemiddelkontroll, 1, 13, 1989) WHO Comment : Minocycline, a semi-synthetic tetracycline derivative was introduced in 1967. It is used today in the treatment of bacterial, rickettsial and amoebic infections. Symptoms described as dizziness or vertigo have been recognized in association with minocycline administration, however, these symptoms are usually not severe. Minocycline is registered in many countries and the World Health Organization is not aware that registration has been refused elsewhere.
Product Name	Misoprostol	
C.A.S. number	59122-46-2	
Scientific and common names, and synonyms		
SC-29333. METHYL 7-(1R,2R,3R)-3-HYDROXY-2-[(E)-(4RS)-4-HYDROXY-4-METHYLOCT-1-ENYL]-5-OXOCYCLOPENTYL]HEPTANOATE (11 ALPHA, 13E)-11, 16-DIHYDROXY-16-METHYL-9-OXOPROST-13-EN-1-OIC ACID METHYL ESTER		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
OMN	Apr 2000	The Directorate General of Pharmaceutical Affairs & Drug Control has rescheduled misoprostol as a non-psychotropic restricted controlled item because of international data concerning its potential abuse and risk of dependence. (Reference: (OMNCR) Circular, No. 25/2000, , 25 Apr 2000)
THA	Oct 2000	This drug has been severely restricted for use in hospitals only. (Reference: (THACW) Communication to WHO, , , 28 Sep 2001)
Product Name	Mofebutazone	
C.A.S. number	2210-63-1	
Scientific and common names, and synonyms		
4-BUTYL-1-PHENYL-3,5-PYRAZOLIDINEDIONE		
Legislative or regulative action		

Legislative or regulation action

Product Name	Mofebutazone	
C.A.S. number	2210-63-1	
Country	Effective Date	Description of action taken Grounds for decision
DEU	1985	Indications are restricted to symptomatic treatment of acute exacerbations of arthroses including chronic articular rheumatism, peri-arthritis, tendinitis, ankylosing spondylitis and superficial thrombophlebitis.
OMN	1986	The Ministry of Health has prohibited the import of preparations containing mofebutazone except those intended for topical use.
AUT		Indications restricted to exacerbations of gout and other arthritic conditions. Treatment should not exceed seven days and doctors are advised not to prescribe this drug to children under 14 years of age or elderly patients. (Reference: (WIMAM) Wichtige Mitteilung ueber Arzneimittel, (1), , 1984)
WHO Comment : Mofebutazone, a pyrazolone with anti-inflammatory, analgesic and antipyretic activity, was introduced in 1962 for the treatment of rheumatic disorders. As it is structurally related to phenylbutazone it is subjected to rigorously restricted indications by some national regulatory authorities. See WHO comment for phenylbutazone.		

Product Name	Moxisylyte	
C.A.S. number	54-32-0	
Scientific and common names, and synonyms		
THYMOXAMINE		
4-(2-DIMETHYLAMINOETHOXY)5-ISOPROPYL-2-METHYLPHENYL ACETATE		

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
FRA	28 Jun 1993	The manufacturer of moxisylyte has decided to withdraw the product from the market in France. The action was taken in the light of evidence of dose-dependent hepatotoxicity and after discussion with the National Pharmacovigilance Commission. Although patients have recovered after withdrawal of therapy, the benefit/risk ratio for this product is considered unfavourable. (Reference: (FRAARN) Adverse Reaction Newsletter, No.2, p.9, June 1993)
WHO Comment : Moxisylyte was introduced in the late 1980s. It belongs to the group of a-adrenergic blocking agents. In France it is indicated for the treatment of manifestations of benign prostatic hypertrophy. It is also marketed in the UK at lower dosages for the treatment of peripheral vascular disorders (Raynaud's disease).		

Product Name	Mucopolysaccharide polysulfuric acid ester	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
CHE	May 1988	The Intercantonal Office for Drug Control has suspended indefinitely the marketing authorization for products containing mucopolysaccharide polysulfuric acid ester.
FRA	1992	Acting on the advice of the National Commission for Pharmacovigilance, the Ministry of Health suspended for one year the marketing authorization for a mixture of aqueous calf cartilage and bone marrow extract indicated as a chondroprotective agent. The decision was taken having regard to reports of allergic reactions. (Reference: (FRARP) La Revue Prescrire, 12(121), 415, 1992)

Legislative or regulation action

Product Name **Mucopolysaccharide polysulfuric acid ester**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
PRT	02 Jul 1992	The Ministry of Health suspended the marketing authorization for a product containing mucopolysaccharide polysulfuric acid ester indicated as a chondroprotective agent pending a thorough evaluation of reported adverse reactions. (Reference: (PRTMH) Ministry of Health, , 02 July 1992)
AUT	07 Jul 1992	The Ministry of Health suspended a product indicated as a chondroprotective agent and containing mucopolysaccharide polysulfuric acid ester (Ateparon(R): Luitpold) pending the results of further investigations. The decision was taken after two deaths associated with the use of this product were reported in Germany. The product containing mucopolysaccharide polysulfuric acid ester was initially suspended at the beginning of 1988 after reports of serious adverse reactions including cerebral bleeding which gave rise to concern about its safety. It was reintroduced in 1989 since results did not confirm a causal relationship at the time. (Reference: (AUTMH) Ministry of Health, , 07 July 1992)
DEU	28 Jul 1992	The Federal Health Office amended the product information for a topical mucopolysaccharide polysulfuric acid ester indicated as treatment for thrombophlebitis, varicose veins, haematoma, and oedema to alert prescribers to cases of skin irritation and allergy. The contraindications have been extended to patients known to be hypersensitive to any component of the product. The manufacturer of a product containing mucopolysaccharide polysulfuric acid ester and indicated as a chondroprotective agent voluntarily withdrew the product from the market. (Reference: (DEUCDC) Communication, , 28 July 1992) (Reference: (BGHBL) Bundesgesundheitsblatt, 2/92, 109, Feb 1992)

WHO Comment : Mucopolysaccharide polysulfuric acid ester is a heparinoid used in the treatment of rheumatoid arthritis. Those formulations of mucopolysaccharide polysulfuric acid esters indicated for topical application have been associated with adverse drug reactions in the form of skin irritations. In 1992 contraindications for the topical mucopolysaccharide polysulfuric acid ester (Huridoid R) were altered to include all patients known to be hypersensitive to any component of the product.

Product Name **Muzolimine**

C.A.S. number **55294-15-0**

Scientific and common names, and synonyms

3H-PYRAZOL-3-ONE, 5-AMINO-2-(1-(3,4-DICHLOROPHENYL)ETHYL)-2,4-DIHYDRO-
3-AMINO-1-(3,4-DICHLORO-ALPHA-METHYLBENZYL)-2-PYRAZOLIN-5-ONE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
DEU	1987	Following discussions with the Federal Health Office, the manufacturer has voluntarily suspended the sale of products containing muzolimine.
FRA	1987	Following discussions with the Directorate of Pharmacy and Medicines, the manufacturer has voluntarily suspended the sale of products containing muzolimine. (Reference: (FMOPL) Le Moniteur des Pharmacies et des Laboratoires, 1762(10), , 1987)
NOR	1987	Muzolimine is not approved for registration on grounds of positive carcinogenicity tests and because the risk of carcinogenic effect in man is not excluded. WHO Comment : Reports of neurological adverse effects, including paraesthesiae and paralyses, associated with prolonged use of high dosages of muzolimine, were received shortly after its introduction in 1984.

Legislative or regulation action

Product Name	Muzolimine	
C.A.S. number	55294-15-0	
Product Name	Nabilone	
C.A.S. number	51022-71-0	
Scientific and common names, and synonyms	<p>9H-DIBENZO(B,D)PYRAN-9-ONE, 3-(1,1-DIMETHYLHEPTYL)-6,6A,7,8,10,10A- HEXAHYDRO-1-HYDROXY-6,6-DIMETHYL, TRANS-, (+/-)</p> <p>(+/-)-3-(1,1-DIMETHYLHEPTYL-6,6A BETA,7,8,10,10A ALPHA-HEXAHYDRO-1- HYDROXY-6,6-DIMETHYL-9H-DIBENZO(B,D)PYRAN-9-ONE</p>	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
USA	Apr 1987	<p>The Drug Enforcement Administration of the Department of Justice has placed nabilone under Schedule II of the Controlled Substances Act. (Reference: (FEREAC) Federal Register, 52(66), 11042-3, 1987)</p> <p>WHO Comment : Nabilone is a structural analogue of dronabinol (delta-9-tetrahydrocannabinol), the major active component of cannabis.</p>
Product Name	Naftidrofuryl (parenteral formulations)	
C.A.S. number	31329-57-4	
Scientific and common names, and synonyms	<p>NAFRONYL OXALATE</p> <p>2-FURANPROPANOIC ACID, TETRAHYDRO-?--(1-NAPHTHALENYLMETHYL)-, 2-(DIETHYLAMINO)ETHYL ESTER,ETHANEDIOATE (1:1)</p>	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GBR	Feb 1995	<p>The Committee on Safety of Medicines, after having received 63 reports of adverse reactions associated with naftidrofuryl, considers that naftidrofuryl must not be given as a bolus and the rate of infusion should not exceed 200mg in 90 minutes, as indicated in the current data sheet. (Reference: (GBRCP) Current Problems in Pharmacovigilance, Vol.21, , Feb 1995)</p>
FRA	May 1995	<p>The infusion formulation of naftidrofuryl has been withdrawn after a review showing that the risks of cardiac and neurological toxicity outweigh the benefit of intravenous administration. The oral form remains available for use. (Reference: (FRARP) La Revue Prescrire, Vol. 15(151), p.348, May 1995)</p>
DEU	26 Jan 1996	<p>The Federal Institute for Drugs and Medical Devices has revoked the marketing approval for the injectable formulation of the vasodilator, naftidrofuryl, after reports of two fatal cases of hypersensitivity reactions associated with its use. Subsequently cases of other serious adverse reactions were reported in other countries, including severe hepatic and cardiac reactions. (Reference: (DEUPZ) Pharmazeutische Zeitung, 141(6): 432, , 1996)</p> <p>WHO Comment : Naftidrofuryl is a vasoactive spasmolytic used to treat peripheral vascular disease. It also improves the oxygen utilization in tissues.</p>
Product Name	Nandrolone decanoate (injectable)	
C.A.S. number	360-70-3	
Scientific and common names, and synonyms	<p>ESTR-4-EN-3-ONE, 17-((1-OXODECYL)OXY)-, (17BETA)</p> <p>NORTESTOSTERONE DECYLATE</p>	
Legislative or regulation action		

Product Name **Nandrolone decanoate (injectable)**

C.A.S. number **360-70-3**

Scientific and common names, and synonyms

NORTESTERONE DECYCLATE

17BETA-HYDROXYESTR-4-EN-3-ONE DECANOATE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
BGD	1982	Under the provisions of the Drugs (Control) Ordinance, low-strength preparations were banned following unacceptable promotion encouraging their use in children suffering from malnutrition. (Reference: (BGDCO) The Drugs (Control) Ordinance, , , 1982)
FRA	Apr 1998	The Medicines Agency has withdrawn from the market all injectable formulations of the anabolic steroid, following a routine re-evaluation of the benefit/risk ratio showing a lack of clinical data to support the efficacy of the product in the claimed indication (confirmed osteoporosis in postmenopausal women). (Reference: (FRAAMC) Communiqué de Presse, , , 03 Apr 1998)

WHO Comment : Nandrolone decanoate, an anabolic steroid, was introduced in 1962. In 1982, low dosage preparations were prohibited in Bangladesh due to inadmissible promotion of products containing anabolic steroids for malnourished children. Higher dosage preparations of nandrolone decanoate remain available in many countries, including Bangladesh, for several highly specific but limited indications that apply to patients with chronic debilitating and emaciating diseases, particularly associated with neoplasia and some types of aplastic anaemia.

Product Name **Nandrolone phenylpropionate (injectable)**

C.A.S. number **62-90-8**

Scientific and common names, and synonyms

ESTR-4-EN-3-ONE, 17-(1-OXO-3-PHENYLPROPOXY)-, (17BETA)-

NORTESTOSTERONE PHENYLPROPIONATE

NANDROLONE PHENPROPIONATE

17BETA-HYDROXYESTR-4-EN-3-ONE HYDROCINNAMATE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
BGD	1982	Under the provisions of the Drugs (Control) Ordinance, low-strength preparations were banned following unacceptable promotion encouraging their use in children suffering from malnutrition. (Reference: (BGDCO) The Drugs (Control) Ordinance, , , 1982)

WHO Comment : Nandrolone phenylpropionate, an anabolic steroid, was introduced in 1959. In 1982, low dosage preparations were prohibited in Bangladesh due to inadmissible promotion of products containing anabolic steroids for malnourished children. Higher dosage preparations of nandrolone phenylpropionate remain available in many countries, including Bangladesh, for several highly specific but limited indications that apply to patients with chronic debilitating and emaciating diseases, particularly associated with neoplasia and some types of aplastic anaemia.

Product Name **Nebacumab**

Legislative or regulation action

Product Name **Nebacumab**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
@WD	1993	The manufacturer of the human monoclonal HA-1A antibody, nebacumab, has withdrawn the product worldwide following preliminary results of a trial conducted in the United States of America which showed that there was no reduction in mortality in patients treated with nebacumab who had Gram-negative bacteraemia. Furthermore, mortality was increased among patients who did not have Gram-negative bacteraemia receiving nebacumab than among those receiving placebo.

Product Name **Nefazodone**

C.A.S. number **2004-0-0008**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
ESP	01 Mar 2003	Nefazodone suspended due to life-threatening hepatotoxicity. (Reference: (ESPSMA) Communication to WHO, , , 01 Mar 2003)
TUR	21 Mar 2003	The Directorate General of Pharmaceuticals and Pharmacy has decided to suspend the license for nefazodone hydrochloride preparations (Serzone) held by Bristol Meyers Squibb Drugs Inc. in Turkey since the latest data received by the Turkish Ministry of Health as well as worldwide developments that suggest acute hepatic failure associated with nefazodone use. (Reference: (TURDPC) Communication to WHO, , , 21 Mar 2003)
CAN	27 Nov 2003	Sale of nefazodone has been discontinued in Canada due to adverse hepatic events. (Reference: (CANBMS) "Dear Healthcare Professional " letter, , , 02 Oct 2003)
SGP	01 Mar 2004	Withdrawn from the market. (Reference: (SGPHSA) Communication to WHO, , , 01 Mar 2004)

Product Name **Neomycin sulfate**

C.A.S. number **1405-10-3**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
BGD	1982	Under the provisions of the Drugs (Control) Ordinance, this product has been banned since it has been shown to cause malabsorption in children and to be of little or no therapeutic value. (Reference: (BGDCO) The Drugs (Control) Ordinance, , , 1982)
PHL	Jul 1982	All anti-diarrhoeal preparations for oral administration containing this product have been banned. Most cases of diarrhoea have been found to be resistant to the drug and its constant use promotes pseudomembranous colitis in infants and children. Neomycin can cause other serious adverse effects including renal damage, neuro-muscular blockage and ototoxicity, possibly leading to deafness in some patients. (Reference: (PHADO) Administrative Order, 24, , July 1982)
NGA	1983	Because of the risk of bacterial resistance arising from the use of anti-diarrhoeals containing neomycin in small amounts, these products have been withdrawn. (Reference: (NGAPN) Pharmanews, 10(11), 15, 1988)

WHO Comment : Neomycin sulfate, a broad-spectrum antibiotic, was first isolated in 1949 and has subsequently been included in topical, oral and parenteral

Legislative or regulation action

Product Name	Neomycin sulfate	
C.A.S. number	1405-10-3	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		preparations. Its value in the treatment of diarrhoea is widely questioned although it is still contained in a number of widely available antidiarrhoeal preparations. In some countries the officially approved indications for oral preparations are restricted to the preparation of the bowel prior to surgery and the management of hepatic coma.

Product Name	Nevirapine	
C.A.S. number	129618-40-2	
Scientific and common names, and synonyms		
11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',1,3'-E][1,4]DIAZEPIN-6-ONE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
THA	Feb 2001	Precautionary note added about hepatotoxicity. (Reference: (THACW) Communication to WHO, , , 28 Sep 2001)

Product Name	Nialamide	
C.A.S. number	51-12-7	
Scientific and common names, and synonyms		
ISONICOTINIC ACID 2-((2-BENZYL CARBAMOYL)ETHYL)HYDRAZIDE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
JPN	Nov 1974	The Ministry of Health and Welfare withdrew all products containing isocarboxazid and nialamide on the grounds that they lack substantial evidence of efficacy and safety.
IND	1983	Prohibited for manufacture and sale for reasons of health risks associated with use and/or questionable therapeutic value. (Reference: (GAZIE) The Gazette of India: Extraordinary, II-3i, , 23 July 1986)
CUB		Prohibited from use by the National Formulary Commission (1982) on grounds of reported toxicity and in view of the availability of other less toxic drugs.
DNK		Withdrawn from the market by the manufacturer.
SAU		Products now controlled by the authorities.
THA		Products have been banned.
VEN		Banned for use and/or sale.
WHO Comment : Nialamide, a monoamine oxidase inhibitor (MAOI), was introduced in 1959 for the treatment of depressive illness. Subsequently concern regarding potentially serious interactions between MAOIs and foods containing tyramine inspired much restrictive regulatory action. However, MAOIs still retain a place in the treatment of serious depressive illness although there is no international consensus on which compounds should be preferred. Thus nialamide remains available in several countries.		

Product Name	Nifedipine	
Legislative or regulation action		

C.A.S. number	21829-25-4	
Scientific and common names, and synonyms	3,5-PYRIDINEDICARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-4-(2-NITROPHENYL)-, DIMETHYL ESTER	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
AUS	11 Mar 1996	In agreement with the Australian Drug Evaluation Committee, the manufacturer has withdrawn the 10mg capsule formulation of nifedipine, since the tablet formulation has now been approved. This action was based on reports of serious adverse effects related to the more rapid release and higher peak serum concentrations from the capsule formulation. The Committee has deferred its decision on the 5mg capsule for twelve months. (Reference: (AUDEC) Report of the Australian Drug Evaluation Committee, Res No. 5969, , 11 Mar 1996)
IRL	May 1996	Following review and evaluation of data at a national level, the Irish Medicines Board recommends that, regarding ischaemic heart disease the use of nifedipine should be restricted to the prophylaxis of stable angina. Its use is contraindicated in patients with unstable angina. (Reference: (IRDDS) Drug Safety Newsletter, No.2, , May 1996)
JPN	Jul 1996	The Pharmaceutical Affairs Bureau has revised the data sheet for nifedipine, which is now contraindicated in patients with acute myocardial infarction and care is recommended in its administration in patients with unstable angina pectoris. (Reference: (JPNARD) Information on Adverse Reactions to Drugs, No.138, , July 1996)
DEU	1 Jul 1997	See under calcium channel blockers. WHO Comment : Nifedipine is a dihydropyridine calcium channel blocker. It is listed in the WHO Model List of Essential Drugs. The 10mg tablet is retained on the list for short-term treatment of hypertension. Sustained-release preparations are advised for long-term treatment.

Product Name	Nimesulide	
C.A.S. number	51803-78-2	
Scientific and common names, and synonyms	N-(4-NITRO-2-PHENOXYPHENYL)METHANESULFONAMIDE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
ESP	May 2002	The Spanish Committee on Safety of Medicines has recommended the temporary suspension of nimesulide pending evaluation of reports of hepatotoxicity with the drug by the European Agency for the Evaluation of Medicinal Products. (Reference: (ESPCDR) Communication on Drug Risks, No.2002/03, , 03 May 2002)
BGD	11 Jun 2003	The manufacture, distribution, sale and use of all dosage forms of nimesulide paediatric preparations were officially banned in Bangladesh. (Reference: (BGDDDA) Communication to WHO, , , 11 June 2003)

Product Name	Nitrefazole	
C.A.S. number	21721-92-6	
Scientific and common names, and synonyms	2-METHYL-4-NITRO-1-(4-NITROPHENYL)IMIDAZOLE	
Legislative or regulative action		

Legislative or regulation action

Product Name		Nitrefazole
C.A.S. number		21721-92-6
Country	Effective Date	Description of action taken Grounds for decision
DEU	1 Jun 1984	The Federal Health Office has withdrawn nitrefazole following reports of hepatotoxicity.
AUT	Jul 1984	The Federal Ministry of Health and Environmental Protection has withdrawn nitrefazole following reports of hepatotoxicity.
<p>WHO Comment : Nitrefazole, which is used in the treatment of alcoholism, was introduced in the early 1980s. By 1984 its use had been associated with hepatotoxic reactions, some of which were fatal. This led to its withdrawal in at least two countries. WHO has no information to suggest that preparations containing nitrefazole remain commercially available.</p>		

Product Name		Nitrendipine
C.A.S. number		39562-70-4
Scientific and common names, and synonyms		
<p>(+/-)-ETHYLMETHYL-1,4-DIHYDRO-2,6-DIMETHYL-4-(M-NITROPHENYL)-3,5- PYRIDINEDICARBOXYLATE, 3,5-PYRIDINEDICARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-4-(3- NITROPHENYL)-, ETHYL METHYL ESTER, (+/-)</p>		
Legislative or regulative action		

Country	Effective Date	Description of action taken Grounds for decision
AUS		Registration refused on grounds of inadequate data on pharmacokinetics, absolute bioavailability and toxicity, and insufficient clinical data on long-term safety, use in patients with a history of angina and concomitant use with angiotensin-converting enzyme blocking agents and other drugs likely to be taken by the target population. (Reference: (AUDEC) Report of the Australian Drug Evaluation Committee, 133, 06, 1968)

Product Name		Nitrofur
C.A.S. number		59-87-0
Scientific and common names, and synonyms		
<p>5-NITRO-2-FURALDEHYDE SEMICARBAZONE HYDRAZINECARBOXAMIDE, 2-((5-NITRO-2-FURANYL)METHYLENE)- NITROFURAZONE</p>		
Legislative or regulative action		

Country	Effective Date	Description of action taken Grounds for decision
JPN	Jul 1977	A nitrofur compound withdrawn from all marketed preparations in Japan on the grounds that it had been superseded by safer and more effective preparations.
ITA	1983	The following warning has been inserted on the label: "Experimental data on animals recommend the use of the product for systemic route only for short periods and under the physician's guidance".
DEU	May 1992	The indications for products containing nitrofur were restricted to the treatment of furuncles, carbuncles, abscesses, burns, chronic ulcers, mastitis and skin transplants; the use of the drug in trivial infections was approved only when alternative therapeutic interventions had failed and for no longer than is required to assure a satisfactory response. (Reference: (DAZ) Deutsche Apotheker Zeitung, 132(21), VIII, 1992)
<p>WHO Comment : Nitrofur, a nitrofur derivative with broad-spectrum antibacterial activity, was introduced in the early 1940s for the topical treatment of</p>		

Legislative or regulation action

Product Name	Nitrofurural	
C.A.S. number	59-87-0	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		various skin conditions. It has also been used systemically for the treatment of African trypanosomiasis. Following recent findings of in vitro mutagenicity and of carcinogenicity in experimental animals, use of topical preparations containing this substance was restricted in Germany. Nitrofurural remains registered in several countries and the World Health Organization is not aware of restrictive action having been taken elsewhere.
Bibliographical references		
		IARC MONOGRAPH, 50, 195, 1990 WHO FOOD ADD., 31, 125, 1993
Product Name	Nitrofurantoin	
C.A.S. number	67-20-9	
Scientific and common names, and synonyms		
	2,4-IMIDAZOLIDINEDIONE, 1-[5-NITRO-2-FURANYL]METHYLENE[AMINO]-	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	23 Nov 1993	The Drug Commission of the German Medical Profession recommended that the use of preparations containing the nitrofurantoin derivative, nitrofurantoin, be restricted to cases of acute, superficial and uncomplicated infections of the bladder and the urinary tract. This recommendation is based both on evidence of limited efficacy and severe adverse reactions associated with use of these products, including neuropathy, lung reactions and hepatitis. Nitrofurantoin is contraindicated in patients with impaired renal function and in all persons over 60 years of age. Either creatinine serum levels or creatinine clearance should be measured before starting therapy with nitrofurantoin. Fixed combinations of nitrofurantoin with other drugs should be avoided. (Reference: (DEUCDC) Communication, , , 23 Nov 1993)
Product Name	Nitroxoline	
C.A.S. number	4008-48-4	
Scientific and common names, and synonyms		
	5-NITRO-8-QUINOLINOL	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
IRL	1973	The National Drugs Advisory Board has withdrawn nitroxoline from the market. No serious adverse reactions have been reported in human beings, but cataracts have developed in rats in prolonged dosage studies. (Reference: (IRDAB) National Drugs Advisory Board Annual Report, 19, , 1973)
THA	Jan 1975	Registration permit has been revoked for pharmaceutical preparations containing this ingredient.
VEN		Not approved for use and/or sale.
WHO Comment : Nitroxoline, a urinary antiseptic, was introduced in the mid-1960s. By the early 1970s long-term animal studies revealed the development of cataracts in rats and, although no serious adverse effects had been reported in man, the drug was withdrawn in at least two countries. Preparations containing nitroxoline		

Legislative or regulation action

Product Name	Nitroxoline	
C.A.S. number	4008-48-4	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		remain widely available.

Product Name	Nomifensine	
C.A.S. number	24526-64-5	
Scientific and common names, and synonyms		
	8-ISOQUINOLINAMINE, 1,2,3,4,-TETRAHYDRO-2-METHYL-4-PHENYL, 8-AMINO-1,2,3,4-TETRAHYDRO-2-METHYL-4-PHENYLISOQUINOLINE	
Legislative or regulative action		

Country	Effective Date	Description of action taken Grounds for decision
@WD	Jan 1986	The antidepressant nomifensine has been withdrawn worldwide by the major manufacturer following reports of cases of haemolytic anaemia associated with its use, some of which were fatal.
DEU	Jan 1986	Withdrawn from the market by the major manufacturer following reports of cases of haemolytic anaemia associated with its use.
GBR	Jan 1986	Withdrawn from the market by the major manufacturer following reports of cases of haemolytic anaemia associated with its use.
		WHO Comment : Nomifensine, an antidepressant indicated for the treatment of a wide range of depressive illness, was introduced in 1976. Subsequently rare cases of haemolytic anaemia - sometimes fatal - thrombocytopenia, hepatotoxicity and fever were associated with the use of the drug. Following discussions with regulatory authorities in the United Kingdom and the Federal Republic of Germany the major manufacturer withdrew all preparations containing nomifensine worldwide in January 1986.

Product Name	Norethisterone enantate (injectable)	
C.A.S. number	3836-23-5	
Scientific and common names, and synonyms		
	NORETHINDRONE 19-NORPREGN-4-EN-20-YN-3-ONE, 17-HYDROXY-, (17ALPHA)- 17-HYDROXY-19-NOR-17ALPHA-PREGN-4-EN-20-YN-3-ONE	
Legislative or regulative action		

Country	Effective Date	Description of action taken Grounds for decision
DEU	1983	The use of injectable steroid preparations for contraceptive purposes has been restricted to use by women with a normal menstrual cycle who do not tolerate other forms of contraception. Pregnancy must be excluded before treatment is started and it is contraindicated during lactation. The label must bear a warning about adverse effects including menstrual disturbances and headaches.
		WHO Comment : Norethisterone enantate was introduced in 1978 for use as a long-acting injectable contraceptive. Risk-benefit judgements differ significantly from country to country, having regard to differing national circumstances. Norethisterone enantate is, however, widely available and is included as a complementary drug in the WHO Model List of Essential Drugs. (Reference: (WHODI) WHO Drug Information, 2(1), , 1988)

Legislative or regulation action

Product Name	Norethisterone enantate (injectable)	
C.A.S. number	3836-23-5	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
Product Name	Noscapine	
C.A.S. number	128-62-1	
Scientific and common names, and synonyms		
NARCOTINE		
1(3H)-ISOBENZOFURANONE, 6,7-DIMETHOXY-3-(5,6,7,8-TETRAHYDRO-4-METHOXY-6-METHYL-1,3-DIOXOLO[4,5-G]-ISOQUINOLIN-T-YL), [S-(R*,S*)]		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
IRL	1990	The National Drugs Advisory Board has recommended that antitussives containing the opioid, noscapine, should not be approved for use in children. (Reference: (IRDAB) National Drugs Advisory Board Annual Report, , 27, 1990)
DEU	1991	The approved information of products containing noscapine was amended to state that pregnancy must be excluded before treatment is instituted; conception should be avoided during treatment; and breastfeeding should be discontinued until 24 hours after treatment. These amendments were made in view of the mutagenic potential of noscapine. (Reference: (DAZ) Deutsche Apotheker Zeitung, 131(36), VI, 1991)
GBR	1991	Cough mixtures containing noscapine were voluntarily withdrawn by the manufacturer and all other noscapine products were placed under prescription control, following concern that the drug may be genotoxic. In addition, the manufacturer reformulated preparations containing papaveretum to exclude noscapine. (Reference: (GBRPHJ) The Pharmaceutical Journal, , 783, 14 Dec 1991) (Reference: (GBRCSM) Committee on Safety of Medicines, Current problems, 31, , June 1991)
NLD	1991	Following discussions with the Board for the Evaluation of Medicines, manufacturers and importers discontinued marketing of products containing noscapine, having regard to their mutagenic potential. Extemporaneous preparations containing noscapine remained available on medical prescription and with an absolute contraindication for pregnant women. (Reference: (GENMB) Geneesmiddelenbulletin, 25/9, 34, 1991)
MYS	Jan 1992	The Drug Control Authority has issued a warning to all prescribers that noscapine has been shown to exert a mutagenic effect in vitro. Its use is contraindicated in women of childbearing potential. (Reference: (MYSDN) Berita Ubat-Ubatan (Drug Newsletter), 6(2):2, , 1992)
WHO Comment : Noscapine, a centrally-acting cough suppressant and one of several alkaloids present in papaveretum (opium concentrate) was introduced into medicine many years ago. Subsequently, it was shown to increase the number of chromosomes in mammalian cell lines maintained in vitro. Although the clinical significance of this finding is uncertain, restrictive action was taken in a few countries since the possibility of a genotoxic effect cannot be excluded. On 4 December 1992 the European Committee on Proprietary Medicinal Products concluded that the available evidence does not indicate that use of noscapine holds any significant hazard. The Swedish Medical Products Agency also concluded that there is no justification to restrict the use of noscapine in women of childbearing age.		

Legislative or regulation action

Product Name	Novobiocin	
C.A.S. number	303-81-1	
Scientific and common names, and synonyms	BENZAMIDE,N-(7-((3-O-(AMINOCARBONYL)-6-DEOXY-5-C-METHYL-4-O-METHYL-BETA-L-LYXO- HEXOPYRANOSYL)OXY)-4-HYDROXY-8-METHYL-2-OXO-2H-1-BENZOPYRAN-3-YL)-4-HYDROXY-3-(3-METHYL-2- BUTENYL)- STRETONOVICIN	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
MYS	Jul 1987	All products containing novobiocin may not be registered. (Reference: (MYSDC) Malaysian Drug Control Authority, No.11, , July 1987) WHO Comment : Novobiocin, an antibiotic with a narrow spectrum of activity, was introduced in 1956. Its use was subsequently associated with serious adverse effects including blood dyscrasias. In view of its toxicity there are no current valid indications for its use. Although preparations containing novobiocin may remain available in some countries it has largely lapsed into disuse.
Product Name	Omeprazole	
C.A.S. number	73590-58-6	
Scientific and common names, and synonyms	1H-BENZIMIDAZOLE, 5-METHOXY-2-[[[(4-METHOXY-3,5-DIMETHYL-2-PYRIDINYL)METHYL]SULFINYL]-	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	11 Aug 1995	The German Federal Health Office has suspended marketing authorization for bolus injection formulations of pharmaceutical products containing the proton pump inhibitor, omeprazole, from 2 August 1994. The revocation of marketing authorization took effect from 31 July 1995. The other parenteral dosage formulation (infusion) and the oral dosage formulation may still be marketed with revised product information listing visual and auditory adverse reactions. (Reference: (DEUCFI) Communication, 2-Aug-94, 31-May-9, 11 Aug 1995) WHO Comment : Omeprazole was introduced in the 1980s. It belongs to a group of agents that have an inhibitory effect on the secretion of hydrochloric acid in the stomach (gastric acid proton pump inhibitors) and is used in the treatment of upper gastrointestinal tract disorders. The Committee for Proprietary Medicinal Products of the European Commission has concluded that a causal association between the reactions reported in Germany and the use of omeprazole had not been established. Nevertheless oral administration should be preferred. (Reference: (CPMPPO) Pharmacovigilance Opinion, No.16 , , 25 July 1994)
Product Name	Opium in antitussive preparations	
C.A.S. number	8008-60-4	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
BGD	Jun 1982	Banned in tincture and spirit form due to its liability for addiction and misuse.
ITA		This substance for use as an antitussive has been removed from the market owing to an unfavourable risk-benefit ratio and lack of substantial evidence of efficacy. WHO Comment : Opium, which is extracted from the unripe seed capsules of the

Legislative or regulation action

Product Name	Opium in antitussive preparations	
C.A.S. number	8008-60-4	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		poppy plant, has been used throughout recorded history both in a medicinal and recreational context. Of the pharmacologically active constituents, several alkaloids, including morphine, codeine, papaverine and noscapine, have wide clinical use. Opium produces both physical and psychological dependence and is controlled under Schedule I of the 1961 Single Convention on Narcotic Drugs. (Reference: (UNSD) United Nations Single Convention on Narcotic Drugs I, , 1972)
Product Name	Oral rehydration salts	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
NPL	2 Jul 1986	Import, sale and distribution of oral rehydration salts which do not comply with WHO recommendations are prohibited.
OMN	Aug 1988	Import and marketing of oral rehydration salts which do not comply with the WHO/UNICEF formula were prohibited. (Reference: (OMNCR) Circular, 21/88, , June 1988)
Product Name	Orgotein	
C.A.S. number	9016-01-7	
Scientific and common names, and synonyms		
BOVINE SUPEROXIDE DISMUTASE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
CHE	May 1990	The marketing authorization for products containing orgotein has been withdrawn, on the grounds that a great number of anaphylactic reactions associated with their use has been reported, particularly in the Federal Republic of Germany, and that they are of questionable efficacy in some of the indications claimed by the manufacturers. (Reference: (CHBCM) Bulletin Mensuel, 8, , 24 Sep 1990)
DEU	25 Mar 1994	The Federal Health Office has suspended as from 25 March 1994 the marketing authorization for pharmaceutical products containing orgotein on the grounds that unjustifiable risk outweighs the benefits. The Agency has received about 400 reports of adverse reactions - 90 of these reports describe serious hypersensitivity reactions, some of which were fatal. (Reference: (DEUPD) BGA Pressedienst, 19/1994, , 30 Mar 1994)
PRT	20 May 1994	The Ministry of Health has suspended the marketing authorization for medicines containing orgotein (bovine superoxide dismutase) for a period of 90 days. The products, which are indicated for the treatment of rheumatic conditions, radiation-induced cystitis and interstitial cystitis, have been associated with severe adverse effects, including hypersensitivity reactions. (Reference: (PRTOC) Official Communication: Suspension of medicines containing orgotein, , , 20 May 1994)
WHO Comment : Orgotein, bovine superoxide dismutase with anti-inflammatory activity, was introduced in 1968 for the management of rheumatic disorders and for		

Legislative or regulation action

Product Name **Orgotein**

C.A.S. number **9016-01-7**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
		the amelioration of side-effects of radiotherapy. Although not widely registered, it remains available in other countries.

Product Name **Oxeladin**

C.A.S. number **468-68-1**

Scientific and common names, and synonyms

2-(2-DIETHYLAMINOETHOXY)ETHYL 2-ETHYL-2-PHENYLBUTYRATE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
DEU	14 Mar 1994	The Institute has issued a Rapid Alert to all the pharmaceutical companies concerned requesting their comments on a graduated plan of withdrawal of marketing authorizations for all medicinal products containing oxeladin pending further studies on the carcinogenicity of the product. (Reference: (DEURFI) Rapid Alert - Pharmacovigilance, , , 14 Mar 1995)
FRA	19 Apr 1995	Since the results of the German study on the potential carcinogenicity of oxeladin were disseminated, the Medicinal Products Agency has recalled all batches of pharmaceutical products containing, oxeladin (Paxeladine®: Beaufour). (Reference: (FRAAMN) Notification, , , 19 Apr 1995)

Product Name **Oxeladin citrate**

C.A.S. number **52432-72-1**

Scientific and common names, and synonyms

2-(2-DIETHYLAMINOETHOXY)ETHYL 2-ETHYL-2-PHENYLBUTARATE DIHYDROGEN CITRATE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
ARM	Jul 2000	The Drug and Medical Technology Agency rejected the registration of oxeladin since studies in Germany have shown potential carcinogenicity of the drug. (Reference: (ARMCW) Communication to WHO, , , 09 Aug 2000)

Product Name **Oxyphenbutazone**

C.A.S. number **129-20-4**

Scientific and common names, and synonyms

BUTANOVA
HYDROXYPHENYLBUTAZONE
HYDROXYPHENBUTAZONE
OXAZOLIDIN
3,5-PYRAZOLIDINEDIONE, 4-BUTYL-1-(4-HYDROXYPHENYL)-2-PHENYL-
4-BUTYL-1-(P-HYDROXYPHENYL)-2-PHENYL-3,5-PYRAZOLIDINEDIONE

Legislative or regulative action

Legislative or regulation action

Product Name		Oxyphenbutazone	
C.A.S. number		129-20-4	
Country	Effective Date	Description of action taken Grounds for decision	
JPN	Jul 1977	Indications are restricted to acute exacerbations of rheumatoid arthritis and osteoarthritis. Doctors are advised to prescribe this drug only to adults and for periods of no longer than one week.	
AUT	1984	Indications are restricted to exacerbations of gout and other arthritic conditions. Treatment should not exceed seven days and doctors are advised not to prescribe this drug to children under 14 years of age or elderly patients. (Reference: (WIMAM) Wichtige Mitteilung ueber Arzneimittel, (1), , 1984)	
CYP	1984	Withdrawn from the market due to the potential to cause serious adverse reactions. Exemption applies for products intended for local ophthalmic use.	
FIN	1984	Oral and rectal preparations have been withdrawn from the market.	
IRL	1984	Approved indications for phenylbutazone and oxyphenbutazone revised: now restricted to cases of acute gout, ankylosing spondylitis, and chronic arthritis in patients unsuited to alternative therapy. Treatment of acute gout should not extend beyond 7-10 days and the lowest effective dose should be used. Treated arthritic patients should remain under regular surveillance and specialist supervision. Doctors are advised not to prescribe these drugs for children or pregnant women and to reduce the dose in elderly patients. Certain contraindications include previous or existing gastrointestinal disease, blood dyscrasias, hepatic or renal dysfunction, cardiac or pulmonary insufficiency, thyroid or salivary gland disorders or hypersensitivity. Combination products with other active ingredients have been withdrawn from use.	
TUN	1984	All preparations of oxyphenbutazone have been banned for use.	
ARE	19 Mar 1984	Pharmaceutical preparations containing oxyphenbutazone are banned. (Reference: (UAEMD) Ministry of Health Decree, No.480, , 1984)	
KWT	Apr 1984	Approved indications have been restricted to ankylosing spondylitis and acute gout and oxyphenbutazone should not be dispensed without a prescription. (Reference: (KTMD) Ministerial Decree, 160/84, , 1984)	
BRB	25 Jun 1984	Indications for oxyphenbutazone are limited to active ankylosing spondylitis, gout and pseudo-gout. It may also be used to treat acute exacerbations of rheumatoid arthritis and osteoarthritis and acute non-articular rheumatoid disease unresponsive to other non-steroidal anti-inflammatory drugs.	
ZWE	Jul 1984	The Drugs Control Council requested manufacturers to withdraw preparations containing oxyphenbutazone from the market and to exhaust stocks by June 1985. (Reference: (ZWDCC) Drugs Control Council, News Bulletin, , , 1985)	
ESP	15 Jul 1984	Approved indications have been restricted to inflammatory arthritic conditions, active ankylosing spondylitis and other inflammatory spondylopathies, acute attacks of gout and pseudo-gout, acute exacerbations of rheumatoid arthritis and other polyarthritic conditions. Parenteral preparations have been restricted to hospital use only.	
JOR	1 Oct 1984	Registration of all pharmaceutical products containing oxyphenbutazone has been withdrawn. (Reference: (JORMH) Ministry of Health Resolution, No.4/2/1559, , Apr 1984)	
BGD	Nov 1984	Use has been banned due to reported severe adverse reactions.	
DEU	1985	Indications are restricted to severe exacerbations of rheumatism and acute gout. Duration of oral treatment should not exceed one week. Parenteral preparations are indicated only for initiating therapy. A single injection only is recommended because local tissue damage may occur. Preparations are contraindicated in children under 14 years of age.	
ETH	1985	Banned from the market due to reported serious adverse reactions.	
GRC	1985	Withdrawn from the market.	
NLD	1 Jan 1985	Parenteral dosage forms and combination products containing oxyphenbutazone have	

Legislative or regulation action

Product Name Oxyphenbutazone

C.A.S. number 129-20-4

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
		been withdrawn from the market. The approved indications have been restricted to the treatment of spondyloarthritis unresponsive to other non-steroidal anti-inflammatory agents. (Reference: (NETJAN) Nederlands Tijdschrift voor Geneeskunde, 128(50), , 1984)
SWE	1 Jan 1985	Withdrawn from the market after joint discussions between the National Board of Health and Welfare and the importer on the grounds of serious blood dyscrasias associated with its use.
NZL	Apr 1985	Voluntarily withdrawn from the market.
CHL	4 Jun 1985	Preparations containing oxyphenbutazone have been prohibited. (Reference: (CHLRS) Resolution of the Minister of Health, No. 2660, , Apr 1984)
GHA	1986	Use of oxyphenbutazone has been banned.
OMN	1986	Oxyphenbutazone for internal use (tablets, injections, syrups and suppositories) should neither be imported nor marketed after the stock in the local market has been used.
TUR	1 Mar 1986	The Ministry of Health has prohibited the manufacture and sale of preparations containing oxyphenbutazone for oral, rectal and topical use.
MYS	Jan 1987	All products containing oxyphenbutazone have been withdrawn. (Reference: (MYSDC) Malaysian Drug Control Authority, No.6, , Oct 1986)
HKG	1 Sep 1987	The Pharmacy and Poisons Committee no longer allows the registration, sale or distribution of products containing oxyphenbutazone.
BEL	1 Jan 1988	Preparations containing oxyphenbutazone have been placed in List IV of the Arrêt, du R,gent of 2 June 1946 and as such can be administered only on prescription. They must be kept in a poisons cabinet and carry the skull and cross-bones label. (Reference: (BELAR) Arrêté Royal, , , June 1987)
LKA	1 Jan 1992	The Ministry of Health withdrew from sale pharmaceutical products containing oxyphenbutazone (tablet formulation). This action was based on the potential of these products to induce suppression of the bone marrow. (Reference: (LKADIB) Drug Information Bulletin, University of Peradeniya and Ministry of Health, 41(1), , 1992)
BHR		Preparations containing oxyphenbutazone have been withdrawn.
COG		Injectable preparations have been withdrawn from the market. Oral preparations have indications restricted to the treatment of ankylosing spondylitis, gout and periarticular rheumatism.
GBR		All product licences for preparations containing oxyphenbutazone have been revoked with the exception of those for eye ointments.
HUN		Indications are restricted to ankylosing spondylitis and related diseases, acute gout attacks, acute exacerbations of rheumatoid arthritis and inflamed osteoarthritis. The duration of treatment is restricted to 14 days. There is only one registered preparation containing oxyphenbutazone; its dispensing is restricted to individual cases authorized by the Ministry of Health at special request.
ISR		The pharmaceutical administration of the Ministry of Health withdrew from use all preparations containing oxyphenbutazone.
		WHO Comment : Oxyphenbutazone, a pyrazolone derivative with anti-inflammatory, analgesic and antipyretic activity, was introduced in 1955 for the treatment of rheumatic disorders. It is one of the active metabolites of phenylbutazone and has a similar spectrum of activity including an association with serious and sometimes fatal adverse reactions, notably cases of aplastic anaemia and agranulocytosis. Many national drug regulatory authorities consider that more recently introduced

Legislative or regulation action

Product Name	Oxyphenbutazone	
C.A.S. number	129-20-4	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		drugs offer a safer alternative for most, if not all, patients requiring antiinflammatory agents. Although oxyphenbutazone has been widely withdrawn it remains available in some countries.

Product Name	Oxyphenisatine acetate	
C.A.S. number	115-33-3	
Scientific and common names, and synonyms		
	ACETPHENOLISATIN	
	BISATIN	
	DIPHESATIN	
	DIASATIN	
	DIACETYLDIPHENOLISATIN	
	DIACETOXYDIPHENYLISATIN	
	ISAPHENIN	
	OXYPHENISATIN DIACETATE	
	PHENLAXINE	
	2H-INDOL-2-ONE,3,3-BIS(4-ACETYLOXY)PHENYL)-1,3-DIHYDRO-	
	3,3-BIS(P-HYDROXYPHENYL)-2-INDOLINONE DIACETATE	

Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
CUB	1970	Banned for use following reports of hepatotoxicity.
AUS	1972	The Department of Health of the Commonwealth withdrew from the market all preparations containing oxyphenisatine acetate (diacetoxydiphenolisatin) and triacetyldiphenolisatin. This recommendation was based on an increasing number of reports, including one fatality, implicating these compounds as a cause of acute and chronic liver disease.
USA	Feb 1972	Preparations for oral or rectal use withdrawn by the Food and Drug Administration (oral preparations withdrawn 2/72; rectal preparations withdrawn 3/73) on grounds of safety considerations. After a review of the clinical evidence, the FDA concluded that in view of the hazards associated with the use of these drugs, including hepatitis and jaundice, and the availability of alternative drugs having a wider margin of safety, the benefit/risk ratio did not justify their continued marketing. (Reference: (FEREAC) Federal Register, 38, 6419, Mar 1973)
JPN	Mar 1972	Banned by the Pharmaceutical Affairs Bureau in over-the-counter drugs, due to hepatic damage (e.g. jaundice) observed with long-term use.
NOR	1974	Withdrawn from the market.
DNK	Oct 1975	Registration for these products has been cancelled. (Reference: (DENBH) Danish National Board of Health, Circular Letter, , , July 1985)
DEU	1976	Withdrawn following a review of published cases of acute and chronic liver disease.
ITA	1976	Preparations for oral, rectal and topical use have been withdrawn from the market due to the risk of sensitization.
AUT	Mar 1977	Withdrawn by the Federal Ministry of Health and Environmental Protection following reports of cases of acute and chronic liver disease associated with this drug.

Legislative or regulation action

Product Name	Oxyphenisatine acetate	
C.A.S. number	115-33-3	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GBR	1978	All products containing this substance have been withdrawn except for rectal suppositories for single-dose use.
CAN	1 Jul 1978	All preparations containing this substance have been withdrawn from sale. (Reference: (CANGZ) Canada Gazette, 113/(10), , 1979)
FRA	30 Mar 1979	The Commission on Drug Monitoring of the Ministry of Health has called for the exclusion of oxyphenisatine from proprietary laxative products, having regard to the established relationship between this substance and chronic hepatic damage.
KWT	Jan 1980	The importation of oxyphenisatine and related compounds is prohibited.
BEL	14 Jan 1981	Pharmaceutical preparations containing oxyphenisatine acetate are prohibited. (Reference: (BELAR) Arrêté Royal, , , Jan 1981)
MUS	9 Mar 1982	Under the Pharmacy and Poisons (Prohibitions of Harmful Drugs) Regulations, this drug is deemed "harmful" by the Ministry of Health and is prohibited for import, manufacture, storage, distribution, sale, possession, use, export or other transaction. (Reference: (MPPHD) Pharmacy & Poisons (Prohibitions of Harmful Drugs) Regulations, , , Mar 1982)
ESP	1 Mar 1985	Products containing oxyphenisatine have been withdrawn from the market because of its potential to induce hepatitis. (Reference: (ESPMC) Programa Selectivo de Revisión de Medicamentos, , , 1985)
CYP		Products containing oxyphenisatine acetate have been withdrawn having regard to the risk of liver damage in patients receiving this drug.
NLD		Products containing oxyphenisatine have been withdrawn from the market.
NZL		Voluntarily withdrawn from the market.
VEN		Not approved for use and/or sale.
WHO Comment : Oxyphenisatine acetate was widely used as a laxative after its cathartic activity was first described in 1925. In 1969 its use was first associated with cases of acute and chronic liver disease. This association is considered by some, but not all, national drug regulatory authorities to warrant the withdrawal from the market of preparations containing oxyphenisatine and its derivatives.		

Product Name	Oxytocin	
C.A.S. number	50-56-6	
Scientific and common names, and synonyms	L-CYSTEINYL-L-TYROSYL-L-ISOLEUCYL-L-GLUTAMINYL-L-ASPARGINYL-L-CYSTEINYL-L-PROLYL-LEUCYLGLYCINAMIDE CYCLIC (1 6) -DISULFIDE LEUCYLGLYCINAMIDE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
MUS		Oxytocin injections have been restricted for use only in public and private hospitals with maternity units and will no longer be available in retail pharmacies.

Product Name	Pangamic acid	
C.A.S. number	13149-68-3	
Scientific and common names, and synonyms		

Legislative or regulation action

Product Name	Pangamic acid	
C.A.S. number	13149-68-3	
Scientific and common names, and synonyms	GLUCONIC ACID 6-BIS(N-DI-ISOPROPYLAMINO)ACETATE VITAMIN B15	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GRC	1984	Withdrawn from the market having regard to its low benefit to risk ratio (mutagenicity). WHO Comment : Pangamic acid, which is extracted from apricot kernels and rice bran, has been described as Vitamin-B15. Although there is no evidence that it is a vitamin, it remains available in some preparations sold in health food stores.
Product Name	Paracetamol	
C.A.S. number	103-90-2	
Scientific and common names, and synonyms	ACETAMINOPHEN ACETAMIDE, N-(4-HYDROXYPHENYL)- P-(ACETYLAMINO)PHENOL	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
THA	Feb 1994	The Ministry of Public Health has revised the product information for pharmaceutical products containing paracetamol to include a warning on hepatotoxicity if used over the recommended doses or prolonged use of more than five days. Patients with impaired hepatic or kidney function should consult their doctors or pharmacists before receiving the drug. (Reference: (THAFDA) Communication to WHO, , , 04 Feb 1994)
MYS	Nov 1996	The Drug Control Authority has decided to cancel the registration of all paracetamol 500-mg/5ml liquid preparations due to cases of overdosage in children associated with the use of paracetamol 500-mg/5ml instead of the 120-mg/5ml preparation. (Reference: (MYSDI) Berita Ubat-Ubat (Drug Information), 10(3): 11, , 1996)
GBR	Apr 1997	The Medicines Control Agency has proposed to restrict pack sizes of paracetamol and set a maximum that pharmacists are allowed to sell, because of the risk of overdosage. No changes are proposed for packs of effervescent tablets, granules or liquid products for general sale. (Reference: (GBRPHJ) The Pharmaceutical Journal, Vol.256, p.785, 30 Nov 1996)
THA	Feb 2001	Precautions in children's dosage for paracetamol drop formulation have been revised. (Reference: (THACW) Communication to WHO, , , 28 Sep 2001) WHO Comment : Paracetamol, a widely used analgesic and antipyretic is known, in case of overdose, to cause liver damage, frequently with fatal outcome. In recommended dosages this risk does not occur. Paracetamol is listed in the WHO Model List of Essential Drugs.
Product Name	Paromomycin	
C.A.S. number	7542-37-2	
Scientific and common names, and synonyms	D-STREPTAMINE,O-2-AMINO-2-DEOXY-ALPHA-D-GLUCOPYRANOSYL-1(1-->4)-O-[O-2,6-DIAMINO-2,6-DIDEOXY-BETA-L-IDOPYRANOSYL-(1-->3)-BETA-D-RIBOFURANOSYL-(1-->5)]-2-DEOXY-	

Legislative or regulation action

Product Name	Paromomycin	
C.A.S. number	7542-37-2	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
ESP	1989	All parenteral forms of preparations containing paromomycin have been withdrawn, having regard to their unacceptably high toxicity. (Reference: (ESPINS) Información Terapéutica de la Seguridad Social, 13(1), 7, 1989) WHO Comment : Paromomycin, an aminoglycoside antibiotic was introduced into medicine in 1959 for the treatment of protozoal, helminthic and bacterial infections. It has been associated, particularly when used by parenteral route, with severe adverse effects including renal damage, neuromuscular blockage and ototoxicity, possibly leading to deafness in some patients. This route of administration is now considered obsolete. However, parenteral dosage forms of paromomycin may still remain available in certain countries.
Product Name	Paroxetine	
C.A.S. number	2004-0-0010	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GBR	10 Jun 2003	The CSM has advised that paroxetine should not be used in children and adolescents under the age of 18 years to treat depressive illness, due to its unfavourable risk benefit ratio. (Reference: (GBRLFC) Letter from the Chairman, , , 10 June 2003)
Product Name	Pectin	
C.A.S. number	9000-69-5	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
LIY	May 1990	The use of pectin for children was banned. (Reference: (LIYRL) Resolution of the General People's Health Committee, 141, , 21 May 1990)
IND	11 Feb 1991	The Central Government banned the manufacture and sale of combinations of fixed doses of pectin with any other drug. (Reference: (INDC) Drugs Controller, , , Mar 1992)
LKA	1 Jan 1992	The Ministry of Health withdrew from sale all liquid preparations containing pectin. Pectin is of doubtful efficacy in the management of diarrhoea and its use may lead to increased salt and water loss. (Reference: (LKADIB) Drug Information Bulletin, University of Peradeniya and Ministry of Health, 4(1), , 1992) WHO Comment : Pectin is a purified carbohydrate product isolated from the rinds of citrus fruits or green apples. Its major constituent is polygalacturonic acid, and it is almost completely digested and absorbed in the intestine. Pectin became popular as a simple remedy for diarrhoea in the early 1900s. It does not affect the frequency of stool or stool weight. Use of such products diverts attention away from more important aspects of treatment, such as rehydration, proper nutrition and in the case of cholera and dysentery, appropriate antibiotics.

Legislative or regulation action

Product Name	Pemoline	
C.A.S. number	2152-34-3	
Scientific and common names, and synonyms	4(5H)-OXAZOLONE, 2-AMINO-5-PHENYL-	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
ARG	Nov 1996	The Administración Nacional de Medicamentos, Alimentos y Tecnología Médica has restricted the use of pemoline to special prescription control. Pemoline in combination with other agents will be supplied under official prescription. The action has been taken because pemoline has been used for a variety of indications without medical supervision. (Reference: (ARGBO) Boletín oficial, No.28.516, , 06 Nov 1996)
USA	Mar 1997	The manufacturer of the central stimulant, pemoline, has revised the product labelling to include a boxed warning describing liver failure and to indicate that pemoline should not ordinarily be considered as a first-line drug therapy for attention-deficit hyperactivity disorder. (Reference: (FDAMB) FDA Medical Bulletin, , p.6, Mar 1997) WHO Comment : Pemoline was introduced in 1975 for the treatment of attention-deficit disorder. Because of its central stimulating effects it has also been used in weight control in combination with anorectic agents, laxatives.
Product Name	Pentazocine	
C.A.S. number	359-83-1	
Scientific and common names, and synonyms	(2R*,6R*,11R*)-1,2,3,4,5,6-HEXAHYDRO-6,11-DIMETHYL-3-(3-METHYL-2-BUTENYL)-2,6-METHANO-3-BENZAZOCIN-8-OL 2,6-METHANO-3-BENZAZOCIN-8-OL, 1,2,3,4,5,6-HEXAHYDRO-6,11-DIMETHYL-3-(3-METHYL-2-BUTENYL)-, (2ALPHA,6ALPHA-11R*)-	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
AUT		Subjected to control at national level analogous to that provided by Schedule I of the 1961 Single Convention on Narcotic Drugs. WHO Comment : Pentazocine, which has both agonist and weak opioid antagonist activity, was introduced in 1967 for the treatment of moderate and severe pain. The risk of drug dependence is lower with pentazocine than with morphine-like drugs and pentazocine has been controlled under Section III of the 1971 Convention on Psychotropic Substances since 1984. The risk of dependence is now widely acknowledged to exist in vulnerable individuals and at least one country has applied controls analogous to those of Schedule I of the 1961 Single Convention on Narcotic Drugs. (Reference: (UNCPS3) United Nations Convention on Psychotropic Substances (III), , , 1971)
Product Name	Pentobarbital	
C.A.S. number	76-74-4	
Scientific and common names, and synonyms	5-ETHYL-5-(1-METHYLBUTYL)BARBITURIC ACID PENTOBARBITONE 2,4,6-(1H,3H,5H)-PYRIMIDINETRIONE, 5-ETHYL-5-(1-METHYLBUTYL)-	
Legislative or regulative action		

Legislative or regulation action

Product Name	Pentobarbital	
C.A.S. number	76-74-4	
Country	Effective Date	Description of action taken Grounds for decision
SWE	Jul 1985	Withdrawn following discussions between the manufacturer and the National Board of Health and Welfare. Fatal intoxications and abuse are associated with use of preparations containing pentobarbital. WHO Comment : Pentobarbital is a short-acting barbiturate which is controlled under Schedule III of the 1971 Convention on Psychotropic Substances. See WHO comment for barbiturates. (Reference: (UNCPS3) United Nations Convention on Psychotropic Substances (III), , , 1971)

Product Name	Pentosan polysulfate sodium	
C.A.S. number	116001-96-8	
Scientific and common names, and synonyms		
SODIUM XYLANPOLYSULPHATE SODIUM PENTOSAN POLYSULPHATE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
FRA	Aug 1994	The Medicines Agency has withdrawn the product licences for injectable and tablet formulations of the antithrombotic agent, pentosane polysulfate sodium, citing its unfavourable risk/benefit profile, and particularly reports of thrombocytopenia associated with its use. (Reference: (FRAAMN) Notification, , , Aug 1994)

Product Name	Pexiganan	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
USA	Mar 2000	The Food and Drug Administration has not approved marketing of the topical anti-infective agent pexiganan acetate on the grounds that efficacy has not been sufficiently demonstrated. (Reference: (USADAC) The US FDA's Anti-infective Drugs Advisory Committee, , , 04 Mar 2000)

Product Name	Phenacetin	
C.A.S. number	62-44-2	
Scientific and common names, and synonyms		
ACETOPHENETIDIN ACETOPHENETHIDINE ACETAMIDE, N-(4-ETHOXYPHENOL)- N-(4-ETHOXYPHENYL) ACETAMIDE P-ACETOPHENETIDIDE		
Legislative or regulative action		

Legislative or regulation action

Product Name		Phenacetin	
C.A.S. number		62-44-2	
Country	Effective Date	Description of action taken Grounds for decision	
FIN	1965	Prohibited due to the well-documented association between its long-term use and nephropathy.	
CAN	1973	No manufacturer or importer shall sell a drug that contains phenacetin in combination with any salt or derivative of salicylic acid. (Reference: (CANGZ) Canada Gazette, , , June 1973)	
ITA	1973	Withdrawn from the market due to suspected liver and kidney toxicity.	
KWT	1973	Preparations containing phenacetin in combination with salicylates are no longer allowed. (Reference: (KTMD) Ministerial Decree, No.53, , 1973)	
NZL	1974	Phenacetin was scheduled as a prescription drug in 1974, and was subsequently voluntarily withdrawn.	
NGA	Mar 1978	Prohibited for import, distribution and sale based on a survey and review of the literature, and clinical and experimental data regarding toxic effects on the kidney and liver.	
CYP	1979	The Drug Council decided to withdraw all products containing phenacetin and its derivatives having regard to the risk of liver damage in patients receiving this drug.	
YEM	1979	Preparations containing phenacetin have been withdrawn.	
PHL	Jun 1980	Phenacetin-containing drugs are no longer registrable due to the risk of developing methaemoglobinaemia.	
GBR	27 Mar 1980	The Phenacetin Prohibition Order has prohibited the sale, supply or importation of any medicinal product containing phenacetin. Certain exemptions may apply. (Reference: (GBPHA) Phenacetin Prohibition Order, 1181, , 1979)	
ISR	1981	The sale of analgesic combination products containing phenacetin has been prohibited. Paracetamol has been recommended as a substitute for phenacetin.	
NOR	1981	Withdrawn from the market.	
ARE	9 Jun 1981	Pharmaceutical preparations containing phenacetin are banned. (Reference: (UAEMD) Ministry of Health Decree, No.694, , 1981)	
BRA	27 Nov 1981	Products containing phenacetin are prohibited. (Reference: (BRAPT) Portaria do Servico Publico Federal, No.23, , Nov 1981)	
ROM	1982	The Minister of Health has recommended the gradual reduction in the use of this product until it has been phased out of use completely.	
TUR	1982	Preparations containing phenacetin in combination with analgesics and antipyretics have been withdrawn by the Ministry of Health with the recommendation that such formulations be changed, due to the risk of nephropathy from long-term use. Export of this product is prohibited.	
BGD	Mar 1982	Under the provisions of the Drugs (Control) Ordinance, this product has been banned, since the phenacetin component is toxic and liable to be abused. (Reference: (BGDCO) The Drugs (Control) Ordinance, , , 1982)	
MUS	9 Mar 1982	Under the Pharmacy and Poisons (Prohibitions of Harmful Drugs) Regulations, this drug is deemed "harmful" by the Ministry of Health and is prohibited for import, manufacture, storage, distribution, sale, possession, use, export or other transaction. (Reference: (MPPHD) Pharmacy & Poisons (Prohibitions of Harmful Drugs) Regulations, , , Mar 1982)	
SWE	Jul 1982	Banned for use and/or sale for domestic purpose due to the risk of carcinogenicity and renal damage on long-term use and the presence of alternative therapy. Although Sweden has no legal powers to prohibit export, no export of this product occurs.	
HKG	1 Jul 1982	The Pharmacy and Poisons Committee no longer allows the registration, sale or distribution of products containing phenacetin.	

Legislative or regulation action

Product Name		Phenacetin
C.A.S. number		62-44-2
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
JPN	Aug 1982	The Ministry of Health and Welfare banned phenacetin in proprietary drugs because of its propensity to cause renal damage and its carcinogenicity.
IND	1983	Prohibited for manufacture, sale and import for reasons of health risks associated with use and/or questionable therapeutic value. (Reference: (GAZIE) The Gazette of India: Extraordinary, II-3i, , 23 July 1986)
NPL	1983	Preparations containing phenacetin have been banned from use.
THA	Feb 1983	Registration permit has been revoked for pharmaceutical preparations containing this ingredient.
RWA	1 Oct 1983	Products containing phenacetin have been banned following established evidence of adverse effects of these preparations.
USA	4 Nov 1983	Withdrawn from the market and prohibited for export by the Food and Drug Administration due to its high potential for abuse and its unfavourable benefit-to-risk ratio with excessive chronic use. Risks cited include kidney damage and the possibility of haemolytic anaemia and methaemoglobinaemia resulting from abuse. (Reference: (FEREAC) Federal Register, 48(194), 45466, 1983)
CHL	1984	Products containing phenacetin have been withdrawn from the market in view of the risk of renal damage and methaemoglobinaemia with use.
ETH	1984	Withdrawn from the market due to the association of long-term use and nephropathy.
GRC	1984	Withdrawn from the market.
DNK	31 Dec 1984	Products containing phenacetin have been withdrawn from the market due to their potential risks of carcinogenicity and nephrotoxicity. (Reference: (UGLAAD) Ugeskrift for Laeger, 3769, , Nov 1984)
PAN	16 Sep 1985	The Ministry of Health has banned the import and sale of pharmaceuticals containing phenacetin. (Reference: (PANMR) Ministry of Health Resolution, No.7-DG, , June 1985)
DEU	1 Apr 1986	Preparations containing phenacetin have been withdrawn from the market and will no longer be considered for registration.
MYS	Nov 1986	All products containing phenacetin have been withdrawn. (Reference: (MYSDC) Malaysian Drug Control Authority, No.4, , Aug 1986)
OMN	1 Jan 1987	The Ministry of Health has prohibited the import and marketing of products containing phenacetin.
AUT	1 Jan 1988	The distribution and use of medicines containing phenacetin are prohibited. (Reference: (AUTGB) Bundesgesetzblatt für die Republik Oesterreich, No.284, , 1987)
BEL	1 Jan 1988	Preparations containing phenacetin have been placed in List IV of the 'Arrêt, du R,gent' of 2 June 1946 and as such can be administered only on prescription. They must be kept in a poisons cabinet and carry the skull and crossbones label. (Reference: (BELAR) Arrêté Royal, , , June 1987)
BHR		Preparations containing phenacetin have been withdrawn.
EGY		The Technical Committee for Drug Control has instructed manufacturers to reformulate products to exclude this substance due to its potential to cause cumulative kidney damage.
IRL		Products containing phenacetin have been withdrawn.
NLD		Products containing phenacetin have been banned.
SAU		Not approved, having regard to the risk of liver damage as well as nephropathy.

Legislative or regulation action

Product Name	Phenacetin	
C.A.S. number	62-44-2	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
SUR		Registration of all pharmaceutical products containing phenacetin has been withdrawn. WHO Comment : Phenacetin, an aniline derivative, was introduced into medicine as an antipyretic over a century ago. It subsequently gained recognition as an analgesic and was available in many proprietary analgesic preparations. However, in the 1940s its habitual use was first implicated as the cause of methaemoglobinaemia and chronic haemolysis. Since 1950 there have been many reports published indicating that abusive use is associated with cumulative renal damage. Evidence also exists to suggest that it may have a carcinogenic potential. The drug has been withdrawn in many countries but may remain available in others. (Reference: (WHODI) WHO Drug Information, 1, 5, 1980)

Product Name	Phenazone	
C.A.S. number	60-80-0	
Scientific and common names, and synonyms		
AZOPHENUM		
ANTIPYRINE		
1,2-DIHYDRO-1,5-DIMETHYL-2-PHENYL-3H-PYRAZOLE-3-ONE		
2,3-DIMETHYL-1-PHENYL-3-PYRAZOLIN-5-ONE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
ARE	9 Jun 1981	Pharmaceutical preparations containing phenazone are banned. (Reference: (UAEMD) Ministry of Health Decree, 694, , 1981)
MYS	Nov 1986	All products containing phenazone have been withdrawn. (Reference: (MYSDC) Malaysian Drug Control Authority, No.4, , Nov 1986)
BHR		Preparations containing phenazone have been withdrawn. WHO Comment : Phenazone is a pyrazolone derivative chemically related to aminophenazone. Some regulatory authorities have imposed restrictions on its use on these grounds. However, a recent international study showed no statistically-based evidence of an association with agranulocytosis or aplastic anaemia. Nor does it share with aminophenazone the propensity to produce potentially carcinogenic nitrosamines.

Product Name	Phenazopyridine	
C.A.S. number	94-78-0	
Scientific and common names, and synonyms		
2,6-PYRIDINEDIAMINE, 3-(PHENYLAZO)		
2,6-DIAMINO-3-(PHENYLAZO)PYRIDINE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GRC	1984	Withdrawn from the market having regard to its unacceptable benefit to risk ratio (carcinogenic potential).

Legislative or regulation action

Product Name	Phenazopyridine	
C.A.S. number	94-78-0	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		WHO Comment : Phenazopyridine, an azo dye, was introduced in the 1950s as a urinary antiseptic. It was withdrawn in Greece in 1984 on grounds that it has a carcinogenic potential but it remains available in other countries, most frequently as a constituent of combination products.

Product Name	Phendimetrazine	
C.A.S. number	634-03-7	
Scientific and common names, and synonyms		
	MORPHOLINE, 3,4-DIMETHYL-2-PHENYL-, (2S-TRANS)-	
	PHENIMETHOXAZINE	
	(2S,3S)-3,4-DIMETHYL-2-PHENYLMORPHOLINE	
	(+)-3,4-DIMETHYL-2-PHENYLMORPHOLINE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
TUR	6 Sep 1982	Banned for production, import, export, sale and use.
		WHO Comment : Phendimetrazine, a sympathomimetic amine, was introduced in 1961 for use as an anorexic agent. It retains a place in the treatment of obesity. However, since it has been subject to abuse and because dependence can occur, phendimetrazine is controlled under Schedule IV of the 1971 Convention on Psychotropic Substances. (Reference: (UNCPS4) United Nations Convention on Psychotropic Substances (IV), , , 1971)

Product Name	Phenformin	
C.A.S. number	114-86-3	
Scientific and common names, and synonyms		
	IMIDODICARBONIMIDIC DIAMIDE, N-(2-PHENYLETHYL)-	
	PHENFORMIN HYDROCHLORIDE	
	1-PHENETHYLBIGUANIDE HCL	
	1-PHENETHYLBIGUANIDE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
TUR	1970	Due to published evidence of occasional fatal cases of lactic acidosis from this substance, the Ministry of Health has withdrawn all products containing phenformin and used metformin as a replacement. Export of this product is prohibited.
CAN	1977	Voluntarily withdrawn from sale as a result of concern regarding lactic acidosis. Metformin remains available for use.
CHE	1977	Withdrawn following reports of occasional but sometimes fatal cases of lactic acidosis among diabetics receiving biguanides. (Reference: (UGLAAD) Ugeskrift for Laeger, 140, 181, 1978)
NOR	1977	Phenformin was withdrawn following a review of the published evidence relating to the development of lactic acidosis in diabetics treated with this drug. In the view of the

Legislative or regulation action

Product Name		Phenformin
C.A.S. number		114-86-3
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		specialities board adequate alternative treatment is available that does not involve a comparable risk.
NZL	1977	Voluntarily withdrawn from the market.
SGP	Aug 1977	Banned for importation.
BRA	14 Dec 1977	Combination products containing phenformin are prohibited. (Reference: (BRAPT) Portaria do Servico Publico Federal, No.30, , Dec 1977)
DNK	1978	Withdrawn following reports of occasional but sometimes fatal cases of lactic acidosis among diabetics receiving biguanides. (Reference: (UGLAAD) Ugeskrift for Laeger, 140, 181, 1978)
FIN	1978	Withdrawn from the market by the manufacturers since it has been shown to cause lactic acidosis among diabetics receiving biguanides.
ITA	1978	Warnings and contraindications have been added to currently marketed products with this ingredient. It has been recommended that dosages lower than 100 mg/day be followed due to the risk of lactic acidosis.
DEU	Mar 1978	Withdrawn from the market because of occurrence of lactic acidosis.
FRA	31 May 1978	Withdrawn following reports of occasional but sometimes fatal cases of lactic acidosis among diabetics receiving biguanides. (Reference: (UGLAAD) Ugeskrift for Laeger, 140, 181, 1978)
AUT	Sep 1978	In conformity with the decision taken in several other countries, and following reports of occasional lactic acidosis, all products containing phenformin and buformin have been withdrawn. Metformin remains available for limited indications.
SWE	Oct 1978	Withdrawn from domestic use due to several cases of lactic acidosis, some of which have been fatal. This product is no longer manufactured in Sweden. Although Sweden has no legal powers to prohibit export, no export of this product occurs.
THA	Nov 1978	Registration permit has been revoked for pharmaceutical preparations containing this ingredient.
USA	15 Nov 1978	Withdrawn from the market and prohibited for export by the Food and Drug Administration following reports of cases of lactic acidosis. Special arrangements have been made to allow doctors to obtain, on request, supplies of phenformin for the treatment of specific patients in whom the "benefits of the drug are considered to outweigh the risks." (Reference: (FEREAC) Federal Register, 44(68), 20966, 1979)
CYP	1979	The Drug Council withdrew all products containing phenformin following a review of published literature relating to the development of fatal acidosis in diabetics treated with this drug.
ETH	1979	Withdrawn from the market following reports of fatal lactic acidosis.
IRL	1979	Phenformin and buformin were withdrawn from the market as a result of concern regarding lactic acidosis. (Reference: (IRDAB) National Drugs Advisory Board Annual Report, 14, , 1979)
YEM	1979	Withdrawn following reports of fatal lactic acidosis.
KWT	Jan 1980	Prohibited for import.
GBR	1982	Withdrawn from the market by the manufacturer owing to evidence of lactic acidosis with its use.
HKG	14 Oct 1985	The Pharmacy and Poisons Committee no longer allows the registration, sale or distribution of products containing phenformin.

Legislative or regulation action

Product Name	Phenformin	
C.A.S. number	114-86-3	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
IND		Currently available on the market. Precautionary information is required to be given with this drug.
MUS		The Committee on Safety of Drugs has issued a circular letter to all doctors informing them of contraindications to phenformin and the precautions to be observed when the drug is used.
NLD		Withdrawn from the market.
SAU		Prohibited following reports of lactic acidosis.
VEN		Subject to restricted use and/or sale.
<p>WHO Comment : Phenformin, a biguanide with oral hypoglycaemic activity, was introduced in 1957 for the management of diabetes mellitus. By 1970 its use had been associated with incidences of lactic acidosis and by 1976 clinical studies had conclusively demonstrated that the hazards of phenformin treatment outweighed the benefits. Preparations containing phenformin were withdrawn in several countries and their use restricted in others. Elsewhere, however, proprietary preparations containing this drug may remain available. The related biguanide, buformin, has been also associated with lactic acidosis and has been subjected to similar restrictions as phenformin, whereas there is some evidence that metformin is less liable to induce lactic acidosis.</p> <p>(Reference: (WHODI) WHO Drug Information, 2, 4, 1977)</p>		

Product Name	Phenicarbazide	
C.A.S. number	103-03-7	
Scientific and common names, and synonyms		
1-PHENYLSEMICARBAZIDE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
IRL		Having regard to the serious nature of the adverse effects, products containing phenicarbazide have been withdrawn.
<p>WHO Comment : Phenicarbazide, which has analgesic and antipyretic activity, was introduced in the 1970s. It has been withdrawn in at least one country on grounds of its adverse effect profile and it appears to have fallen into disuse in others.</p>		

Product Name	Phenmetrazine	
C.A.S. number	134-49-6	
Scientific and common names, and synonyms		
MORPHOLINE, 3-METHYL-2-PHENYL		
3-METHYL-2-PHENYLMORPHOLINE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
TUR	6 Sep 1982	Banned for production, import, export, sale and use.

Legislative or regulation action

Product Name		Phenmetrazine	
C.A.S. number		134-49-6	
Legislative or regulative action			
Country	Effective Date	Description of action taken Grounds for decision	
OMN	10 May 1982	Import and marketing of products containing phenmetrazine were prohibited. (Reference: (OMNCR) Circular, 11/82, , May 1982)	
NGA	1988	All products containing phenmetrazine have been banned. (Reference: (NGAPN) Pharmanews, 10(11), 15, 1988)	
<p>WHO Comment : Phenmetrazine, a sympathomimetic amine, was introduced in 1956 for use as an anorexic agent. Although preparations remain available, the use of phenmetrazine is no longer indicated for the treatment of obesity. Moreover, since it has been subject to abuse, and because dependence can occur, it is now controlled under Schedule II of the 1971 Convention on Psychotropic Substances. (Reference: (UNCPS2) United Nations Convention on Psychotropic Substances (II), , , 1971)</p>			
Product Name		Phenobarbital	
C.A.S. number		50-06-6	
Scientific and common names, and synonyms			
5-ETHYL-5-PHENYLBARBITURIC ACID			
PHENOBARBITONE			
PHENEMALUM			
2,4,6(1H,3H,5H)-PYRIMIDINETRIONE, 5-ETHYL-5-PHENYL-			
Legislative or regulative action			
Country	Effective Date	Description of action taken Grounds for decision	
SWE	Jul 1985	Withdrawn following discussions between the manufacturer and the National Board of Health and Welfare. Fatal intoxications and abuse are associated with use of preparations containing phenobarbital.	
ARG	Dec 1996	The Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) has restricted the use of phenobarbital to special prescription control including a requirement for record-keeping. (Reference: (ARGBO) Boletín oficial, No.28.552, 6019/96, 27 Dec 1996)	
MUS	2001	Based on the regulatory decision taken by the Agence Française de Sécurité des Produits de Santé on 21 February 2001 on phenobarbitone preparations used as mild sedatives, all phenobarbital preparations other than those used as anti-epileptic products are being phased out of the market in Mauritius. Further import permits have not been issued. (Reference: (MUSCW) Communication to WHO, , , 27 Aug 2002)	
FRA	Apr 2001	Phenobarbital has been suspended due to reports of rare but severe cutaneous and mucosal reactions including Lyell Syndrome and Stevens-Johnson syndrome. (Reference: (FRACW) Communication to WHO, , , 05 Oct 2001)	
<p>WHO Comment : Phenobarbital is a long-acting barbiturate which is controlled under Schedule IV of the 1971 Convention on Psychotropic Substances. Phenobarbital is of value in the treatment of epilepsy and preparations for such use are included in the WHO Model List of Essential Drugs. See also WHO comment for barbiturates. (Reference: (UNCPS4) United Nations Convention on Psychotropic Substances (IV), , , 1971)</p>			

Legislative or regulation action

Product Name	Phenol	
C.A.S. number	108-95-2	
Scientific and common names, and synonyms	HYDROXYBENZENE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DOM	1983	Domestic manufacturers and importers have been requested to eliminate this ingredient from their marketed products since studies worldwide have shown that its antiseptic benefits do not outweigh the risks associated with use.
LTH	Dec 2000	Phenol aerosol was not granted marketing authorization on the grounds that other safer antiseptics are now available. (Reference: (LTHCW) Communication to WHO, , , 24 Aug 2001) WHO Comment : Phenol became widely used as an antiseptic following demonstration of its germicidal activity in 1867. It is an intensely corrosive substance and percutaneous absorption can produce serious systemic toxicity. It has been withdrawn from pharmaceutical preparations by at least one national regulatory authority. However, it is still used widely in concentrations of the order of 1.4% in proprietary preparations for the relief of soreness of the mouth and throat.
Bibliographical references		
IPCS ENVIRONMENTAL HEALTH CRITERIA, 161, , 1994 IPCS HEALTH AND SAFETY GUIDE, 88, , 1994		

Product Name	Phenolphthalein	
C.A.S. number	77-09-8	
Scientific and common names, and synonyms	1(3H)-ISOBENZOFURANONE, 3,3-BIS(4-HYDROXYPHENYL) 2(3H)-ISOBENZOFURANONE, 3,3-BIS(4-HYDROXYPHENYL)- 3,3-BIS-(P-HYDROXYPHENYL)PHTHALIDE 3,3-BIS(4-HYDROXYPHENYL)-1(3H)-ISOBENZOFURANONE 3,3-BIS(4-HYDROPHENYL)-PHTHALIDE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
NOR	1979	Withdrawn from the market.
YEM	1979	All products containing phenolphthalein have been withdrawn.
BGD	1982	Under the provisions of the Drugs (Control) Ordinance, this product has been banned due to evidence of insufficient therapeutic value. (Reference: (BGDCO) The Drugs (Control) Ordinance, , , 1982)
GRC	1985	Withdrawn from the market.
CAN	30 Sep 1997	After reviewing the benefits and risks associated with the use of phenolphthalein-containing laxatives, Health Canada has concluded that there is a risk that phenolphthalein may cause cancer in humans; therefore the authority to sell and distribute these products has been revoked. (Reference: (CANPR) Press Release, 1997-54, , 30 Sep 1997)
FRA	Oct 1997	Following the opinion of the CPMP that the availability of phenolphthalein-containing laxatives should be restricted in view of the potential carcinogenicity of phenolphthalein, the Agence du Médicament has decided to suspend the marketing authorization of products containing phenolphthalein.

Legislative or regulation action

Country	Effective Date	Description of action taken Grounds for decision
Product Name Phenolphthalein		
C.A.S. number 77-09-8		
Legislative or regulative action		
MAR	Nov 1997	(Reference: (FRAAMC) Communiqué de Presse, , , 03 Oct 1997) The Direction du médicament et de la pharmacie has suspended marketing authorization for phenolphthalein. (Reference: (MARDMP) Letter to WHO, , , 08 Sep 2000)
OMN	Dec 1997	The Directorate General of Pharmaceutical Affairs & Drug Control has prohibited the registration, import and sale of phenolphthalein in all laxative preparations, including candies or chewing gum, because of a potential risk of carcinogenicity. (Reference: (OMNPN) Pharmaceutical Newsletter, 5(4): 8, , 1997)
@EC	17 Dec 1997	At a Pharmacovigilance Working Party meeting in September 1997, it was indicated that national competent authorities were either considering immediate suspension of phenolphthalein or were discussing with the relevant marketing authorization holders the withdrawal on a voluntary basis. If voluntary action was not agreed by marketing authorization holders, the national competent authorities concerned would consider suspension of the products. (Reference: (CPMPPP) Position paper on the genotoxic and carcinogenic potential of phenolphthalein, , , 17 Dec 1997)
OMN	1998	The Directorate General of Pharmaceutical Affairs & Drug Control has prohibited the registration, import and sale of phenolphthalein in all laxative preparations, including candies or chewing gum, because of a potential risk of carcinogenicity. (Reference: (OMNPN) Pharmaceutical Newsletter, 5(4): 8, , 1997)
JPN	27 Jan 1998	Manufacturers have voluntarily withdrawn products containing phenolphthalein from the market. (Reference: (JPNPMB) Communication, , , 27 Jan 1998)
SAU	Jun 1999	The Ministry of Health has withdrawn from the market laxative products containing phenolphthalein because of a potential risk of carcinogenicity. (Reference: (SAUCW) Notification, , , 20 June 1999)
BHR		Preparations containing phenolphthalein have been withdrawn.
SGP		The National Pharmaceutical Administration in the Ministry of Health has rescheduled phenolphthalein to a Prescription- Only-Medicine due to its genotoxic and carcinogenic potential. (Reference: (SGPCW) Communication to WHO, , , 02 Aug 2000)
WHO Comment : Phenolphthalein has been widely used as a laxative since its cathartic activity was first described in 1902. Because it undergoes enterohepatic circulation it is eliminated slowly and it has been associated with adverse effects, notably skin reactions, potassium loss and atonia. This has led to the withdrawal of phenolphthalein from pharmaceutical preparations in several countries. Elsewhere, it remains available, often in over-the-counter preparations.		
Product Name Phenoxybenzamine		
C.A.S. number 59-96-1		
Scientific and common names, and synonyms BENZENEMETHANAMINE, N-(2-CHLOROETHYL)-N-(1-METHYL-2-PHENOXYETHYL) N-(2-CHLOROETHYL)-N-(1-METHYL-2-PHENOXYETHYL)BENZYLAMINE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision

Legislative or regulation action

Product Name	Phenoxybenzamine	
C.A.S. number	59-96-1	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
AUS	Jul 1984	The Australian Drug Evaluation Committee has recommended that phenoxybenzamine should be restricted to use in phaeochromocytoma and neurogenic retention of urine having regard to reported carcinogenicity and mutagenicity in animal studies. (Reference: (AUDEC) Report of the Australian Drug Evaluation Committee, 114, , July 1984) WHO Comment : Phenoxybenzamine, a long-acting alpha-adrenoreceptor antagonist, was introduced in 1953 and has been used in a variety of peripheral vascular disorders. In 1982 it was shown to have mutagenic activity and in 1985 it was found to be carcinogenic in the rat. Its approved use was subsequently restricted by several regulatory authorities and phenoxybenzamine is currently used to manage hypertensive episodes associated with phaeochromocytoma, as an adjunct to the short-term management of urinary retention due to neurogenic bladder, in the short-term treatment of benign prostatic hypertrophy in patients awaiting surgery, and in inoperable benign prostatic hypertrophy.
Product Name		
Phentermine		
C.A.S. number	122-09-8	
Scientific and common names, and synonyms		
ALPHA,ALPHA-DIMETHYLPHENETHYLAMINE		
A,A-DIMETHYLPHENETHYLAMIN		
BENZENEETHANAMINE, ALPHA,ALPHA-DIMETHYL		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
SWE	Jan 1981	Phentermine-containing appetite suppressants have been withdrawn from the market. There is a lack of evidence of their value in long-term management of obesity, they have the potential for abuse and despite warnings they are frequently used over unacceptably prolonged periods.
ARE	9 Jun 1981	Pharmaceutical preparations containing phentermine are banned. (Reference: (UAEMD) Ministry of Health Decree, No.694, , 1981)
MUS	9 Mar 1982	Under the Pharmacy and Poisons (Prohibitions of Harmful Drugs) Regulations, this drug is deemed "harmful" by the Ministry of Health and is prohibited for import, manufacture, storage, distribution, sale, possession, use, export or other transaction. (Reference: (MPPHD) Pharmacy & Poisons (Prohibitions of Harmful Drugs) Regulations, , , Mar 1982)
TUR	6 Sep 1982	Banned for production, import, export, sale and use.
OMN	11 Jan 1987	Import and marketing of products containing phentermine were prohibited. (Reference: (OMNCR) Circular, 2/87, , Jan 1987)
GBR	Apr 2000	The Medicines Control Agency has banned the anorectic agent, phentermine on the basis of a European Commission decision stating that risks outweigh the benefits. (Ref: Communication to WHO, 30 August 2000 from the Medicines Control Agency, Department of Health, United Kingdom.) (Reference: (GBRMCA) Communication to WHO, , , 30 Aug 2000)
VEN		Phentermine is not approved for use and/or sale. WHO Comment : Phentermine, a sympathomimetic amine, was introduced in 1959 for use as an anorexic agent. It retains a place in the treatment of obesity. However,

Legislative or regulation action

Product Name	Phentermine	
C.A.S. number	122-09-8	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		since it has been subject to abuse and because dependence can occur, phentermine is controlled under Schedule IV of the 1971 Convention on Psychotropic Substances. (Reference: (UNCPS4) United Nations Convention on Psychotropic Substances (IV), , , 1971)

Product Name	Phentolamine mesilate	
C.A.S. number	65-28-1	
Scientific and common names, and synonyms		
PHENTOLAMINI MESILAS. 3-[N-(2-IMIDAZOLIN-2-YLMETHYL)-P-TOLUIDINO]PHENOL METHANESULPHONATE PHENTOLAMINE METHANESULPHONATE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
SGP		The National Pharmaceutical Administration in the Ministry of Health has not approved phentolamine mesylate, a drug used for the treatment of erectile dysfunction because of abnormal findings in rat carcinogenicity studies. (Reference: (SGPCW) Communication to WHO, , , 02 Aug 2000)

Product Name	Phenylbutazone	
C.A.S. number	50-33-9	
Scientific and common names, and synonyms		
BUTADIONE 3,5-PYRAZOLIDINEDIONE, 4-BUTYL-1,2-DIPHENYL- 4-BUTYL-1,2-DIPHENYL-3,5-PYRAZOLIDINEDIONE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
JPN	Jul 1977	Indications are restricted to acute exacerbations of rheumatoid arthritis, ankylosing spondylitis and acute gout. Doctors are advised to prescribe these drugs only to adults and for periods of no longer than one week.
HUN	1984	Indications are restricted to ankylosing spondylitis and related diseases, acute gout attacks, acute exacerbations of rheumatoid arthritis and inflamed osteoarthritis. The duration of treatment is restricted to 14 days. (Reference: (BNIPH) Bulletin of the National Institute of Pharmacy, 34(6), 186, 1984)
IRL	1984	Approved indications for phenylbutazone and oxyphenbutazone revised: now restricted to cases of acute gout, ankylosing spondylitis, and chronic arthritis in patients unsuited to alternative therapy. Treatment of acute gout should not extend beyond 7-10 days and the lowest effective dose should be used. Treated arthritic patients should remain under regular surveillance and specialist supervision. Doctors are advised not to prescribe these drugs for children or pregnant women and to reduce the dose in elderly patients. Certain contraindications include previous or existing gastrointestinal disease, blood dyscrasias, hepatic or renal dysfunction, cardiac or pulmonary insufficiency, thyroid or salivary gland disorders or hypersensitivity. Combination products with other active ingredients have been withdrawn from use.

Legislative or regulation action

Product Name **Phenylbutazone**

C.A.S. number **50-33-9**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
TUN	1984	Injectable and topical preparations are prohibited. Tablets and suppositories are restricted to the treatment of ankylosing spondylitis and gout.
ARE	19 Mar 1984	Pharmaceutical preparations containing phenylbutazone are banned. (Reference: (UAEMD) Ministry of Health Decree, No.480, , 1984)
KWT	Apr 1984	Approved indications have been restricted to ankylosing spondylitis and acute gout and phenylbutazone should not be dispensed without a prescription. (Reference: (KTMD) Ministerial Decree, No.160, , 1984)
BRB	25 Jun 1984	Indications for phenylbutazone are limited to active ankylosing spondylitis, gout and pseudo-gout. It may also be used to treat acute exacerbations of rheumatoid arthritis and osteoarthritis and acute non-articular rheumatoid disease unresponsive to other non-steroidal antiinflammatory drugs.
ZWE	Jul 1984	Approved indications are restricted to ankylosing spondylitis. The duration of therapy should not exceed seven days. Labelling must contain a warning that adverse haematological effects may occur and that the blood count should be monitored before and during therapy. Topical products have been withdrawn. (Reference: (ZWDCC) Drugs Control Council, News Bulletin, , , Aug 1985)
ESP	15 Jul 1984	Approved indications have been restricted to inflammatory arthritic conditions, active ankylosing spondylitis and other inflammatory spondylopathies, acute attacks of gout and pseudo-gout, acute exacerbations of rheumatoid arthritis and other polyarthritic conditions. Parenteral preparations have been restricted to hospital use only.
COG	1 Aug 1984	Indications for phenylbutazone have been restricted to ankylosing spondylitis.
JOR	1 Oct 1984	Registration of all pharmaceutical products containing phenylbutazone has been withdrawn. (Reference: (JORMH) Ministry of Health Resolution, 4/2/1559, , Apr 1984)
BGD	Nov 1984	Use has been banned due to reported severe adverse reactions.
DEU	1985	Indications have been restricted to exacerbations of rheumatism and acute gout. Duration of oral treatment should not exceed one week. Parenteral preparations are indicated only for initiating therapy. A single injection only is recommended because local tissue damage may occur. Preparations are contraindicated in children under 14 years of age.
ETH	1985	Banned from the market due to reported serious adverse reactions.
GRC	1985	Indications have been restricted.
NLD	1 Jan 1985	Parenteral dosage forms and combination products containing phenylbutazone have been withdrawn from the market. The approved indications have been restricted to the treatment of spondyloarthritis unresponsive to other non-steroidal antiinflammatory agents. (Reference: (NETJAN) Nederlands Tijdschrift voor Geneeskunde, 128(50), , 1984)
SWE	Feb 1985	Indications for use have been restricted to acute gout and morbus Bechterew on the grounds of serious blood dyscrasias associated with its use.
NZL	Apr 1985	Indications for phenylbutazone have been restricted.
CHL	4 Jun 1985	Preparations containing phenylbutazone have been prohibited. (Reference: (CHLRS) Resolution of the Minister of Health, No.2660, , Apr 1984)
OMN	22 Sep 1985	Phenylbutazone is available in small quantities only in government hospitals for the treatment of patients unresponsive to other therapy. The Ministry of Health has prohibited import of preparations containing phenylbutazone except combinations containing phenylbutazone and clofexamide (clofezone) intended for topical use.

Legislative or regulation action

Product Name		Phenylbutazone	
C.A.S. number		50-33-9	
Legislative or regulative action			
Country	Effective Date	Description of action taken Grounds for decision	
		(Reference: (OMNMH) Ministry of Health, 3, , 1985)	
HKG	2 Oct 1985	The use of preparations containing phenylbutazone has been restricted.	
PAN	1 Jan 1986	The Ministry of Health has suspended the import and sale of pharmaceuticals containing phenylbutazone with the exception of parenteral preparations for which use will be confined to hospitals. (Reference: (PANMR) Ministry of Health Resolution, No.9/III-DG, ,)	
TUR	12 Mar 1986	Production and sale of preparations containing phenylbutazone have been banned with the exception of topical preparations.	
MYS	Jan 1987	All products containing phenylbutazone have been withdrawn. (Reference: (MYSDC) Malaysian Drug Control Authority, No.6, , Oct 1986)	
BEL	1 Jan 1988	Preparations containing phenylbutazone have been placed in List IV of the 'Arrêt, du R,gent' of 2 June 1946 and as such can be administered only on prescription. They must be kept in a poisons cabinet and carry the skull and crossbones label. (Reference: (BELAR) Arrêté Royal, , , June 1987)	
GHA	1 Sep 1989	Products containing phenylbutazone, its salts or derivatives have been banned. (Reference: (GHAPDR) Pharmacy and Drugs (Banned Drugs) Regulations, Legislative Instruments, 1484, , 1989)	
LKA	1 Jan 1992	The Ministry of Health withdrew from sale pharmaceutical products containing phenylbutazone. This action was based on the potential of these products to induce suppression of the bone marrow. (Reference: (LKADIB) Drug Information Bulletin, University of Peradeniya and Ministry of Health, 4(1), , 1992)	
ARM		The Drug and Medical Technology Agency has suspended the marketing authorization of phenylbutazone for oral, parenteral and topical use because of its toxicity. (Reference: (ARMCW) Communication to WHO, , , 09 Aug 2000)	
AUS		Indications are restricted to seronegative spondyloarthropathies, acute gout and rheumatoid arthritis not responding to other non-steroidal anti-inflammatory drugs.	
AUT		Indications are restricted to exacerbations of gout and other arthritic conditions. Treatment should not exceed seven days and doctors are advised not to prescribe this drug to children under 14 years of age or elderly patients. (Reference: (WIMAM) Wichtige Mitteilung ueber Arzneimittel, (1), , 1984)	
BHR		Preparations containing phenylbutazone have been withdrawn.	
CYP		All combination products withdrawn from the market due to the potential to cause serious adverse reactions. The indications for monocomponent products have been restricted to ankylosing spondylitis.	
GBR		Approved indications are restricted to ankylosing spondylitis. Use is restricted to hospitals.	
ISR		The Pharmaceutical Administration of the Ministry of Health has notified the World Health Organization of its intention to withdraw from use all preparations containing oxyphenbutazone and to restrict the approved indication for preparations containing phenylbutazone to ankylosing spondylitis.	
ITA		Indications have been restricted to the acute phase of ankylosing spondylitis, acute gout and the acute phase of pelvispondylitis and psoriatic polyarthritis. Use should only be considered when alternative treatment is ineffective or inappropriate. No course of treatment should exceed seven to ten days.	
PHL		Due to its risk of toxicity, phenylbutazone is recommended for use only when other agents fail.	

Legislative or regulation action

Product Name	Phenylbutazone	
C.A.S. number	50-33-9	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		WHO Comment : Phenylbutazone, a pyrazolone derivative with anti-inflammatory, analgesic and antipyretic activity, was introduced in 1949 for the treatment of rheumatic disorders. Its use was subsequently associated with serious and sometimes fatal adverse reactions, notably cases of aplastic anaemia and agranulocytosis. Many national drug regulatory authorities consider that more recently introduced drugs offer a safer alternative for most, if not all, patients requiring anti-inflammatory agents. Phenylbutazone has thus been either withdrawn at the national level or retained with rigorously restricted indications for patients unresponsive to other therapy. These restrictions also apply, in general, to combination products containing phenylbutazone.
Product Name	Phenylephrine	
C.A.S. number	59-42-7	
Scientific and common names, and synonyms		
BENZENEMETHANOL, 3-HYDROXY-ALPHA-((METHYLAMINO)METHYL)		
(-)-M-HYDROXY-ALPHA-((METHYLAMINO)METHYL)BENZYL ALCOHOL		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GBR	Jun 1987	The Department of Health and Social Security has refused to extend the product licence for eyedrops containing phenylephrine having regard to the possibility that use in the eye may result in delayed healing, reactive hyperaemia and the precipitation of closed angle glaucoma.
Product Name	Phenylpropanolamine	
C.A.S. number	14838-15-4	
Scientific and common names, and synonyms		
BENZENEMETHANOL, ALPHA-(1-AMINOETHYL)-,(R*,S*); (+/-)		
DL-ERYTHRO-2-AMINO-1-PHENYL-1-PROPANOL		
(+/-)-NOREPHEDRINE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GBR	Nov 1985	The Committee on the Review of Medicines has recommended that preparations containing phenylpropanolamine for treatment of cough and cold (other than nasal sprays and drops) should be subjected to prescription control if the recommended dosage exceeds, for slow-release forms, 50 mg (single dose), 100 mg (daily dose); or for immediate release dosage forms, 25 mg (single dose), 100 mg (daily dose). Slow-release preparations are contraindicated in children and all formulations are contraindicated in hypertensive patients and those currently receiving (or within two weeks of stopping) therapy with monoamine oxidase inhibitors. (Reference: (GBMIL) Medicines Act Information Letter, 45, , Nov 1985)
HKG	Nov 1985	The Pharmacy and Poisons Committee has issued guidelines restricting the use of phenylpropanolamine.
DEU	1987	Approval of products containing phenylpropanolamine as appetite suppressants and for the symptomatic treatment of the common cold was withdrawn, because of their

Legislative or regulation action

Product Name **Phenylpropanolamine**

C.A.S. number **14838-15-4**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
		association with hypertensive episodes in susceptible individuals, particularly when taken together with coffee, alcohol, antihistamines or neuroleptics. (Reference: (BGHBL) Bundesgesundheitsblatt, 30(5), 187, 1987)
BRA	Nov 2000	The National Health Surveillance Agency stopped the sale of all products containing phenylpropanolamine due to the potential of these products to induce several adverse reactions including cerebral haemorrhage. (Reference: (BRARES) Resolucao n., 96/ANVISA, , 10 Nov 2000)
LTH	Nov 2000	The classification status of all medicinal products containing phenylpropanolamine was changed from over-the-counter (OTC) to prescription-medicines-only (PMO). Restrictions in dosage (not to exceed 100 mg daily dose) and contraindications (not to be used in patients with arterial hypertension, atherosclerosis of cerebral arteries and in patients on concurrent anticoagulant therapy) and dosage adjustment in children were recommended. Usage in children below 12 years of age was banned. (Reference: (LTHPHB) LSMCA bulletin "Pharmacon", No. 24, 2000, , 17 Aug 2001) (Reference: (LTHMCA) Order of State Medicines Control Agency, order no. 136, , 16 Nov 2000)
MYS	Nov 2000	The Ministry of Health suspended the registration of all medicines containing phenylpropanolamine (PPA) following a US report of increased risk of haemorrhagic stroke in people taking medicines containing PPA. (Reference: (MYSCW) Communication to WHO, , , 05 Oct 2001)
SGP	Nov 2000	Manufacturers were asked to withdraw all products containing phenylpropanolamine (PPA) from the market following reports of increased risk of haemorrhagic stroke. Manufacturers have been advised to re-formulate their products without PPA. (Reference: (SGPCW) Communication to WHO, , , 19 Sep 2001)
USA	Nov 2000	All phenylpropanolamine (PPA) containing products were withdrawn due to risk of haemorrhagic stroke after a research study by scientists at Yale University showed a significant increase in the risk for haemorrhagic strokes among women who had taken PPA as an appetite suppressant. (Reference: (USAPHA) Public Health Advisory, , , 06 Nov 2000)
GBR	Dec 2000	The Committee on Safety of Medicines (CSM) concluded that the evidence of a link between haemorrhagic stroke and phenylpropanolamine (PPA) is weak and recommend that the Medicines Control Agency should work closely with manufacturers to improve existing product information on the packs and patient information leaflets for PPA containing products with more prominent warnings. (Reference: (GBRSMU) Safety Message Update, , ,)
OMN	Dec 2000	The registration of all products containing phenylpropanolamine has been cancelled in Oman. (Reference: (OMNCR) Circular, 64/2000, , 02 Oct 2001)
CAN	2001	Health Canada has directed the removal of all phenylpropanolamine containing products from the Canadian market due to the risk of serious haemorrhagic strokes with phenylpropanolamine. (Reference: (CANWHC) Warnings/Advisories, , , May 2001)
IDN	Apr 2001	The National Agency for Drug and Food Control (NADFC) in Indonesia has allowed the marketing of phenylpropanolamine containing products with restrictions on the maximum strength per unit dose and maximum daily dose (adult 15 mg/unit dose; 60 mg per day; children 7.5 mg/unit dose; 30 mg per day). (Reference: (IDNCW) Communication to WHO, , , 13 Sep 2001)
CUB	May 2001	The Centre for State Control of Drug Quality (CECMED) issued a resolution banning the use of phenylpropanolamine products in Cuba.

Legislative or regulation action

Product Name	Phenylpropanolamine	
C.A.S. number	14838-15-4	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		(Reference: (CUBCDQ) CECMED Resolution, No. 7/2001, , 16 May 2001)
CHL	Oct 2001	The Public Health Institute of Chile has modified the labels of products containing phenylpropanolamine, warning against their use in children under the age of 12 years and advising patients to immediately report to their physicians all adverse reactions experienced with phenylpropanolamine products. (Reference: (CHLCW) Communication to WHO, , , 26 Sep 2001)
JPN	15 Aug 2003	The Ministry of Health, Labour and Welfare (MHLW) has asked manufacturers of products containing phenylpropanolamine (PPA) to include new warnings on cardiovascular risks. The move follows several reports of cerebral haemorrhage and other problems associated with the use of PPA containing products. (Reference: (JPNSWP) Scrip World Pharmaceutical News, No.2876, , 15 Aug 2003)
WHO Comment : Phenylpropanolamine, a symopathomimetic amine, has been widely available in over-the-counter preparations since 1941. It is one of the most frequently used nasal decongestants and it is a common ingredient in preparations for weight reduction, although doubts have been raised about its usefulness in this indication. It is also used in stress incontinence. Its use has been associated with occasional excessive elevation of blood pressure, especially in hypersensitive individuals.		

Product Name	Phthalylsulfathiazole	
C.A.S. number	85-73-4	
Scientific and common names, and synonyms		
6'-(THIAZOLYLAMINOSULFAMOYL)PHTHALANILIC ACID		
BENZOIC ACID, 2-(((4-((2-THIAZOLYLAMINO)SULFONYL)PHENYL)AMINO)-CARBONYL)-		
4-(2-THIAZOLYLSULFAMOYL)PHTHALANILIC ACID		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
BGD	1982	Under the provisions of the Drugs (Control) Ordinance, this product has been banned. It has been found to be of little or no therapeutic value, its side effects can be harmful, and it is subject to misuse. (Reference: (BGDCO) The Drugs (Control) Ordinance, , , 1982)
WHO Comment : Phthalylsulfathiazole, a sulfonamide anti-infective agent, was introduced in 1946 for the treatment of bacterial infections. The importance of sulfonamides has subsequently decreased as a result of increasing bacterial resistance and their replacement by antibiotics which are generally more active and less toxic. Although phthalylsulfathiazole, which is poorly absorbed from the gastrointestinal tract, is no longer recommended in some countries, it continues to be used in others for the treatment of local intestinal infections, including bacterial dysentery, and for pre-operative bowel preparation.		

Product Name	Pipamazine	
C.A.S. number	84-04-8	
Scientific and common names, and synonyms		
10-(3-(4-CARBAMOYLPIPERIDINO)PROPYL)-2-CHLOROPHENOTHIAZINE		
Legislative or regulative action		

Legislative or regulation action

Product Name	Pipamazine	
C.A.S. number	84-04-8	
Country	Effective Date	Description of action taken Grounds for decision
USA	Jul 1969	Withdrawn from the market and prohibited for export by the Food and Drug Administration due to the lack of proof of efficacy and safety for use as an antinauseant and antiemetic for pregnant women. WHO Comment : Pipamazine, which is pharmacologically similar to chlorpromazine, was introduced in 1959 for the treatment of nausea and vomiting. Although it was withdrawn in 1969 by the United States FDA on grounds of lack of proof of efficacy and safety, it remains available in some countries.

Product Name	Pipenzolate	
C.A.S. number	13473-38-6	
Scientific and common names, and synonyms		
1-ETHYL-3-HYDROXY-1-METHYLPYPERIDINIUM BENZILATE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
PAK	Jun 1990	Paediatric formulations of antidiarrhoeal products containing pipenzolate were banned. WHO Comment : Pipenzolate, an anticholinergic agent, was introduced in 1960 for the treatment of spastic conditions of the gastro-intestinal tract. It has never been widely used for the treatment of diarrhoea, and WHO is not aware of any such preparations that remain available.

Product Name	Piperazine	
C.A.S. number	110-85-0	
Scientific and common names, and synonyms		
BUTADIONE 3,5-PYRAZOLIDINEDIONE, 4-BUTYL-1,2-DIPHENYL-4-BUTYL-1,2-DIPHENYL-3,5-PYRAZOLIDINEDIONE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
ITA	1977	Products with anthelmintic indications have been withdrawn due to an unfavourable risk/benefit balance. Since 1975, warnings have been added to the labels concerning the possibility of neurotoxic effects with high dosages. In 1979, the label was revised to advise use on an empty stomach and for short periods of time with long intervals, in order to avoid interaction with nitrites.
SWE	1983	In the light of the carcinogenic and mutagenic potential of piperazine demonstrated in recent studies, discussions between the manufacturers and the Department of Drugs have led to the withdrawal of registration for this drug.
DNK	2 Jul 1984	Following recent evidence leading to the possibility that carcinogenic nitroso-derivatives may be generated in vivo, preparations containing piperazine have been placed under prescription control. (Reference: (UGLAAD) Ugeskrift for Laeger, 1949, , June 1984)
NLD	1 Jan 1985	The Board of Evaluation of Drugs has concluded that other anthelmintics have a more favourable risk-benefit ratio than piperazine, which may also give rise to potentially carcinogenic nitroso-derivatives. Manufacturers have been requested to withdraw products containing piperazine. (Reference: (NETJAN) Nederlands Tijdschrift voor Geneeskunde, 128(41), , 1984)

Legislative or regulation action

Product Name	Piperazine	
C.A.S. number	110-85-0	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
MYS	1996	The Drug Control Authority withdrew registration of products containing the anthelmintic, piperazine, because of reports of severe neurotoxicity and hypersensitivity reactions. Moreover, the mononitrosation of piperazine in the stomach can produce the potential carcinogen N-mononitrosopiperazine. (Reference: (MYSDI) Berita Ubat-Ubatan (Drug Information), 10(1): 4, , 1996)
ARM	Jul 2000	The Drug and Medical Technology Agency withdrew registration of the anthelmintic product, piperazine because of reports of questionable safety with detection of neurotoxicity, hypersensitivity and nitrosamine-generating ability. (Reference: (ARMCW) Communication to WHO, , , 09 Aug 2000)
THA		The use of pharmaceutical preparations containing piperazine is severely restricted. WHO Comment : Piperazine was first used as a treatment for gout earlier this century and its anthelmintic activity was discovered in 1949. It is also considerably cheaper than other anthelmintic drugs. In some countries where ascariasis is not endemic and where piperazine was used predominantly for the treatment of pinworm it has been withdrawn from use on the grounds that other more effective and less toxic drugs are now available (see full list). In other such countries, however, piperazine remains available in over-the-counter preparations. Clinical dosages occasionally induce transient neurological signs and concern has been expressed that in some circumstances the drug may generate small amounts of nitrosamine in the stomach. However, it is widely considered that these trace doses are unlikely to give rise to a significant carcinogenic potential. (Reference: (WHODIB) WHO Drug Information Bulletin, 1: 5, , 1983)

Product Name	Pipradrol	
C.A.S. number	467-80-7	
Scientific and common names, and synonyms		
ALPHA,ALPHA-DIPHENYL-2-PIPERIDINEMETHANOL 1,1-DIPHENYL-1-(2-PIPERIDYL)-METHANOL		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
TUR	6 Sep 1982	Banned for production, import, export, sale and use.
DNK		Withdrawn from the market by the manufacturer.
VEN		Not approved for use and/or sale. WHO Comment : Pipradrol, a central nervous system stimulant, was introduced in 1955 for use as an anorexic agent. Pipradrol is controlled under Schedule IV of the 1971 Convention on Psychotropic Substances. (Reference: (UNCPS4) United Nations Convention on Psychotropic Substances (IV), , , 1971)

Product Name	Pirprofen	
C.A.S. number	31793-07-4	
Scientific and common names, and synonyms		
BENZENEACETIC ACID,3-CHLORO-4-(2,5-DIHYDRO-1H-PYRROL-1-YL)-ALPHA-METHYL-2-(3-CHLORO-4-(3-PYOLIN-1-YL)PHENYL) PROPIONIC ACID		

Legislative or regulation action

Product Name Pirprofen

C.A.S. number 31793-07-4

Scientific and common names, and synonyms

3-CHLORO-4-(3-PYRROLIN-1-YL) HYDRATROPIC ACID

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
@WD	30 Sep 1990	<p>Products containing pirofen have been voluntarily discontinued by the manufacturer. (Reference: (CGPR) Press release from Ciba-Geigy, , , 15 Mar 1990)</p> <p>WHO Comment : Pirprofen, a nonsteroidal anti-inflammatory agent, was introduced in 1982 primarily for the treatment of rheumatic diseases, as well as for use in post-traumatic and post-operative inflammatory conditions, acute gout and dysmenorrhoea. Reports of serious adverse effects, in particular cases of liver toxicity, some of which were fatal, led the manufacturer, in 1985 and in 1989, to amend the approved product information of the drug, limiting duration of treatment and lowering the recommended doses. In the light of these successive restrictions, which have considerably reduced the field of application of pirofen and in view of available alternatives, the manufacturer has decided to discontinue the drug worldwide.</p>

Product Name Pituitary-chorionic gonadotropin (injectable)

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
USA	Jul 1972	<p>Gonadotropins of animal origin have been withdrawn from use and prohibited for export by the Food and Drug Administration on grounds of safety and efficacy. In its decision the FDA cited the risk of eliciting antibodies to animal protein, leading to allergic reactions, and the availability of safer and more effective alternatives. (Reference: (FEREAC) Federal Register, 37(130), 13284, 1972)</p> <p>WHO Comment : The World Health Organization has no information further to the above regarding preparations containing pituitary chorionic gonadotropin or to indicate that preparations are still commercially manufactured.</p>

Product Name Placental tissue derived medicine

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
FRA	23 Jul 1992	<p>The Directorate of Pharmacy has suspended the marketing authorization of certain medicinal products derived from human placental tissue: Placentafil, injectable and typical formulations and Placenta Soca, ointment (Laboratoire gerda). This does not necessarily include other products made from placental tissue. (Reference: (FRAMHH) Ministry of Health and Humanitarian Action, , , 23 July 1992)</p> <p>WHO Comment : Placental derived products, both topical and injectable, have been used to treat arthritis, eczema, acne vulgaris and numerous other ailments. In 1989 the European Community raised concerns regarding the risk of viral infection and it was this that stimulated restrictive regulatory action. Other placental products including some preparations of albumin remain on the market. Indeed, worldwide, placental tissue continues to be a prime source of albumin.</p>

Product Name Podophyllum resin

Scientific and common names, and synonyms

PODOPHYLLIN

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
ITA	1970	Withdrawn from the market owing to the risk of teratogenicity.
FRA	30 Mar 1979	Having regard to the presumed teratogenic risk, the Commission on Drug Monitoring of the Ministry of Health recommended that podophyllin be removed from all medicinal products intended for internal use.
EGY	1984	Preparations containing podophyllum will not be considered for registration, having regard to the potential risk of teratogenicity.
CUB		Restricted to hospital use for the treatment of cutaneous lesions only. Oral and parenteral preparations are banned.
SAU		Available medicinal products containing this drug are intended for topical use only.

WHO Comment : Podophyllum resin, which is extracted from Indian podophyllum, is highly irritant to the skin and mucous membranes and its use in purgatives is now obsolescent. However, topical preparations remain available for the treatment of venereal and other warts and the drug is included in the WHO Model List of Essential Drugs for this purpose. Podophyllin extracts have been demonstrated to have a teratogenic potential which has led to their withdrawal in some countries and restriction of use in others. They are best avoided during pregnancy. (Reference: (WHTAC1) The Use of Essential Drugs, 2nd Report of the WHO Expert Committee, 722, , 1985)

Product Name Polidexide sulfate

C.A.S. number 56227-39-5

Scientific and common names, and synonyms

DEXTRAN 2-(DIETHYLAMINO)ETHYL 2-((2-(DIETHYLAMINO)ETHYL)DIETHYLAMMONIO) ETHYL ETHER SULFATE, EPICHLOROHYDRIN CROSSLINKED

DEAE-SEPHADEX

POLY(2-(DIETHYLAMINO)ETHYL)POLYGLYCERYLENE)DEXTRAN

PDX-CHLORIDE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
GBR	1977	This substance, except for the intravenous preparation, has been withdrawn by the company following evidence of oculo-mucocutaneous syndrome.

WHO Comment : Polidexide sulfate, an anion-exchange resin, was formerly used in the treatment of hypercholesterolaemia. The drug, which was marketed only in the United Kingdom, was withdrawn in the mid-1970s on the basis of new safety findings.

Product Name Polyoxyethylated castor oil

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
---------	----------------	---

Legislative or regulation action

Product Name Polyoxyethylated castor oil

Legislative or regulatory action

Country	Effective Date	Description of action taken Grounds for decision
ITA	1984	The Italian Ministry of Health has suspended the marketing authorization of two anaesthetic preparations containing polyoxyethylated castor oil.
@WD	Jun 1984	The manufacturer of an anaesthetic agent containing polyoxyethylated castor oil has withdrawn the product worldwide.
EGY	26 Mar 1985	Preparations containing polyoxyethylated castor oil will no longer be approved for registration and the substance should be withdrawn from all pharmaceutical and cosmetic products. WHO Comment : Polyoxyethylated castor oil is a non-ionic emulsifying agent produced by reacting ethylene oxide with castor oil. It has been used for over 20 years to prepare stable injectable liquid preparations of drugs with low aqueous solubility. By the mid-1970s, its use had been associated with cases of severe anaphylactoid reactions and haematological changes including hyperlipidaemia, altered blood viscosity and erythrocyte aggregation. For the formulation of certain lipophilic substances such as ciclosporin there is currently no viable alternative to this pharmaceutical aid. It continues to be approved in some countries whereas its use is restricted or banned in others. One manufacturer has withdrawn worldwide all products containing polyoxyethylated castor oil.

Product Name Polyvidone

C.A.S. number 9003-39-8

Scientific and common names, and synonyms

PVP
POVIDONE
POLYVINYLPIRROLIDONE
1-VINYL-2-PYRROLIDINONE POLYMER
2-PYRROLIDINONE, 1-ETHENYL-, HOMOPOLYMER

Legislative or regulatory action

Country	Effective Date	Description of action taken Grounds for decision
DEU	1983	All injectable products containing PVP with a molecular weight of approximately 12000 have been reformulated or withdrawn. PVP content of remaining products and an appropriate warning regarding their risks must be widely displayed on the labelling. PVPs have been widely used as stabilisers in injectable products, but the Federal Health Office considers that safer substances are now available for this purpose. It is now recognized that PVPs of high molecular weight are sequestered in the body. Their accumulation may cause pain at the site of injection and granulomatous lesions have developed that have been mistaken for neoplastic tumors.
PAK	1988	Plasma expanders containing polyvidone were withdrawn. (Reference: (PAKMH) Ministry of Health, Special Education and Social Welfare, , , Aug 1988)
EGY		Registration of injectable preparations containing polyvidone with a molecular weight greater than 12000 are not approved because such preparations can cause painful granulomatous lesions at the site of administration. Currently registered products were reformulated to exclude this product. WHO Comment : Polyvidone, a polymer of vinylpyrrolidinone, is an excipient used as a suspending and dispersing agent. Injectable preparations containing polymers with a molecular weight in the order of 12,000 have caused painful local

Legislative or regulation action

Product Name	Polyvidone	
C.A.S. number	9003-39-8	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		granulomatous lesions. This has led to the withdrawal of polyvidone from such preparations in some countries. Polyvidone was formerly also used as a plasma expander but, because it was sequestered within the liver and spleen, this use has been discontinued. However, it remains widely used as a vehicle for ophthalmic preparations, and as the major component of artificial tears.
Product Name	Potassium canrenoate	
C.A.S. number	2181-04-6	
Scientific and common names, and synonyms		
ALDADIENE POTASSIUM		
PREGNA-4,6-DIENE-21-CARBOXYLIC ACID, 17-HYDROXY-3-OXO, POTASSIUM SALT (17ALPHA)-		
POTASSIUM 17-HYDROXY-3-OXO-17ALPHA-PREGNA-4,6-DIENE-21-CARBOXYLATE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	Sep 1986	The indications for preparations containing potassium canrenoate are restricted having regard to the possible carcinogenic risk associated with long-term use. All combination products containing potassium canrenoate have been withdrawn. (Reference: (DEUAB) Deutsches Aertzteblatt, 83, , 1986)
WHO Comment : Potassium canrenoate, which has no intrinsic aldosterone antagonist activity, owes its therapeutic effect to the enzymatic interconversion in the body to canrenone. Evidence that long-term administration of high doses are tumorigenic in the rat has recently led to restriction of its use by some national regulatory authorities. See also WHO comments for canrenone and spironolactone.		
Product Name	Potassium chloride	
C.A.S. number	7447-40-7	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
BEL	1982	Having regard to their association with ulceration of the gastrointestinal tract, fast-acting tablet formulations of potassium salts, including potassium chloride, are prohibited. Sustained-release tablets, tablets intended to be dissolved and liquid formulations remain available.
FRA	31 Mar 1989	Fast-acting tablets containing potassium chloride have been withdrawn, in the light of evidence that rapid release of potassium can induce intestinal perforation. (Reference: (FRARP) La Revue Prescrire, 9(82), 59, 1989)
WHO Comment : Potassium chloride has been used for many years to correct potassium deficiency. The use of fast-acting tablets has been associated with lesions of the gastro-intestinal mucosa, which have led to their general withdrawal.		
Product Name	Potassium nitrate	
C.A.S. number	7757-79-1	
Scientific and common names, and synonyms		

Legislative or regulation action

Product Name **Potassium nitrate**

C.A.S. number **7757-79-1**

Scientific and common names, and synonyms

NITRE
SALTPETRE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
FRA	Jan 1981	Having regard to their obsolescence in clinical medicine and the potential carcinogenic risk attached to excessive use of nitrates, medicinal preparations of potassium nitrate were withdrawn from the market.
EGY	Mar 1984	No registration licence is to be granted for oral pharmaceutical preparations containing potassium nitrate to avoid any carcinogenic risk resulting from excessive use of nitrates.
VEN		Not approved for use and/or sale.

WHO Comment : Potassium nitrate was formerly used as a diuretic. Its use for this purpose is now considered obsolete but it is still available in at least one country for the correction of potassium deficiency. It is also widely permitted at concentrations of the order of 5% in proprietary toothpastes. In some countries the drug has been banned due to a potential carcinogenic risk arising from the excessive use of nitrates and their transformation to nitrosamines.

Product Name **Practolol**

C.A.S. number **6673-35-4**

Scientific and common names, and synonyms

ACETAMIDE, N-(4-(2-HYDROXY-3-((1-METHYLETHYL)AMINO)PROPOXY)PHENYL)-
4-(2-HYDROXY-3-(ISOPROPYLAMINO)-PROPOXY)ACETANILIDE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
FIN	1975	Restricted for use only in cases of cardiac dysrhythmias due to the oculo-mucocutaneous syndrome. The only available preparation is a solution for intravenous use.
GRC	1975	Withdrawn from the market.
TUR	1975	Withdrawn from the market by the Ministry of Health due to published evidence of its harmful effects on hearing and on the eyes and skin. Export of this product is prohibited.
NZL	Mar 1975	Voluntarily withdrawn from the market.
SWE	1 May 1975	An intravenous preparation remains on the market for treatment of selected cardiac dysrhythmias.
DNK	1 Jul 1975	Registration has been cancelled for the product in tablet form. Administration by injection is allowed. (Reference: (UGLAAD) Ugeskrift for Laeger, 137, 1016, Apr 1975)
THA	Dec 1975	Products containing this ingredient have been banned.
SGP	Jul 1976	Banned for importation.
GBR	1977	This substance except for the intravenous preparation has been withdrawn from use by the company following evidence of oculo-mucocutaneous syndrome.
MUS	9 Mar 1982	Under the Pharmacy and Poisons (Prohibitions of Harmful Drugs) Regulations, this drug is deemed "harmful" by the Ministry of Health and is prohibited for import, manufacture, storage, distribution, sale, possession, use, export or other transaction. (Reference: (MPPHD) Pharmacy & Poisons (Prohibitions of Harmful Drugs) Regulations, , , Mar 1982)

Legislative or regulation action

Product Name	Practolol	
C.A.S. number	6673-35-4	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
IND	1983	Prohibited for manufacture and sale for reasons of health risks associated with use and/or questionable therapeutic value. (Reference: (GAZIE) The Gazette of India: Extraordinary, II-3i, , 23 July 1986)
DEU	25 Mar 1994	The Federal Health Office has suspended the marketing authorization for pharmaceutical products containing orgotein on the grounds that unjustifiable risk outweighs the benefits. The Agency has received about 400 reports of adverse reactions - 90 of these reports describe serious hypersensitivity reactions, some of which were fatal. (Reference: (DEUPD) BGA Pressedienst, 19/1994, , 30 Mar 1994)
NOR	1995	Preparations for oral use were withdrawn from the market in 1975. Preparations for parenteral use have been withdrawn from the market.
VEN		Banned due to undesirable effects.
WHO Comment : Practolol, a beta-adrenoreceptor antagonist, was introduced in 1970 for the treatment of angina and cardiac dysrhythmias. By 1974 long-term use had been associated with serious delayed idiosyncratic reactions (oculo-mucocutaneous syndrome) and this led to the withdrawal of oral preparations by the major manufacturer on a worldwide basis. There is no evidence to suggest that other beta-adrenoreceptor antagonist are associated with this risk. Intravenous preparations of practolol remain available in many countries for the emergency treatment of selected cardiac dysrhythmias.		

Product Name	Prasterone	
C.A.S. number	53-43-0	
Scientific and common names, and synonyms		
DHEA		
DEHYDROEPIANDROSTERONE		
DEHYDROANDROSTERONE		
3BETA-HYDROXYANDROST-5-EN-17-ONE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
USA	1985	The Food and Drug Administration has withdrawn products containing prasterone on grounds of lack of information on efficacy and safety of long-term use. These products, which were available without prescription, were promoted for weight reduction, enhanced sexual function and extension of life. (Reference: (HHSNS) HHS News: US Department of Health and Human Services, , , Apr 1985)
WHO Comment : The World Health Organization has no information further to the above regarding preparations containing prasterone or to indicate that such preparations remain available.		

Product Name	Prenylamine	
C.A.S. number	390-64-7	
Scientific and common names, and synonyms		
BENZENEPROPANAMINE, N-(1-METHYL-2-PHENYLETHYL)-GAMMA-PHENYL-		
N-(3,3-DIPHENYLPROPYL)-ALPHA-METHYLPHENETHYLAMINE		

Legislative or regulation action

Product Name	Prenylamine	
C.A.S. number	390-64-7	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
@WD	31 Mar 1989	<p>Following reports of polymorphic ventricular tachycardia that led to withdrawal of prenylamine in the United Kingdom and the Federal Republic of Germany, the manufacturer has decided to withdraw the product from the market worldwide from 31 March 1989.</p> <p>WHO Comment : Prenylamine is a calcium-channel blocking agent which was introduced in 1960. It has been widely used for the prophylaxis of angina pectoris and long-term treatment of coronary heart disease. Concern about its propensity to induce dangerous cardiac dysrhythmias led the company to withdraw it from the market.</p>
Product Name	Progabide	
C.A.S. number	62666-20-0	
Scientific and common names, and synonyms		
<p>BUTANAMIDE, 4-(((4-CHLOROPHENYL)(5-FLUORO-2-HYDROXYPHENYL)METHYLENE) AMINO)-4-((ALPHA-(P-CHLOROPHENYL)-5-FLUOROSALICYLIDENE)AMINO)BUTYRAMIDE</p>		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
FRA	17 Mar 1986	<p>Following the development of icteric hepatitis in patients taking progabide, the major manufacturer advised doctors that its use should be restricted to patients unresponsive to other anticonvulsants.</p> <p>WHO Comment : Progabide, an anticonvulsant, was introduced in France in 1985 for the treatment of epilepsy. Its use has occasionally been associated with clinically evident signs of icteric hepatitis developing within the first six months of treatment. These signs are generally reversible on withdrawal of the drug but continuation of treatment has been associated with three reported fatalities (two of which are doubtfully related to the drug). The manufacturer revised the data sheet in March 1986 advising that use of progabide should be reserved for patients unresponsive to other anticonvulsants.</p>
Product Name	Promethazine	
C.A.S. number	60-87-7	
Scientific and common names, and synonyms		
<p>10H-PHENOTHIAZINE-10-ETHANAMINE, N,N,?-TRIMETHYL-, MONOHYDROCHLORIDE 10H-PHENOTHIAZINE-10-ETHANAMINE, N,N,ALPHA-TRIMETHYL- 10-[2-(DIMETHYLAMINO)PROPYL]-PHENOTHIAZINE</p>		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GBR	Oct 1994	<p>The section on contraindications in the data sheet for the antihistamine, promethazine will now state: "Not for use in children under two years of age because safety of such use has not been established". (Reference: (GBRPHJ) The Pharmaceutical Journal, 253: 512, , 08 Oct 1994)</p>
MAR	May 2000	<p>The National Commission form Pharmacovigilance has restricted the administration of this product for children over 2 years of age.</p>

Legislative or regulation action

Product Name	Promethazine	
C.A.S. number	60-87-7	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		(Reference: (MARDMP) Letter to WHO, , , 08 Sep 2000) WHO Comment : Introduced in 1946, promethazine, a phenothiazine derivative has a variety of pharmacological properties. At present it is mainly used as an antihistamine and anti-motion-sickness drug. Promethazine is listed in the WHO Model List of Essential Drugs.

Product Name	Propafenone	
C.A.S. number	54063-53-5	
Scientific and common names, and synonyms		
	1-PROPANONE, 1-[2-[2-HYDROXY-3-(PROPYLAMINO)PROPOXY]PHENYL]-3-PHENYL- 2'-[HYDROXY-3-(PROPYLAMINO)PROPOXY]-3-PHENYLPROPIOPHENONE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
JPN	Sep 1990	Products containing propafenone were restricted to the treatment of patients unsuitable for or unresponsive to other antiarrhythmic agents, on the grounds that they had been associated with cases of ventricular tachycardia and fibrillation, some of which were fatal. (Reference: (JPNARD) Information on Adverse Reactions to Drugs, 104, , Sep 1990)
MYS	Feb 1991	The indications for products containing propafenone were restricted to the suppression of life-threatening ventricular arrhythmias, including sustained ventricular tachycardia, on the grounds that their potential to induce adverse effects must be assumed to be similar to that of encainide and flecainide. (Reference: (MYSDN) Berita Ubat-Ubatan (Drug Newsletter), 5(1):2, , 1991) WHO Comment : Propafenone, a membrane-stabilizing antiarrhythmic agent, was introduced into medicine in the mid 1980s. Shortly afterwards, its use became associated with cases of severe cardiac arrhythmias, which led to notable restrictions in the drug's indications in at least two countries. See also WHO comment for flecainide.

Product Name	Propionic acid	
C.A.S. number	79-09-4	
Scientific and common names, and synonyms		
	PROPANOIC ACID	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	1987	Having regard to proliferative lesions associated with administration of high dosages of propionic acid to experimental animals, the Federal Health Office restricted its use as a preservative and prohibited its use in bread. (Reference: (BGHBL) Bundesgesundheitsblatt, 30(10), 370, 1987)

Product Name	Propofol	
C.A.S. number	2078-54-8	
Scientific and common names, and synonyms		

Legislative or regulation action

Product Name Propofol
C.A.S. number 2078-54-8
Scientific and common names, and synonyms
 DISOPROFOL
 2,6-DI-ISOPROPYLPHENOL
 2,6-BIS(1-METHYLETHYL)PHENOL

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
ISR	1992	The Ministry of Health has not approved propofol for use in children. (Reference: (ISRMH) Ministry of Health, Israel, , , 29 June 1992)
NOR	06 Apr 1992	The use of propofol for long term sedation in children was not approved in Norway. The drug authorities in Norway strongly advised Norwegian hospitals not to use propofol in children. (Reference: (NORMCA) Norwegian Medicines Control Authority, , , 06 Apr 1992)
GBR	Jun 1992	The Committee on Safety of Medicines reminded doctors that the use of propofol for sedation in children has not been evaluated and, in light of serious and sometimes fatal reactions, such use is not recommended. (Reference: (GBRCSM) Committee on Safety of Medicines, Current problems, 34, , June 1992)
LTH	Mar 2001	The State Medicines Control Agency of Lithuania (SMCA) has further extended the restrictions on the use of propofol. The agency has advised that propofol is not a recommended drug and should not be used for sedation in children below the age of 16 years. (Reference: (LTHPHB) LSMCA bulletin "Pharmacon", No. 5-6, 2001, , 17 Sep 2001) (Reference: (LTHMCA) Order of State Medicines Control Agency, order no. 43, , 23 Mar 2001)

WHO Comment : Propofol, a short acting injectable anaesthetic, was introduced in 1987. In April 1992, the Norwegian Medicines Control Board reported that prolonged use of propofol had been associated with two fatalities in children characterized by metabolic acidosis, liver enlargement, and cerebral oedema. The UK Committee on the Safety of Medicines has received 5 reports of deaths occurring in children who had received propofol while in intensive care.

Product Name Propylhexedrine
C.A.S. number 3595-11-7
Scientific and common names, and synonyms
 CYCLOHEXANEETHANAMINE, N,ALPHA-DIMETHYL-(+/-)
 (+/-)-N,ALPHA-DIMETHYLCYCLOHEXANEETHYLAMINE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
DEU	Jul 1981	Administration of centrally active appetite inhibiting preparations containing propylhexedrine has been restricted to four weeks. A warning concerning the risk of dependence has been included in the package leaflet. WHO Comment : Propylhexedrine, a sympathomimetic amine, has been widely available since 1949 in over-the-counter inhalants for nasal decongestion and in oral anorexic preparations. As dependence can occur and because abuse has been reported, propylhexedrine was subjected in 1986 to control under Schedule IV of the 1971 Convention on Psychotropic Substances. (Reference: (WHTAC2) 2nd Report of the WHO Expert Committee on Drug Dependence (IV), 729, , 1985)

Legislative or regulation action

Product Name	Propylhexedrine	
C.A.S. number	3595-11-7	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
<hr/>		
Product Name	Propyphenazone	
C.A.S. number	479-92-5	
Scientific and common names, and synonyms		
ISOPROPYLANTIPYRINE		
4-ISOPROPYL-2,3-DIMETHYL-1-PHENYL-3-PYRAZOLIN-5-ONE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
<hr/>		
TUR	Jan 1986	Banned for production and sale having regard to severe adverse reactions.
ITA	1989	Having regard to the adverse effects associated with their long-term use, products containing propyphenazone may now be indicated only for the short-term treatment of severe pain or pyrexia. (Reference: (BIFTI) Bolletino d'Informazione sui Farmaci, 13(2), 5, 1989)
ARE		Pharmaceutical preparations containing propyphenazone are banned.
BHR		Preparations containing propyphenazone have been withdrawn.
IRL		Following the occurrence of a case of fatal aplastic anaemia in a patient taking a propyphenazone-containing product for a prolonged period, the regulatory authority requested that the product be reformulated to exclude this ingredient. WHO Comment : Propyphenazone, a pyrazolone derivative with anti-inflammatory, analgesic and antipyretic activity, was introduced in 1951 for the treatment of rheumatic disorders. As it is structurally related to aminophenazone it has been associated with severe blood dyscrasias. However, it cannot be transformed into potentially carcinogenic nitrosamines and has therefore been widely used as a replacement drug for aminophenazone. In certain countries, products containing propyphenazone have now been restricted in their indications, whereas in others they are still available, sometimes as over-the-counter preparations. See also WHO comment for aminophenazone.
<hr/>		
Product Name	Proxibarbal	
C.A.S. number	2537-29-3	
Scientific and common names, and synonyms		
5-ALLYL-5-(2-HYDROXYPROPYL)BARBITURIC ACID		
PROXIBARBITAL		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
<hr/>		
FRA	Apr 1998	The Medicines Agency has withdrawn proxibarbal from the market after a benefit/risk evaluation showed that it may induce immunoallergic thrombocytopenia with potentially severe consequences. Proxibarbal was indicated for the treatment of minor signs of anxiety and hot flushes of the menopause and migraine. The company has already withdrawn proxibarbal in Italy, Spain, Portugal and Turkey. It is still marketed in Hungary and Poland. (Reference: (FRAAMC) Communiqué de Presse, , , 16 Apr 1998)

Legislative or regulation action

Product Name	Proxibarbal	
C.A.S. number	2537-29-3	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
FRA	Apr 1998	The manufacturer has voluntarily withdrawn proxibarbal in France after an evaluation by the Medicines Agency concluded that the risk-benefit ratio of proxibarbal is unfavourable given the identified risk of immunoallergic thrombopenia. (Reference: (FRAAMC) Communiqué de Presse, , , 16 Apr 1998)

Product Name	Pumactant	
Scientific and common names, and synonyms		
ARTIFICIAL LUNG EXPANDING COMPOUND		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GBR	Apr 2000	Pumactant was voluntarily withdrawn from the market by the licence holder following the results of a randomized clinical trial which showed unexpectedly higher mortality rate in neonates given pumactant. (Reference: (GBRMCA) Communication to WHO, , , 30 Aug 2000)

Product Name	Pyridoxine (Vitamin B6)	
C.A.S. number	65-23-6	
Scientific and common names, and synonyms		
3,4-PYRIDINEDIMETHANOL, 5-HYDROXY-6-METHYL-, HYDROCHLORIDE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GBR	Jul 1997	The Committee on the Safety of Medicines has advised that vitamin B6 in daily dose above 50mg should be available on prescription only, and that the general sales supply of vitamin B6 should be restricted to products providing a daily dose of 10mg or less. This action has been taken because of reports of peripheral neuropathy after daily doses of 50-mg. (Reference: (GBRPHJ) The Pharmaceutical Journal, 259 : 46, , 12 July 1997) WHO Comment : Pyridoxine (vitamin B6) is listed in theWHO Model List of Essential Drugs.

Product Name	Pyrithione zinc	
C.A.S. number	13463-41-7	
Scientific and common names, and synonyms		
ZINC PYRIDINETHIONE, SKIN-CA ZINC 2-PYRIDINETHIOL 1-OXIDE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
ARE	1997	The Ministry of Health has withdrawn the marketing approval for pyrithione zinc that is indicated for the treatment of dandruff or psoriasis. This follows concern raised by the

Legislative or regulation action

Product Name	Pyrrhione zinc	
C.A.S. number	13463-41-7	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
ARM	Aug 1999	FDA and Canada after closer analysis of the product revealed that it contained an (unlabelled) prescription strength corticosteroid (clobetasol). (Reference: (UAEDIB) Drug Information Bulletin, No. 3, p.2, 1997) The Drug and Medical Technology Agency has restricted the indications for pyrrhione zinc to seborrhoeic dermatitis. (Reference: (ARMCW) Communication to WHO, , , 09 Aug 2000)

Product Name	Pyritinol	
C.A.S. number	1098-97-1	
Scientific and common names, and synonyms		
	PYRITHIOXINE 3,3'-(DITHIODIMETHYLENE)BIS(5-HYDROXY-6-METHYL-4-PYRIDINEMETHANOL)	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
BGD	1982	Under the provisions of the Drugs (Control) Ordinance, this product has been banned due to evidence of insufficient therapeutic value and risk of misuse. (Reference: (BGDCO) The Drugs (Control) Ordinance, , , 1982) WHO Comment : Pyritinol, which is claimed to promote the uptake of glucose in the brain, is used in the treatment of cerebrovascular disorders. However, WHO is not aware of controlled experimental data to show that it has any therapeutic effect.

Product Name	Pyrrrolizidine	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	1992	The Federal Health Office has decided to withdraw certain medicines containing pyrrrolizidine alkaloids with a 1,2 unsaturated necine structure which occur in the cells of many plant species on the grounds that they are potentially carcinogenic and hepatotoxic. (Reference: (DEUPZ) Pharmazeutische Zeitung, 137(32):2400, , 1992)
BEL	02 Sep 1992	The Minister of Social Integration, Public Health and the Environment decided to prohibit the use of medicinal products derived from plants containing pyrrrolizidine alkaloids having regard to the potential of these substances to induce veno-occlusive liver disease, pulmonary and central nervous system toxicity, as well as their potential carcinogenicity, mutagenicity and teratogenicity. (Reference: (BELMD) Ministerial Decree, , , 02 Sep 1992)
GBR	20 Mar 1993	Tablet and capsule formulations of comfrey containing pyrrrolizidine alkaloids have been voluntarily withdrawn from the market following reports of liver toxicity. (Reference: (GBRPHJ) The Pharmaceutical Journal, 377, , 20 Mar 1993) WHO Comment : Plants containing pyrrrolizidine alkaloids have traditionally been made into teas in the Caribbean and South-East Asia and several of these active substances have been incorporated into medicines for use in treatment for a variety of illnesses. The decision to prohibit use of these products was based on their association with a variety of adverse effects and on their hepatotoxic and

Legislative or regulation action

Product Name **Pyrrrolizidine**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
		carcinogenic potential as seen in both laboratory animals and in communities that commonly use plants containing these compounds to prepare teas and other beverages.

Product Name **Quinine sulfate**

C.A.S. number **804-63-7**

Scientific and common names, and synonyms

CINCHONAN-9-OL, 6'-METHOXY-, (8?, 9R)-, SULFATE (2:1) (SALT)
CHININI SULFAS

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
USA	22 Aug 1994	After reviewing the available information concerning over-the-counter drug products for the treatment and/or prevention of nocturnal leg muscle cramps, the Food and Drug Administration has concluded that the risk associated with use of quinine sulfate, in the absence of evidence of its effectiveness, outweighs any potential benefit in treating and/or preventing this benign, self-limiting condition. Moreover, in doses used to treat or prevent this condition, quinine sulfate has caused adverse events such as transient visual and auditory disturbances, dizziness, fever, nausea, vomiting and diarrhoea. Quinine sulfate has been reported to cause unpredictable serious and life-threatening hypersensitivity reactions requiring medical intervention and hospitalization, including fatalities. (Reference: (FEREAC) Federal Register, 59(161) , p. 43234, 1994)
USA	20 Mar 1998	The Food and Drug Administration has issued a final rule revoking approval for over-the-counter sale of products containing quinine for the treatment and/or prevention of malaria because the treatment of malaria requires medical supervision. Additionally, the agency is concerned about the possible misuse of quinine for the treatment or prevention of night-time leg muscle cramps, an indication that has been revoked (see other entry). (Reference: (FEREAC) Federal Register, 63(54) , p. 13526, 1998) WHO Comment : Quinine is an important drug in the treatment of multi- drug-resistant forms of malaria. Its use in nocturnal leg muscle cramps, a benign and self-limiting condition, is connected with unjustified risks. Quinine is listed in the WHO Model List of Essential Drugs for treatment of malaria.

Product Name **Remifentanil**

C.A.S. number **132875-61-7**

Scientific and common names, and synonyms

1-PIPERIDINEPROPANOIC ACID, 4-(METHOXYCARBONYL)-4-[(1-OXOPROPYL)PHENYLAMINO]-, METHYL ESTER, MONOHYDROCHLORIDE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
USA	Nov 1996	The Drug Enforcement Administration has rescheduled the narcotic analgesic, remifentanil and its salts, into Schedule II of the Controlled Substances Act, thus subjecting it to the corresponding regulatory controls and criminal sanctions governing its manufacture, distribution, dispensing, importation and exportation. (Reference: (FEREAC) Federal Register, 61(222) , p. 58471, 1996)

Legislative or regulation action

Product Name	Remifentanyl	
C.A.S. number	132875-61-7	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
WHO Comment : Remifentanyl is defined as an opioid narcotic with an addiction-forming and addiction-sustaining liability similar to morphine.		
Product Name	Remoxipride	
C.A.S. number	117591-79-4	
Scientific and common names, and synonyms		
BENZAMIDE, 3-BROMO-N-[(1-ETHYL-2-PYRROLIDINYL)METHYL]-2,6-DIMETHOXY-, (S)		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
@WD	14 Mar 1994	The manufacturer of the antipsychotic dopamine antagonist, remoxipride, has decided to withdraw the product licence worldwide following concern about an association with its use and aplastic anaemia. It will, however, remain available on a compassionate basis for named patients. (Reference: (ASTRA) Communication from Astra, , 14 Mar 1994)
Product Name	Retinol	
C.A.S. number	68-26-8	
Scientific and common names, and synonyms		
AXEROPHTHOCUM VITAMIN A 3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)-2,4,6,8-NONATETRAEN-1-OL		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	1 Apr 1989	Oral dosage forms of products containing vitamin A (retinol) are required to bear the following warnings: 1) preparations bearing a maximum recommended daily dosage of more than 25000 IU: "Because of danger of congenital malformations, not allowed during pregnancy nor for women of childbearing age." 2) preparations bearing a maximum recommended daily dosage of 10000 IU to 25000 IU: "Contraindicated during pregnancy because of danger of congenital malformations." 3) preparations bearing a maximum recommended daily dosage of 10000 IU: "Pregnant women should not exceed the recommended daily dosage except on medical advice." (Reference: (DAZ) Deutsche Apotheker Zeitung, 128(41), 85, 1988)
AUS	1996	The Adverse Drug Reactions Advisory Committee has reminded prescribers of the need to advise patients who are pregnant or likely to become pregnant not to exceed the recommended daily allowance of vitamin A (retinol) from all sources because of the risk of birth defects. The label should also bear the following warning statement: "WARNING - Taking more than 25,000 IU a day during pregnancy may cause birth defects". (Reference: (AUSADR) Australian Adverse Drug Reactions Bulletin, 15(4):14, , 1996)
IRL	May 1996	Following the review of a study that concluded that high dietary intake of Vitamin A (retinol) appears to be teratogenic, the Irish Medicines Board requested marketing authorization holders to update product authorization documents for these products accordingly and stresses that women who are pregnant or likely to become pregnant should be aware of the potential risks associated with high doses of Vitamin A both from

Legislative or regulation action

Product Name	Retinol	
C.A.S. number	68-26-8	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		<p>dietary and supplementary sources (more than 10,000 units per day). (Reference: (NEJOM) New England Journal of Medicine, 333:1369-73, , 1995) (Reference: (IRDDS) Drug Safety Newsletter, No. 2, , May 1996)</p> <p>WHO Comment : Vitamin A, a fat-soluble vitamin, is used in the treatment and prevention of vitamin A deficiency resulting from inadequate dietary intake. It has been demonstrated to be teratogenic at high doses (more than 25,000 IU per day). Daily dosages of less than 10000 IU seem to be free of this risk. Retinol (vitamin A) is listed in the WHO Model List of Essential Drugs.</p>
Product Name	Rituximab	
C.A.S. number	174722-31-7	
Scientific and common names, and synonyms		
IDEC-102		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GBR	Feb 1999	<p>The Medicines Control Agency has severely restricted the use of the monoclonal antibody used in the treatment of non- Hodgkin's lymphoma. Treatment should now only be undertaken in a hospital environment under the close supervision of a specialist oncologist/haematologist who has access to full resuscitation facilities. This is because of a number of cases of serious infusion-related reactions reported worldwide including 8 with a fatal outcome. (Reference: (GBRMCA) Communication to WHO, , , 30 Aug 2000)</p>
Product Name	Rubiae tinctorum radix	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	29 Apr 1992	<p>The Federal Health Office has decided to revoke the marketing authorization of all medicinal products containing derivatives of Rubiae tinctorum radix, including lucidin and other derivatives of anthraquinone. (Reference: (DEUFHO) Communication from Federal Health Office, , , 29 Apr 1992)</p> <p>WHO Comment : Extracts of Rubiae tinctorum radix have traditionally been used as treatment for a variety of diseases. Regulatory action has been taken because insufficient evidence has been gathered about its efficacy. Lucidin (1,2-dihydroxyanthraquinone), a component of Rubia tinctorum, has been shown in animal experiments to induce both benign and malignant tumours in the gastric and intestinal mucosa. Lucidin is positive for the Ames test indicating possible genotoxicity.</p>
Product Name	Santonin	
C.A.S. number	481-06-1	
Legislative or regulative action		

Legislative or regulation action

Product Name	Santonin	
C.A.S. number	481-06-1	
Country	Effective Date	Description of action taken Grounds for decision
SGP	Oct 1978	Importation prohibited. WHO Comment : Santonin, a crystalline lactone obtained from flowerheads of species of <i>Artemisia</i> , was formerly used as an anthelmintic. Its use was associated with a range of adverse effects, mainly involving the sense organs and the central nervous system, some of which were fatal. It has been superseded by other less toxic and more effective anthelmintics.

Product Name	Scopolamine	
C.A.S. number	51-34-3	
Scientific and common names, and synonyms		
6BETA,7BETA-EPOXY-1ALPHA,5ALPHA-TROPAN-3ALPHA-OL(-)-TROPATE (ESTER) BENZENEACETIC ACID, ALPHA-(HYDROXYMETHYL)-, 9-METHYL-3-OXA-9-AZATRICYCLO[3.3.1.0.???]NON-7-YL ESTER, [7(S)-(1ALPHA,2BETA,4BETA,5ALPHA,7BETA)- HYSOCINE		

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
NOR	1 Mar 1988	Depot plasters containing scopolamine have been subjected to prescription control, on the grounds of adverse effects including visual disturbances, hallucinations and glaucoma. (Reference: (NNSLM) Nytt fra Statens Legemiddelkontroll, 2, 8, 1988) WHO Comment : Scopolamine, an alkaloid with anticholinergic activity extracted from solanaceous plants, was introduced into medicine in 1888. It is used as a mydriatic, as an anti-emetic for the control of motion sickness, and for premedication in general anaesthesia. Shortly after their introduction in the early 1980's, transdermal delivery systems containing scopolamine that were indicated for the prevention of motion sickness were associated with visual disorders (e.g. mydriasis, glaucoma) and hallucinations. The action taken in Norway is in accordance with the legislation in several other countries where these preparations have always been subjected to prescription control.

Product Name	Secobarbital	
C.A.S. number	76-73-3	
Scientific and common names, and synonyms		
5-ALLYL-5-(1-METHYLBUTYL) BARBITURIC ACID QUINALBARBITONE 2,4,6-(1H,3H,5H)-PYRIMIDINETRIONE, 5-(1-METHYLBUTYL)-5-(2-PROPENYL)-		

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
GHA	1 Sep 1989	Products containing secobarbital have been banned. (Reference: (GHAPDR) Pharmacy and Drugs (Banned Drugs) Regulations, Legislative Instruments, 1484, , 1989)
NZL	1990	In agreement with the Department of Health, products containing secobarbital sodium have been withdrawn by the manufacturer. (Reference: (NZCSL) Clinical Services Letter, Department of Health, 258, , 16 July 1990)

Legislative or regulation action

Product Name	Secobarbital	
C.A.S. number	76-73-3	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
OMN	May 1991	Import and marketing of products containing secobarbital were prohibited. (Reference: (OMNCR) Circular, 16/91, , May 1991) WHO Comment : Secobarbital is a short to intermediate-acting barbiturate which is controlled under Schedule III of the 1971 Convention on Psychotropic Substances. See WHO comment for barbiturates. (Reference: (UNCPS3) United Nations Convention on Psychotropic Substances (III), , , 1971)

Product Name	Selegiline	
C.A.S. number	14611-51-9	
Scientific and common names, and synonyms		
BENZENEETHANAMINE, N,?-DIMETHYL-N-2-PROPYNYL-, HYDROCHLORIDE, (R)-DEPRENYL		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
USA	Feb 1995	The Food and Drug Administration modified the data sheet for selegiline to reflect the risk of severe adverse events when the drug is used in patients taking antidepressants or selective serotonin receptor antagonists. (Reference: (FDAMB) FDA Medical Bulletin, 25(1), p.6, Feb 1995)
USA	Mar 1997	The Food and Drug Administration modified the data sheet for selegiline to note that a few reports of hypertensive reactions associated with the ingestion of tyramine-containing foods have occurred in patients receiving the product at the recommended dose (5 mg, twice daily). (Reference: (FDAMB) FDA Medical Bulletin, 27(1), p.5, Mar 1997)
USA	Mar 1997	The Food and Drug Administration refused marketing approval for selegiline citrate for the treatment of Alzheimer's disease. (Reference: (FEREAC) Federal Register, 59(96) , p. 26239, 19 May 1994) WHO Comment : Selegiline was introduced in the early 1990s. It is a monoamine oxidase inhibitor and is used in the management of Parkinson's disease. A symptomatic effect of selegiline in Parkinson's disease has been shown, but longer follow-up failed to provide any definitive evidence of ability to retard the loss of dopaminergic neurons (Parkinson's Study Group, 1993).

Product Name	Sertindole	
C.A.S. number	106515-24-9	
Scientific and common names, and synonyms		
LU-23-174 1-(2-(4-[5-CHLORO-1-(P-FLUOROPHENYL)INDOL-3-YL]PIPERIDINE)ETHYL)2-IMIDAZOLIDINONE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GBR	Dec 1998	The manufacturer of the antipsychotic medication, sertindole (serdolect) voluntarily suspended the availability of serdolect. This is because of concerns about reports of

Legislative or regulation action

Product Name Sertindole

C.A.S. number 106515-24-9

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
BGR		cardiac arrhythmias and sudden cardiac death associated with its use. (Reference: (GBRCW) Communication, , , 02 Dec 1998) The Bulgarian Drug Agency in the Ministry of Health withdrew the atypical antipsychotic agent sertindole (serdolect) because of serious adverse reactions worldwide. (Reference: (BGRBDA) Communication to WHO, , ,)

Product Name Sibutramine

C.A.S. number 106650-56-0

Scientific and common names, and synonyms

BTS-54524 (SIBUTAMINE HYDROCHLORIDE)

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
USA	1998	The Drug Enforcement Administration has placed sibutramine for the management of obesity, in Schedule IV of the Controlled Substances Act. This scheduling is based on the low potential for abuse of sibutramine and the fact that it has a currently accepted medical use in treatment in the United States. (Reference: (FEREAC) Federal Register, 63(28) , p. 6862, 1998)

Product Name Sildenafil

C.A.S. number 139755-83-2

Scientific and common names, and synonyms

1-[[3-(4,7-DIHYDRO-1-METHYL-7-OXO-3-PROPYL-1-H-PYRAZOLO[4,3-D]PYRIMIDIN-5-YL)-4-ETHOXYPHENYL]SULFONYL]-4-METHYLPIPERAZINE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
CHL	Sep 2001	The Public Health Institute of Chile modified the labels to include the information that a medical evaluation is needed before administering this medication. (Reference: (CHLCW) Communication to WHO, , , 26 Sep 2001)

Product Name Silver acetate

C.A.S. number 563-63-3

Scientific and common names, and synonyms

ARGENTI ACETATE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
CYP	23 Oct 1992	The Drugs Council rejected a marketing application for a lozenge preparation containing silver acetate intended as a smoking deterrent. (Reference: (CYPPS) Pharmaceutical Services, Ministry of Health, , , 23 Oct 1992) WHO Comment : Silver acetate has been used as a disinfectant and as an anti-smoking aid. It was refused registration in Cyprus on the grounds that prolonged

Legislative or regulation action

Product Name **Silver acetate**

C.A.S. number **563-63-3**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
		use of silver salts can cause permanent argyria and that no well-controlled trials have been performed to establish the safety and efficacy of the preparation. It remains registered as an aid to stopping smoking in Canada and the United States.

Product Name **Sodium dibunate**

C.A.S. number **14992-59-2**

Scientific and common names, and synonyms

SODIUM 2,6-DI-TERT-BUTYL-1(OR 3)-NAPHTHALENESULFONATE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
PHL	Apr 1982	Withdrawn from use as an antitussive following demonstration of central nervous system toxicity in experimental mice. Prolonged administration in humans results in reduction in granular leukocytes.

Product Name **Sodium hydrogen bicarbonate (paediatric)**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
NPL	21 Jul 1997	The health authorities have banned the importation, manufacture, sale, distribution and storage of sodium hydrogen bicarbonate in liquid formulations intended for paediatric use. This action has been taken on the basis of safety concerns relating to this product. (Reference: (NPLGZ) Nepal Gazette, Part 47(15), Notice 1, 21 July 1997)

Product Name **Somatropin (pituitary-derived)**

C.A.S. number **12629-01-5**

Scientific and common names, and synonyms

GROWTH HORMONE, HUMAN

HGH

STH

SOMATOTROPIN

SOMATOTROPHIN

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
CYP	1985	Voluntarily withdrawn by Kabi Vitrum following reports of deaths associated with its use.
IRL	1985	Some preparations containing growth hormone derived from human pituitary have been withdrawn while use of others is severely restricted.
ISR	1985	The Ministry of Health has decided that no patients should be newly placed on growth hormone therapy unless they are suffering from associated hypoglycaemia. (Reference: (ISRDB) Israel Drug Information Bulletin, , , Feb 1987)

Legislative or regulation action

Product Name		Somatropin (pituitary-derived)	
C.A.S. number		12629-01-5	
Legislative or regulative action			
Country	Effective Date	Description of action taken Grounds for decision	
NZL	1985	Preparations of somatropin (growth hormone) extracted from human pituitary glands have been withdrawn by the Department of Health following reports of Creutzfeldt-Jakob disease associated with their use. (Reference: (NZCSL) Clinical Services Letter, Department of Health, , ,)	
BEL	May 1985	The National Commission for Pituitary Dwarfism has advised doctors not to prescribe somatropin (human growth hormone) following reports of Creutzfeldt-Jakob disease associated with their use. (Reference: (BFOLP) Folia Pharmacotherapeutica, 12(6), 46, 1985)	
GBR	May 1985	Withdrawn following reports of deaths associated with its use.	
NLD	May 1985	The use of products containing pituitary-derived human growth hormone (somatropin) was discontinued following reports of Creutzfeldt-Jakob disease associated with their use.	
EGY	9 Jul 1985	Withdrawn from the market.	
USA	Aug 1985	The Food and Drug Administration has withdrawn the licence of the National Pituitary Agency for manufacture of human growth hormone preparations following reports of death associated with their use. (Reference: (FDADB) FDA Drug Bulletin, 15(2), 17-18, 1985)	
DEU	Sep 1985	The Federal Health Office has informed doctors to restrict the use of human somatropin (growth hormone) to the treatment of pituitary dwarfism with hypoglycaemic reactions or before the end of the growth period. Preparations must bear a warning that some patients contracted Creutzfeldt-Jakob disease after treatment. No more than three batches should be used for each patient.	
TUR	Oct 1985	Banned for production, import, export, sale and use having regard to severe adverse reactions.	
OMN	16 Jan 1986	Import of pharmaceutical preparations containing somatropin (human growth hormone) has been prohibited following reports of Creutzfeldt-Jakob disease associated with their use. (Reference: (OMNMH) Ministry of Health, 2, , 1986)	
ITA		The manufacture and use of somatropin (human growth) hormone have been restricted following reports of Creutzfeldt-Jakob disease associated with its use.	
THA		Preparations containing somatropin are not approved for use.	
<p>WHO Comment : Somatropin, a pituitary-derived human growth hormone, has been used in the treatment of hypopituitary dwarfism for over twenty years. In 1985 it became known that Creutzfeldt-Jakob disease, a potentially fatal form of brain degeneration resulting from a slow neurotropic viral infection, had developed in several patients who had received preparations of somatropin in the late 1960s/early 1970s. This led to the withdrawal of these preparations in many countries. An international collaborative effort was maintained to identify newly-diagnosed cases. By 1990 a total of 30 such cases had been notified. More efficient purification procedures introduced during the 1970s greatly reduced the risk of viral contamination, but products containing pituitary-derived somatropin have been superseded by biosynthetically-manufactured preparations produced using recombinant techniques.</p>			

Product Name		Sotalol	
C.A.S. number		3930-20-9	
Scientific and common names, and synonyms			
METHANESULFONAMIDE, N-[4-[1-HYDROXY-2-[(1-METHYLETHYL)AMINO]ETHYL]-PHENYL]-, MONOHYDROCHLORIDE			

Legislative or regulation action

Product Name	Sotalol	
C.A.S. number	3930-20-9	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GBR	Jul 1996	The Committee on Safety of Medicines has restricted the indications of sotalol to the treatment of ventricular arrhythmias or prophylaxis of supraventricular arrhythmias. (Reference: (GBRCP) Current Problems in Pharmacovigilance, 22:6-7, , July 1996) WHO Comment : Sotalol is a non-selectiveβ-adrenoreceptor antagonist. It should be noted that when stopping sotalol the dose should be reduced gradually.
Product Name	Sparfloxacin	
C.A.S. number	110871-86-8	
Scientific and common names, and synonyms		
5-AMINO-1-CYCLOPROPYL-7-(CIS-3,5-DIMETHYLPYPERAZIN-1-YL)-6,8-DIFLUORO-4-OXOQUINOLINE-3-CARBOXYLIC ACID		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
JPN	1995	The Pharmaceutical Affairs Bureau has decided to include a warning statement in the data sheet for sparfloxacin about photosensitivity and rash related to exposure to sunlight. (Reference: (JPNARD) Information on Adverse Reactions to Drugs, No.127, , July 1994)
FRA	Jun 1995	The Medicines Agency has announced that in view of a large number of reports of phototoxicity associated with the use of sparfloxacin, the indications for the use of sparfloxacin have been restricted to: acute bacterial pneumonia, diagnostically confirmed by X-ray, and to acute bacterial sinusitis with documented evidence of pneumococcus with reduced sensitivity to penicillin. (Reference: (FRAAMC) Communiqué de Presse, , , 06 June 1995) WHO Comment : Sparfloxacin is a quinolone antimicrobial agent. See also under quinolone and fluoroquinolone antimicrobial agents.
Product Name	Spirolactone	
C.A.S. number	52-01-7	
Scientific and common names, and synonyms		
PREGN-4-ENE-21-CARBOXYLIC ACID, 7-(ACETYLTHTIO)-17-HYDROXY-3-OXO,GAMMA- LACTONE, (7ALPHA,17ALPHA)-17-HYDROXY-7ALPHA-MERCAPTO-3-OXO-17ALPHA-PREGN-4-ENE-21-CARBOXYLIC ACID, GAMMA-LACTONE ACETATE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GBR	Oct 1986	Having regard to the possible carcinogenic risk associated with long-term use of spironolactone, the approved indications of products containing spironolactone are now restricted to cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, the diagnosis and treatment of primary hyperaldosteronism, and congestive heart failure. WHO Comment : Spirolactone, an aldosterone antagonist, has been widely used for over 25 years in the treatment of hypertension and in the management of refractive oedema. Evidence that long-term administration of high doses are tumorigenic in the rat has recently led to restriction of its use by some national regulatory authorities although the significance of this finding with respect to clinical use is not certain. In 1987 spironolactone was transferred from the main list to the complementary list of the WHO Model List of Essential Drugs. (See also

Legislative or regulation action

Product Name	Spironolactone	
C.A.S. number	52-01-7	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
WHO comments for canrenone and potassium canrenoate). (Reference: (WHODI) WHO Drug Information, 2(1), , 1988)		
Product Name	Streptomycin	
C.A.S. number	57-92-1	
Scientific and common names, and synonyms		
D-STREPTAMINE, O-2-DEOXY-2-(METHYLAMINO)-ALPHA-L-GLUCOPYRANOSYL-(1->2)-O-5-DEOXY-3-C-FORMYL-ALPHA-L-LYXOFURANOSYL-(1->4)-N,N'-BIS(AMINOIMINOMETHYL)-		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
KOR	May 1991	Antidiarrhoeal products containing streptomycin were not accepted for registration. (Reference: (KRMHSA) Ministry of Health and Social Affairs - Communication to WHO, , , 13 Dec 1991)
LBN	03 Aug 1991	Liquid formulations of products containing streptomycin indicated for the treatment of diarrhoea in children were withdrawn. (Reference: (LBNMHD) Ministry of Health and Social Affairs Decree, 150/1, , Aug 1991)
WHO Comment : Oral preparations of streptomycin, an aminoglycoside antibiotic isolated from streptomyces griseus in 1944, were formerly widely used to treat intestinal infections. There is no evidence that streptomycin is effective in this indication and its widespread use promotes the emergence of resistant strains of bacteria. The World Health Organization recommends that streptomycin should not be used for the treatment of diarrhoea. (Reference: (WHORUD) The Rational Use of Drugs, , , 1990)		
Product Name	Strychnine and salts	
C.A.S. number	57-24-9	
Scientific and common names, and synonyms		
STRYCHNIN (DEU)		
STRYCHNIDIN-10-ONE		
STRICNINA (ITA)		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
CAN	1979	The Health Protection Branch has considered the value of strychnine in drugs for human use and concluded that this substance has no established therapeutic significance. S.C. 01.038 of the Food and Drug Act states that "A drug for human use is adulterated if it contains: a) strychnine or any of its salts, b) extracts or tinctures of 1) Strychnos nuxvomica 2) Strychnos ignatii or 3) Strychnos species containing strychnine, other than those species mentioned in sub paragraph 1) and 2)".
BRA	17 Jul 1980	Products containing strychnine are prohibited. (Reference: (BRAPT) Portaria do Servico Publico Federal, (12), , 1980)
BGD	Mar 1982	Under the provisions of the Drugs (Control) Ordinance, this product has been banned. Authorities feel that "Strychnine should only be used as a rodenticide".

Legislative or regulation action

Product Name	Strychnine and salts	
C.A.S. number	57-24-9	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		(Reference: (BGDCO) The Drugs (Control) Ordinance, , , 1982)
JPN	1987	Preparations containing strychnine have been withdrawn.
PAK	Jan 1987	The Registration Board of the Ministry of Health has directed manufacturers to reformulate all preparations containing strychnine so as to delete this ingredient.
BRA	Feb 2001	Registration of combination products containing strychnine are banned because of the potential to cause convulsions. (Reference: (BRARES) Resolucao n., 147/ANVISA, , 14 Aug 2001)
ARE		Pharmaceutical preparations containing strychnine are banned.
PHL		Products containing strychnine are banned for use and sale.
WHO Comment : Strychnine, the principal alkaloid present in nux vomica, was first used in medicine several centuries ago. However, it has no demonstrated therapeutic value and there is no current justification for its presence in any medication. It continues to be used as a rodenticide though such use is severely restricted in many countries since accidental ingestion can be lethal.		

Product Name	Sulfacarbamide	
C.A.S. number	547-44-4	
Scientific and common names, and synonyms		
SULFANILYLUREA		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	1992	The Federal Health Office withdrew products containing sulfacarbamide from the market. This decision is based on a review carried out by the Advisory Panel for the Evaluation of Medicines which concluded that the benefit/risk ratio for these products is negative. (Reference: (DWM) Wichtige Mitteilungen, 18, , 1992) (Reference: (DAZ) Deutsche Apotheker Zeitung, 132(11), , 1992)
WHO Comment : Sulfacarbamide, a sulfonamide anti-infective agent, was introduced in the 1940's for the treatment of bacterial infections. The importance of sulfonamides has subsequently decreased as a result of increasing bacterial resistance and their replacement by antibiotics which are generally more active and less toxic. The Sulfacarbamide are known to cause serious adverse effects such as renal toxicity, sometimes fatal exfoliative dermatitis and erythema multiforma and dangerous adverse reactions affecting blood formation such as agranulocytosis and haemolytic or aplastic anaemia. Sulfacarbamide still remains available in at least one country for the treatment of urinary infections.		

Product Name	Sulfadiazine	
C.A.S. number	115-68-4	
Scientific and common names, and synonyms		
3-METHYL-N-SULPHANILYLCROTONAMIDE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision

Legislative or regulation action

Product Name	Sulfadicramide	
C.A.S. number	115-68-4	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	1992	<p>The Federal Health Office has withdrawn products containing sulfanilamide from the market. This decision is based on a review carried out by the Advisory Panel for the Evaluation of Medicines which concluded that the benefit/risk ratio for these products is negative.</p> <p>(Reference: (DWM) Wichtige Mitteilungen, 18, , 1992) (Reference: (DAZ) Deutsche Apotheker Zeitung, 132(11), , 1992)</p> <p>WHO Comment : Sulfadicramide, a sulfonamide anti-infective agent, was introduced in 1942 for the treatment of bacterial infections. The importance of sulfonamides has subsequently decreased as a result of increasing resistance and their replacement by antibiotics which are generally more active and less toxic. The sulfonamides are known to cause serious adverse effects such as renal toxicity, sometimes fatal exfoliative dermatitis and erythema multiforma and dangerous adverse reactions affecting blood formation such as agranulocytosis and haemolytic or aplastic anaemia. Sulfadicramide is still used in some countries as a 15% ointment for application to the eye.</p>

Product Name	Sulfadimidine	
C.A.S. number	57-68-1	
Scientific and common names, and synonyms		
SULFAMETHAZINE		
SULFADIMIDINUM		
SULFADIMEZINIUM		
SULFADIMETHYLPYRIMIDINE		
SULFADIMERAZINE		
4-(4,6-DIMETHYLPRIMIDINE-2-YL)SULPHANILIMIDE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	1992	<p>The Federal Health Office has withdrawn products containing sulfadimidine from the market. This decision is based on a review carried out by the Advisory Panel for the Evaluation of Medicines which concluded that the benefit/risk ratio for these products is negative.</p> <p>(Reference: (DWM) Wichtige Mitteilungen, 18, , 1992) (Reference: (DAZ) Deutsche Apotheker Zeitung, 132(11), , 1992)</p> <p>WHO Comment : Sulfadimidine, a sulfonamide anti-infective agent, was introduced in 1942 for the treatment of bacterial infections. The importance of sulfonamides has subsequently decreased as a result of increasing resistance and their replacement by antibiotics which are generally more active and less toxic. The sulfonamides are known to cause serious adverse effects such as renal toxicity, sometimes fatal exfoliative dermatitis and erythema multiforma and dangerous adverse reactions affecting blood formation such as agranulocytosis and haemolytic or aplastic anaemia. Sulfadimidine is still used in some countries as a injectable or oral antimicrobial for susceptible infections.</p>

Product Name	Sulfaguanidine	
C.A.S. number	57-67-0	
Scientific and common names, and synonyms		

Legislative or regulation action

Product Name **Sulfaguanidine**

C.A.S. number **57-67-0**

Scientific and common names, and synonyms

BENZENESULFONAMIDE, 4-AMINO-N-(DIAMINOMETHYLENE)-
N-AMIDINOSULPHANILAMIDE MONOHYDRATE
N1-(DIAMINOMETHYLENE)SULFANILAMIDE
SULGIN
SULGINUM
SOLFAGUANIDINA
SULFAMIDINUM

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
DOM	Jun 1971	Prohibited for import, manufacture, distribution, storage, sale or medical prescription. It has been found to be ineffectual in the treatment of acute bacterial dysentery and in therapeutic use with colon surgery in reducing hospitalization. Furthermore, it has been shown that most strains of Shigella have developed a resistance against this drug in vivo.
IRN	1972	The Ministry of Health has prohibited the importation and production of all drugs containing sulfaguanidine.
THA	Jan 1975	May only be used in the treatment of diarrhoea.
TUR	4 Mar 1985	Banned for production and sale having regard to severe adverse reactions.
PAK	1988	Tablets containing sulfaguanidine were withdrawn. (Reference: (PAKMH) Ministry of Health, Special Education and Social Welfare, , , Aug 1988)
NPL	1991	Products containing sulfaguanidine either alone or in combination, and intended for the treatment of diarrhoea in children, were banned. (Reference: (NPLDDA) Communication from the Department of Drug Administration, , , 27 Feb 1992)
DEU	1992	The Federal Health Office has withdrawn products containing sulfaguanidine from the market. This decision is based on a review carried out by the Advisory Panel for the Evaluation of Medicines which concluded that the benefit/risk ratio for these products is negative. (Reference: (DWM) Wichtige Mitteilungen, 18, , 1992) (Reference: (DAZ) Deutsche Apotheker Zeitung, 132(11), , 1992)
ARM	Jul 2000	The Drug and Medical Technology Agency withdrew registration of the antidiarrhoeal drug sulgin because of increasing resistance to sulfonamides and also because nonabsorbable sulfonamides containing antidiarrhoeal products are not recommended in the treatment of diarrhoea. (Reference: (ARMCW) Communication to WHO, , , 09 Aug 2000)
DNK		Withdrawn from the market by the manufacturer.
VEN		Not approved for use and/or sale. Compound currently under study.

WHO Comment : Sulfaguanidine, a sulfonamide anti-infective agent, was introduced in 1941 for the treatment of bacterial infections. The importance of sulfonamides has subsequently decreased as a result of increasing bacterial resistance and their replacement by antibiotics which are generally more active and less toxic. The sulfonamides are known to cause serious adverse effects such as renal toxicity sometimes fatal exfoliative dermatitis and erythema multiforma and dangerous adverse reactions affecting blood formation such as agranulocytosis and haemolytic or aplastic anaemia. Although sulfaguanidine, which is poorly absorbed from the gastrointestinal tract, is no longer recommended in some countries, it continues to be used in others for the treatment of local intestinal infections, including bacterial dysentery, and for pre-

Legislative or regulation action

Product Name	Sulfaguanidine	
C.A.S. number	57-67-0	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		operative bowel preparation.
Product Name	Sulfamerazine sodium	
C.A.S. number	127-58-2	
Scientific and common names, and synonyms		
	SULFAMERAZINUM NATRICUM	
	SOLUBLE SULPHERAMERAZINE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	1992	The Federal Health Office has withdrawn products containing sulfamerazine sodium from the market. This decision is based on a review carried out by the Advisory Panel for the Evaluation of Medicines which concluded that the benefit/risk ratio for these products is negative. (Reference: (DWM) Wichtige Mitteilungen, 18, , 1992) (Reference: (DAZ) Deutsche Apotheker Zeitung, 132(11), , 1992) WHO Comment : Sulfamerazine sodium, a sulfonamide anti-infective agent, was introduced several decades ago for the treatment of bacterial infections. The importance of sulfonamides has subsequently decreased as a result of increasing resistance and their replacement by antibiotics which are generally more active and less toxic. The sulfonamides are known to cause serious adverse effects such as renal toxicity, sometimes fatal exfoliative dermatitis and erythema multiforma and dangerous adverse reactions affecting blood formation such as agranulocytosis and haemolytic or aplastic anaemia. Sulfamerazine is still used in some countries usually in combination with other sulfonamides.
Product Name	Sulfamethizole	
C.A.S. number	144-82-1	
Scientific and common names, and synonyms		
	BENZENESULFONAMIDE, 4-AMINO-N-(5-METHYL-1,3,4-THIADIAZOL-2-YL)-	
	N1-(5-METHYL-1,3,4-THIADIAZOL-2-YL)SULPHANILAMIDE	
	N1-(5-METHYL-1,3,4-THIADIAZOL-2-YL)-SULFANILAMIDE	
	SULPHAMETHIZOLE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
SWE	1 Feb 1984	Withdrawn following discussions between the manufacturer and the National Board of Health and Welfare. A combination of adverse reactions and low sales led to this decision. WHO Comment : Sulfamethizole, a sulfonamide anti-infective agent, was introduced in 1953 for the treatment of bacterial infections. The importance of sulfonamides has subsequently decreased as a result of increasing bacterial resistance and their replacement by antibiotics which are generally more active and less toxic. However sulfamethizole, which is rapidly eliminated, retains a place in the treatment of urinary infections in some countries whereas in others its use

Legislative or regulation action

Product Name	Sulfamethizole	
C.A.S. number	144-82-1	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		has been discontinued.
Product Name	Sulfamethoxy pyridazine	
C.A.S. number	80-35-3	
Scientific and common names, and synonyms		
	N1-(6-METHOXYPYRIDAZIN-3-YL)SULPHANILAMIDE	
	N1-(6-METHOXY-3-PYRIDAZINYL)SULFANILAMIDE	
	SULPHAMETHOXYPYRIDAZINE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
SWE	1 Feb 1984	Withdrawn following discussions between the manufacturer and the National Board of Health and Welfare. A combination of adverse reactions and low sales led to this decision.
PAK	1988	Products containing sulfamethoxy pyridazine were withdrawn. (Reference: (PAKMH) Ministry of Health, Special Education and Social Welfare, , , Aug 1988)
ARE		Pharmaceutical preparations containing sulfamethoxy pyridazine are banned. WHO Comment : Sulfamethoxy pyridazine, a sulfonamide anti-infective agent, was introduced in 1957 for the treatment of bacterial infections. The importance of sulfonamides has subsequently decreased as a result of increasing bacterial resistance and their replacement by antibiotics which are generally more active and less toxic. The sulfonamides are known to cause serious adverse effects such as renal toxicity, sometimes fatal exfoliative dermatitis and erythema multiforma and dangerous adverse reactions affecting blood formation such as agranulocytosis and haemolytic or aplastic anaemia. Commercial manufacture of the drug has been discontinued by at least one major manufacturer but supplies can still be obtained on special request, particularly for patients with dermatitis herpetiformis in which condition it has been claimed to be beneficial.
Product Name	Sulfanilamide	
C.A.S. number	63-74-1	
Scientific and common names, and synonyms		
	SULFANILAMIDUM	
	SULFAMINUM	
	STREPTOCIDIN	
	SOLFAMMIDE	
	4-AMINO BENZENESULPHONAMIDE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	1992	The Federal Health Office has withdrawn products containing sulfanilamide from the market. This decision is based on a review carried out by the Advisory Panel for the Evaluation of Medicines which concluded that the benefit/risk ratio for these products is

Legislative or regulation action

Product Name	Sulfanilamide	
C.A.S. number	63-74-1	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		<p>negative. (Reference: (DWM) Wichtige Mitteilungen, 18, , 1992) (Reference: (DAZ) Deutsche Apotheker Zeitung, 132(11), , 1992)</p> <p>WHO Comment : Sulfanilamide, a sulfonamide anti-infective agent, was introduced in 1936 for the treatment of bacterial infections. The importance of sulfonamides has subsequently decreased as a result of increasing resistance and their replacement by antibiotics which are generally more active and less toxic. The sulfonamides are known to cause serious adverse effects such as renal toxicity, sometimes fatal exfoliative dermatitis and erythema multiforma and dangerous adverse reactions affecting blood formation such as agranulocytosis and haemolytic or aplastic anaemia. Sulfanilamide is still used in some countries as pessaries or as vaginal cream.</p>
Product Name	Sulfathiazole	
C.A.S. number	72-14-0	
Scientific and common names, and synonyms	<p>BENZENESULFONAMIDE, 4-AMINO-N-2-THIAZOLYL NORSULFAZOLUM N1-2-THIAZOLYLSULFANILAMIDE N1-(THIAZOL-2-YL)SULPHANILAMIDE SULFONAZOLUM SULFANILAMIDOTHIAZOLUM</p>	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
USA	Sep 1970	<p>Sulfathiazole has been withdrawn as an ingredient in products for systemic use due to the known serious hazards associated with this compound. The Food and Drug Administration has determined that the benefit/risk ratio associated with this compound is unfavourable especially in the light of the availability of other sulfonamides with equivalent benefits and less risk. Prohibited for export. (Reference: (FEREAC) Federal Register, 35, 16190, Oct 1970)</p>
PHL	May 1971	<p>The use of this drug as an anti-diarrhoeal has been withdrawn due to the risk of crystalluria.</p>
DOM	Mar 1982	<p>Preparations containing sulfathiazole or its sesquihydrate or monohydrate as the active ingredient have been prohibited for use and/or sale since they have been associated with serious side effects and shown to be of questionable efficacy.</p> <p>WHO Comment : Sulfathiazole, a sulfonamide anti-infective agent, was introduced more than 25 years ago for the treatment of bacterial infections. The importance of sulfonamides has subsequently decreased as a result of increasing bacterial resistance and their replacement by antibiotics which are generally more active and less toxic. The sulfonamides are known to cause serious adverse effects such as renal toxicity, sometimes fatal exfoliative dermatitis and erythema multiforma and dangerous adverse reactions affecting blood formation such as agranulocytosis and haemolytic or aplastic anaemia. Although preparations remain available, use of the drug has been discontinued in many countries.</p>
Bibliographical references		
WHO FOOD ADD., 25, 95, 1991		

Product Name **Sulfisomidine**

C.A.S. number **515-64-0**

Scientific and common names, and synonyms

N-(2,6-DIMETHYLPYRIMIDIN-4-YL)SULPHANILAMIDE

SULFASOMIDINE

SULFAISODIMIDINE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
DEU	1992	<p>The Federal Health Office has withdrawn products containing sulfisomide from the market. This decision is based on a review carried out by the Advisory Panel for the Evaluation of Medicines which concluded that the benefit/risk ratio for these products is negative.</p> <p>(Reference: (DWM) Wichtige Mitteilungen, 18, , 1992)</p> <p>(Reference: (DAZ) Deutsche Apotheker Zeitung, 132(11), , 1992)</p> <p>WHO Comment : Sulfisomide, a sulfonamide anti-infective agent, was introduced several decades ago for the treatment of bacterial infections. The importance of sulfonamides has subsequently decreased as a result of increasing resistance and their replacement by antibiotics which are generally more active and less toxic. The sulfonamides are known to cause serious adverse effects such as renal toxicity, sometimes fatal exfoliative dermatitis and erythema multiforma and dangerous adverse reactions affecting blood formation such as agranulocytosis and haemolytic or aplastic anaemia. Sulfisomide is still used topically in some countries for vaginal infection.</p>

Product Name **Sulfonamides (topical preparations)**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
CHL		<p>Pharmaceutical preparations for topical use containing sulfonamide and its derivatives are prohibited.</p> <p>(Reference: (CHLRS) Resolution of the Minister of Health, No.10154, , Oct 1986)</p>

Product Name **Suloctidil**

C.A.S. number **54767-75-8**

Scientific and common names, and synonyms

BENZENEMETHANOL, 4-((1-METHYLETHYL)THIO)-ALPHA-(1-(OCTYLAMINO)ETHYL)-, (R*,S*)-

ERYTHRO-P-(ISOPROPYLTHIO)-ALPHA-(1-(OCTYLAMINO)ETHYL)BENZYL ALCOHOL

1-(4-ISOPROPYLTHIOPHENYL)-2-OCTYLAMINOPROPAN-1-OL

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
@WD	1985	Suloctidil, a vasodilator, was voluntarily withdrawn worldwide by the manufacturer following several reports of hepatitis associated with its use, some of which were fatal.
DEU	Jul 1985	The Federal Office of Health has not renewed its approval for suloctidil following reports of hepatitis. Meanwhile the manufacturer stopped the sale of this drug and recalled all distributed packages.
AUT	Oct 1985	The Federal Ministry of Health and Environmental Protection prohibited the use of preparations containing suloctidil following reports of hepatotoxic effects.

Legislative or regulation action

Product Name	Suloctidil	
C.A.S. number	54767-75-8	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
CYP		Voluntarily withdrawn by the manufacturer following reports of hepatitis. WHO Comment : Suloctidil, a peripheral vasodilator, was introduced in 1975 for the treatment of arterial disease. By 1985 its use had been associated with serious adverse effects, including deaths from hepatitis. In July 1985 renewal for approval was refused in the Federal Republic of Germany. This was followed by the voluntary withdrawal of the drug by the manufacturer firstly in several European countries and ultimately on a worldwide basis.

Product Name	Sulprostone	
C.A.S. number	60325-46-4	
Scientific and common names, and synonyms		
[1R-{1ALPHA(Z),2BETA(1E,3R'),3ALPHA}]-7-[3-HYDROXY-2-(3-HYDROXY-4-PHENOXY-1-BUTENYL)-5-OXOCYCLOPENTYL]-N-(METHYLSULFONYL)-5-HEPTENAMIDE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
THA	Apr 2001	Severely restricted prescription drug to be used in hospitals only. (Reference: (THACW) Communication to WHO, , , 28 Sep 2001)

Product Name	Sultopride	
C.A.S. number	53583-79-2	
Scientific and common names, and synonyms		
N-[(1-ETHYL-2-PYRROLIDINYL)METHYL]-5-(ETHYLSULFONYL)-O-ANISAMIDE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
FRA	Oct 1991	The Ministry of Health extended the contraindications for products containing sultopride to patients with bradycardia and hypokalaemia; to those receiving drugs that may induce bradycardia, hypokalaemia, impairment of intracardiac conduction and ventricular arrhythmias; and to breastfeeding women. The association of sultopride with other phenothiazines was also discouraged. A warning was required in the product information stating that patients with severe cardiovascular disorders are at risk of hypotension and cardiac arrhythmias. These amendments to the approved product information were made following reports of ventricular arrhythmias in patients treated with sultopride. (Reference: (FRAMHH) Ministry of Health and Humanitarian Action, , , 11 Dec 1992) WHO Comment : Sultopride, a neuroleptic indicated for the treatment of acute and chronic psychoses, was introduced on the market in 1976. In the early 1990s, its use was associated with cardiac arrhythmias, some of which were fatal. This led the regulatory authority in France to take restrictive action on the product. Sultopride continues to be marketed in several other countries.

Product Name	Sumatriptan	
C.A.S. number	103628-48-4	
Scientific and common names, and synonyms		
1H-INDOLE-5-METHANESULFONAMIDE, 3-[2-(DIMETHYLAMINO)ETHYL]-N-METHYL-, BUTANEDIOATE (1:1)		

Legislative or regulation action

Product Name **Sumatriptan**

C.A.S. number **103628-48-4**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
BEL	1993	The Ministry of Health has modified the approved data sheet for products containing the serotonin receptor agonist, sumatriptan, to include the following precautions: at least one hour should elapse between any two injections; treatment is contraindicated in persons suffering from coronary vasospasm or other cardiovascular disorders; the effects of sumatriptan may be potentiated by ergotamine. (Reference: (BELARD) 1993 Annual Report, , May 1994)
DEU	Feb 1994	The Federal Health Office has amended the data sheet for pharmaceutical products containing the serotonin receptor agonist, sumatriptan (Imigran: Glaxo), to include all degrees of hypersensitivity including shock in the listed adverse effects associated with treatment. (Reference: (BGHBL) Bundesgesundheitsblatt, No. 2/94, p.94, Feb 1994)
DEU	May 1994	The Federal Health Office proposed to revise the product information for pharmaceutical products containing sumatriptan (Avessa, Imigran: Glaxo) to state that patients should not be treated concomitantly with sumatriptan and medicinal products which influence the serotonin metabolism (MAO inhibitors, inhibitors of serotonin re-uptake, clomipramine, lithium), and that the use of sumatriptan is contraindicated in patients with migraine accompanied by unilateral weakness or paralysis, paralysis of the eye muscles (hemiplegic migraine), or temporary disturbance of vision resulting in double images or blind spots (ophthalmoplegic migraine). Sumatriptan is also contraindicated in patients who suffer from heart diseases and it shall be given with caution and only after careful evaluation to asymptomatic patients with clinically important risk factors for coronary heart disease (hyperlipidemia, obesity, diabetes mellitus, smoking). (Reference: (DEUFHO) Communication from Federal Health Office, , 25 May 1994)
DEU	Oct 1994	The manufacturer of the serotonin receptor agonist, sumatriptan (Imigran: Glaxo) has revised the prescribing information for this product in the light of severe adverse reactions which have been ascribed to the incorrect use of sumatriptan, some of which were fatal. Sumatriptan should only be used for the treatment of migraine or confirmed cluster headache. Sumatriptan should not be administered to patients who develop unexplained thoracic symptoms (e.g. angina-like symptoms) until cardiovascular disease can be excluded. Sumatriptan should be administered only after cardiovascular disease has been excluded to patients with existing heart disease or asymptomatic patients with risk factors for coronary heart disease (older than 40 years, high blood pressure, smoking, diabetes mellitus, obesity, long-term use of high-dose ergotamine preparations). (Reference: (DEUFHO) Communication from Federal Health Office, , 25 May 1994)
FRA	Feb 1995	Following a request from the manufacturer of the serotonin receptor agonist, sumatriptan (Imigran: Glaxo), the French Commission of Pharmacovigilance has revised the product information for this product as follows. Concurrent use with monoamine oxidase inhibitors, serotonin receptor antagonists and ergot derivatives is now contraindicated. A previous history of allergy to sulfonamides will be mentioned in this section because of serious cross-reactions due to a sulfonamide group in the sumatriptan molecular structure. The warnings section will carry a reminder that sumatriptan should be administered only after a diagnosis of migraine or facial vascular algia has been clearly established and that if the first injection is ineffective, the diagnosis has to be reconsidered before a second dose is administered in case the headache may be a symptom of another condition. A reminder will be included concerning cardiovascular risk factors and the section on precautions for use will state that in patients with a history of convulsions or epilepsy, the occurrence of seizures must be taken into account. The section adverse effects will include allergic reactions and convulsions. (Reference: (FRAAMC) Communiqué de Presse, , 02 Feb 1995)
GBR	Feb 1995	The manufacturer of the serotonin receptor agonist, sumatriptan (Imigran: Glaxo) has revised the prescribing information for this product on the basis of adverse cardiac effects from post-marketing safety monitoring data and with the aim of promoting its appropriate use. The existing warnings and precautions section has been strengthened

Legislative or regulation action

Product Name	Sumatriptan	
C.A.S. number	103628-48-4	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		to ensure that there is a clear diagnosis of migraine/cluster headache before administration of sumatriptan; patients in whom unrecognized coronary disease is likely (postmenopausal women, men over 40 or patients with other cardiovascular risk factors) do not receive sumatriptan until an appropriate evaluation has been performed to exclude underlying heart disease since extremely rare cases of cardiac arrhythmias, transient ischaemic ECG changes or myocardial infarction have been reported; if symptoms consistent with ischaemic heart disease occur, an appropriate evaluation should be carried out. The list of contraindications now includes concomitant use of derivatives of ergotamine as well as ergotamine, and the list of adverse effects additionally lists tachycardia and palpitations. (Reference: (GLAXO) Communication, , , 03 Feb 1995)
USA	Aug 1995	The manufacturer of sumatriptan (Imitrex : Glaxo) has issued a "Dear Health Professional" letter stating that sumatriptan should be prescribed only when a clear diagnosis of migraine has been established. It should not be given to patients in whom unrecognized coronary artery disease is likely without a prior evaluation for underlying cardiovascular disease. (Reference: (FDAMB) FDA Medical Bulletin, 25(2), p. 6, Aug 1995)

Product Name	Suprofen	
C.A.S. number	40828-46-4	
Scientific and common names, and synonyms		
BENZENACETIC ACID, ALPHA-METHYL-4-(2-THIENYL CARBONYL)- PARA-2-THENOYLHYDRATROPIC ACID		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
@WD		The manufacturer has suspended sales worldwide. WHO Comment : Suprofen, a nonsteroidal anti-inflammatory agent, was introduced in 1983 for use as an analgesic for the symptomatic relief of mild to moderate pain and for primary dysmenorrhoea. By 1986 it had become evident that its use was occasionally associated with flank pain sometimes accompanied by evidence of decreased renal function. The Arthritis Advisory Committee of the United States Food and Drug Administration met in December 1986 to review the situation and decided against withdrawing suprofen from the market. However, in May 1987 the Committee for Proprietary Medicinal Products of the European Community recommended that all marketing authorizations should be suspended. The manufacturer subsequently decided to suspend sale worldwide on the grounds that sales had diminished to the point where the product was no longer economically viable.

Product Name	Suxamethonium chloride	
C.A.S. number	71-27-2	
Scientific and common names, and synonyms		
ETHANAMINIUM, 2,2'-[(1,4-DIOXO-1,4,-BUTANEDIYL)BIS(OXY)]BIS[N,N,N,-TRIMETHYL-], DICHLORIDE SUCCINYLCHOLINE CHLORIDE		
Legislative or regulative action		

Legislative or regulation action

Product Name	Suxamethonium chloride	
C.A.S. number	71-27-2	
Country	Effective Date	Description of action taken Grounds for decision
DEU	Feb 1995	The Federal Institute for Drugs and Medical Devices revised the product information to include a warning concerning possible irreversible cardiac arrest in children and adolescents. Because of the life-threatening nature of the adverse reaction, it is recommended that administration of suxamethonium chloride to children and adolescents, even if they appear to be healthy, should be considered only when immediate intubation is planned or where there are facilities for maintaining the airway in emergency. (Reference: (DEURFI) Rapid Alert - Pharmacovigilance, , , 03 Feb 1995) WHO Comment : Suxamethonium chloride is a short-acting muscle relaxant. It is used in surgery. Suxamethonium chloride is listed in the WHO Model List of Essential Drugs.

Product Name	Suxibuzone	
C.A.S. number	27470-51-5	
Scientific and common names, and synonyms		
4-BUTYL-(4-HYDROXYMETHYL)-1,2-DIPHENYL-3,5-PYRAZOLIDINEDIONE HYDROGEN SUCCINATE		
Legislative or regulative action		

Country	Effective Date	Description of action taken Grounds for decision
JPN	Jul 1977	Indications are restricted to severe exacerbations of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. Doctors are advised to prescribe this drug only to adults and for periods of no longer than one week.
DEU	1985	Indications are restricted to severe exacerbations of rheumatism and acute gout. Duration of oral treatment should not exceed one week. Parenteral preparations are indicated only for initiating therapy. A single injection only is recommended because local tissue damage may occur. Preparations are contraindicated in children under 14 years of age.
OMN	Sep 1986	The Ministry of Health has prohibited the import of preparations containing suxibuzone except those intended for topical use.
ITA		Withdrawn from the market owing to an unfavourable risk-benefit ratio and the lack of substantial evidence of efficacy. WHO Comment : Suxibuzone, a pyrazolone derivative with anti-inflammatory, analgesic and antipyretic activity, was introduced in 1974 for the treatment of rheumatic disorders. As it is structurally related to phenylbutazone, it is subjected to rigorously restricted indications by some national regulatory authorities. See WHO comment for phenylbutazone.

Product Name	Tamoxifen	
C.A.S. number	10540-29-1	
Scientific and common names, and synonyms		
ETHANAMINE, 2-[4-(1,2-DIPHENYL-1-BUTENYL)PHENOXY]-N,N-DIMETHYL-, (Z)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1)		

Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	Dec 1995	The Federal Institute for Drugs and Medical Devices has decided that the following warnings should be included in the product information for pharmaceutical products

Legislative or regulation action

Product Name	Tamoxifen	
C.A.S. number	10540-29-1	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
ZAF	Jun 1996	<p>containing tamoxifen: "Investigations in different in vivo and in vitro systems prove that tamoxifen has a genotoxic potential following hepatic activation; clinical reports yield signs of an increased risk of developing endometrial tumours". (Reference: (DEURFI) Rapid Alert - Pharmacovigilance, , , 23 Dec 1995)</p> <p>The Medicines Control Council has revised the package insert for pharmaceutical products containing tamoxifen to include a warning about an increased incidence of endometrial changes, including hyperplasia, polyps and cancer reported in association with tamoxifen treatment. (Reference: (ZAFMCC) Communication, , , 22 June 1996)</p> <p>WHO Comment : Tamoxifen is an anti-estrogen agent used mainly to treat breast cancer. Tamoxifen is listed in the WHO Model List of Essential Drugs.</p>
Product Name	Tartrazine	
C.A.S. number	1934-21-0	
Scientific and common names, and synonyms		
COLOUR INDEX NO. 19140		
CI FOOD YELLOW 4		
E 102		
FD&C YELLOW NO.5		
TRISODIUM 5-HYDROXY-1-(4-SULPHONATOPHENYL)-4-(4-SULPHONATOPHENYLAZO) PYRAZOLE-3-CARBOXYLATE		
TARTRAZOL YELLOW		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GRC	1984	Not allowed in antihistamines and bronchodilators. All other products must bear a warning about allergic reactions.
NZL	Aug 1984	<p>The inclusion of tartrazine in medicines for internal use will be phased out over the next two years having regard to its allergenic potential. It can be used in products for external use. (Reference: (NZCSL) Clinical Services Letter, Department of Health, 224, , Jan 1984)</p>
IRL	1985	<p>Products intended for the management of allergic states and for prolonged use should be reformulated to exclude tartrazine. Use of tartrazine should be discouraged in all other preparations and where it is present it should be declared on the label. (Reference: (IRDAB) National Drugs Advisory Board Annual Report, , , 1985)</p>
HUN	31 Mar 1990	<p>Tartrazine is no longer accepted as a colouring agent in pharmaceutical products submitted for registration. In registered products it must be replaced by 31 December 1992 and, in the meantime, these products must bear the warning: "This preparation contains tartrazine which may cause allergic reactions in sensitized individuals". (Reference: (HUNIP) National Institute of Pharmacy, , , 08 Feb 1990)</p>
OMN	Mar 2002	<p>The Directorate General of Pharmaceutical Affairs and Drug Control has banned the use of Tartrazine FD&C Yellow No. 5 in pharmaceutical products, in any pharmaceutical form, following similar restrictions worldwide due to a spectrum of side effects such as allergies, thyroid tumors, lymphocytic lymphomas, chromosomal damage, asthma attacks, urticaria and hyperactivity. (Reference: (OMNCR) Circular, 50/2001, , 12 Nov 2001)</p> <p>WHO Comment : Tartrazine is widely used as a permitted colouring agent in food</p>

Legislative or regulation action

Product Name	Tartrazine	
C.A.S. number	1934-21-0	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		and pharmaceutical preparations. Its use has been associated with allergic reactions some of which have been severe. Several national drug regulatory authorities now require a warning on labels of products containing tartrazine and some manufacturers have voluntarily withdrawn this compound from their products.
Product Name	Temafloxacin	
C.A.S. number	108319-06-8	
Scientific and common names, and synonyms		
(±)-(2,4-DIFLUOROPHENYL)-6-FLUORO-1,4-DIHYDRO-7-(3-METHYL-1-PIPERAZINYL)-4-OXO-3-QUINOLINECARBOXYLIC ACID		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
@WD	Jun 1992	Products containing temafloxacin were withdrawn worldwide by the manufacturer, having regard to severe adverse reactions associated with their use, some of which were fatal. (Reference: (HHSNS) HHS News: US Department of Health and Human Services, P92-16, , 05 June 1992)
OMN	22 Jun 1992	Products containing temafloxacin will not be allowed for import and marketing. (Reference: (OMNCR) Circular, 25/92, , June 1992) WHO Comment : Temafloxacin, a quinolone antimicrobial, was introduced in 1991. Shortly afterwards, its use became associated with severe adverse effects, including hypoglycaemia, haemolytic anaemia, renal failure, hepatitis and anaphylactic reactions. This led to its worldwide withdrawal by the manufacturer.
Product Name	Temazepam	
C.A.S. number	864-50-4	
Scientific and common names, and synonyms		
7-CHLORO-3-HYDROXY-1-METHYL-5-PHENYL-1,4-BENZODIAZEPIN-2-ONE 3-HYDROXYDIAZEPAM		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GBR	Sep 1995	The authorities in the United Kingdom have announced that temazepam is to be subjected to stricter regulations and is to be transferred from Schedule 4 of the Misuse of Drugs Regulations 1985 to Schedule 3, however with some exemptions. These measures are being taken in an attempt to prevent misuse of temazepam. (Reference: (GBRPR) Press Release, , , 12 Sep 1995) WHO Comment : Temazepam is a widely used benzodiazepine derivative. As with other drugs in this class, cases of misuse and drug dependence are known.
Product Name	Terbinafine	
C.A.S. number	91161-71-6	
Scientific and common names, and synonyms		

Legislative or regulation action

Product Name	Terbinafine	
C.A.S. number	91161-71-6	
Scientific and common names, and synonyms	1-NAPHTHALENEMETHANAMINE, N-(6,6-DIMETHYL-2-HEPTEN-4-YNYL)-N-METHYL-, (E)-	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
FRA	25 Jan 1995	The National Commission of Pharmacovigilance has revised the product information to include serious adverse effects associated with the use of the antifungal agent, terbinafine (Lamisil®), including severe cutaneous disorders, haematological and hepatic risks, and possible taste disorders in the section on "Adverse effects". (Reference: (FRAAMN) Notification, , , 25 Jan 1995)
Product Name		
Terconazole		
C.A.S. number	67915-31-5	
Scientific and common names, and synonyms	CIS-1-[P-((2-(2,4-DICHLOROPHENYL)-2-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL]-4-ISOPROPYLPYPERAZINE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	Dec 1988	The marketing authorization of vaginal suppositories containing 160 mg terconazole has been suspended, having regard to reports of fever, shivering, headache and circulatory reactions associated with their use. Lower dose formulations remain available. (Reference: (BGHBL) Bundesgesundheitsblatt, 12, 492, 1988)
SWE	Jul 1991	The marketing authorization for vaginal suppositories containing 80 mg and 160 mg terconazole was withdrawn, after these preparations had been associated with febrile reactions, often accompanied by influenza-like symptoms. (Reference: (SWEILS) Information från Läkemedelsverket, 2(3), 158, 1991)
WHO Comment : Terconazole, an antifungal agent, was introduced into medicine in 1980. It is indicated for the treatment of vaginal candidiasis. It is not yet clear whether the adverse effects associated with high dose formulations are due to terconazole itself, to an excipient in the preparation or to fungal constituent.		
Product Name		
Terfenadine		
C.A.S. number	50679-08-8	
Scientific and common names, and synonyms	A-[4-(1,1-DIMETHYLETHYL)PHENYL]-4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDINEBUTANOL 1-PIPERIDINEBUTANOL, ?-[4-(1,1-DIMETHYLETHYL)PHENYL]-4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDINEBUTANOL	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
FIN	Sep 1994	The National Agency for Medicines has withdrawn from OTC sale and placed under prescription control products containing terfenadine. Adverse reactions have been reported in cases where terfenadine was used concomitantly with ketoconazole and macrolide antibiotics; the possibility that such reactions might occur when terfenadine is used for self-medication cannot be excluded. (Reference: (FINNAM) Notice, , , 21 Sep 1994)
JPN	Feb 1995	The Pharmaceutical Affairs Bureau has decided to include in the labelling of terfenadine

Legislative or regulation action

Product Name		Terfenadine
C.A.S. number		50679-08-8
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		a boxed warning drawing attention to the fact that the metabolism of terfenadine is inhibited either by concomitant medication of imidazole antifungal agents or macrolide antibiotics, or in patients with serious liver damage, or in patients liable to QT prolongation. This may lead to serious cardiovascular adverse reactions. (Reference: (JPNARD) Information on Adverse Reactions to Drugs, No.130, , Feb 1995)
NZL	Oct 1996	Terfenadine has been reclassified to Restricted Medicine (an OTC classification, but may only be sold personally by a pharmacist). (Reference: (NZLPU) Prescriber Update, No.13, , Oct 1996)
OMN	1997	The Directorate General of Pharmaceutical Affairs & Drug Control has prohibited the registration, import and sale of terfenadine due to reported serious cardiac adverse effects associated with its inappropriate use. (Reference: (OMNPN) Pharmaceutical Newsletter, 5(4): 8, , 1997)
FRA	Feb 1997	The French Health Authority has suspended the marketing authorization for terfenadine for one year because of the risk of rare but serious ventricular arrhythmias following overdosage and the risk of hepatic damage and cardiac reaction when taken concomitantly with imidazole antifungal agents. (Reference: (FRAAMP) Press Release, , , 13 Feb 1997)
JPN	Feb 1997	The Pharmaceutical Affairs Bureau has expanded its warnings in the labelling for terfenadine by adding the possibility of dangerous interactions with some antiarrhythmic drugs, diuretics, psychotropic drugs and probucol. (Reference: (JPNMHC) Communication to WHO, , , 13 Feb 1997)
MAR	Feb 1997	The National Advisory Commission for Pharmacovigilance has reviewed the overall risk-benefit of terfenadine and decided to withdraw terfenadine from the market because of the risk of cardiac arrhythmia associated with the administration of terfenadine. (Reference: (MARDMP) Letter to WHO, , , 24 Aug 1999)
GBR	16 Sep 1997	The Committee on Safety of Medicines has decided that as from 16 September 1997, terfenadine will only be available on prescription. In addition to conditions for use of terfenadine issued in other countries the CSM advises patients not to drink grapefruit juice while taking terfenadine. (Reference: (GBRCP) Current Problems in Pharmacovigilance, Vol.23, , Sep 1997)
OMN	Dec 1997	The Directorate General of Pharmaceutical Affairs & Drug Control has prohibited the registration, import and sale of terfenadine due to reported serious cardiac adverse effects associated with its inappropriate use. (Reference: (OMNPN) Pharmaceutical Newsletter, 5(4): 8, , 1997)
USA	1998	Hoechst, Marion Roussel and Baker Norton Pharmaceuticals have voluntarily discontinued distribution and marketing of all terfenadine-containing antihistamine products in the United States. Terfenadine-containing products have been associated with rare, but serious heart problems when taken with certain antibiotics and antifungals. The FDA reminded consumers and health care providers that equally safe and effective alternative drugs are available. (Reference: (FDATPW) FDA Talk Paper www.fda.gov/bbs/topics/ANSWERS/ANS00853.html , , ,)
MUS	Dec 1998	The Ministry of Health and Quality of Life has withdrawn terfenadine from the market following reports of fatal drug interactions with commonly use drugs. . (Reference: (MUSMHQ) Letter to WHO, , , 27 Dec 2000)
FRA	1999	The Agence du Médicament has withdrawn the antihistamine, terfenadine from the market because the risk of ventricular arrhythmias does not justify the continuation of terfenadine on the market. (Reference: (FRACCE) Décision, , , 22 Sep 1998)

Legislative or regulation action

Product Name	Terfenadine	
C.A.S. number	50679-08-8	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
ISL	Jan 1999	The State Committee on Pharmaceuticals in Iceland withdrew the marketing authorization for 120 mg tablets of terfenadine and 60 mg tablets were switched from OTC to POM status in January 1998 due to the occurrence of serious adverse effects. (Reference: (ISLSCP) Communication to WHO, , , 17 Oct 2000)
SAU	Jun 1999	The Ministry of Health has withdrawn from the market products containing the histamine H1-receptor antagonist, terfenadine, because of reports of a potentially fatal heart condition associated with its use. (Reference: (SAUCW) Notification, , , 20 June 1999)
BRA	Jul 2000	Withdrawn from the Brazilian market due to the increased risk of producing cardiac arrhythmias.
CHL	Mar 2001	The Public Health Institute of Chile has banned the use of terfenadine due to serious cardiotoxic effects reported in conjunction with other drugs. (Reference: (CHLCW) Communication to WHO, , , 26 Sep 2001)
ARG	19 Aug 2003	The Food, Drug and Medical Devices agency in Argentina, ANMAT, has withdrawn the marketing authorization for all products containing terfenadine. This measure follows associations of life-threatening ventricular arrhythmias with terfenadine. (Reference: (ARGFDM) Communication from ANMAT, , , 19 Aug 2003)
SGP		The National Pharmaceutical Administration in the Ministry of Health has banned terfenadine because of its association with rare but serious heart problems when taken with certain drugs, including antibiotics and antifungal drugs. (Reference: (SGPCW) Communication to WHO, , , 02 Aug 2000)
WHO Comment : The first clinically interesting histamine H-receptor1 antagonists were introduced in the late 1940s and early 1950s. Several H-antihistaminics have a similar cardiac effect to that seen with astemizole1 and terfenadine. Serious cardiovascular adverse reactions have been reported when used concomitantly with imidazole antifungals and macrolide antibiotics. See also under astemizole.		
Product Name	Terodiline	
C.A.S. number	15793-40-5	
Scientific and common names, and synonyms		
BENZENEPROPANAMINE, N-(1,1-DIMETHYLETHYL)-ALPHA-METHYL-GAMMA-PHENYL-N-TERT-BUTYL-1-METHYL-3,3-DIPHEYLPROPYLAMINE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
@WD	1992	Products containing terodiline were withdrawn from the market worldwide by the manufacturer, following reports of cardiac adverse reactions, including ventricular tachycardia, heart block and bradycardia associated with their use. (Reference: (DCCKB) Drug company communication - Kabi Pharmacia, , , 26 Sep 1991)
WHO Comment : Terodiline, an anticholinergic and calcium-channel blocking agent, was first introduced into medicine in the mid 1960s for the treatment of angina pectoris. In 1986, it was registered for the indication of urinary incontinence. In 1991, its use in urinary incontinence was reported to be associated with severe cardiac arrhythmias. This led to a temporary withdrawal in a few Member States in 1991, followed by a final withdrawal by the manufacturer in 1992.		

Legislative or regulation action

Product Name	Testosterone propionate (injectable)	
C.A.S. number	57-85-2	
Scientific and common names, and synonyms	ANDROST-4-EN-3-ONE, 17-(1-OXOPROPOXY)-, (17BETA)- TESTOSTERONE PROPIONATE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
BGD	1982	Under the provisions of the Drugs (Control) Ordinance, low dosage forms (100mg ampoules) were banned on grounds of inadmissible promotion and misuse. Higher dosage forms (250mg ampoules) remain available for use in selected patients under medical supervision. (Reference: (BGDCO) The Drugs (Control) Ordinance, , , 1982) WHO Comment : In 1982, low dosage preparations of testosterone propionate, a synthetic ester of the naturally-occurring androgen, testosterone, were prohibited in Bangladesh following their inadmissible promotion as anabolic agents for use in malnourished children. Higher dosage preparations of testosterone propionate remain available in many countries, including Bangladesh, for several highly specific but limited indications including hypogonadism and the palliative treatment of inoperable breast cancer.

Product Name	Tetracycline (paediatric)	
C.A.S. number	60-54-8	
Scientific and common names, and synonyms	2-NAPHTHACENECARBOXAMIDE, 4-(DIMETHYLAMINO)-1,4,4A,5,5A,6,11,12A- OCTAHYDRO-3,6,10,12,12A-PENTAHYDROXY-6-METHYL-1,11-DIOXO- (4S-(4ALPHA,4AALPHA,5AALPHA,6BETA,12AALPHA)) 4-(DIMETHYLAMINO)-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-3,6,10,12,12A- PENTAHYDROXY-6-METHYL-1,11-DIOXO-2-NAPHTHACENECARBOXAMIDE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
JOR	1973	The Ministry of Health withdrew syrup formulations of tetracyclines (mixtures, suspension or drops) particularly intended for pediatric use on the grounds that tetracyclines interfere with the growth of bones and teeth in infants.
PER	1974	The package insert and/or label for this product requires a warning that its use may be dangerous in nursing infants, children under 3 years of age and pregnant women, due to the drug's well known effects on bone formation.
ITA	1975	Preparations for rectal use have been withdrawn from the market owing to their non-constant absorption. Since 1979, labels of concentrated liquid preparations have warned about possible dischromic effects on tooth enamel.
PHL	1978	Preparations containing chlortetracycline, oxytetracycline, tetracycline, demeclocycline, rolitetracycline, methacycline, doxycycline, minocycline, and other tetracycline derivatives in the form of syrup (mixture or suspension) or drops particularly intended for pediatric use are no longer acceptable. (Reference: (PHADO) Administrative Order, 342, , 1978)
USA	2 Jan 1979	Tetracycline drops intended for pediatric use have been withdrawn from the market. Doctors have been advised that liquid preparations of tetracycline and its congeners should not be administered to pregnant women or children under 9 years of age. (Reference: (FEREAC) Federal Register, 43(211), 50676, 1978)
GHA	1980	Paediatric preparations have been banned.
ARE	9 Jun 1981	Tetracyclines in syrups and paediatric drops are banned. (Reference: (UAEMD) Ministry of Health Decree, No.694, , 1981)

Legislative or regulation action

Product Name **Tetracycline (paediatric)**

C.A.S. number **60-54-8**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
BGD	1982	Under the provisions of the Drugs (Control) Ordinance, tetracycline syrups have been banned as they are harmful to children and pregnant mothers; they disturb bone growth of children up to 12 years of age and discolour teeth. (Reference: (BGDCO) The Drugs (Control) Ordinance, , , 1982)
SDN	1982	The Ministry of Health no longer allows registration of tetracycline syrups. Syrups will only be available to government health units for specific treatment.
IND	1983	Liquid oral dosage preparations have been prohibited for manufacture and sale for reasons of health risks associated with use and/or questionable therapeutic value. (Reference: (GAZIE) The Gazette of India: Extraordinary, II-3i, , 23 July 1986)
OMN	Sep 1985	Tetracycline pediatric suspension has been prohibited for import, selling and marketing.
PAK	1988	Products containing tetracyclines for paediatric use, including tetracycline, oxytetracycline and doxycycline were withdrawn. (Reference: (PAKMH) Ministry of Health, Special Education and Social Welfare, , , Aug 1988)
CHL	31 Aug 1990	All products containing tetracycline, demeclocycline, doxycycline, metacycline, oxytetracycline or other tetracycline derivatives were required to bear a warning stating that they should not be administered to children under 8 years of age, or to pregnant or lactating women. (Reference: (BMCHL) Boletin Informativo Sobre Medicamentos, 8(1), 14, 1991)
NPL	1991	Liquid oral preparations containing tetracycline, and intended for the treatment of diarrhoea in children, were banned. (Reference: (NPLDDA) Communication from the Department of Drug Administration, , , 27 Feb 1992)
AUS		The Australian Drug Evaluation Committee has recommended that all pediatric formulations of tetracyclines should be withdrawn from the market in view of their propensity to stain teeth and retard bone growth. (Reference: (AUDEC) Report of the Australian Drug Evaluation Committee, No.71, ,)
BEL		Preparations containing tetracyclines intended for internal use must carry a warning stating that the preparation should not be administered to children under eight years of age or to pregnant women after the fourth month of pregnancy except on medical advice.
NZL		Pediatric preparations have been voluntarily withdrawn.
SAU		Following reports indicating interference with bone growth and teeth in infants the use of all tetracycline preparations is prohibited in pregnant women and children below twelve years of age. WHO Comment : The first tetracycline antibiotic, chlortetracycline, was introduced in 1948 and subsequently several semisynthetic derivatives have been used as antibacterial, antiamoebic and antirickettsial agents. All tetracyclines accumulate in the developing bones and teeth of the foetus and young children which can result in retarded bone growth and dental staining. Preparations intended specifically for children have been withdrawn in some countries, whereas in others warnings are required on the label advising against administration of tetracyclines to young children and pregnant women. Non-paediatric dosage forms of tetracycline remain in the WHO Model List of Essential Drugs. (Reference: (WHTAC1) The Use of Essential Drugs, 2nd Report of the WHO Expert Committee, 722, , 1985)

Product Name **Thalidomide**

Legislative or regulation action

C.A.S. number 50-35-1

Scientific and common names, and synonyms

?(N-PHTHALIMIDO)GLUTARIMIDE
 ALPHA-(N-PHTHALIMIDO)GLUTARIMIDE
 N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
 1H-ISOINDOLE-1,3(2H)-DIONE, 2-(2,6-DIOXO-3-PIPERIDINYL)-

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
BEL	1963	Pharmaceutical preparations containing thalidomide were prohibited in 1963. In 1983 they were reintroduced for limited use in special circumstances.
FIN	1963	Prohibited due to its well-known teratogenic effects.
IDN	1963	Prohibited for importation, production, sale and distribution by the Ministry of Health.
CAN	Jul 1984	Total ban under S.15 of the Food and Drugs Act has been revoked. Thalidomide is now available on a limited basis, upon specific authorization for emergency purposes only.
BRA	4 Jul 1994	The Ministry of Health has issued an Order prohibiting the prescription of thalidomide for women of childbearing age. This action has been taken in consideration of the risks of teratogenic effects of thalidomide associated with indiscriminate use of the product. (Reference: (BRASVS) Secretaria de Vigilancia Sanitaria, Portaria 63, , 04 July 1994)
BRA	04 Jul 1994	The Ministry of Health has issued an Order prohibiting the prescription of thalidomide for women of childbearing age. This action has been taken in consideration of the risks of teratogenic effects of thalidomide associated with indiscriminate use of the product. (Reference: (BRACVS) Centro de Vigilancia Sanitaria, 63, , 04 July 1994)
ARG	Jul 1996	The Ministry of Health and Social Affairs has restricted the use of thalidomide to ensure that it is not accessible to pregnant women. (Reference: (ARGANM) Communication, , , 19 July 1996)
DNK		Prohibited for import, production, sale and distribution by the Ministry of Health.
IND		Prohibited for import due to the lack of substantial evidence of safety and/or efficacy, except for specially authorized use in leprosy patients in leprosy hospitals excluding women patients of childbearing age.
NZL		This product is a controlled drug and is available on a very restricted basis.
SGP		Banned for importation.
VEN		Not approved for use and/or sale.

WHO Comment : Notwithstanding the highly potent teratogenic action of thalidomide, this drug retains a place in the treatment of reactional lepromatous leprosy and several serious dermatological conditions refractory to other treatment. In many countries, the competent authorities have granted exemption from licensing requirements to enable doctors to obtain limited supplies of thalidomide under strictly controlled circumstances for use in named patients. Arrangements have also been made by some national drug regulatory authorities for thalidomide to be used in institutions concerned with the treatment of leprosy.

Product Name Thenalidine

C.A.S. number 86-12-4

Scientific and common names, and synonyms

THENOPHENOPIPERIDINE
 1-METHYL-4-N-2-THENYLANILINOPIPERIDINE

Legislative or regulative action

Legislative or regulation action

Product Name		Thenalidine	
C.A.S. number		86-12-4	
Country	Effective Date	Description of action taken Grounds for decision	
USA	17 Jul 1958	Thenalidine was withdrawn in the United States of America after four cases of severe neutropenia, two of which were fatal, were reported in patients treated continuously over periods of several months.	
GBR	1961	Thenalidine was withdrawn in the United States of America after four cases of severe neutropenia, two of which were fatal, were reported in patients treated continuously over periods of several months. It was subsequently withdrawn in the United Kingdom.	
SWE	Apr 1976	Withdrawn following reports of neutropenia associated with its use.	
FRA	16 Jun 1978	Voluntarily withdrawn following reports of neutropenia associated with its use.	
CYP	1980	Products containing thenalidine were withdrawn following reports of neutropenia associated with their use.	
AUS		Voluntarily withdrawn following reports of neutropenia associated with its use.	
FIN		Voluntarily withdrawn following reports of neutropenia associated with its use.	
NOR		Withdrawn following reports of neutropenia associated with its use.	
VEN		Not approved for use and/or sale.	
<p>WHO Comment : Thenalidine, a piperidine antihistamine, was introduced in 1953 for the management of dermatologic and allergic conditions. By 1958 its use had been associated with cases of severe neutropenia, two of them fatal, which led to its withdrawal in the United States of America and subsequently in the United Kingdom. Over the next fifteen years, continued reports of its association with cases of neutropenia resulted in further withdrawals in many countries. It is apparently still available, however, in some combination products. (Reference: (WHODI) WHO Drug Information, 1, 5, 1979)</p>			

Product Name		Thiomersal	
C.A.S. number		56-64-8	
Scientific and common names, and synonyms			
ETHYL(2-MERCAPTOBENZOATO-S)MERCURY			
MERCURY, ETHYL(4-MERCAPTOBENZOATO-S)-, SODIUM SALT			
THIMEROSAL			

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
MYS		The Drug Control Authority in Malaysia has directed manufacturers to discontinue the use of thiomersal as a preservative in vaccines and to replace it with other permitted preservatives.
MYS	Sep 1995	The Drug Control Authority has rejected an application for registration of contact lens products and ophthalmological preparations containing thiomersal on the grounds that mercury is absorbed from such preparations in significant amounts. Thiomersal can also cause sensitization after repeated use. (Reference: (MYSDI) Berita Ubat-Ubatan (Drug Information), 9(3): 3, , Sep 1995)
BRA	Jun 2001	Products containing thiomersal are prohibited except those intended for vaccine conservation. (Reference: (BRARES) Resolucao n., 528/ANVISA, , 06 Aug 2001)

Product Name		Tianeptine sodium	
--------------	--	--------------------------	--

Legislative or regulation action

C.A.S. number	30123-17-2
Scientific and common names, and synonyms	TIANEPTINE, 7-[(3-CHLORO-6,11?DIHYDRO-6-METHYLDIBENZO[C,F][1,2] THIAZEPIN-11-YL)AMINO]HEPTANOIC ACID S,S DIOXIDE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
BHR		The Drug Control Directorate has classified tianeptine sodium under the 'special-drugs-under-controlled prescriptions' category due to increasing reports of misuse and abuse by patients.
SGP		The National Pharmaceutical Administration in the Ministry of Health has restricted the use of tianeptine sodium to psychiatrists due to its abuse potential. (Reference: (SGPCW) Communication to WHO, , , 02 Aug 2000)

Product Name **Tiaprofenic acid**

C.A.S. number **33005-95-7**

Scientific and common names, and synonyms

5-BENZOYL-7-METHYL-2-THIOPHENEACETIC ACID

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
GBR	Aug 1994	In view of the high number of reports of cystitis, the Committee on Safety of Medicines recommends that tiaprofenic acid should not be given to patients with pre-existing urinary tract disorders and that if urinary tract symptoms develop tiaprofenic acid should be stopped. (Reference: (GBRCP) Current Problems in Pharmacovigilance, 20: 11, , Aug 1994)
DEU	Oct 1994	The manufacturer of the nonsteroidal anti-inflammatory agent, tiaprofenic acid revised the product information to include a reference to the potential of this product to induce cystitis, which is initially reversible on discontinuation of treatment and to stress the need to interrupt therapy with tiaprofenic acid as soon as urinary disturbances are reported by the patient. (Reference: (DEUPZ) Pharmazeutische Zeitung, 139(40): 3401, , 1994)
MYS	Dec 1995	In view of reports from other countries of cystitis in patients receiving the nonsteroidal anti-inflammatory agent, tiaprofenic acid, the Drug Control Authority has decided to revise the product information to include the following precautionary statement: Urinary symptoms (bladder pain, dysuria and frequency), haematuria or cystitis may occur. In certain exceptional cases, the symptoms have become severe on continued treatment. Should urinary symptoms occur, treatment with tiaprofenic acid must be stopped. (Reference: (MYSDI) Berita Ubat-Ubat (Drug Information), 9(4): 2, , 1995)

WHO Comment : See comment under "Nonsteroidal anti-inflammatory agents".

Product Name **Ticlopidine**

C.A.S. number **55142-85-3**

Scientific and common names, and synonyms

5-(O-CHLOROBENZYL)-4,5,6,7-TETRAHYDROTHIENO-(3,2-C)PYRIDINE
THIENO(3,2-C)PYRIDINE, 5-((2-CHLOROPHENYL)METHYL)-4,5,6,7-TETRAHYDRO-

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
DEU	1983	Registered solely for the treatment of haemodialysis patients, with shunt complications, who are intolerant to acetylsalicylic acid. A full blood count should be made before

Legislative or regulation action

Product Name	Ticlopidine	
C.A.S. number	55142-85-3	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GRC	1984	treatment and every 14 days, then subsequently every month throughout treatment. Use is restricted to patients with severe renal damage who do not tolerate acetylsalicylic acid having regard to the occurrence of severe blood reactions.
ITA		Approved indications for use have been restricted to antithrombotic therapy in haemodialysis, peripheral obliterating arteriopathy, thrombosis of the central retinal vein, maintenance of extracorporeal circulation and aortic-coronary by-pass. Haematological monitoring is advised throughout treatment. (Reference: (BIFTI) Bolletino d'Informazione sui Farmaci, (3), , 1984) WHO Comment : Ticlopidine, an inhibitor of platelet aggregation, was introduced in 1978 for use as an antithrombotic agent. By 1982 its use had been associated with cases of agranulocytosis, severe leucopenia and impaired haemostasis. The drug remains available in most countries in which it was approved with appropriate warnings in the product information.

Product Name	Tienilic acid	
C.A.S. number	40180-04-9	
Scientific and common names, and synonyms		
ACETIC ACID, (2,3-DICHLORO-4-(2-THIENYLCARBONYL)PHENOXY)- TICRYNAFEN (2,3-DICHLORO-4-(2-THIENYLCARBONYL)PHENOXY)-ACETIC ACID (2,3-DICHLORO-4-(2-THENOYL)-PHENOXY)ACETIC ACID 4-(2-THENOYL)-2,3-DICHLOROPHENOXYACETIC ACID		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GRC	1980	The Ministry of Health and Welfare has withdrawn this product from domestic use. (Reference: (GRAGA) Ministry of Health Decision, 12946, , Dec 1980)
PHL	Jan 1980	Withdrawn by the manufacturer after reports from other countries that prolonged use in some patients resulted in deaths due to liver dysfunction.
USA	30 Jan 1980	Withdrawn from the market following reports of liver toxicity.
BRA	31 Jan 1980	Products containing tienilic acid are prohibited. (Reference: (BRAPT) Portaria do Servico Publico Federal, (01), , Nov 1980)
DEU	Dec 1980	Voluntarily withdrawn from the market following cases of hepatic failure some of which were fatal.
PAN	10 Apr 1981	The Ministry of Health has banned the sale of pharmaceuticals and cosmetics containing tienilic acid. (Reference: (PANMR) Ministry of Health Resolution, 28, , Apr 1981)
FRA	1991	Voluntarily withdrawn from the market by the manufacturer, following reports of hepatitis associated with its use. (Reference: (FRARP) La Revue Prescrire, 12(114), 28, 1992)
IND		Not approved for marketing after withdrawal in the United States following reports of liver toxicity.
VEN		Not approved for use and/or sale.

Legislative or regulation action

Product Name	Tienilic acid	
C.A.S. number	40180-04-9	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		WHO Comment : Tienilic acid, a diuretic agent with uricosuric and antihypertensive activity, was introduced in 1976. By 1979 its use had been associated with cases of hepatic toxicity, some of which were fatal, which led to the withdrawal of the drug in most countries in which it was marketed. In France, however, precautions regarding the use of tienilic acid were issued by the Pharmacovigilance Commission and the drug remained available for another decade. In 1991, it was eventually also withdrawn there since cases of hepatitis, some of which were fulminant, had continued to occur.

Product Name	Tilbroquinol	
C.A.S. number	7175-09-9	
Scientific and common names, and synonyms		
	7-BROMO-5-METHYL-8-QUINOLINOL	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
FRA	Jul 1997	The Agence du Médicament has decided to suspend the marketing authorization for tilbroquinol (Intetrix® P) and batches were recalled on 5 July 1997. This decision was reached in view of the absence of efficacy data for the treatment of infectious diarrhoeas and because of the risk of liver toxicity. [See also tilbroquinol/tiliquinol in Combination products]. (Reference: (FRAAMI) Infofax - Pharmacovigilance, , , 04 July 1997)
MAR	Nov 1997	The Direction du médicament et de la pharmacie has suspended marketing authorization for the paediatric formulation of tilbroquinol and the therapeutic indications for the adult formulation were restricted to the treatment of intestinal amoebiasis. (Reference: (MARDMP) Letter to WHO, , , 08 Sep 2000)
FRA	1999	The Agence du Médicament has withdrawn the antiprotozoal, tilbroquinol from the market because the hepatotoxicity of the drug outweighs the potential benefit. (Reference: (FRADRA) Décision de retrait de l'autorisation de mise sur le marché d'Intetrix P granulés, , , 05 July 1999)
SAU	Jun 1999	The Ministry of Health has withdrawn from the market products containing tilbroquinol and a combination product containing tilbroquinol/tiliquinol because of a risk of hepatotoxicity associated with their use. (Reference: (SAUCW) Notification, , , 20 June 1999)

Product Name	Tocainide	
C.A.S. number	41708-72-9	
Scientific and common names, and synonyms		
	PROPANAMIDE, 2-AMINO-N-(2,6-DIMETHYLPHENYL)- 2-AMINO-2',6'-PROPIONOXYLIDIDE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
IRL	1985	Use of tocinide has been limited to named patients under the supervision of a consultant, having regard to cases of agranulocytosis associated with its use.

Legislative or regulation action

Product Name	Tocainide	
C.A.S. number	41708-72-9	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
NLD	1986	(Reference: (IRDAB) National Drugs Advisory Board Annual Report, , , 1985) Having regard to reports of blood dyscrasias associated with its use, indications are restricted to the symptomatic treatment of ventricular dysrhythmias when other treatments fail or are contraindicated. (Reference: (NPHWB) Pharmaceutisch Weekblad, 121, 167, 1986) WHO Comment : Tocainide, an antidysrhythmic agent, was introduced in 1981 for the treatment of ventricular dysrhythmias. By 1984 its use was associated with cases of agranulocytosis, aplastic anaemia and thrombocytopenia, some of which were fatal. This led some regulatory authorities to restrict the indications for its use. The major manufacturer has subsequently restricted its use on a worldwide basis to the treatment of symptomatic ventricular dysrhythmias not responding to other therapy, or when other therapy is contraindicated.

Product Name	Tolcapone	
C.A.S. number	134308-13-7	
Scientific and common names, and synonyms		
3,4-DIHYDROXY-5-NITROPHENYL (4-METHYLPHENYL)METAHANONE 3,4-DIHYDROXY-4'-METHYL-5 NITROBENZOPHENONE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
EME	Nov 1998	The European Agency for the Evaluation of Medicinal Products has recommended the suspension of the marketing authorization for tolcapone. This follows several reports of severe and unpredictable hepatic reactions including fatal fulminant hepatitis. (Reference: (EMEAPR) EMEA Press Release, , , 17 Nov 1998)
GBR	Nov 1998	The manufacturer of the antiparkinsonism drug, tolcapone has voluntarily withdrawn it from the market. This follows a review of the hepatotoxic effects by the European Committee for Proprietary Medicinal Products (CPMP) which found that the overall balance of risks and benefit was no longer favourable. . (Reference: (GBRMCA) Communication to WHO, , , 30 Aug 2000)
ISL	Nov 1998	The State Committee on Pharmaceuticals in Iceland withdrew the marketing authorization for tolcapone due to serious adverse effects. Since then the product has been available to specialist neurologists for the treatment of severe cases of Parkinson's disease. (Reference: (ISLSCP) Communication to WHO, , , 17 Oct 2000)
LTH	Dec 1998	The State Medicines Control Agency has withdrawn from the market tablets of tolcapone. (Reference: (LTHMCA) Order of State Medicines Control Agency, No. 123, , 15 Dec 1998)
AUS	Feb 1999	Following overseas reports of serious and unpredictable hepatotoxicity associated with the use of the catechol-O-methyl transferase inhibitor, tolcapone (TamarR), including 3 fatalities, its registration has been withdrawn in Australia. (Reference: (AUSADR) Australian Adverse Drug Reactions Bulletin, 18(1), , Feb 1999)
BGR	Apr 1999	The Bulgarian Drug Agency in the Ministry of Health withdrew the antiparkinsonism agent, tolcapone because of serious adverse reactions worldwide. (Reference: (BGRBDA) Communication to WHO, , ,)
SGP		The National Pharmaceutical Administration in the Ministry of Health has restricted the use of tolcapone to neurologists as there are concerns over reports of severe

Legislative or regulation action

Product Name	Tolcapone	
C.A.S. number	134308-13-7	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		hepatotoxicity associated with the use of the drug. (Reference: (SGPCW) Communication to WHO, , , 02 Aug 2000)
Product Name	Tolrestat	
C.A.S. number	82964-04-3	
Scientific and common names, and synonyms		
GLYCINE, N-[[6-METHOXY-5-(TRIFLUOROMETHYL)-1-NAPHTHALENYL]THIOXOMETHYL]-N-METHYL		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
@WD	Nov 1996	In October 1996 the manufacturer withdrew tolrestat from the market worldwide following a case of hepatic necrosis and death notified to the National Pharmacovigilance System in Argentina in 1995 and of two additional deaths from hepatic necrosis associated with the use of tolrestat in Canada and Italy. (Reference: (LANCET) Foppiano M & Lombardo G. Worldwide pharmacovigilance systems and tolrestat withdrawal, Lancet 349, p.399 , 08 Feb 1997) (Reference: (ARGANM) Communication, , , 05 Nov 1996)
Product Name	Tramadol	
C.A.S. number	27203-92-5	
Scientific and common names, and synonyms		
CYCLOHEXANOL,2-((DIMETHYLAMINO)METHYL)-1-(3-METHOXYPHENYL)-, TRANS-(+/-)		
CG-315		
(+/-)-TRANS 2-((DIMETHYLAMINO)METHYL)-1-(M-METHOXYPHENYL)CYCLOHEXANOL		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
AUT	1 Oct 1985	The drug substance and finished preparations are subject to control at national level analogous to that provided by Schedules I and III of the 1961 Single Convention on Narcotic Drugs.
BHR	2000	The Ministry of Health has restricted the prescription of medicines containing tramadol as controlled medicines that should be dispensed only on special prescriptions issued by the Directorate of Pharmacy and Drug Control at the Ministry of Health with effect from 2 May 2000. (Reference: (BHRCW) Communication with WHO, , , 27 June 2000)
MUS	Oct 2000	The Ministry of Health and Quality of Life has moved the product tramadol from Prescription-only status to Psychotropic in Schedule III of the New Dangerous Drugs Act based on 1988 Convention Classification. This is because of widespread 1988 Convention Classification. This is because of widespread abuse resulting from unsupervised sales in pharmacies. (Reference: (MUSMHQ) Letter to WHO, , , 27 Dec 2000)
Product Name	Tranlycypromine	
C.A.S. number	155-09-9	

Legislative or regulation action

Product Name **Tranlycypromine**
C.A.S. number **155-09-9**
Scientific and common names, and synonyms
 CYCLOPROPANAMINE, 2-PHENYL-, TRANS-(+/-)-
 TRANSAMINE SULPHATE
 (+/-)-TRANS-2-PHENYLCYCLOPROPYLAMINE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
ITA	1964	Withdrawn from the market by the Ministry of Health.
BEL	1965	The Ministry of Health has withdrawn drugs containing tranlycypromine.
SAU		Products with this ingredient are now under strict control.
VEN		Not approved for use and/or sale.

WHO Comment : Tranlycypromine, a monoamine oxidase inhibitor (MAOI), was introduced in 1961 for the treatment of depressive illness. By 1964 its use had been associated with transient hypertensive crises and other adverse effects when taken together with certain cheeses and other foods containing tyramine. This led to the withdrawal of the drug in several countries and the suspension of marketing on a worldwide basis by the major manufacturer pending review of these adverse reactions. Subsequently, in response to requests from the medical profession, tranlycypromine was resubmitted for registration with appropriate warnings in the product information and it is now marketed in more than 30 countries.

Product Name **Trazodone**
C.A.S. number **19794-93-5**
Scientific and common names, and synonyms
 1,2,4-TRIAZOLO(4,3-A)PYRIDIN-3(2H)-ONE, 2-(3-(4-(3-CHLOROPHENYL)-1-PIPERAZINYL)PROPYL)-
 2-(3-(4-(M-CHLOROPHENYL)-1-PIPERAZINYL)PROPYL)-S-TRIAZOLO(4,3-A) PYRIDIN-3(2H)-ONE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
NOR	1985	Not approved for registration because the results of a two-year study in rats gave rise to suspicion of a carcinogenic effect, and carcinogenic studies in another animal species were not submitted. (Reference: (NNSLM) Nytt fra Statens Legemiddelkontroll, (1), , 1985)

WHO Comment : Trazodone, an antidepressant indicated for the treatment of a wide range of depressive illness, was introduced in 1973. Although it is registered for use in many countries with highly evolved regulatory authorities, approval for registration was not granted in Norway because of a suspicion of carcinogenicity in a two-year rat study.

Product Name **Tretinoin**
C.A.S. number **302-79-4**
Scientific and common names, and synonyms
 ALL-TRANS-RETINOIC ACID
 RETINOIC ACID

Legislative or regulative action

Legislative or regulation action

Product Name		Tretinoin	
C.A.S. number		302-79-4	
Country	Effective Date	Description of action taken Grounds for decision	
OMN	24 Dec 1985	Having regard to its teratogenicity, tretinoin may only be used under the supervision and control of a hospital dermatologist. (Reference: (OMNMH) Ministry of Health, No.5, , 1985)	
DEU	29 Mar 1988	Tretinoin may no longer be included as an ingredient in cosmetic products, having regard to its teratogenic potential. (Reference: (DAZ) Deutsche Apotheker Zeitung, 128(21), 35, 1988)	
NZL	4 Nov 1993	Tretinoin in topical preparations for the treatment of acne has been reclassified from Restricted Medicine (an OTC classification, but may only be sold personally by a pharmacist) to Prescription Medicine because of its teratogenic potential. (Reference: (NZLPU) Prescriber Update, No.5, , May 1994)	
DEU	28 Jul 1994	The Federal Institute for Drugs and Medical Devices has revised the product information for topical formulations containing the retinoid, tretinoin. The section on toxicological properties will state that in animal experiments teratogenicity has been demonstrated both after systemic and local administration. As a consequence, the product is now contraindicated during pregnancy. (Reference: (DEUPZ) Pharmazeutische Zeitung, 139(30): 2379, , 1994)	
WHO Comment : Tretinoin, a retinol derivative, was introduced in 1973 exclusively for the topical treatment of severe acne. Preparations of tretinoin are indicated for topical use only since oral administration has been associated with risk of toxicity from hypervitaminosis-A and subsequently of teratogenicity.			

Product Name		Triacetyldiphenolisatin	
C.A.S. number		18869-73-3	
Scientific and common names, and synonyms			
PHENISATINE			
Legislative or regulative action			
Country	Effective Date	Description of action taken Grounds for decision	
DEU	1976	Withdrawn following a review of published cases of acute and chronic liver disease. The action was consonant with decisions previously taken in a number of countries including Australia and the United States. Some other national authorities have chosen to place products containing this compound under prescription control.	
ITA	1976	Preparations for oral, rectal and topical use have been withdrawn from the market due to the risk of sensitization.	
CAN	1978	All preparations containing this substance were withdrawn from sale in Canada. (Reference: (CANGZ) Canada Gazette, , , May 1978)	
CYP		Products containing triacetyldiphenolisatin have been withdrawn having regard to the risk of liver damage in patients receiving this drug.	
NZL		Voluntarily withdrawn from the market.	
VEN		Not approved for use and/or sale.	
WHO Comment : Triacetyldiphenolisatin is a derivative of oxyphenisatine. See WHO comment for oxyphenisatine acetate.			

Product Name **Triazolam**
 C.A.S. number **28911-01-5**
 Scientific and common names, and synonyms

Legislative or regulation action

Product Name **Triazolam**

C.A.S. number **28911-01-5**

Scientific and common names, and synonyms

8-CHLORO-6-(O-CHLOROPHENYL)-1-METHYL-4H-S-TRIAZOLO(4,3-A)(1,4) BENZODIAZEPINE

CLORAZOLAM

4H-(1,2,4)TRIAZOLO(4,3-A)(1,4)BENZODIAZEPINE, 8-CHLORO-6-(2- CHLOROPHENYL)-1-METHYL-

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
MUS	9 Mar 1982	Under the Pharmacy and Poisons (Prohibitions of Harmful Drugs) Regulations, this drug is deemed "harmful" by the Ministry of Health and is prohibited for import, manufacture, storage, distribution, sale, possession, use, export or other transaction. (Reference: (MPPHD) Pharmacy & Poisons (Prohibitions of Harmful Drugs) Regulations, , , Mar 1982)
AUS	11 Apr 1986	Tablets containing 0.50mg and 0.25mg triazolam were not approved by the Australian Drug Evaluation Committee, having regard to the risk of adverse effects due to inappropriate use. Tablets containing 0.125mg triazolam were approved for the treatment of insomnia. (Reference: (AUDEC) Report of the Australian Drug Evaluation Committee, 123, , Apr 1986)
ITA	9 Mar 1987	The marketing authorization of tablets containing 0.50 mg triazolam was withdrawn by Ministerial Decree on the basis of evidence that use of 0.50 mg tablets had caused incidents of anterograde amnesia, mental confusion and behavioural disorders. The package insert must state that the recommended dose of 0.25 mg should only be exceeded in very exceptional cases to treat particularly resistant insomnia. (Reference: (ITAMD) Ministerial Decree, No.7639/R, , Mar 1987)
DEU	Apr 1988	The Federal Health Office has decided to withdraw the registration of tablets containing 0.5 mg triazolam and the indications for tablets containing 0.25 mg have been restricted to short-term treatment of sleep disturbances.
CHL	14 Mar 1989	Products containing 0.125 mg and 0.250 mg triazolam have been subjected to prescription control and must carry the following warning: "This product may only be administered under strict medical control and supervision." These measures were taken on the grounds of reports of serious adverse psychiatric effects. (Reference: (CHLMS) Letter to WHO from the Ministerio de Salud, , , Sep 1990) (Reference: (BMCHL) Boletín Informativo Sobre Medicamentos, 6(1), 13, 1989)
@EC	16 Oct 1991	The Committee for Proprietary Medicinal Products recommended that the indications for products containing triazolam should be restricted to the treatment of severe disabling sleeping disorders or to insomnia causing extreme distress; duration of treatment should not exceed 2-3 weeks; the lowest effective dose should be used and a dose of 0.250 mg should not be exceeded; for the elderly, debilitated patients and patients with disturbed liver/kidney function, the dose should not exceed 0.125 mg; the compound should not be administered to patients with major psychiatric disorders; packs of not more than seven tablets should be made available. (Reference: (CPMPPS) Position Statement, , , Oct 1991)
ESP	Dec 1991	The marketing authorization for tablets containing 0.250 mg triazolam was suspended by the manufacturer, because of association with serious psychiatric adverse reactions, particularly anterograde amnesia.
FRA	30 Dec 1991	The marketing authorization for tablets containing 0.250 mg triazolam was suspended, because this high dosage formulation was considered to present risks, especially amnesia, that outweigh the therapeutic benefits. Duration of treatment for tablets containing 0.125 mg was restricted to two weeks and the package size was limited to seven tablets. Tablets containing 0.5 mg triazolam had been withdrawn in the late 1980s. (Reference: (FRAMS) Ministry of Social Affairs and Integration, , , 30 Dec 1991)
PAK	Jan 1992	The Drug Registration Board decided that triazolam tablets should bear a warning that they are contraindicated in patients with a major psychiatric disorder.

Legislative or regulation action

Product Name		Triazolam
C.A.S. number		28911-01-5
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		(Reference: (PAKDI) Pakistan Drug Information, 3, , Jan 1992)
NOR	Feb 1992	Following their initial suspension from the market on 4 October 1991, products containing triazolam were withdrawn because of their association with serious psychiatric adverse effects, including memory disturbances, anxiety, depression and aggression. (Reference: (NORMCA) Norwegian Medicines Control Authority, , , Oct 1992)
JPN	Mar 1992	The Pharmaceutical Affairs Bureau decided to reduce the recommended dosage regimen for triazolam. It is proposed that treatment should be initiated at a nightly dose of 0.125 mg or less, and that under no circumstances should the dose exceed 0.5 mg. (Reference: (JPNARD) Information on Adverse Reactions to Drugs, 113, , Mar 1992)
BRA	Jun 1992	The Centre for Pharmacovigilance of the State of Sao Paulo prohibited the sale and use of pharmaceutical products containing triazolam. The National Secretariat for Pharmacovigilance suspended indefinitely the manufacture and marketing of such products with effect from 5 June 1992. (Reference: (BRAPT) Portaria do Servico Publico Federal, 59, , June 1992) (Reference: (BRADMS) Diario Oficial Ministerio da Saude, , , June 1992) (Reference: (BRACVS) Centro de Vigilancia Sanitaria, , , June 1992)
CYP	23 Oct 1992	The Drug Council withdrew the marketing licence for tablets containing 0.5 mg of triazolam and revised the product information for lower dose formulations. These products are now indicated exclusively for sleeping disorders that are "severe, disabling or cause extreme distress". (Reference: (CYPPS) Pharmaceutical Services, Ministry of Health, , , 23 Oct 1992)
OMN	Nov 1992	The Directorate General of Pharmaceutical Affairs and Drug Control has decided to suspend the sale of pharmaceutical products containing triazolam as a precautionary measure. This decision will be reviewed when further information concerning the safety of triazolam is available. (Reference: (OMNDGP) Directorate General of Pharmaceutical Affairs, , , Nov 1992)
FIN	13 Jan 1993	Following the initial suspension of registration of products containing triazolam pending a reassessment of their benefits and risks, these products were reintroduced to the market with restricted indications. Tablets of 0.125mg and 0.25mg and buccal tablets 0.2mg only are available. The indications are restricted to transient but disabling short-term insomnia. (Reference: (FINAWH) National Agency for Welfare and Health, , , 13 Jan 1993)
GBR	09 Jun 1993	Products containing triazolam were withdrawn in 1991 because of their association with serious, though reversible psychiatric adverse effects, particularly loss of memory and depression. After several appeals to this decision, the United Kingdom Licensing Authority decided to uphold its decision to revoke the licence of all products containing triazolam. (Reference: (DCCUJC) Upjohn News Release, , , 09 June 1993)
<p>WHO Comment : Triazolam, a benzodiazepine derivative with sedative and hypnotic activity, was introduced in 1978 for the management of insomnia. It is controlled under Schedule IV of the 1971 Convention of Psychotropic Substances. Concern regarding the psychotropic effects of triazolam was first raised in the Netherlands in 1979 when this compound was suspended for sale and subsequently withdrawn by the Committee for the Evaluation of Medicines on the basis of reports of a reversible complex of symptoms including paranoia, depersonalization, nightmares, suicidal tendency and hyperaesthesia in patients receiving the drug. The basis for this decision was later successfully contested by the manufacturer and the drug was reregistered in early 1990 with a revised product information. However, concern was regenerated elsewhere that higher doses are associated with an unacceptable incidence of unwanted effects and the manufacturer has eventually withdrawn 0.5 mg tablets on a worldwide basis. In</p>		

Product Name	Triazolam	
C.A.S. number	28911-01-5	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		1991 the issue of the safety of triazolam was again reopened by reports of retrograde amnesia and depression among patients taking the decreased recommended dosages. The product information has been revised by the United States FDA to include more rigorous cautions regarding dosage. In the Member States of the European Communities the products have been suspended pending further review by the EC Committee on Proprietary Medicinal Products. (Reference: (UNCPS4) United Nations Convention on Psychotropic Substances (IV), , , 1971)
Product Name	Trimipramine	
C.A.S. number	739-71-9	
Scientific and common names, and synonyms		
DIMETHYL-[3-(3-(10,11-DIHYDRO-5H-DIENZ[B,F]AZEPIN-5-YL-2-METHYL)PROPYL)AMINE TRIMEPRIMINE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
NOR	1992	The Medicines Control Authority has decided that the 50 mg tablet formulation of trimipramine may be prescribed only in hospitals and specialized clinics because of the toxic potential of these products and the risk of overdosage and suicide with the high dose formula. (Reference: (NNSLM) Nytt fra Statens Legemiddelkontroll, 1, 9, 1992) WHO Comment : Trimipramine, a tricyclic antidepressant was introduced in 1961 for the management of endogenous depression. Much of the adverse effects are caused by its antimuscarinic actions. These include dry mouth, cardiac arrhythmias, central nervous system disturbances, blood disorders and risk of suicide. The risk of suicide and dangers related to overdosage led Norwegian Medicines Control Authority to put the higher strength formulation under prescribing restriction in 1992. The risk of death following overdosage is apparently higher for products containing tricyclic compounds as compared with nontricyclic products.
Product Name	Troglitazone	
C.A.S. number	97322-87-7	
Scientific and common names, and synonyms		
(±)-ALL-RAC-5-[P-]([6-HYDROXY-2,5,7,8-TETRA-METHYL-2-CHROMANYL]METHOXY]BENZYL]-2,4-THIAZOLIDINEDIONE 2,4-THIAZOLIDINEDIONE, 5-[[4-[3,4-DIHYDRO-6-HYDROXY-2,5,7,8-TETRAMETHYL-2H-BENZOPYRAN-2-YL]METHOXY]-PHENYL]METHYL]-		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GBR	Dec 1997	In relation with hepatic reactions including cases of severe hepatocellular damage, hepatic necrosis and hepatic failure, troglitazone has now been voluntarily withdrawn from the UK by the companies concerned. (Reference: (GBRMCA) Communication to WHO, , , 01 Dec 1997)
JPN	Dec 1997	The product information for troglitazone has been revised to include a warning about

Legislative or regulation action

Product Name	Troglitazone	
C.A.S. number	97322-87-7	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		significant hepatic dysfunction and doctors have been required to monitor liver function of patients periodically (at least once a month). (Reference: (JPNPMB) Communication, , , 01 Dec 1997)
USA	Dec 1997	The FDA has issued new advice about the use of troglitazone. Patients taking troglitazone should be monitored at least once a month for signs of injury to the liver during the first six months of treatment, and periodically thereafter. In addition, warning information about potential liver toxicity will be more prominently featured in the drug's labelling. (Reference: (FDATP) Food and Drug Administration Talk Paper, T97-61, , 01 Dec 1997)
JAM	2 Feb 1998	The Ministry of Health, Standards and Regulation did not approve registration of the antidiabetic agent troglitazone (Rezulin) due its hepatotoxicity. (Reference: (JAMMHS) Communication to WHO, , , 26 Sep 2000)
USA	Jun 1999	The FDA and the manufacturer of troglitazone (RezulinR: Parke-Davis) - a drug used to treat type 2 diabetes mellitus (non-insulin dependent diabetes mellitus, or adult onset diabetes) has notified significant new changes to the labelling and recommended uses for this product. These changes are being made because new safety information (i.e., further evidence of serious and sometimes fatal liver injury in patients treated with troglitazone) indicates that its use should be limited to patients not adequately controlled by other therapy and should not be used as initial single agent therapy in the treatment of type 2 diabetes. The labelling changes also include recommendations for more extensive monitoring of liver function in patients using troglitazone. (Reference: (FDATP) Food and Drug Administration Talk Paper, T99-28, , 16 June 1999)
PER	May 2000	La Dirección General de Medicamentos, Insumos y Drogas (DIGEMID) of the Ministry of Health has communicated to health professionals that Warner Lambert Peru S.A. has voluntarily withdrawn the antidiabetic agent troglitazone from the market because of severe hepatic adverse effects associated with the use of this medicine. (Reference: (PERDGM) Alerta DIGEMID, No. 6-2000, , 26 May 2000)
CHL	Oct 2000	Use in formulations has been banned by the Public Health Institute of Chile; the marketing authorization has been cancelled. (Reference: (CHLCW) Communication to WHO, , , 26 Sep 2001)

Product Name	Trolamine	
C.A.S. number	102-71-6	
Scientific and common names, and synonyms		
	ETHANOL, 2,2',2'-NITRILOTRIS-	
	TRIETHANOLAMINE	
	2,2',2'-NITRILOTRIETHANOL	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
CHE	30 Jun 1992	Trolamine and its salts can no longer be contained in products intended for oral use, because under certain circumstances this emulsifying agent can be concerted in the stomach into carcinogenic N-nitrosamines. In products for external and parenteral use trolamine may still be used, but in strictly limited amounts. (Reference: (CHBCM) Bulletin Mensuel, 11, 760, 1990)
WHO Comment : Trolamine is widely used as an emulsifier in combination with fatty acids in pharmaceutical and cosmetic products. The World Health		

Legislative or regulation action

Product Name	Trolamine	
C.A.S. number	102-71-6	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
Organization is not aware of restrictive action having been taken elsewhere.		
Product Name	Trovafloxacin mesilate	
C.A.S. number	147059-72-1	
Scientific and common names, and synonyms		
	CP-99219-27	
	TROVAFLOXACIN MESYLATE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
SYR	1999	The Suprim Technical Committee and the Ministry of Health has withdrawn the licensing approval for trovafloxacin and cancelled it from the national essential drug list. (Reference: (SYRAFD) Announcement from the Directorate, 4/2/1989, , 02 Sep 1999)
EME	May 1999	The European Agency for the Evaluation of Medicinal Products (EMA) has recommended that marketing authorization for products containing trovafloxacin or alatrofloxacin be suspended. This follows reports of serious adverse hepatic events. (Reference: (EMEAPS) Public statement, No.17438/99, , May 1999)
ESP	Jun 1999	The Spanish Medicines Agency has suspended the use of medicinal products contain the fluoroquinolone antibiotic, trovafloxacin and the intravenous formulation of the drug, alatrofloxacin (Reference: (ESPAES) Communication, , , 15 June 1999)
MAR	Jun 1999	The National Advisory Commission for Pharmacovigilance has decided to restrict the use of trovafloxacin and alatrofloxacin only to university hospitals under professional control and after a total examination of hepatic function. In the meantime, the Commission has launched a survey among prescribers in order to evaluate the risk/benefit balance of this product. (Reference: (MARDMP) Letter to WHO, , , 24 Aug 1999)
VTN	Jul 1999	The Drug Administration of Viet Nam in the Ministry of Health has not approved the registration of trovafloxacin (Trovan) solution for injection 5 mg/ml and tablet 200 mg on the basis that these products have a potential for hepatotoxicity. (Reference: (VTNMHD) Directive, 2785, QLD, 15 July 1999)
PHL	Jan 2000	The Department of Health Bureau of Food and Drugs have banned and withdrawn trovafloxacin since it is associated with hepatic adverse reactions. (Reference: (PHADO) Administrative Order, (1) s. 2000, , 03 Jan 2000)
SGP		The National Pharmaceutical Administration in the Ministry of Health has not approved trovafloxacin since it is associated with hepatic adverse reactions. (Reference: (SGPCW) Communication to WHO, , , 02 Aug 2000)
USA		The Food and Drug Administration has restricted the indications for products containing trovafloxacin or alatrofloxacin to patients having nosocomial infections or complicated intra-abdominal infections that are serious or life- threatening. This is due to concerns over the risks of serious liver toxicity. (Reference: (FDATP) Food and Drug Administration Talk Paper, T99-26, , June 1999)
Product Name	Trypsin	
C.A.S. number	9002-07-7	
Legislative or regulation action		

Product Name	Trypsin	
C.A.S. number	9002-07-7	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
SLV	Jun 2001	Injections for intramuscular use were not approved because of incomplete data on safety and efficacy. (Reference: (SLVCW) Communication to WHO, , , 24 Aug 2001)

Product Name	Urethane	
C.A.S. number	51-79-6	
Scientific and common names, and synonyms		
	CARBAMIC ACID, ETHYL ESTER	
	ETHYLURETHANE	
	ETHYL CARBAMATE	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
BRA	16 Sep 1963	Products containing urethane are prohibited. (Reference: (BRAPT) Portaria do Servico Publico Federal, No.13, , Sep 1963)
CUB	1964	The use of urethane both as a solvent and an antineoplastic agent was prohibited due to the availability of less toxic and more effective drugs.
DNK	1967	Registration has been cancelled. (Reference: (UGLAAD) Ugeskrift for Laeger, 136, 2093, Sep 1974)
EGY	1975	Products containing urethane were withdrawn having regard to the carcinogenic potential of the drug.
JPN	Jul 1975	Banned as a co-solvent in drugs by Pharmaceutical Affairs Bureau, for reasons of carcinogenicity.
THA	Dec 1975	Use as a stabilizer or solubilizer in drug preparations is prohibited.
USA	Mar 1977	Withdrawn from use and/or sale by the Food and Drug Administration as an ingredient in pharmaceutical products due to its carcinogenic nature. Prohibited for export in pharmaceutical products.
ITA	1979	Withdrawn from the market owing to suspected carcinogenicity.
GRC	1980	Withdrawn as an excipient in pharmaceutical preparations.
DEU	Jan 1982	Registration for all products containing urethane was cancelled due to the carcinogenic potential of the drug.
VEN		Not approved for use and/or sale in pharmaceutical products.
		WHO Comment : Urethane was formerly used as an antineoplastic agent in the treatment of chronic myeloid leukaemia. It is also a mild hypnotic which has been used as an anaesthetic for veterinary practice. It has been reported to have both a carcinogenic and mutagenic potential. Although urethane continues to be used as an industrial solvent, WHO has no information to suggest that it remains commercially available in pharmaceutical preparations.

Bibliographical references

IARC MONOGRAPH, 7, 111, 1974

Product Name	Vaccines for mumps, measles, and rubella
---------------------	---

Legislative or regulation action

Product Name Vaccines for mumps, measles, and rubella

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
@WD	16 Sep 1992	In agreement with regulatory agencies SmithKline Beecham decided to discontinue marketing all vaccines which contain the Urabe Am 9 strain of the mumps virus in those countries where an alternative vaccine containing other strains of the mumps virus is available. This decision is based on the reported incidence of meningeal reactions (1: 11,000) associated with this strain of virus. (Reference: (DCCSKB) Drug company communication - Smith Kline Beecham, , , 16 Sep 1992)
GBR	19 Sep 1992	The Department of Health restricted future purchasing of mumps, measles and rubella vaccine to MMR-II which is marketed by Wellcome Medical Division and contains the Jeryl Lynn (B level) strain of the mumps virus. (Reference: (GBRPHJ) The Pharmaceutical Journal, 358, , 19 Sep 1992)
CYP	23 Oct 1992	The Drug Council in Cyprus withdrew the marketing licence for SmithKline Beecham triple vaccine Pluserix, the mumps/measles vaccine Rimparix, the mumps vaccine Pariorix and two other MMR vaccines, Trimovax and Imovax (Pasteur Merieux). (Reference: (CYPPS) Pharmaceutical Services, Ministry of Health, , , 23 Oct 1992)

WHO Comment : Mumps, measles and rubella vaccine is a mixed preparation containing live attenuated strains of the measles, mumps and rubella virus. There are different strains of the mumps virus and it is suggested that meningitis may occur marginally more frequently with vaccine containing the Urabe Am 9 strain of the mumps virus than the Jeryl Lynn strain. However, a number of regulatory authorities still accept the Urabe Am 9 strain of the mumps virus on the grounds that no permanent damage arises from the aseptic meningitis.

Product Name Valproic acid

C.A.S. number 99-66-1

Scientific and common names, and synonyms
2-PROPYLPENTANOIC ACID

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
CHL	Nov 2001	The Public Health Institute of Chile has modified the labels to include warnings about the adverse reactions (pancreatitis and its symptoms) associated with the drug. (Reference: (CHLCW) Communication to WHO, , , 26 Sep 2001)

Product Name Vigabatrin

C.A.S. number 60643-86-9

Scientific and common names, and synonyms
GAMMA-VINYL AMINOBUTYRIC ACID
GAMMA VINYL-GABA
4-AMINOHEX-5-ENOIC ACID

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
NOR	1991	The Medicines Control Authority has refused an application of registration of the anticonvulsant, vigabatrin, on grounds that the product is not medically justified.

Legislative or regulation action

Product Name	Vigabatrin	
C.A.S. number	60643-86-9	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		(Reference: (NNSLM) Nytt fra Statens Legemiddelkontroll, 1, 27, 1991) WHO Comment : Vigabatrin, an irreversible inhibitor of GABA-transaminase was introduced in 1989 as a anticonvulsant for management of epilepsy unresponsive to other antiepilepsy agents. In 1991 it was refused registration in Norway because it induced toxic changes, including microvacuolation in the brain of two animal species, at doses that are close to therapeutic dosage levels in man. It is still marketed in Sweden and the United Kingdom.
Product Name	Vinarol and viga (dietary supplements)	
C.A.S. number	2004-0-0011	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
USA	04 Apr 2003	Two dietary supplement products (Vinarol and Viga) are being voluntarily recalled by the respective companies due to the unlabeled presence of sildenafil. (Reference: (USAMSA) Medwatch Safety Alert, , , 23 May 2003) (Reference: (USAMSA) Medwatch Safety Alert, , , 04 Apr 2003)
Product Name	Vinbarbital	
C.A.S. number	125-42-8	
Scientific and common names, and synonyms		
5-ETHYL-5-(1-METHYLBUT-1-ENYL)BARBITURIC ACID VINBARBITONE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
SWE	Jul 1984	Withdrawn following discussions between the manufacturer and the National Board of Health and Welfare. Fatal intoxications and abuse are associated with use of preparations containing vinbarbital. WHO Comment : Vinbarbital is an intermediate-acting barbiturate. See WHO comment for barbiturates.
Product Name	Vincamine	
C.A.S. number	1617-90-9	
Scientific and common names, and synonyms		
METHYL(3ALPHA,16ALPHA)-14,15-DIHYDRO-14BETA-HYDROXYEBURNAMENINE-14- CARBOXYLATE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
HUN	1980	Intravenous administration of preparations containing vincamine was prohibited, following association with cardia arrhythmias. (Reference: (HUNIP) National Institute of Pharmacy, , , 21 Aug 1980)

Legislative or regulation action

Product Name	Vincamine	
C.A.S. number	1617-90-9	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
DEU	1987	The Federal Health Office has withdrawn herbal preparations containing vincamine on grounds of inadequate evidence of efficacy and risk of blood dyscrasias. (Reference: (DEUPD) BGA Pressedienst, No.38, , July 1987) WHO Comment : Vincamine, an alkaloid derived from Vinca minor, is claimed to increase cerebral circulation and utilization of oxygen. It is used in a variety of cerebral disorders and is widely marketed for this purpose.
Product Name	Voglibose	
C.A.S. number	83480-39-9	
Scientific and common names, and synonyms		
3,4-DIDEOXY-4-[[2-HYDROXY-1-(HYDROXYMETHYL)ETHYL]AMINO]-2-C-(HYDROXYMETHYL)-D-EPI-INOSITOL		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
JPN	Dec 1996	The product information for voglibose has been revised to state that hypoglycaemic symptoms were observed following monotherapy, in particular in patients with severe hepatic dysfunction when no other antidiabetics were administered. [See also acarbose.] (Reference: (JPNARD) Information on Adverse Reactions to Drugs, No.140, , Dec 1996) WHO Comment : Acarbose and voglibose are alpha-glucosidase inhibitors and delay digestion/absorption of carbohydrates as well as improving postprandial hyperglycaemia.
Product Name	Warfarin	
C.A.S. number	81-81-2	
Scientific and common names, and synonyms		
2H-1-BENZOPYRAN-2-ONE,4-HYDROXY-3-(3-OXO-1-PHENYLBUTYL)- 3-(ALPHA-ACETONYLBENZYL)-4-HYDROXYCOUMARIN		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
EGY	1988	Products containing warfarin must bear a warning advising against the use during the first trimester of pregnancy, having regard to their teratogenic potential. (Reference: (EGYDI) Drug Information, 6(4), 1, 1988) WHO Comment : Warfarin, a coumarin anticoagulant, was introduced into medicine in 1950 for the prevention and management of thrombo-embolic disorders. Its use during the first trimester of pregnancy has been associated with birth malformations, particularly in relation to cranial and limb development, and there have been reports of foetal death due to haemorrhage following administration of the drug during the late stages of pregnancy. The decision of the Egyptian agency to require a warning regarding teratogenicity to be included in the approved information of products containing warfarin being the text of the package insert in line with those approved in other countries. Warfarin is included in the WHO Model List of Essential Drugs. (Reference: (WHTAC4) The Use of Essential Drugs, 4th Report of the WHO Expert Committee, 796, , 1990)

Legislative or regulation action

Product Name **Xenazoic acid**

C.A.S. number **1174-11-4**

Scientific and common names, and synonyms

P-((ALPHA-ETHOXY-P-PHENYLPHENACYL)AMINO)BENZOIC ACID
 XENALMINE
 XENALAMINE
 4-(2-(BIPHENYL-4-YL)-1-ETHOXY-2-OXOETHYLAMINO)BENZOIC ACID

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
BEL	1965	The Ministry of Health has suspended the sale of drugs containing xenazoic acid.
FRA	1965	The Ministry of Health withdrew approval of xenazoic acid since liver damage had been noted during administration of this drug.
VEN		Not approved for use and/or sale.

WHO Comment : Xenazoic acid, an antiviral agent, was introduced in the early 1960s. Its use was associated with hepatic toxicity which resulted in its withdrawal from the market in at least two countries in 1965. WHO has no information to suggest that xenazoic acid remains commercially available.

Product Name **Zimeldine**

C.A.S. number **56775-88-3**

Scientific and common names, and synonyms

(Z)-3-(1-P-BROMOPHENYL)-3-(DIMETHYLAMINO)PROPENYL-PYRIDINE
 2-PROPEN-1-AMINE, 3-(4-BROMOPHENYL)-N,N-DIMETHYL-3-(3-PYRIDINYL-, (Z)-

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
@WD	Jul 1983	This antidepressant drug was withdrawn worldwide by the manufacturer following consultations with the Swedish Department of Drugs. This action was taken in consequence of reports of hypersensitivity reactions which, in a few instances, were accompanied by neurological complications.

WHO Comment : Zimeldine, an inhibitor of serotonin uptake, was introduced in 1982 for the treatment of depressive illness. By 1983 its use had been associated with incidences of hypersensitivity of varying severity and serious neurological side effects including the Guillain-Barré syndrome. Following discussions with the National Board of Health and Welfare of Sweden, the major manufacturer decided to withdraw the drug on a worldwide basis.

Product Name **Zipeprol**

C.A.S. number **34758-83-3**

Scientific and common names, and synonyms

ALPHA-(ALPHA-METHOXYBENZYL)-4-(BETA-METHOXYPHENETHYL)-1- PIPERAZINEETHANOL
 1-METHOXY 3-(4-(BETA-METHOXYPHENETHYL)-PIPERAZIN-1-YL)-1-PHENYLPROPAN- 2-OL

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
PHL	Jun 1982	Withdrawn from use as an antitussive since toxicological studies with rhesus monkeys have shown respiratory arrest after administration.

Legislative or regulation action

Product Name	Ziperol	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
BRA	Oct 1993	The Brazilian Ministry of Health has withdrawn Ziperol from the market and prohibited its importation or production due to several cases of deaths among street children. (Reference: (BRASDP) Centro Brasileiro de Informacoes Sobre Drogas Psicotropicas, , , 05 Oct 1993)
Product Name	Zomepirac	
C.A.S. number	33369-31-2	
Scientific and common names, and synonyms		
5-(P-CHLOROBENZOYL)-1,4-DIMETHYLPYRROLE-2-ACETIC ACID		
5-(P-CHLOROBENZOYL)-1,4-DIMETHYLPYRROLE-2-ACETATE		
1H-PYRROLE-2-ACETIC ACID, 5-(4-CHLOROBENZOYL)-1,4-DIMETHYL-		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
@WD	Mar 1983	The US Food and Drug Administration has informed the World Health Organization that this nonsteroidal anti-inflammatory drug has been withdrawn voluntarily from the market by the manufacturers following reports of serious allergic reactions, including five deaths from anaphylaxis. The drug was approved for marketing within the USA in October 1980. In April 1982 the labelling was revised to warn of the occurrence of allergic reactions, but because of the subsequent increase in the incidence of anaphylactoid reactions and reports of four deaths in the first three months of 1983, the company advised the FDA that it was temporarily withdrawing zomepirac worldwide pending further evaluation. WHO Comment : Zomepirac, a nonsteroidal anti-inflammatory agent, was introduced in 1979 for the treatment of rheumatic disorders and the management of moderate to severe pain. By 1983 its use had been associated with serious allergic reactions, including five deaths from anaphylaxis. This led to voluntary withdrawal of the drug from markets worldwide by the major manufacturer.
Product Name	Zopiclone	
C.A.S. number	43200-80-2	
Scientific and common names, and synonyms		
ZOPICLONUM		
27267-RP		
4-METHYL-1-PIPERAZINECARBOXYLIC ACID ESTER WITH 6-(5-CHLORO-2-PYRIDYL)- 6,7-DIHYDRO-7-HYDROXY-5H-PYRROLO(3,4-B)PYRAZIN-5-ONE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
ISL	25 Feb 1986	Zopiclone is not approved for registration on grounds of positive findings in carcinogenicity tests in animals and adverse effects in humans.
NOR	1987	Zopiclone is not approved for registration on grounds that animal studies have disclosed thyroid disorders and neoplasms.
MUS	May 2000	The Ministry of Health and Quality of Life has rescheduled the antipsychotic agent zopiclone into Schedule III of the consolidated Dangerous Drugs Act 2000 following observations of irrational use and emerging abuse.

Legislative or regulation action

Product Name **Zopiclone**

C.A.S. number **43200-80-2**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
		(Reference: (MUSMHQ) Letter to WHO, , , 27 Dec 2000) WHO Comment : Zopiclone was introduced as a sedative in 1985. It remains registered in several countries and the World Health Organization is not aware of any other country that has refused registration.

Legislative or regulation action

Pharmaceuticals(Combination and Group Products)

Twelfth Issue

PHARMACEUTICALS (COMBINATION AND GROUP PRODUCTS)

284

Product Name **ACE-Inhibitors**

Scientific and common names, and synonyms

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
DEU	Sep 1988	The Federal Health Office re-emphasized that products containing ACE-inhibitors are contraindicated during pregnancy. Exposure to enalapril or captopril in utero has resulted in a state of potentially reversible anuria in newly born infants. (Reference: (BGHBL) Bundesgesundheitsblatt, 31/9, 369, 1988)
GBR	Dec 1989	The product information of ACE-inhibitors including captopril, enalapril, lisinopril and quinapril was amended to emphasize that these products are contraindicated in pregnancy, following their association with shortage of amniotic fluid in mothers and abnormal skull ossification, hypotension, renal failure and anuria in exposed infants. (Reference: (GBRCSM) Committee on Safety of Medicines, Current problems, 27, , Dec 1989)
ITA	Jul 1990	Use of products containing ACE-inhibitors was contraindicated during pregnancy, following their association with shortage of amniotic fluid in mothers and incomplete cranial ossification in neonates. (Reference: (BIFTI) Bolletino d'Informazione sui Farmaci, XIV(7):4, , 1990)
MYS	1992	Manufacturers and importers of products containing ACE-inhibitors were notified by the Drug Control Authority to include a warning that ACE-inhibitors have been shown to be fetotoxic in animal studies and their use in women in the later stages of pregnancy has been associated with an increased incidence of serious fetal/neonatal conditions. (Reference: (MYSDN) Berita Ubat-Ubat (Drug Newsletter), 6(2):2, , 1992)
NZL	1992	Having regard to reports of foetal damage, including kidney failure and face or skull deformities attributed to angiotensin-converting enzyme inhibitors, women in New Zealand who become pregnant while receiving such a product have been advised to consult their doctor in order that an alternative treatment may be prescribed. (Reference: (NZCSL) Clinical Services Letter, Department of Health, 266, , 28 Aug 1992)
PRT	1992	The Ministry of Health revised the product information for angiotensin-converting enzyme (ACE) inhibitorsto contraindicate their use during pregnancy. (Reference: (PRTIT) Informacao terapeutica, 1(1), , May 1992)
SWE	1992	The Medical Product Agency recommended that treatment with ACE-inhibitors be discontinued immediately should the patient become pregnant. (Reference: (SWEILS) Information från Läkemedelsverket, 2(3):89, , 1992)
USA	Mar 1992	Product containing ACE-inhibitors, including captopril, fosinopril, benazepril, ramipril, lisinopril, enalapril, enalaprilat and quinapril were required to carry a boxed warning regarding risks of exposure during the later stages of pregnancy, following reports of kidney failure, and abnormalities in the face and cranium of the foetus. (Reference: (HHSNS) HHS News: US Department of Health and Human Services, P92-8, , 13 Mar 1992)
ESP	21 Apr 1992	The Directorate General of Pharmacy and Health Products of the Ministry of Health and Consumer Affairs decided that ACE-inhibitors treatment during pregnancy should be contraindicated. (Reference: (ESPOR) Ministerio de Sanidad y Consumo, , , 02 July 1992)
THA	Feb 1994	The Ministry of Public Health has decided to add a warning to the labelling of products containing angiotensin-converting enzyme (ACE) inhibitors stating that the drug should not be used in pregnancy, that it may increase blood potassium level, provoke kidney failure, angioneurotic oedema and other adverse effects. (Reference: (THAFDA) Communication to WHO, , , 08 Feb 1994)

Legislative or regulation action

Product Name **ACE-Inhibitors**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
		WHO Comment : The tolerability profile of ACE-inhibitors (including captopril, enalapril, lisinopril, quinapril, ramipril etc.) is by now well established. Captopril is listed in the WHO Model List of Essential Drugs.

Product Name **Acetylsalicylic acid/antacid**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
USA	Apr 1994	The Food and Drug Administration proposed to revise the labelling of products containing acetylsalicylic acid (including buffered acetylsalicylic) alone or in combination with an antacid to include the following statement: ?IMPORTANT: See your doctor before taking this product for your heart or for other new uses of aspirin [acetylsalicylic acid], because serious side effects could occur with self-treatment? . (Reference: (FEREAC) Federal Register, 58(201) , p. 54224, 1993) WHO Comment : See under Acetylsalicylic acid.

Product Name **Acetylsalicylic acid/codeine**

Scientific and common names, and synonyms

CODEINE/ACETYLSALICYLIC ACID

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
SWE	1 Jan 1990	All fixed combination preparations containing acetylsalicylic acid 500 mg + codeine phosphate 10 mg have been withdrawn, on the grounds that the low dose of codeine in these preparations does not contribute to the analgesic effect, but may cause adverse effects and induce dependence. (Reference: (SSLMS) Information från Socialstyrelsens Läkemedelsavdelning, 15(2), 59, 1990)

Product Name **Acetylsalicylic acid/phenacetin/caffeine (APC)**

Scientific and common names, and synonyms

APC
CAFFEINE/PHENACETIN/ACETYLSALICYLIC ACID
PHENACETIN/ACETYLSALICYLIC ACID/CAFFEINE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
THA	1983	Banned for manufacture. Preparations must be reformulated to contain only acetylsalicylic acid.

Legislative or regulation action

Product Name **Allopurinol and benzbromarone**

C.A.S. number **2003-1-1001**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
FRA	Feb 2001	This anti-gout preparation has been withdrawn in France due to associations of adverse hepatic effects with benzbromarone and toxic skin and hypersensitivity reactions with allopurinol. (Reference: (FRACW) Communication to WHO, , , 05 Oct 2001)

Product Name **Amoxicillin/clavulanic acid**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
GRC	8 Jun 1995	The injectable form of the combination antibiotic was suspended after reports of cases of severe allergic reactions were received. (Reference: (GRANDO) Communication, , , 08 June 1995)
GBR	May 1997	The Committee on Safety of Medicines has restricted the indications for the combination antibiotic, amoxicillin/clavulanic acid, to bacterial infections likely or known to be caused by amoxicillin-resistant beta-lactamase producing strains. This action has been taken after reports were received of cholestatic jaundice occurring during or shortly after the use of this product. (Reference: (GBRCPP) Current Problems in Pharmacovigilance, Vol. 23, p.6, May 1997) WHO Comment : The amoxicillin/clavulanic acid combination should be reserved for infections likely or known to be caused by amoxicillin- resistant beta-lactamase producing strains. Amoxicillin/clavulanic acid is listed in the WHO Model List of Essential Drugs.

Product Name **Ampicillin/cloxacillin**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
MYS	Jun 1995	The Drug Control Authority has cancelled the registration of fixed-dose combination products containing ampicillin and cloxacillin because this combination does not meet the criteria set for combination products. (Reference: (MYSDI) Berita Ubat-Ubat (Drug Information), 9(2): 3, , June 1995) WHO Comment : Ampicillin and cloxacillin are listed separately in the WHO Model List of Essential Drugs.

Product Name **Analgesics in combination**

Scientific and common names, and synonyms

ANALGESICS/BENZODIAZEPINES

ANALGESICS/MEPROBAMATE

Legislative or regulative action

Legislative or regulation action

Product Name			Analgesics in combination
Country	Effective Date	Description of action taken Grounds for decision	
DEU	1991	The marketing authorization for products containing analgesics in combination with benzodiazepines or neprobamate was withdrawn, because sedative components in analgesic preparations create unnecessary risks of abuse, addiction and subsequently adverse effects due to chronic misuse of the analgesics. (Reference: (DEUPZ) Pharmazeutische Zeitung, 136/8, 402, 1991)	
JPN	28 Sep 1995	The Central Pharmaceutical Affairs Council issued an alert concerning analgesics and cold remedies containing antifever agents including acetylsalicylic acid, paracetamol and ibuprofen available for sale over-the-counter (OTC), after over 40 reports were received of severe adverse reactions necessitating hospitalization. In most cases, the patient had a history of hypersensitivity but ignored the warning in the package insert. (Reference: (JPNPAC) Central Pharmaceutical Affairs Council, , , 28 Sep 1995) WHO Comment : There is a growing awareness of serious health risks associated with indiscriminate use of these drugs. Acetylsalicylic acid, ibuprofen and paracetamol are listed as individual agents in the WHO Model List of Essential Drugs.	
Product Name			Anorectic drugs
Scientific and common names, and synonyms			
AMFETAMINE-LIKE COMPOUNDS			
DEXFENFLURAMINE			
FENFLURAMINE			
PHENTERMINE			
PHENDIMETRAZINE			
Legislative or regulative action			
Country	Effective Date	Description of action taken Grounds for decision	
BRA	18 Aug 1994	The Ministry of Health has issued an order prohibiting the manufacture, distribution and sale of anorectic substances promoted as "anti-obesity" drugs. The substances at issue are: fepramone, dexfenfluramine, fenfluramine, levofenfluramine, fenproporex and mazindol either as single ingredient drugs or in combination with other anorectic agents. (Reference: (BRASVS) Secretaria de Vigilancia Sanitaria, Portaria 87, , 18 Aug 1994)	
FRA	May 1995	Because of cases of pulmonary hypertension, the French Medicines Agency has made the following restrictions in the use of amphetamine-based anorectic agents: they are indicated only for the treatment of severe obesity in patients whose body mass index is over 30, which constitutes a severe cardiovascular risk factor; duration of treatment (cumulative) is limited to three months; they are contraindicated in combination with other drugs. (Reference: (FRAAMC) Communiqué de Presse, , , 12 May 1995)	
@EC	18 Jul 1996	The Committee on Proprietary Medicinal Products recommends the inclusion of a boxed warning in the Summary Product Characteristics that clearly sets out the risks of pulmonary hypertension that is associated with anorectic agents, including the serotonergic compounds dexfenfluramine and fenfluramine; and the ?amphetamine-like? compounds: amfepramone, clobenzorex, fenbutrazate, fenproporex, mazindol, mefenorex, cathine (norpseudoephedrine), phendimetrazine, phenmetrazine, phentermine and propylhexedrine. The Committee concluded that the risk-benefit balance is favourable provided that the products are used under strict supervision by specialist in carefully selected patients. (Reference: (CPMPAR) PMP Assessment Report for Anorectic Agents, , , 18 July 1996)	

Legislative or regulation action

Product Name **Anorectic drugs**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
PRT	Sep 1999	The Portuguese Medicines Evaluation Committee has recommended to the Board of INFARMED the suspension of marketing authorizations for all medicinal products containing clobenzorex and fenproporex. This recommendation follows the final opinions of the Committee on Proprietary Medicinal Products that recommends the withdrawal of the marketing authorizations for medicinal products containing amfepramone, phentermine, clobenzorex, fenproporex, mefenorex, norpseudoephedrine and phendimetrazine based on the lack of therapeutic efficacy of these products leading to an unfavourable benefit/risk balance and the withdrawal of the marketing authorizations for fenfluramine and dexfenfluramine containing medicinal products, based on an unacceptable safety profile under normal conditions of use and limited therapeutic efficacy, leading to an unfavourable benefit/risk balance. (Reference: (PRTIFM) Communication, , , 14 Sep 1999)
FRA	Oct 1999	The Agency Française de Sécurité Sanitaire des Produits de Santé (AFSSPS) has suspended the marketing authorizations for medicinal products containing the anorectic agents amfepramone, clobenzorex, dexfenfluramine, fenfluramine, fenproporex and mefenorex because of their implication in the occurrence of arterial pulmonary hypertension. (Reference: (FRARP) La Revue Prescrire, Vol. 19(199), , Oct 1999)
OMN	Apr 2000	The Directorate General of Pharmaceutical Affairs & Drug Control has banned the registration and import of the following anorectic agents: Clobenzorex, mefenorex, phedimetrazine, fenproporex, nor pseudoephedrine, febutazate and propylhexedrine. This action was taken because of lack of therapeutic efficacy leading to an unfavourable benefit/risk balance. . (Reference: (OMNCR) Circular, No. 26/2000, , 26 Apr 2000)

Product Name **Anorectic dugs in combinations**

Scientific and common names, and synonyms

AMFEPRAMONE,BENZFETAMINE,BENFLUOREX,FENFLURAMINE,PHENDIMETRAZINE,PHENTERMINE/TIRATRICOL/THYROID HORMONE/METFORMIN

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
ITA	26 May 1987	Extemporaneous preparation of products in which anorectic agents including amfepramone, benzfetamine, benfluorex, fenfluramine, phendimetrazine and phentermine are combined with tiratricol, thyroid hormone or metformin has been prohibited. Prohibition of manufacture of preparations containing anorectics in combination with other active principles. (Reference: (ITADMS) Decree of the Ministero della Sanita, , , 26 May 1987) WHO Comment : Anotectics have been introduced many years ago for use as adjuncts to dietary control in the short-term management of obesity. Their use in combination with other drugs such as thyroid hormone, tiratricol or metformin to increase weight loss is considered inappropriate and dangerous. Although they may lead to weight loss, thyroid hormone and tiratricol should only be used in obese patients with a proven thyroid deficiency and metformin should only be administered to overweight patients suffering from diabetes. Moreover, all three drugs are associated with serious adverse effects. Extemporaneous preparations of products containing anorectics in combination with other active ingredients has been prohibited in Italy. In some other countries, although discouraged, it still remains a common practice.

Legislative or regulation action

Product Name Anorectic dugs in combinations

Product Name Antidiarrhoeal combinations

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
OMN	1989	Import and marketing of antidiarrhoeal preparations containing antibiotics or antimicrobial agents were prohibited. (Reference: (OMNCR) Circular, 31/89, , 1989) (Reference: (OMNCR) Circular, 15/89, , 1989)
LBN	03 Aug 1991	Registered only as a wood preservative for a very specific use.
IDN	Oct 1991	Solid and liquid formulations of preparations containing streptomycin, kanamycin, neomycin, non-absorbable sulfonamides, hydroxyquinolines, antihistamines or vitamins intended for the treatment of diarrhoea in children were banned. (Reference: (IDMH) Ministry of Health, , , 19 Nov 1991)
BRA	14 Sep 1994	The Ministry of Health has issued an order withdrawing a number of paediatric formulations of antidiarrhoeal preparations on the grounds of low or unproven efficacy. For another group of substances the order requires that the product information include the phrase: "Not indicated in acute or persistent diarrhoea in children". (Reference: (BRASVS) Secretaria de Vigilancia Sanitaria, Portaria 106, , 14 Sep 1994)
IND	Apr 1995	The Drug Controller of India has banned the manufacture and sale of six antidiarrhoeal products on the grounds that they do not have any therapeutic justification and are likely to involve a risk for patients, especially in children for whom oral rehydration therapy is preferred. (Reference: (INDEPH) The Eastern Pharmacist, , , Apr 1995)
MYS	Jun 1995	The Drug Control Authority has withdrawn the registration for liquid oral forms of antidiarrhoeal preparations containing loperamide and diphenoxylate for use in young children. (Reference: (MYS DI) Berita Ubat-Ubat (Drug Information), 9(2): 7, , June 1995)
		WHO Comment : The list of agents concerned is very long. Refer to original references. The aminoglycoside antibiotics streptomycin, kanamycin and neomycin, non-absorbable sulfonamides (i.e. sulfaguanidine, succinyl-sulfathiazole, phthalylsulfathiazole) and halogenated hydroxyquinolines (e.g. clioquinol, broxyquinoline, chlorquinaldol) have been used as antidiarrhoeal agents. However, there is no satisfactory evidence that they are effective, they have occasionally been associated with severe adverse reactions and some promote the emergence of bacterial resistance. The World Health Organization recommends that they should not be used for the management of diarrhoea in children. (Reference: (WHTAC5) The rational use of drugs in the management of acute diarrhoea in children, , , 1990)

Product Name Antirheumatic combinations with glucocorticosteroids

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
AUT	Jan 1986	Enteral preparations have been withdrawn and parenteral preparations may only be used for very limited indications and under strict medical supervision.
DEU	1 Jan 1986	Fixed combinations have been withdrawn since concurrent administration of such drugs potentiates adverse effects without increasing benefit.

Legislative or regulation action

Product Name **Antirheumatic combinations with glucocorticosteroids**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
---------	----------------	---

Product Name **Atropine in combination**

C.A.S. number **51-55-8**

Scientific and common names, and synonyms

BENZENEACETIC ACID, ALPHA-(HYDROXYMETHYL)-8-METHYL-8-AZABICYLO[3.2.1]OCT-3-YL ESTER, ENDO(+/-)-1ALPHA H, 5ALPHA H-TROPAN-3ALPHA-OL (+/-)-TROPATE (ESTER)

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
---------	----------------	---

PHL **Sep 1976** Combinations of atropine sulfate with difenoxylate, furazolidone and dimethylpolysiloxane were withdrawn because of potential adverse reactions including dysuria (from atropine and furazolidone), tachycardia, palpitation and blurring of vision.

KOR **Dec 1991** Products containing atropine indicated for the treatment of acute diarrhoea were banned because there are many preparations which are safer and more effective.
(Reference: (KRMHSA) Ministry of Health and Social Affairs - Communication to WHO, , , 13 Dec 1991)

WHO Comment : Atropine, an alkaloid with anticholinergic activity extracted from *Atropa belladonna*, has been widely used in medicines for centuries for its antispasmodic and mydriatic properties. It is also used for premedication prior to anaesthesia. Preparations containing atropine remain available and the substance is included in the WHO Model List of Essential Drugs.

(Reference: (WHTAC4) The Use of Essential Drugs, 4th Report of the WHO Expert Committee, 796, , 1990)

Product Name **Azatadine maleate/pseudoephedrine sulfate**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
---------	----------------	---

NLD **May 1994** The marketing authorization of a combination tablet formulation containing azatadine maleate and pseudoephedrine sulfate indicated for treatment of congestion associated with the common cold was withdrawn because of doubtful efficacy and greater risk of adverse effects with products intended for systemic use rather than topical use.
(Reference: (NPHWB) Pharmaceutisch Weekblad, 28(5):126, , 1994)

Product Name **Barbiturates in asthma preparations**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
---------	----------------	---

ZAF **1998** The South African Medicines Control Council has withdrawn asthmatic preparations containing barbiturates because of the unacceptable risk-benefit profile which is not in the interest of public health.

Legislative or regulation action

Product Name **Barbiturates in asthma preparations**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
(Reference: (ZAFPS) Information from the Pharmaceutical Services, , ,)		

Product Name **Barbiturates in combination**

Scientific and common names, and synonyms

ATRIUM
 ANTI-ASTHMATICS/BARBITURATES
 ANTACIDS/BARBITURATES
 ANALGESICS/BARBITURATES
 BARBITURATES/ANTI-ASTHMATICS
 BARBITURATES/ANTACIDS
 BARBITURATES/ANALGESICS
 1-(3-BUTOXY-2-HYDROXYPROPYL)-5-ETHYL-5-PHENYLBARBITURIC ACID CARBAMATE ESTER/1,3-BIS-(3-BUTOXY-2-HYDROXYPROPYL)-5-ETHYL-5-PHENYLBARBITURIC ACID DICARBAMATE ESTER/ 5-ETHYL-5-PHENYLBARBITURIC ACID DICARBAMATE ESTER

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
TUR	1982	Combination products with barbiturates and analgesics have been withdrawn by the Ministry of Health due to the lack of substantial evidence of efficacy and the risk of dependence. Export of these products is prohibited.
DEU	1 Jun 1986	The Federal Health Office has withdrawn approval for the inclusion of barbiturates in analgesic and antirheumatic preparations since their inclusion in such products serves no purpose and creates unnecessary risks of abuse and sedation.
MYS	Nov 1986	All combination products containing barbiturates have been withdrawn. (Reference: (MYSDC) Malaysian Drug Control Authority, No.4, , Nov 1986)
DEU	Jun 1994	The Federal Institute for Drugs and Medical Devices has restricted the indications for barbiturates to focal (partial) epileptic fits or generalized epileptic fits, and anaesthesia or pre-anaesthesia. Marketing authorization for these medicinal products was revoked for all other indications. (Reference: (DEUCFI) Communication, , , 20 June 1994)
FRA	4 Apr 1997	The marketing authorization of the 100-mg formulation of Atrium®, a combination product containing febarbamate, difebarbamate and phenobarbital indicated for the treatment of minor anxiety, has been withdrawn following an evaluation which concluded that the benefit/risk ratio is unfavourable, and in view of the potential risk of liver damage occurrence. The indication for the 300-mg formulation of Atrium® is restricted to the treatment of alcoholic withdrawal syndrome with a maximum treatment duration of four weeks. (Reference: (FRAAMA) Pharmacovigilance Alert, , , 04 Apr 1997)
SAU	Jun 1999	The Ministry of Health has withdrawn from the market a fixed combination barbiturate product containing phenobarbital, febarbamate and difebarbamate because of reports of hepatotoxicity. (Reference: (SAUCW) Notification, , , 20 June 1999)
GBR		Barbiturates and antacids in combination have been withdrawn from the market by manufacturers, for general safety reasons in relation to barbiturates. Combination products with barbiturates and antiasthmatics have been withdrawn by manufacturers because barbiturates may depress respiration.

Legislative or regulation action

Product Name **Barbiturates in combination**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
		<p>WHO Comment : Barbiturates were introduced at the beginning of the 20th century and have been extensively used as sedative-hypnotic drugs. Their use in the treatment of sleep disorders and anxiety has been largely superseded by the benzodiazepines since the former have a greater liability for abuse and development of tolerance and withdrawal syndrome, a lower therapeutic index and a higher incidence of drug interactions and adverse effects possibly including carcinogenic, mutagenic and teratogenic effects. Although many preparations containing barbiturates remain available, some regulatory authorities have severely restricted their approved indications and withdrawn product licences for combination products containing these substances (see full list). The type of product, its dose and duration of use are in this context of great importance. Several barbiturates are controlled under the 1971 Convention on Psychotropic Substances. The long-acting barbiturates phenobarbital and methylphenobarbital are of value in the treatment of epilepsy and several short-acting barbiturates are still used in anaesthesia.</p> <p>(Reference: (UNCPS) United Nations Convention on Psychotropic Substances, , , 1971)</p>

Product Name **Benzbromarone and Benziodarone**

C.A.S. number **2004-1-1001**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
ESP	10 Feb 2004	<p>Following reports of hepatotoxicity, the Spanish Safety Committee has withdrawn the marketing authorizations for benziodarone and benzbromarone-allopurinol fixed dose combination products. Benzbromarone has been brought under restricted use, to be prescribed by specialists in hospitals, for treating hyperuricaemia in allopurinol-intolerant patients with gout polyarticular or gout tophaceous, renal failure and renal transplantation.</p> <p>(Reference: (ESPSMA) Communication to WHO, Ref: 2004/02, , 10 Feb 2004)</p>

Product Name **Boric acid and borates**

C.A.S. number **10043-35-3**

Scientific and common names, and synonyms
BORIC ACID (H3BO3)

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
BRA	Apr 2001	<p>Boric acid and borax have been eliminated from preparations for topical administration in infants.</p> <p>(Reference: (BRARES) Resolucao n., 552/ANVISA, , 30 Apr 2001)</p>

Product Name **Calcium bromidum and chloral hydrate**

C.A.S. number **2003-1-1002**

Legislative or regulative action

Legislative or regulation action

Product Name	Calcium bromidum and chloral hydrate	
C.A.S. number	2003-1-1002	
Country	Effective Date	Description of action taken Grounds for decision
FRA	Aug 2001	Withdrawn due to the mutagenic and carcinogenic potential of chloral hydrate. (Reference: (FRACW) Communication to WHO, , , 05 Oct 2001)

Product Name	Calcium channel blockers	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
NZL	Oct 1996	Monotherapy with short-acting calcium channel blockers (nifedipine) is no longer recommended for patients with angina or clinical evidence of coronary artery disease. (Reference: (NZLTN) Therapeutic Notes, No.22, , Oct 1996)
DEU	1 Jul 1997	The Federal Institute for Drugs and Medical Devices has amended the authorizations for medicinal products containing the calcium antagonists amlodipine, folidipine, isradipine, nicardipine, nifedipine, nilvadipine, nimodipine, nisoldipine and nitrendipine with effect from 1 July 1997. The indications for nifedipine have been restricted to vasospastic angina pectoris (variant angina), chronic stable angina pectoris, essential hypertension, hypertensive crisis, and Raynaud's syndrome. Contraindications have been extended to include unstable angina pectoris, and acute myocardial infarction. The adverse reactions section will include a warning that occasionally patients with existing angina pectoris may experience an increase in frequency, duration and severity of angina pectoris attacks, and that myocardial infarction has occasionally been observed. Because of dose related cardiovascular complications, therapy with immediate-release products containing nifedipine should be initiated only when other products are contraindicated. The maximum daily intake has been restricted to 60mg. (Reference: (DEUCFI) Communication, , , 07 Apr 1994) (Reference: (DAZ) Deutsche Apotheker Zeitung, 137(15):1172, , 1997) WHO Comment : Calcium channel blockers were introduced in the sixties. They are mainly used in coronary heart disease, as antiarrhythmic agents and also in the treatment of hypertension. The long-acting calcium channel blockers like verapamil and diltiazem, due to their longer half-life time, have a somewhat different therapeutic and safety profile from the short-acting agents discussed above. Nifedipine and verapamil are listed in the WHO Model List of Essential Drugs.

Product Name	Chloramphenicol in combination	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
BEL	1980	Preparations containing chloramphenicol in combination with tetracyclines are prohibited having regard to the cumulative toxicity of the two antibiotics. (Reference: (BELAR) Arrêté Royal, , , Oct 1980)
ESP	Mar 1985	Registration of combination products containing chloramphenicol was disallowed because of the propensity of this drug to cause aplastic anaemia.
IND	Nov 1988	Fixed dose oral and parenteral combination products containing chloramphenicol were banned. (Reference: (INDDHS) Directorate of Health Services, , , 11 Mar 1992)

Legislative or regulation action

Product Name **Chloramphenicol in combination**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
THA	Oct 1989	Products containing chloramphenicol in combination with nitrofurantoin, sulfisoxazole and methylene blue have been withdrawn for reasons of increased risk of toxicity, especially blood dyscrasias, and lack of therapeutic advantage over products containing chloramphenicol only. (Reference: (THAMH) Ministry of Public Health, , , 15 Apr 1991)

Product Name **Chlormadinone acetate/mestranol (in oral contraceptives)**

Scientific and common names, and synonyms

MESTRANOL/CHLORMADINONE ACETATE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
USA	1970	Oral contraceptives containing this combination were voluntarily withdrawn from the market because of the development of breast nodules in beagle dogs administered 10 to 25 times the human dosage of active components. The beagle is especially prone to breast nodules, regularly developing these in later life. The naturally occurring nodules are generally accepted to be benign mixed tumours. However, in these studies, the treated dogs developed more nodules at an earlier age than did the control dogs which were not given the drug. Species difference in the metabolism of the chemicals and the large doses used also prevent direct transposition of these data to human beings.
SAU		Oral contraceptives with these and other ingredients are available only on a prescription basis.
VEN		Not approved for use and/or sale as ingredients in oral contraceptives.

Product Name **Clopamide, reserpine and dihydroergocristine mesilate**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
LTH	May 2000	The State Medicines Control Agency has not renewed marketing authorization for combination products containing clopamide, reserpine and dihydroergocristine mesilate on the grounds that safer and more effective medicinal products are available. (Reference: (LTHMCA) Order of State Medicines Control Agency, No. 61, , 17 May 2000)

Product Name **Contrast media (ionic and non-ionic)**

Scientific and common names, and synonyms

IOXITALAMIC ACID

IOXAGLIC ACID

IOMEPROL

IOVERSOL

IOHEXOL

IOPAMIDOL

Legislative or regulation action

Product Name **Contrast media (ionic and non-ionic)**
Scientific and common names, and synonyms

IOTROLAN
 IOTALAMIC ACID
 IODIXANOL
 LYSINE AMIDOTRIZOATE

Legislative or regulatory action

Country	Effective Date	Description of action taken Grounds for decision
DEU	Nov 1995	Pending an evaluation by the Federal Institute for Drugs and Medical Devices and in view of an increased number of hypersensitivity reactions, sometimes delayed, that have been observed after the administration of iodixanol or iotrolan, the manufacturer has temporarily suspended marketing of iotrolan (Isovist®-280). (Reference: (DEURFI) Rapid Alert - Pharmacovigilance, , , 13 Oct 1995) (Reference: (DEUCFI) Communication, , , 28 Nov 1995)
JPN	Mar 1996	The Pharmaceutical Affairs Bureau issued a warning about adverse reactions to non-ionic contrast media which, although less frequent than those reported with ionic contrast media, may be serious and are often delayed in onset. The products involved are iopamidol, iohexol, ioversol, iomeprol and ioxaglic acid. The reactions concern delayed allergic reactions including shock and anaphylactoid symptoms. Emergency measures for the treatment of shock should be available when x-rays are performed using these preparations. (Reference: (JPNARD) Information on Adverse Reactions to Drugs, No. 136, , Mar 1996)
DEU	Sep 1997	The Federal Institute of Drugs and Medical Devices has withdrawn the marketing authorization for an ionic contrast medium containing lysine amidotriazoate (Peritrist®-180/36%), since new large-scale studies show that low osmolar non-ionic contrast media have a much lower risk potential than high osmolar ionic contrast media, including Peritrist®-180/36%, and therefore the use of these products can no longer be justified. (Reference: (DEUPZ) Pharmazeutische Zeitung, 142(37): 3096, , 1997)
DEU	Jul 1998	The Federal Institute of Drugs and Medical Devices has announced its intention to revoke the marketing authorizations for ionic contrast media containing lysine amidotriazoate, iotalamic acid or ioxitalamic acid, either alone or in combination, for intravascular administration, because their use has been associated with severe adverse reactions including hypotension, arrhythmias, pulmonary oedema and renal disorders. At the same time, products that are indicated for intra-arterial and intravenous use and for use in the body cavities may now only be used in the body cavities. (Reference: (DEUNFI) Notification, , , 06 July 1998)

Product Name **Cycloserine/isoniazid**
Scientific and common names, and synonyms

ISONIAZID/CYCLOSERINE

Legislative or regulatory action

Country	Effective Date	Description of action taken Grounds for decision
DOM		This combination has been prohibited for use and/or sale since the benefits of treatment have not been found to outweigh the risks.

Product Name **Desensitizing vaccines**
Legislative or regulation action

Product Name **Desensitizing vaccines**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
GBR	May 1994	The Committee on Safety of Medicines has reviewed the efficacy and safety of desensitizing vaccines and has concluded that these products should be used only for the following indications: seasonal allergic hay fever not responding to anti-allergy drugs and hypersensitivity to wasp and bee venoms. Desensitization should be carried out only where facilities for cardiopulmonary resuscitation are immediately available. (Reference: (GBRCP) Current Problems in Pharmacovigilance, Vol. 20, , May 1994)

Product Name **Dicycloverine(dicyclomine)/doxylamine/pyridoxine)**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
THA	8 Feb 1994	The Ministry of Public Health has decided to withdraw all combination pharmaceutical products indicated for the prevention of vomiting containing dicycloverine (dicyclomine), doxylamine and pyridoxine. This action is based on the perceived teratogenic potential of this combination preparation. (Reference: (THAFDA) Communication to WHO, , , 08 Feb 1994) WHO Comment : See also under dicycloverine alone in full edition. Its use was restricted in several countries for reasons other than suspicions of teratogenicity associated with the combination preparation.

Product Name **Dihydroergotamine/heparin**

C.A.S. number **511-12-6**

Scientific and common names, and synonyms

HEPARIN/DIHYDROERGOTAMINE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
SWE	9 Feb 1988	The approved indications of injectable preparations containing dihydroergotamine in combination with heparin have been amended to limit their use as follows: "post-operative prophylaxis against deep vein thromboses and lung embolism in pateints at high risk of thrombotic complications who have undergone elective non-traumatic surgery". This reflects the risk of vasospastic reations, some of which have necessitated limb amputation, in particular in treated patients who had undergone surgery for trauma. (In addition to the reference given, also see Farmaceutiska specialiteter i Sverige. L,kemedelsinformation AB, 23,635,1988). (Reference: (SWEFSL) Farmaceutiska specialiteter i Sverige. Läkemedelsinformation AB, 23, 635-636, 1988) (Reference: (SSLMS) Information från Socialstyrelsens Läkemedelsavdelning, 13(4), 115, 1988)

Product Name **Dihydrostreptomycin sulfate/streptomycin sulfate**

Scientific and common names, and synonyms

STREPTOMYCIN SULFATE/DIHYDROSTREPTOMYCIN SULFATE

Legislative or regulation action

Product Name **Dihydrostreptomycin sulfate/streptomycin sulfate**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
USA		Combination withdrawn from the market and prohibited for export by the Food and Drug Administration on the grounds of an unfavourable benefit/risk ratio.

Product Name **Dipotassium clorazepate/acepromazine/aceprometazine**

Scientific and common names, and synonyms

ACEPROMETAZINE/ACEPROMAZINE/DIPOTASSIUM CLORAZEPATE
ACEPROMAZINE/DIPOTASSIUM CLORAZEPATE/ACEPROMETAZINE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
PHL	Mar 1983	Disapproved for use due to effects of liver toxicity and Parkinsonism. There is a lack of evidence of greater efficacy in the combination than with the component drugs given individually. Acepromazine is approved for veterinary use only.

Product Name **Estrogen-progestogen preparations for secondary amenorrhea**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
DNK	Oct 1974	Use of high-dosage products has been cancelled.
DEU	1980	The Federal Health Office has withdrawn from the market relatively high-dosage combination products containing estrogens and progestogens indicated for the treatment of secondary amenorrhoea. An expert committee had emphasized the need to exclude pregnancy before such products are used, having regard to their propensity to induce abortion.
SAU		The Drug Committee has advised using these combination products only after pregnancy has been ruled out. Relatively high-dosage products are restricted for use.
VEN		Combinations for secondary amenorrhoea are not approved for use and/or sale.

Product Name **Estrogens**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
USA	Sep 1989	Products containing estrogens may no longer be indicated for suppression of lactation and prevention of breast engorgement in mothers who elect not to breastfeed. (Reference: (FDATP) Food and Drug Administration Talk Paper, T89-56, , 27 Sep 1989)
DEU	Jan 1992	The use of estrogens for substitution therapy was restricted to the treatment of post-menopausal women who have undergone hysterectomy. (Reference: (DEUPZ) Pharmazeutische Zeitung, 136(3), 85, 1992)
BEL	7 Jun 1993	The Ministry of Health has subjected preparations containing estrogens for vaginal use to

Legislative or regulation action

Product Name **Estrogens**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
		<p>prescription control. They will be required to be labelled with the skull and crossbones symbol and stored in a poisons cupboard. (Reference: (BELAP) Annales Pharmaceutiques belges, Dec. 8/9: 19, , 07 June 1993)</p> <p>WHO Comment : Estrogens have been used for the prevention of postpartum breast pain and engorgement. However, because of an increased risk of puerperal thromboembolism and a risk of rebound effect, and since only 10% of women benefit therapeutically from such intervention, the United States Food and Drug Administration has requested manufacturers to no longer indicate preparations containing estrogens for this purpose. The World Health Organization is not aware of similar action having been taken elsewhere.</p>

Product Name **Estrogens (in oral contraceptives)**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
USA	Apr 1988	<p>Oral contraceptives containing more than 50 mcg of estrogen have been voluntarily withdrawn by the manufacturers, because they are associated with a higher risk of venous thrombo-embolism than low dose preparations. (Reference: (HHSNS) HHS News: US Department of Health and Human Services, P88-7, , 14 Apr 1988)</p> <p>WHO Comment : Preparations containing both an estrogen and a progestogen in fixed combination were introduced for oral contraception in 1960. In late 1960's, use of products containing more than 50 mcg of estrogen was demonstrated to be associated with an increased risk of thrombo-embolic disease. Such formulations, which offer no advantage in terms of efficacy have subsequently been largely abandoned.</p>

Product Name **Estrogens/testosterone**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
BGD	1982	<p>Under the provisions of the Drugs (Control) Ordinance, combinations of ethinyl estradiol and methyltestosterone have been banned. It has been found to be a highly misused preparation with carcinogenic properties and side effects include menstrual irregularities, increased blood pressure, uterine bleeding and others. (Reference: (BGDCO) The Drugs (Control) Ordinance, , , 1982)</p>

Product Name **Etamivan in combination**

Scientific and common names, and synonyms

BENZAMIDE, N,N-DIETHYL-4-HYDROXY-3-METHOXY-
ETHAMIVAN
N,N-DIETHYLVANILLAMIDE

Legislative or regulation action

Product Name **Etamivan in combination**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
THA	Feb 1994	The Ministry of Public Health has decided to withdraw all combination pharmaceutical products containing etamivan, including etamivan/etofylline and etamivan/hexobendine dihydrochloride. Single component injectable and oral solution formulations will remain available but have been rescheduled as "specially controlled drugs" for use in hospitals only. (Reference: (THAFDA) Communication to WHO, , , 08 Feb 1994) WHO Comment : Etamivan is a central and respiratory stimulant.

Product Name **Ethinylestradiol/methyltestosterone**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
BGD	1982	Combinations of ethinyl estradiol and methyltestosterone were banned under the provisions of the Drugs (Control) Ordinance. They were subject to misuse and had been associated with carcinogenic properties, menstrual irregularities, increased blood pressure and uterine bleeding. (Reference: (BGDCO) The Drugs (Control) Ordinance, , , 1982)

Product Name **Etidocaine hydrochloride/epinephrine tartrate**

Scientific and common names, and synonyms

EPINEPHRINE TARTRATE/ETIDOCAINE HYDROCHLORIDE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
PHL	Mar 1977	This combination, for use as an anesthetic and analgesic, has been disapproved. Hypertensive crisis may result when used on individuals with high blood pressure.

Product Name **Fluphenazine and nortriptyline**

C.A.S. number **2003-1-1003**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
FRA	2000	This combination was suspended due to the unfavourable risk-benefit ratio; the combination of the neuroleptic agent and the antidepressant provided no special advantage while exposing the patients to unjustifiable risk. (Reference: (FRACW) Communication to WHO, , , 05 Oct 2001)

Product Name **Gangliosides**

Legislative or regulative action

Legislative or regulation action

Product Name **Gangliosides**

Country	Effective Date	Description of action taken Grounds for decision
BRA	Jun 2001	Registration has been cancelled due to association with cases of Guillain-Barre Syndrome. Some cases were fatal. (Reference: (BRARES) Resolucao n., 527/ANVISA, , 08 June 2001)

Product Name **Guaifenesin/camphor/ether**
Scientific and common names, and synonyms

CAMPHOR/GUAIFENESIN/ETHER

ETHER/CAMPHOR/GUIFENESIN

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
PHL	Nov 1983	Combinations of these ingredients mixed with an alcohol (e.g. phenol, cincol, eucalyptol, chlorobutanol) are being phased out of use since they are ineffective in cough relief and may cause lipodystrophy and lipoid pneumonia.

Product Name **Herbal dietary supplements**
C.A.S. number **2003-1-5001**
Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
CAN	Feb 2002	The manufacturer has issued a product recall for herbal medicines PC-SPES and SPES since these products were found to contain warfarin and alprazolam, respectively. Consumers have been advised to stop using these products and consult their physicians. (Reference: (CANWHC) Warnings/Advisories, , , 08 Feb 2002)
IRL	Feb 2002	The manufacturer has issued a product recall for herbal medicines PC-SPES and SPES since these products were found to contain warfarin and alprazolam, respectively. Consumers have been advised to stop using these products and consult their physicians. (Reference: (IRLCN) Current News & IMB Statements, , , 15 Feb 2002)
USA	Feb 2002	The manufacturer has issued a product recall for herbal medicines PC-SPES and SPES since these products were found to contain warfarin and alprazolam, respectively. Consumers have been advised to stop using these products and consult their physicians. (Reference: (USAOPA) Warning, , , Feb 2002)

Product Name **Hormonal pregnancy tests**
Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
NOR	1970	Withdrawn from the market.
USA	Feb 1975	The combination of norethindrone acetate and ethinyl estradiol has been withdrawn from the market by the Food and Drug Administration as a presumptive test for pregnancy due to a lack of proof of safety for that use in view of the potential danger in the presence of pregnancy and the availability of accurate alternatives. Prohibited for export.

Legislative or regulation action

Product Name **Hormonal pregnancy tests**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
GBR	1977	Owing to evidence of congenital abnormalities, these products were withdrawn by the manufacturer.
AUT	1978	Withdrawn in view of their apparent association with birth defects.
BEL	1978	Withdrawn from the market following consideration of the evidence associating their use with birth defects.
DEU	1978	Withdrawn from the market.
ITA	1978	Withdrawn from the market.
SGP	Apr 1978	Banned for importation.
ETH	1979	Estrogen/progestogen preparations should no longer be promoted for pregnancy testing. This use should be included among the contraindications listed in package inserts.
GRC	1980	All preparations containing estrogens and progestogens intended for pregnancy testing were withdrawn.
NZL		Voluntarily withdrawn from the market.
SAU		In view of their association with birth defects, all such estrogen/progestogen preparations are not recommended for use.
THA		Pregnancy tests with a combination of norethisterone and estradiol are prohibited.
VEN		Not approved for use and/or sale.
ZAF		Preparations for oral use are not indicated and may not be promoted for pregnancy testing, based on information received from the World Health Organization.

Product Name **Hydrochlorothiazide/potassium**
Scientific and common names, and synonyms

POTASSIUM/HYDROCHLOROTHIAZIDE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
DOM		Products with this combination of ingredients have been prohibited for use and/or sale since they have been shown to cause small bowel ulceration.

Bibliographical references

IARC MONOGRAPH, 50, 337, 1990

Product Name **Hydroxyquinolines in combination**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
IND	Feb 1996	The Drug Controller of India has banned the manufacture, sale and distribution of fixed-dose combinations of hydroxyquinolines with other drugs, except for preparations intended for external use. This action has been taken because the fixed-dose combination products are considered either as not having the therapeutic value claimed or they contain ingredients and in quantities for which there is no therapeutic justification.

Legislative or regulation action

Product Name	Kava products	
C.A.S. number	2003-1-5002	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
IRL	Jul 2002	The Irish Medicines Board has decided to maintain the on-going voluntary withdrawal of all kava containing products that was initiated in February 2002. This decision follows the German Regulatory Authority's conclusion that kava products have an unfavourable risk-benefit profile. (Reference: (IRLPSI) Kava Statement, , ,)
SGP	Jul 2002	The Singapore Health Sciences Authority (HAS) is proceeding to gazette kava-kava and its constituents under the Poisons Act to prohibit importation following German Regulatory measures for kava. (Reference: (SGPPR) Press Release, , , 25 July 2002)
AUS	Aug 2002	Australia's Therapeutic Goods Administration (TGA) has initiated a voluntary recall of all complementary medicines containing the herb kava. The action follows the death of a woman in Australia who used a medicine containing kava. The TGA will undertake further evaluation to determine additional regulatory measures. (Reference: (AUSMDR) Media Release, TW20/02, , 15 Aug 2002)
CAN	Aug 2002	Health Canada has ordered a stop-sale and recall of all kava-containing products from the Canadian market following Canadian and worldwide reports of liver failure. (Reference: (CANWHC) Warnings/Advisories, , , 21 Aug 2002)
GBR	Dec 2002	An order prohibiting the supply of medicinal products containing kava has been issued in the UK following the UK Medicines Control Agency's investigation into cases of liver toxicity from kava. (Reference: (GBRKPR) MCA Press Release, 2002/0528, , 20 Dec 2002)

Product Name	Lidocaine, salicylic acid and chloral hydrate	
C.A.S. number	2003-1-1004	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
FRA	Aug 2001	Withdrawn due to the mutagenic and carcinogenic potential of chloral hydrate which make its use unfavourable in the treatment of buccal infections or as an oral rinse in stomatologic procedures. (Reference: (FRACW) Communication to WHO, , , 05 Oct 2001)

Product Name	Loratadine and pseudoephedrine	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
PHL	2000	The Department of Health Bureau of Food and Drugs has banned and withdrawn the fixed-dose combination, loratadine + pseudoephedrine. (Reference: (PHADO) Administrative Order, (99) s. 2000, , 09 Aug 2000)

Product Name	Medroxyprogesterone acetate/ethinylestradiol	
Scientific and common names, and synonyms		

Legislative or regulation action

Product Name		Medroxyprogesterone acetate/ethinylestradiol
Scientific and common names, and synonyms		
ETHINYLESTRADIOL/MEDROXYPROGESTERONE ACETATE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
USA		Withdrawn from the market and prohibited for export by the Food and Drug Administration after studies in dogs showed an increased incidence of mammary tumors from the medroxyprogesterone acetate component.
Product Name		Meprobamate/diazepines
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GRC	1980	Withdrawn from the market since the combination is considered unacceptable having regard to the higher incidence of adverse reactions than reported with monocomponent preparations.
Product Name		Mepyramine maleate/pamabrom
Scientific and common names, and synonyms		
PYRILAMINE MALEATE/PAMABROM		
PAMABROM/PYRILAMINE MALEATE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
USA	1974	Combinations of pamabrom and mepyramine maleate (pyrilamine maleate) have been withdrawn from the market.
Product Name		Mercuric derivatives (topical)
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
JPN	Jul 1969	Aminomercuric chloride was banned by the Pharmaceutical Affairs Bureau due to skin disorders associated with long-term use.
BRA	15 Jul 1980	Products containing mercuric derivatives, with the exception of merbromin and thiomersal, are prohibited. (Reference: (BRAPT) Portaria do Servico Publico Federal, No.10, , July 1980)
PHL	Nov 1983	Mercury-based products for topical use are being phased out due to dubious efficacy and safety.
FRA	19 Dec 1986	The Ministry of Health has decided to withdraw dermatological preparations containing ammoniated mercury following a warning that such products may produce allergic reactions and mercury intoxication. (Reference: (FRAPC) Press Communiqué, , , Dec 1986)

Legislative or regulation action

Product Name		
Mercuric derivatives (topical)		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
NGA	1988	All soaps containing mercury compounds have been banned. (Reference: (NGAPN) Pharmanews, 10(11), 15, 1988)
GHA	1 Sep 1989	All mercury based soaps have been banned. (Reference: (GHAPDR) Pharmacy and Drugs (Banned Drugs) Regulations, Legislative Instruments, 1484, , 1989)
CAN	Apr 1997	Health Canada has warned consumers not to use DianaR Cream (Diana de Beauté), a product that is used for skin lightening, mainly by Afro and Caribbean communities. The product, which is manufactured in the Lebanon, has not been approved for sale in Canada and is being illegally imported. It contains ammoniated mercury, bismuth subnitrate and salicylic acid and the mercury content poses a high risk of mercury poisoning in adults and a serious health hazard to unborn and nursing infants of women who use the product. (Reference: (CANPR) Press Release, 1997-28, , 18 Apr 1997)
ITA		Withdrawn from the market owing to an unfavourable risk-benefit ratio and the lack of substantial evidence of efficacy. WHO Comment : Mercuric derivatives were formerly widely available in topical anti-infective preparations. The hazards associated with their use, including hypersensitivity and allergy, outweigh any therapeutic benefit and such preparations have been withdrawn in many countries. Systemic absorption has resulted in chronic mercury poisoning and acrodynia (pink disease) in children.

Product Name		
Metamizole sodium, fempiverinium bromide and pitofenone hcl		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
LTH	May 2000	The State Medicines Control Agency has not renewed marketing authorization for combination products of metamizole sodium, fempiverinium bromide and pitofenone hydrochloride for reasons of safety. (Reference: (LTHMCA) Order of State Medicines Control Agency, No. 8, , 22 Sep 2000)

Product Name		
Metoclopramide/polidocanol		
Scientific and common names, and synonyms		
POLIDOCANOL/METOCLOPRAMIDE		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
PHL	Mar 1983	Disapproved for use in gastrointestinal disturbances since marked liver toxicity limits its therapeutic use.

Product Name		
Neomycin sulfate/polymyxin bisulfate/nystatin/acetarsol		
Legislative or regulation action		

Product Name **Oral contraceptives (third generation)**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
		risks associated with these pills. Combined oral contraceptives containing gestodene or desogestrel should not be used by women with risk factors for venous thromboembolism (e.g. obesity) and should only be used by women who are intolerant of other combined contraceptives and who are prepared to accept an increased risk of thromboembolism. (Reference: (GBRCW) Communication, , , 18 Oct 1995)
NOR	Dec 1995	The Norwegian Medicines Control Authority has restricted the indications for oral contraceptives containing desogestrel or gestodene to oral contraception where other oral contraceptives are not considered suitable. (Reference: (NORMCA) Norwegian Medicines Control Authority, , , 20 Dec 1995)
CHE	14 Dec 1995	The Intercantonal Office for the Control of Medicines has revised the product information for combined oral contraceptives containing gestodene or desogestrel to include a statement concerning risk factors that should be taken into account when prescribing these products. Contraindications include a history of pulmonary embolism or venous thromboembolism or a high incidence in the family (cases of venous thromboembolism in close relatives in their youth). Caution must be exercised in women with pronounced obesity and in mature women with serious varicose veins. (Reference: (CHEOCM) Statement on venous thrombosis and "pills", , , 18 Apr 1996)
NZL	Jul 1996	It is recommended that, because of the higher risk of venous thrombo- embolism with the third generation oral contraceptives compared with earlier combined oral contraceptives, in women who have no contraindications to the use of a combined low dose oral contraceptive and have indicated that they wish to take a combined oral contraceptive, consideration should be given to prescribing a low dose combined oral contraceptive containing no more than 35 micrograms ethinylestradiol and a progestogen other than desogestrel or gestodene. (Reference: (NZLPU) Prescriber Update, No.12, , July 1996)
<p>WHO Comment : Data from three independently conducted epidemiological studies have raised the problem of thromboembolic risks associated with combination oral contraceptives containing desogestrel or gestodene (so-called third generation oral contraceptives) in comparison with the same type of risk associated with the levonorgestrel-containing oral contraceptives (so-called second generation contraceptives). There are differences between countries in the evaluation of risks associated with different combination oral contraceptives. There is no plausible biological explanation for the differences between the two groups of oral contraceptives; however, inherent biases cannot be excluded. Thus the matter remains open.</p>		

Product Name **Oral sodium phosphate bowel preparations**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
NZL	Apr 1998	Oral sodium phosphate bowel preparations have been reclassified to Prescription Medicine, because of the risk of potentially life-threatening dehydration and electrolyte imbalance with incorrect use. (Reference: (NZLPU) Prescriber Update, No.16, , Apr 1998)
USA	21 May 1998	Following reports of deaths associated with an overdosage of sodium phosphates oral solution when the product was packaged in a larger-size container and a larger than intended dose was ingested inadvertently, the Food and Drug Administration has limited the container size for sodium phosphates oral solution (dibasic sodium phosphate/

Legislative or regulation action

Product Name	Phenobarbital, difebarbamate and febarbamate (Tetrabamate)	
C.A.S. number	2003-1-1005	
FRA	Mar 2001	The combination of febarbamate, difebarbamate and phenobarbital has been withdrawn in France due to reports of serious hepatic effects and cutaneous reactions including Lyell syndrome. (Reference: (FRACW) Communication to WHO, , , 05 Oct 2001)
ESP	May 2002	The Spanish Committee on the Safety of Medicines has ordered the suspension of tetrabamate (a complex of phenobarbital, difebarbamate and febarbamate) due to reports of hepatotoxicity and the unfavourable risk-benefit ratio. (Reference: (ESPCDR) Communication on Drug Risks, No. 2002/04, , 03 May 2002)

Product Name	Phlebotonics	
C.A.S. number	2003-1-5003	

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
ESP	Sep 2002	The Spanish Medicines Agency has withdrawn the marketing authorization for several oral vascular disorder therapies (phlebotonics) including those containing diosmin, horse chestnut extract, naftazone and troxerutin because of unfavourable risk-benefit profile. Calcium dobesilate has been restricted to the treatment of diabetic retinopathy while all other oral vascular therapies remaining on the market are authorized only for the short-term relief (2-3 months) of oedema and other symptoms of chronic venous insufficiency. (Reference: (ESPMAD) Document, 2002/09, , 10 Sep 2002)

Product Name	Pipradol/hesperidin	
---------------------	----------------------------	--

Scientific and common names, and synonyms

HESPERIDIN/PIPRADOL

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
DOM		Products with this combination of ingredients have been prohibited for use and/or sale since they have been found to be harmful.

Product Name	Prednisolone/phenobarbital	
---------------------	-----------------------------------	--

Scientific and common names, and synonyms

PHENOBARBITAL/PREDNISOLONE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
THA		Not permitted in combination for the treatment of asthma.

Product Name	Promethazine in combination	
---------------------	------------------------------------	--

Legislative or regulative action

Legislative or regulation action

Product Name **Promethazine in combination**

Country	Effective Date	Description of action taken Grounds for decision
USA	Sep 1989	Combination preparations containing promethazine, indicated for the symptomatic relief of upper respiratory infections, were subjected to prescription control because their use in children of less than two years of age had been associated with sudden infant death syndrome. Concern was also raised about their potential to induce extrapyramidal disorders. In the light of these concerns, two combination preparations were voluntarily withdrawn by the manufacturer in 1991. (Reference: (FEREAC) Federal Register, 58(50), 10904, 1991) WHO Comment : See WHO comment for H1-antihistamines.

Product Name **Pseudoephedrine and phenylpropanolamine**
Scientific and common names, and synonyms

D-ISOEPHEDRINE.D-?-EPHEDRINE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
MAR	Aug 1999	The Commission for Pharmacovigilance in Morocco decided to restrict the use of all drug products containing pseudoephedrine or phenylpropanolamine to adults and has prohibited their use in children under 12 years. The products have also been subjected to prescription control. This decision was taken following reports of serious risks to health associated with the intake of these vasoconstrictors, including 83 neuropsychiatric effects, 4 cardiovascular problems and 2 deaths. Therefore the French Agency of Medicines has restricted the use of pseudoephedrine and phenylpropanolamine products for adults. (Reference: (MARDMP) Letter to WHO, , , 24 Aug 1999)
OMN	2000	The Directorate General of Pharmaceutical Affairs & Drug Control has restricted the prescribing of any preparation containing phenylproanalamine hydrochloride or pseudoephedrine hydrochloride to adults and children over 2 years of age. This action has been taken following the results of research performed by the French Commission for Pharmacovigilance which revealed serious risks to health associated with the intake of these vasoconstrictors in paediatric use. (Reference: (OMNCR) Circular, No. 3/2000, , 13 May 2000)

Product Name **Pyrazolones in combination (see also aminophenazone, metamizole sc**
Scientific and common names, and synonymsAMIDOPYRINE
ISOPYRINE
METAMIZOLE SODIUM
NIFENAZONE**Legislative or regulative action**

Country	Effective Date	Description of action taken Grounds for decision
JPN	Sep 1977	The Central Pharmaceutical Affairs Council recommended that, because of their propensity to cause skin eruptions and shock, pyrazolones should no longer be included in proprietary cold medicines or in antipyretic-analgesic preparations available without a doctor's prescription.

Legislative or regulation action

Product Name **Pyrazolones in combination (see also aminophenazone, metamizole sodium)**

Legislative or regulatory action

Country	Effective Date	Description of action taken Grounds for decision
PHL	May 1979	Several combination products containing pyrazolones have been disapproved for use.
GRC	Oct 1980	The Ministry of Health and Welfare has severely restricted the use and sale of these products for domestic use. (Reference: (GRAGA) Ministry of Health Decision, No.7116, , July 1983)
DEU	1982	Eighty analgesic preparations containing a pyrazolone in combination with another active compound were withdrawn from sale either: 1) because their indications were not consonant with those approved by the Federal Health Office, or 2) on suspicion that the other active constituent might potentiate the accepted known risk of the pyrazolone component. These actions were largely directed against drugs containing metamizole sodium, but products containing isopyrine and nifenazone were also implicated. The situation is complex, however, since preparations containing one or more active ingredient remain on the market.
DEU	1983	Labelling for certain pyrazolone-containing drugs was recently revised to limit indications for use. Substances affected include: metamizole, isopropylaminophenazone, nifenazone, propyphenazone, phenazone and morazone. Indications were limited to the treatment of acute severe pain, such as post-traumatic and post-operative pain and colic, and high fever unresponsive to other therapy. Specific contraindications include use in inflammatory arthroses, conditions predisposing to shock or bone marrow depression, known allergy to pyrazolones and phenylbutazone, and certain metabolic deficiencies such as hepatic porphyria. The importance of weighing the need for treatment against the slight but life-threatening risks of anaphylactic shock and agranulocytosis is stressed.
ISR	1983	The Pharmaceutical Administration of the Ministry of Health has suspended all combination products containing noramidopyrine methanesulfonate sodium (metamizole sodium).
ITA	1989	Having regard to the adverse effects associated with their long-term use, products containing pyrazolones may now be indicated only for the short-term treatment of severe acute pain or pyrexia. (Reference: (BIFTI) Bolletino d'Informazione sui Farmaci, 13(2), 5, 1989)
MEX		Combinations of pyrazolones with antihistamines, vasoconstrictors, decongestants, muscle relaxants, antibiotics or vitamins are prohibited due to the toxic properties of pyrazolones.
SAU		All pyrazolones are used only under prescription.

WHO Comment : Pyrazolone derivatives, which include aminophenazone, metamizole sodium, phenylbutazone and propyphenazone have been associated with serious adverse effects. Since safer alternatives are widely available some regulatory authorities have withdrawn or severely restricted all pharmaceutical preparations containing pyrazolone derivatives. See also WHO comments for aminophenazone, metamizole sodium, phenylbutazone and propyphenazone.

Product Name **Pyrethroids**

Scientific and common names, and synonyms

BIOALLETHRIN
CARBARIL
PHENOTHRIN
PERMETHRIN
TETRAMETHRIN

Legislative or regulation action

Product Name **Pyrethroids**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
OMN	1997	The Directorate General of Pharmaceutical Affairs & Drug Control has prohibited the registration, import and sale of pyrethroids such as bioallethrin, permethrin, phenothrin, tetramethrin and carbaril in all parasitocidal preparations because of a potential risk of carcinogenicity. (Reference: (OMNPN) Pharmaceutical Newsletter, 5(4): 8, , 1997)
OMN	Dec 1997	The Directorate General of Pharmaceutical Affairs & Drug Control has prohibited the registration, import and sale of pyrethroids such as bioallethrin, permethrin, phenothrin, tetramethrin and carbaril in all parasitocidal preparations because of a potential risk of carcinogenicity. (Reference: (OMNPN) Pharmaceutical Newsletter, 5(4): 8, , 1997)

Product Name **Quinidine/verapamil**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
DEU	1996	In order to minimize the risks associated with fixed combination products containing the antiarrhythmics quinidine and verapamil, the Federal Institute for Drugs and Medical Devices has restricted the indications to: cardioversion in vestibular flutter and fibrillation when electrocardioversion cannot be carried out, and recurrent chronic vestibular flutter after successful conversion with this drug in patients in whom restoration of the sinus rhythm has led to an improvement of severe symptoms. (Reference: (DAZ) Deutsche Apotheker Zeitung, 136(29):2438, , 1996) WHO Comment : Quinidine and verapamil are listed separately in theWHO Model List of Essential Drugs.

Product Name **Quinolone antimicrobial agents**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
NOR	Jun 1993	The Medicines Control Authority has decided to restrict the indications for parenteral formulations of the quinolone antibiotics, ciprofloxacin (Ciproxin: Bayer) and ofloxacin (Tarivid: Hoechst) as follow: (1) Parenteral ciprofloxacin: severe salmonella infections, complicated urinary tract infections and osteomyelitis due to sensitive gram-negative staphylococci when oral treatment is not possible. (2) Parenteral ofloxacin: complicated urinary tract infections due to sensitive gram-negative staphylococci when oral treatment is not possible. Because of the risk of development of resistance, ciprofloxacin is not approved for treatment of sepsis. The Medicines Control Authority emphasizes that parenteral treatment with quinolone antibiotics should only be carried out in a hospital. (Reference: (NNSLM) Nytt fra Statens Legemiddelkontroll, No.2, p.3, 1993)
JPN	Oct 1994	The Pharmaceutical Affairs Bureau has amended the product information for enoxacin, fleroxacin, norfloxacin, sparfloxacin and tosufloxacin tosylate to state that rhabdomyolysis may occur. (Reference: (JPNARD) Information on Adverse Reactions to Drugs, No.128, , Oct 1994)
LKA	Nov 1996	The Drug Evaluation Sub-Committee has decided that the product information of fluoroquinolone antibiotics should include a warning stating: "The onset of tendon pain

Legislative or regulation action

Product Name **Quinolone antimicrobial agents**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
		calls for immediate withdrawal of fluoroquinolone antibiotics." (Reference: (LKADES) Drug Evaluation Sub-Committee, 27th Meeting, , 26 Nov 1996) WHO Comment : Since their introduction on the market in 1988 sporadic cases of tendinitis and rhabdomyolysis have been reported with quinolone antibacterial agents which are used in a large variety of infections.

Product Name **Repaglinide and gemfibrozil**

C.A.S. number **2004-1-1002**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
EME	21 May 2003	The use of repaglinide is contraindicated with gemfibrozil. (Reference: (EMEAPS) Public statement, EMEA/11700/03, , 21 May 2003)

Product Name **Sulfathiazole sodium with sodium lactate or sodium bicarbonate**

Scientific and common names, and synonyms

SODIUM LACTATE/SULFATHIAZOLE SODIUM
SODIUM BICARBONATE/SULFATHIAZOLE SODIUM

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
DOM		Combinations of sulfathiazole sodium with sodium lactate or sodium bicarbonate or other sulfonamides have been prohibited for use and/or sale since they have been associated with serious side effects and recent studies have shown them to be of questionable efficacy. The risks of these combinations have not been found to outweigh the benefits and other sulfonamides are available that present much lower risk with use.

Product Name **Superheporin**

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
IDN	1980	Superheporin capsules, a traditional herbal mixture of angelica radix, ligustica rhizoma, salviae radix, pteropii excrementum and carthamic flos, has been withdrawn from sale following reports of congenital malformations in babies whose mothers had taken this compound in early pregnancy.
VEN		Not approved for use and/or sale.

Product Name **Tetracycline in combination**

Scientific and common names, and synonyms

Legislative or regulation action

Product Name **Tetracycline in combination**
Scientific and common names, and synonyms

CHLORAMPHENICOL/TETRACYCLINE

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
SWE	1971	This combination, for oral and parenteral use, was withdrawn from the market.
DOM		Tetracycline in combination with oleandomycin or with novobiocin is prohibited for use and/or sale since studies have shown that this combination can be hazardous to health.
VEN		Banned for use and/or sale.

Product Name **Theophylline/meprobamate/barbiturates**
Scientific and common names, and synonyms

BARBITURATES/MEPROBAMATE/THEOPHYLLINE

MEPROBAMATE/THEOPHYLLINE/BARBITURATES

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
GRC	1986	Withdrawn from the market having regard to its low benefit-to-risk ratio (respiratory depression).

Product Name **Thiazides/potassium chloride**
Scientific and common names, and synonyms

POTASSIUM CHLORIDE/THIAZIDES

Legislative or regulative action

Country	Effective Date	Description of action taken Grounds for decision
USA	Oct 1971	The combination of these two compounds, alone or with reserpine or rauwolfia serpentina, has been withdrawn from the market and prohibited for export by the Food and Drug Administration on the grounds that no adequate data demonstrating safety and efficacy exist. These combinations were used as diuretics to treat certain edemas due to cardiac, renal and hepatic failure, and to treat specific cases of hypertension. In its decision, the FDA cited cases of small-bowel lesions that had developed with the administration of these drugs, for which a causal relationship had not been excluded by appropriate tests.
SAU		Following reports of small bowel lesions resulting in ulcers, obstruction, haemorrhage and perforation, this combination was withdrawn.

Product Name **Tilbroquinol/tiliquinol**
Scientific and common names, and synonyms

7-BROMO-5-METHYL-8-QUINOLINOL / 5-METHYL-8-QUINOLINOL

Legislative or regulative action

Legislative or regulation action

Product Name		Tilbroquinol/tiliquinol
Country	Effective Date	Description of action taken Grounds for decision
FRA	Jul 1997	The Agence du Médicament has decided that the therapeutic indications of tilbroquinol/tiliquinol (Intetrix®) will be restricted to the treatment of intestinal amoebiasis as an adjuvant to a tissular amoebicide, or as monotherapy in health carriers contaminated with interluminal amoebae. This decision was reached in the absence of efficacy data for the treatment of infectious diarrhoeas and because of the risk of liver toxicity. (Reference: (FRAAMI) Infofax - Pharmacovigilance, , , 04 July 1997)

Product Name		Tiratricol/cyclovalone/retinol
Scientific and common names, and synonyms		
CYCLOVALONE/TIRATRICOL/RETINOL RETINOL/CYCLOVALONE/TIRATRICOL		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
FRA	30 Oct 1988	A preparation containing an association of tiratricol, cyclovalone and retinol has been withdrawn from the market. (Reference: (FRARP) La Revue Prescrire, 9(81), 18, 1989) WHO Comment : This combination product, indicated for the treatment of obesity, has not been demonstrated to possess anytherapeutic effect and has been associated with cases of cellular hepatitis, of which at least one was fatal. It is not yet known which of the constituents is the causative agent.

Product Name		Trancylopramine and trifluoperazine
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
GBR	1999	The licence for the antidepressant, trancylopramine and trifluoperazine has not been renewed by the Committee on Safety of Medicines because of concerns over drug interactions and the risk of severe hypertensive crises. As a result the company have withdrawn the product from the market. (Reference: (GBRCPP) Current Problems in Pharmacovigilance, Vol. 25, , June 1999)

Product Name		Trimethoprim/sulfamethoxazole
C.A.S. number		8064-90-2
Scientific and common names, and synonyms		
CO-TRIMOXAZOLE SULFAMETHOXAZOLE/TRIMETHOPRIM		
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
SWE	1987	The approved indications for products containing trimethoprim and sulfamethoxazole were restricted to exclude the treatment of urinary tract infections, having regard to the

Legislative or regulation action

Product Name	Trimethoprim/sulfamethoxazole	
C.A.S. number	8064-90-2	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
		association of these combination products with severe and even fatal adverse effects, including sensitivity reactions, mucocutaneous syndrome, blood dyscrasias and hepatic disorders. A similar restriction applies to products containing trimethoprim and sulfadiazine. (Reference: (SSLMS) Information från Socialstyrelsens Läkemedelsavdelning, 3(12), 48, 1987)
IRL	Jun 1987	Products containing trimethoprim and sulfamethoxazole may now be indicated only for respiratory and urinary tract infections, on the grounds that they are associated with a greater risk of adverse effects, in particular in the elderly, including potentially fatal cases of blood dyscrasias and erythema multiforme, than other commonly used anti-infectives. (Reference: (IRDAB) National Drugs Advisory Board Annual Report, , 26, 1987)
GBR	Jul 1995	In view of reports of serious adverse reactions, blood dyscrasias and generalized skin disorders, the Committee on Safety of Medicines recommends that the use of trimethoprim/sulfamethoxazole (co-trimoxazole) should be limited to : Pneumocystis carinii pneumonia; toxoplasmosis and nocardiasis; acute exacerbations of chronic bronchitis and infections of the urinary tract when there is bacteriological evidence of sensitivity to trimethoprim/sulfamethoxazole and good reason to prefer this to single antibiotics. (Reference: (GBRCP) Current Problems in Pharmacovigilance, Vol.21, , July 1995) WHO Comment : The combination of sulfamethoxazole and trimethoprim (5:1) was introduced in 1971 for the treatment of a wide variety of bacterial infections. Its use has been associated with severe sensitivity reactions, many of which have been attributed to the sulphonamide component. Elderly people seem to be more vulnerable. The World Health Organization has no information further to the above concerning restrictive action taken on this combination. Trimethoprim/sulfamethoxazole is listed in the WHO Model List of Essential Drugs.

Product Name	Tyrothricin/fomocaine/diphenhydramine	
Legislative or regulative action		
Country	Effective Date	Description of action taken Grounds for decision
CYP	23 Oct 1992	The Drugs Council decided to withdraw the marketing approval for a gel preparation containing tyrothricin 0.1%, fomocaine hydrochloride 2.5% and diphenhydramine 1% used for the treatment of wounds and burns. The decision also applies to the powder formulation. (Reference: (CYPPS) Pharmaceutical Services, Ministry of Health, , , 23 Oct 1992) WHO Comment : Tyrothricin, fomocaine and diphenhydramine is a combination of antimicrobial, local anaesthetic and H1 receptor antagonist respectively. Tyrothricin, which is a mixture containing gramacidin and tyrocidine, is too toxic to be administered systematically because of liver and kidney toxicity. The product has been removed on the grounds that absorption of tyrothricin through broken skin may result in renal myelotoxicity.

Product Name	Xibornol and lidocaine	
C.A.S. number	2003-1-1006	
Legislative or regulative action		

Legislative or regulation action

Product Name	Xibornol and lidocaine	
C.A.S. number	2003-1-1006	
Country	Effective Date	Description of action taken Grounds for decision
FRA	Apr 2001	Suspended due to grave allergic reactions including oedema of Quincke, anaphylaxis and bullous eruptions associated with xibornol. (Reference: (FRACW) Communication to WHO, , , 05 Oct 2001)

Legislative or regulation action

Product Name Acetanilide

C.A.S. number 103-84-4

Trade and brand names

Acetanil	Capsula dr. knapf	Diqiseb
Phenalqin		

For regulatory information, see page 31

Product Name Acetarsol

C.A.S. number 97-44-9

Trade and brand names

190 f	Acetarsolum	Acetarstone
Acetphenarsine	Acetylarsan	Amarson
Amoebal	Arsabott	Arsaphen
Arsonine	Auryphan	Chrlich 594
Collarsin	Devegan	Disparicida
Dynarsan	Edoiacolo	Ehrlich 594
F 190	Fluryl	Fourneau 190
Ginarsol	Goyl	Gynoplax
Kharophen	Kharophene	Kubarsol
Limarsol	Monarqan	Neo-vaqex
Nilacid	Oralcid	Orarsan
Osarsal	Osarsol	Osarsole
Osvarsan	Pallacid	Paroxyl
Rvc	Spirozid	Stovarsol
Stovarsolan	Svc	Trichovan
Vaqipurin	Vaqiseb	Vaqival
Vaqoflor		

For regulatory information, see page 31

Product Name Acetylfuratriline

C.A.S. number 1789-26-0

Trade and brand names

Panfuran	Panfuran-troche
----------	-----------------

For regulatory information, see page 32

Product Name Acetylsalicylic acid (paediatric)

C.A.S. number 50-78-2

Trade and brand names

Aspirin	Compralgyl	Melabon
Rumicine	Salipran	Spalt
Tapal	Zorprin	

For regulatory information, see page 32

Product Name Acitretin

C.A.S. number 55079-83-9

Trade and brand names

Etretin	Neotigason	Neotigason (r) 10
Neotigason roche 10 mg	Neotigason sauter kapsein 25 mg	Soriatane

For regulatory information, see page 35

Product Name Acridine derivatives
C.A.S. number 260-94-6

Trade and brand names

Euflovin Proflavin

For regulatory information, see page 36

Product Name Alclofenac
C.A.S. number 22131-79-9

Trade and brand names

Allopydin	Allopydinac	Alopidin
Alopydin	Arqan	Arqun
Darkeyfenac	Desinflam	Epinal
Medifenac	Mervan	Mevan
Mirvan	Mirvan a	My 101
Neosten	Neoston	Prinalgin
Reufenac	Vanadian	W7320
W-7320	Zubirol	Zumaril

For regulatory information, see page 38

Product Name Allergen extracts
C.A.S. number UN-87-0001

Trade and brand names

A.d.l.	Alavac	Alavac-p
Alavac-s	Albay pure venom	Allpyral specific
Allpyral-d	Allpyral-q	Allpyral-mite fortified house dust
Aurafair	Auralqicin	Bencard skin testin solutions
Bencard-a	Coniuvac two grass	Glycerinated skin testing solutions
Merck skin testin solutions	Miqen	Norisen
Norisen grass	Otipyrin	Pharmalgen
Pollinex	Rapifen	S.d.l.
Sdv specific desentistising caccine	Spectralqen	Spectralqen pollens
Suspal	Tyrivac	

For regulatory information, see page 39

Product Name Aloxiprin
C.A.S. number 9014-67-9

Trade and brand names

Aloxiprine tablets	Lyman tabs	Palaprin forte
Paloxin	Palprin	Rumatral
Shin-rheufen	Superpyrin	Tiatral

For regulatory information, see page 40

Product Name Alprostadil
C.A.S. number 745-65-3

Trade and brand names

Coverject	Liple	Minprog
Minprog pad	Postivas	Prostadin
Prostalgin	Prostandin	Prostavasin
Prostin vr pediatric	Prostin-vr	Prostivas

For regulatory information, see page 40

Product Name Alprostadil
C.A.S. number 745-65-3

Trade and brand names

Product Name Amfepramone
C.A.S. number 90-84-6

Trade and brand names

Adiposan	Adiposon	Adipyn
Alipid	Amfepromone	Anfamom
Anorex	Apisate	Bonumin
Brenalalit	Brendalit	Cegramine
Controlgras	D.i.p.	D.i.p.n
Danylen	Delqamer	Deramix
Derfon	Dietec	Dietil retard
Dietil-retard	Dobesin	Frekentine
Lineal-plus	Lineal-rivo	Lineal-valeas
Linea-valeas	Lipomin	Liposlim
Maqrene	Menutil	Moderatan
Moderatan diffucap	Neobes	Nobensin-75
Nobensine	Nobesine	Nobesine-25
Nulobes	Obesitex	Perfamone
Prefamone	Propion	Redicres
Regenon	Regenon retard	Reqibon
Sinapet	Slim-plus	Super emeqrin
T-712	Tenuate	Tenuate dospan
Tenucap	Tepanil	Tylinal

For regulatory information, see page 42

Product Name Amfetamine
C.A.S. number 300-62-9

Trade and brand names

Actedron	Adipan	Allodene
Amfetamin	Amfetasul	Amphamed
Amphedrine	Anorexine	Benzebar
Benzedrine	Benzolone	Bifentamin
Centramina	Dexamin	Dexatrine
Durophet	Elastonon	Finam
Isoamyn	Isomyn	Mecodrin
Neoton	Norphedrane	Novydrine
Novydrinene	Obesin	Obesine
Obesitab	Obetrol	Oktadrin
Ortedrine	Percomon	Perduretas anfetamina
Phenedrine	Phenopromin	Profamina
Propisamine	Raphetamine	Rhinalator
Simpamina	Simpatedrin	Simpatina
Sympamine	Sympatedrin	Sympatina
Synatan	Wekamine	Zedrine

For regulatory information, see page 42

Product Name Aminoglutethimide
C.A.S. number 125-84-8

Trade and brand names

16038	Ba-16038	C-16038-ba
Crytraden	Cytadren	Doredin
Elipten	Mamomit	Orimeten
Ormeten		

For regulatory information, see page 44

Product Name Aminophenazone
C.A.S. number 58-15-1

Trade and brand names

Adexoqan	Aqevis	Alqimicin anttitermico
Amidazopen	Amidazophen	Amidazophene
Amidozen	Aminophenazonum	Anafebrin
Anafebrina	Aneuxol	Anoixal
Antiqripina	Areumal	Axiston
Balbion	Barsedan	Baukal
Baukal suppositories	Bayer 1387 p	Bronchisan
Brufaneuseol	Brufaneuxol	Butapyrine
Capsyka dr knapf	Capysal	Chinopyrin
Cibalqin	Ciclazon	Clinit
Coffan	Compral	Cusayth
Demolpas	Dentigoa	Depiral c
Dereuma	Dexa escopyrin	Dha 51
Dialpyrin	Diqisab	Dimametten
Dimapyrin	Dimopyrin	Dipirin
Diprin	Dipyrin	Dipyrine
Dolo-attirin	Dolo-optineural	Dolorphen
Dolovosano	Donobin	Duerin
Dysmensan	Escopyrinus	Espasnatex
Eufibran	Eunalqit	Euproqan
Febren	Febrinina	Febron
Febrosolvin	Fenodon	Fenodone
Fever	Flivalqin	Flumil
Fortalidon	Framidone	Ftalazon
Funapon	Galenopyrin	Glucopirina
Glucopitina	Helvaqit-f	Hemicraneal
Hisense-p	Hyparon	Influnal depot
Inst	Irgapyrine	Isoftal
Itamidone	Kalmine	Katareuma
Laqaflex	Latepyrine	Lauroanginol
Mamallet-a	Manslu	Medispanmin
Melaforte	Meloka	Metapirazone
Netsusarin	Neuro-demoplast	Nifedon
Nikartrone	Nostress	Novamidon
Optalidon	Optineural(analgesic)	Optipax
Osadrine	Osmotipax	P.s.b.p.
Paralgin	Piracodid	Piradenil
Piradol	Piramidon	Piramidone
Pirasco	Piraseptolo	Piridol

Product Name Aminophenazone
C.A.S. number 58-15-1

Trade and brand names

Piro rectal	Piromidina	Piroleumal
Pneumol	Polinalin	Premineat
Prontylin	Pyradon	Pyraelmedal
Pyramidon	Pyramidone	Pyrodin
Reqitol	Remlomed	Reu-bon
Reumanova	Reumasedina	Reumo termina
Reumoftal	Reumotranc	Revulex
Rini c	Rinoplex	Sanqlin
Sapotera	Sedafen	Selbon-a
Somnopyrin	Spasmo-barbanub	Spasmo-deterex
Spasmo-dimonil	Spasmo-tropax	Spasmovalin
Spasmoverlqin	Spasmus	Supnnon
Tonosan	Troqal	Tropax
Tsefokon	Tympaesic	Viadol
Waudobuzon		

For regulatory information, see page 44

Product Name Aminophylline
C.A.S. number 317-34-0

Trade and brand names

Afonilum	Aminocardol	Aminodrox
Aminodur	Aminomal	Aminophylline
Aminophylline injection	Aminophylline mudrane	Aminophylline oral
Amino-slow	Amnivent	Asmafilin
Cardophyllin	Cardophylline	Carena
Carine	Colonofilin	Corfilamine
Corophyllin	Corophylline	Corphyllamin
Diaphylline	Duraphyllin	Escophylline
Ethophylline	Eudiamine	Eufilina
Euphyllin	Euphyllin 0.48	Euphyllin retard
Euphyllin cr	Euphyllina	Fadfilina
Godafilin	Inophylline	Jaa aminophylline
Mini-lix	Mudrane	Mudrane qq
Mundiphyllin	Myocardon	Palaran
Palaron	Pecram	Pecran
Peterphylin	Phyllocontin	Phyllotemp
Planphylline	Somophyllin	Somophyllin-12
Syntophyllin	Tefamin	Teophyllamin
Thodrox	Truphylline	Variaphylline

For regulatory information, see page 47

Product Name Aminorex
C.A.S. number 2207-50-3

Trade and brand names

Aminoxafen	Aminoxaphen	Apiquel
Mcn 742	Menocil	

For regulatory information, see page 47

Product Name **Amitriptyline**
C.A.S. number **50-48-6**

Trade and brand names

Adepril	Amavil	Ami-anelun
Amilent	Amilit-ifi	Amineurin
Aminiurin	Amitimid	Amitril
Amitrip	Amitriptol	Amitrol
Amyline	Amyzol	Annolytin
Apo-amitriptylline	Apo-pram	Deprelie
Deprestal	Diapatal	Domical
Elatrol	Elatrolet	Elavil
Elavil plus	Emitrip	Endep
Enovil	Entrafon-210	Entrafon-2-10
Entrafon-2-25	Entrafon-a	Entrafon-forte
Etarfon	Etrafon-a	Etrafon-forte
Euplit	Laroxal	Laroxyl
Larozyl	Lentizol	Levat
Levate	Limbatrail	Limbatral
Limbitryl	Limitrol	Longopax
Loxaryl	Mareline	Meravil
Muaban d	Mutaban a/d/f	Mutabase
Nobrital	Normaln	Novotriptyn
Novotryptin	Novo-tryptin	Pantrop
Parks-plus	Pms levazine	Prouvil
Redomex	Saratem	Saroten
Sarotena	Sarotex	Sedans
Sk-amitriptyline	Sylvemid	Tensorelax
Teperin	Trepiline	Trepulin
Triavil	Triptizol	Triptonal
Triptpane	Trivial	Trivial-4-10
Trivial-4-50		

For regulatory information, see page 48

Product Name **Amobarbital**
C.A.S. number **57-43-2**

Trade and brand names

Altinal	Alupent-sed	Amal
Amasust	Ambese-la	Amital
Amobell	Amsal	Amsebarb
Amybal	Amycal	Amydorm
Amylbarb	Amylobeta	Amytal
Amytal sodium	Analqilasa	Appenil
Asthmin	Barbamyl	Beatol
Binoctal	Bludex	Calavon
Cuaot	Dexaspan	Dexital
Dorlotyn	Dorminal	Dormytal
Ergo-lonarid	Estimal	Etamyl
Eunoctal	Ifenin	Isoamitil sedante
Isobec	Isomyl	Isomytal
Isonal	Jalonac	Lonarid n
Medi-trol	Mudeka	Mylodorm

Product Name Amobarbital
C.A.S. number 57-43-2

Trade and brand names

Mylodorm sustrel	N 8	Neur-amyl
Novambobarb	Novoqen	Obe_slim
Pentymal	Placidel	Protasma
Robarb	Schiwanox	Sednotic
Sedo-rythmodan	Somnal	Somvit
Stadadorm	Sumital	Sy-dexam
Talamo	Tensophoril	Transital
Tuinal		

For regulatory information, see page 49

Product Name Amodiaquine
C.A.S. number 86-42-0

Trade and brand names

Amodoquin tablets	Basoquin	Camoquin
Caniquin	Flavoquin	Flavoquine

For regulatory information, see page 49

Product Name Ampicillin/cloxacillin
C.A.S. number 2002-1-1003

Trade and brand names

Pfizerpen

For regulatory information, see page 286

Product Name Aprobarbital
C.A.S. number 77-02-1

Trade and brand names

Allypropymal	Alurate	Alurate sodium
Aprozal	Isonal	Nervisal
Numal	Somnipron	

For regulatory information, see page 52

Product Name Aristolochic acid
C.A.S. number 313-67-7

Trade and brand names

Acidum aristolchicum	Descresepet	Faço-paraxin
Fluocinova	Predno-facilus haemota	Tardolyt
Tr 1736		

For regulatory information, see page 52

Product Name Astemizole
C.A.S. number 68844-77-9

Trade and brand names

Alermizol	Astezol	Astol
Hismanal	Histamanal	Novo-nastizol

For regulatory information, see page 54

Product Name Azapropazone

C.A.S. number 13539-59-8

Trade and brand names

Ahr 3018	Apazone	Azapren
Cinnamin	Cinnopropazone	Dolo-prolixan
Pentosol	Prodisan	Prolix
Prolixan	Prolixana	Rheumox
Sinnamin	Tolyprin	Tolyprina
Xani		

For regulatory information, see page 56

Product Name Azaribine

C.A.S. number 2169-64-6

Trade and brand names

Cb 304	Ribo-azauracil	Triazure
--------	----------------	----------

For regulatory information, see page 56

Product Name Azatadine maleate/pseudoephedrine sulfate

C.A.S. number 2002-1-1004

Trade and brand names

Verban

For regulatory information, see page 290

Product Name Barbital

C.A.S. number 57-44-3

Trade and brand names

Deba	Diemal	Dormileno
Dormon	Dormonal	Escoderm
Hypnogene	Hypnox	Lidor
Malonal	Meqal	Plexonal
Sedeval	Somnytic tablets	Uronal
Verinogen	Verodon	Veroletten
Verolitten	Veronal	Veroniqen

For regulatory information, see page 57

Product Name Bencyclane

C.A.S. number 2179-37-5

Trade and brand names

Angiociclan	Angiodel	Bioarterol
Card-fludilat	Dantrium	Desoblit
Dilanqio	Dilanqio caposium	Dilapres
Fludilat	Fludilat (r)-dti	Fludilat amp 50 mg
Fludilat draq 100 mg	Fludilat draqee	Fludilat retard
Fludilat tropfen	Flussema	Fluxema
Halidor	Iloramina	Ludilat
Ludilat dti	Novo card-fludilat	Tardilat
Tensilence	Vasodarkey	

For regulatory information, see page 58

Product Name Benorilate
C.A.S. number 5003-48-5

Trade and brand names

Benolat	Benoral	Benorile
Benortan	Benorylate	Benotamol
Bentum	Doline	Durium
Duvium	Faw 76	Fenasprate
Quinexin	Salipran	Sinalqin
Spierifex	Triadol	Vetedol
Win 11450	Winolate	Winorlate
Winorylate	Winrolate	Wiolate

For regulatory information, see page 58

Product Name Benoxaprofen
C.A.S. number 51234-28-7

Trade and brand names

90459 compound	Benoxapran	Bexopron
Compound 90459	Coxiqon	Inflamid
Lilly 3794	Lilly 90459	Lrcl 3794
Opren	Oprenal	Oraflex
Uniprofen		

For regulatory information, see page 58

Product Name Benzarone
C.A.S. number 1477-19-6

Trade and brand names

Benzarin	Fraqivix	Fraqivix (r) forte
Vasco	Vasoc	Venaqil

For regulatory information, see page 59

Product Name Benzbromarone
C.A.S. number 2004-0-0001

Trade and brand names

Desuric

For regulatory information, see page 59

Product Name Benzoylperoxide
C.A.S. number 94-36-0

Trade and brand names

Altex

For regulatory information, see page 59

Product Name Benzyl alcohol
C.A.S. number 100-51-6

Trade and brand names

Actamin c	Benhur	Bigram
B-neuron	Brophylline	D & m tablets
Dermaspray	Dex-a-vet	Duphaspasmin
Eclipse	Fertagyl	Hydraplex
Lidazon	Lokalin	Madinex

Product Name Benzyl alcohol

C.A.S. number 100-51-6

Trade and brand names

Omnadren	Orostat	Parkestat
Procadolor	Reflex-spray	Solvidont
Sudocrem	Topic	Triofan

For regulatory information, see page 60

Product Name Benzylpenicillin sodium (topical preparations)

C.A.S. number 69-57-8

Trade and brand names

Abbecillin	Bicillin	Bicillin all purpose
Ceilipen	Cidan	Cidan-cilina
Cilipen	Coliriocilina	Crisocilin-q
Cristapen	Crystamycin	Crystapen
Crystapen q	Demosa casi penicilina	Dermosa cusipenicilina
Falaper	Gonoper	Hormocillin forte
Hyasorb	Ilcocillin	Juvanesta
Lasacilina	Liademycin	M-cillin b
Megacillin	Monocillin	Natricilin
Novopen	P.q.a.	P-50
Paclia q	Patosica	Penibiot
Penicilina klari	Penilevel	Penimiluy
Peniroger	Penitasa "450" simple	Pentids
Pfizerpen	Sancilin	Saniciline
Servipan	Sk-penicillin q	Sodiopen
Sodipen	Specilline	Specilline q
Sugracillin	Tabillin	Therapen-na
Triplopen	Unicilina	Unicilina sodia

For regulatory information, see page 61

Product Name Berberine

C.A.S. number 2086-83-1

Trade and brand names

3 p maid	Berberal	Berbericine
Berberil	Detal	Kenmin-s
Kinosin s	Phelloverin a	Tangenin
Thalsin	Umbellatin	Umbellatine

For regulatory information, see page 62

Product Name Bithionol

C.A.S. number 97-18-7

Trade and brand names

Actamer	Anafoqone	Bacteriostat cs-1
Bidiphen	Bit	Bithin
Bitin	Cp 3438	Lorothidol
Lorothiodol	Neopellis	Nobacter
Prevenol	Tbp	Vancid
Vancide bl	XI 7	

For regulatory information, see page 65

Product Name	Boric acid and borates	
C.A.S. number	10043-35-3	
Trade and brand names		
Alpaqelle	Anoiel	Anuqard
Anoiel	Anuqard	Anusol hc
Anusol hc	Berlicetin	Betadrin
Berlicetin	Betadrin	Bexon
Bexon	Bluboro	Boroformal
Bluboro	Boroformal	Boroqal
Boroqal	Borsyre viskos	Cacimaq
Borsyre viskos	Cacimaq	Caclcifor
Caclcifor	Calcamyl-24	Calcibenzamin
Calcamyl-24	Calcibenzamin	Camilca
Camilca	Chibro	Coneolent
Chibro	Coneolent	Cutaden
Cutaden	Dissol	Ear-dry
Dissol	Ear-dry	Egosol-bs
Egosol-bs	Evercil	Fermakzem
Evercil	Fermakzem	Flex-care
Flex-care	Glaucaдрine	Glucocalcium
Glaucaдрine	Glucocalcium	Gynedron
Gynedron	Kalopsisi	Kerapos
Kalopsisi	Kerapos	Kodomo smarin
Kodomo smarin	Komex	Lindemil
Komex	Lindemil	Macaldex
Macaldex	Mentol sedans sulfamidad	Neo-smarin dia
Mentol sedans sulfamidad	Neo-smarin dia	Neo-vaqipurin
Neo-vaqipurin	Normol	O-biol
Normol	O-biol	Oestro-qynedron
Oestro-qynedron	Ophtalmin	Otocaina
Ophtalmin	Otocaina	Pedoz
Pedoz	Perborate	Phoscanol
Perborate	Phoscanol	Phytex
Phytex	Poly-qynedron	Preferal
Poly-qynedron	Preferal	Proculin
Proculin	Rhinophenazol	Saddle mate
Rhinophenazol	Saddle mate	Swim-ear
Swim-ear	Swim-eye	Tensophoril
Swim-eye	Tensophoril	Timazincum
Timazincum	Tipolin	Tricho-qynedron
Tipolin	Tricho-qynedron	Unisol
Unisol	Vetacalin-m	Alpaqelle
Vetacalin-m		

For regulatory information, see page 65

Product Name	Bromocriptine	
C.A.S. number	25614-03-3	
Trade and brand names		
Bromed	Lactismine	Parilac
Parlodol	Umprel	

For regulatory information, see page 68

Product Name Bromocriptine
C.A.S. number 25614-03-3

Trade and brand names

Product Name Broxyquinoline (see also halogenated hydroxyquinoline derivatives)
C.A.S. number 521-74-4

Trade and brand names

Aprilin	Auanosept	Brodial
Bromoxin	Colepur	Colipar
Dibromoksin	Dibromoquin	Dibromoxin
Dibromoxine	Digesept	Diromo
Dirorno	Dysentrocym	Enosept
Enterokvin	Fenilor	Intestopan
Intestopan-q	Noroquinol	Paramiba
Paramibe	Paramibrodial	Phenipan
Sandocycline	Sandoin	Staroqyn
Susifform ad is vet		

For regulatory information, see page 68

Product Name Bucetin
C.A.S. number 1083-57-4

Trade and brand names

Beelin	Bonanza	Haitmin
Hoe 15239	New isomidon	Ringl-s

For regulatory information, see page 69

Product Name Bufexamac
C.A.S. number 2438-72-4

Trade and brand names

Anderm	Bufemac	Bufexamac-ratiopharm (r) creme
Bufexine	Bufexine ratiopharm(r) f-sable	Calmaderm
Droxan	Droxarol	Droxaryl
Droxaryl zalf 50 mq	Duradermal	Floqicid
Floqocid	Floqocid gel n.n	Floqocid sable
Malipuram	Mofenar	Norfemac
Paraderm	Parafenac	Parafenac (r) milch
Parafenac 5% creme	Parafenac basishad	Parafenac sable
Parafenal	Parfenac	Parfenal
Parfenal creme derm	Viafen	Viafen u est.crema 40 g

For regulatory information, see page 69

Product Name Buformin
C.A.S. number 692-13-7

Trade and brand names

Adebit	Andebit	Andelit
Andere	Biforon	Bigunal
Biquinal	Bs-5892	Bufonamin
Bulbonin	Diabrin	Dibetos
Dutformin	Gliporal	Glybigid
Insulamin	Krebon	Panformin
Silubin	Silubin retard	Sindiatil

Product Name Buformin
C.A.S. number 692-13-7
Trade and brand names
Tidemol retard Ziavetine

For regulatory information, see page 69

Product Name Bumadizone
C.A.S. number 3583-64-0
Trade and brand names
Bumadizon Bumaflex Eumatol
Rheumatol

For regulatory information, see page 70

Product Name Bunamiodyl
C.A.S. number 1233-53-0
Trade and brand names
Bunaiod Buniodyl Orabilex
Orabilix

For regulatory information, see page 71

Product Name Buprenorphine
C.A.S. number 52485-79-7
Trade and brand names
Buprenex Buprex Buprx
Finibron Prefin Temagesic
Temgesic

For regulatory information, see page 71

Product Name Cadralazine
C.A.S. number 64241-34-5
Trade and brand names
Cadraten Cadraten 21 cpr 20 mg Cadraten 30 cpr 10 mg
Cadraten 30 cpr 15 mg Cadratin Cadrilan

For regulatory information, see page 72

Product Name Calamus
C.A.S. number 8015-79-0
Trade and brand names
Acore vrai Oil of calamus Sweet flag root

For regulatory information, see page 73

Product Name Camelia sinensis
C.A.S. number 2004-0-0003
Trade and brand names
Exolise

For regulatory information, see page 73

Product Name Camphor
C.A.S. number 76-22-2

Trade and brand names

Anbesol	Caladryl	Cresophene
Dasin	Ddd	Endrine
Makatussin	Mentol sedans sulfamidad	Nasello
Resol	Root bark oil	Spirit of camphor
Tcp	Tetesept	Topic

For regulatory information, see page 73

Product Name Canrenone
C.A.S. number 976-71-6

Trade and brand names

Luvion

For regulatory information, see page 74

Product Name Canthaxanthin
C.A.S. number 514-78-3

Trade and brand names

Apotrin	Food orange 8	Phenoro
---------	---------------	---------

For regulatory information, see page 74

Product Name Cathine
C.A.S. number 492-39-7

Trade and brand names

Adiposetten n	Amorphan	Amorphan depot
Andiposetten	Appetrol	Dietene
Exponcit	Insacial	Miniscap
Minusin depot	Mirapront n	Neo-soldana
Novese	Phyteia schlankheitsdragees	Reduform
Redufrom	Thinz	

For regulatory information, see page 76

Product Name Cefalosporins (topical preparations)
C.A.S. number UN-88-0002

Trade and brand names

Cepalorin	Ceporin	Faredina
Latorex	Lauridin	

For regulatory information, see page 76

Product Name Cerivastatin
C.A.S. number 145599-86-6

Trade and brand names

Cholstat	Lipobay	Rivastatin
----------	---------	------------

For regulatory information, see page 77

Product Name Chenodeoxycholic acid
C.A.S. number 474-25-9

Trade and brand names

Product Name Chenodeoxycholic acid
C.A.S. number 474-25-9

Trade and brand names

Chendol

For regulatory information, see page 78

Product Name Chloramphenicol
C.A.S. number 56-75-7

Trade and brand names

Acne-sol	Acnoxin	Actimac
Actinac	Alficetyn	Alficetyn susp.
Altabactin	Ambofen	Ambrasynth
Amphemycin-prednisonum	Amphenicol	Amphicol
Ampliomycin	Amseclim	Amseclor
Anacetin	Angimidone	Angiters
Antibiopto	Aquamycetin	Aquapred
Armacol	Arrlicetin	Austracol
Aviatrin	Balkamycin	B-cpct
Bemacol	Berlicetin	Biocetin
Biofeniol	Biophenicol	Biophtas
Biotocap	Bismophenyl	Bitencyl
C. o fluo-fenicol	C. o hidrocor-clora	Caf
Cafenolo	Caladryl	Calmina
Cam	Campiol	Caosol
Cap	Catilan	Cavumycetina
Ccombinado balsamico	Ccorticol	Cebenicol
Cetina	Chemibal	Chemicetin
Chemicetina	Chemyzin	Chlomin
Chlomycol	Chloramex	Chloramfenicol
Chloramficin	Chloramfilin	Chloramol
Chloramphenicol cinnamate	Chloramphenicol intervetra	Chloramphenicol sodium succinate
Chloramphenicol-pos	Chloramphycin	Chloramplast
Chloramsaar	Chloramson	Chloranfeni-mck
Chloranfeni-opipno	Chloranfeni-otico	Chloranfeni-ungena
Chlorasol	Chlora-tabs	Chloreptic
Chlorical	Chloricol	Chlornitromycin
Chloro-25 vetaq	Chloroantibion	Chlorocaps
Chlorocid	Chlorocide	Chlorocidin c
Chlorocidin c tetran	Chlorocortal	Chlorofair
Chloroject I	Chloroject s	Chloromex
Chloromik	Chloromimyxin	Chloromycetin
Chloromycetin kapseals	Chloromycetin palmitate	Chloromycetin sodium succinate
Chloronittrin	Chloroptic	Chloroptic p. oint.
Chlorosol	Chlorostrep	Chlorotin
Chlorotyxin	Chlorovules	Chlorsiq
Chlotaon	Ciclepen	Cidocetin
Ciplamycetin	Clinafenol	Clofenal
Clofibrase	Clomicin enzym	Cloramex
Cloramfen	Cloramicol	Cloramidina
Cloran	Cloranfenicol-mck	Cloranfeni-opifno
Cloranfeni-otico	Cloranfeni-ungena	Cloransul

Product Name	Chloramphenicol	
C.A.S. number	56-75-7	
Trade and brand names		
Clorbiotina	Clorbis supp.	Clorocyn
Clorofenicina	Cloromicetin	Cloromisan
Cloromoin	Cloromycetin	Cloroptic
Cloroptic farmicetina	Clorosyntex	Colidene
Colimy-c	Comycetin	Cortican
Cortidermale	Cortimisin	Cortiphenicol
Cortison-quemicet	Cortivert	Cortol
Cph	Cutispray no. 4	Cyphenicol
Cysticat	Davuron sedante	D-chloramphenicol
Dectamicina	Delta optil	Desphen
Detreomycin	Devamycetin	Dexa-biofinicol
Dextromycetin	Doctamicina	Dorsec
D-threo-chloramphenicol	Duphenicol	Econoclor
Eijificol	Eijificol strept	Eijificol sulfa
Elaste chloromycel	Embacetin	Emetren
Enicol	Enteromycetin	Enttocetrin
Erbaplast	Eritriconic	Erteilen
Esterofenil	Estevecicina cloranfenico	Eubetal
Extracilina	Faço-praxin	Farmicetina
Fenicol	Fluorobioptal	Furacol I
Furamecetil alpha magna	Furamecetil magna	Furatrimon
Furokatin	Gammaphenicol	Ginetrin
Gino-dectacil	Gliscol	Globenicol
Globveticol	Glorous	Goticas
Gotimycetin	Ichthoseptal	Intramycetin
Irujol	Irujolom	Isicetina
Ismicetina	Isopto fenicol	Juvamycetin
Kamaver	Kavipe	Kemicetine
Kloramfex	Klorita	Klorocid s
Kloromicin	Labamicol	Labamicol-bismuth
Lennacol	Leuchlon	Leukamycetin
Leukomyan	Leukomycin	Levocycline
Levomanilin	Levomycetina	Levomycin
Levomitsetin	Levomycetin	Levomycetina
Levoninizol	Levopa	Levosin
Levovetin	Lifabiotico	Liquichlor
Lisoprecol	Locomycetine	Lomecetina
Loromisin	Mammphenicol	Mastiphen
Mediamycetin	Medichol	Medicol
Meliplus	Mephenicol powder	Metisept
Miclorelin	Micoclorina	Micoclorine
Micodry	Micofilina	Microcetina
Mindaril	Minims	Minims chloramphenicol
Misetin	Muracin	Mycetin
Mycetobis	Mychel	Mychel-s
Mychel-vet	Mycinol	Myclocin
Mycochlorin	Naxogin compositum	Neocetin
Neo-dexoclin	Niamycetin	Nitrocetin
Nitrocol	Norbun	Normimycin v

Product Name	Chloramphenicol	
C.A.S. number	56-75-7	
Trade and brand names		
Nova-phenicol	Novoclorocap	Novomyctin
Oftalent	Oftan	Oleomyctin
Opclor	Ophthaphenicol	Ophthochlor
Ophthalon	Optrin	Oralmisetin
Otachron	Otiprin	Otophen
Otopred ear drops	Pantofenicol	Pantovernil
Paraxin	Parcyclin	Pedimycetin
Pentamycetin	Pentocetina	Pertaril
Pimabiciron	Pinimentac	Plastoderma
Prednomycetine	Procusulf	Proterciclina
Prurivet	Pulmo vinco	Quemisetina
Quitrase	Quitrase antibiotico	Ranphenicol
Ranstrepcol	Reclor	Redidropsol
Renegen	Reocetin	Reostop
Rheofin	Rivomycin	Rivomycin sulfa
Rolintrex	Romphenil	Roncovita
Ronphenil	Roscomycin	Rovictor
Samaphenicol	Scanicol	Scanicoline
Scieramycetin	Septicol	Sergo-amigdalar
Serviclofen	Sificetina	Sigmicilina
Sintomicetin	Sintomicetina	Sintomicetine r
Sintomitsin	Snophenicol	Soludectancil
Sopamycetin	Spasmo-paraxin	Spersanicol
Stanomycetin	Strepticine	Streptoqlobenicol
Streptophenicol	Subital supp.	Suismyctin
Sulfaqlobenicol	Sulfamycetin	Synthomycetin
Synthomycetina	Synthomycetine	Synthophtone
Tardomyocel	Teqa-cetin	Tetrachlorasone
Tetracol	Tetranfen	Tetraphenicol
Tetra-phenicol oculos	Tevcocin	Tifomycine
Tiframilk	Tiromycetin	Toramin
Transicetina	Transpulmycin	Tribiotic
Trophen	Troymyctin	Tusolone
Tycloran	Unimycetin	Uro-qliscal
Uro-qliscal 500	Uroletten-s	Uroplex 4
Ut forte	Uvomycin	Vaqisept
Variolan	V-crayolan	Vetical
Vetophenicol	Viceton	Viklorin
Viroqin	Vitaklorin	Vsmpozim
Wintetil	Zoppib spray blu	

For regulatory information, see page 78

Product Name	Chlormadinone acetate	
C.A.S. number	302-22-7	
Trade and brand names		
Gestafortin	Luteran	Ovosiston

For regulatory information, see page 79

Product Name Chlornaphazine

C.A.S. number 494-03-1

Trade and brand names

Aleukon	Chloronaftina	Erysan
Nafticlorina	Naphthylamine mustard	

For regulatory information, see page 81

Product Name Chloroform

C.A.S. number 67-66-3

Trade and brand names

Ametuss	Benafed	Benatuss
Benyphed	Broncho-rivo syrup	Chlor-histine
Codacol	Codimal dm	Co-specto
Cotrol-d	Cyprol expectrant	Dalet
Dectuss	Eludril	Expec-c
Fk-tussex	Guanor	Histalix
Hydril	Kentuss	Linctuss
Mc 3	Muflin	Naqalyn
Notose	Orthos kavident	Panosoma
Penta-zine	Phenacol-dm	Phenatuss
Phlogarol	P-m-z	Promex
R 20	Rexahisine	

For regulatory information, see page 81

Product Name Chloroquine

C.A.S. number 54-05-7

Trade and brand names

Aralen	Aralen hcl	Aralin (diphosphate)
Artrichin	Artrochin	Avloclor (diphosphate)
Bemaphate	Bipiquin	Chemochin
Chlorochin	Cidanchin	Clorochina
Delaqil	Dichinalex	Endamal
Erestol	Gontochin	Hiliopar
Imagon	Instana	Lagaquin
Letaquine	Malaraqin	Malarex (diphosphate)
Malariron (diphosphate)	Malquin	Mesylith
Miniquine	Nivaquine	Nivaquine b'
Nivembin	Norolon	Pfizerquin
Presocyl	Quinachlor	Quinercyl
Resichin	Resochin (diphosphate)	Resoquine
Reumachlor	Rivoquin	Salestol
Sanoquin	Scaniquine (diphosphate)	Serviquin
Silbesan	Siraqon	Tanakan
Tresochin	Trochin	

For regulatory information, see page 83

Product Name Chlorphentermine

C.A.S. number 461-78-9

Trade and brand names

Apsedon	Avicol	Avipron
---------	--------	---------

Product Name Chlorphentermine

C.A.S. number 461-78-9

Trade and brand names

Chenracol	Clorfentermina	Desopimon
Effox	Lucofen	Lucofen retard
Lucofen sa	Minilip	Phenacon
Pre-sate	Reamine	Sinfat
Teramine		

For regulatory information, see page 84

Product Name Cianidanol

C.A.S. number 154-23-4

Trade and brand names

Ausoliver	Catergen	Cirramina
Drenoliver	Transepar	

For regulatory information, see page 84

Product Name Cinchophen

C.A.S. number 132-60-5

Trade and brand names

Aqlophenyl	Aqotan	Alcophenyl
Alutyl	Artam	Artexin
Atiqoa	Atocin	Atofan
Atophan	Cefeno	Cinchophene
Cinconal	Cincosal	Fenofan
Iriphan	Mylofanol	Mylophanol
Phenoquin	Rhematan	Rheumin
Tervalon	Tophol	Traubofan
Vantyl	Viophan	

For regulatory information, see page 85

Product Name Cinnarizine

C.A.S. number 298-57-7

Trade and brand names

Rinomar

For regulatory information, see page 86

Product Name Cisapride

C.A.S. number 810968-60-4

Trade and brand names

Calmax	Cisapid	Cismotil
Diqenol		

For regulatory information, see page 86

Product Name Clemastine

C.A.S. number 15686-51-8

Trade and brand names

Agasten	Alagyl	Aller-ez
Aller-ez plus	Alogynan	Alphamin
Anhistan	Antihist-1	Arrest

Product Name Clemastine
C.A.S. number 15686-51-8

Trade and brand names

Benaznyl	Clemanil	Clemastin fumerate syrup
Corto-taveqil	Dexa-taveqil	Fuluminol
Fumarsutin	Inbestan	Kinotomin
Lacretin	Licasol	Maikohist
Mallermin	Marsthine	Masletine
Piloral	Rhinergal	Rhinergal taveqil
Taveqil	Taveqyl	Tavist
Tavist 1	Tavist tablets	Tavist-1
Tavist-d	Tavist-syrup	Telqin-q
Xolamin		

For regulatory information, see page 89

Product Name Clioquinol (see also halogenated hydroxyquinoline derivatives)
C.A.S. number 130-26-7

Trade and brand names

Alchloquin	Amebio-formo	Amoenol
Anterobe	Aristoform	Aristoform "d"
Aristoform "r"	Bactol	Barquinol
Barquinol hc	Betnorate-c	Britaderm
Britadex-vioform	Budoform	Carboform
Cifoform	Cleocin	Cliquinol
Cloro-yodo-hidroxi	Clorpine	Combias
Copover	Cortex	Corticreme
Corti-glottyl	Crema-quin	Dependal
Dermadex	Derma-quinol	Dermozolan
Dexalocal	Diaban	Dioderm
Dioderm c	Dioderm c-c	Diodotracin
Dioquinol	Diproform	Dizenterol
Domeform	Eczeccidin	Emaform
Enteral	Enteritan	Ente-rivo
Enterokin	Enterosan	Enterosept
Enteroseptol	Entero-valodon	Entero-vioform
Entero-vioformio	Entero-vioformo	Enterozol
Enterquinol	Entox	Entrasorb
Entrokin	Entrokinol	Fraquinol
Fusalor-yodocloro	Fyloxxal	Gmd
Guanosept	Haelan-c	Hi-enterol
Hocacorten-vioform	Hydroform	Hysone
Iodenterol	Iodochlorhydroxyquinol	Iodo-cortifair
Iodocortindon	Iodoenterol	Iodo-max
Isoderm	Khlorlinkotsin	Klinicin
Lecortin	Lederform-d	Lekosept
Lemoderm	Linola	Locacorten-vioform
Locorten	Locorten-vioform	Metrijet
Metrityl	Mexafermento	Mexafom
Mexaform	Mycoquin	Nasello
Nefurox	Nioform	Obstecrim
Oralcer	Oxyquin	Pedi-cort

Product Name Clioquinol (see also halogenated hydroxyquinoline derivatives)
C.A.S. number 130-26-7

Trade and brand names

Percural	Phen-ortis	Pricort cream
Propaderm-c	Quadri-derm	Quin
Quin iii	Quina band	Quinambicide
Quiniodochlor	Reticus	Rheaform
Rometin	Sebryl	Sedacol
Septo-canulase	Silic c	Steroderm
Synalar-c	Tequinophil	Toptic
Toro-for	Unidiarea	Uteroject
Ventribex	Viform	Vioform
Vioform bolus	Vioform hydrocortisan	Vioform hydrocortisone
Vioforme	Viosept	

For regulatory information, see page 89

Product Name Clobenzorex
C.A.S. number 13364-32-4

Trade and brand names

Asenlix	Finedal
---------	---------

For regulatory information, see page 91

Product Name Clofibrate
C.A.S. number 637-07-0

Trade and brand names

Aatroayerst	Aitiflus	Amotril
Angiocapsul	Anparton	Antilipid
Apolan	Arterioflexin	Arterioflexion
Artes	Artevil	Artriosan
Asa/cpib	Ateculon	Aterioplexin
Ateriosan	Ateroayrest	Ateroclar
Aterofront	Ateronlen	Aterosol
Atevil	Atheroayerst	Atheromide
Atheropront	Atroayerst	Atrofort
Atrolan	Atrolen	Atromid
Atromidin	Atromid-s	Atrom-s
Atrovis	Ay 61	Azionyl
Biocleran	Bioscleran	Cartaqyl
Cinnarizin	Citiflus	Clareden
Claresan	Claripex	Claripex cpib
Cloberab	Cloberat	Clobrat
Clobrate	Clobren	Clobren-5 f
Clof	Clofenit	Clofibral
Clofibrat	Clofibrate ayerst	Clofibrate compose
Clofibrato ayerst	Clofibrato procaps	Clofibrem
Clofimide	Clofini	Clofin-icn
Clofinit	Clofipront	Clofipront 5000
Clofirem	Clofirin	Clofi-t
Clopin	Col 180	Contra-lipide
Corafen	Cr/085	Dabical
Delipid	Deliva	Dilectus

Product Name Clofibrate
C.A.S. number 637-07-0

Trade and brand names

Doctus	Duplinal	Duraclofibrate
Ellemger	Elpi	Epib
Eramid	Fibramid	Fibrolynt
Geri-70	Geromid	Gerostop
Healthstyle	Hyclorate	Ici 28257nt
Ipolipid	Klofibrat	Klofiran
Kontalipide	Levatram	Levatrom
Liapten	Liparil	Lipaten
Lipavil	Lipavlon	Lipavlon 500
Lipicidon	Lipidicon	Lipofacton
Lipomid	Liponorm	Liporan
Liporeduct	Liporil	Liposid
Liprin	Liprinal	Liptrinal
Lobetrin	Lostat	Miscleron
Neqalip	Neotromid	Neo-atromid
Nibratal	Nibratol	Nnormet
Nobret	Norinolipol	Normalip
Normet	Normet richter	Normolipol
Nosterolin	Novofibrate	Omelip
Persantinat	Provasa	Recade
Recolip	Regelan	Regelan n 500
Sclerovasal	Serolipid	Serotinex
Sestron	Sinteroid	Sklero
Sklerocip	Sklerolip	Skleromex
Skleromexe	Sklero-tablinen	Sklerovasal
Supraoxid	Tepincal	Tepingal
Ticlobran	Vimedel	Vocaline
Xyduril	Yoclo	

For regulatory information, see page 92

Product Name Cloforex
C.A.S. number 14261-75-7

Trade and brand names

Avicol sl	Avicol-la	Chloferex
D 237	Frenapyl	Lipociden
Oberex	Vidipon	Zeisin

For regulatory information, see page 94

Product Name Clomethiazole
C.A.S. number 533-45-9

Trade and brand names

Clomiazin	Distraneurin	Distraneurine
Emineurina	Gebriazol	Hemineurin
Hemineurine	Hemineurin	Somnevrin

For regulatory information, see page 95

Product Name Clozapine**C.A.S. number** 5786-21-0**Trade and brand names**

Clozaril	Iprox	Leponex
Leponox		

For regulatory information, see page 95**Product Name** Cobalt (non-radioactive forms)**C.A.S. number** 7440-48-4**Trade and brand names**

C.i. 77320	Cobalt-59	Impromin
Inter-con	Kometileneamin	Levacide-c
Orkomin	Panacur	Sofracaps
Tasvite	Trelenium	

For regulatory information, see page 96**Product Name** Codeine**C.A.S. number** 6095-47-8**Trade and brand names**

Alqisedal	Codicept	Codol
Diarrest	Methylmorphin	Novacetol
Sedarene		

For regulatory information, see page 97**Product Name** Cyclamates in drugs**C.A.S. number** 139-05-9**Trade and brand names**

Adocyl	Ampenoline balsamoco	Assuqrin
Azucrona	Cyclarin	Glusac super
Ilqon	Sladicin	Sucaryl
Sucaryl calcium	Sucaryl sodium	Sucrum
Sucrum 7		

For regulatory information, see page 98**Product Name** Cyproheptadine**C.A.S. number** 129-03-3**Trade and brand names**

Anarexal	Antegan	Apeplus
Brantina	Brantine	Brontin
Carniqol	Carpantin	Ciplactin
Cipractin	Cipro	Cipro n
Ciprocort	Cypromin	Cyrasarl
Eiproheptadine	Estialim	Histatets
Ifrasarl	Kontrast u	Naidoretico
Nuran	Nurdelin	Nuttriben
Oractine	Orexigen	Periactin
Periactine	Periactinol	Periactol
Perideca	Peritol	Pranzo
Reparal carnitina	Siglatan	Sigloton
Sipraktin	Siprodin	Vimicon

Product Name **Cyproheptadine**
C.A.S. number **129-03-3**
Trade and brand names
For regulatory information, see page **99**

Product Name **Danazol**
C.A.S. number **2004-0-0004**
Trade and brand names

Danol

For regulatory information, see page **101**

Product Name **Dantron**
C.A.S. number **117-10-2**
Trade and brand names

Doss

Normax

Requlex-d

For regulatory information, see page **101**

Product Name **Depot medroxyprogesterone acetate (DMPA)**
C.A.S. number **71-58-9**
Trade and brand names

Amen

Clinovie

Cliovir

Curretab

Dep0-clinover

Dep0-map

Depcorlutin

Depo-prodasone

Depo-progevera

Depo-promone

Depo-provera

Deporone

Dugen

Farlurin

Farlutal

Farlutale

Gesinal

Gestapuran

Gestapuron

G-farlutal

Hysron

Intex

Luteocrin orale

Luteodione

Luteos

Lutoporal

Lutoral

Meprate

Metiqestene

Metiqestrona

Nadiqest

Nidaxin

Noqest

Onco-provera

Oraqest

Perlutest

Perlutex

Petogen

Piermap

Povera

Prodasone

Progestalfa

Progevera

Promone-e

Pronone

Provera

Proverone

Provest

Repromix

Sindomens

Sirprogen

Sodelut

Sodelut "q"

Supprestal

Verafen

Veramix

Veramix plus v

For regulatory information, see page **102**

Product Name **Dequalinium chloride**
C.A.S. number **522-51-0**
Trade and brand names

Decabis

Dequacaine

Dequafungan

Dequin

Evazol

Faringina

Gargilon

Grocreme

Labosept

Maltyl

Phylletten

Soor-gel

Sorot

Tetesept

For regulatory information, see page **103**

Product Name Dequalinium chloride
C.A.S. number 522-51-0

Trade and brand names

Product Name Dexamfetamine
C.A.S. number 51-64-9

Trade and brand names

Adiparthrol	Afatin	Amfe-dyn
Amphaetex	Bipheramine	Curban
D-amfetasul	Dexadrine	Dexamed
Dexamin	Dexampex	Dexedrina
Dexedrine	Dexten	Dextro-profetamine
Drinamyl	Durophet	Durophet-m
Ferndex	Maxiton	Mephadexamine-r
Mephadexamin-r	Obetrol	Obotan
Proptan	Robese	Simpamina d
Steladex	Stil-2	Synatan

For regulatory information, see page 104

Product Name Dexfenfluramine
C.A.S. number 3239-44-9

Trade and brand names

d-Fenfluramine Diomeride

For regulatory information, see page 104

Product Name Dextromethorphan
C.A.S. number 125-71-3

Trade and brand names

Aqrippol Dextophan Dextrophen

For regulatory information, see page 105

Product Name Dibenzepin hydrochloride
C.A.S. number 315-80-0

Trade and brand names

Ansiopax	Deprex	Ecatrol
Hf 1927	Neodalit	Neodit
Noveril	Victoril	

For regulatory information, see page 105

Product Name Diclofenac sodium
C.A.S. number 15307-79-6

Trade and brand names

Aflamin	Alfamin	Allvoran
Artren	Blesin	B-voltaren
Cqp 9194	Chlorqyl	Ct-diclo
Delphimix	Dichloronic	Dichronic
Diclo attritin	Diclo spondril	Diclo-attritin
Diclo-burg	Diclo-phlohont	Diclo-puren
Diclo-ecip	Dicloream	Diclo-spondyryl
Diclo-wolf	Dolaren	Dolobasan
Dolotrem	Doragon	Duravolten

Product Name Diclofenac sodium
C.A.S. number 15307-79-6

Trade and brand names

Duvavotten	Effekton	Feloran
Fenoflam	Floqofenac	Floqogenac
Forqenac	Inflamac	Klast
Kriplex	Monoflam	Myogit
Neriodin	Neuro-effekton	Neurofenac
Neuro-voltaren	Neviodin	Novapirina
Olfen	Panamor	Parsal
Prophenatin	Rewodina	Rheumalgen
Rheumavincin	Rheumavincin-n	Seecoren
Shiqnol	Silino	Sofarin
Sorelmon	Thicataren	Toryxil
Tsudohmin	Tsudomin	Valetan
Voltaren	Voltarene	Voltarol

For regulatory information, see page 105

Product Name Dicycloverine
C.A.S. number 77-19-0

Trade and brand names

Abacid plus	Ametil	Atumin
Babypasmil	Babyspasm	Babyspasmil
Baycyclomine	Benacol	Bendectin
Bentomine	Bentyl	Bentylol
Clomin	Colix	Cyclobex
Cyclocen	Debendox	Diarrest
Diclophen	Dicyclomine	Dicycloverin
Diocyl	Dyspas	Eatonqel
Esentil	Fomulex	Formulex
Gastrosilane	Icramin	Incramin
Incron	Inctacol-c	Isospamex
Kolanticon	Kolantyl	Lagasediv
Lomine	Mamiesan	Menospasm
Merbantal	Merbentyl	Mydocalm
Neoquess	Nomocramp	Notensyl
Or-tyl	Ovol	Pamin
Panakiron	Prinel	Procyclomin
Protylol	Sawamin	Spactil
Spasmoban	Spastil	Tarestin
Viscerol	Wyovin	

For regulatory information, see page 106

Product Name Dienestrol
C.A.S. number 84-17-3

Trade and brand names

Agaldog	Avc/dienestrol	Crinohermal fem
Cycladiene	D.v.	Dehydrostilboestrol
Dienoestrol	Dienol	Dienoestrol cream
Dienstrogen	Dinestrol	Dinol
Dinovex	Dufemine	Dv

Product Name Dienestrol
C.A.S. number 84-17-3

Trade and brand names

Estraquard	Estrodiol	Estroral
Farmacyrol	Follidien	Follormon
Foraqynol	Frein	Gynefollin
Hormofemin	Isodienestrol	Klianyi forte
Klianyl	Lipamone	Neo-oestrogenine
Oestrasid	Oestrodien	Oestrodien
Oestrodienol	Oestroral	Oestrovis
Ortho	Ortho (cream)	Ortho dienestrol cream
Para-dien	Restrol	Retalon
Sexadien	Sexadieno	Synestrol
Synoestrol	Teserene	Willnestrol

For regulatory information, see page 107

Product Name Diethylaminoethoxyhexestrol
C.A.S. number 2691-45-4

Trade and brand names

Coralqil	Coralqina	Coralqyl
Trimanyl		

For regulatory information, see page 107

Product Name Diethylstilbestrol
C.A.S. number 56-53-1

Trade and brand names

Distilbene	Oestro-gynedron	Stilphostrol
------------	-----------------	--------------

For regulatory information, see page 107

Product Name Difenoxin
C.A.S. number 28782-42-5

Trade and brand names

Diocin	Lyspafen	Lyspofen
Lyspofenac	Motofen	

For regulatory information, see page 109

Product Name Difurazone
C.A.S. number 804-36-4

Trade and brand names

Panzon	Payzone
--------	---------

For regulatory information, see page 109

Product Name Dihydrostreptomycin
C.A.S. number 128-46-1

Trade and brand names

Abiocine	Abocillin	Biostrep
Complexobiotico	Dhsm	Diapenin 3
Diapenin balsamico	Diarrestival	Didromycin
Didrothenate	Dihydrocidan sulfato	Dihydrostreptofar
Dihydrostreptom	Diidro-pantostrept	Distreptopab

Product Name Dihydrostreptomycin
C.A.S. number 128-46-1

Trade and brand names

Dreiciclina balsamica	Dst	Entera-strept
Estreptoluy	Estreptosirup	Helle-strep-forte
Hp 48	Mastiquin	Mixtencillin
Retromyopen	Rocopenstrep	Sanstrepto
Solmycin	Solvo-strept	Streptoduocin
Veticar	Veycil-as	Vibriomycin

For regulatory information, see page 109

Product Name Dihydroxymethylfuratrizine
C.A.S. number 794-93-4

Trade and brand names

Furatone	Panfuran s	Panfuran-s
----------	------------	------------

For regulatory information, see page 110

Product Name Dimazole
C.A.S. number 95-27-2

Trade and brand names

Asterol	Atelor	Atelora
Aterola	Kesten	Mycotol

For regulatory information, see page 111

Product Name Dinoprostone
C.A.S. number 363-24-6

Trade and brand names

Minprostin	Prostaglandin E2	Prostarmon e
Prostenon	Prostin e2	Prostin vr pediatric

For regulatory information, see page 111

Product Name Diphenoxylate
C.A.S. number 915-30-0

Trade and brand names

Diaphem	Diarsed	Diarsed-neomycin
Diatro	Eldox	Loqen
Lomanate	Lomax	Lomotil
Lomotil liquid	Lonox	Protector
Reasec	Saleton	Sedistal

For regulatory information, see page 112

Product Name Dithiazanine iodide
C.A.S. number 514-73-8

Trade and brand names

Abminthic	Anelmid	Anquifugan
D.i.m.	Dejo	Delvex
Deselmine	Dilombrine	Dithiazine (dye)
Dizan	Dtdc	Eastman 7663
Elmizin	Nekel	Netocycd
Omni-passin	Ossiurene	Partel

Product Name Dithiazanine iodide
C.A.S. number 514-73-8

Trade and brand names

Telmicid	Telmid	Telmide
----------	--------	---------

For regulatory information, see page 113

Product Name Domperidone(injectable)
C.A.S. number 57808-66-9

Trade and brand names

Euciton	Evixub	Kw 5338
Moperidona	Motilium	Nauzelin
Neta662	Peridon	Peridys
R 33812	Tametil	Touristic

For regulatory information, see page 114

Product Name Doxepin
C.A.S. number 1668-19-5

Trade and brand names

Adapin	Apo-doxepin	Aponal
Co dox	Deptran	Doksapan
Dolat	Doxal	Doxedyn
Doxepin hcl	Gilex	Novo-doxepin
Novoxapin	Quitaxon	Sinequan
Sinquan	Sinquan concentrate	Sinquane
Tolllluan	Triadapin	Zonalon

For regulatory information, see page 114

Product Name Doxycycline hyclate(injectable)
C.A.S. number 24390-14-5

Trade and brand names

Abadox	Azudoxat	Bassado
Bio-tab	Clisemina	Cloran
Cyclidox	Deoxymykoine	Diocimex
Docostyl	Doryx	Dosil
Dotur	Doxatet	Doxi sergo
Doxicento	Doxifin	Doxilen
Doximycin	Doxin	Doxina
Doxinate	Doxiten bio	Doxivis
Doxy	Doxy-100	Doxy-basan
Doxybiocin	Doxychel	Doxycyl
Doxy-diolan	Doxydyn	Doxyfim
Doxygram	Doxylaq	Doxylan
Doxylar	Doxylets	Doxylin
Doxymycin	Doxy-p	Doxytem
Doxy-wolff	Dumoxin	Duradoxal
Esadoxi	Farmodoxi	Ghimadox
Gram-val	Granudoxy	Helvedoclyn
Icladox	Idocyklin	Mespafin
Miraclin	Monocline	Monodox
Monodoxin	Nordox	Novelciclina

Product Name Doxycycline hyclate(injectable)
C.A.S. number 24390-14-5

Trade and brand names

Philcociclina	Radox	Retens
Roximycin	Roxyne	Samecin
Semelciclina	Siqadoxin	Solupen
Spanor	Stamicina	Supracyclin
Tetradox	Tetrasan	Unacil
Unidox	Vibracina	Vibramicina
Vibramycin	Vibramycin hyclate	Vibramycine
Vibra-tab	Vibra-tabs	Vibraveineuse
Vibravenos	Vibravenosa	Ximicina
Zadorin		

For regulatory information, see page 115

Product Name Droperidol
C.A.S. number 548-73-2

Trade and brand names

Dehydrobenzperidol	Diaperidol	Inopsin
--------------------	------------	---------

For regulatory information, see page 116

Product Name Emetine
C.A.S. number 483-18-1

Trade and brand names

Asmorex	Broncho-tetracycline	Dicton-retard
Emedrin	Emetin	Emetina
Emetocamphrol	Hemometina	Optairosol
Pectinfant		

For regulatory information, see page 117

Product Name Ephedra
C.A.S. number 2004-0-0005

Trade and brand names

Maqic herb

For regulatory information, see page 118

Product Name Epinephrine
C.A.S. number 51-43-4

Trade and brand names

Adnephrine	Adrefil	Adrehinal
Adren	Adrenal	Adrenalin
Adrenalin chloride	Adrenalin medihal	Adrenalina ace.p.d.
Adrenalina clorhi	Adrenalina delta	Adrenalina fustery
Adrenalina hormona	Adrenalina p davis	Adrenalina wiener
Adrenaline	Adrenamine	Adrin
Bronkaid mistometer	Cetanest	Chelafrin
D epinefrin	Dento-caine	D-epifrin
Depinefrin	Dysne-inhal	E-caprine
Epiboran ofteno	Epifrin	Epiglauftrin
Epinephrine hcl	Epinephrine pediatric	Epineramine

Product Name	Epinephrine	
C.A.S. number	51-43-4	
Trade and brand names		
Epipen	Epirenan	Epitrate
Exadrin	Ganda	Glaucadrin
Glaucadrine	Glaucoacon	Glaucan
Glaucanin	Glaucozan	Glaucotahil
Glycirenan	Haemostasin	Hektalin
Hemisine	Hemostatin	Intranefrin
Isopto epinefrina	Kidoline	L-caine
L-epinephrine	Levorenine	Levoreninl-adrenaline
Licothionil	Lidoacton	Lyodrin
Lyophrin	Marcaom	Medihaler-epi
Metanephrine	Methylaminoethanolcatechol	Methylarterenol
Mucidrina	Neo-rybarex	Nephridine
Nieraline	Niphridine	Octacaine
Orostat	P2e1	Paranephrine
Pe	Piladren	Primatene mist
Renaqladin	Renaqlandin	Renaqlandulin
Renaleptine	Renalina	Renoform
Renostypticin	Renostyptin	Scurenaline
Sedo-asmol	Simplene	Styptirenal
Supracapsulin	Supranephrane	Supranephrine
Suprarenaline	Suprarenine	Suprel
Suprexon	Suprexon 5	Surrenine
Susphrine	Sus-phrine	Sympathin i
Takamina	Vaponefrin	Vaponephrine
Vasoconstrictine	Vasoconstrictor	Vasodrine
Vasotonin	Xylestesin a	Xylotox

For regulatory information, see page 118

Product Name	Erythromycin estolate	
C.A.S. number	3521-62-8	
Trade and brand names		
Antibio-aberel	Apo-erythro-s	Bio-exazol
Biometran	Biomicron	Bristamycin
Chemthromycin	Cimetrin	Cusimicina balsamica
Doboiosol	Dowmicyn	Dreimicina
Duoazplin vitaminado	Dynabiotol	E.e.s
Ees-200	Ees-400	E-mycin
E-mycine	Endoeritrina	Erimec
Eriobios	Eriscel	Eritrazol
Eritrobios	Eritrobiotic	Eritrocin
Eritrodes	Eritroger	Eritronicol
Eritropan	Eritroveinte	Eritrovienite
Eritrowolf	Eritro-wolf	Ermysin
Eromycin	Ery derm	Eryc
Erymycin	Erypar	Eryped
Ery-tar	Erythrocin	Erythromictine
Erythromid	Erythro-prat	Ery-toxinal
Erytrarco	Erytrodol	Erytro-prot

Product Name Erythromycin estolate
C.A.S. number 3521-62-8

Trade and brand names

Eryt-toxinal	Espimina	Estimina
Estomicina	Estomiicina	Estomycin
Ethril	Fesmicina	Iloson
Ilosone	Ilosone pulvules	Ilosone ready-mix
Ilothycin	Ilotycin	Kesso-mycin
Laucetin	Laurilin	Lauritran
Lauromicina	Liferitrin	Loderm
Lubomycina	Lubomycine	Makrocyklina
Manilina	Marcoeritrex	Marocid
Mistral	Monomycin	Neo-erycinum
Neo-ilolycina	Neo-iloticina	Niux
Novorythro	Pediamycin	Pels
Pfizer-e	Propiocrine enfant	Propriocin enfant
Prospiocine	Proterytrin	Pulmomas
Purmycin	Ritromin	Robimycin
Roxo chemil	Roxochemil	Rp-mycin
Rubibacter	Selvicin	Sk-erythromycin
Spetrasone	Stella micina	Stellamicina
Taimoxin	Toqerin	Toqiren
Toqrien	Tosinova	Tropoxin
Wyamycin	Wyamycin e	Wyamycin s

For regulatory information, see page 120

Product Name Etanercept
C.A.S. number 185243-69-0

Trade and brand names

Enbrel	Tanercept	yhu TNFR: Fc
--------	-----------	--------------

For regulatory information, see page 121

Product Name Ethambutol
C.A.S. number 74-55-5

Trade and brand names

Aethambutolum	Embutol	Ebutol
---------------	---------	--------

For regulatory information, see page 121

Product Name Ethanol
C.A.S. number 64-17-5

Trade and brand names

Absolute alcohol	Alcohol aethylicus	Alcool
Avitoin	Banatul	B-tonin
Colfin	Desqyam-x	Duonale-e
Efatin	Equithesin	Hizeneck-d
Honkon-n	Kapsitrin	Keralyt
Levovinizol	Mikrozid	Neotizol
Panoxy	Papette	Piadam
Polislerol	Protectaderm	Sicol
Sodaphilline	Softa man	Sotracarix

Product Name Ethanol
C.A.S. number 64-17-5

Trade and brand names

Verucid Weingeist Xeracin

For regulatory information, see page 121

Product Name Ethylestrenol
C.A.S. number 965-90-2

Trade and brand names

Dexabolin Durabolin-o Duraboral
 Ethylnandrol Fertabolin Maxibolin
 Neodurabolin Orabolin Orgabolin
 Orgaboral Vibolin

For regulatory information, see page 123

Product Name Etomidate
C.A.S. number 33125-97-2

Trade and brand names

Amidate Hypnomidat Hypnomidate
 Hypnomidate concentrate Hypnomidate injection Hypromidate
 Nalqol Radenarcon Sibul

For regulatory information, see page 124

Product Name Etretnate
C.A.S. number 54350-48-0

Trade and brand names

Ro 10-9359 Tegison Tigason

For regulatory information, see page 124

Product Name Factor IX
C.A.S. number UN-87-0003

Trade and brand names

Bebulin Haimaplex Preconativ
 Profilnine Proplex Prothromplex

For regulatory information, see page 125

Product Name Factor VIII
C.A.S. number UN-87-0004

Trade and brand names

Factorate Hemofil Humafac
 Humanate Hyate:c Koate
 Kryobulin Profilate

For regulatory information, see page 126

Product Name Famotidine
C.A.S. number 76824-35-6

Trade and brand names

Amifatidine Famodil Pepsidac

Product Name Famotidine
C.A.S. number 76824-35-6
Trade and brand names
For regulatory information, see page 126

Product Name Fenclofenac
C.A.S. number 34645-84-6
Trade and brand names
 Feclan Flenac Gidalon
 Monosan Rx 67408nac

For regulatory information, see page 126

Product Name Fenetylline
C.A.S. number 3736-08-1
Trade and brand names
 Biocapton Captagon Captagon cpr nsfp

For regulatory information, see page 127

Product Name Fenoterol
C.A.S. number 13392-18-2
Trade and brand names
 Berotec Dosberotec Duivent
 Fensol Partusisten

For regulatory information, see page 128

Product Name Feprazone
C.A.S. number 30748-29-9
Trade and brand names
 Analud Bentudor Brotazona
 Cocresol Da 2370 Danfenona
 Feniprenazone Fepramole Golaman
 Grisona Impremial Methrazone
 Metrazone Naloven Naoven
 Nazona Nessazona Nilatin
 Prenakes Prenazon Prenazone
 Rangozona Represil Sollelin
 Tabrien Tbrien Vapesin
 Zepelin Zontal Zoontal

For regulatory information, see page 128

Product Name Fipexide
C.A.S. number 34161-24-5
Trade and brand names
 Attenil Attenil 30 conf. 20 mg Fipexitum
 Fipexium Vigilor Vigilor 200 mg cpr msfp

For regulatory information, see page 129

Product Name Flecainide
C.A.S. number 54143-55-4
Trade and brand names

Product Name Flecainide
C.A.S. number 54143-55-4

Trade and brand names

Flecaine

For regulatory information, see page 129

Product Name Floctafenine
C.A.S. number 23779-99-9

Trade and brand names

Tambocor

For regulatory information, see page 131

Product Name Flunitrazepam
C.A.S. number 1622-62-4

Trade and brand names

Darkene	Flunipam	Flunipam
Hipnosedon	Hiposedon	Hypnodorm
Hypnosedon	Libelins	Narcozep
Noviel	Primun	Riopnol
Rohipnol	Rohpinol	Rohpnol
Rohypnol	Roipnol	Valsera
Valseram		

For regulatory information, see page 132

Product Name Fluvoxamine
C.A.S. number 54739-18-3

Trade and brand names

Faverin	Fevarin
---------	---------

For regulatory information, see page 133

Product Name Furazolidone
C.A.S. number 67-45-8

Trade and brand names

Benilen	B-fsudi	Carbopuradin
Coryzium	Dapecfuran	Dectolin
Diafuron	Dialidene	Diarexin
Diarin	Diclofur	Doreplston
Dushel	Enterar	Enteroxon
Foroxon	Foroxone	Framenterol
Ft 15	Furaberin	Furacol I.
Furacort	Furalatin p.	Furalidan
Furaliqua	Furall	Furazol
Furazon	Furovaq	Furox
Furoxal	Furoxane	Furoxon
Furoxona	Furoxona-cp	Furoxone
Furoxone swine mix	Fuvitan	Fuxol
Fuzatyl	Galacid	Gamafur s.
Giardil	Giarlam	Giarlin
Ginvel	Injecur	Intefuran
Kalpec-f	Lacolysat	Mastisept

Product Name Furazolidone

C.A.S. number 67-45-8

Trade and brand names

Medaron	Multi-med 2	Multi-med 3
Multi-med 6	Neforox	Neforox alpha cpto
Neftin	Neftivit	Nf 180
Nicolen	Nicolen r	Nifulidone
Nifulin	Nifuran	Optazol
Parkestress forte	Puradin	Roptazol
Saleton	Scantrimon	Sclaventerol
Sibren	Sirben	Syralbuna
Tetrafur	Tikofuran	Topazone
Tranatogen-ova	Trichofuron	Tricofuron
Tricoron	Trifurox	Ufa-cfo-400
Uterojekt	Vaqifurona	Vetoprim
Viofuraqyn	Vsf-medical q 15	

For regulatory information, see page 133

Product Name Gallopamil

C.A.S. number 1662-47-8

Trade and brand names

Benpredil	Corapamil	Methoxyverapamil
-----------	-----------	------------------

For regulatory information, see page 134

Product Name Gamelonic acid

C.A.S. number 2003-0-1001

Trade and brand names

Efamast	Epogam
---------	--------

For regulatory information, see page 135

Product Name Gemfibrozil

C.A.S. number 25812-30-0

Trade and brand names

Gevilon	Hipolixan	Ipolipid
Lipur	Lopid	Tenorac

For regulatory information, see page 135

Product Name Ginkgo biloba

C.A.S. number 2002-0-1010

Trade and brand names

Tanakan

For regulatory information, see page 137

Product Name Glafenine

C.A.S. number 3820-67-5

Trade and brand names

Adalgur	Disipan	Espasmo-giliganan
Exidol	Glafezon	Glifadex
Glifan	Glifanan	Glifarelux
Osodent	Privadol	

Product Name Glafenine
C.A.S. number 3820-67-5

Trade and brand names

For regulatory information, see page 137

Product Name Glucosamine sulfate
C.A.S. number 3416-24-8

Trade and brand names

Adaxil	Anartril	Antaril
Arthryl	Chitosamine	Corti-anartril
Dona 200-s	Dona compositum	Donna 200
Pona	Terramycin	Terrastatom
Tetracyn	Thiocondramine	Viartril

For regulatory information, see page 138

Product Name Glutethimide
C.A.S. number 77-21-4

Trade and brand names

Alfimid	C "5"	Doriden
Doridene	Doriden-sed	Doridine
Dorimid	Dorimide	Elrodorm
Glimid	Gludorm	Noxyron
Rigenox	Sarodormin	Somid
Tardyl		

For regulatory information, see page 139

Product Name Griseofulvin
C.A.S. number 126-07-8

Trade and brand names

Ansaid	B-qf	Cebutid
Delmoflavin	Delmoflavina	Fluqolin
Flurofen	Froben	Fulcin
Fulcine	Fulcine-125	Fulcine-s
Fulvicin	Fulvicin p/q	Fulvicin u/f
Fulvicina	Fungivin	Gefulvine
Greosin	Grfulvin v	Gricin
Grifulin	Grifulvin	Grifulvin v
Grisactin	Grisaltin	Grisefalin
Griseofulin	Griseofulvin	Griseo
Griseomed	Griseostatin	Grisol
Grisovin	Grisovina	Grisovina fp
Grisovine	Grisovin-fp	Grisowen
Gris-peq	Grysio	Lamoryl
Lamoryl-novum	Lamoyl	Likuden
Likuden m	Microcidal	Neo fulcin
Neo-filcin	Norofluvin	Ocufen
Polygris	Sulvina	

For regulatory information, see page 140

Product Name Halogenated hydroxyquinoline derivatives
C.A.S. number 148-24-3

Trade and brand names

Aci-jel	Benzease	Chinosol
Cp-cap	Dermacid	Dermoplast
Fennosan h 30	Heriat	Hydroxybenoxopyridine
Medicone derma-hc	Oxin	Oxine
Oxykin	Oxyquinoline-rhp	Pedivol
Phenopyridine	Preconsol	Quinoderm
Quinoped	Quinophenol	Recta medicone-hc
Semori	Serohinol	Serorhinol
Superol	Trimo-san	Triva douch powder
Triva jel	Tumex	

For regulatory information, see page 142

Product Name Halogenated salicylanilides
C.A.S. number UN-KG-0034

Trade and brand names

Alamin	Annul	Bada
Hilomid	Salinidol	Temasept

For regulatory information, see page 143

Product Name Heptabarb
C.A.S. number 509-86-4

Trade and brand names

Heptadorm	Medapan	Medomin
Medomina	Medomine	

For regulatory information, see page 144

Product Name Herpes simplex vaccines
C.A.S. number UN-KG-0035

Trade and brand names

Deptavac hvt	Herpevac	Herpevax
Herpevax hvt	Hexidol	Marimune
Taf test	Tracherine	

For regulatory information, see page 144

Product Name Hexachlorophene
C.A.S. number 70-30-4

Trade and brand names

99 armour formula	Acnestrol (broparestrol)	Acnestrol 3
Aeroseb-hc	Akne pyodron kur	Aknefuq
Aknelan	Anacal	Armohex
Asecool	Aserbine cream	Bilevon
Bilvon vet	Bismodyne	Cidal
Cinthol	Clenisep	Coopaphene
Cordocel-h	Cotofilm	Cresophene
Delta pimafucort	Derivative	Derl
Derma 10	Derma leaf	Dermaxex
Dermohex	Dermolle	Dexolan

Product Name	Hexachlorophene	
C.A.S. number	70-30-4	
Trade and brand names		
Dial toilet soap	Distocid	Dk 2
Dovaso	Ecto pellicur	Ectofum
Emlab	Exofene	E-z scrub
Fisohen	Fisohexx	Fitty derm
Flenapthol	G-11	Gamophen
Gamophen surgical soap	Germibon	Gill soap
Haemovin	Hcp	Heksaden
Hepadist	Hexabalm	Hexadespon
Hexal	Hexaph	Hexaphenyl
Hexaphenyl(1&b)	Hexascrub	Hexocreme
Hexosan	Hex-o-san	Jabon antiseptico
Kalacid	Lf 530	Loftyzon
Mamex	Mantacido	Med liquide san t
Micoqamma	Nabac	Nestosyl
P 47	Paradentol	Permucal
Phaisohex	Phasca	Phiso scrub
Phisodan	Phisohex	Phisohex(winthrop)
Phiso-med	Phisoscrub	Phlebodine
Phorac	Phosohex	Predekzem
Pre-op	Pretulon	Proct anex
Prodermopur	Sapo-chlor	Sapoderm
Sebbafon	Sebo-cds	Serqi-cen
Skrub kreme	Solu-heks	Soy-dome
Steraskin	Steridermis	Steridermis washing cream
Ster-zac	Ster-zac antibacterial shaving foam	Ster-zac antibacterial soap
Ster-zac dc skin cleanser	Ster-zac powder	Sumasept
Super sat	Surq salve	Surge vet
Surqi-cen	Surofene	Tersaseptic
Toracsol	Torbetol lotion	Vanseb
Vetalderm	Vulnusol spray	Wesco hex
Wescohex	Westasept	Xerac
Zalpon	Zalpon antibacterial washing cream	

For regulatory information, see page 145

Product Name	Hexestrol	
C.A.S. number	5635-50-7	
Trade and brand names		
Dihydrodiethylstilbestrol	Synoestrolum	

For regulatory information, see page 145

Product Name	Hexobarbital	
C.A.S. number	56-29-1	
Trade and brand names		
Citodon	Citopan	Cyclonal
Cyclonal sodium	Cyclopan	Dorico
Dorico soluble	Eviderm	Evipal
Evipal sodium	Evipan	Evipanl
Hexanal	Hexanastab	Hexanastab oral

Product Name Hexobarbital**C.A.S. number** 56-29-1**Trade and brand names**

Hexatrol	Hexenal	Methexenyl sodium
Narcosan soluble	Noctivane	Noctivane sodium
Privenal	Sleepwell	Sodium narcosate
Sombucaps	Sombulex	Somnalert
Stodinox	Tobinal	Toleran

For regulatory information, see page 146**Product Name** Hyaluronidase**C.A.S. number** 9001-54-1**Trade and brand names**

Diffusin	Hylase
----------	--------

For regulatory information, see page 147**Product Name** Hydroquinone**C.A.S. number** 123-31-9A**Trade and brand names**

Aida	Ambi- skin tone	Artra
Black and white	Creme des 3 fleur d'orient	Eldopaque
Eldopaque forte	Eldoquin	Eldoquin forte 4% cream
Epocler	Esoterica	Esoterica facial
Esoterica regular	Esoterica sensitive skin	Esoterica sunscreen
Melanex	Melanex topical sollution	Melpaque hp
Melqui hp	Neostrata aha gel	Neostrata hq
Nuquin hp	Phiaquin	Pigmanorm
Porcelana	Sinquin	Solaquin
Solaquin forte	Solaquin forte sun bleaching	Superfade aqe spot
Ultraquin	Ultraquin plaine	

For regulatory information, see page 147**Product Name** Hyoscine methonitrate**C.A.S. number** 6106-46-3**Trade and brand names**

Mescomine	Mesconit	Skopolate
Skopyl	Skopyle	Viscope

For regulatory information, see page 148**Product Name** Ibuprofen**C.A.S. number** 15687-27-1**Trade and brand names**

Abbifen	Abuprohm	Abu-tab
Aches-n-pain	Acril	Actifen
Actiprofen	Actren	Addaprin
Advil	Advil 200 mg	Advil cold & sinus
Agisan	Aktren	Aldospray
Algiasdin	Algifor	Agisan
Algofen	Algofer	Altior
Amersol	Anadin ibuprofen	Analgesico

Product Name	Ibuprofen	
C.A.S. number	15687-27-1	
Trade and brand names		
Analgil	Analqyl	Anco
Andran	Anflagen	Antalgil
Antiflam	Antiruqqen	Apo-ibuprofen
Apsifen	Arfen	Artofen
Artren	Artril	Artrofen
Bayer select	Bayer select ibuprofen pain reliever	Benfloqin
Betaqesic	Betaprofen	Brofen 200 mg
Brofen 400 mg	Brufanic	Brufen
Brufert	Brufort	Buborone
Bufedon	Bufigen	Burana
Butylenin	Cesra	Children's advil
Children's motrin	Coadvil	Codafen
Codafen continus	Contraneural	Contrneural
Cope	Cuisialiqil	Cunil
Cuprofen	Danilon	Dansida
Dentiqoa	Dentiqoa forte	Dignoflex
Dimetap sinus	Dimidon	Dismenodl n
Dolqirit	Dolqit	Dolocyl
Dolo-dolqit	Doloqesic	Dolo-neos
Dolo-puren	Doltibil	Dolven
Donjust-b	Dorival	Dristan sinus
Duradyne	Dura-ibu	Duralbuprofen
Dysdolen	Ebufac	Ecoprofen
Ediluna	Emodin	Epobron
Esprenit	Evasprin	Excedrin ib
Exidol	Exneural	Femafen
Femapirin	Femidol	Fenalqic
Fenbid	Fenlong	Flubenil
Focus	Genpril	Guildprofen
Halprin	Haltran	Ibenon
Ibol	Ibosure	Ibruthalal
Ibu-atritin	Ibucasen	Ibu-cream
Ibufac	Ibufen tablets	Ibufen-l
Ibufuq	Ibuqel	Ibuqesic
Ibuhexal	Ibular	Ibulav
Ibuleve	Ibulqan	Ibumetin
Ibuphloqont	Ibupirac	Ibuprin
Ibuprocin	Ibuprofen 200	Ibuprohm
Ibu-slo	Ibu-slow	Ibusure
Ibu-tab	Ibutad	Ibutid
Ibutop	Ibuvivimed	Ibux
Imben	Imbun	Inabrin
Incefal	Inflam	Inoven
Inza	Ipren	Iproben
Irfen	Isdol	Isisfen
Junifen	Kalma	Kos
Lacondan	Lamidon	Leonal
Librofem	Librofen	Lidifen
Liptan	Lisi-budol	Medipren

Product Name **Ibuprofen**
C.A.S. number **15687-27-1**

Trade and brand names

Mediprofen	Melfen	Menado ibuprofen usp
Midol	Midol 200 advanced pain formula	Midol ib
Miqrafen	Minadol	Mobilat
Moment	Motrin	Motrin ib
Myprodol	Narfen	Neobrufen
Neobrufen	Nerofen	Niapren
Nobfelon	Nobfen	Novaprin
Novoqent	Novoprofen	Nu-ibuprofen
Nuprin	Nurofen	Optalidon
Optifen	Opturem	Pacifene
Padudent	Pamprin	Pantrop
Parsal	Paxofen	Pediaprofen
Pfeil	Phor pain	Posodolor
Proflex	Prontalgin	Rafen
Rebuqen	Recudik	Relcofen
Rheufen	Rimafen	Rofen
Roidenin	Rufen	Saleta
Saleta-600	Seclodin	Sedaspray
Serviprofen	Sine-aid ib	Solufen
Spedifen	Stadasan	Superior pain medicine
Supreme pain medicine	Supren	Suspren
Tabalon	Tempil	Tendar
Todalqil	Trauma-dolgit	Ultraprin
Urem	Valprin	

For regulatory information, see page **148**

Product Name **Indalpine**
C.A.S. number **63758-79-2**

Trade and brand names

Lm 5008	Upstene
---------	---------

For regulatory information, see page **149**

Product Name **Indometacin and indometacin farnesil**
C.A.S. number **53-86-1**

Trade and brand names

Arqan

For regulatory information, see page **149**

Product Name **Indoprofen**
C.A.S. number **31842-01-0**

Trade and brand names

Bor-ind	Endyne	Fenint
Flogosan	Flosin	Flosine
Flosint	Flosyn	Isindone
K 4277	Miantor	Praxis
Reumofene		

For regulatory information, see page **150**

Product Name Iodinated casein strophanthin (neo-barine)
C.A.S. number UN-KG-0038

Trade and brand names

Coratose

For regulatory information, see page 150

Product Name Iproniazid
C.A.S. number 54-92-2

Trade and brand names

Euphozid	Ipropran	Isotamine
Laniazid	Marsilid	Nydrazid
P-1-n forte	Pms isoniazid	Rifamate
Rimactane	Rimifon	Ro 7-1554
Teebaconin	Triniad	Uniad

For regulatory information, see page 151

Product Name Isaxonine phosphate
C.A.S. number 4214-72-6

Trade and brand names

Nerfactor	Verfactor
-----------	-----------

For regulatory information, see page 151

Product Name Isocarboxazid
C.A.S. number 59-63-2

Trade and brand names

Enerzer	Marplan	Marplon
Ro 5-0831/1		

For regulatory information, see page 151

Product Name Isoprenaline
C.A.S. number 7683-59-2

Trade and brand names

Aerolone	Aerotrol	Afdosa
Aldo asma	Aleudrin	Aleudrina
Aludrin	Anthastmin	Asmadren
Asmalar	Asmastop	Atom-asma
Bellasthman	Dey-dose	Dispos-a-med
Duo-autohaler	Duo-medihaler	Dyspnoesan
Erydin	Euspiran	Frenal compositum
Imuprel	Ingelan	Intal compositum
Iprenol	Iso-autohaler	Isomenyl
Isonorin	Isoprel	Isoprel-neomistometer
Isoprop	Isorenin	Isovon
Isuprel	Katwilon n	Lenoprel
Luf-iso	Medihaler-duo	Medihaler-iso
Meterdos-iso	Neo epinine	Nephenalin
Norisodrin aerotol	Norisodrin with calcium iodide	Norosodrine
Novodrin	Older	Orotenol
Prenomiser	Propynalin	Protenol
Saventrine	Sedantosol	Sooner

Product Name Isoprenaline

C.A.S. number 7683-59-2

Trade and brand names

Suscardia	Vapo-iso	Vapo-n-iso
-----------	----------	------------

For regulatory information, see page 152

Product Name Isotretinoin

C.A.S. number 4759-48-2

Trade and brand names

Accutane	Accutane roche	Apsor
Isotretinoin	Neovamin a acid	Neovitamin a acid
Ro 4-3780	Roaccutan	Roaccutane
Roacutan		

For regulatory information, see page 152

Product Name Isoxicam

C.A.S. number 34552-84-6

Trade and brand names

Floxicam	Maxicam	Pacy
Pacyl	Vectren	

For regulatory information, see page 154

Product Name Kaolin

C.A.S. number 1332-58-7

Trade and brand names

Biskapect	Chloropect	Collodyne
Diaquard forte	Diastat	Donnaqel
Donnaqel pq liquid	Donnaqel-mb	Donnaqel-pq
Enterosan	Fissan	Kaodinnon-narcotic
Kaolin w/pectin	Kaomagma with pectin	Kaomycin
Kaoneo	Kaopectate	Kaopectate n
Kaoprompt-h	Kao-spen	Kapetolin
Kc	Kln	Medipect
Noventerol	Parepectolin	Pectolin
Pectrolyte	Peterpect	Streptomagma

For regulatory information, see page 154

Product Name Kebuzone

C.A.S. number 853-34-9

Trade and brand names

Benior	Chebutan	Chepirol
Chetazol	Chetazolidin	Chetil
Chetopir	Chetosol	Copirene
Ejor	Gammachetone	Hichillos
Kentan	Kentan-s	Kenta-s
Kenzon r	Ketanol	Ketazon
Ketazone	Ketobutane-jade	Ketofen
Neo-panalgyl	Neufenil	Neuphenyl
Pecnon	Phloguron	Recheton
Reuchetal	Reumo	Tkb

Product Name Kebuzone
C.A.S. number 853-34-9

Trade and brand names

Vintab Vintop

For regulatory information, see page 155

Product Name Ketoconazole
C.A.S. number 65277-42-1

Trade and brand names

Cerozalol	Cetonax	Fetonal
Fungarest	Fungarol	Fungo-hubber
Ketocidin	Ketoderm	Ketoisdin
Ketonan	Ketoral	Micoral
Micotek	Micoticum	Nizcrem
Nizoral	Nizoral 2% shampoo	Nizoral 20% cream
Nizovules	Nizshampoo	Oromycosal
Oronazol	Panfungol	Rofenid
Spike	Unidox	

For regulatory information, see page 156

Product Name Latamoxef
C.A.S. number 64952-97-2

Trade and brand names

Baxal	Betalactam	Festamoxin
Latoxacet	Mactam	Moxacef
Moxalactam	Moxam	Moxatres
Oxacef	Priollat	Sectam
Shiomalin	Shiomarin	

For regulatory information, see page 158

Product Name Lead oxide and lead salts
C.A.S. number UN-KG-0040

Trade and brand names

Hiroval Wndomethasone

For regulatory information, see page 159

Product Name Levacetylmethadol
C.A.S. number 34433-66-4

Trade and brand names

Levomethadylacetate Orlaam

For regulatory information, see page 159

Product Name Levamfetamine
C.A.S. number 156-34-3

Trade and brand names

Amphedrine-m Cydril

For regulatory information, see page 159

Product Name Levamisole hydrochloride
C.A.S. number 16595-80-5

Trade and brand names

Vermisol

For regulatory information, see page 160

Product Name Levarterenol
C.A.S. number 51-41-2

Trade and brand names

Adrenor

Levophed

Noradrec

Xylotox

For regulatory information, see page 160

Product Name Lindane
C.A.S. number 58-89-9A

Trade and brand names

Benhexachlor

Gamex

Gamma benzene

Hexachloride

For regulatory information, see page 161

Product Name Lipoic acid
C.A.S. number 1077-28-7

Trade and brand names

Liposan

Thioactacid

For regulatory information, see page 162

Product Name Loperamide
C.A.S. number 53179-11-6

Trade and brand names

Amerol

Ami-29

Arret

Blox

Brek

Colifelin

Colifilm

Diareze

Dissenten

Dissenter

Duplibiot

Elcoman

Firtasec

Fortasec

Imodium

Imosec

Lopemid

Lopemin

Loperam

Loperan

Loperin

Lopermid

Loperyl

Motilix

Orulop

Pf 185

Pricilone

R-18553

Regulan

Regulane

Seldiar

Suprasec

Taquinol

Tebloc

Telboc

Totrtasec

For regulatory information, see page 162

Product Name L-Tryptophan
C.A.S. number 73-22-3

Trade and brand names

Ardeytopin

Kalma

Optimax

Sedanact

Tryptan

For regulatory information, see page 164

Product Name Lynestrenol
C.A.S. number 52-76-6

Trade and brand names

Anacyclin	Anacycline 101	Anacylin
Anacylin 101	Anacylin 28	Ancylin
Athilyn	Endometril	Exlutena
Exlution	Exluton	Exluton (a)
Exlutona	Fysioquens	Fysioquens
Fysionorm	Fysioquens	Gestrol
Lindiol 2.5	Lyn_ratiopharm	Lyn_ratiopharm_sequenz
Lyndeol	Lyndile tt	Lyndiol
Lyndiol e	Lyndiol e.	Lyndiolett
Lynoenstrenol	Lyn-ratiopharm	Minette
Mini pregnon	Minifol	Minilyn
Ministat	Neo lyndiol	Neo-lindiol
Neo-lynobol	Nonovulet	Noracyclin
Noracyclin 22	Noracycline	Normophasic
Novostat	Orq 485-50	Orgaluton
Orgametil	Orgametril	Orgametrol
Ovamezzo	Ovanon	Ovanone
Ovanon-e	Ovariostat	Ovoresta
Ovoresta m	Ovoresta micro	Ovosta
Ovostat	Ovostat-28	Ovostat-micro
Phasicon	Physiostat	Physistat
Pregnon	Pregnon-28	Restovar
Yermonil		

For regulatory information, see page 166

Product Name Mazindol
C.A.S. number 22232-71-9

Trade and brand names

Dasten	Deqonon	Faqolipo
Lipese	Maqrilan	Mazanor
Mazanor tablets	Mazeldene	Mazinil
Maznor	Sanorex	Tenorac
Terenac	Teronac	

For regulatory information, see page 166

Product Name Meclozine
C.A.S. number 569-65-3

Trade and brand names

Ancolan	Ancoloxin	Ancoloxine
Antivert	Bonamina	Bonamine
Bonine	Calmonal	Chiclida
Cobinamide	Diadril	Dradril
Duremesan	Itinerol	Mecazine
Navicalm	Neo-istafenc	Neo-istafene
Peremesin	Postafen	Postafene
Premesin	Ravelon	Rovert-m
Ru-vert-m	Sabari	Sea-leg
Supermesin	Superminal	Suprimal

Product Name **Meclozine**
C.A.S. number **569-65-3**
Trade and brand names

Taizerl	Ucb 5062	V-cline
Veritab	Vertizine	Vomaxine
Vomisseis		

For regulatory information, see page **167**

Product Name **Megestrol acetate**
C.A.S. number **3562-63-8**
Trade and brand names

Citestrol	Co-ervonum	Combiquens
Femaquest	Kombiquens	Megace
Meqecat	Meqeron	Meqestat
Menoquens	Neo-delpregnin	Nia
Niaestine	Niaquestin	Niaquestine
Novaquin	Novokvens	Novolina
Novoquens	Oracolnal	Ovaban
Ovarid	Pallace	Serial 28
Volidan	Volplan	

For regulatory information, see page **168**

Product Name **Mephenesin**
C.A.S. number **59-47-2**
Trade and brand names

Atensin	Avosyl	Bioglan m/q
Cresoxydiol	Curythan	Daserd
Daserol	Decontractyl	Decontractyl
Decontractyl-baum	Diloxol	Dioloxol
Forte	Geno-sal	Glykresinum
Glytol	Glyptol	Kencaps
Kinavosyl	Lissephen	Mefentil
Memphenesin	Mepha-qesic	Mepherol
Mephesin	Mephesol	Mephson
Midisalb-m	Myanesin	Myocalm
Myocuran	Myolisysin	Myoxane
Neo-xoline-m	Nochyrol	Noctynol
Oranixon	Prolax	Relaxar
Relaxil	Relaxil-q	Renarcol
Rhex	Rhex "hobein"	Rp 3602
Salimed compound	Sansdolor	Sinan
Spartoloxyn	Spasmolyn	Stilalqin
Thioxidil	Tolansin	Tolax
Tolcil	Tolhart	Tolosate
Toloxyn	Tolseram	Tolserol
Tolseron	Tolsin	Tolulexin
Tolulox	Tolyspaz	Walconesin

For regulatory information, see page **170**

Product Name	Meprobamate	
C.A.S. number	57-53-4	
Trade and brand names		
3p bamte	Anepromat	Amosene
Anastress	Anatimon	Andaxin
Aneural	Ansietan	Ansiowas
Anzil	Apascil	Apo-meprobamate
Arcoban	Artolon	Atraxin
Ayeramate	Bamo 400	Biobamat
Biobamate	Calmax	Calmiren
Canquil-400	Cap-o-tran	Carb-a-med
Carbaxin	Cirpon	Cirponyl
Clindoorm	Coprobate	Crestanil
Cusitan	Cyrpon	Dapaz
Daritrans	Detensitral	Dicandiol
Diron	Dolovisano	Dormabrol
Dormilfo n	Dystoid	Ecuanil
Edental	Epikur	Equanil
Equiner	Equinil	Equqtrqte
Fas-cile 200	Gadexyl	Gene-bamate
Harmonin	Hartol	Holbamate
Idemin	Indemin	Irs 109 a
Iterco	Juamidon	Kaoloqeais
Kesso-bamate	Klort	Lan-dol
Larten	Lenicor	Lepetown
Libiolan	M.a.s.	M.p. trantabs
Mar-bate	Marqaris	Meditran
Mepantin	Mepavlon	Mep-e
Meposed	Meprate	Mepriam
Meprin	Meprindon	Mepro
Meprobadal	Meprobamat	Meproban
Meprobil	Meprocompren	Meprocon cmc
Meprodil	Meprogesic q	Meprol
Meprolin	Mepron	Mepronel
Mepronil	Meprosa	Mepro-secerqan 400
Meproserpina	Meprospan	Meprospan 400
Meprotabs	Meproten	Meprotil
Meproyrin	Meprozine	Meptran
Meriprobate	Mesmar	Metranquil
Micrainin	Microbamat	Midixin
Milspan	Miltaun	Miltown
Miltown s-r	Misedant	Morbam
My-trans	Neo-nervostal	Neo-tran
Nervonus	Neuramate	Neuro
Neurocalm	Novomato	Novomepro
Nyktoqen	Oasil	Oasil procalmidol
Odsil 10	Panquil	Paxin
Pensive	Pentaneural	Perequil
Pertranquil	Placitate	Pm 2
Pmb 4000	Prequil	Probal
Probasan	Probromato	Procalmidol
Promate	Protran	Psico-retard

Product Name Meprobamate**C.A.S. number** 57-53-4**Trade and brand names**

Quaname	Quanil	Quietidon
Rastenil	Regium	Relaxin
Reostrat	Restenil	Rilax
Robamate	Seda baxacor	Sedanyl
Sedavier	Sedazil	Selene
Selodorm	Serenade	Seril
Setran	Shalvaton	Sintown
Sk-bamate	Sopanil	Sowell
Spantran	Spasmobamat	Stensolo
Stopayne	Tamate	Tcm 200
Tcm 400	Trankilin	Trankvilan
Tranlisant	Tranmep	Tranquil
Tranquilan	Tranquifax	Tranquiline
Trelmar	Tri-reumo-campil	Urbil
Urbilat	Vasocalm	Vio-bamate
Visano cor	Vistabamate	Wescomep

For regulatory information, see page 170**Product Name** Mercuric derivatives (topical)**C.A.S. number** UN-KG-0046**Trade and brand names**

Mercuro clinico	Mercurocol	Neko
-----------------	------------	------

For regulatory information, see page 304**Product Name** Mesna**C.A.S. number** 19767-45-4**Trade and brand names**

Ausobrone	Mexnex	Mistabron
Mistabron co	Mistabronco	Mistalon
Mucofluid	Mucolene	Uromitexan
Uronexitan		

For regulatory information, see page 170**Product Name** Metamfetamine**C.A.S. number** 537-46-2**Trade and brand names**

Amone	Desoxyn	Dexophrine
Dexoval	Doxyfed	Doxyn
Drinalfa	Eroxine	Euphrodinal
Gardstat	Gerobit	Geronyl
Lemobese	Madrine	Mediatric
Meloda	Metamsustac	Methampex
Methedrinal	Methedrine	Neodrine
Neodrine-triple	Norodin	Obedrin-la
Obelones	Obe-slim	Pervitin
Phedrisox	Phelantin	Philopon
Soxympamine	Syndrox	Tonedron

Product Name Metamfetamine
C.A.S. number 537-46-2

Trade and brand names

Uno

For regulatory information, see page 171

Product Name Metamizole sodium
C.A.S. number 68-89-3

Trade and brand names

Abalgine	Acabel compositum	Acefalgin
Acrobal	Acrogesico	Adolkin
Algia-nil	Alginodia	Alginodia compose.
Alqisedal	Alqobuscopan	Alqocalmin
Alqopriv	Alqopyrin	Alqopyriv
Alkozin	Amiglan	Aminocid
Amitralil	Ampi tumisan	Anadex
Analcedor	Analgin	Analginum
Analject	Anarinyl	Anchrina
Andolor	Anespas cpto	Angiter
Ankaljin	An-t	Apasmo
Arantil	Arpf	Arquidon
Artritex	Ascorbalgine	Ascortin
Aseptobron	Atecilina	Atn-020/2
Aureomicina	Avafortan	Ayoral
Baralgín	Baralgine	Bayer 1387
Bebealjin	Bebiqut	Belatropin
Belflex/2	Beneurin	Beserol
Bexopirona	Bioqamma2	Biotangin
Bipasmin compuesto	Bonpyrin	Bort
Bristacilia	Britercina	Bromalgín
Bromalqon	Broncofenil	Broncolysin
Bucarboxal	Buscapina comp.	Buscapina compuesto
Buscapina compuestum	Buscol compositum	Buscopan composto
Buscopan compostum	Buscopina compostum	Butalgine
Butylpan	Byladoce	Calqayan-c
Calmetron	Camizol	Causalon
Cessantyl	Chini-med	Cintaverin compuesto
Citalqan	Clizim	Clofexan
Codalqin	Codasal injetavel	Cofen
Colqenol	Comaril 5000	Conmel
Corilin pediatric	Cortempirol	Cortitracin
Cronopen balsamico	Deltricin	Devalgín
Dexa butarin	Di-bal-rone	Dimethedon
Dinopirina	Dioxadol	Dipiron
Dipirona	Dipirone	Diprofarm
Dipyrivo	Dipyrone	Dispalgine
Divarin	Divarmin	Do-ba-rone
Dobetin	Dolaren	Dolatets
Dolazon	Dolemicin	Dolispan
Dolispasmo	Dolo adamon	Dolo baralgine
Dolo buscopan	Dolo nerv	Dolo neurobion

Product Name	Metamizole sodium	
C.A.S. number	68-89-3	
Trade and brand names		
Dolo neurobion forte	Dolo pangavit	Dolo raptalqin
Dolo spasuret	Dolojudolor	Dolo-neurobion
Dolopirina	Doloscopin	Dopiral
Dorflex merrell	Dorlisin	Doron
Dorscopena	Dorsedin	D-pron
Dumalqin	Duralnordin	Dya-tran
Edgartet	Eespanal	Enzipan combinado
Espasfher	Espasmir	Espasmo-cibalqina
Espasmoqual	Espasmotex	Espasmoviral
Espyre	Farbinol	Farmolisina
Feverall	Fevonil	Flogolisin
Formatrix	G.r. ulix compuesto	Genservet
Gentil	Geralqine	Gifaril
Glutisal	Greplicina belsa	H 116
H 117	H 118	Haqalqin
Hasain	Indextron	Influbene
Kb-502	Kefren	Kesan
Keypyrone	Killgrip	Kipyrone
Kitax alpha	Kitax n	Konitan
Labymetacincpo	Lactmicina	Laqalqin
Laqalqine	Lamprcsnum	Lapalqine
Larq 731	Lasain	Lavaciclina
Levapa	Levismon	Lisador
Lisalqil	Maqdor	Magnalsa
Magnemidon	MaqnoI	Magnopyrol
Mapir	Mecoten	Megal
Melpen	Menalqine	Metapyrin
Methampyrone	Metilon	Mialqan
Minalqin	Minalqine	Minoval
Miocitalqan	Nadalqine	Naftalqin
Naltrium	Napasone	Naron
Nartate	Natralqin	Natric
Neo-melubrim	Neo-melubrin	Neo-melubrina
Neo-melubrine	Neo-oxipen	Neosal-n
Neosoldina	Neuro-fortamin	Nevralqin
Nevralqina	Nisidina	Nlo conicilina balsamica
Nobelqin	Nolotil	Nolotil composirum
Notermin	Novacid	Novalcina
Novaldin	Novalqetol	Novalqin
Novalqin quinine	Novalqina	Novalqine
Nova-lyseen	Novamidazofen	Novamidazophen
Novamideazophene	Novamina	Novaminophenazone
Novaminsulfon	Novaminsulfon ratiopharm	Novaminsulfone sodium
Novaminsulfonium	Novaminsulfonum	Novaminsulton
Novazolon dexametasona	Noveltex	Novemida
Novemina	Novil	Oftlamin
Optalgin	Orphalginen	Ortopirona
Oxiquiunazine	Pabron gold	Panalvon
Panax	Patalgin	Pentrodin

Product Name Metamizole sodium
C.A.S. number 68-89-3

Trade and brand names

Phanalgin	Pharmalgine	Porbiot
Pplan 2500	Probaphen	Prodol
Prydonnal	Pydirone	Pyralgin
Pyralgine	Pyretin	Pyril
Pyrilgin	Pyriligin	Pyrisan
Pyrojec	Quarelin	Reflex rectal
Relexal compuesto	Repriman	Resquim
Rheuma-spalt	Ridol	Rumalisine
Rupalgin	Santeprednisan a	Sebon
Sedabel	Sedarel	Sedarene
Sedazepane	Selpiran	Sertalanalgésico
Severen	Severin	Sinalgex
Sintaverin	Sinvicol	Sistalgin
Spasdolsom	Spaslar	Spasmalgon
Spasmin	Spasmiun-comp.	Spasmizol
Spasmodor	Spasmopyralgin	Spasmothil
Sufonovin	Sulfonovin	Sulpin
Sulpyrin	Sulpyrine	Supadol
Supergine	Surpyrine	Syntaverin
Tanper	Tapal	Teqa-pyrone
Temp	Tempil	Tepal
Termonil	Tetrabal-hosbon	Tetraspasnil
Tiadexol	Tiartan	Toloxin andromaco
Treteron	Triartan	Trinalgin
Tumisan globulina	Ultraqim	Ultraqin
Unagen	Unalgen hc	Vetalgin
Viperone	Visceralgine forte	

For regulatory information, see page 171

Product Name Methapyrilene
C.A.S. number 91-80-5

Trade and brand names

3p pane	Brexin	Conac
Dexapirilene	Dormin	Duohist
Duo-tussin	Dylhista	Histadyl
Histadyl ec	Hitalones	Isopap
Lallamin	Lullamin	M.p.
Methistaline	Methril spansul	M-p
Myci-spray	Norane	Paradormalene
Peral	Placitabs	Pyrahtyn
Pyrinistab	Pyrinistol	Rejam
Rest-on	Restryl	Semikon
Tenalin	Thenylene	Thionylan
W83		

For regulatory information, see page 175

Product Name **Methaqualone**
C.A.S. number **72-44-6**

Trade and brand names

Aqual	Babix-rectal	Bon-sonnilal
Cateudyl	Citexal	Diudorm
Divinoctal	Dormiqoa	Dormiqoa-schlafmittel
Dormir	Dormisedilal	Dormogen
Dormutil	Duromine m 40	Eatan
Fadormir	Holodorm	Hyminal
Hypocol	Hyptor	Hyptor base
Ipnofil	Isonox	Jurmun
Mandrax	Maoa	Melsed
Melsedin	Melsedine base	Melsomin
Mepalqic	Mequal	Mequelon
Mequin	Metadorm	Metakualon
Metakvalon	Metaqualon	Methadorm
Methaquaion	Methaqualoneinone	Methased
Methasedil	Metodril	Metodril 2
Metodril napa	Metolquizolone	Mollinox
Motolon	Mozambin	Mtq
Neuro a2	Nitro-tromacardin	Nobadorm
Nobadorm compostium	Nobedorm	Noctilene
Noctulon	Normi-nox	Normorest
Noxybel	Oblioser	Omnyl
Optimil	Optinoxan	Orthonal
Ortonal	Paldona	Pallidan
Papatral	Parest	Parmilene
Paxidorm	Pexaqualone	Portaderm
Pro dorm	Quaalude	Qz 2
Rebuso	Rectulon	Revonal
Ric 272	Riporest	Rm 526
Rorer 148	Rorer 714	Roulone
Rouqualone	Rovonal	Savedorm
Sedalone	Sedanocit	Sedatyl
Silternum	Sindesvel	Sleepinal
Somberol	Somnafac	Somnex
Somnibel	Somnium	Somnofac
Somnomed	Somnosan	Somnotropon
Sonal	Sopor	Soval
Sovelin	Soverin	Sovinal
Spasmopront	Tiqualone	Toquilone
Toraflo	Toriador	Torinal
Tr 495	Tualone	Tuazole
Tuazolona	Tuazolone	Vitalone

For regulatory information, see page 176

Product Name **Methiodal sodium**
C.A.S. number **126-31-8**

Trade and brand names

Abrodan	Abrodil	Conturex
Diagnorenol	Kontrast	Myelotrast

Product Name **Methiodal sodium**
C.A.S. number **126-31-8**
Trade and brand names

Neo-sombraven	Radiographol	Seqosin
Serqozin	Skiodan sodium	Urombal

For regulatory information, see page **177**

Product Name **Methylphenidate**
C.A.S. number **113-45-1**
Trade and brand names

4311 ciba	Calocain	Centedrin
Cetedrin	Meridil	Methidate
Ritalin	Ritalin sr	Ritaline
Rubifen		

For regulatory information, see page **177**

Product Name **Methyprylon**
C.A.S. number **125-64-4**
Trade and brand names

Noludar	Nolurate
---------	----------

For regulatory information, see page **178**

Product Name **Metofoline**
C.A.S. number **2154-02-1**
Trade and brand names

R 4-1778/1	Versidyne
------------	-----------

For regulatory information, see page **179**

Product Name **Mianserin**
C.A.S. number **24219-97-4**
Trade and brand names

Athimil	Athymil	Bolvidon
Lantanon	Lerivon	Miansan
Norval	Orq qb 94	Tolvin
Tolvon		

For regulatory information, see page **180**

Product Name **Mifepristone**
C.A.S. number **84371-65-3**
Trade and brand names

Mifeqyne	Ru-486
----------	--------

For regulatory information, see page **181**

Product Name **Miglustat**
C.A.S. number **72599-27-0**
Trade and brand names

Vevesca

For regulatory information, see page **181**

Product Name Minocycline

C.A.S. number 10118-90-8

Trade and brand names

Klinomycin	Lederderm	Mino-50
Minocin	Minomycin	Mynocine

For regulatory information, see page 182

Product Name Misoprostol

C.A.S. number 59122-46-2

Trade and brand names

Cyprostol	Oxaprost	Prostalgin
-----------	----------	------------

For regulatory information, see page 182

Product Name Mofebutazone

C.A.S. number 2210-63-1

Trade and brand names

Arcobutine	Arcomonol	Buta lyseen
Butazone	Chemiartrrol	Clinit
Diadin	Fenartril	Jovapyrin
Mobutazone	Mobuzon	Mofasal
Mofesal	Monazan	Monazone
Monbutina	Monobutina	Monobutyl
Monofen	Monomil	Monoprine
Monorheumetten	Monozon	Mozol
Reumatox	Rheuma	Rheuma-cur
Rheumaorctat	Rivodol	Sodepyrine b 1

For regulatory information, see page 182

Product Name Nabilone

C.A.S. number 51022-71-0

Trade and brand names

Cesamet

For regulatory information, see page 185

Product Name Nandrolone decanoate (injectable)

C.A.S. number 360-70-3

Trade and brand names

Abolon	Activin	Anabolin la 100
Anador	Anadur	Analone-50
Androlone d	Androlone d 100	Androlone d 50
Decabolin	Deca-durabol	Deca-durabolin
Deca-durabolin decanoate	Deca-hybolin	Deca-noralone
Docabolin	Durabol	Durabolin
Fherbolico	Fortabolin	Hybolin-decanoate
Iebolan	Kabolin	Keratyl
Methybol	Methybol-depot	Nandrolone decanoate
Nordecon	Retabolil	Stenabolin
Sterobolin	Turinabol-depot	

For regulatory information, see page 186

Product Name Nandrolone phenylpropionate (injectable)
C.A.S. number 62-90-8

Trade and brand names

Activin	Anabolicas	Anabolicus
Anabolin depot	Anabolin Ia-100	Anador
Anadur	Androline	Androlone
Androlone-d	Anticatabolin	Bexobolic
Deca-durabol	Decadurabolin	Deca-durabolin
Docabolin	Durabolin	Durabolin phenpropionate
Dynabalon	Energital	Fenobolin
Fherbolico	Fts	Hepa-obaton
Hybolin decabiate	Hybolin improved	Kabolin
Keratyl	Kompleteron	Menidrabol
Methybol-depot	Nandrobolic	Nandrolin
Neo-durabolic	Nerobil	Nerobolil
Nerobolin	Neurosteron	Norabol
Noralone	Norandrol	Norandros
Noromon	Norstenol	Nortesto
Npp	Ntpp	Orgabolin
Phenobolin	Sintabolin	Stenabolin
Strabolene	Superanabolon	Superbolin
Suprabolin	Turinabol	

For regulatory information, see page 186

Product Name Nefazodone
C.A.S. number 2004-0-0008

Trade and brand names

Serzone

For regulatory information, see page 187

Product Name Neomycin sulfate
C.A.S. number 1405-10-3

Trade and brand names

Abilene	Akentect	Amcort
Amphocort	Antibitulle	Apokalin
Aurex	Auriod	Baneopol
Barriere-mycin	Bastu-angin	Bedermin 100
Benestermycin	Bio hubber	Biodry
Biofradin	Biofur	Biosol
Biosol-m	Bio-vitastrept	Bivacyn
Blastoestimulina	Bykanula	Bykomycin
Canaural	Canoral	Cebemyxine
Cefrocyn	Cq 3224	Cicatrex
Cleniderm	Conderm	Conjuctilone
Cornemin	Cortinen	Damapo
Davimycin	Degramycin	Derbitan antibiotico
Dermicema	Dermo sonerge	Dermoface
Dermosan	Dermovate-nn	Derobion
Dexaamisolone-n	Dexabiotan	Dexacidin
Dexamist	Dexavetaderm	Diacin
Dia-ject	Diarest	Dicortineff

Product Name	Neomycin sulfate	
C.A.S. number	1405-10-3	
Trade and brand names		
Dienterol	Dimicina	Doreplaston/doser/f
Dorithicin	Dulcicortine	Duphacerate
Dv 201	Emcortina	Emorex k berna
Enbacin	Endomixin	Enteromac
Enteropast	Enterosintex	Eustoporin
Extracort	Febrizene	Fissan
Fl 6321 n	Floqocid	Fluonid
Fml-neo-liquifilm	Foille	Forbesotic
Formula 888	Forte	Forticillin
Fradyl	Frakidex	Frakitacine
Gastromycin	Gregoderm	Gustibon
H plus n	Hagrosept	Halicomb
Haloq	Heliomycort	Hydrocortiderm
Hydro-neo oculos	I-caps	Idepa
Ido-op	Intradermo caf	Iodentero0neomicina
Itro	Jenomycin	Kaomycin
Kaopectate n	Kortikiod mepha	Lanbiotic
Larmicin	Latodurin	Linitut
Locorten	Mammanopen	Mastrinal
Medisec neo	Medisec-cloxa	Medri-biotic
Meimyd	Menaderm antiacne	Myacyne
Mycerin	Mycidex	Mycifradin
Myciquent	Mycimist	Mycipo
Mytrex	Nasomixin	Naso-neomicin
Nasydrin	Nefluan	Neimicina roqer
Neo decaderm	Neo-analsona	Neoaristovet
Neobacimyx-h	Neobicin	Neobiotic
Neobrettin	Neobristan	Neo-cantil
Neocidin	Neocillin	Neoclox
Neocones	Neodecasona	Neo-delta-cortef
Neofluid	Neo-hydro	Neointestin
Neolate	Neo-m	Neomac
Neo-mantle	Neo-mastitar	Neomin
Neomix	Neomycane	Neo-myx
Neo-otosol-hc	Neopec	Neopenol
Neopt	Neo-remusin	Neostrep
Neosule	Neosulf	Nifuramicin
Nisocla	Nisoclyn	Nisodyn
Nivemycin	Nodryl	Nokamycin
Noperil	Normoc	Npa
Ophthlmycin	Optiprime ophthcoat	Optison
Optisone	Oribiotic	Oterna
Oticair	Oto vitna	Otocortison
Oto-flunal	Otomycin	Oto-sinerbe
Panotile	Paralen	Parkeole
Parkesteron	Pentalmicina	Pervet
Phytacorcin	Pivalone	Polemycin
Polybactrin-g	Polydexa	Polygynax
Poly-pred	Polyspecrin	Porcijec

Product Name Neomycin sulfate
C.A.S. number 1405-10-3

Trade and brand names

Prednicidin	Prevotec	Propaderm-n
Pulveodil	Pyocidin hc	Quadrex
Renokab	Rino	Rino vitna
Rinofilax	Rinojet	Rovicine
Saleton	Salvacolina nn	Sanibiovit
Sanimix	Sanistress	Secantol
Septa	Septomixine forte	Silderm
Siquent neomycin	Sofan	Sorbitoxin
Spersapolymyxin dispersa	Steros-anal	S-thalmic
Stiedex	Sulfix-6	Super masticort
Super mastitare	Synalar polyvalent	Syralbina
Tampovaqan	Tariston	Telestyl
Tiframild	Tobispray	Topicon
Topitasico	Tresaderm	Tribiotic
Tri-bow	Tricilone	Tri-optics
Troc	Trofodermin	Tweenal
Ubrocelan	Ucb 630	Uniriod
Uro-beniktol	Uro-nebctin	Varicella-rit
V-cortanmycetine	Vetroyl	Vetsovate
Vista-methasone n	V-softa	

For regulatory information, see page 187

Product Name Nevirapine
C.A.S. number 129618-40-2

Trade and brand names

Nevimune Viramune

For regulatory information, see page 188

Product Name Nialamide
C.A.S. number 51-12-7

Trade and brand names

Espril	Nialamid	Niamid
Niamidal	Niamide	Niaquital
Niaquitol	Niazin	Novazid
Nuredal	Nyazin	Psyco-retard
Surqexl		

For regulatory information, see page 188

Product Name Nimesulide
C.A.S. number 51803-78-2

Trade and brand names

Nimulid

For regulatory information, see page 189

Product Name Nitrefazole
C.A.S. number 21721-92-6

Trade and brand names

Product Name Nitrefazole
C.A.S. number 21721-92-6
Trade and brand names
 Altimol Emd 15700

For regulatory information, see page 190

Product Name Nitrofurural
C.A.S. number 59-87-0

Trade and brand names

Acmor	Acmor-s	Acutol
Akutol	Aldomycin	Alfucin
Amifur	Anginofur	Auroid
Babrocid	Beca furazona	Bifuran
Burnazone	Chemofuran	Coxistat
Dermobion	Dymazone	Ectofural
Escofuran	Escofuron	Fluorobiotal
Fultrexin	Fura	Furacilinum
Furacin	Furacinas	Furacine
Furacinethin	Furacinetten	Furacin-sol
Furacin-streusol	Furacoccid	Furacocid
Furacol	Furaderm	Furaldon
Furalone	Furan	Furan-ofteno
Furaplast	Furaseptin	Fura-septin
Furaskin	Fura-vet	Furazin
Furazina	Furazol w	Furea
Furesan	Furesol	Furosem
Furotalqin	Furovol	Germax
Germex	Ginejuvent	I fomula
Ii fomula	Kamfomen	Kindroq
Lifuzol	Macmiror	Mammex
Mammiject	Mastidol	Mastofuran
Muldacin	Nefco	Neovaqon
Nfs	Nfz 1	Nfz mix
Nifucin	Nifuzon	Nitocetin
Nitrocol plus	Nitro-rea	Nitrozone
Notaba	Rivafurazon	Sanifur
Scandantin	Shield	Sulfamyton-n
Taristop	Tranoxa	Tuocurine
Urafadyn	Uroletten	Vabrocid
Viropulver	Yalrocin	Yatrocin
Zoppin spray blu		

For regulatory information, see page 190

Product Name Nitrofurantoin
C.A.S. number 67-20-9
Trade and brand names
 Furan Nitrofan

For regulatory information, see page 191

Product Name Nitroxoline
C.A.S. number 4008-48-4

Trade and brand names

5-nitrok	Dovenix	Entercol
Enterocol	Isinok	Nibiol
Nicene	Nikinol	Nikopet
Noxibiol	Noxine	Trodax
Uritrol	Urocoli	Uro-coli

For regulatory information, see page 191

Product Name Nomifensine
C.A.S. number 24526-64-5

Trade and brand names

Alival	Anametrin	Caribium
Hoe 984	Hostalival	Merital
Merival	Musettamycin	Neurolene
Nomival	Psicronizer	Psyton

For regulatory information, see page 192

Product Name Norethisterone enantate (injectable)
C.A.S. number 3836-23-5

Trade and brand names

Binovum	Brevicon	Brevinor
Conceplan	Doryxas	Gesta plan
Lq 335	Medicon	Menonorm
Menophase	Miconor	Modicon
Neocon	Nor 50	Noriday
Noriquest	Norimin	Noristerat
Norlutate acetate	Nor-q-d	Norquentiel
Norquest fe	Novulon	Nur-isterate
Orlestrin	Ortho-novum	Ovcon-50
Ovismen	Ovosiston	Ovysmen
Primolut	Tri-norinyl	Utovlar

For regulatory information, see page 192

Product Name Noscapine
C.A.S. number 128-62-1

Trade and brand names

Bequitussin	Bisolvon compositum	Broncha-tulisan eucalyptol
Broncho-tulisan eucalyptol	Brosolin-rectocap	Capval
Codipect	Codyl	Codyl cum expectoras
Coscopin	Coscotab	Deqoran
Dettuso	Difimetus	Difimetus compositum
Finipect	Hederix	Lyabex retard
Lyobex	Narcotussin	Nipaxan
Nipaxon	Nitepax	Nosaclin
Noscalin	Noscapal	Noscapect
Noscarex	Noscatuss	Reatos
Rectolmin bronquial	Ribelfan	Spasmofen
Stilco	Teletux	Tucotin

Product Name **Noscapine**
C.A.S. number **128-62-1**
Trade and brand names

Tuscapin	Tussamine plus	Tussanil n
Tusscalman	Tussicure	Tussisedal
Tussoretard		

For regulatory information, see page **193**

Product Name **Novobiocin**
C.A.S. number **303-81-1**
Trade and brand names

Albamycin

For regulatory information, see page **194**

Product Name **Opium in antitussive preparations**
C.A.S. number **8008-60-4**
Trade and brand names

Dia-quel	Escopon	Ka-thal-pec
Pantopon	Pat	

For regulatory information, see page **195**

Product Name **Oxyphenbutazone**
C.A.S. number **129-20-4**
Trade and brand names

Alqi-tandril	Anarreumol-b	Artroflog
Artzone	Butaflogin	Butapirone
Butazonic	Buteril	Butilene
Californit	Campozim	Crovaril
Defolqin	Difmedol	Dolo-phlogase
Dolo-tandril	Fibutrox	Flanaril
Floqhene	Flogistin	Floqitolo
Flogodin	Flogoril	Gp 40705
Iltazon	Iltaxon	Imbun
Inflamil	Iridil	Isobutil
Kymalzone	Metabolite i	Mindaril
Miyadril	Mysite	Neo-farmadol
Offitril	Oflamin	Optimal
Otone	Oxalid	Oxybutazone
Oxybutol	Oxybuton	Oxyperol
Oxyphenbutone	Oxyphentamin	Phlogase
Phlogistol	Phlogont	Phloquran
Pilabutina	Piraflogin	Rapostan
Realin	Rheumapax	Rumapax
Sequdol	Suganril	Tanal
Tandacot	Tandalqesic	Tandearil
Tanderil	Telidal	Tendearil
Teneral	Vefren	Visubutina

For regulatory information, see page **197**

Product Name Oxyphenisatine acetate
C.A.S. number 115-33-3

Trade and brand names

Acelax	Acetalax	Alophen pills
Ameiax	Api-slender	Artroflog
Artzone	Belloform	Biivectan
Bisflatan	Boxoqetten	Brocatine
Buta pirone	Butaflogin	Buteril
Butilene	Butofen	Butolfen
Bydolax	Californit	Chlofel
Chur-lax	Ciracen	Cirotex
Cirotyl	Contax	Critex
Curolax	Darmoletten	Deililax
Dialose plus	Diasatin	Ditinil
Ditmedol	Esotabs	Eulaxin
Evac-u-gen	Evac-u-lax	Ex-lax
Ex-lax pills	Febutolo	Fenisan
Fibutrox	Fim-a-mint	Fin-a-mint gum
Fisiolax	Flib 518	Floqistin
Flogitolo	Flogodin	Imbun
Inlax	Ipebutona	Iridil
Isaaxan	Isacen	Isaphen
Isaphenyn	Isobutil	Isocrin
Izaman	La 96	Lavema
Laveman	Laxan-vomoxin	Laxaseptol
Laxem	Laxnormal	Laxocol
Laxocoleva	Laxo-isatin	Laxon
Laxos	Laxyl	Lisaqal
Med-laxan	Menabil complex	Muxol
Naleran	Neocervulax	Neo-favmadol
Neo-soldana	Nourilax	Nurilaksi
Obstilax	Otone	Oxalid
Oxibutol	Oxybutazone	Phenlaxine
Phenolax	Phlogase	Phlogistol
Phloqont	Piraflogin	Polifloqil
Potsilo	Promassolax	Promassoletten
Prulet	Prulet liquitab	Prusol
Puraqaceen	Purgaceen	Purgophen
Rapostan	Regal	Rheumapax
Rivolax	Rumapax	Sanapert
Schokilax	Syndian	Tandacote
Tandalqesic	Tandearil	Tanderil
Tanderil-alka	Tete-lax	Validil
Veripaque		

For regulatory information, see page 199

Product Name Oxytocin
C.A.S. number 50-56-6

Trade and brand names

Oxytocin Pituitrin

For regulatory information, see page 201

Product Name Oxytocin
C.A.S. number 50-56-6

Trade and brand names

Product Name Paracetamol
C.A.S. number 103-90-2

Trade and brand names

Anacin Crocin Tylenol

For regulatory information, see page 201

Product Name Paromomycin
C.A.S. number 7542-37-2

Trade and brand names

Gabbroral Humaqel Humatin
 Sinosid

For regulatory information, see page 202

Product Name Pectin
C.A.S. number 9000-69-5

Trade and brand names

Adm	Arhemapectin	Astriharina s
Betaine digestive aid	Bio hubber	Bio hubber fuerte
Biskapect	Chloropect	Collodyne
Dexinca	Diacalm	Diaquard
Diaquard forte	Diareze	Diarrhosan d
Diastat	Diban	Diban diet complex 1500
Diet-trim	Donnaqel	Donnaqel
Donnaqel pq capsule	Donnaqel-mb	Donnaqel-pq
Enterolyte	Estreptopectil	Estreptonetrol
Estreptoral	Estreptosirup	Fiblet
H.e.c	Humaqel	Kantrexil
Kaomagma	Kaomagma with pectin	Kaomycin
Kaoneo	Kaopectate	Kaopectate n
Kaopectin	Kaoprompt-h	Kao-spen
Kaostaten	Kln	Medipect
Neopec	Norquinol	Noventerol
Orahesive	Parepectolin	Pectiqels
Pectolin	Pectrolyte	Peterpect
Pomana a	Salvacolina nn	Sorbitoxin
Streptomagma	Varihesive	

For regulatory information, see page 203

Product Name Pentazocine
C.A.S. number 359-83-1

Trade and brand names

Fortagesic	Fortal	Fortalgesic
Fortral	Fortralin	Fortwin
Liticon	Pentafen	Pentalgina
Sosegon	Talacen	Talwin
Talwin nx		

Product Name Pentazocine
C.A.S. number 359-83-1
Trade and brand names
For regulatory information, see page 204

Product Name Pentobarbital
C.A.S. number 76-74-4

Trade and brand names

Aethaminalum	Barbityral	Barbopent
Burtylonel	Butylone	Cafergot p.b.
Calpental	Carbital	Chloropent
Continal	Di-barbs	Dipental
Distonocalm	Embutal	Erqobel plus
Ethaminal	Hypnol	Hypnotal
Hyptonal	Insom rapido	Isoamytal
Isobarb	Isom rapido	Iturate
Mebubarbital	Mintal	Napental
Narcoren	Nembudeine	Nembutal
Neodorm	Nicaphloqyl	Novarectal
Nova-rectal	Novopentobarb	Novo-pentobarb
Or-trin	Pacifan	Palpent
Pembul	Penbar	Penbon
Pental	Pentalgin	Pentanca
Pentobarb	Pentodorm	Pentodormol
Pentogen	Pentolos	Penton
Pentone	Petab	Petonel
Praecicalm	Prodormol	Repocal
Rivadorm	Schlafen	Sedanox
Sombutol	Somnopentyl	Somnophyt
Somnotol	Sonistan	Sopental
S-spac	Stopp-15	Wans
Wigraine-pb	Yastyl	

For regulatory information, see page 204

Product Name Phenacetin
C.A.S. number 62-44-2

Trade and brand names

292-comprimes	369, pulvules	3p bugesic
Acetylosal	Achrocidin	Acifein
Acromas	Acropac	Alqocratine
Alumidyne	Amypron	Amypylo-n
Anapac	Angifebrine	Anodin
Antiflu des	Anti-opt	Apadine
Apc	Apidin	Apracur
Arcin	Asa compound	Asceine
Ascophen	Ascthimindon	Asfeen
Ban-o-pain	Bexophene	Bromo quinina
Bromo seltzer	Buff-a-comp	Butal compound
Butorinal	Calmante muri	Capacetyl
Capramin	Caps dr knapp	Capsula dr. knapp
Ceachin	Cefinal	Cequinyl fort

Product Name	Phenacetin	
C.A.S. number	62-44-2	
Trade and brand names		
Chloracet	Citra-fort	Citramol
Clistanol	Codempiral	Codopyrin
Codral	Compralqyl	Conta-schmerz
Contradoleur	Coricidin	Coricidin f
Coriforte	Coryban-d	Cotradol
Daprisal	Darvocomp-n	Darvon compound
Darvon compuesto 65	Darvon n compuesto	Dasikon
Dasin	Dasin ch	Dbnf
Dentocaps	Dolafort	Dolene
Dolomo	Dolostop	Doloxene comp forte, capsules
Dolviron	Doregrippin	Doscafis
Doviron	Drinacet	Edrisal
Empiral	Empirin compound	Emprazil
Emprazil-c	Epraqen	Estrifen
Femcaps	Fenacetina	Fenascor
Fenbutal	Fenidina	Fenina
Fiorinal	Flexalqit	Florital
Fonal	Fortacyl	Fridol
Friocellin	Funapann	Gelonida
Gesic	Gewodin	Gripanidan
Harbureta	Helvaqit	Hemaqene taylor
Hjorton's powder	Hocophen	lcn 65
Influenza tabs	Isollyl	Isomidon
Kafa	Kalmin	Kapron
Kataqrip	Lekasin	Linarol
Malex	Manasul	Mardon
Melabon	Miqesic	Mironal
Monacet	Myolate	Neopyrine
Nevral vit b1 b6	Norqesic	Novacetol
Novosephalqin	Olfano	Omnidadol
Pamprin	Papnin	Para-grip
Paramette	Parametten	Paratodol
Parqesic compound	Pasadex	Pediqel
Percobarb	Percodan	Pertonal
Phenacet	Phenacetine powder	Phenacetinum
Phenacitin	Phenacon	Phenaphen
Phenaphen plus	Phenazetin	Phenazetina
Phenedina	Phenidin	Phenin
Phenodyne	Phenorial	Polypyrrine
Poxy	Procomp-65	Prodigestan
Prodolor	Proqesic	Protension
Pyraphen	Pyroxate	Quadrochin
Quadronal	Rectoral	Refaqan
Reformin	Repro	Respritin
Rhinazol	Rilan	Rinurel
Rinutan	Robaxisal-ph	Robaxisan-pm
Ron-drive	Rumicine	S antineuralgic
S fc	Sacadol	Sadaspir
Salgydal	Sanalgin	Sanalgin

Product Name Phenacetin

C.A.S. number 62-44-2

Trade and brand names

Saridon	Sedalmerck	Seranex
Sinedal	Sinutab	Sinutab ii
Sk 65 compound	Sk 65 compound caps.	Soma
Soma compound	Soma compuesto	Sonalqin
Spacin	Spasmindon	Spasmo-compralqyl
Stellacyl	Super anahist	Supralqin
Synalqos	Synalqos-dc	T h
Tacol	Terracydin	Tetrex-apc
Tetracydin	Thephorin a-c	Tiomapirina
Tomapiena	Treupel	Tripin
Triplex	Uqa-no	Valcophen
Vandar-65	Vasoqesic	Veqanine
Vicks action 500	Viden	Wigraine
Xaril	Zactirin compound-100	

For regulatory information, see page 205

Product Name Phenazone

C.A.S. number 60-80-0

Trade and brand names

Aerol	Analgesine	Anodynin
Anodynine	Antigestin	Antipyrin
Apirelina	Asthma dellipsoids	Aurafair
Auralqan	Auralqicin	Auraltone
Azophen	Azophene	Bajumol
Breezeazy	Calmasmin	Cetussan
Codalqin	Crema antisolar evanescente	Doleron novum
Dolo-med-much	Dol-stop	Felsol
Fenazone	lap	Kalopsis
Lanceotic	Lavylqan	Methozin
Miq-antos	Migranin	Natt-lunedon
Neo-felsol	Orecil	Otipyrin
Otosan-sulfan	Otothricinol	Palacaine
Parodyne	Pasta antisola	Phenazon
Phenicarbazide	Phenylon	Pomada heridas
Prednefrin	Prefrin	Prefrin liquifilm
Prefrin z	Priatan	Prophyllen
Pyrazophyl	Remolmed	Salicopil
Sanasthmyl	Sedatin	Sedatine
Sedaural	Sedonan	Shhe 21
Spalt	Spalt n	Tympagesic
Visublefarite		

For regulatory information, see page 207

Product Name Phenazopyridine

C.A.S. number 94-78-0

Trade and brand names

Azo gantrisin	Azodine	Phenazo
Pyridiate	Pyridium	Pyronium

Product Name Phenazopyridine
C.A.S. number 94-78-0

Trade and brand names

Sedural

For regulatory information, see page 208

Product Name Phendimetrazine
C.A.S. number 634-03-7

Trade and brand names

Adipo ii	Adipost	Adphen
Amphasub	Anorex	Anoxine-t
Antapentan	Arcotrol	Bacarate
Bontril	Di-ap-trol	Dietrol
Dital	Dyrexan-od	Elphemet
Forte	Fringanor	Hourbese
Hyrex	Hyrex-105	Limit
Melfiat	Minus	Neo-nilorex
Obe-del	Obepar	Obesan
Obesan-x	Obex la	Obex-la
Obezine	Panrexin-m	Phenazine
Plegine	Plegline	Prelu-2
Pt-1-5	Reducto	Reton
S 7	Sedafamen	Sly-II
Slyn-II	Sprx 105	Statobex
Statobex-d	Stodex	Symetra
Trimcaps	Trimstat	Trimtabs
Wehless	Weighttrol	X-troazine

For regulatory information, see page 208

Product Name Phenformin
C.A.S. number 114-86-3

Trade and brand names

Adibetin	Antipond	Azucaps
Beta-pebq	Bi-uqlucon ud87	Cronoformin
D retard	Daopar	Db comb.
Db retard	Dbi	Db-retard
De be	Debej	Debeon
Debinyl	Diabis	Diaformin
Dibein	Dibein retard	Dibenide
Dibinyl	Dibiraf	Dibolin
Dibophen	Dibotin	Dibun
Diebin	Diebin retard	Diquabet
Dipar	Dobeom	Fequanide
Fenfoduron	Fenformin	Fenquanide
Fenormin	Gluciferne	Glucifrene
Glucopostin	Glucopstin	Glukopostin
Glyphen	Insoral	Kataglicina
Lentobetic	Ls 6030	Meltrol
Nci-c01741	Normoglucina	Oraleo
Pbi	Pedg	Phenformine
Phenformix	Prontoformin	Retard

Product Name Phenformin

C.A.S. number 114-86-3

Trade and brand names

 Retardo Tolbrtaphen W 32

For regulatory information, see page 209

Product Name Phenicarbazide

C.A.S. number 103-03-7

Trade and brand names

 Antipyretic dellepsoids d26

For regulatory information, see page 211

Product Name Phenmetrazine

C.A.S. number 134-49-6

Trade and brand names

A 66	Anorex	Bromadryl
Emaqrin	Filon	Gratsidin
Marsin	Neo-zine	Oxazimedrine
Phenmetrazine	Prelazine	Preludin
Probese-p	Psychamine a 66	

For regulatory information, see page 211

Product Name Phenobarbital

C.A.S. number 50-06-6

Trade and brand names

3p spas	Aaciasthma	Adocor
Adonal	Aqrypna	Allergasthmin
Alnagon	Amylofene	Anaspaz
Anti-spas	Apb	Aphenylbarbit
Asmo fedrilum	Asthmatussin	Austrominal
Bakersed	Barbellen	Barbenyl
Barberine	Barbilletae	Barbiphenyl
Barbipil	Barbita	Barbivis
Barcole	Barophen	Bay-ase
Bebtoyl	Bediphen	Belergamin
Belladema l s	Belladenal	Bellasectal
Bellastal	Bellerqal	Bellerqal s
Bellumal	Bergofen	Blu-phen
Bock-ase	Bonexyl	Broncosmin
C 147	Calminal	Ce 10010
Ceepa	Cemealonal	Clemodril
Coffecodin	Cor-asthmolyticum	Cortasmyl
Corverum	Dafodil	Damoral
Digi-pulsnorma	Dithene-r	Dolo-eupaco
Donibin	Donna-lix	Donnaplex
Donnatal	Dormiral	Doscalun
Duneryl	Duovent	Eeskabarb span
Elibese	Elmigrin	Enso barb
Ephedrobarbital-t	Ephestmin	Epidormb
Epilantin	Epsylone	Ergojuvan

Product Name	Phenobarbital	
C.A.S. number	50-06-6	
Trade and brand names		
Eskabarb	Espafren	Extrovent
Fasconal	Fedrilum	Fedrial
Fenalqin	Fenemal	Fenilcal
Fenosed	Fenosed bitabs	Gardenal
Gardenale	Gardepanyl	Gastrop
Gentarol	Giolate	Glyanphen
Glyuferal	Gourmase	Gratusminal
Hasp	Hyonol	Hypnaletten
Hypnolone	Hysteps	Ila-med
Irs 109a	Kenedes	Koronar
Laqasperm	Lardet	Legatin
Lepinal	Lepinaletten	Liquital
Lircapil	Lixophen	Luberqal
Lumcalcio	Luminal	Lunadon
Lysadestal	Mazur-a	Md 1020
Mediphen	Meprobit	Mepropon
Metroien	Mialqone	Migrane-dolviran
Modirit	Myocardon	Neo-nervostat
Neurobarb	Nilspasm	Noptil
Nova-pheno	Novodon	Novospasmin
Nunol	Oasil	Oxabar
Oxoids	Pavadel	Peba
Pencardin	Pen-nitate	Pentran
Perphyllon	Phen bar	Phenaemal
Phen-bel	Phenemal	Phenobar
Phenobarbyl	Phenoqen	Pheno-qesic
Phenonyl	Phental	Phentral cratecil
Phob	Piraminal	Plivalqin
Preminal	Prenoxan	Pribetal
Purphen	Quad-sed	Rau-fridetten
Resirol	Respisane	S 611-3
Salviton	Sanepil	Sapos
Scotatal	Secophen-c	Sedacoral
Seda-intestain	Seda-ko	Sedalqin
Sedapar	Seda-tablinen	Sedo corodil
Sedonal	Sedophen	Sedopsic
Sedraqesic	Sevenal	Solofoton
Somonal	Soniphen	Spascol
Spasdel	Spasmalones	Spasmo-compraqyl
Spasmoqentarol	Spasmotal	Spasmo-van
Spasmoveraqin	SpastyI	Spondyneuron
Stental extentabs	Stollerine	Supamidal
Susano	Syntospon	Tedralan
Teofedrin	Teolaxin	Thefederal
Theodrine	Theotabs	Tridezibarbitur
Triphenatol	Tropax	Valpin
Vanital	Vantal	Versomnal
Zirkonorm		

Product Name Phenobarbital
C.A.S. number 50-06-6

Trade and brand names

For regulatory information, see page 211

Product Name Phenol
C.A.S. number 108-95-2

Trade and brand names

3p maid	Aqre-qola	Anbesol
Apralan	Benamine	Benzenol
Carbolic acid	Cepastat	Chloraseptic
Chloraseptic dm	Derma cas	Ego psoryl
Eqomycol	Epivetol	Fenicado
Hydroxybenzene	Izal	Izal germicide
Merastat	Monophenol	Pao sole
Paoscle	Pernomol	Phenylic acid
Poscle	Pregine	Protaphane hm insulin
Sarna	Sedaural	Ura
Vaopin		

For regulatory information, see page 212

Product Name Phenolphthalein
C.A.S. number 77-09-8

Trade and brand names

Aqaffin	Aqarol	Aqoral
Alophen	Alophen pills	Anodyne dellipsoids 4
Ap-la-day	Bold laxine	Bom-bon
Bon-bon	Canisan	Certolax
Chocolax	D & m tablets	Darmol
Dormol	Doxidan	Espotabs
Euchessina	Euchessinia	Evac-q-tabs
Evac-qwik tablets	Evactil	Evac-u-qen
Ex-lax	Feen-a-mint	Formosa camphor
Fractines vichy	Fractine-vichy	Fructines-vichy
Gum camphor	Japan camphor	Kalimalterin
Kest	Kondremul with phenolphtalein	Koprol
Laurel camphor	Laxante yer	Laxatabs
Laxatone	Laxen busto	Laxin
Laxoqen	Lilo	Minilax
Modane	Modane plus	Mucinum
Musilaks	Neoprunex	Neopurghes
Novopuren	Paradeines	Peplax
Petrolaqlar emulsion	Petro-mul-phen	Phenolax
Phillips laxcaps	Prifunal	Prulet
Prunetta	Puqrante el aleman	Purex
Purqa	Purqanol	Purqanos-daquin
Purgant aleman	Purgante	Purgante orravan
Purgen	Purgenum	Purgestol
Purgoids	Purgyl	Purjen sahap
Sarolax	Spulmako-lax	Thalinol
Thalinol mrt	Trilax	Unisvelt

Product Name Phenolphthalein
C.A.S. number 77-09-8

Trade and brand names

Veracolate

For regulatory information, see page 213

Product Name Phenoxybenzamine
C.A.S. number 59-96-1

Trade and brand names

Dibenziline

Dibenzyline

Dibenzyran

For regulatory information, see page 214

Product Name Phentermine
C.A.S. number 122-09-8

Trade and brand names

Adipex

Adipex nouveau

Adipex-p

Aneroxina

Bellapront

Dapex

Duromin

Ex-adipos

Fastin

Inonamin

Ionakraft

Ionamin

Ionamine

Levum

Linyl

Lipopill

Minobese

Minobese forte

Mirapront

Netto-longcaps

Obestin 30

Oby-trim

Omnibex

Ona-mast

Panbesy

Panshape

Parmine

Phentermyl

Pronidin

Raucherstop 5 ht

Reducyl

Regulin

Span r/d

Teramine

For regulatory information, see page 214

Product Name Phenylbutazone
C.A.S. number 50-33-9

Trade and brand names

Alqesin

Alqirreudin

Alqoverine

Alindor

Alka butazolidin

Alkabutazona

Alkabutazone

Alka-phenylbutazone

Alka-sterazolidin

Ambene

Anarthral

Antadol

Anuspiramin

Apophenylbutazone

Apo-phenylbutazone

Arteopan

Arthirikin

Artibrin

Artrisin

Artrizin

Artrodesmol extra

Artropan

Azolid

Benzone

Betazed

Bizolin 20

Bizolin 700

Butacal

Butacol

Butacompren

Butacote

Butadilat

Butadin

Butadion

Butadiona

Butadyne

Butafenil

Butagesic

Butaqros

Butakvertin

Butalan

Butalgin

Butalgina

Butaluy

Butaparin

Butaphen

Buta-phen

Butapirazol

Butarex

Butartiril

Butatril

Butazina

Butazolidin

Butazolidin alka

Product Name	Phenylbutazone	
C.A.S. number	50-33-9	
Trade and brand names		
Butazolidina	Butazone	Butial
Butidiona	Butinol	Butiwas
Buto beta	Butone	Butoroid
Butoroid cream	Butoz	Butrex
Buvetzone	Buzon	Carudol
Celestalgon	Celestazone	Chembutazone
Colfezone	Corbuvit	Dartranol
Debutazon	Delta-butazolidin	Delta-demoplas
Delta-myogit	Delta-tomanol	Deltawaukobuzon
Demoplas	Dephimixn	Dexa tomanol
Dexa-atritin	Dexa-escopyrin	Dexamed
Dexatrzona	Dibuzon	Diqibutina
Diossidone	Direstop	Ditrone
Doctofril	Dolosin dexa	Dolpirina
Ecobutazone	Ectobutazone	Elmedal
Equi bute	Equipalazone	Eributazone
Escopyrin	Ethibute	Exraheudon
Exrheudon	F 650	Fenibutasan
Fenibutina	Fenibutol	Fenotone
Flebosil	Flexazone	Glycyl
Hepabuzon	la-but	Inflazone
Intalbut	Intrabutazone	Intrabuzone
Intrazone	Kadol	Malgesic
Mammyl	Megazone	Mephabutazon
Mepha-butazone	Mepropyrin	Merizone
Mi 540	Nadozone	Naupax
Neo-zoline	Neuro-demoplas	Neuro-elmedal
Neuzoline m	Novobutazone	Novophenyl
Oluprin	Oppazoan	Osadrinin
Panazone	Parazolidin	Parzolidon
Pasirheuman	Pbz	Penetradol
Phebuzin	Phenbuff	Phenbutazol
Phenbutazone	Phenylarthritis	Phenylbetazone
Phenylon plus	Phenylone	Phenyzone
Phlebolan	Pirabutil	Pirarreamol-b
Pirarreamol-p	Praecirheumin	Prebutex
Precirhemim	Prednirheumin	Proxyfezone
Proydynam	Pyrbital	Ranocor
Rectofasa	Reopin	Reumasyl
Reumazin	Reumilene	Reumuzol
Reupolar	Rheopyrin	Rheosolon
Rheumanoln	Rheumaphen	Rheumycalm
Rhumalqan	Robizone-v	Salzone
Schemergen	Servizolidin	Shigrodin
Sigma-elmedal	Sintobutina	Spondyryl
Stabilat	Tetnor	Tevocodyn
Therazone	Tibutazone	Ticinil
Ticinil calcio	Ticinil calico	Todalgil
Trabar	Trabit	Uzone

Product Name Phenylbutazone
C.A.S. number 50-33-9

Trade and brand names

Waukobuzon	Wescozone	Wofapyrin
Zolapelin	Zolidinium	

For regulatory information, see page 215

Product Name Phenylephrine
C.A.S. number 59-42-7

Trade and brand names

Fenox	Forte	Isopto frin
Minims	Mydfrin	Neo-synephrine
Nostril	Prefrin	Visadron

For regulatory information, see page 218

Product Name Phenylpropanolamine
C.A.S. number 14838-15-4

Trade and brand names

A.g.multix	Acutrim	Adistop-f
Amertuss	Amplisiex	Am-tuss liq
Anorexin	Antiadiposium	Apoephedrine
Aridose	Arm	Bifed-20
Biphetane	Biphetap	Blu-hist
Brocon cr	Bromanate	Bromepaph
Brometapp	Bromophen	Bronco-quintoxil
Cenadex	Chlor-rest	Cinturex
Cletanol	Codimal	Cofpac
Cold cap	Coldecon	Col-decon
Conex-grippe	Contop	Control
Coricidin f	Corsym	Coryztime
Cremacoat	Dalca	Day nurse
Decidex	Decomine	Demazine
Deprecstop	Dexatrim	Dimetane
Dimotane	D-sinus	Efed ii
Eficol	Endal	Endecon
Endex	E-son	Espornade spansule
E-tapp 3	Exyphen	Factus
Fornagest	Fuqoa n	Gardax
Ginsopan	Headway	Histabid
Histade	Histatapp	Hsp 540
Ilvin	Ipercron	Kol-tac
Kontexin	Koryza	Leder
Lipo-sinahist	Lunerin	Mardram
Minus-x	Monatuss	Monydrin
Mucolyt-expecto	Mucorama	Nd-hist
Nectatussin	Neosoldana	Nexaam
Nobese	Norephedrine	Nornatane
Obestat	Ornacol	Ornatos
Ornex	Pabron nose	Panacorn
Panadyl	Parhist	Partapp
Partuss	Permatrim	Phenapap

Product Name Phenylpropanolamine
C.A.S. number 14838-15-4

Trade and brand names

Pholcolix	Pholcolix spansule	Pneumidex
Polcimut	Probocon	Profenade
Propadrin	Propadrine	Propaqest
Reduzin	Rhindecon	Rhinerqal
Rhinervert	Rhinicept	Rhinidrin
Rhinocap	Rinexin	Rinomar
Rinotussal	Rinurel	Rinurel lictus
Rinurel tablets	Rinutan	Rotabromophen
Rupton	Ru-tuss	Rynatapp
Rynex	Ryza-qesic	Sacietyl
Scotuss	Secron	Sinac
Sinacin	Sinubid	Sinudan
Sinu-lets	Sinus	Sinutab cough I
Spandecon	Srda	Sto-caps
Sulfa-probocon	Symptrol	Syrtussar
Taviset	Tepanil	Tinaroc
Totolin	Tricon	Tri-congestic
Triogesic elixir	Triominic	Triotussic
Tritane	Turbispan	Tussilene-dm
V cold	Veltane	Veltap
Vernate	Vistaminic	Voxin-pq
W 58	W 66	X 112 antiadipo
Zerinol		

For regulatory information, see page 218

Product Name Phthalylsulfathiazole
C.A.S. number 85-73-4

Trade and brand names

Afi-ftalyl	Canidis-anti-diarr	Carbidiar
Carbotalin	Colicitina	Coliclase
Crematalil	Cremothalidine	Diacolin
Direver	Disenterol	Ef-micin
Enteramida	Enterocalme	Entero-hermes
Entero-red	Enterosteril	Entero-sulfina
Entero-toxan	Entexidina	Esteraplidin maq
Eugeniteed	Fitazil	Ftalil-esteve
Ftalil-septol	Ftalil-tiazol	Ftalysept
Ilentazol	Inrestibla strepto	Intestiazol
Iodentero-neomicina	Loqical	Massotalil
Neo-sulfazon	Novosulfina	Phtalazol
Phtazol	Septiftalil	Sulfacetil
Sulfathalidine	Sulftalyl	Syptan
Taleudron	Talidine	Talisulfazol
Taloudron	Tamil	Thalazole
Thalinil	Thalistanin	Thalistatyl
Thiazole	Ultratiazol	Vetoryl

For regulatory information, see page 220

Product Name Piperazine
C.A.S. number 110-85-0

Trade and brand names

Noxiurotan	Ogen	Okuside
Optiverm	Oxiril syrup (hydrate)	Oxiuran (hydrate)
Oxiurasin	Oxiustip	Oxiustip elix
Oxivermin	Oxizin	Oxucid
Oxurasin	Oxuril	Oxypaat
Oxypip	Oxyzin	P.c. (citrate)
Padrax	Paravermin	Parazine
Pariamate	Parid	Par-teqa
Perin	Piaverm	Piavermi
Pincet	Pincide	Pinozan
Pinrou	Pinsirup	Pin-teqa
Pipadox	Pipan	Pip-a-ray
Pipenin	Piperacid	Piperamicin
Piperascat	Piperaskat	Piperasol
Piperate	Piperaverm	Piperazate
Piperazinal	Piperazine (adipate)	Pipercrean
Piperex	Piperiod	Piperital od
Piperitol	Piper-iodina	Piperol fort
Piperone	Piperoverm	Pipertox
Piperver	Piperzinal	Pipeverm
Pipezol	Pipizan	Pipizan citrate
Pipracid	Piprazid	Piprazyl
Pipricide	Piptelate	Piverma
Polo-verm	Polyquil	Pripsen
Provtovermil	Pulvex	Razinol
Rhomex	Rondelim	Rondoxy
Safersan	Santoban	Siropar
Supraverm	Taenifiqin	Tasnon
Ta-verm	Teniver	Thelmin
Thenatol	Tivazine	Toxocan
Uricida	Uridina	Uroclear (hexamine)
Urodan (phosphate)	Urosolvina	Uvilon syrup (hydrate)
Vanpar (hydrate)	Veripar	Vermaqo
Vermazine	Vermenter	Vermicompre
Vermidol	Vermifug	Vermilass
Vermipan	Vermipharmette	Vermiquimpe
Vermiquimyc	Vermisit	Vermisol
Vermitox	Vermofrik	Verocid
Veroxil	Wairmex	Worm-away
Wurmex	Wurmrazin	Wurmsirup siegfried

For regulatory information, see page 221

Product Name Pipradrol
C.A.S. number 467-80-7

Trade and brand names

Alertonic	Detaril	Gerodryl
Leptidrol	Meratonic	Meratran
Metadin	Peratran	Piridrol

Product Name Pipradrol
C.A.S. number 467-80-7

Trade and brand names

Stimolaq fortis

For regulatory information, see page 222

Product Name Pituitary-chorionic gonadotropin (injectable)
C.A.S. number UN-KG-0058

Trade and brand names

A.p.l.	Antuitrin	Choraqon
Choriantin	Choritropin	Chorulon
Dap-test	Ekluton	Endocorion
Entromone	Ferti-cept	Follutein
Fractolon	Gonabion	Gonadex
Gonadoplex	Gonafollin	Gonaqestrol
Gonault	Gravimun	Grom hqh
Hcq	Hcq standard tablets	Lh 5000
Luteovet	Neogonadil	Nymfalon
Praelutin forate	Pregnesin	Profasi hp
Puberogen	Rioqon	Sensi-t
Suiqonan		

For regulatory information, see page 223

Product Name Podophyllum resin
C.A.S. number UN-KG-0059

Trade and brand names

Biliboldo	Bon korets	Condilomin
Condyline	Dermacytostat	Podofilm
Salicylin-p	Vericap	Wartec
Warticon	Wartkil	Wart-off

For regulatory information, see page 224

Product Name Polyoxyethylated castor oil
C.A.S. number UN-87-0006

Trade and brand names

Cremophor rh40	Cremophor rh60
----------------	----------------

For regulatory information, see page 225

Product Name Polyvidone
C.A.S. number 9003-39-8

Trade and brand names

Acu-dyne	Adapettes	Adsorbobase
Adsovbotear	Aqent at 717	Albigen a
Aldacol q	Amiodel eritro	Amyderm s
Anbesol	Andrestrac 2-10	Anexa
At 717	B 7509	Betadine
Betaisod	Bolinan	Bridine
Clinidine	Crospovidone	Disphex
Efo-dine	Final step	Frepp
Frepp/sepp	Ganex p 804	Ga-pvp-101

Product Name Polyvidone
C.A.S. number 9003-39-8

Trade and brand names

Gyno-bidex	Hemodesis	Hemodez
Iodopiron	Isodine	Isoline
Isoplasma	Jodoplex	K 115
K 15	K 25	K 30
K 60	K 90	Kollidon
Kollidon 12pf	Kollidon 17	Kollidon 25
Kollidon 30	Kollidon 90	Kollidon ce 50/50
Kollidon k 25	Kollidon k 30	Luviskol
Luviskol k 17	Luviskol k 25	Luviskol k 30
Luviskol k 90	Luvisteol	Medicort
Molycu	Mundidon	Neojodin
Oftan flurekain	Peraqal st	Periston
Periston-n	Periston-n-toxobin	Pevidine
Peviston	Plasdone	Plasmadone
Plasmoid	Plasmosan	Plassint
Podiodine	Polyclar at	Polyclar h
Polyclar l	Poly-karaya	Polyplasdone xl
Polyvidone-escupient	Polyvidonum	Polyvinyl pyrrolidone
Povadyne	Povidone k 29-32	Protaqent
Providine	Pvp 40	Pvp 50
Pvp0	Pvp-k 15	Pvp-k 25
Pvp-k 3	Pvp-k 30	Pvp-k 60
Pvp-k 90	Pvp-macrose	Pvp-macrox
Pvpp	Rocmuth	Sd 13
Sepp	Soft-care	Subtosan
Tears plus	Traumasept	Ultradine
Venostasin retard	Vetedine	Vini
Vinisol	Yodiplexin	

For regulatory information, see page 225

Product Name Potassium canrenoate
C.A.S. number 2181-04-6

Trade and brand names

Aldactone	Aldactone-diurapid	Aldadiene potassium
Kadiur	Kanrenol	Lasiren
Luvion	Osiren	Osirenol
Osyrol	Osyrol-lasix	Phanurane
Sincomen	Sincomen pro injectione	Soldactone
Soludactone	Speroctan-m	Spiroctan
Venactone		

For regulatory information, see page 226

Product Name Potassium chloride
C.A.S. number 7447-40-7

Trade and brand names

Apo-k	Celeka	Chlorvescent
Diffu-k	Durules-k	Kadalex
Kalinorm	Kalipor	Kalitabs

Product Name Potassium chloride
C.A.S. number 7447-40-7

Trade and brand names

Kalium durules	Kaon-cl	Kato
Kay-cee-l	K-contin	K-dur
K-lease	K-long	K-lor
Klor-con	Klorvess	Klotrix
K-lyte/cl	K-norm	K-tab
Lento-kalium	Leo k	Miopotasio
Nu-k	Plenish-k	Potasion
Rekawan	Roychlor	Rum-k
Slow-k	Span-k	Swiss-kal sr
Ten-k	Ultra-k-chlor	

For regulatory information, see page 226

Product Name Potassium nitrate
C.A.S. number 7757-79-1

Trade and brand names

Cholal modifico	Cholal simple	Collo-bo
Dewitt's pills for backache and joint pain	Viridite	Viridite k

For regulatory information, see page 227

Product Name Practolol
C.A.S. number 6673-35-4

Trade and brand names

A 25	Cardiol	Cordialina
Dalzic	Eraldin	Eraldina
Praktol	Pralon	Teranol

For regulatory information, see page 227

Product Name Prasterone
C.A.S. number 53-43-0

Trade and brand names

17-chetovis	17-hormoforin	Astenile
Cetavister	Climatost	Dastonil
Deandros	Dha-s (prasterone)	Diandron
Diandrone	Gynodian	Longevital 5000
Maxepa	Mentalormon	Mylis
Neurocotex	Psicosterone	Ro 66827
Sh 833	Ultrapla	

For regulatory information, see page 228

Product Name Progabide
C.A.S. number 62666-20-0

Trade and brand names

Gabaphore	Gabren	Gabrene
Halogabide	SI 76 002	

For regulatory information, see page 229

Product Name Propafenone

C.A.S. number 54063-53-5

Trade and brand names

Arythmol	Nofenan	Nofenon
Nomorytmin	Normotrytmin	Normotrytmin (r) 10 mg
Prolekofen	Retmonorm	Ryhmonorma
Rythmole	Rytmonorm	

For regulatory information, see page 230

Product Name Propofol

C.A.S. number 2078-54-8

Trade and brand names

Diprivan	Disoprivan	Disprofol
Rapinovet		

For regulatory information, see page 231

Product Name Propylhexedrine

C.A.S. number 3595-11-7

Trade and brand names

Benzedrex	Chp-depot	Cyclexedrine
Dristan	Eggobesin	Eventin

For regulatory information, see page 231

Product Name Propyphenazone

C.A.S. number 479-92-5

Trade and brand names

539 grippe-draagees	Amipylo-n	Azur
Balpiren	Baukal	Budirof
Caffalgina	Camoplex	Cantacin
Causyth	Cerebrol	Cibalgina
Commotional	Daturmed	Degripol
Dentocaps a	Dim-antos	Dolibral
Dolibrax	Dolo-mineuron	Dysmalgin
Ejcopyrin	Epizon	Escomen
Estesina	Eufibron	Europan
Fd 8	Febral	Finiqripp
Grippocaps	Heaven	Infantex
Influvit	Isopronazon	Kavapyret
Kuronde	Larodon	Lysadestat
Mamaslu	Milneuron	Myo-europan
Neuramin	Neuridal	Neuro-spondryl
Nodiras	Noric	Otobacid
Pfeil	Reomin	Retamex
Rheumanol	Rhinivict	Sanalgin-p
Saridon neu	Saridone	Sedospin
Servalgin	Sonotryl	Spalt
Spongamed	Stona	Synpyrin
Vivcet	Wauco-sin	Wecontrin

For regulatory information, see page 232

Product Name Pyritinol
C.A.S. number 1098-97-1

Trade and brand names

Biocefalin	Biontabol	Bonifen
Bonifwn	Bonol	Cefalogen
Cerebrotrofina	Cervitalin	Danaden
Divalvon-d	Enbol	Encefabol
Encefort	Encephabol	Encerbrovit
Encerebron	Enerbol	Epocan
Fulneurina	Geribolina	Gerontabol comp.
Juniormen	Leonar	Life
Loqos	Maind	Musa
Neuroxin	Piriditol	Piririomin
Piritinol	Piritiomin	Plenumil
Sawaxin	Scintidin	Tibased
Tomevit	Tonobrein	Tonomentis

For regulatory information, see page 234

Product Name Retinol
C.A.S. number 68-26-8

Trade and brand names

Avibon

For regulatory information, see page 236

Product Name Santonin
C.A.S. number 481-06-1

Trade and brand names

Semenen

For regulatory information, see page 237

Product Name Scopolamine
C.A.S. number 51-34-3

Trade and brand names

Diban	Donnaqel	Donnaqel-pq
Donnatal	Phenacon	Ru-tuss
Scopoderm tts	Spasmofen	Susano
Transcop	Tropax	

For regulatory information, see page 238

Product Name Secobabital
C.A.S. number 76-73-3

Trade and brand names

Immenoctal	Seconal	Seconal sodium
Tuinal		

For regulatory information, see page 238

Product Name Sildenafil
C.A.S. number 139755-83-2

Trade and brand names

Segurex	Viagra
---------	--------

Product Name Sildenafil
C.A.S. number 139755-83-2

Trade and brand names

For regulatory information, see page 240

Product Name Silver acetate
C.A.S. number 563-63-3

Trade and brand names

Smokerette Tabmint

For regulatory information, see page 240

Product Name Sodium dibunat
C.A.S. number 14992-59-2

Trade and brand names

Antussan	Balmini	Becantal
Becantex	Bechisan	Bexedyl dibunaat
Bexedyl dibunaat expectasans	Cito-quakalin	Expect-blacken-pastillen n
Makatussin	Pastillas koki	Sedobex
Super koki		

For regulatory information, see page 241

Product Name Somatropin (pituitary-derived)
C.A.S. number 12629-01-5

Trade and brand names

22krl	Antuitrin growth	Antuitrin-t
Asellacrin	Cb 311	Corpormon
Crescomon	Gorm	Hqh
Human groth hormone	Human growth hormon	Humatrope
Leutrophin	Nanormin	Nanormon
Phynatol	Phyol	Phyoneon
Protopin	Protropin	Rx 099916
Somacton	Somatonorm	Somatormone
Somatotrope choay	Somatrofin	Somatropin
Sth		

For regulatory information, see page 241

Product Name Spironolactone
C.A.S. number 52-01-7

Trade and brand names

Acelat	Airolactone	Aldace
Aldactazide	Aldactide	Aldactide 25
Aldactone	Aldactone-a	Aldazida
Aldonorm	Aldopur	Aldospirone
Aldozone	Alexan	Almatol
Alpamed	Altex	Altexide
Aporasnon	Aquareduct	Carditan
Crk 635	Ct-spiro	Deverol
Diatensec	Digi-aldopur	Dilakton
Dira	Duraspiron	Euteberol
Hexalacton	Hokulaton	Hokuraton

Product Name Spiro nolactone
C.A.S. number 52-01-7

Trade and brand names

Hydrospiron	Idrolatton	Idrolattone
Lacalmin	Lacdene	Lacilactone
Laractone	Laralmin	Lasilacton
Lasitone	Loractone	Mf 218d
Nefurofan	Noidouble	Novospiroton
Novospirozone	Novosprioton	Novospriozine
Osiren	Osyrol	Penantin
Pirolacton	Pirolcaton	Plarenil
Practon	Practon 50	Raudazida
Risicordin	Rolactone	Rolactone microfine
Saqisal	Sali-spiroctan	Saluretin
Sas 1060	Sc 9420	Servilactone
Sincomen	Spiractin	Spiresis
Spiretic	Spiridazide	Spiridon
Spirix	Spiro	Spiro comp
Spiro50-d	Spiroctan	Spirodigital
Spiro-f	Spirolanq	Spiron
Spironazide	Spironomocompren	Spironone
Spironothiazide	Spiropal	Spiroprop
Spirostada	Spiro-tablinen	Spirotone
Suprapuren	Supra-puren	Suracton
Synureticum	Tensin	Tensoflex
Uractone	Urosanine	Urusonin
Verospiron	Verospirone	Xenalone
Xeualon		

For regulatory information, see page 243

Product Name Streptomycin
C.A.S. number 57-92-1

Trade and brand names

Antidiarrhoicum	Bio hubber	Bio hubber fuerte
Bio hubbersimple	Cidan est	Darostrep
Derbitan antibiotico	Diastat	Direver
Estrepromade	Estrepromicina	Estrepto e
Estrepto level	Estrepto ph	Estrepto wolner
Estreptomicina normon	Gamafin	Injectin
Neodistreptotab	Neodualtrepto	Novostrep
Novo-strep	Servistrep	Solustrep
Solvo-strep-s	Solvo-strept-s	Strep-diva
Strepolin	Streptan	Streptaquine
Streptocal	Strepto-fatal	Streptomycin
Streptosol 25	Streptothemat	Stretobretin
Strycin	Sul-mycin ii	

For regulatory information, see page 244

Product Name Sulfadiazine
C.A.S. number 115-68-4

Trade and brand names

Product Name **Sulfadiazine**
C.A.S. number **115-68-4**
Trade and brand names

Inqamid Inqamid ophtal Irqamid

For regulatory information, see page **245**

Product Name **Sulfadimidine**
C.A.S. number **57-68-1**
Trade and brand names

Crermomethazine	Deladine	Dimezathine
Dimidin	Hava-span	Intradin
Neotrizine	Riqesol	Rivodin
S-dimidine	Spanbolet	Sulka-s
Sulphamezathine	Sulphfmezatine	Superseptyl
Sustain iii	Tersulpha	Trisulfaminic
Trisulfaminie		

For regulatory information, see page **246**

Product Name **Sulfaguanidine**
C.A.S. number **57-67-0**
Trade and brand names

Aseptil-guanidina	Aterian	Coliseptale
Devaquanil	Diacta	Dirkan
Emerin	Ente-rivo simplex	Ganidan
Granidan	Guamide	Guanicil
Guanidan	Guanimycin	Guanowept
Guasept	Inorgan	Intestovet
Ordenol	Orqaquanidon	Resulfon
Ruocil	Sqd	S-guanidan
S-guanidine	Shiqatox	Suganyl
Sulfacarbon	Sulfentidine	Sulfoqua
Sulqin	Tetrawest	Trisulvet

For regulatory information, see page **246**

Product Name **Sulfamerazine sodium**
C.A.S. number **127-58-2**
Trade and brand names

Bio hubber simple	Crema-merazine	Debnal m
Mebacid	Neotrizine	Peccocode
Septosil	Spanbolet ii	Tersulpha
Trisulfaminic	Trisulpha	

For regulatory information, see page **248**

Product Name **Sulfamethizole**
C.A.S. number **144-82-1**
Trade and brand names

3p methazol	Amer-azo	Ayerlucil
Azocline	Azotrex	Dorsec
Famet	Lu	Lucatyl
Lucosil	Methazol	Methisul

Product Name Sulfamethizole
C.A.S. number 144-82-1

Trade and brand names

Microsul	Micturol ampicilina seda	Nicene
Orozl	Procijec	Proklar-m
Renasul	Rp 2145	Rufol
Salimol	S-methizole	Spasmo-harnosal
Starisil	Suladyne	Sulfa gram
Sulfametin	Sulfapyelon	Sulfstat
Sulfurine	Tetracid	Thidicur
Thiosulfil	Thiosulfil a	Tiosulfan
Ultrasul	Uratrac	Urobiotic
Urocydal	Urodiaton	Urolex
Urolucosil	Uroluxcosil	Uro-nebactin
Uropeutic	Urotrex	Uroz
Utrasul	Vk 53	

For regulatory information, see page 248

Product Name Sulfamethoxyypyridazine
C.A.S. number 80-35-3

Trade and brand names

Amidin	Aseptilex	Asey-sulfa
Bimalong	Biocorn	Bio-cron
Bio-pectodil	Davosin	Davosin suspension
Deltavaqin	Depovernil	Desulfon
Durasul	Durasul jarabe	Durox
Elix	Ensulfa	Eusulfa
Exazol	Exazole	Farinfnicol
Fercasulf	Hesse-sulfon	Ketiak
Kiron	Kynex	Kynex acetyl
Lederkyn	Lentac	Lentosulfa
Linder	Loqisul jarabe	Longamid
Longisul	Metamit	Metazina
Metuzina	Microcid	Midicel
Midikel	Minikel	Myasul
Mylosul	Novosulfin	Opinsul
Paramid supra	Petrisul	Pirasulfon
Quinoseptyl	Ralenta	Retasulfin
Rotardon	S.d.m.	Septotryl
Smop	Spofadazine	Sulamin
Sulfa spiriq	Sulfabon	Sulfadazina
Sulfadepot	Sulfadin	Sulfadurazin
Sulfaintensa	Sulfakeyn	Sulfalex
Sulfametopyridazin	Sulfamizina	Sulfamyd
Sulfapyrazin	Sulfatar	Sulfdurazin
Sulfocidan	Sulfonamid	Sulforetent
Sulfo-rit	Sultirene	Unisulfa
Unisulfa dulcis	Uroplex	Valetan
Velaten	Vinces	Volocid
Vtg 44		

For regulatory information, see page 248

Product Name Sulfamethoxypridazine
C.A.S. number 80-35-3

Trade and brand names

Product Name Sulfanilamide
C.A.S. number 63-74-1

Trade and brand names

Acetonal vaginal	Amidrin	Astreptine
Avc	Avc cream suppositoty	Avc/dienestrol
Avril	Azol	Azol polvo
Azol pomada	Buco pental	Buco reqis
Chemiovis	Daromid	Defonamid
Dorsec	Exoseptoplix	Expseptoplix
Faderma	Fricton	Gaqaril sulfamida
Gynaedron	Instilin	Jacosulfon
Medeyol	Mentol sedans sulfamidad	Nasopomada
Odamida	Oestro-gyneadron	Otocaina
Otonasal	Otorrilan	Ovuthricinol
Oxidermiol	Paraseptol	Pental
Pental forte	Pentalmicina	Polvo sulfamida leti
Polvo sulfamida orrvan	Polvos wilfe	Pomada heridas
Pomada wilfe	Prontablin	Pulvi bacteramide
Pyodental	Pyodron	Quimpeamida
Rhinamide	Rino glucol sulf	Septoplix
Streptamin	Sulfacromo	Sulfonamid spuman
Sulfonamide-spuman-style	Sulfonanilamid	Sulfosellan-salbe
Unq. vemleiqh	Vaqitrol	

For regulatory information, see page 249

Product Name Sulfathiazole
C.A.S. number 72-14-0

Trade and brand names

Arqazol	Azoseptale	Bucosol
Chemiovis	Chemosept	Cibazol
Coryza	Crionil	Csp 500
Csp-250	Edifeno	Eleudron
Femakzem	Flumamine	Formotablin antidiarreico
Gyne-sulf	Gyn-sulf	Inqalipt
Neosutrin	Polvos wilfe	Pomada wilfe
Prothiazol	Septex cream no. 2	Septozol
Streptacillin	Streptotriad	Sulfamul
Sulfa-orzon	Sulfavitina	Sulfazol
Sulfex	Sulfhatose	Sulfintestin
Sulfopyrol	Sulfour	Sulfzol
Sulnac	Sulphatriad	Sultrin
Sulzol	Tampovaqan pss	Thiadyl
Thiazamid	Thiazamide	Thiuramide
Tiadyl	Trimeto	Trisulpha
Trysul	Tylasul	Ufa 902-duo
Vetoprim mi	Wintrazol	

For regulatory information, see page 250

Product Name Sulfathiazole
C.A.S. number 72-14-0

Trade and brand names

Product Name Sulfisomidine
C.A.S. number 515-64-0

Trade and brand names

Aristamid	Elkosin	Gynedron
Isosulf	Oestro-gynedron	Poly-gynedron
Sulfamethine	Tricho-gynedron	

For regulatory information, see page 250

Product Name Suloctidil
C.A.S. number 54767-75-8

Trade and brand names

Bemperil	Cerebro	Circleton
Cp 556s	Dulasi	Duloctil
Euvasal	Farectil	Fluversin
Fluvisco	Hemoantin	langene
Ibisul	Loctidon	Locton
Metactiv	Octamet	Polivasal
Sudil	Sulc	Sulocton
Sulodene	Suloktil	Sutidil
Tamid	Vascudil	

For regulatory information, see page 251

Product Name Sulprostone
C.A.S. number 60325-46-4

Trade and brand names

CP-34089	Nalador
----------	---------

For regulatory information, see page 252

Product Name Sultopride
C.A.S. number 53583-79-2

Trade and brand names

Banotil	Barnetil	Barnotil
Topral		

For regulatory information, see page 252

Product Name Suprofen
C.A.S. number 40828-46-4

Trade and brand names

Alqiamida	Alqiasdi	Bordol
Erdol	Maldocil	Masterfen
Sufenid	Supranol	Suprol
Surfex		

For regulatory information, see page 254

Product Name Suxibuzone
C.A.S. number 27470-51-5

Trade and brand names

Calibene	Danalon om	Danilon
Flamilon	Flofos	Floqos
Solurool		

For regulatory information, see page 255

Product Name Tartrazine
C.A.S. number 1934-21-0

Trade and brand names

1 yellow	1409 yellow	A.f. yellow no.4
Acid leather yellow t	Acid yellow 23	Acid yellow t
Acilan yellow	Acilan yellow qq	Airedale yellow t
Aizen tartrazine	Amacid yellow t	Amacid yellow t-ex
Atul tartrazine	Ayellow t	B 3014
Biovital	C.i. 19140	C.i. acid yellow 23
C.i. food yellow 4	Calcocid yellow mcq	Calcocid yellow xx
Cancert tartrazine	Certecol tartrazol yellow s	Cilefa yellow t
Curon	D and c yellow no. 5	Dolkwal tartrazine
Dye yellow lake	E 102	E 102 (dye)
Edicol supra tartrazine n	Eqq yellow a	Erio tartrazine
Erio yellow t supra	Eurocert tartrazine	Fast yellow 5q
Fd and c yellow no. 5	Fenazo yellow t 4	Food dye yellow 4
Food yellow 4	Food yellow no. 4	Galinid
Hd tartrazine	Hd tartrazine supra	Hexacert yellow no 5
Hexacol tartrazine	Hispacid fast yellow t	Hydrazine yellow
Hydroxine yellow l	Japan yellow no. 4	Jaun tartrique
Kako tartrazine	Kayaku food colour yellow no. 4	Kayaku tartrazine
Kca foodcol tartrazine pf	Kca tartrazine pf	Kiton yellow t
L yellow z 1020	Lake yellow	Lemon yellow a
Lemon yellow a qeiyq	Maple tartrazol yellow	Mitsui tartrazine
Naphtocard yelow o	Neklacid yellow t	Oxanal yellow t
San ei tartrazine	Sugai tartrazine	Tartar yellow fs
Tartar yellow n	Tartar yellow pf	Tartar yellow s
Tartran yellow	Tartraphenine	Tartrayellow
Tartrazin	Tartrazine a export	Tartrazine b
Tartrazine b.p.c.	Tartrazine c	Tartrazine extra pure a
Tartrazine fq	Tartrazine q	Tartrazine lake
Tartrazine lake yellow n	Tartrazine m	Tartrazine mcql
Tartrazine n	Tartrazine ns	Tartrazine o
Tartrazine o specially pure	Tartrazine t	Tartrazine xx
Tartrazine xx especially pure	Tartrazine xxx	Tartrazine yellow
Tartrazol bpc	Tartrazol yellow	Tartrine yellow o
Unitertracid yellow te	Usacert yellow no 5	Vondacid tartrazine
Wood yellow	Xylene fast yellow qt	Yellow lake 69

For regulatory information, see page 256

Product Name Temafloxacin
C.A.S. number 108319-06-8

Trade and brand names

Product Name **Testosterone propionate (injectable)**
C.A.S. number **57-85-2**

Trade and brand names

Testobase	Testodet	Testodrin
Testogen	Testoici	Testoidral
Testolets	Testonate	Testonique
Testopin	Testopinate	Testopropon
Testoral	Testo-retard	Testormol
Testosid	Testoviron	Testoviron (ampule)
Testoviron-10/-25/-50	Testoviron-depot-50/-100	Testovis
Testoxyl	Testrex	Testron
Tostrina	Triomone	Uniteston
Vantostol-p	Viromon	Viormone
Virosterone		

For regulatory information, see page **260**

Product Name **Tetracycline (paediatric)**
C.A.S. number **60-54-8**

Trade and brand names

Achrocidin	Achromycin	Achromycin v
Achromycin y	Apo-tetra	Cyclopar
Decycline	Double-t	Gt-250
Hosta-500	Medicycline	Muracine
Mysteclin-f	Nasopomada	Neo-tetrine
Nor-tet	Novotetra	Panmycin
Retet	Robitet	Sk-tetracycline
Steclin	Sumycin	Tepcycline
Teropicycline	Tetrabotic	Tetra-c
Tetracap	Tetracaps	Tetracyn
Tetralan	Tetram	Tetrex
Tetrpsol	Wintracin	

For regulatory information, see page **261**

Product Name **Thalidomide**
C.A.S. number **50-35-1**

Trade and brand names

Algosediv	Asidon	Bonbrain
Contergan	Distaval	E-217
Funed	Glupan	Glutanon
Hippuzon	Imidan	Isomin
Kevadon	Kevadone	Nerufatin
Neurosedyn	Pangul	Pantosedive
Pro-ban	Quetimid	Sanodormin
Sedalis	Sedoval	Shinaito
Shinnibrol	Sleepan	Slipro
Softenil	Softenon	Talimol
Tlargan	Yodomin	

For regulatory information, see page **262**

Product Name **Thenalidine**
C.A.S. number **86-12-4**

Trade and brand names

Sanbosten	Sandosten	Sandostene
-----------	-----------	------------

For regulatory information, see page **263**

Product Name **Thiomersal**
C.A.S. number **56-64-8**

Trade and brand names

Thiobactal

For regulatory information, see page **264**

Product Name **Tianeptine sodium**
C.A.S. number **30123-17-2**

Trade and brand names

Coaxil	Stablon
--------	---------

For regulatory information, see page **264**

Product Name **Ticlopidine**
C.A.S. number **55142-85-3**

Trade and brand names

4-c-32	53-32-c	Anagregal
Aplaquette	Caudaline	Derivatives
Klodin	Opteron	Panaldine
Pcr 5332	Tcp	Ticlid
Ticlidan	Ticlodix	Ticlodone
Ticlopedine	Ticlosan	Tiklid
Tiklyd	Tilcid	

For regulatory information, see page **265**

Product Name **Tienilic acid**
C.A.S. number **40180-04-9**

Trade and brand names

Anp 3624	Diflarex	Diflurex
Fr 3068	Selacryn	Selcryn
Skf-62698	Ticrex	Ticrynafen
Ticrynapen		

For regulatory information, see page **266**

Product Name **Tocainide**
C.A.S. number **41708-72-9**

Trade and brand names

Apx	Citocard	Taquidil
Tonocard	Toquidil	Xylotocan

For regulatory information, see page **267**

Product Name **Tramadol**
C.A.S. number **27203-92-5**

Trade and brand names

Product Name Tramadol
C.A.S. number 27203-92-5

Trade and brand names

Trabar Tramal

For regulatory information, see page 269

Product Name Tranlycypromine
C.A.S. number 155-09-9

Trade and brand names

Cuait	Estelapar	Jatrosom
Oculocidon	Parnate	Parnate tylciprine
Parnetene	Parstelazin	Parstelin
Stelapar	Transamin	Transaminase
Transaminase sqo	Transaminase sqp	Transamine
Tylciprine		

For regulatory information, see page 269

Product Name Trazodone
C.A.S. number 19794-93-5

Trade and brand names

Beneficat	Bimaran	Deprax
Desyrel	Devidone	Manegan
Molipaxin	Pragmarel	Pragmazone
Taxagon	Thittico	Thombran
Thromban	Tombran	Tramensan
Tritico	Trittico	

For regulatory information, see page 270

Product Name Tretinoin
C.A.S. number 302-79-4

Trade and brand names

A-acido	Aberel	Aberela
Acid a vit	Acnavit	Acnavyse
Acretin	Airoderm	Airol
Aknebon	Aknefuq	Aknoten
Anition	Antibio-aberel	Apsor
A-vitamisyre	Avitoin	Cordes vas
Dermairol	Dermoclar	Dermojuventas
Deruqin	Effederm	Epi-aberel
Eudyna	Locacid	Pigmanorm
R0 22-6595	Reiderma	Retin a
Retin-a	Ro 1-5488	Roacutane
Sebo-psor	Stie vaa	Stievaa
Tretin m	Vas dexta	Verra-med
Vitacid a	Vitamin a acid	

For regulatory information, see page 270

Product Name Triacetyldiphenolisatin
C.A.S. number 18869-73-3

Trade and brand names

Product Name Triacetyldiphenolisatin
C.A.S. number 18869-73-3

Trade and brand names

Schlakforte

For regulatory information, see page 271

Product Name Triazolam
C.A.S. number 28911-01-5

Trade and brand names

Halcion	Novidorm	Novoderma
Novodorm	Nuctane	Songar
Songarn		

For regulatory information, see page 271

Product Name Trimipramine
C.A.S. number 739-71-9

Trade and brand names

Apo-trimip	Herphonal	No-tripramine
Novo-tripramine	Rhotrimine	Rhotromine
Sapilant	Stangyl	Surmantil
Surmontil	Tydamine	

For regulatory information, see page 274

Product Name Troglitazone
C.A.S. number 97322-87-7

Trade and brand names

Rezulin	Ronqlitazone
---------	--------------

For regulatory information, see page 274

Product Name Trolamine
C.A.S. number 102-71-6

Trade and brand names

Sabril	Sabrillex
--------	-----------

For regulatory information, see page 275

Product Name Trypsin
C.A.S. number 9002-07-7

Trade and brand names

Parenzyme	Trypsillin
-----------	------------

For regulatory information, see page 276

Product Name Valproic acid
C.A.S. number 99-66-1

Trade and brand names

Valproine	Vederon
-----------	---------

For regulatory information, see page 278

Product Name **Vigabatrin**
C.A.S. number **60643-86-9**

Trade and brand names

Sabril	Sobril	Sobril tab 25 mg
--------	--------	------------------

For regulatory information, see page **278**

Product Name **Vinbarbital**
C.A.S. number **125-42-8**

Trade and brand names

Butenemal	Delvinal	Delvinal sodium
Diminal	Suppoptanox	Vinbarbiton

For regulatory information, see page **279**

Product Name **Vincamine**
C.A.S. number **1617-90-9**

Trade and brand names

Angiopac	Cerebroxine	Cetal
Equipur	Ocu-vinc	Oxyqeron
Pervincamine	Vadicate	Vinca
Vinca minor	Vincacen	Vincapront
Vincavix	Vincimax	

For regulatory information, see page **279**

Product Name **Warfarin**
C.A.S. number **81-81-2**

Trade and brand names

Athrombin	Coumadin	Coumadine
Marevan	Mervan	Sofarin
Waran	Warfilone	

For regulatory information, see page **280**

Product Name **Xenazoic acid**
C.A.S. number **1174-11-4**

Trade and brand names

Cv 58903	Xenamine	Xenovis
----------	----------	---------

For regulatory information, see page **281**

Product Name **Zimeldine**
C.A.S. number **56775-88-3**

Trade and brand names

Normid	Normud	Zelmid
Zelmidine		

For regulatory information, see page **281**

Product Name **Zipeprol**
C.A.S. number **34758-83-3**

Trade and brand names

Antitaxil-z	Antituxil-z	Balutox
Broncozina	Bronx	Cerm-3024

Product Name Zipeprol
C.A.S. number 34758-83-3

Trade and brand names

Citizeta	Mirsol	Oqylene
Respilene	Respirase	Respirex
Santus	Talasa	Zitoxil

For regulatory information, see page 281

Product Name Zomepirac
C.A.S. number 33369-31-2

Trade and brand names

Calinador	Calmador	Dolgenal
Dolwas	McN 2783	McN 2783-21-98
Miranil	Zomax	Zomaxin
Zopirac		

For regulatory information, see page 282

Product Name Zopiclone
C.A.S. number 43200-80-2

Trade and brand names

Zimovane

For regulatory information, see page 282

A. INDEX BY CHEMICAL ABSTRACT SERVICE REGISTRY NUMBERS

CAS	Product name	Page
10043-35-3	Boric acid and borates.....	65, 292, 329
100-51-6	Benzyl alcohol.....	60, 327, 328
100981-43-9	Ebrotidine.....	117
10118-90-8	Minocycline.....	182, 374
102-71-6	Trolamine.....	275, 412
103-03-7	Phenicarbazide.....	211, 387
103628-48-4	Sumatriptan.....	252
103-84-4	Acetanilide.....	31, 319
103-90-2	Paracetamol.....	201
10540-29-1	Tamoxifen.....	255
106515-24-9	Sertindole.....	239
106650-56-0	Sibutramine.....	240
107-06-2	Ethylene dichloride.....	123
1077-28-7	Lipoic acid.....	162, 364
108319-06-8	Temafloxacin.....	257, 407, 408
1083-57-4	Bucetin.....	69, 330
108-95-2	Phenol.....	212, 389
1098-97-1	Pyritinol.....	234, 400
109-95-5	Ethyl nitrite (spirit).....	122
110-85-0	Piperazine.....	221, 394, 395
110871-86-8	Sparfloxacin.....	243
113427-24-0	Epoetin alfa.....	119
113-45-1	Methylphenidate.....	177, 373
114-86-3	Phenformin.....	209, 386, 387
115-33-3	Oxyphenisatine acetate.....	199
115-68-4	Sulfadiazine.....	245, 402, 403
116001-96-8	Pentosan polysulfate sodium.....	204
116644-53-2	Mibefradil.....	180
117-10-2	Dantron.....	101
1174-11-4	Xenazoic acid.....	281, 413
117591-79-4	Remoxipride.....	236
122-09-8	Phentermine.....	214, 390

A. INDEX BY CHEMICAL ABSTRACT SERVICE REGISTRY NUMBERS

CAS	Product name	Page
122312-54-3	Epoetin beta.....	119
123-31-9A	Hydroquinone.....	147
1233-53-0	Bunamiodyl.....	71, 331
125-42-8	Vinbarbital.....	279, 413
125-64-4	Methypylon.....	178, 373
125-71-3	Dextromethorphan.....	105, 343
125-84-8	Aminoglutethimide.....	44, 322
126-07-8	Griseofulvin.....	140
12629-01-5	Somatropin (pituitary-derived).....	241, 401
126-31-8	Methiodal sodium.....	177, 372, 373
127-58-2	Sulfamerazine sodium.....	248, 403
128-46-1	Dihydrostreptomycin.....	109, 345, 346
128-62-1	Noscapine.....	193
129-03-3	Cyproheptadine.....	99
129-20-4	Oxyphenbutazone.....	197
129618-40-2	Nevirapine.....	188, 377
130-26-7	Clioquinol (see also halogenated hydroxyquinoline derivatives).....	89
13149-68-3	Pangamic acid.....	201
132-60-5	Cinchophen.....	85
132875-61-7	Remifentanyl.....	235
1332-58-7	Kaolin.....	154, 362
13364-32-4	Clobenzorex.....	91
13392-18-2	Fenoterol.....	128, 352
134308-13-7	Tolcapone.....	268
134-49-6	Phenmetrazine.....	211, 387
13463-41-7	Pyrithione zinc.....	233
134678-17-4	Lamivudine.....	157
13473-38-6	Pipenzolate.....	221, 394
134-80-5	Amfepramone hydrochloride.....	42
13539-59-8	Azapropazone.....	56, 326
13838-14-7	Diphenazine.....	112
139-05-9	Cyclamates in drugs.....	98

A. INDEX BY CHEMICAL ABSTRACT SERVICE REGISTRY NUMBERS

CAS	Product name	Page
139133-26-9	Lexipafant.....	161
139755-83-2	Sildenafil.....	240, 400, 401
1403-66-3	Gentamicin (topical preparations).....	136
1405-10-3	Neomycin sulfate.....	187, 375, 376, 377
14261-75-7	Cloforex.....	94
144-82-1	Sulfamethizole.....	248, 403, 404
145599-86-6	Cerivastatin.....	77, 332
14611-51-9	Selegiline.....	239
147059-72-1	Trovafoxacin mesilate.....	276
1477-19-6	Benzarone.....	59, 327
148-24-3	Halogenated hydroxyquinoline derivatives.....	142
14838-15-4	Phenylpropanolamine.....	218, 392, 393
14882-27-4	Bismuth subsalicylate.....	64
149-80-6	Acetyllecine.....	32
14992-59-2	Sodium dibunate.....	241, 401
15307-79-6	Diclofenac sodium.....	105, 343, 344
154-23-4	Cianidanol.....	84
155-09-9	Tranylcypromine.....	269, 411
156-34-3	Levamphetamine.....	159, 363
15686-51-8	Clemastine.....	89
15687-27-1	Ibuprofen.....	148
157605-25-9	Alatrofloxacin mesilate.....	37
15793-40-5	Terodiline.....	260, 408
1617-90-9	Vincamine.....	279, 413
161967-81-3	Grepafloxacin hydrochloride.....	139
1622-62-4	Flunitrazepam.....	132, 353
16595-80-5	Levamisole hydrochloride.....	160, 364
1662-47-8	Gallopamil.....	134, 354
1668-19-5	Doxepin.....	114, 347
174722-31-7	Rituximab.....	237
1789-26-0	Acetylfurtrizine.....	32, 319
185243-69-0	Etanercept.....	121, 350

A. INDEX BY CHEMICAL ABSTRACT SERVICE REGISTRY NUMBERS

CAS	Product name	Page
1867-66-9	Ketamine hydrochloride.....	155
18869-73-3	Triacetyldiphenolisatin.....	271, 411, 412
1934-21-0	Tartrazine.....	256, 407
1972-08-3	Dronabinol.....	116
19767-45-4	Mesna.....	170, 368
19794-93-5	Trazodone.....	270, 411
2002-0-1001	Albumin.....	37
2002-0-1002	Amyl nitrite.....	50
2002-0-1003	Human dura mater.....	146
2002-0-1004	Hydroquinidine.....	147
2002-0-1005	Sodium hydrogen bicarbonate (paediatric).....	241
2002-0-1006	Aldesleukin.....	39
2002-0-1007	Aristolochia.....	52
2002-0-1008	Pexiganan.....	205
2002-0-1009	Pumactant.....	233
2002-0-1010	Ginkgo biloba.....	137, 354
2002-1-1001	Acetylsalicylic acid/antacid.....	285
2002-1-1002	Amoxicillin/clavulanic acid.....	286
2002-1-1003	Ampicillin/cloxacillin.....	286, 325
2002-1-1004	Azatadine maleate/pseudoephedrine sulfate.....	290, 326
2002-1-1005	Dicycloverine(dicyclomine)/doxylamine/pyridoxine).....	296
2002-1-1006	Etamivan in combination.....	298
2002-1-1007	Hydroxyquinolines in combination.....	301
2002-1-1008	Paracetamol/methionine.....	308
2002-1-1009	Quinidine/verapamil.....	313
2002-1-1010	Tilbroquinol/tiliquinol.....	315
2002-1-1012	Barbiturates in asthma preparations.....	290
2002-1-1013	Cloпамide, reserpine and dihydroergocristine mesilate.....	294
2002-1-1014	Kaolin and pectin.....	302
2002-1-1015	Loratadine and pseudoephedrine.....	303
2002-1-1016	Metamizole sodium, fempiverinium bromide and pitofenone hcl.....	305
2002-1-1017	Pseudoephedrine and phenylpropanolamine.....	311

A. INDEX BY CHEMICAL ABSTRACT SERVICE REGISTRY NUMBERS

CAS	Product name	Page
2002-1-1018	Trancylopramine and trifluoperazine.....	316
2002-1-5001	Anorectic drugs.....	287
2002-1-5003	Calcium channel blockers.....	293
2002-1-5004	Contrast media (ionic and non-ionic).....	294
2002-1-5005	Desensitizing vaccines.....	295
2002-1-5007	Iron preparations.....	302
2002-1-5008	Nitrates.....	306
2002-1-5009	Nonsteroidal anti-inflammatory agents.....	306
2002-1-5010	Oral contraceptives (third generation).....	306
2002-1-5011	Oral sodium phosphate bowel preparations.....	307
2002-1-5012	Pancreatic enzymes.....	308
2002-1-5013	Pyrethroids.....	312
2002-1-5014	Quinolone antimicrobial agents.....	313
2003-0-1001	Gamelonic acid.....	135, 354
2003-0-1002	Glutoxim.....	139
2003-1-1001	Allopurinol and benzbromarone.....	286
2003-1-1002	Calcium bromidum and chloral hydrate.....	292
2003-1-1003	Fluphenazine and nortriptyline.....	299
2003-1-1004	Lidocaine, salicylic acid and chloral hydrate.....	303
2003-1-1005	Phenobarbital, difebarbamate and febarbamate (Tetrabamate).....	309
2003-1-1006	Xibornol and lidocaine.....	317
2003-1-5001	Herbal dietary supplements.....	300
2003-1-5002	Kava products.....	302
2003-1-5003	Phlebotonics.....	310
2004-0-0001	Benzbromarone.....	59, 327
2004-0-0002	Bicalutamide.....	63
2004-0-0003	Camelia sinensis.....	73, 331
2004-0-0004	Danazol.....	101
2004-0-0005	Ephedra.....	118, 348
2004-0-0007	Metrodin HP.....	179
2004-0-0008	Nefazodone.....	187, 375
2004-0-0010	Paroxetine.....	202

A. INDEX BY CHEMICAL ABSTRACT SERVICE REGISTRY NUMBERS

CAS	Product name	Page
2004-0-0011	Vinarol and viga (dietary supplements).....	279
2004-1-1001	Benzbromarone and Benziodarone.....	292
2004-1-1002	Repaglinide and gemfibrozil.....	314
2078-54-8	Propofol.....	231, 399
2086-83-1	Berberine.....	62, 328
2098-66-0	Cyproterone acetate.....	100
2152-34-3	Pemoline.....	203
2154-02-1	Metofoline.....	179, 373
2169-64-6	Azaribine.....	56, 326
21721-92-6	Nitrefazole.....	190, 377, 378
2179-37-5	Bencyclane.....	58, 326
2181-04-6	Potassium canrenoate.....	226, 397
21829-25-4	Nifedipine.....	189
2207-50-3	Aminorex.....	47, 323
2210-63-1	Mofebutazone.....	182, 374
22131-79-9	Alclofenac.....	38, 320
22232-71-9	Mazindol.....	166, 365
23779-99-9	Floctafenine.....	131, 353
23887-46-9	Cinepazide.....	85
24219-97-4	Mianserin.....	180, 373
2438-72-4	Bufexamac.....	69, 330
24390-14-5	Doxycycline hyclate (injectable).....	115, 347, 348
24526-64-5	Nomifensine.....	192
2537-29-3	Proxibarbal.....	232
25614-03-3	Bromocriptine.....	68, 329, 330
25803-14-9	Clometacin.....	94
25812-30-0	Gemfibrozil.....	135, 354
260-94-6	Acridine derivatives.....	36, 320
2691-45-4	Diethylaminoethoxyhexestrol.....	107, 345
27203-92-5	Tramadol.....	269, 410, 411
27469-53-0	Almitrine.....	39
27470-51-5	Suxibuzone.....	255, 407

A. INDEX BY CHEMICAL ABSTRACT SERVICE REGISTRY NUMBERS

CAS	Product name	Page
28782-42-5	Difenoxin.....	109, 345
28911-01-5	Triazolam.....	271, 412
298-57-7	Cinnarizine.....	86
29883-15-6	Laetrile.....	157
300-25-4	Guanofuracin.....	141
300-62-9	Amfetamine.....	42, 321
30123-17-2	Tianeptine sodium.....	264, 410
302-22-7	Chlormadinone acetate.....	79, 335
302-79-4	Tretinoin.....	270, 411
303-81-1	Novobiocin.....	194
30748-29-9	Feprazone.....	128, 352
31329-57-4	Naftidrofuryl (parenteral formulations).....	185
313-67-7	Aristolochic acid.....	52, 325
3137-73-3	Anagestone acetate.....	50
315-80-0	Dibenzepin hydrochloride.....	105, 343
317-34-0	Aminophylline.....	47, 323
31793-07-4	Pirprofen.....	223
31842-01-0	Indoprofen.....	150
32359-34-5	Medifoxamine.....	167
3239-44-9	Dexfenfluramine.....	104, 343
3239-45-0	Dexfenfluramine hydrochloride.....	104
33005-95-7	Tiaprofenic acid.....	265
33125-97-2	Etomidate.....	124, 351
33369-31-2	Zomepirac.....	282, 414
33386-08-2	Buspirone hydrochloride.....	72
34161-24-5	Fipexide.....	129, 352
3416-24-8	Glucosamine sulfate.....	138
34433-66-4	Levacetylmethadol.....	159, 363
34552-84-6	Isoxicam.....	154, 362
34645-84-6	Fenclofenac.....	126, 352
34758-83-3	Zipeprol.....	281, 413, 414
3521-62-8	Erythromycin estolate.....	120, 349, 350

A. INDEX BY CHEMICAL ABSTRACT SERVICE REGISTRY NUMBERS

CAS	Product name	Page
3562-63-8	Megestrol acetate.....	168, 366
3583-64-0	Bumadizone.....	70, 331
3595-11-7	Propylhexedrine.....	231, 399
359-83-1	Pentazocine.....	204
360-70-3	Nandrolone decanoate (injectable).....	186, 374
363-24-6	Dinoprostone.....	111, 346
364-62-5	Metoclopramide (paediatric).....	179
3736-08-1	Fenetyline.....	127, 352
37612-13-8	Encainide.....	117
3820-67-5	Glafenine.....	137, 354
3836-23-5	Norethisterone enantate (injectable).....	192
390-64-7	Prenylamine.....	229
3930-20-9	Sotalol.....	242
39562-70-4	Nitrendipine.....	190
4008-48-4	Nitroxoline.....	191
40180-04-9	Tienilic acid.....	266, 410
40828-46-4	Suprofen.....	254, 406
41708-72-9	Tocainide.....	267, 410
4214-72-6	Isaxonine phosphate.....	151, 361
43200-80-2	Zopiclone.....	282, 414
456-59-7	Cyclandelate.....	98
458-24-2	Fenfluramine.....	127
461-78-9	Chlorphentermine.....	84, 336
467-80-7	Pipradrol.....	222, 395, 396
468-68-1	Oxeladin.....	196
474-25-9	Chenodeoxycholic acid.....	78, 332, 333
4759-48-2	Isotretinoin.....	152, 362
479-92-5	Propyphenazone.....	232, 399
481-06-1	Santonin.....	237, 400
483-18-1	Emetine.....	117, 348
492-39-7	Cathine.....	76, 332
494-03-1	Chlornaphazine.....	81, 336

A. INDEX BY CHEMICAL ABSTRACT SERVICE REGISTRY NUMBERS

CAS	Product name	Page
496-67-3	Bromisoval.....	67
5003-48-5	Benorilate.....	58, 327
50-06-6	Phenobarbital.....	211, 387, 388, 389
50-29-3A	Clofenotane.....	91
50-33-9	Phenylbutazone.....	215, 390, 391, 392
50-35-1	Thalidomide.....	262, 409
50-48-6	Amitriptyline.....	48, 324
50-56-6	Oxytocin.....	201
50-59-9	Cefaloridine.....	76
50679-08-8	Terfenadine.....	258, 408
50-78-2	Acetylsalicylic acid (paediatric).....	32, 319
509-86-4	Heptabarb.....	144
51022-71-0	Nabilone.....	185, 374
511-12-6	Dihydroergotamine/heparin.....	296
51-12-7	Nialamide.....	188, 377
51234-28-7	Benoxaprofen.....	58, 327
51-34-3	Scopolamine.....	238, 400
51-41-2	Levarterenol.....	160, 364
51-43-4	Epinephrine.....	118, 348, 349
514-73-8	Dithiazanine iodide.....	113, 346, 347
514-78-3	Canthaxanthin.....	74, 332
51-55-8	Atropine in combination.....	290
515-64-0	Sulfisomidine.....	250, 406
51-64-9	Dexamfetamine.....	104, 343
51-79-6	Urethane.....	277
51803-78-2	Nimesulide.....	189, 377
52-01-7	Spirolactone.....	243, 401, 402
521-74-4	Broxyquinoline (see also halogenated hydroxyquinoline derivatives).....	68, 330
52214-84-3	Ciprofibrate.....	86
522-51-0	Dequalinium chloride.....	103, 343
52432-72-1	Oxeladin citrate.....	196
52468-60-7	Flunarizine.....	131

A. INDEX BY CHEMICAL ABSTRACT SERVICE REGISTRY NUMBERS

CAS	Product name	Page
52485-79-7	Buprenorphine.....	71, 331
52-76-6	Lynestrenol.....	166, 365
53179-11-6	Loperamide.....	162, 364
53230-10-7	Mefloquine.....	167
533-45-9	Clomethiazole.....	95
53-43-0	Prasterone.....	228, 398
53583-79-2	Sultopride.....	252, 406
537-46-2	Metamfetamine.....	171, 368, 369
53-86-1	Indometacin and indometacin farnesil.....	149
539-08-2	Beta ethoxylacetanilide.....	62
54-05-7	Chloroquine.....	83, 336
54063-53-5	Propafenone.....	230, 399
54143-55-4	Flecainide.....	129, 352, 353
54-32-0	Moxisylyte.....	183
54350-48-0	Etretinate.....	124, 351
54739-18-3	Fluvoxamine.....	133, 353
547-44-4	Sulfacarbamide.....	245
54767-75-8	Suloctidil.....	251, 406
548-62-9	Methylrosanilinium chloride.....	178
548-73-2	Droperidol.....	116, 348
54910-89-3	Fluoxetine.....	133
54-92-2	Iproniazid.....	151, 361
55079-83-9	Acitretin.....	35, 319
55142-85-3	Ticlopidine.....	265, 410
55294-15-0	Muzolimine.....	184
55937-99-0	Beclobrate.....	57
56180-94-0	Acarbose.....	31
56227-39-5	Polidexide sulfate.....	224
56-29-1	Hexobarbital.....	146
5635-50-7	Hexestrol.....	145
563-63-3	Silver acetate.....	240, 401
56-53-1	Diethylstilbestrol.....	107, 345

A. INDEX BY CHEMICAL ABSTRACT SERVICE REGISTRY NUMBERS

CAS	Product name	Page
56-64-8	Thiomersal.....	264, 410
56-75-7	Chloramphenicol.....	78, 333, 334, 335
56775-88-3	Zimeldine.....	281, 413
56824-20-5	Amiprilose.....	48
569-65-3	Meclozine.....	167, 365, 366
57-24-9	Strychnine and salts.....	244
57-43-2	Amobarbital.....	49, 324, 325
57-44-3	Barbital.....	57, 326
57-53-4	Meprobamate.....	170, 367, 368
57574-09-1	Amineptine.....	43
57-67-0	Sulfaguanidine.....	246, 403
57-68-1	Sulfadimidine.....	246, 403
57808-66-9	Domperidone(injectable).....	114, 347
57-85-2	Testosterone propionate (injectable).....	260, 408, 409
5786-21-0	Clozapine.....	95
57-92-1	Streptomycin.....	244, 402
58-15-1	Aminophenazone.....	44, 322, 323
58-89-9A	Lindane.....	161, 364
59122-46-2	Misoprostol.....	182, 374
59-42-7	Phenylephrine.....	218, 392
59-47-2	Mephesisin.....	170, 366
59-63-2	Isocarboxazid.....	151, 361
59-87-0	Nitrofur.....	190, 378
59-96-1	Phenoxybenzamine.....	214, 390
60325-46-4	Sulprostone.....	252, 406
60-54-8	Tetracycline (paediatric).....	261, 409
60643-86-9	Vigabatrin.....	278, 413
60-80-0	Phenazone.....	207, 385
60-87-7	Promethazine.....	229
6095-47-8	Codeine.....	97
6106-46-3	Hyoscine methonitrate.....	148
62-44-2	Phenacetin.....	205, 385

A. INDEX BY CHEMICAL ABSTRACT SERVICE REGISTRY NUMBERS

CAS	Product name	Page
62666-20-0	Progabide.....	229, 398
62-90-8	Nandrolone phenylpropionate (injectable).....	186, 375
634-03-7	Phendimetrazine.....	208, 386
637-07-0	Clofibrate.....	92
63-74-1	Sulfanilamide.....	249, 405
63758-79-2	Indalpine.....	149
64-17-5	Ethanol.....	121, 350, 351
64241-34-5	Cadralazine.....	72, 331
64952-97-2	Latamoxef.....	158, 363
65-23-6	Pyridoxine (Vitamin B6).....	233
65277-42-1	Ketoconazole.....	156, 363
65-28-1	Phentolamine mesilate.....	215
657-24-9	Metformin.....	175
66195-31-1	Ibopamine.....	148
6673-35-4	Practolol.....	227, 398
6707-58-0	Dequalinium.....	103
67-20-9	Nitrofurantoin.....	191, 378
67-45-8	Furazolidone.....	133, 353, 354
67-56-1	Methanol.....	175
67-66-3	Chloroform.....	81, 336
67915-31-5	Terconazole.....	258, 408
68-26-8	Retinol.....	236, 400
68767-14-6	Loxoprofen sodium.....	164
68844-77-9	Astemizole.....	54, 325
68-89-3	Metamizole sodium.....	171, 369, 370, 371
692-13-7	Buformin.....	69, 330, 331
69-57-8	Benzylpenicillin sodium (topical preparations).....	61, 328
69756-53-2	Halofantrine.....	142
70-30-4	Hexachlorophene.....	145
71-27-2	Suxamethonium chloride.....	254
71-58-9	Depot medroxyprogesterone acetate (DMPA).....	102
7175-09-9	Tilbroquinol.....	267

A. INDEX BY CHEMICAL ABSTRACT SERVICE REGISTRY NUMBERS

CAS	Product name	Page
72-14-0	Sulfathiazole.....	250, 405, 406
72-44-6	Methaqualone.....	176, 372
72599-27-0	Miglustat.....	181, 373
7297-25-8	Erythryl tetranitrate.....	119
73-22-3	L-Tryptophan.....	164, 364
73-31-4	Melatonin.....	169
73590-58-6	Omeprazole.....	194
739-71-9	Trimipramine.....	274, 412
74103-06-3	Ketorolac.....	156
742-20-1	Cyclopenthiiazide.....	99
7440-48-4	Cobalt (non-radioactive forms).....	96
7447-40-7	Potassium chloride.....	226, 397, 398
74-55-5	Ethambutol.....	121, 350
745-65-3	Alprostadil.....	40, 320, 321
7542-37-2	Paromomycin.....	202
75659-07-3	Dilevalol.....	110
76-22-2	Camphor.....	73, 332
76568-02-0	Flosequinan.....	131
76-73-3	Secobarbital.....	238, 400
76-74-4	Pentobarbital.....	204
76824-35-6	Famotidine.....	126, 351, 352
7683-59-2	Isoprenaline.....	152, 361, 362
77-02-1	Aprobarbital.....	52, 325
77-09-8	Phenolphthalein.....	213, 389, 390
77-19-0	Dicycloverine.....	106, 344
77-21-4	Glutethimide.....	139
7757-79-1	Potassium nitrate.....	227, 398
79-09-4	Propionic acid.....	230
794-93-4	Dihydroxymethylfuratrizine.....	110, 346
8008-60-4	Opium in antitussive preparations.....	195
8015-79-0	Calamus.....	73, 331
80-35-3	Sulfamethoxy pyridazine.....	248, 404, 405

A. INDEX BY CHEMICAL ABSTRACT SERVICE REGISTRY NUMBERS

CAS	Product name	Page
80387-96-8	Difemerine.....	108
804-36-4	Difurazone.....	109, 345
804-63-7	Quinine sulfate.....	235
8064-90-2	Trimethoprim/sulfamethoxazole.....	316
80-77-3	Chlormezanone.....	80
810968-60-4	Cisapride.....	86
81-81-2	Warfarin.....	280, 413
82626-01-5	Alpidem.....	40
82964-04-3	Tolrestat.....	269
83480-39-9	Voglibose.....	280
83-89-6	Mepacrine.....	169
84-04-8	Pipamazine.....	221, 394
84057-84-1	Lamotrigine.....	158
84-17-3	Dienestrol.....	107, 344, 345
84371-65-3	Mifepristone.....	181, 373
853-34-9	Kebuzone.....	155, 362, 363
85-73-4	Phthalylsulfathiazole.....	220, 393
86-12-4	Thenalidine.....	263, 410
86-42-0	Amodiaquine.....	49, 325
864-50-4	Temazepam.....	257
9000-69-5	Pectin.....	203
9001-54-1	Hyaluronidase.....	147
9002-07-7	Trypsin.....	276, 412
9003-39-8	Polyvidone.....	225, 396, 397
90101-16-9	Droxicam.....	116
9014-67-9	Aloxiprin.....	40, 320
9016-01-7	Orgotein.....	195
90-84-6	Amfepramone.....	42, 321
91161-71-6	Terbinafine.....	257
915-30-0	Diphenoxylate.....	112, 346
915-67-3	Amaranth.....	41
91-64-5	Coumarin (synthetic).....	97

A. INDEX BY CHEMICAL ABSTRACT SERVICE REGISTRY NUMBERS

CAS	Product name	Page
91714-94-2	Bromfenac.....	67
91-80-5	Methapyrilene.....	175, 371
94-36-0	Benzoylperoxide.....	59, 327
94-78-0	Phenazopyridine.....	208, 385, 386
95-27-2	Dimazole.....	111, 346
965-90-2	Ethylestrenol.....	123, 351
97-18-7	Bithionol.....	65, 328
97322-87-7	Troglitazone.....	274, 412
97-44-9	Acetarsol.....	31, 319
976-71-6	Canrenone.....	74, 332
99-66-1	Valproic acid.....	278, 412
UN-87-0001	Allergen extracts.....	39, 320
UN-87-0003	Factor IX.....	125, 351
UN-87-0004	Factor VIII.....	126, 351
UN-87-0006	Polyoxyethylated castor oil.....	225, 396
UN-87-0008	Oral rehydration salts.....	195
UN-88-0001	Antirheumatic combinations with glucocorticosteroids.....	289
UN-88-0002	Cefalosporins (topical preparations).....	76, 332
UN-88-0004	Sulfonamides (topical preparations).....	251
UN-88-0007	Meprobamate/diazepines.....	304
UN-88-0008	Penicillin/streptomycin.....	308
UN-88-0009	Phenformin/chlorpropamide.....	309
UN-88-0010	Theophylline/meprobamate/barbiturates.....	315
UN-90-0001	Mucopolysaccharide polysulfuric acid ester.....	183
UN-92-0001	Anabolic steroids.....	50
UN-92-0002	Androgens.....	51
UN-92-0003	H1-Antihistamines.....	141
UN-92-0004	Aphrodisiac drugs.....	52
UN-92-0005	Cell preparations.....	77
UN-92-0006	Estrogens.....	297
UN-92-1001	Acetylsalicylic acid/codeine.....	285
UN-92-1002	Anorectic dugs in combinations.....	288

A. INDEX BY CHEMICAL ABSTRACT SERVICE REGISTRY NUMBERS

CAS	Product name	Page
UN-92-1003	Estrogens (in oral contraceptives).....	298
UN-92-1004	Tiratricol/cyclovalone/retinol.....	316
UN-95-0001	ACE-Inhibitors.....	284
UN-95-0002	Antihistamine (topical).....	51
UN-95-0003	Bovine tissue derived medicines.....	66
UN-95-0004	Cartilage extract.....	75
UN-95-0005	Gangliosides.....	135, 299
UN-95-0006	Germander.....	136
UN-95-0007	Nebacumab.....	187
UN-95-0008	Placental tissue derived medicine.....	223
UN-95-0009	Pyrrrolizidine.....	234
UN-95-0011	Rubiae tinctorum radix.....	237
UN-95-0012	Vaccines for mumps, measles, and rubella.....	277
UN-95-0013	Ziperol.....	282
UN-95-1001	Analgesics in combination.....	286
UN-95-1002	Antidiarrhoeal combinations.....	289
UN-95-1003	Ethinylestradiol/methyltestosterone.....	299
UN-95-1004	Promethazine in combination.....	310
UN-95-1005	Tyrothricin/fomocaine/diphenhydramine.....	317
UN-CJ-0001	Pyrazolones in combination (see also aminophenazone, metamizole sodi)	311
UN-KG-0001	Acetylsalicylic acid/phenacetin/caffeine (APC).....	285
UN-KG-0012	Arsenic-based compounds.....	53
UN-KG-0014	Barbiturates in combination.....	291
UN-KG-0015	Bismuth salts.....	63
UN-KG-0017	Chloramphenicol in combination.....	293
UN-KG-0018	Chlormadinone acetate/mestranol (in oral contraceptives).....	294
UN-KG-0019	Cycloserine/isoniazid.....	295
UN-KG-0020	Dalkon shield.....	100
UN-KG-0022	Dihydrostreptomycin sulfate/streptomycin sulfate.....	296
UN-KG-0024	Dipotassium clorazepate/acepromazine/aceprometazine.....	297
UN-KG-0028	Estrogen-progestogen preparations for secondary amenorrhea.....	297
UN-KG-0030	Estrogens/testosterone.....	298

A. INDEX BY CHEMICAL ABSTRACT SERVICE REGISTRY NUMBERS

CAS	Product name	Page
UN-KG-0031	Etidocaine hydrochloride/epinephrine tartrate.....	299
UN-KG-0033	Guaifenesin/camphor/ether.....	300
UN-KG-0034	Halogenated salicylanilides.....	143
UN-KG-0035	Herpes simplex vaccines.....	144
UN-KG-0036	Hormonal pregnancy tests.....	300
UN-KG-0037	Hydrochlorothiazide/potassium.....	301
UN-KG-0038	Iodinated casein strophanthin (neo-barine).....	150, 361
UN-KG-0040	Lead oxide and lead salts.....	159, 363
UN-KG-0041	Lobelia.....	162
UN-KG-0044	Medroxyprogesterone acetate/ethinylestradiol.....	303
UN-KG-0045	Mepyramine maleate/pamabrom.....	304
UN-KG-0046	Mercuric derivatives (topical).....	304, 368
UN-KG-0047	Metoclopramide/polidocanol.....	305
UN-KG-0049	Neomycin sulfate/polymyxin bisulfate/nystatin/acetarsol.....	305
UN-KG-0050	Dionaea muscipula (extract).....	112
UN-KG-0055	Penicillin/tetracycline.....	309
UN-KG-0057	Pipradol/hesperidin.....	310
UN-KG-0058	Pituitary-chorionic gonadotropin (injectable).....	223, 396
UN-KG-0059	Podophyllum resin.....	224, 396
UN-KG-0060	Prednisolone/phenobarbital.....	310
UN-KG-0065	Sulfathiazole sodium with sodium lactate or sodium bicarbonate.....	314
UN-KG-0066	Superheporin.....	314
UN-KG-0068	Tetracycline in combination.....	314
UN-KG-0069	Thiazides/potassium chloride.....	315

**B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC
AND COMMON NAMES, AND SYNONYMS**

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
A,A-DIMETHYLPHENETHYLAMIN.....	214
A-[4-(1,1-DIMETHYLETHYL)PHENYL]-4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDINEBUTANOL.....	258
ACEPROMAZINE/DIPOTASSIUM CLORAZEPATE/ACEPROMETAZINE.....	297
ACEPROMETAZINE/ACEPROMAZINE/DIPOTASSIUM CLORAZEPATE.....	297
ACETAMIDE, 2,2-DICHLORO-N-(2-HYDROXY-1-(HYDROXYMETHYL)-2-(4-NITROPHENYL)ETHYL)-, (R-(R*,R*)).....	78
ACETAMIDE, N-(4-(2-HYDROXY-3-((1-METHYLETHYL)AMINO)PROPOXY)PHENYL)-.....	227
ACETAMIDE, N-(4-ETHOXYPHENOL)-.....	205
ACETAMIDE, N-(4-HYDROXYPHENYL)-.....	201
ACETAMINOPHEN.....	201
ACETARSONE.....	31
ACETIC ACID, (2,3-DICHLORO-4-(2-THIENYL CARBONYL)PHENOXY)-.....	266
ACETIC ACID, O-(2,6-DICHLOROANILINO)PHENYL)-, MONOSODIUM SALT.....	106
ACETOPHENETHIDINE.....	205
ACETOPHENETIDIN.....	205
ACETPHENOLISATIN.....	199
ACRIFLAVINE.....	36
ADRENALINE.....	118
AHR-10282.....	67
AHR-3070-C.....	179
ALBA.....	154
ALCANFOR.....	73
ALCOHOL.....	121
ALDADIENE.....	74
ALDADIENE POTASSIUM.....	226
ALL-TRANS-RETINOIC ACID.....	270
ALPHA-(ALPHA-METHOXYBENZYL)-4-(BETA-METHOXYPHENETHYL)-1-PIPERAZINEETHANOL.....	281
ALPHA-(N-PHTHALIMIDO)GLUTARIMIDE.....	263
ALPHA,ALPHA-BIS(P-CHLOROPHENYL)-BETA,BETA,BETA-TRICHLORETHANE.....	91
ALPHA,ALPHA'-DIETHYL-(E)-4,4'-STILBENEDIOL.....	108
ALPHA,ALPHA-DIMETHYLPHENETHYLAMINE.....	214
ALPHA,ALPHA-DIPHENYL-2-PIPERIDINEMETHANOL.....	222

**B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC
AND COMMON NAMES, AND SYNONYMS**

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
ALPHA[3-[[2-(3,4-DIMETHOXYPHENYL)ETHYL]METHYLAMINO]PROPYL]-3,4,5-TRIMETHOXY-ALPHA-(1-METHYL-ETHYL) BENZEN	134
ALPHA-HYDROXYTOLUENE.....	60
ALPHA-TOLUENOL.....	60
AMFEPRAMONE,BENZFETAMINE,BENFLUOREX,FENFLURAMINE,PHENDIMETRAZINE,PHENTERMINE/TIRATRICOL/THYROID H	288
AMFETAMINE-LIKE COMPOUNDS.....	287
AMFETYLINE.....	127
AMIDAZOFEN.....	45
AMIDOPYRINE.....	45
AMIDOPYRINE.....	311
AMIDOPYRINE-PYRAMIDON.....	45
AMINACRINE.....	36
AMINOPHYLLINUM.....	47
AMINOPYRINE.....	44
AMINOXAPHEN.....	48
AMPHETAMINE.....	43
AMYCAZOL.....	111
AMYGDALIN.....	157
AMYLBARBITONE.....	49
ANALESICS/MEPROBAMATE.....	286
ANALGESICS/BARBITURATES.....	291
ANALGESICS/BENZODIAZEPINES.....	286
ANALGIN.....	171
ANDROST-4-EN-3-ONE, 17-(1-OXOPROPOXY)-, (17BETA)-.....	261
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS.....	284
ANTACIDS/BARBITURATES.....	291
ANTIASTHMATICS/BARBITURATES.....	291
ANTIFEBRIN.....	31
ANTIMALARINAE CHLORHYDRAS.....	169
ANTIPYRINE.....	44
ANTRAPUROL.....	101
APAZONE.....	56

**B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC
AND COMMON NAMES, AND SYNONYMS**

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
APC.....	285
APROBARBITONE.....	52
AQUEOUS CALF CARTILAGE & BONE MARROW EXTRACT.....	75
ARGENTI ACETATE.....	240
ARISTOLOCHINE.....	53
ARRITHINUM.....	169
ARTIFICIAL LUNG EXPANDING COMPOUND.....	233
ASPIRIN.....	32
AS-TRIAZINE-3,5-(2H,4H)-DIONE, 2-(2',3',5'-TRIACETYL-BETA-D- RIBOFURANOSYL)-.....	56
ATRIUM.....	291
AXEROPHTHOCUM.....	236
AZOPHENUM.....	208
BARBITONE.....	57
BARBITURATES/ANALGESICS.....	291
BARBITURATES/ANTACIDS.....	291
BARBITURATES/ANTIASTHMATICS.....	291
BARBITURATES/MEPROBAMATE/THEOPHYLLINE.....	315
BENEZENEMETHANOL, ALPHA-(1-AMINOETHYL)-,(R*,S*)-, (+/-).....	218
BENORYLATE.....	58
BENZAMIDE, 3-BROMO-N-[(1-ETHYL-2-PYRROLIDINYL)METHYL]-2,6-DIMETHOXY-, (S).....	236
BENZAMIDE, N-(2-PIPERIDINYL METHYL)-2,5-BIS(2,2,2-TRIFLUOROETHOXY)-.....	129
BENZAMIDE, N,N-DIETHYL-4-HYDROXY-3-METHOXY-.....	298
BENZAMIDE,2-HYDROXY-5-[1-HYDROXY-2-[(1-METHYL-3-PHENYLPROPYL)AMINO]ETHYL]-,[R-(R*,R*)].....	111
BENZAMIDE,4-METHOXY-N-[2-[2-(1-METHYL-2-PIPERIDINYL)ETHYL]-PHENYL]-,(N̄).....	117
BENZAMIDE,N-(7-[(3-O-(AMINOCARBONYL)-6-DEOXY-5-C-METHYL-4-O-METHYL-BETA-L-LYXO-HEXOPYRANOSYL)OXY]-4-HYDR	194
BENZENACETIC ACID, ALPHA-METHYL-4-(2-THIENYL CARBONYL)-.....	254
BENZENE HEXACHLORIDE, GAMMA.....	161
BENZENEACETIC ACID, 2-((2,6-DICHLOROPHENYL)AMINO)-, MONOSODIUM SALT.....	106
BENZENEACETIC ACID, 2-(2,4-DICHLOROPHENOXY)-.....	126
BENZENEACETIC ACID, 3-CHLRO-4-(2-PROPENYLOXY)-.....	38
BENZENEACETIC ACID, 4-(1,3-DIHYDRO-1-OXO-2H-ISOINDOL-2-YL)-ALPHA-METHYL.....	150

B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC AND COMMON NAMES, AND SYNONYMS

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
BENZENEACETIC ACID, ALPHA-(HYDROXYMETHYL)-,9-METHYL-3-OXA-9-AZATRICYCLO[3.3.1.0.??]NON-7-YL ESTER,[7(S)-(1AL	238
BENZENEACETIC ACID, ALPHA-(HYDROXYMETHYL)-8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL ESTER, ENDO(+/-)-.....	290
BENZENEACETIC ACID,3-CHLORO-4-(2,5-DIHYDRO-1H-PYRROL-1-YL)-ALPHA-METHYL-.....	223
BENZENECARBINOL.....	60
BENZENEETHANAMINE, ALPHA,ALPHA-DIMETHYL.....	214
BENZENEETHANAMINE, ALPHA-METHYL-, (+/-).....	43
BENZENEETHANAMINE, ALPHA-METHYL-,(S)-.....	104
BENZENEETHANAMINE, N,?-DIMETHYL-N-2-PROPYNYL-, HYDROCHLORIDE, (R)-.....	239
BENZENEETHANAMINE, N-ETHYL- -METHYL-3-(TRIFLUOROMETHYL)-, HYDROCHLORIDE.....	127
BENZENEETHANAMINE, N-ETHYL-?-METHYL-3-(TRIFLUOROMETHYL)-, HYDROCHLORIDE.....	127
BENZENEMETHANAMINE, N-(2-CHLOROETHYL)-N-(1-METHYL-2-PHENOXYETHYL).....	214
BENZENEMETHANOL.....	60
BENZENEMETHANOL, 3-HYDROXY-ALPHA-((METHYLAMINO)METHYL).....	218
BENZENEMETHANOL, 4-((1-METHYLETHYL)THIO)-ALPHA-(1-(OCTYLAMINO)ETHYL-, (R*,S*)-.....	251
BENZENEPROPANAMINE, N-(1,1-DIMETHYLETHYL)-ALPHA-METHYL-GAMMA-PHENYL-.....	260
BENZENEPROPANAMINE, N-(1-METHYL-2-PHENYLETHYL)-GAMMA-PHENYL-.....	229
BENZENEPROPANAMINE, N-METHYL-G-[4-(TRIFLUOROMETHYL)- PHENOXYL]-, (±)-.....	133
BENZENESULFONAMIDE, 4-AMINO-N-(5-METHYL-1,3,4-THIADIAZOL-2-YL)-.....	248
BENZENESULFONAMIDE, 4-AMINO-N-(DIAMINOMETHYLENE)-.....	246
BENZENESULFONAMIDE, 4-AMINO-N-2-THIAZOLYL.....	250
BENZOIC ACID, 2-(((4-((2-THIAZOLYLAMINO)SULFONYL)PHENYL)AMINO)-CARBONYL)-.....	220
BENZOIC ACID, 2-(ACETYLOXY)-.....	32
BENZOIC ACID, 2-[[8-(TRIFLUOROMETHYL)-4-QUINOLINYL]AMINO]-,2,3-DIHYDROXYPROPYL ESTER.....	131
BENZOIC ACID, PEROXIDE.....	60
BENZOTHIAZOL,6-(2-DIETHYLAMINOETHOXY)-2-DIMETHYLAMINO-.....	111
BENZOYL PEROXIDE.....	59
BENZYL PENICILLIN.....	61
BERBERICINE.....	62
BERBERIN.....	62
BETA,BETA-CAROTENE-4,4'-DIONE.....	74
BETA-NAPHTHYLBIS(BETA-CHLOROETHYL)AMINE.....	81

**B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC
AND COMMON NAMES, AND SYNONYMS**

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
BIOALLETHRIN.....	312
BIS(2-HYDROXY-3,5-DICHLOROPHENYL)SULFIDE.....	65
BIS(HYDROXYMETHYL)FURATRIZINE.....	110
BISATIN.....	199
BOLUS.....	154
BORDEAUX-S.....	41
BORIC ACID (H3BO3).....	65
BORIC ACID (H3BO3).....	292
BOVINE SUPEROXIDE DISMUTASE.....	195
BROCIDE.....	123
BROMISOVALERYLUREA.....	68
BROMVALERYLUREA.....	68
BROMVALETONE.....	68
BROMYLUM.....	68
BTS-54524 (SIBUTAMINE HYDROCHLORIDE).....	240
BUFORMINE.....	70
BUTADIONE.....	216
BUTANAMIDE, 4-(((4-CHLOROPHENYL)(5-FLUORO-2-HYDROXYPHENYL)METHYLENE) AMINO)-.....	229
BUTANOVA.....	197
BUTFORMIN.....	70
BUTYLBIGUANIDE.....	70
BUTYLDIGUANIDE.....	69
BUTYLFORMIN.....	69
BUTYLMALONIC ACID MONO(1,2-DIPHENYLHYDRAZIDE).....	70
CAFFEINE/PHENACETIN/ACETYLSALICYLIC ACID.....	285
CAMPHOR/GUAIFENESIN/ETHER.....	300
CAMPHORA.....	73
CANTHARIDES.....	52
CARBAMIC ACID, ETHYL ESTER.....	277
CARBARIL.....	312
CEPHALORIDINE.....	76

**B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC
AND COMMON NAMES, AND SYNONYMS**

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
CG-315.....	269
CHENODIOL.....	78
CHINACRINA MEPACRINI HYDROCHLORIDIUM.....	169
CHININI SULFAS.....	235
CHINOFORM.....	89
CHITOSAMINE SULFATE.....	138
CHLORAMPHENICOL/TETRACYCLINE.....	315
CHLORETHIAZOL.....	95
CHLORETHIAZOLE.....	95
CHLORMETHAZANONE.....	80
CHLOROIDOQUIN.....	89
CHLOROPHENOTHANE.....	91
CHLORPROPAMIDE/PHENFORMIN.....	309
CHOLAN-24-OIC ACID, 3,7-DIHYDROXY-, (3ALPHA,5BETA,7ALPHA)-.....	78
CHRYSAZIN.....	101
CI ACID RED 27.....	41
CI FOOD ORANGE 8.....	74
CI FOOD RED 9.....	41
CI FOOD YELLOW 4.....	256
CIANIDOL.....	84
CINCHONAN-9-OL, 6'-METHOXY-, (8?, 9R)-, SULFATE (2:1) (SALT).....	235
CINCHONINIC ACID, 2-PHENYL-.....	85
CINNAMIC ACID, 3-BUTYRAMIDO-ALPHA-ETHYL-2,4,6-TRIIODO-,.....	71
CIS-1-[P-((2-(2,4-DICHLOROPHENYL)-2-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL]-4-ISOPROPYL.....	258
CIS-4-AMINO-5-CHLORO-N-[1-[3-(P-FLUOROPHENOXY)PROPYL]-3-METHOXY-4-PIPERIDYL]-O-ANISAMIDE;.....	87
CISAPRIDUM.....	87
CL BASIC VIOLET.....	178
CL-581.....	155
CLOPHOREX.....	94
CLORAZOLAM.....	272
CN-52372-2.....	155

**B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC
AND COMMON NAMES, AND SYNONYMS**

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
CODEINE/ACETYLSALICYLIC ACID.....	285
COLOUR INDEX NO. 19140.....	256
COLOUR INDEX NO.16185.....	41
COLOUR INDEX NO.40850.....	74
CO-TRIMOXAZOLE.....	316
CP-99219-27.....	276
CRYSTAL VIOLET.....	178
CRYSTALLINE PENICILLIN G SODIUM.....	61
CYCLOHEXANE, 1,2,3,4,5,6-HEXACHLORO-,(1ALPHA,2ALPHA,3BETA,4ALPHA,5ALPHA,6BETA)-.....	161
CYCLOHEXANEETHANAMINE, N,ALPHA-DIMETHYL-(+/-).....	231
CYCLOHEXANESULFAMIC ACID.....	98
CYCLOHEXANOL,2-((DIMETHYLAMINO)METHYL)-1-(3-METHOXYPHENYL)-, TRANS-(+/-).....	269
CYCLOPROPANAMINE, 2-PHENYL-, TRANS-(+/-)-.....	270
CYCLOVALONE/TIRATRICAL/RETINOL.....	316
DANTHRON.....	101
DDT.....	91
DEAE-SEPHADEX.....	224
DECALINIUM CHLORIDE.....	103
DECAMINIUM.....	103
DEHYDROANDROSTERONE.....	228
DEHYDROEPIANDROSTERONE.....	228
DEPRENYL.....	239
DETHYLPROPION HYDROCHLORIDE.....	42
DEXAMPHETAMINE.....	104
DEXFENFLURAMINE.....	287
DEXTRAN 2-(DIETHYLAMINO)ETHYL 2-((2-(DIETHYLAMINO)ETHYL)DIETHYLAMMONIO) ETHYL ETHER SULFATE, EPICHLOROH	224
DEXTROAMPHETAMINE.....	104
D-GLUCOSE, 2-AMINO-2-DEOXY-, SULFATE.....	138
D-GLUCOSE, O-4,6-DIDEOXY-4-[[[1S-(1?,4?, 5?, 6?)]-4,5,6-TRIHYDROXY-3-(HYDROXYMETHYL)-2-CYCLOHEXEN-1-YL]-AMINO]-1-	31
DHEA.....	228
DHSM.....	110

B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC AND COMMON NAMES, AND SYNONYMS

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
DIACETOXYDIPHENYLISATIN.....	199
DIACETYLDIPHENOLISATIN.....	199
DIAMTHAZOLE DIHYDROCHLORIDE.....	111
DIANTHON.....	101
DIASATIN.....	199
DIBENZO(C,F)-PYRAZINO(1,2-A)AZEPINE, 1,2,3,4,10,14B-HEXAHYDRO-2- METHYL.....	180
DIBENZOYL PEROXIDE.....	60
DIBROMSALAN.....	143
DICHLORODIPHENYLTRICHLOROETHANE (USA).....	91
DICYCLOMINE.....	106
DIEMALUM.....	57
DIENOL.....	107
DIETHYLMALONYLUREA.....	57
DIETHYLPROPION.....	42
DIETHYLSTILBOESTROL.....	108
DIFENOXYLIC ACID.....	109
DIHYDROQUINIDINE.....	147
DIHYDROSTILBOESTROL.....	146
DIMETHYL-{3-(3-(10,11-DIHYDRO-5H-DIHENZ[B,F]AZEPIN-5-YL-2-METHYL)PROPYL)AMINE.....	274
DIMETHYLAMINOANTIPYRINE.....	45
DIMETHYLAMINOPHENAZONE.....	45
DINOVEX.....	107
DIPHENOXYLATI HYDROCHLORIDIUM.....	113
DIPHESATIN.....	199
DIPYRON.....	171
DIPYRONE.....	171
D-ISOEPHEDRINE.D-?-EPHEDRINE.....	311
DISOPROFOL.....	231
DL-ERYTHRO-2-AMINO-1-PHENYL-1-PROPANOL.....	218
DMPA.....	102
DST.....	110

**B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC
AND COMMON NAMES, AND SYNONYMS**

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
D-STREPTAMINE, O-2-DEOXY-2-(METHYLAMINO)-ALPHA-L-GLUCOPYRANOSYL-(1->2)-O-5-DEOXY-3-C-FORMYL-ALPHA-L-LYXO	244
D-STREPTAMINE, O-2-AMINO-2-DEOXY-ALPHA-D-GLUCOPYRANOSYL-1(1->4)-O-[O-2,6-DIAMINO-2,6-DIDEOXY-BETA-L-IDOPYR	202
D-THREO-(-)-2,2-DICHLORO-N-(BETA-HYDROXY-ALPHA-(HYDROXYMETHYL)-P-NITROPHENETHYL)ACETAMIDE.....	78
DUTCH LIQUID.....	123
E 102.....	256
E.161.G.....	74
E123.....	41
EMETAN, 6',7',10,11-TETRAMETHOXY.....	117
EPIDERMAL THYMOCYTE ACTIVATING FACTOR.....	39
EPINEPHRINE TARTRATE/ETIDOCAINE HYDROCHLORIDE.....	299
ERGOTAMAN-3',6',18-TRIONE,2-BROMO-12'-HYDROXY-2'-(1-METHYLETHYL)-5-(2-METHYLPROPYL)-(5'ALPHA)-.....	68
ERYTHROL NITRATE.....	120
ERYTHROMYCIN 2'-PROPANOATE DODECYL SULPHATE.....	120
ERYTHROMYCIN PROPIONATE LAURYL SULPHATE.....	120
ERYTHROMYCIN, 2'PROPIONATE, DODECYL SULPHATE.....	120
ERYTHRO-P-(ISOPROPYLTHIO)-ALPHA-(1-(OCTYLAMINO)ETHYL)BENZYL ALCOHOL.....	251
ERYTHROPOEITIN.....	119
ESTR-4-EN-3-ONE, 17-((1-OXODECYL)OXY)-, (17BETA).....	186
ESTR-4-EN-3-ONE, 17-(1-OXO-3-PHENYLPROPOXY)-, (17BETA)-.....	186
ESTROGENS.....	52
ETHACRIDINE.....	36
ETHAMIVAN.....	298
ETHANAMINE, 2-[4-(1,2-DIPHENYL-1-BUTENYL)PHENOXY]N,N-DIMETHYL, (Z)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE	255
ETHANAMINIUM, 2,2'-[(1,4-DIOXO-1,4-BUTANEDIYL)BIS(OXY)]BIS[N,N,N-TRIMETHYL-], DICHLORIDE.....	254
ETHANE, 1,1,1-TRICHLORO-2,2-BIS(P-CHLOROPHENYL).....	91
ETHANE, 1,2-DICHLORO-.....	123
ETHANESULFONIC ACID, 2-MERCAPTO-, MONOSODIUM SALT.....	170
ETHANOL, 2,2',2'-NITRILOTRIS-.....	275
ETHER/CAMPHOR/GUIFENESIN.....	300
ETHINYLESTRADIOL/MEDROXYPROGESTERONE ACETATE.....	304
ETHYL (ALL-E)-9-(4-METHOXY-2,3,6-TRIMETHYLPHENYL)-3,7-DIMETHYL-2,4,6,8- NONATETRAENOATE.....	124

B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC AND COMMON NAMES, AND SYNONYMS

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
ETHYL 1-(3-CYANO-3,3-DIPHENYLPROPY-4-PHENYLISONIPECOTATE.....	113
ETHYL 2-(PARA-CHLOROPHENOXY)-2-METHYLPROPIONATE.....	92
ETHYL 2-(P-CHLOROPHENOXY)ISOBTYRATE.....	92
ETHYL 6-[(2-HYDROXYPROPYL)AMINO]-3-PYRIDAZINYL]HYDRAZINECARBOXYLIC ACID ETHYL ESTER.....	72
ETHYL ALCOHOL.....	121
ETHYL ALPHA-(4-CHLOROPHENOXY)-ALPHA-METHYLPROPIONATE.....	92
ETHYL CARBAMATE.....	277
ETHYL CLOFIBRATE.....	92
ETHYL(+)-2-[[ALPHA-(P-CHLOROPHENYL)-P-TOLYL]OXY]-2-METHYLBUTYRATE.....	57
ETHYL(2-MERCAPTOBENZOATO-S)MERCURY.....	264
ETHYL(P-CHLORO-ALPHA,ALPHA-DIMETHYLPHENETHYL)-CARBAMATE.....	94
ETHYLENEDIAMINE.....	47
ETHYL-N-METHYL-N-[A-(2-METHYLIMIDAZOLE[4,5-C]PYRIDIN-1-YL)TOSYL]-L-LEUCINATE.....	161
ETHYLOESTRENOL.....	123
ETHYLURETHANE.....	277
EUFLAVINE.....	36
EUPHYLLINUM.....	47
FD&C RED NO.2.....	41
FD&C YELLOW NO.5.....	256
FENETHYLLINE.....	127
FENFLURAMINE.....	287
FOSSIL TREE.....	137
GAMMA VINYL-GABA.....	278
GAMMA-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE.....	161
GAMMA-VINYL AMINOBTYRIC ACID.....	278
GBE-761.....	137
GENTIAN VIOLET.....	178
GLAPHENINE.....	137
GLUCONIC ACID 6-BIS(N-DI-ISOPROPYLAMINO)ACETATE.....	201
GLUTEMIDE.....	139
GLYBIGIDUM.....	70

**B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC
AND COMMON NAMES, AND SYNONYMS**

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
GLYCINE, N-[[6-METHOXY-5-(TRIFLUOROMETHYL)-1-NAPHTHALENYL]THIOXOMETHYL]-N-METHYL.....	269
GROWTH HORMONE, HUMAN.....	241
HEPARIN/DIHYDROERGOTAMINE.....	296
HEPTABARBITONE.....	144
HEPTAMALUM.....	144
HESPERIDIN/PIPRADOL.....	310
HEXACHLOROPHANE.....	145
HEXOBARBITONE.....	146
HEXOESTROL.....	146
HGH.....	241
HISTAMINE H1 RECEPTOR ANTAGONISTS.....	141
H-PYRROLIZINE-1-CARBOXYLIC ACID, 5-BENZOYL-2,3-DIHYDRO, (+/-)-, COMPOUND WITH 2-AMINO-2-(HYDROXYMETHYL)-1,3	156
HYDRAZINECARBOXAMIDE, 2-((5-NITRO-2-FURANYL)METHYLENE)-.....	190
HYDROCHINONUM, BENZENE-1,4-DIOL.....	147
HYDROXYBENZENE.....	212
HYDROXYPHENBUTAZONE.....	197
HYDROXYPHENYLBUTAZONE.....	197
HYOSCINE METHYLNITRATE.....	148
HYSOCINE.....	238
IDEC-102.....	237
IMIDAZOL[1,2-?]PYRIDINE-3-ACETAMIDE, 6-CHLORO-2-(4-CHLOROPHENYL)-N,N-DIPROPYL.....	40
IMIDODICARBONIMIDIC DIAMIDE, N-(2-PHENYLETHYL)-.....	209
IMIDODICARBONIMIDIC DIAMIDE-, N,N-DIMETHYL-.....	175
INTERLEUKIN-2.....	39
IODIXANOL.....	295
IDOCHLORHYDROXYQUIN.....	89
IDOCHLORHYDROXYQUINOLINE.....	89
IOHEXOL.....	294
IOMEPROL.....	294
IOPAMIDOL.....	294
IOTALAMIC ACID.....	295

**B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC
AND COMMON NAMES, AND SYNONYMS**

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
IOTROLAN.....	294
IOVERSOL.....	294
IOXAGLIC ACID.....	294
IOXITALAMIC ACID.....	294
ISAPHENIN.....	199
ISONIAZID/CYCLOSERINE.....	295
ISONICOTINIC ACID 2-((2-BENZYL CARBAMOYL)ETHYL)HYDRAZIDE.....	188
ISONICOTINIC ACID 2-ISOPROPYLHYDRAZIDE.....	151
ISOPROPYLANTIPYRINE.....	232
ISOPROPYLARTERENOL.....	152
ISOPROPYLNORADRENALINE.....	152
ISOPROTERENOL.....	152
ISOPYRINE.....	311
ISOQUINOLINE,1-(2-(4-CHLOROPHENYL)ETHYL)-1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-2-METHYL-.....	179
KETAMINI HYDROCHLORIDUM.....	155
KETOROLAC TROMETAMOL.....	156
KETOROLAC TROMETHAMINE.....	156
KEW TREE.....	137
L-2-AMINO-3-(INDOL-3-YL) PROPIONIC ACID.....	164
LACTIC ACID-P-PHENETIDINE.....	63
LACTYLPHENETIDINE.....	63
LAEVOMYCETINUM.....	78
LAMOXACTAM.....	158
L-CYSTEINYL-L-TYROSYL-L-ISOLEUCYL-L-GLUTAMINYL-L-ASPARGINYL-L-CYSTEINYL-L-PROLYL-LEUCYLGLYCINAMIDE CYCL	201
LEVAMISOLI HYDROCHLORIDUM.....	160
LEVAMPHETAMINE.....	159
L-TETRAMISOLE HYDROCHLORIDE.....	160
LU-23-174.....	239
LYNENOL.....	166
LYNOESTRENOL.....	166
LYSINE AMIDOTRIZOATE.....	295

B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC AND COMMON NAMES, AND SYNONYMS

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
MAIDENHAIR TREE.....	137
MALONAL.....	57
MECLIZINE.....	167
MEPROBAMATE/THEOPHYLLINE/BARBITURATES.....	315
MERCURY, ETHYL(4-MERCAPTOBENZOATO-S)-, SODIUM SALT.....	264
MESTRANOL/CHLORMADINONE ACETATE.....	294
METABROMSALAN.....	143
METAMIZOLE SODIUM.....	311
METAMPHETAMINE.....	171
METAPHYLLIN.....	47
METHAMPYRONE.....	171
METHANE, TRICHLORO-.....	81
METHANESULFONAMIDE, N-[4-[1-HYDROXY-2-[(1-METHYLETHYL)AMINO]ETHYL]-PHENYL]-, MONOHYDROCHLORIDE.....	242
METHANESULFONIC ACID.....	171
METHANESULFONIC ACID, ((2,3-DIHYDRO-1,5-DIMETHYL-3-OXO-2-PHENYL-1H-PYRAZOL-4-YL)METHYLAMINO)-, SODIUM SALT.....	171
METHANESULFONIC ACID, IODO-, SODIUM SALT.....	177
METHANOL.....	175
METHOPHOLINE.....	179
METHYL ALCOHOL.....	175
METHYL ALPHA-PHENYL-2-PIPERIDINEACETATE.....	178
METHYL(3ALPHA,16ALPHA)-14,15-DIHYDRO-14BETA-HYDROXYEBURNAMENINE-14- CARBOXYLATE.....	279
METHYLAMPHETAMINE.....	171
METHYLOSANILINE CHLORIDE.....	178
METHYLSCOPOLAMINE NITRATE.....	148
METHYLTESTOSTERONE.....	52
METOCLOPRAMIDI HYDROCHLORIDIUM.....	179
MIXTURE OF NITROUS ACID, 2-METHYLBUTYL ESTER AND NITROUS ACID, 3-METHYLBUTYL ESTER.....	50
MONOSODIUM (2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-(2-PHENYLACETAMIDO)-4-THIA- 1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXY	61
MORPHINAN-6-OL, 7,8-DIDEHYDRO-4,5-EPOXY-3-METHOXY-17-METHYL-, MONOHYDRATE, (5ALPHA,6ALPHA).....	97
MORPHOLINE, 3,4-DIMETHYL-2-PHENYL-, (2S-TRANS)-.....	208
MORPHOLINE, 3-METHYL-2-PHENYL.....	211

**B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC
AND COMMON NAMES, AND SYNONYMS**

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
MOXALACTAM.....	158
N-(2,6-DIMETHYLPYRIMIDIN-4-YL)SULPHANILAMIDE.....	250
N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE.....	263
N-(2-CHLOROETHYL)-N-(1-METHYL-2-PHENOXYETHYL)BENZYLAMINE.....	214
N-(2-PIPERIDYLMETHYL)-2,5-BIS(2,2,2-TRIFLUOROETHOXY)BENZAMIDE.....	129
N-(3,3-DIPHENYLPROPYL)-ALPHA-METHYLPHENETHYLAMINE.....	229
N-(4-ETHOXYPHENYL) ACETAMIDE.....	205
N-(4-ETHOXYPHENYL)-2-HYDROXYPROPANAMIDE.....	63
N-(4-NITRO-2-PHENOXYPHENYL)METHANESULFONAMIDE.....	189
N-(6-(2-(5-NITRO-2-FURYL)VINYL)-1,2,4-TRIAZIN-3-YL) ACETAMIDE.....	32
N-(PARA-ETHOXYPHENYL) LACTAMIDE.....	63
N,N-BIS(2-CHLOROETHYL)- 2-NAPHTHYLAMINE.....	81
N,N-DIETHYLVANILLAMIDE.....	298
N-[(1-ETHYL-2-PYRROLIDINYL)METHYL]-5-(ETHYLSULFONYL)-O-ANISAMIDE.....	252
N1-(5-METHYL-1,3,4-THIADIAZOL-2-YL)-SULFANILAMIDE.....	248
N1-(5-METHYL-1,3,4-THIADIAZOL-2-YL)SULPHANILAMIDE.....	248
N1-(6-METHOXY-3-PYRIDAZINYL)SULFANILAMIDE.....	249
N1-(6-METHOXPYRIDAZIN-3-YL)SULPHANILAMIDE.....	248
N1-(DIAMINOMETHYLENE)SULFANILAMIDE.....	247
N1-(THIAZOL-2-YL)SULPHANILAMIDE.....	250
N1-2-THIAZOLYLSULFANILAMIDE.....	250
N-ACETYL-4-HYDROXY-M-ARSANILIC ACID.....	31
N-ACETYL-DL-LEUCINE.....	32
NAFRONYL OXALATE.....	185
N-AMIDINOSULPHANILAMIDE MONOHYDRATE.....	246
NANDROLONE PHENPROPIONATE.....	186
NAPHTHYLAMINE MUSTARD.....	81
NARCOTINE.....	193
N-BUTYLDIGUANIDE.....	70
N-BUTYL-IMIDODICARBONIMIDIC DIAMIDE.....	70
NIFENAZONE.....	311

**B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC
AND COMMON NAMES, AND SYNONYMS**

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
NIFURAZOLIDONUM.....	133
NITRE.....	227
NITROERYTHRITE.....	120
NITROERYTHROL.....	120
NITROFURAZOLIDONUM.....	133
NITROFURAZONE.....	191
NITROUS ETHER SPIRIT.....	122
NN-DIMETHYL-2,2-DIPHENOXYETHYLAMINE.....	167
NORADRENALINE.....	160
NORAMIDOPYRINE METHANESULFONATE SODIUM.....	171
NOREPINEPHRINE.....	160
NORETHINDRONE.....	192
NORSULFAZOLUM.....	250
NORTESTERONE DECYCLATE.....	186
NORTESTOSTERONE DECYLATE.....	186
NORTESTOSTERONE PHENYLPROPIONATE.....	186
N-PHENYLACETAMIDE.....	31
NSC-134454.....	116
N-TERT-BUTYL-1-METHYL-3,3-DIPHEYLPROPYLAMINE.....	260
NUX VOMICA.....	52
O-3-DEOXY-4-C-METHYL-3-(METHYLAMINO- -L-ARABINO-PYRANOSYL-(1 6)-O-[2,6,DIAMINO-2,3,4,6-TETRADEOXY- -D-ERYTHRO	136
O-3-DEOXY-4-C-METHYL-3-(METHYLAMINO-?-L-ARABINO-PYRANOSYL-(1?6)-O-[2,6,DIAMINO-2,3,4,6-TETRADEOXY-?-D-ERYTH	136
OIL OF CALAMUS.....	73
OPC-17116.....	140
OXAZOLIDIN.....	197
OXINE.....	143
OXYPHENISATIN DIACETATE.....	199
OXYQUINOL.....	143
OXYQUINOLINE.....	143
P-((ALPHA-ETHOXY-P-PHENYLPHENACYL)AMINO)BENZOIC ACID.....	281
P-(1-OXO-2-ISOINDOLINYL)HYDRATROPIC ACID.....	150

**B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC
AND COMMON NAMES, AND SYNONYMS**

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
P-(ACETYLAMINO)PHENOL.....	201
P,P'-DICHLORODIPHENYLTRICHLOROETHANE.....	91
P-[(2-OXOCYCLOPENTYL)METHYL]HYDRATROPATE DIHYDRATE.....	164
P-ACETOPHENETIDIDE.....	205
PAMABROM/PYRILAMINE MALEATE.....	304
PARA-2-THENOYLHYDRATROPIC ACID.....	254
P-BROMO-N-[(E)-{(2-[(2-DIAMINOMETHYLENE)AMINO]4-THIAZOYL)METHYL)THIO]ETHYL)AMINO)METHYLENE]BENZENESULF	117
P-CHLORO-ALPHA,ALPHA-DIMETHYLPHENETHYLAMINE.....	84
PDX-CHLORIDE.....	224
PENICILLIN.....	61
PENICILLIN G.....	61
PENTANOIC ACID, 5-(2,5-DIMETHYLPHENOXY)-2,2-DIMETHYL.....	135
PENTOBARBITONE.....	204
PERMETHRIN.....	312
PGE1, PROSTAGLANDIN E1.....	40
PHENACETIN/ACETYLSALICYLIC ACID/CAFFEINE.....	285
PHENDIMETRAZINE.....	287
PHENEMALUM.....	211
PHENFORMIN HYDROCHLORIDE.....	209
PHENIMETHOXAZINE.....	208
PHENISATINE.....	271
PHENLAXINE.....	199
PHENOBARBITAL/PREDNISOLONE.....	310
PHENOBARBITONE.....	211
PHENOL, 2,2'-METHYLENEBIS[3,4,6-TRICHLORO-.....	145
PHENOL, 4-((7-CHLORO-4-QUINOLINYL)AMINO)-2-((DIETHYLAMINO)METHYL)-.....	49
PHENOL, 4,4'-(1,2-DIETHYL-1,2-ETHENEDIYL)BIS-,(E)-.....	108
PHENOL, 4,4'-(DIETHYLIDENEETHYLENE)DI-.....	107
PHENOTHRIN.....	312
PHENTERMINE.....	287
PHENTOLAMINE METHANESULPHONATE.....	215

**B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC
AND COMMON NAMES, AND SYNONYMS**

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
PHENTOLAMINI MESILAS. 3-[N-(2-IMIDAZOLIN-2-YLMETHYL)-P-TOLUIDINO]PHENOL METHANESULPHONATE.....	215
PHENYL CARBINOL.....	60
PHENYL METHANOL.....	60
PHENYL METHYL ALCOHOL.....	60
PHENYL PRENAZONE.....	128
PIPERAZINE, 1-((4-CHLOROPHENYL)PHENYLMETHYL)-4-((3-METHYLPHENYL)METHYL)-.....	167
PIPERAZINE, 1-(DIPHENYLMETHYL)-4-(3-PHENYL-2-PROPENYL).....	86
PIPERAZINE, 1-[BIS(4-FLUOROPHENYL)METHYL]-4-(3-PHENYL-2-PROPENYL)-,(E)-.....	131
PIPERIDINE, 4-(5H-DIBENZO[A,D]-CYCLOHEPTEN-5-YLIDENE)-1-METHYL-, HYDROCHLORIDE, SESQUIHYDRATE.....	99
PIPERIDINE, 4-(5H-DIBENZO(A,D)CYCLOHEPTEN-5-YLIDENE)-1-METHYL-.....	99
PIPERIDINEDIONE.....	178
P-LACTOPHENETIDINE.....	63
PODOPHYLLIN.....	224
POLIDOCANOL/METOCLOPRAMIDE.....	305
POLY(2-(DIETHYLAMINO)ETHYL)POLYGLYCERYLENE)DEXTRAN.....	224
POLYMERIC CONDENSATION PRODUCT OF ALUMINIUM OXIDE AND 0- ACETYLSALICYLIC ACID.....	40
POLYVINYLPIRROLIDONE.....	225
POTASSIUM 17-HYDROXY-3-OXO-17ALPHA-PREGNA-4,6-DIENE-21-CARBOXYLATE.....	226
POTASSIUM CHLORIDE/THIAZIDES.....	315
POTASSIUM/HYDROCHLOROTHIAZIDE.....	301
POVIDONE.....	225
PREGN-4-EN-20-ONE, 17-(ACETYLOXY)-6-METHYL-, (6ALPHA).....	50
PREGN-4-ENE, 3,20-DIONE, 17-(ACETYLOXY)-6-METHYL-, (6ALPHA).....	102
PREGN-4-ENE-21-CARBOXYLIC ACID, 7-(ACETYLTIO)-17-HYDROXY-3-OXO, GAMMA- LACTONE, (7ALPHA, 17ALPHA)-.....	243
PREGNA-4,6-DIENE-21-CARBOXYLIC ACID, 17-HYDROXY-3-OXO-, GAMMA-LACTONE (17ALPHA)-.....	74
PREGNA-4,6-DIENE-21-CARBOXYLIC ACID, 17-HYDROXY-3-OXO, POTASSIUM SALT (17ALPHA)-.....	226
PREGNA-4,6-DIENE-3,20-DIONE, 17-(ACETYLOXY)-6-CHLORO.....	80
PREGNA-4,6-DIENE-3,20-DIONE, 17-(ACETYLOXY)-6-METHYL.....	168
PRENAZONE.....	128
PRIMROSE OIL DERIVATIVE.....	135
PROFLAVINE.....	36

B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC AND COMMON NAMES, AND SYNONYMS

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
PROPANAMIDE, 2-AMINO-N-(2,6-DIMETHYLPHENYL).....	267
PROPANOIC ACID.....	230
PROPANOIC ACID, 2-(4-CHLOROPHENOXY)-2-METHYL, ETHYL ESTER.....	92
PROPANOIC ACID, 2-(P-CHLOROPHENOXY)-2-METHYL, ETHYL ESTER.....	92
PROPANOIC ACID, 2-[4-(2,2-DICHLOROCYCLOPROPYL)PHENOXYL]-2-METHYL.....	86
PROPANOIC ACID, 2-METHYL-, 4-[2-(METHYLAMINO)ETHYL]-1,2-PHENYLENE ESTER.....	148
PROST-13-EN-1-OIC ACID, 11,15,-DIGYDROXY-9-OXO-, (11ALPHA, 13E, 15S)-.....	40
PROSTA-5,13-DIEN-1-OIC ACID, 11,15-DIHYDROXY-9-OXO-, (5Z, 11ALPHA, 13E, 15S)-.....	111
PROSTAGLANDIN E2.....	111
PROXIBARBITAL.....	232
PVP.....	225
PYRIDIUM, 1-[[2-CARBOXY-8-OXO-7-[(2-THIENYLACETYL)AMINO]-5-THIA-1-AZABICYCLO[4.2.0]-OCT-2-EN-3-YL]METHYL]-, HYDRC	76
PYRILAMINE MALEATE/PAMABROM.....	304
PYRITHIOXINE.....	234
PYRROLIDINE, 2-[[1-(4-CHLOROPHENYL)-1-PHENYLETHOXY]ETHYL]-1-METHYL-, [R-(R*,R*)]-.....	89
QUINACRINE HYDROCHLORIDE.....	169
QUINALBARBITONE.....	238
R-1132.....	113
R-51619.....	87
RETINOIC ACID.....	270
RETINOIC ACID, 13-CIS.....	152
RETINOL/CYCLOVALONE/TIRATRICAL.....	316
ROOT BARK OIL.....	73
SALICYLIC ACID ACETATE.....	33
SALTPETRE.....	227
SC-29333. METHYL 7-(1R,2R,3R)-3-HYDROXY-2-[(E)-(4RS)-4-HYDROXY-4-METHYLOCT-1-ENYL]-5-OXOCYCLOPENTYL]HEPTANO	182
SODIUM (O-(2,6-DICHLOROANILINO)PHENYL) ACETATE.....	106
SODIUM 2,6-DI-TERT-BUTYL-1(OR 3)-NAPHTHALENESULFONATE.....	241
SODIUM 2-MERCAPTOETHANESULFONATE.....	170
SODIUM BICARBONATE/SULFATHIAZOLE SODIUM.....	314
SODIUM IODOMETHANE SULPHONATE.....	177

B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC AND COMMON NAMES, AND SYNONYMS

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
SODIUM IODOMETHANESULFONATE.....	177
SODIUM LACTATE/SULFATHIAZOLE SODIUM.....	314
SODIUM PENTOSAN POLYSULPHATE.....	205
SODIUM XYLANPOLYSULPHATE.....	205
SODIUM[2-AMINO-3-(P-BROMOBENZOYL)PHELYL]ACETATE SESQUIHYDRATE.....	67
SOLFAGUANIDINA.....	247
SOLFAMMIDE.....	249
SOLUBLE SULPHERAMERAZINE.....	248
SOMATOTROPHIN.....	241
SOMATOTROPIN.....	241
SPIRO(BENZOFURAN-2(3H), 1'-(2)CYCLOHEXENE)-3,4'-DIONE, 7-CHLORO-2',4,6- TRIMETHOXY-6'-METHYL-,(1'S-TRANS)-.....	140
STH.....	241
STILBOESTROL.....	108
STREPTOCIDIN.....	249
STREPTOMYCIN SULFATE/DIHYDROSTREPTOMYCIN SULFATE.....	296
STREPTOMYCIN/PENICILLIN.....	309
STRETONOVICIN.....	194
STRICNINA (ITA).....	244
STRYCHNIDIN-10-ONE.....	244
STRYCHNIN (DEU).....	244
STRYCHNINE.....	52
SUCCINYLCHOLINE CHLORIDE.....	254
SULFADIMERAZINE.....	246
SULFADIMETHYLPYRIMIDINE.....	246
SULFADIMEZINIUM.....	246
SULFADIMIDINUM.....	246
SULFAISODIMIDINE.....	250
SULFAMERAZINUM NATRICUM.....	248
SULFAMETHAZINE.....	246
SULFAMETHOXAZOLE/TRIMETHOPRIM.....	316
SULFAMIC ACID, CYCLOHEXYL-.....	98

**B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC
AND COMMON NAMES, AND SYNONYMS**

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
SULFAMIDINUM.....	247
SULFAMINUM.....	249
SULFANILAMIDOTHIAZOLUM.....	250
SULFANILAMIDUM.....	249
SULFANILYLUREA.....	245
SULFASOMIDINE.....	250
SULFONAZOLUM.....	250
SULGIN.....	247
SULGINUM.....	247
SULPHAMETHIZOLE.....	248
SULPHAMETHOXYPYRIDAZINE.....	249
SULPYRIN.....	172
SULPYRINE.....	171
SWEET NITRE SPIRIT.....	122
SYNESTROL.....	146
TARTRAZOL YELLOW.....	256
T-CELL GROWTH FACTOR.....	39
TESTOSTERONE.....	52
TESTOSTERONE PROPIONATE.....	261
TETRACHLOROSALICYLANILIDE.....	143
TETRACYCLINE/PENICILLIN.....	309
TETRAMETHRIN.....	312
TEUCRIUM CHAMAEDRYS.....	136
THENOPHENOPIPERIDINE.....	263
THEOPHYLLAMINUM.....	47
THEOPHYLLINE.....	47
THIENO(3,2-C)PYRIDINE, 5-((2-CHLOROPHENYL)METHYL)-4,5,6,7-TETRAHYDRO-.....	265
THIMEROSAL.....	264
THYMOXAMINE.....	183
TIANEPTINE. 7-[(3-CHLORO-6,11?DIHYDRO-6-METHYLDIBENZO[C,F][1,2] THIAZEPIN-11-YL)AMINO]HEPTANOIC ACID S,S DIOXI	265
TICRYNAFEN.....	266

B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC AND COMMON NAMES, AND SYNONYMS

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
TRANSAMINE SULPHATE.....	270
TRACETYL AZAURIDINE.....	56
TRIBROMSALAN.....	143
TRICHLOROBIS(4-CHLOROPHENYL)ETHANE.....	92
TRICHLOROFORM.....	81
TRICHLOROMETHANE.....	81
TRIETHANOLAMINE.....	275
TRIMEPRIMINE.....	274
TRISODIUM 5-HYDROXY-1-(4-SULPHONATOPHENYL)-4-(4-SULPHONATOPHENYLAZO) PYRAZOLE-3-CARBOXYLATE.....	256
TROVAFLOXACIN MESYLATE.....	276
UMBELLATIN.....	62
VENUS FLY TRAP.....	112
VINBARBITONE.....	279
VITAMIN A.....	236
VITAMIN B15.....	201
VITAMIN B17.....	157
XENALAMINE.....	281
XENALMINE.....	281
YOHIMBINE.....	52
ZINC 2-PYRIDINETHIOL 1-OXIDE.....	233
ZINC PYRIDINETHIONE, SKIN-CA.....	233
ZOPICLONUM.....	282
[1R-[1ALPHA(Z),2BETA(1E,3R*),3ALPHA]]-7-[3-HYDROXY-2-(3-HYDROXY-4-PHENOXY-1-BUTENYL)-5-OXOCYCLOPENTYL]-N-(ME	252
[S-(R*, R*)]-2,2 1-(1,2-ETHANEDIYLDIIMINO)BIS(1-BUTANOL);.....	121
(((6-2(5-NITRO-2-FURYL)VINYL)-AS-TRIAZIN-3-YL)IMIDO)DI-METHANOL.....	110
(-)-2-DEOXY-3-THIACYTIDINE.....	158
(-)-3,4-DIHYDROXY-ALPHA-((METHYLAMINO)METHYL)BENZYL ALCOHOL.....	118
(-)-5-[(1R)-1-HYDROXY-2-[(1R)-1-METHYL-3-PHENYLPROPYL]AMINO]ETHYL SALICYLAMIDE.....	111
(-)-6(DIMETHYLAMINO)-4,4-DIPHENYL-3-HEPTANOL ACETATE (ESTER).....	159
(-)-ALPHA-METHYLBENZENEETHANAMINE.....	159
(-)-ALPHA-METHYLPHENETHYLAMINE.....	159

B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC AND COMMON NAMES, AND SYNONYMS

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
(-)-M-HYDROXY-ALPHA-((METHYLAMINO)METHYL)BENZYL ALCOHOL.....	218
(+)-(2R)-2-[-[(R)-P-CHLORO-ALPHA-METHYL-ALPHA-PHENYLBENZYL]OXY]ETHYL]-1-METHYLPYRROL.....	89
(+)-2-METHYLAMINO-1-PHENYLPROPANE.....	171
(+)-3,4-DIMETHYL-2-PHENYLMORPHOLINE.....	208
(+)-ALPHA-METHYLPHENETHYLAMINE.....	104
(+)-CATECHOL.....	84
(+)-ETHYL 1-(ALPHA-METHYLBENZYL)IMIDAZOLE-5-CARBOXYLATE.....	124
(+)-N-(O-CHLOROBENZYL)-ALPHA-METHYLPHENETHYLAMINE.....	91
(+)-NORPSEUDOEPHEDRINE.....	76
(+)-THREO-2-AMINO-1-HYDROXY-1-PHENYLPROPYLPROPANE.....	76
(+/-)-(2,4-DIFLUOROPHENYL)-6-FLUORO-1,4-DIHYDRO-7-(3-METHYL-1-PIPERAZINYL)-4-OXO-3-QUINOLINECARBOXYLIC ACID..	257
(+/-)-2-(P-CHLOROPHENYL)-ALPHA-METHYL-5-BENZOXAZOLEACETIC ACID.....	59
(+/-)-3-(1,1-DIMETHYLHEPTYL-6,6A BETA,7,8,10,10A ALPHA-HEXAHYDRO-1- HYDROXY-6,6-DIMETHYL-9H-DIBENZO(B,D)PYRAN-	185
(+/-)-ALPHA-METHYLPHENETHYLAMINE.....	43
(+/-)-CIS-1-ACETYL-4-[P-[[2-(2,4-DICHLOROPHENYL)-2-(IMIDAZOL-1-YLMETHYL)-1,3-DIOX-OLAN-4-YL]METHOXYLPHENYL]PIPERA	156
(+/-)-ETHYLMETHYL-1,4-DIHYDRO-2,6-DIMETHYL-4-(M-NITROPHENYL)-3,5- PYRIDINEDICARBOXYLATE,.....	190
(+/-)-N,ALPHA-DIMETHYLCYCLOHEXANEETHYLAMINE.....	231
(+/-)-NOREPHEDRINE.....	218
(+/-)-TRANS 2-((DIMETHYLAMINO)METHYL)-1-(M-METHOXYPHENYL)CYCLOHEXANOL.....	269
(+/-)-TRANS-2-PHENYLCYCLOPROPYLAMINE.....	270
(±)-ALL-RAC-5-[P-[[6-HYDROXY-2,5,7,8-TETRA-METHYL-2-CHROMANYL]METHOXY]BENZYL]-2,4-THIAZOLIDINEDIONE.....	274
(1 ALPHA,2 ALPHA,3 BETA,4 ALPHA,5 ALPHA,6 BETA)-HEXACHLOROCYCLOHEXANE.....	161
(11 ALPHA, 13E)-11, 16-DIHYDROXY-16-METHYL-9-OXOPROST-13-EN-1-OIC ACID METHYL ESTER.....	182
(1R,2R,3R)-3-HYDROXY-2-[(E)-(3S)-HYDROXY-1-OCTENYL]-5-OXOCYCLOPENTANEHEPTANOIC ACID.....	40
(1S,2S)-(2-[[3-(2-BENZINIDAZOYL)PROPYL]METHYLAMINE]-ETHYL-6-FLUORO-1,2,3,4-TETRAHYDRO-1-ISOPROPYL-2-NAPHT	180
(2-(4-CHLOROPHENYL)-1,1-DIMETHYLETHYL)-CARBAMIC ACID.....	94
(2,3-DICHLORO-4-(2-THENOYL)-PHENOXY)ACETIC ACID.....	266
(2,3-DICHLORO-4-(2-THIENYLCARBONYL)PHENOXY)-ACETIC ACID.....	266
(2-HYDROXY-BENZOATO-O)-OXOBISMUTH.....	64
(2R*,6R*,11R*)-1,2,3,4,5,6-HEXAHYDRO-6,11-DIMETHYL-3-(3-METHYL-2- BUTENYL)-2,6-METHANO-3-BENZAZOCIN-8-OL.....	204
(2S,3S)-3,4-DIMETHYL-2-PHENYLMORPHOLINE.....	208

B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC AND COMMON NAMES, AND SYNONYMS

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
(3R,5S,6E)-7-[4-(4-FLUOROPHENYL)-2,6-DIISOPROPYL-5-(METHOXYMETHYL)-3-PYRIDYL]-3,5-DIHYDROXY-6-HEPTENOIC ACID.....	77
(4-ALLYLOXY-3-CHLOROPHENYL) ACETIC ACID.....	38
(5Z, 11ALPHA, 13E, 15S)-11, 15-DIHYDROXY-9-OXOPROSTA-5, 13-DIEN-1-OIC ACID.....	111
(9ALPHA,13ALPHA,14ALPHA)-3-METHOXY-17-METHYLMORPHINAN.....	105
(BICYCLOHEXYL)-1-CARBOXYLIC ACID, 2-(DIETHYLAMINO)ETHYL ESTER.....	106
(E)-1-[BIS-(P-FLUOROPHENYL)METHYL]-4-CINNAMYLPIPERAZINE.....	131
(E,Z)-(1R,2R,3R)-7-[3-HYDROXY-2-[(3S)-(3-HYDROXY-1-OCTENYL)]-5-OXOCYCLOPENTYL]-5-HEPTENOIC ACID.....	111
(ETHYL-5 QUINUCLIDINYL-2(2)) (METHOXY-6' QUINOLYL-(4)).....	147
(HYDROXYMETHYL)BENZENE.....	60
(Ñ)-2'-[2-(1-METHYL-2-PIPERIDYL)ETHYL]-P-ANISANILIDE.....	117
(O-(2,4-DICHLOROPHENOXY)PHENYL)ACETIC ACID.....	126
(O-(6-O-BETA-D-GLUCOPYRANOSYL-BETA-D-GLUCOPYRANOSIDE)-D-MANDELONITRILE.....	157
(P-CHLORO-ALPHA,ALPHA-DIMETHYLPHENETHYL)-CARBAMIC ACID.....	94
(S)-N-ETHYL-ALPHA-METHYL-3-(TRIFLUOROMETHYL)BENZENEETHANAMINE.....	104
(S)-N-ETHYL-A-METHYL-3-TRIFLUROROMETHYLPHENETHYLAMINE HYDROCHLORIDE.....	105
(Z)-3-(1-P-BROMOPHENYL)-3-(DIMETHYLAMINO)PROPENYL-PYRIDINE.....	281
1-(2-[4-[5-CHLORO-1-(P-FLUOROPHENYL)INDOL-3-YL]PIPERIDINE]ETHYL)2-IMIDAZOLIDINONE.....	239
1-(3,4-DIHYDROXYPHENYL)-2-ISOPROPYLAMINOETHANOL.....	152
1-(3-BUTOXY-2-HYDROXYPROPYL)-5-ETHYL-5-PHENYLBARBITURIC ACID CARBAMATE ESTER/1,3-BIS-(3-BUTOXY-2-HYDROXY	291
1-(3-CYANO-3,3-DIPHENYLPROPYL)-4-PHENYL-ISONIPECOTIC ACID.....	109
1(3H)-ISOBENZOFURANONE, 3,3-BIS(4-HYDROXYPHENYL).....	213
1(3H)-ISOBENZOFURANONE, 6,7-DIMETHOXY-3-(5,6,7,8-TETRAHYDRO-4-METHOXY-6-METHYL-1,3-DIOXOLO[4,5-G]-ISOQUINOLI	193
1-(4-ISOPROPYLTHIOPHENYL)-2-OCTYLAMINOPROPAN-1-OL.....	251
1-(P-CHLORO-ALPHA-PHENYLBENZYL)-4-(M-METHYLBENZYL)PIPERAZINE.....	167
1-(P-CHLOROPHENETHYL)-1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-2- METHYLISOQUINOLINE.....	179
1-(P-CHLOROPHENYL)-2-METHYL-2-AMINOPROPANE.....	84
1-(P-FLUOROBENZYL)-2-[[1-(P-METHOXYPHENETHYL)-4-PIPERIDYL]AMINO]BENZIMIDAZOLE.....	54
1,1,1-TRICHLOR-2,2-BIS(4-CHLOOR FENYL)-ETHAAN (NLD).....	92
1,1,1-TRICHLOR-2,2-BIS(4-CHLOR-PHENYL)-AETHAN (DEU).....	92
1,1,1-TRICHLORO-2,2-BIS(4-CHLOROPHENYL)ETHANE.....	92
1,1,1-TRICHLORO-2,2-BIS(P-CHLOROPHENYL)ETHANE.....	92

B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC AND COMMON NAMES, AND SYNONYMS

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
1,1,1-TRICHLORO-2,2-DI(4-CHLOROPHENYL)-ETHANE.....	92
1,1,1-TRICHLORO-2,2-BIS(4-CLORO-FENIL)-ETANO (ITA).....	92
1,1'-DECAMETHYLENEBIS (4-AMINOQUINALDINIUM CHLORIDE).....	104
1,1-DIPHENYL-1-(2-PIPERIDYL)-METHANOL.....	222
1,2,3,4,10,14B-HEXAHYDRO-2-METHYLDIBENZO(C,F)-PYRAZINO(1,2-A)AZEPINE.....	180
1,2,4-TRIAZINE-3,5(2H,4H)-DIONE, 2-(2,3,5-TRI-O-ACETYL-BETA- RIBOFURANOSYL)-.....	56
1,2,4-TRIAZINE-3,5-DIAMINE, 6-(2,3-DICHLOROPHENYL)-.....	158
1,2,4-TRIAZOLO(4,3-A)PYRIDIN-3(2H)-ONE, 2-(3-(4-(3-CHLOROPHENYL)-1- PIPERAZINYL)PROPYL)-.....	270
1,2-DICHLOROETHANE.....	123
1,2-DIHYDRO-1,5-DIMETHYL-2-PHENYL-3H-PYRAZOLE-3-ONE.....	208
1,2-DITHIOLANE-3-PENTANOIC ACID.....	162
1,2-ETHANEDIAMINE, N,N-DIMETHYL-N'-2-PYRIDINYL-N'-(2-THIENYLMETHYL).....	175
1,3-BENZENEDIOL,5-[1-HYDROXY-2-[[2-(4-HYDROXYPHENYL-1-METHYLETHYL)AMINO]ETHYL]-.....	128
1,3-BIS(5-NITROFURFURYLIDEN)ACETONEGUANYLHYDRAZONE.....	109
1,3-PROPANEDIOL, 2-METHYL-2-PROPYL-, DICARBAMATE.....	170
1,4-BIS(1-PHENYLISOPROPYL)PIPERAZINE.....	112
1,4-BIS(ALPHA-METHYLPHENETHYL)PIPERAZINE.....	112
1,4-PENTANEDIAMINE, N4-(7-CHLORO-4-QUINOLINYL)-N1,N1-DIETHYL-.....	83
1,5-(BUTYLIMINO)-1,5-DIDEOXY-D-GLUCITOL.....	181
1,7,7-TRIMETHYLBICYCLO(2,2,1)HEPTANE-2-ONE.....	73
1,8-DIHYDROXYANTHRAQUINONE.....	101
1-[(1-PYRROLIDINYLCARBONYL)METHYL]-4-(3,4,5-TRIMETHOXYCINNAMOYL) PIPERAZINE.....	85
1-[(4-FLUOROPHENYL)METHYL]-N-[1-[2-(4-METHOXYPHENYL)ETHYL]- 4-PIPERIDINYL]-1H-BENZIMIDAZOL-2-AMINE.....	54
1-[(P-CHLOROPHENOXY)ACETYL]-4-PIPERONYLPIPERAZINE.....	129
1-[[3-(4,7-DIHYDRO-1-METHYL-7-OXO-3-PROPYL-1-H-PYRAZOLO[4,3-D]PYRIMIDIN-5-YL)-4-ETHOXYPHENYL]SULFONYL]-4-METH-.....	240
1-[1-[4-(FLUOROPHENYL)-4-OXOBUTYL]-1,2,3,6-TETRAHYDRO-4-PYRIDINYL]-1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE.....	116
10-(2-DIMETHYLAMINO)ETHYL]-5,10-DIHYDRO-5-METHYL-11H-DIBENZO(B,E),(1,4)-DIAZEPIN-11-ONE MONOHYDROCHLORIDE..	105
10-(3-(4-CARBAMOYLPIPERIDINO)PROPYL)-2-CHLOROPHENOTHIAZINE.....	221
10-[2-(DIMETHYLAMINO)PROPYL]-PHENOTHIAZINE.....	230
10H-PHENOTHIAZINE-10-ETHANAMINE, N,N,ALPHA-TRIMETHYL-.....	230
10H-PHENOTHIAZINE-10-ETHANAMINE, N,N,?-TRIMETHYL-, MONOHYDROCHLORIDE.....	230

B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC AND COMMON NAMES, AND SYNONYMS

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
11BETA-[P-(DIMETHYLAMINO)PHENYL]-17BETA-HYDROXY-17-(1-PROPYNYL)ESTRA-4,9-DIEN-3-ONE.....	181
11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2 1,3 1-E][1,4]DIAZEPIN-6-ONE.....	188
11H-DIBENZO(B,E)(1,4)-DIAZEPIN-11-ONE, 10-(2-DIMETHYLAMINO)-ETHYL-5, 10-DIHYDRO-5-METHYL-, MONOHYDROCHLORID	105
1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN GAM	121
17ALPHA-(2-CARBOXYETHYL)-17BETA-HYDROXYANDROSTA-4,6-DIEN-3-ONE LACTONE.....	74
17BETA-HYDROXYESTR-4-EN-3-ONE DECANOATE.....	186
17BETA-HYDROXYESTR-4-EN-3-ONE HYDROCINNAMATE.....	186
17-HYDROXY-19-NOR-17ALPHA-PREGN-4-EN-20-YN-3-ONE.....	192
17-HYDROXY-3-OXO-17ALPHA-PREGNA-4,6-DIENE-21-CARBOXYLIC ACID GAMMA- LACTONE.....	74
17-HYDROXY-6ALPHA-METHYL-PREGN-4EN-20-ONE-ACETATE.....	50
17-HYDROXY-6ALPHA-METHYLPREGN-4-ENE-3,20-DIONE ACETATE.....	102
17-HYDROXY-6-METHYLPREGNA-4,6-DIENE-3,20-DIONE ACETATE.....	168
17-HYDROXY-7ALPHA-MERCAPTO-3-OXO-17ALPHA-PREGN-4-ENE-21-CARBOXYLIC ACID, GAMMA-LACTONE ACETATE.....	243
19 NORPREGN-4-EN-20-YN-17-OL, (17ALPHA)-.....	166
19-NOR-17-ALPHA-PREGN-4-EN-17-BETA-OL.....	123
19-NOR-17-ALPHA-PREGN-4-EN-20-YN-17-OL.....	166
19-NORPREGN-4-EN-17-OL,(17-ALPHA).....	123
19-NORPREGN-4-EN-20-YN-3-ONE, 17-HYDROXY-, (17ALPHA)-.....	192
1ALPHA H, 5ALPHA H-TROPAN-3ALPHA-OL (+/-)-TROPATE (ESTER).....	290
1-BUTYLBIGUANIDE.....	70
1-CINNAMYL-4-(DIPHENYLMETHYL) PIPERAZINE.....	86
1-ETHYL-3-HYDROXY-1-METHYLPYPERIDINIUM BENZILATE.....	221
1H-BENZIMIDAZOL-2-AMINE, 1[(4-FLUOROPHENYL)METHYL]-N-[1-[2-(4-METHOXYPHENYL)ETHYL]-4-PIPERIDINYL]-.....	54
1H-BENZIMIDAZOLE, 5-METHOXY-2-[[[4-METHOXY-3,5-DIMETHYL-2-PYRIDINYL)METHYL]SULFINYL]-.....	194
1H-IMIDAZOLE-5-CARBOXYLIC ACID, 1-(1-PHENYLETHYL)-, ETHYL ESTER(+)......	124
1H-INDOLE-3-ACETIC ACID, 1-(4-CHLOROBENZOYL)-5-METHOXY-2-METHYL-.....	149
1H-INDOLE-5-METHANESULFONAMIDE, 3-[2-(DIMETHYLAMINO)ETHYL]-N-METHYL-, BUTANEDIOATE (1:1).....	252
1H-ISOINDOLE-1,3(2H)-DIONE, 2-(2,6-DIOXO-3-PIPERIDINYL)-.....	263
1H-PURINE-2,6-DIONE,3,7-DIHYDRO-1,3-DIMETHYL-7-[2-[(1-METHYL-2-PHENYLETHYL)AMINO]ETHYL]-.....	127
1H-PYRAZOLO(1,2-A)(1,2,4)BENZOTRIAZINE-1,3(2H)-DIONE, 5-(DIMETHYLAMINO) -9-METHYL-2-PROPYL-.....	56
1H-PYRROLE-2-ACETIC ACID, 5-(4-CHLOROBENZOYL)-1,4-DIMETHYL-.....	282

B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC AND COMMON NAMES, AND SYNONYMS

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
1H-PYRROLIZINE-1-CARBOXYLIC ACID, 5-BENZOYL-2,3-DIHYDRO, (±), COMPOUND WITH 2-AMINO-2-(HYDROXYMETHYL)-1,3-I	156
1-METHOXY 3-(4-(BETA-METHOXYPHENETHYL)-PIPERAZIN-1-YL)-1-PHENYLPROPAN- 2-OL.....	281
1-METHYL-4-N-2-THENYLANILINOPIPERIDINE.....	263
1-NAPHTHALENEMETHANAMINE, N-(6,6-DIMETHYL-2-HEPTEN-4-YNYL)-N-METHYL-, (E)-.....	257
1-PHENETHYLBIGUANIDE.....	209
1-PHENETHYLBIGUANIDE HCL.....	209
1-PHENYLSEMICARBAZIDE.....	211
1-PIPERIDINEBUTANAMIDE, 4-(4-CHLOROPHENYL)-4-HYDROXY-N,N-DIMETHYL-ALPHA, ALPHA-DIPHENYL.....	162
1-PIPERIDINEBUTANOL.....	258
1-PIPERIDINEBUTANOL, ?-[4-(1,1-DIMETHYLETHYL)PHENYL]-4-(HYDROXYDIPHENYLMETHYL)-.....	258
1-PIPERIDINEPROPANOIC ACID, 4-(METHOXYCARBONYL)-4-[(1-OXOPROPYL)PHENYLAMINO]-, METHYL ESTER, MONOHYDRO	235
1-PROPANONE, 1-[2-[2-HYDROXY-3-(PROPYLAMINO)PROPOXY]PHENYL]-3-PHENYL-.....	230
1-PROPANONE, 2-(DIETHYLAMINO)-1-PHENYL-,.....	42
1-VINYL-2-PYRROLIDINONE POLYMER.....	225
2((2-(DIMETHYLAMINO)ETHYL)-2-THENYLAMINO)PYRIDINE.....	175
2-(2-DIETHYLAMINOETHOXY)ETHYL 2 ETHYL-2-PHENYLBUTARATE DIHYDROGEN CITRATE.....	196
2-(2-DIETHYLAMINOETHOXY)ETHYL 2-ETHYL-2-PHENYLBUTYRATE.....	196
2-(3-(4-(M-CHLOROPHENYL)-1-PIPERAZINYL)PROPYL)-S-TRIAZOLO(4,3-A) PYRIDIN-3(2H)-ONE.....	270
2-(3-(4-PIPERIDYL)ETHYL)INDOLE.....	149
2-(3-BUTYRAMIDO-3,4,6-TRIIODOPHENYL-METHYLENE)-BUTYRIC ACID.....	71
2-(3-CHLORO-4-(3-PYOLIN-1-YL)PHENYL) PROPIONIC ACID.....	223
2(3H)-ISOBENZOFURANONE, 3,3-BIS(4-HYDROXYPHENYL)-.....	213
2-(4-AMINOPHENYL)-2-ETHYLGLUTARIMIDE.....	44
2-(4-ISOBUTYLPHENYL)PROPIONIC ACID.....	149
2-(DIETHYLAMINO)ETHYL (BICYCLOHEXYL)-1-CARBOXYLATE.....	106
2-(DIETHYLAMINO)PROIOPHENONE.....	42
2-(DIMETHYLAMINO)-1,1-DIMETHYLETHYL BENZILATE.....	108
2-(ISOPROPYLAMINO)PYRIMIDINE.....	151
2-(P-BUTOXPHEYL)ACETOHYDROXAMIC ACID.....	69
2-(P-CHLOROPHENYL)-TETRAHYDRO-3-METHYL-4H-1,3-THIAZIN-4-ONE 1,1-DIOXIDE.....	80
2,2',2'-NITRILOTRIETHANOL.....	275

B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC AND COMMON NAMES, AND SYNONYMS

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
2,2-BIS(P-CHLOROPHENYL)-1,1,1-TRICHLOROETHANE.....	92
2,2-DIMETHY-5-(2,5-XYLYLOXY)VALERIC ACID.....	135
2,2'-METHYLENEBIS(3,4,6-TRICHLOROPHENOL).....	145
2,2'-THIOBIS(4,6-DICHLOROPHENOL).....	65
2,3-DIHYDROXYPROPYL-N-(7-CHLORO-4-QUINOLYL) ANTHRANILATE.....	137
2,3-DIHYDROXYPROPYL-N-(8-TRIFLUOROMETHYL-4-)QUINOLYL)ANTHRANILATE.....	131
2,3-DIMETHYL-1-PHENYL-3-PYRAZOLIN-5-ONE.....	208
2,4,6(1H,3H,5H)-PYRIMIDINETRIONE, 5-(1-CYCLOHEXEN-1-YL)-1,5-DIMETHYL-.....	146
2,4,6(1H,3H,5H)-PYRIMIDINETRIONE, 5-(1-METHYLBUTYL)-5-(2-PROPENYL)-.....	238
2,4,6(1H,3H,5H)-PYRIMIDINETRIONE, 5-ETHYL-5-(1-METHYLBUTYL)-.....	204
2,4,6(1H,3H,5H)-PYRIMIDINETRIONE, 5-ETHYL-5-(3-METHYL-BUTYL)-.....	49
2,4,6(1H,3H,5H)-PYRIMIDINETRIONE, 5-ETHYL-5-PHENYL-.....	211
2,4,6,8-NONATETRAENOIC ACID, 9-(4-METHOXY-2,3,6-TRIMETHYLPHENYL)-, ETHYL ESTER, (ALL-E)-.....	124
2,4,6,8-NONATRAENOIC ACID, 9-(4-METHOXY-2,3,6-TRIMETHYLPHENYL)-3,7-DIMETHYL-2,4,6,8-NONATETRAENOIC ACID, (ALL-.....	36
2,4-BIS(ALLYLAMINO)-6-(4-(BIS-(P-FLUOROPHENYL)METHYL)-1-PIPERAZINYL)-S- TRIAZINE.....	39
2,4-IMIDAZOLIDENEDIONE, 1-[[5-NITRO-2-FURANYL)METHYLENE]AMINO]-.....	191
2,4-PIPERIDINEDIONE, 3,3-DIETHYL-5-METHYL-.....	178
2,4-THIAZOLIDINEDIONE, 5-[[4-[3,4-DIHYDRO-6-HYDROXY-2,5,7,8-TETRAMETHYL-2H-BENZOPYRAN-2-YL)METHOXY]-PHENYL]N.....	274
2,6-BIS(1-METHYLETHYL)PHENOL.....	231
2,6-DIAMINO-3-(PHENYLAZO)PYRIDINE.....	208
2,6-DI-ISOPROPYLPHENOL.....	231
2,6-METHANO-3-BENZAZOCIN-8-OL, 1,2,3,4,5,6-HEXAHYDRO-6,11-DIMETHYL-3-(3-METHYL-2-BUTENYL)-, (2ALPHA,6ALPHA-11R.....	204
2,6-PIPERIDINEDIONE, 3-(4-AMINOPHENYL)-3-ETHYL-.....	44
2,6-PIPERIDINEDIONE, 3-ETHYL-3-PHENYL-.....	139
2,6-PYRIDINEDIAMINE, 3-(PHENYLAZO).....	208
2'-[HYDROXY-3-(PROPYLAMINO)PROPOXY]-3-PHENYLPROPIOPHENONE.....	230
21-CYCLOPROPYL-7ALPHA-((S)-1-HYDROXY-1,2,2-TRIMETHYLPROPYL))-6,14-ENDO-ETHANO-6,7,8,14-TETRAHYDRO-ORIPAVIN.....	71
27267-RP.....	282
2-AMINO-2',6'-PROPIONOXYLIDIDE.....	267
2-AMINO-2-DEOXY-BETA-D-GLUCOPYRANOSE SULFATE.....	138
2-AMINO-5-PHENYL-2-OXAZOLINE.....	48

B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC AND COMMON NAMES, AND SYNONYMS

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
2-BENZENEDIOL, 4-(1-HYDROXY-2-(METHYLAMINO)ETHYL)-(R)-.....	118
2-BETA-D-RIBOFURANOSYL-AS-TRIAZINE-3, -5(2H,4H)-DIONE 2',3',5',- TRIACETATE.....	56
2-BORNANONE.....	73
2-BROMO-3-METHYLBUTYRYLUREA.....	68
2-BROMO-ALPHA-ERGOCRYPTINE.....	68
2-CAMPHANONE.....	73
2-ETHYL-2-PHENYLGLUTARIMIDE.....	139
2-ETHYLBENZOFURAN-3-YL 4-HYDROXYPHENYL KETONE.....	59
2-FURANPROPANOIC ACID, TETRAHYDRO-?--(1-NAPHTHALENYLMETHYL)-, 2-(DIETHYLAMINO)ETHYL ESTER,ETHANEDIOATE	185
2H-1,2,4-BENZOTHIADIAZINE-7-SULFONAMIDE, 6-CHLORO-3-(CYCLOPENTYLMETHYL)-3,4-DIHYDRO-,1,1-DIOXIDE.....	99
2H-1,2-BENZOTHIAZINE-3-CARBOXIMIDE, 4-HYDROXY-2-METHYL-N-(5-METHYL-3- ISOXAZOLYL)-, 1,1-DIOXIDE.....	154
2H-1,4-BENZODIAZEPIN-2-ONE, 5-(2-FLUOROPHENYL)-1,3-DIHYDRO-1-METHYL-7- NITRO-.....	132
2H-1-BENZOPYRAN-2-ONE.....	97
2H-1-BENZOPYRAN-2-ONE,4-HYDROXY-3-(3-OXO-1-PHENYLBUTYL)-.....	280
2H-BENZIMIDAZOL-2-ONE, 5-CHLORO-1-(1-(3-(2,3-DIHYDRO-2-OXO-1H- BENZIMIDAZOL-1-YL)PROPYL)-4-PIPERIDINYL)1,3-DIHY	114
2H-INDOL-2-ONE,3,3-BIS(4-ACETYLOXY)PHENYL)-1,3-DIHYDRO-.....	199
2-HYDROXYBENZOIC ACID BISMUTH (3+) SALT1.....	64
2-METHYL-2-PROPYL-1,3-PROPANEDIOL DICARBAMATE.....	170
2-METHYL-3-O-TOLYL-4(3H)-QUINAZOLINONE.....	177
2-METHYL-4-NITRO-1-(4-NITROPHENYL)IMIDAZOLE.....	190
2-NAPHTACENECABOXAMIDE,4,7-BIS(DIMETHYLAMINO)-1,-4,4A,5,5A,6,11,12A-OCTAHYDRO-3,10,12,12A-TETRAHYDROXY-1,-11	182
2-NAPHTACENECARBOXAMIDE,4-(DIMETHYLAMINO)-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-3,5,10,12,12A-PENTAHYDROXY-6-MET	115
2-NAPHTHACENECARBOXAMIDE, 4-(DIMETHYLAMINO)-1,4,4A,5,5A,6,11,12A- OCTAHYDRO-3,6,10,12,12A-PENTAHYDROXY-6-M	261
2-NAPHTHALENAMINE, N,N-BIS(2-CHLOROETHYL)-.....	81
2-OXAZOLAMINE, 4,5-DIHYDRO-5-PHENYL-.....	48
2-OXAZOLIDINONE, 3-(((5-NITRO-2-FURANYL)METHYLENE)AMINO)-.....	134
2-PHENYL-2-(2-PIPERIDYL)ACETIC ACID, METHYL ESTER.....	178
2-PHENYLCINCHONINIC ACID.....	85
2-PHENYLQUINOLINE-4-CARBOXYLIC ACID.....	85
2-PIPERIDINEACETIC ACID, ALPHA-PHENYL-, METHYL ESTER, (R*,R*)-(+/-).....	178
2-PROPEN-1-AMINE, 3-(4-BROMOPHENYL)-N,N-DIMETHYL-3-(3-PYRIDINYL-, (Z)-.....	281

B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC AND COMMON NAMES, AND SYNONYMS

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
2-PROPYLPENTANOIC ACID.....	278
2-PYRROLIDINONE, 1-ETHENYL-, HOMOPOLYMER.....	225
3-((5-NITROFURFURYLIDENE)AMINO)-2-OXAZOLIDINONE.....	134
3-((5-NITROFURFURYLIDENE)AMINO)-2-OXAZOLIDONE.....	134
3-(10,11-DIHYDRO-5H-DIBENZO[A,D]CYCLOHEPTEN-5-YLIDENE)PROPYLDIMETHYLAMINE.....	48
3-(ALPHA-ACETONYLBENZYL)-4-HYDROXYCOUMARIN.....	280
3-(DIBENZ[B,E]OXEPIN-11-YLIDENE)PROPYL-DIMETHYLAMINE.....	115
3-(O-METHYLPHENOXY)-1,2-PROPANEDIOL.....	170
3-(P-CHLOROBEZOYL)-6-METHOXY-2-METHYLINDOLE-1-ACETIC ACID.....	94
3,3'-(DITHIODIMETHYLENE)BIS(5-HYDROXY-6-METHYL-4-PYRIDINEMETHANOL).....	234
3,3,5-TRIMETHYLCYCLOHEXANOL ?-PHENYL?-HYDROXYACETATE.....	99
3,3,5-TRIMETHYLCYCLOHEXYL MANDELATE.....	99
3,3-BIS(4-HYDROPHENYL)-PHTHALIDE.....	213
3,3-BIS(4-HYDROXYPHENYL)-1(3H)-ISOBENZOFURANONE.....	213
3,3-BIS(P-HYDROXYPHENYL)-2-INDOLINONE DIACETATE.....	199
3,3-BIS-(P-HYDROXYPHENYL)PHTHALIDE.....	213
3,3-DIETHYL-5-METHYL-2,4-PIPERIDINEDIONE.....	178
3,4-DIDEOXY-4-[[2-HYDROXY-1-(HYDROXYMETHYL)ETHYL]AMINO]-2-C-(HYDROXYMETHYL)-D-EPI-INOSITOL.....	280
3,4-DIHYDROXY-4?-METHYL-5 NITROBENZOPHENONE.....	268
3,4-DIHYDROXY-5-NITROPHENYL (4-METHYLPHENYL)METAHANONE.....	268
3,4-DIHYDROXY-ALPHA-((METHYLAMINO)METHYL)-BENZYL ALCOHOL.....	118
3,4-PYRIDINEDIMETHANOL, 5-HYDROXY-6-METHYL-, HYDROCHLORIDE.....	233
3,5-DIHYDROXY-ALPHA-[[P-HYDROXY-ALPHA-METHYLPHENYLETHYL]AMINO]METHYL]BENZYL ALCOHOL.....	128
3,5-PYRAZOLIDINEDIONE, 4-BUTYL-1-(4-HYDROXYPHENYL)-2-PHENYL.....	197
3,5-PYRAZOLIDINEDIONE, 4-BUTYL-1,2-DIPHENYL.....	216
3,5-PYRAZOLIDINEDIONE, 4-BUTYL-1,2-DIPHENYL-4-BUTYL-1,2-DIPHENYL-3,5-PYRAZOLIDINEDIONE.....	221
3,5-PYRIDINEDICARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-4-(2-NITROPHENYL)-, DIMETHYL ESTER.....	189
3,5-PYRIDINEDICARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-4-(3- NITROPHENYL)-, ETHYL METHYL ESTER, (+/-).....	190
3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)-2,4,6,8-NONATETRAEN-1-OL.....	236
3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)2-CIS-4-TRANS-6- TRANS-8-TRANS-NONATETRAENOIC ACID.....	152
3-[(1/BENZYL)CYCLOHEPTYL]OXY]-N,N-DIMETHYLPROPYLAMINE.....	58

B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC AND COMMON NAMES, AND SYNONYMS

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
3-[[[2-[(AMINOIMINOMETHYL)AMINO]-4-THIAZOLYL]METHYL]THIO-N-(AMINOSULFONYL)PROPANIMIDAMIDE.....	126
3ALPHA,7ALPHA-DIHYDROXY-5BETA-CHOLAN-24-OIC ACID.....	78
3-AMINO-1-(3,4-DICHLORO-ALPHA-METHYLBENZYL)-2-PYRAZOLIN-5-ONE.....	184
3BETA-HYDROXYANDROST-5-EN-17-ONE.....	228
3-CHLORO-4-(3-PYRROLIN-1-YL) HYDRATROPIC ACID.....	223
3-ETHYL-2-(5-(3-ETHYL-2(3H)-BENZOTHIAZOLYLIDENE)-1,3-PENTADIENYL)- BENZOTHIAZOLIUM IODIDE.....	114
3-ETHYL-2-(5-(3-ETHYL-2-BENZOTHIAZOLINYLIDENE)-1,3-PENTADIENYL) BENZOTHIAZOLIUM IODIDE.....	113
3'H-CYCLOPROPA[1,2]PREGNA-1,4,6-TRIENE-3,20-DIONE, 17-(ACETYLOXY)-6-CHLORO-1,2-DIHYDRO-, (1?,2?).....	100
3H-PYRAZOL-3-ONE, 5-AMINO-2-(1-(3,4-DICHLOROPHENYL)ETHYL)-2,4-DIHYDRO-.....	184
3-HYDROXYDIAZEPAM.....	257
3-HYDROXY-P-BUTYROPHENETIDIDE.....	69
3-ISOXAZOLECARBOXYLIC ACID, 5-METHYL-, 2-(PHENYLMETHYL)HYDRAZIDE.....	151
3-METHYL-2-PHENYLMORPHOLINE.....	211
3-METHYL-N-SULPHANILYLCROTONAMIDE.....	245
3TC.....	158
4-((7-CHLORO-4-QUINOLYL)AMINO)-ALPHA-(DIETHYLAMINO)-O-CRESOL.....	49
4-((ALPHA-(P-CHLOROPHENYL)-5-FLUOROSALICYLIDENE)AMINO)BUTYRAMIDE.....	229
4(1H)-QUINOLINONE, 7-FLUORO-1-METHYL-3-(METHYLSULFINYL)-.....	131
4-(1-HYDROXY-2-(METHYLAMINO)-ETHYL)-1,2-BENZENEDIOL.....	118
4-(2-(BIPHENYL-4-YL)-1-ETHOXY-2-OXOETHYLAMINO)BENZOIC ACID.....	281
4-(2-DIMETHYLAMINOETHOXY)5-ISOPROPYL-2-METHYLPHENYL ACETATE.....	183
4'-(2-HYDROXY-3-(ISOPROPYLAMINO)-PROPOXY)ACETANILIDE.....	227
4-(2-THENOYL)-2,3-DICHLOROPHENOXYACETIC ACID.....	266
4'-(2-THIAZOLYLSULFAMOYL)PHTHALANILIC ACID.....	220
4(3H)-QUINAZOLINONE, 2-METHYL-3-(2-METHYLPHENYL)-.....	177
4-(3-METHYL-2-BUTENYL)-1,2-DIPHENYL-3,5-PYRAZOLIDINEDIONE.....	128
4-(3-METHYLBUT-2-ENYL)-1,2-DIPHENYLPYRAZOLIDONE-3,5-DIONE.....	128
4-(3-OXOBUTYL)-1,2-DIPHENYL-3,5-PYRAZOLIDINEDIONE.....	155
4-(4,6-DIMETHYLPRIMIDINE-2-YL)SULPHANILIMIDE.....	246
4(5H)-OXAZOLONE, 2-AMINO-5-PHENYL-.....	203
4-(DIMETHYLAMINO)-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-3,6,10,12,12A- PENTAHYDROXY-6-METHYL-1,11-DIOXO-2-NAPHTHACE	261

B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC AND COMMON NAMES, AND SYNONYMS

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
4-(P-CHLOROPHENYL)-4-HYDROXY-N,N-DIMETHYL-ALPHA,ALPHA-DIPHENYL-1- PIPERIDINEBUTYRAMIDE.....	162
4,4'-(1,2-DIETHYLETHYLENE)DIPHENOL.....	146
4,4'-(1,2-DIETHYLIDENE-1,2-ETHANEDIYL)BIS-PHENOL,(E,E)-.....	107
4,4'-DICHLORODIPHENYLTRICHLOROETHANE.....	92
4-4 1-(1,2-DIETHYL-1,2-ETHANEDIYL)BIS[PHENOL].....	146
4-ACETAMIDOPHENYL SALICYLATE ACETATE.....	58
4-AMINOBENZENESULPHONAMIDE.....	249
4-AMINOHEX-5-ENOIC ACID.....	278
4-BUTYL-(4-HYDROXYMETHYL)-1,2-DIPHENYL-3,5-PYRAZOLIDINEDIONE HYDROGEN SUCCINATE.....	255
4-BUTYL-1-(P-HYDROXYPHENYL)-2-PHENYL-3,5-PYRAZOLIDINEDIONE.....	197
4-BUTYL-1,2-DIPHENYL-3,5-PYRAZOLIDINEDIONE.....	216
4-BUTYL-1-PHENYL-3,5-PYRAZOLIDINEDIONE.....	182
4-CHLORO-ALPHA,ALPHA-DIMETHYL-BENZENEETHANAMINE.....	84
4-DIMETHYLAMINO-2,3-DIMETHYL-1-PHENYL-3-PYRAZOLIN-5-ONE.....	45
4H-(1,2,4)TRIAZOLO(4,3-A)(1,4)BENZODIAZEPINE, 8-CHLORO-6-(2- CHLOROPHENYL)-1-METHYL-.....	272
4-HYDROXY-2-METHYL-N-(5-METHYL-3-ISOXAZOLYL)-2H-1,2-BENZOTHIAZINE-3- CARBOXAMIDE 1,1-DIOXIDE.....	154
4-ISOPROPYL-2,3-DIMETHYL-1-PHENYL-3-PYRAZOLIN-5-ONE.....	232
4-METHYL-1-PIPERAZINECARBOXYLIC ACID ESTER WITH 6-(5-CHLORO-2-PYRIDYL)- 6,7-DIHYDRO-7-HYDROXY-5H-PYRROLO	282
4-PIPERIDINECARBOXYLIC ACID, 1-(3-CYANO-3,3-DIPHENYLPROPYL)-4-PHENYL,-ETHYL.....	113
4-PIPERIDINECARBOXYLIC ACID, 1-(3-CYANO-3,3-DIPHENYLPROPYL)-4-PHENYL-.....	109
4-QUINOLINEMETHANOL, ?-2-PIPERIDINYL-2,8-BIS(TRIFLUOROMETHYL)-, (R*, S*)-(±)-.....	168
5-(1-CYCLOHEXEN-1-YL)-1,5-DIMETHYLBARBITURIC ACID.....	146
5-(2-CHLOROETHYL)-4-METHYLTHIAZOLE.....	95
5-(CYCLOHEPT-1-ENYL)-5-ETHYLBARBITURIC ACID.....	144
5-(CYCLOHEX-1-ENYL)-1,5-DIMETHYLBARBITURIC ACID.....	146
5-(O-CHLOROBENZYL)-4,5,6,7-TETRAHYDROTHIENO-(3,2-C)PYRIDINE.....	265
5-(O-FLUOROPHENYL)-1,3-DIHYDRO-1-METHYL-7-NITRO-2H-1,4-BENZODIAZEPIN-2- ONE.....	132
5-(P-CHLOROBENZOYL)-1,4-DIMETHYLPYRROLE-2-ACETATE.....	282
5-(P-CHLOROBENZOYL)-1,4-DIMETHYLPYRROLE-2-ACETIC ACID.....	282
5-(P-CHLOROPHENYL)-2,5-DIHYDRO-3H-IMIDAZOL[2,1-A]ISOINDOL-5-OL.....	167
5,5-DIETHYLBARBITURIC ACID.....	57

B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC AND COMMON NAMES, AND SYNONYMS

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
5,6-DIHYDRO-9,10-DIMETHOXY-BENZO(G)-1,3-BENZODIOXOLO(5,6-A) QUINOLIZINIUM.....	62
5,7-DIBROMO-8-QUINOLINOL.....	68
5-ALLYL-5-(1-METHYLBUTYL) BARBITURIC ACID.....	238
5-ALLYL-5-(2-HYDROXYPROPYL)BARBITURIC ACID.....	232
5-ALLYL-5-ISOPROPYLBARBITURIC ACID.....	52
5-AMINO-1-CYCLOPROPYL-7-(CIS-3,5-DIMETHYLPIPERAZIN-1-YL)-6,8-DIFLUORO-4-OXOQUINOLINE-3-CARBOXYLIC ACID.....	243
5-BENZOXAZOLEACETIC ACID, 2-(4-CHLOROPHENYL)-ALPHA-METHYL, (+/-).....	59
5-BENZOYL-?-METHYL-2-THIOPHENEACETIC ACID.....	265
5-CHLORO-1-(1-(3-(2-OXO-1-BENZIMIDAZOLINYL)PROPYL)-4-PIPERIDYL)-2- BENZIMIDAZOLINONE.....	114
5-CHLORO-7-iodo-8-QUINOLINOL.....	89
5-CHLORO-7-iodoQUINOLINOL.....	89
5-DIMETHYLAMINO-9-METHYL-2-PROPYL-1H-PYRAZOLO(1,2-A)(1,2,4)BENZOTRIAZINE-1, 3(2H)-DIONE.....	56
5-ETHYL-5-(1-METHYLBUT-1-ENYL)BARBITURIC ACID.....	279
5-ETHYL-5-(1-METHYLBUTYL)BARBITURIC ACID.....	204
5-ETHYL-5-ISOPENTYLBARBITURIC ACID.....	49
5-ETHYL-5-PHENYLBARBITURIC ACID.....	211
5H-DIBENZO(B,E),(1,4)DIAZEPINE, 8-CHLORO-11-(4-METHYL-1-PIPERAZINYL)-.....	95
5-METHOXY-4'-(TRIFLUOROMETHYL)VALEROPHENONE (E)-0-(2-AMINOETHYL)OXIME.....	133
5-METHOXY-N-ACETYL TRYPTAMINE.....	169
5-METHYL-3-(2-PYRIDYL)-2H,5H-1,3-OXAZINO[5,6-C]-[1,2]BENZOTHIAZINE-2,4(3H)-DIONE 6,6-DIOXIDE.....	116
5-METHYL-3-ISOXAZOLECARBOXYLIC ACID 2-BENZYLHYDRAZIDE.....	151
5-NITRO-2-FURALDEHYDE SEMICARBAZONE.....	190
5-NITRO-8-QUINOLINOL.....	191
5-NITROFURFURYLIDENAMINO GUANIDINE.....	141
5-OXA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID,7-((CARBOXY(4-HYDROXYPHENYL)ACETYL)AMINO)-7-METHOXY-	158
6'-(THIAZOLYLAMINOSULFAMOYL)PHTHALANILIC ACID.....	220
6,14-ETHENOMORPHINAN-7-METHANOL, 17-(CYCLOPROPYLMETHYL)-ALPHA-(1,1- DIMETHYLETHYL)-4,5-EPOXY-18,19-DIHYDR	71
6BETA,7BETA-EPOXY-1ALPHAH,5ALPHAH-TROPAN-3ALPHA-OL(-)-TROPATE (ESTER).....	238
6-CHLORO-17-HYDROXYPREGNA-4,6-DIENE-3,20-DIONE ACETATE.....	80
6-DEOXY-5BETA-HYDROXYTETRACYCLINE HYDROCHLORIDE.....	115
6-HYDROXY-3-METHOXY-N-METHYL-4,5 EPOXYMORHIN-7-ENE.....	97

B. INDEX TO PHARMACEUTICALS BY SCIENTIFIC AND COMMON NAMES, AND SYNONYMS

SCIENTIFIC AND COMMON NAMES, AND SYNONYMS	PAGE
7,8,13,13A-TETRAHYDRO-9,10-DIMETHOXY-2,3-METHYLENEDIOXY-BERBINIUM.....	62
7,8-DIDEHYDRO-4,5-ALPHA-EPOXY-3-METHOXY-17-METHYLMORPHINAN-6-ALPHA-OL MONOHYDRATE.....	97
7-[(10,11-DIHYDRO-5H-DIBENZO(A,D)CYCLOHEPTEN-5-YL)AMINO]HEPATANOIC ACID HYDROCHLORIDE.....	43
7-[2-(ALPHA-METHYLPHENETHYL)AMINO]ETHYL]THEOPHYLLINE.....	127
7-[(1R,5S,6S)-6-[(S)-2-AMINOPROPIONAMIDO]PROPIONAMIDO]-3-AZABICYCLO[3.1.0]HEX-3-YL)-1-(2,4-DIFLUOROPHENYL)-6-FLL	37
7-BROMO-5-METHYL-8-QUINOLINOL.....	267
7-BROMO-5-METHYL-8-QUINOLINOL / 5-METHYL-8-QUINOLINOL.....	315
7-CHLORO-2',4,6-TRIMETHOXY-6'BETA-METHYLSPIRO(BENZOFURAN-2(3H),1'-(2) CYCLOHEXENE)-3,4'-DIONE.....	140
7-CHLORO-3-HYDROXY-1-METHYL-5-PHENYL-1,4-BENZODIAZEPIN-2-ONE.....	257
7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)-QUINOLINE.....	83
8-[4-(4-PYRIMIDIN-2-YLPIPERAZIN-L-YL)BUTYL]-8-AZASPIRO[4,5]DECANE-7,9-DIONE HYDROCHLORIDE.....	72
8-AMINO-1,2,3,4-TETRAHYDRO-2-METHYL-4-PHENYLISOQUINOLINE.....	192
8-CHLORO-11-(4-METHYL-1-PIPERAZINYL)-5H-DIBENZO(B,E)(1,4) DIAZEPINE.....	95
8-CHLORO-6-(O-CHLOROPHENYL)-1-METHYL-4H-S-TRIAZOLO(4,3-A)(1,4) BENZODIAZEPINE.....	271
8-ISOQUINOLINAMINE, 1,2,3,4,-TETRAHYDRO-2-METHYL-4-PHENYL,.....	192
8-METHOXY-6-NITROPHENANTHRO(3,4-D)-1,3-DIOXOLE-5-CARBOXYLIC ACID.....	53
8-QUINOLINOL.....	142
9,10-ANTHRACENEDIONE, 1,8-DIHYDROXY-.....	101
9,10-ANTHRACENEDIONE, 1,8-DIHYDROXY, 1,8-DIHYDROXYANTHRAQUINONE.....	101
9H-DIBENZO(B,D)PYRAN-9-ONE, 3-(1,1-DIMETHYLHEPTYL)-6,6A,7,8,10,10A- HEXAHYDRO-1-HYDROXY-6,6-DIMETHYL, TRANS-,	185
9-PHENANTHRENEMETHANOL, 1,3-DICHLORO-?-[2-(DIBUTYLAMINO)ETHYL]-6-(TRIFLUOROMETHYL)-,HYDROCHLORIDE.....	142
?-(N-PHTHALIMIDO)GLUTARIMIDE.....	263
?-D-GLUCOFURANOSE, 3-0-[3-(DIMETHYLAMINO)PROPYL]-1,2-0-(1-METHYLETHYLIDENE)-, HYDROCHLORIDE.....	48

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
A 25	398	A 66	387
A.d.l.	320	A.f. yellow no.4	407
A.g.multix	392	A.p.l.	396
Aciasthma	387	A-acido	411
Aatroayerst	339	Abacid plus	344
Abadox	347	Abalgine	369
Abbifen	358	Abocillin	328
Aberel	411	Aberela	411
Abilene	375	Abiocine	345
Abminthic	346	Abocillin	345
Abolon	374	Abrodan	372
Abrodil	372	Absolute alcohol	350
Abuprohm	358	Abu-tab	358
Acabel compositum	369	Accutane	362
Accutane roche	362	Acefalgin	369
Acelat	401	Acelax	381
Acetalax	381	Acetanil	319
Acetarsolum	319	Acetarsone	319
Acetonal vaginal	405	Acetphenarsine	319
Acetylarsan	319	Acetylosal	383
Aches-n-pain	358	Achrocidin	409
Achrocidin	383	Achromycin	409
Achromycin v	409	Achromycin y	409
Acid a vit	411	Acid leather yellow t	407
Acid yellow 23	407	Acid yellow t	407
Acidum aristolchicum	325	Acifein	383
Aci-jel	356	Acilan yellow	407
Acilan yellow gg	407	Acmor	378
Acmor-s	378	Acnavit	411
Acnavyse	411	Acne-sol	333
Acnestrol (broparestrol)	356	Acnestrol 3	356
Acnoxin	333	Acore vrai	331
Acretin	411	Acril	358
Acrobal	369	Acrogesico	369
Acromas	383	Acropac	383
Actamer	328	Actamin c	327
Actedron	321	Actifen	358
Actimac	333	Actinac	333
Actiprofen	358	Activin	374
Activin	375	Actren	358
Acu-dyne	396	Acutol	378
Acutrim	392	Adalgur	354
Adapettes	396	Adapin	347
Adaxil	355	Addaprin	358
Adebit	330	Adelmintex	394
Adepril	324	Adexogan	322
Adibetin	386	Adipalis	394

C. INDEX TO PHARMACUETICALS BY AVAILABLE TRADE NAMES

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Adipalit	394	Adipan	321
Adiparthrol	343	Adipex	390
Adipex nouveau	390	Adipex-p	390
Adipo ii	386	Adiposan	321
Adiposetten n	332	Adiposon	321
Adipost	386	Adiprazine	394
Adipyn	321	Adistop-f	392
Adiver	394	Adm	382
Adnephrine	348	Adocor	387
Adocyl	341	Adolkin	369
Adonal	387	Adphen	386
Adrefil	348	Adrehinal	348
Adren	348	Adrenal	348
Adrenalin	348	Adrenalin chloride	348
Adrenalin medihal	348	Adrenalina ace.p.d.	348
Adrenalina clorhi	348	Adrenalina delta	348
Adrenalina fustery	348	Adrenalina hormona	348
Adrenalina p davis	348	Adrenalina wiener	348
Adrenaline	348	Adrenamine	348
Adrenor	364	Adrin	348
Adsorbobase	396	Adsovbotear	396
Advil	358	Advil 200 mg	358
Advil cold & sinus	358	Aerol	385
Aerolone	361	Aeroseb-hc	356
Aerotrol	361	Aethambutolum	350
Aethaminalum	383	Afatin	343
Afdosa	361	Afi-ftalyl	393
Aflamin	343	Afonilum	323
Agaffin	389	Agaldog	344
Agarol	389	Agasten	337
Agent at 717	396	Agevis	322
Agisan	358	Aglophenyl	337
Agoral	389	Agotan	337
Agovirin	408	Agre-gola	389
Agrippol	343	AgrypnaI	387
Ahr 3018	326	Aida	358
Airedale yellow t	407	Airoderm	411
Airol	411	Airolactone	401
Aitiflus	339	Aizen tartrazine	407
Akentect	375	Akne pyodron kur	356
Aknebon	411	Aknefug	411
Aknefug	356	Aknelan	356
Aknoten	411	Aktren	358
Akutol	378	Alagyl	337
Alamin	356	Alavac	320
Alavac-p	320	Alavac-s	320
Albamycin	380	Albay pure venom	320

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Albigen a	396	Alchloquin	338
Alcohol aethylicus	350	Alcool	350
Alcophenyl	337	Aldace	401
Aldacol q	396	Aldactazide	401
Aldactide	401	Aldactide 25	401
Aldactone	397	Aldactone	401
Aldactone-a	401	Aldactone-diurapid	397
Aldadiene potassium	397	Aldazida	401
Aldo asma	361	Aldomycin	378
Aldonorm	401	Aldopur	401
Aldospirone	401	Aldospray	358
Aldozone	401	Alermizol	325
Alertonic	395	Aleudrin	361
Aleudrina	361	Aleukon	336
Alexan	401	Alfamin	343
Alficetyn	333	Alficetyn susp.	333
Alfimid	355	Alfucin	378
Algesin	390	Algiamida	406
Algia-nil	369	Algiasdi	406
Algiasdin	358	Algifor	358
Algimicin anttitermico	322	Alginodia	369
Alginodia compose.	369	Algirreudin	390
Algisan	358	Algisedal	369
Algisedal	341	Algi-tandril	380
Algobuscopan	369	Algocalmin	369
Algocratine	383	Algofen	358
Algofer	358	Algopriv	369
Algopyrin	369	Algopyriv	369
Algosediv	409	Algoverine	390
Alindor	390	Alipid	321
Alival	379	Alka butazolidin	390
Alkabutazona	390	Alkabutazone	390
Alka-phenylbutazone	390	Alka-sterazolidin	390
Alkozin	369	Aller-ez	337
Aller-ez plus	337	Allergasthmin	387
Allodene	321	Allopydin	320
Allopydinac	320	Allpyral specific	320
Allpyral-d	320	Allpyral-g	320
Allpyral-mite fortified house dust	320	Allvoran	343
Allypropymal	325	Almatol	401
Alnagon	387	Alogynan	337
Alophen	389	Alophen pills	389
Alophen pills	381	Alopidin	320
Alopydin	320	Aloxipirine tablets	320
Alpagelle	329	Alpamed	401
Alphamin	337	Altabactin	333
Altex	327	Altex	401

C. INDEX TO PHARMACUETICALS BY AVAILABLE TRADE NAMES

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Altexide	401	Altimol	377
Altinal	324	Altior	358
Aludrin	361	Alumidyne	383
Alupent-sed	324	Alurate	325
Alurate sodium	325	Alutyl	337
Amacid yellow t	407	Amacid yellow t-ex	407
Amal	324	Amarson	319
Amasust	324	Amavil	324
Ambene	390	Ambese-la	324
Ambi- skin tone	358	Ambofen	333
Ambrasynth	333	Amcort	375
Amebio-formo	338	Ameiax	381
Amen	342	Amepromat	367
Amer-azo	403	Amerol	364
Amersol	358	Amertuss	392
Ametil	344	Ametuss	336
Amfe-dyn	343	Amfepromone	321
Amfetamin	321	Amfetasul	321
Ami-29	364	Ami-anelun	324
Amidate	351	Amidazopen	322
Amidazophen	322	Amidazophene	322
Amidin	404	Amidozen	322
Amidrin	405	Amifatidine	351
Amifur	378	Amiglan	369
Amilent	324	Amilit-ifi	324
Amineurin	324	Aminiurin	324
Aminocardol	323	Aminocid	369
Aminodrox	323	Aminodur	323
Aminomal	323	Aminophenazonum	322
Aminophylline	323	Aminophylline injection	323
Aminophylline mudrane	323	Aminophylline oral	323
Amino-slow	323	Aminoxafen	323
Aminoxaphen	323	Amiorel eritro	396
Amipylo-n	399	Amital	324
Amitimid	324	Amitralil	369
Amitril	324	Amitrip	324
Amitriptol	324	Amitrol	324
Amnivent	323	Amobell	324
Amodoquin tablets	325	Amoebal	319
Amoenol	338	Amone	368
Amorphan	332	Amorphan depot	332
Amosene	367	Amotril	339
Ampenoline balsamoco	341	Amphaetex	343
Amphamed	321	Amphasub	386
Amphedrine	321	Amphedrine-m	363
Amphemycin-prednisonum	333	Amphenicol	333
Amphicol	333	Amphocort	375

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Ampi tumisan	369	Ampliomocetin	333
Amplisiex	392	Amsal	324
Amsebarb	324	Amseclim	333
Amseclor	333	Am-tuss liq	392
Amybal	324	Amycal	324
Amyderm s	396	Amydorm	324
Amylbarb	324	Amyline	324
Amylobeta	324	Amylofene	387
Amypron	383	Amypylo-n	383
Amytal	324	Amytal sodium	324
Amyzol	324	Anabolics	375
Anabolicus	375	Anabolin depot	375
Anabolin la 100	374	Anabolin la-100	375
Anacal	356	Anacatin	333
Anacin	382	Anacyclin	365
Anacycline 101	365	Anacylin	365
Anacylin 101	365	Anacylin 28	365
Anadex	369	Anadin ibuprofen	358
Anador	374	Anador	375
Anadur	374	Anadur	375
Anafebrin	322	Anafebrina	322
Anafogene	328	Anagregal	410
Analcedor	369	Analgesico	358
Analgesine	385	Analgil	358
Analgilasa	324	Analgin	369
Analginum	369	Analgyl	358
Analject	369	Analone-50	374
Analud	352	Anametrin	379
Anapac	383	Anarexal	341
Anarinyl	369	Anarreumol-b	380
Anarthral	390	Anartril	355
Anaspaz	387	Anastress	367
Anatimon	367	Anbesol	332
Anbesol	396	Anbesol	389
Ancaris thenium	394	Ancazine	394
Anchrina	369	Anco	358
Ancolan	365	Ancoloxin	365
Ancoloxine	365	Ancylin	365
Andaxin	367	Andebit	330
Andelit	330	Andere	330
Anderm	330	Andiposetten	332
Andolor	369	Andran	359
Andrestrac 2-10	396	Andro heart injecta	408
Androfort	408	Androlan in oils	408
Androline	375	Androlone	375
Androlone d	374	Androlone d 100	374
Androlone d 50	374	Androlone-d	375

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Androtest	408	Androteston	408
Anelmid	346	Aneroxina	390
Anertan	408	Anespas cpto	369
Aneural	367	Aneuxol	322
Anexa	396	Anfamon	321
Anflagen	359	Angifebrine	383
Angimidone	333	Anginofur	378
Angiocapsul	339	Angiociclan	326
Angiodel	326	Angiopac	413
Angiter	369	Angiters	333
Anguifugan	346	Anhistan	337
Anition	411	Ankaljin	369
Annolytin	324	Annul	356
Anodin	383	Anodyne dellipsoids 4	389
Anodynin	385	Anodynine	385
Anoixal	322	Anojel	329
Anorex	387	Anorex	321
Anorex	386	Anorexin	392
Anorexine	321	Anoxine-t	386
Anp 3624	410	Anparton	339
Ansaid	355	Ansietan	367
Ansiopax	343	Ansiowas	367
An-t	369	Antadol	390
Antalgil	359	Antapentan	386
Antatril	355	Antegan	341
Antelmina	394	Antepar	394
Antepar (b-w)	394	Anterobe	338
Anterobius	394	Anthalazine	394
Anthastmin	361	Anthelmina	394
Antiadipositum	392	Antibio-aberel	411
Antibio-aberel	349	Antibiopto	333
Antibitulle	375	Anticatabolin	375
Anticucs	394	Antidiarrhoicum	402
Antifen	408	Antiflam	359
Antiflu des	383	Antigestin	385
Antigripina	322	Antihist-1	337
Antilipid	339	Anti-opt	383
Antipond	386	Antipyretic dellepsoids d26	387
Antipyrin	385	Antiren	394
Antiruggen	359	Anti-spas	387
Antitaxil-z	413	Antituxil-z	413
Antivermine	394	Antivert	365
Antoban	394	Antuitrin	396
Antuitrin growth	401	Antuitrin-t	401
Antussan	401	Anugard	329
Anusol hc	329	Anuspiramin	390
Anzil	367	Apadine	383

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Apascil	367	Apasmo	369
Apazone	326	Apb	387
Apc	383	Apeplus	341
Aphenylbarbit	387	Apidin	383
Apiquel	323	Apirelina	385
Apisate	321	Api-slender	381
Ap-la-day	389	Aplaquette	410
Apo-amitriptylline	324	Apo-doxepin	347
Apoephedrine	392	Apo-erythro-s	349
Apo-ibuprofen	359	Apo-k	397
Apokalin	375	Apolan	339
Apo-meprobamate	367	Aponal	347
Apophenylbutazone	390	Apo-phenylbutazone	390
Apo-pram	324	Aporasnon	401
Apo-tetra	409	Apo-trimip	412
Apotrin	332	Appenil	324
Appetrol	332	Apracur	383
Apralan	389	Aprilin	330
Aprozal	325	Apsedon	336
Apsifen	359	Apsor	362
Apsor	411	Apx	410
Aqual	372	Aquamycetin	333
Aquapred	333	Aquareduct	401
Aquaviron	408	Aralen	336
Aralen hcl	336	Aralin (diphosphate)	336
Arantil	369	Arcin	383
Arcoban	367	Arcobutine	374
Arcomonol	374	Arcotrol	386
Ardeytopin	364	Arduvermin	394
Areumal	322	Arfen	359
Argan	360	Argan	320
Argazol	405	Argun	320
Arhemapectin	382	Aridose	392
Aristamid	406	Aristoform	338
Aristoform "d"	338	Aristoform "r"	338
Arm	392	Armacol	333
Armohex	356	Arpezine	394
Arpf	369	Arquidon	369
Arrest	337	Arret	364
Arrlicetin	333	Arsabott	319
Arsaphen	319	Arsonine	319
Artam	337	Arteopan	390
Arterioflexin	339	Arterioflexion	339
Artes	339	Artevil	339
Artexin	337	Arthirikin	390
Arthryl	355	Artibrin	390
Artofen	359	Artolon	367

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Artra	358	Artren	359
Artren	343	Artrichin	336
Artril	359	Artriosan	339
Artrisin	390	Artritex	369
Artrizin	390	Artrochin	336
Artrodesmol extra	390	Artrofen	359
Artroflog	380	Artroflog	381
Artropan	390	Artzone	380
Artzone	381	Arythmol	399
Asa compound	383	Asa/cpib	339
Ascalix	394	Ascarinex	394
Ascarivet	394	Asca-trol no.3	394
Asceine	383	Ascophen	383
Ascorbalgine	369	Ascortin	369
Ascthimindon	383	Asecool	356
Asellacrin	401	Asenlix	339
Asepar	394	Aseptilex	404
Aseptil-guanidina	403	Aseptobron	369
Aserbine cream	356	Asey-sulfa	404
Asfeen	383	Asidon	409
Askaripar	394	Asmadren	361
Asmafilin	323	Asmalar	361
Asmastop	361	Asmo fedrilum	387
Asmorex	348	Aspirin	319
Assugrin	341	Astenile	398
Asterol	346	Astebol	325
Asthma dellipsoids	385	Asthmatussin	387
Asthmin	324	Astol	325
Astreptine	405	Astriharina s	382
At 717	396	Atecilina	369
Ateculon	339	Atelor	346
Atelora	346	Atensin	366
Aterian	403	Aterioplexin	339
Ateriosan	339	Ateroayrest	339
Ateroclar	339	Aterofront	339
Aterola	346	Ateronlen	339
Aterosol	339	Atevil	339
Atheroayerst	339	Atheromide	339
Atheropront	339	Athilyn	365
Athimil	373	Athrombin	413
Athymil	373	Atigoa	337
Atn-020/2	369	Atocin	337
Atofan	337	Atom-asma	361
Atophan	337	Atraxin	367
Atroayerst	339	Atrofort	339
Atrolan	339	Atrolen	339
Atromid	339	Atromidin	339

C. INDEX TO PHARMACUETICALS BY AVAILABLE TRADE NAMES

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Atromid-s	339	Atrom-s	339
Atrovis	339	Attenil	352
Attenil 30 conf. 20 mg	352	Atul tatrazine	407
Atumin	344	Auanosept	330
Aurafair	385	Aurafair	320
Auralgan	385	Auralgicin	320
Auralgicin	385	Auraltone	385
Aureomicina	369	Aurex	375
Auriod	375	Auroid	378
Auryphan	319	Ausobrone	368
Ausoliver	337	Austracol	333
Austrominal	387	Avafortan	369
Avc	405	Avc cream suppositoty	405
Avc/dienestrol	405	Avc/dienestrol	344
Averamexan	394	Aviatrin	333
Avibon	400	Avicol	336
Avicol sl	340	Avicol-la	340
Avipron	336	A-vitamisyre	411
Avitoin	350	Avitoin	411
Avloclor (diphosphate)	336	Avosyl	366
Avril	405	Axiston	322
Ay 61	339	Ayellow t	407
Ayeramate	367	Ayerlucil	403
Ayoral	369	Azapren	326
Azionyl	339	Azo gantrisin	385
Azocline	403	Azodine	385
Azol	405	Azol polvo	405
Azol pomada	405	Azolid	390
Azophen	385	Azophene	385
Azoseptale	405	Azotrex	403
Azucaps	386	Azucrona	341
Azudoxat	347	Azur	399
B 3014	407	B 7509	396
Ba-16038	322	Babix-rectal	372
Babrocid	378	Babypasmil	344
Babyspasm	344	Babyspasmil	344
Bacarate	386	Bacteriostat cs-1	328
Bactol	338	Bada	356
Bajumol	385	Bakersed	387
Balbion	322	Balkamycin	333
Balmini	401	Balpiren	399
Balutox	413	Bamo 400	367
Banatot	350	Baneopol	375
Ban-o-pain	383	Banotil	406
Baralgin	369	Baralgine	369
Barbamyl	324	Barbellen	387
Barbenyl	387	Barberine	387

C. INDEX TO PHARMACUETICALS BY AVAILABLE TRADE NAMES

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Barbilletae	387	Barbiphenyl	387
Barbipil	387	Barbita	387
Barbityral	383	Barbivis	387
Barbopent	383	Barcole	387
Barnetil	406	Barnotil	406
Barophen	387	Barquinol	338
Barquinol hc	338	Barriere-mycin	375
Barsedan	322	Basoquin	325
Bassado	347	Bastu-angin	375
Baukal	399	Baukal	322
Baukal suppositories	322	Baxal	363
Bay-ase	387	Baycyclomine	344
Bayer 1387	369	Bayer 1387 p	322
Bayer select	359	Bayer select ibuprofen pain reliever	359
B-cpct	333	Beatol	324
Bebealjin	369	Bebigut	369
Bebtoyl	387	Bebulin	351
Beca furazona	378	Becantal	401
Becantex	401	Bechisan	401
Bedermin 100	375	Bediphen	387
Beelin	330	Belatropin	369
Belergamin	387	Belflex/2	369
Belladema s	387	Belladenal	387
Bellapront	390	Bellasectal	387
Bellastal	387	Bellasthman	361
Bellergal	387	Bellergal s	387
Bellumal	387	Belloform	381
Bel-zine	394	Bemacol	333
Bemaphate	336	Bemperil	406
Benacol	344	Benafed	336
Benamine	389	Benatuss	336
Benaznyl	337	Bencard skin testin solutions	320
Bencard-a	320	Bendectin	344
Beneficat	411	Benestermycin	375
Beneurin	369	Benflogin	359
Benhexachlor	364	Benhur	327
Benilen	353	Benjor	362
Benolat	327	Benoral	327
Benorile	327	Benortan	327
Benorylate	327	Benotamol	327
Benoxapran	327	Benpredil	354
Bentomine	344	Bentudor	352
Bentum	327	Bentyl	344
Bentylol	344	Benyphed	336
Benzarin	327	Benzease	356
Benzebar	321	Benzedrex	399
Benzedrine	321	Benzenol	389

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Benzolone	321	Benzone	390
Bequitussin	379	Berberal	328
Berbericine	328	Berberil	328
Bergofen	387	Berlicetin	329
Berlicetin	333	Berotec	352
Beserol	369	Betadine	396
Betadrin	329	Betagesic	359
Betaine digestive aid	382	Betaisod	396
Betalactam	363	Beta-pebg	386
Betaprofen	359	Betazed	390
Betnorate-c	338	Bexedyl dibunaat	401
Bexedyl dibunaat expectasans	401	Bexobolic	375
Bexon	329	Bexophene	383
Bexopirona	369	Bexopron	327
B-fsudi	353	B-gf	355
Bicillin	328	Bicillin all purpose	328
Bicor	408	Bidiphen	328
Bifed-20	392	Bifentamin	321
Biforon	330	Bifuran	378
Bigram	327	Bigunal	330
Biivectan	381	Bilevon	356
Biliboldo	396	Bilvon vet	356
Bimalong	404	Bimaran	411
Binoctal	324	Binovum	379
Bio hubber	402	Bio hubber	375
Bio hubber	382	Bio hubber fuerte	382
Bio hubber fuerte	402	Bio hubber simple	403
Bio hubbersimple	402	Bioarterol	326
Biobamat	367	Biobamate	367
Biocapton	352	Biocefalin	400
Biocetin	333	Biocleran	339
Biocorn	404	Bio-cron	404
Biodry	375	Bio-exazol	349
Biofeniol	333	Biofradin	375
Biofur	375	Biogamma2	369
Bioglan m/q	366	Biometran	349
Biomicon	349	Biontabol	400
Bio-pectodil	404	Biophenicol	333
Biophtas	333	Bioscleran	339
Biosol	375	Biosol-m	375
Biostrep	345	Bio-tab	347
Biotangin	369	Bio-testiculina	408
Biotocap	333	Biovital	407
Bio-vitastrept	375	Bioxurin	394
Bipasmin compuesto	369	Bipheramine	343
Biphetane	392	Biphetap	392
Bipiquin	336	Biquinal	330

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Bisflatan	381	Biskapect	382
Biskapect	362	Bismodyne	356
Bismophenyl	333	Bisolvon compositum	379
Bit	328	Bitencyl	333
Bithin	328	Bitin	328
Bi-uglucon ud87	386	Bivacyn	375
Bizolin 20	390	Bizolin 700	390
Black and white	358	Blastoestimulina	375
Blesin	343	Blox	364
Bluboro	329	Bludex	324
Blu-hist	392	Blu-phen	387
B-neuron	327	Bock-ase	387
Bold laxine	389	Bolinan	396
Bolvidon	373	Bom-bon	389
Bon korets	396	Bonamina	365
Bonamine	365	Bonanza	330
Bon-bon	389	Bonbrain	409
Bonexyl	387	Bonifen	400
Bonifwn	400	Bonine	365
Bonol	400	Bonpyrin	369
Bon-sonnilal	372	Bontril	386
Bonumin	321	Bordol	406
Bor-ind	360	Boroformal	329
Borogal	329	Borsyre viskos	329
Bort	369	Boxogetten	381
B-piperazine	394	Brantina	341
Brantine	341	Breezeazy	385
Brek	364	Brenalalit	321
Brendalit	321	Brevicon	379
Brevinor	379	Brexin	371
Bridine	396	Brirel	394
Bristacilia	369	Bristamycin	349
Britaderm	338	Britadex-vioform	338
Britercina	369	Brocatine	381
Brocon cr	392	Brodial	330
Brofen 200 mg	359	Brofen 400 mg	359
Bromadryl	387	Bromalgin	369
Bromalgon	369	Bromanate	392
Bromed	329	Bromepaph	392
Brometapp	392	Bromo quinina	383
Bromo seltzer	383	Bromophen	392
Bromoxin	330	Broncha-tulisan eucalyptol	379
Bronchisan	322	Broncho-rivo syrup	336
Broncho-tetracycline	348	Broncho-tulisan eucalyptol	379
Broncofenil	369	Broncolysin	369
Bronco-quintoxil	392	Broncosmin	387
Broncozina	413	Bronkaid mistometer	348

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Brontin	341	Bronx	413
Brophylline	327	Brosolin-rectocap	379
Brotazona	352	Brufaneuseol	322
Brufaneuxol	322	Brufanic	359
Brufen	359	Brufert	359
Brufort	359	Bryrel	394
Bs-5892	330	B-tonin	350
Buborone	359	Bucarboxal	369
Buco pental	405	Buco regis	405
Bucosol	405	Budirol	399
Budoform	338	Bufedon	359
Bufemac	330	Bufexamac-ratiopharm (r) creme	330
Bufexine	330	Bufexine ratiopharm(r) f-sable	330
Buff-a-comp	383	Bufigen	359
Bufonamin	330	Bulbonin	330
Bumadizon	331	Bumaflex	331
Bunaiod	331	Buniodyl	331
Buprenex	331	Buprex	331
Buprx	331	Burana	359
Burnazone	378	Burtylonel	383
Buscapina comp.	369	Buscapina compuesto	369
Buscapina compuestum	369	Buscol compositum	369
Buscopan composto	369	Buscopan compostum	369
Buscopina compostum	369	Buta lyseen	374
Buta pirone	381	Butacal	390
Butacol	390	Butacompren	390
Butacote	390	Butadilat	390
Butadin	390	Butadion	390
Butadiona	390	Butadyne	390
Butafenil	390	Butaflogin	381
Butaflogin	380	Butagesic	390
Butagros	390	Butakvertin	390
Butal compound	383	Butalan	390
Butalgin	390	Butalgina	390
Butalgine	369	Butaluy	390
Butaparin	390	Butaphen	390
Buta-phen	390	Butapirazol	390
Butapirone	380	Butapyrine	322
Butarex	390	Butartiril	390
Butatril	390	Butazina	390
Butazolidin	390	Butazolidin alka	390
Butazolidina	390	Butazone	374
Butazone	390	Butazonic	380
Butenemal	413	Buteril	380
Buteril	381	Butial	390
Butidiona	391	Butilene	381
Butilene	380	Butinol	391

C. INDEX TO PHARMACUETICALS BY AVAILABLE TRADE NAMES

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Butiwas	391	Buto beta	391
Butofen	381	Butolfen	381
Butone	391	Butorinal	383
Butoroid	391	Butoroid cream	391
Butoz	391	Butrex	391
Butylenin	359	Butylone	383
Butylpan	369	Buvetzone	391
Buzon	391	B-voltaren	343
Bydolax	381	Bykanula	375
Bykomycin	375	Byladoce	369
C "5"	355	C 147	387
C. o fluo-fenicol	333	C. o hidrocor-clora	333
C.i. 19140	407	C.i. 77320	341
C.i. acid yellow 23	407	C.i. food yellow 4	407
C-16038-ba	322	Cacimag	329
Caclcifor	329	Cadraten	331
Cadraten 21 cpr 20 mg	331	Cadraten 30 cpr 10 mg	331
Cadraten 30 cpr 15 mg	331	Cadratin	331
Cadrilan	331	Caf	333
Cafenolo	333	Cafergot p.b.	383
Caffalgina	399	Caladryl	333
Caladryl	332	Calavon	324
Calcamyl-24	329	Calcibenzamin	329
Calcocid yellow mcg	407	Calcocid yellow xx	407
Calgayan-c	369	Calibene	407
Californit	380	Californit	381
Calinador	414	Calmaderm	330
Calmador	414	Calmante muri	383
Calmasmin	385	Calmax	337
Calmax	367	Calmetron	369
Calmina	333	Calminal	387
Calmiren	367	Calmonal	365
Calocain	373	Calpental	383
Cam	333	Camilca	329
Camizol	369	Camoplex	399
Camoquin	325	Campiol	333
Campozim	380	Canaural	375
Cancert tartrazine	407	Candizine	394
Canidis-anti-diarr	393	Caniquin	325
Canisan	389	Canoral	375
Canquil-400	367	Cantacin	399
Caosol	333	Cap	333
Capacetyl	383	Cap-o-tran	367
Capramin	383	Caps dr knapp	383
Capsula dr. knapf	319	Capsula dr. knapp	383
Capsyka dr knapf	322	Captagon	352
Captagon cpr nsfp	352	Capval	379

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Capysal	322	Carb-a-med	367
Carbaxin	367	Carbidiar	393
Carboform	338	Carbolic acid	389
Carbopuradin	353	Carbotalin	393
Carbrital	383	Card-fludilat	326
Cardiol	398	Carditan	401
Cardophyllin	323	Cardophylline	323
Carena	323	Caribium	379
Carine	323	Carnigol	341
Carpantin	341	Cartagyl	339
Carudol	394	Carudol	391
Catergen	337	Cateudyl	372
Catilan	333	Caudaline	410
Causalon	369	Causyth	399
Cavumycetina	333	Cb 304	326
Cb 311	401	Ccombinado balsamico	333
Ccorticol	333	Ce 10010	387
Ceachin	383	Cebemyxine	375
Cebenicol	333	Cebutid	355
Ceepea	387	Cefalogen	400
Cefeno	337	Cefinal	383
Cefrocyn	375	Cegramine	321
Ceilipen	328	Celeka	397
Celestalgol	391	Celestazone	391
Cemealonal	387	Cenadex	392
Centedrin	373	Centramina	321
Cepalorin	332	Cepastat	389
Ceporin	332	Cequinyl fort	383
Cerebro	406	Cerebrol	399
Cerebrotrofina	400	Cerebroxine	413
Cerm-3024	413	Cerozalol	363
Certecol tartrazol yellow s	407	Certolax	389
Cervitalin	400	Cesamet	374
Cesra	359	Cessantyl	369
Cetal	413	Cetanest	348
Cetavister	398	Cetedrin	373
Cetina	333	Cetonax	363
Cetussan	385	Cg 3224	375
Cgp 9194	343	Chebutan	362
Chelafrin	348	Chembutazone	391
Chemiartrol	374	Chemibal	333
Chemicetin	333	Chemicetina	333
Chemiovis	405	Chemiovis	405
Chemochin	336	Chemofuran	378
Chemosept	405	Chemthromycin	349
Chemyzin	333	Chendol	332
Chenracol	336	Chepirol	362

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Chetazol	362	Chetazolidin	362
Chetil	362	Chetopir	362
Chetosol	362	Chibro	329
Chiclida	365	Children's advil	359
Children's motrin	359	Chini-med	369
Chinopyrin	322	Chinosol	356
Chitosamine	355	Chlofel	381
Chloferex	340	Chlomin	333
Chlomycol	333	Chloracet	383
Chloramex	333	Chloramfenicol	333
Chloramficin	333	Chloramfilin	333
Chloramol	333	Chloramphenicol cinnamate	333
Chloramphenicol intervetra	333	Chloramphenicol sodium succinate	333
Chloramphenicol-pos	333	Chloramphycin	333
Chloramplast	333	Chloramsaar	333
Chloramson	333	Chloranfeni-mck	333
Chloranfeni-opipno	333	Chloranfeni-otico	333
Chloranfeni-ungena	333	Chloraseptic	389
Chloraseptic dm	389	Chlorasol	333
Chlora-tabs	333	Chloreptic	333
Chlorgyl	343	Chlor-histine	336
Chlorical	333	Chloricol	333
Chlornitromycin	333	Chloro-25 vetag	333
Chloroantibion	333	Chlorocaps	333
Chlorochin	336	Chlorocid	333
Chlorocide	333	Chlorocidin c	333
Chlorocidin c tetran	333	Chlorocortal	333
Chlorofair	333	Chloroject I	333
Chloroject s	333	Chloromex	333
Chloromik	333	Chloromimyxin	333
Chloromycetin	333	Chloromycetin kapseals	333
Chloromycetin palmitate	333	Chloromycetin sodium succinate	333
Chloronaftina	336	Chloronitrin	333
Chloropect	382	Chloropect	362
Chloropent	383	Chloroptic	333
Chloroptic p. oint.	333	Chlorosol	333
Chlorostrep	333	Chlorotin	333
Chlorotyxin	333	Chlorovules	333
Chlor-rest	392	Chlorsig	333
Chlorvescent	397	Chlotaon	333
Chocolax	389	Cholal modifico	398
Cholal simple	398	Cholstat	332
Choragon	396	Choriantin	396
Choritropin	396	Chorulon	396
Chp-depot	399	Chrlich 594	319
Chur-lax	381	Cibalgin	322
Cibalgina	399	Cibazol	405

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Cicatrex	375	Ciclazon	322
Ciclepen	333	Cidal	356
Cidan	328	Cidan est	402
Cidanchin	336	Cidan-cilina	328
Cidocetin	333	Cifoform	338
Cilefa yellow t	407	Cilipen	328
Cimetrin	349	Cinchophene	337
Cinconal	337	Cincosal	337
Cinnamin	326	Cinnarizin	339
Cinnopropazone	326	Cintaverin compuesto	369
Cinthol	356	Cinturex	392
Ciperazin	394	Ciplactin	341
Ciplamycetin	333	Cipractin	341
Cipro	341	Cipro n	341
Ciprocort	341	Ciracen	381
Circleton	406	Cirotex	381
Cirotyl	381	Cirpon	367
Cirponyl	367	Cirramina	337
Cisapid	337	Cismotil	337
Citalgan	369	Citestrol	366
Citexal	372	Citiflus	339
Citizeta	413	Citocard	410
Citodon	357	Cito-guakalin	401
Citopan	357	Citra-fort	383
Citramol	383	Citrazine	394
Clareden	339	Claresan	339
Claripex	339	Claripex cpib	339
Clemanil	337	Clemastin fumerate syrup	337
Clemodril	387	Cleniderm	375
Clenisep	356	Cleocin	338
Cletanol	392	Climatost	398
Clinafenol	333	Clindoorm	367
Clinidine	396	Clinit	374
Clinit	322	Clinovie	342
Cliovir	342	Cliquinol	338
Clisemina	347	Clistanol	384
Clizim	369	Cloberab	339
Cloberat	339	Clobrat	339
Clobrate	339	Clobren	339
Clobren-5 f	339	Clof	339
Clofenal	333	Clofenit	339
Clofexan	369	Clofibral	339
Clofibrase	333	Clofibrat	339
Clofibrate ayerst	339	Clofibrate compose	339
Clofibrato ayerst	339	Clofibrato procaps	339
Clofibrem	339	Clofimide	339
Clofini	339	Clofin-icn	339

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Clofinit	339	Clofipront	339
Clofipront 5000	339	Clofirem	339
Clofirin	339	Clofi-t	339
Clomiazin	340	Clomicin enzym	333
Clomin	344	Clopin	339
Cloramex	333	Cloramfen	333
Cloramicol	333	Cloramidina	333
Cloran	333	Cloran	347
Cloranfenicol-mck	333	Cloranfeni-opifno	333
Cloranfeni-otico	333	Cloranfeni-ungena	333
Cloransul	333	Clorbiotina	333
Clorbis supp.	333	Clorfentermina	336
Clorochina	336	Clorocyn	333
Clorofenicina	334	Cloromicetin	334
Cloromisan	334	Cloromoin	334
Cloromycetin	334	Cloroptic	334
Cloroptic farmicetina	334	Clorosyntex	334
Cloro-yodo-hidroxi	338	Clorpine	338
Clozaril	341	Co dox	347
Coadvil	359	Coaxil	410
Cobalt-59	341	Cobinamide	365
Cocresol	352	Codacol	336
Codafen	359	Codafen continus	359
Codalgin	385	Codalgin	369
Codasal injetavel	369	Codempiral	384
Codicept	341	Codimal	392
Codimal dm	336	Codipect	379
Codol	341	Codopyrin	384
Codral	384	Codyl	379
Codyl cum expectoras	379	Co-ervonum	366
Cofen	369	Coffan	322
Coffecodin	387	Cofpac	392
Col 180	339	Cold cap	392
Coldecon	392	Col-decon	392
Colepur	330	Colfezone	391
Colfin	350	Colgenol	369
Colicitina	393	Coliclast	393
Colidene	334	Colifelin	364
Colifilm	364	Colimy-c	334
Colipar	330	Coliriocilina	328
Coliseptale	403	Colix	344
Collarsin	319	Collo-bo	398
Collodyne	362	Collodyne	382
Colonofilin	323	Comaril 5000	369
Combias	338	Combiquens	366
Commotional	399	Complexobiotico	345
Compound 90459	327	Compral	322

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Compralgyl	319	Compralgyl	384
Comycetin	334	Conac	371
Conceplan	379	Conderm	375
Condilomin	396	Condyline	396
Coneolent	329	Conex-grippe	392
Conjuctilone	375	Conjuvac two grass	320
Conmel	369	Conta-schmerz	384
Contax	381	Contergan	409
Continal	383	Contop	392
Contradouleur	384	Contra-lipide	339
Contraneural	359	Contrneural	359
Control	392	Controlgras	321
Conturex	372	Coopane	394
Coopaphene	356	Cope	359
Copirene	362	Copover	338
Coprobate	367	Corafen	339
Coralgil	345	Coralgina	345
Coralgyl	345	Corapamil	354
Cor-asthmolyticum	387	Coratose	361
Corbuvit	391	Cordes vas	411
Cordialina	398	Cordocel-h	356
Corfilamine	323	Coricidin	384
Coricidin f	392	Coricidin f	384
Coriforte	384	Corilin pediatric	369
Cornemin	375	Corophyllin	323
Corophylline	323	Corphyllamin	323
Corpormon	401	Corsym	392
Cortasmyl	387	Cortempirol	369
Cortex	338	Corti-anartril	355
Cortican	334	Corticreme	338
Cortidermale	334	Corti-glottyl	338
Cortimisin	334	Cortinen	375
Cortiphenicol	334	Cortison-quemicet	334
Cortitracin	369	Cortivert	334
Cortol	334	Corto-tavegil	338
Cortrifosal	408	Corverum	387
Coryban-d	384	Coryza	405
Coryzium	353	Coryztime	392
Coscopin	379	Coscotab	379
Co-specto	336	Cotofilm	356
Cotradol	384	Cotrol-d	336
Coumadin	413	Coumadine	413
Coverject	320	Coxigon	327
Coxistat	378	Cp 3438	328
Cp 556s	406	CP-34089	406
Cp-cap	356	Cph	334
Cr/085	339	Crema antisolar evanescente	385

C. INDEX TO PHARMACUETICALS BY AVAILABLE TRADE NAMES

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Cremacoat	392	Crematalil	393
Creme des 3 fleur d'orient	358	Crema-merazine	403
Cremophor rh40	396	Cremophor rh60	396
Crema-quin	338	Cremonthalidine	393
Crethemomethazine	403	Crescormon	401
Cresophene	332	Cresophene	356
Cresoxydiol	366	Crestanil	367
Crinohermal fem	344	Crionil	405
Crisocilin-g	328	Cristapen	328
Critex	381	Crk 635	401
Crocic	382	Cronoformin	386
Cronopen balsamico	369	Crospovidone	396
Crovaril	380	Crystamycin	328
Crystapen	328	Crystapen g	328
Crytraden	322	Csp 500	405
Csp-250	405	Ct-diclo	343
Ct-spiro	401	Cuait	411
Cuaot	324	Cuisialigil	359
Cunil	359	Cuprofen	359
Curban	343	Curolax	381
Curon	407	Curretab	342
Curythan	366	Cusayth	322
Cusimicina balsamica	349	Cusitan	367
Cutaden	329	Cutispray no. 4	334
Cv 58903	413	Cycladiene	344
Cyclarin	341	Cyclexedrine	399
Cyclidox	347	Cyclobex	344
Cyclocen	344	Cyclonal	357
Cyclonal sodium	357	Cyclopan	357
Cyclopar	409	Cydril	363
Cyphenicol	334	Cyprol expectrant	336
Cypromin	341	Cyprostol	374
Cyrasarl	341	Cyrpon	367
Cysticat	334	Cytadren	322
D & m tablets	389	D & m tablets	327
D 237	340	D and c yellow no. 5	407
D bretard	386	D epinefrin	348
D.i.m.	346	D.i.p.	321
D.i.p.n	321	D.v.	344
Da 2370	352	Dabical	339
Dafodil	387	Dak	394
Dalca	392	Dalet	336
Dalzic	398	Damapo	375
D-amfetasul	343	Damoral	387
Danaden	400	Danalon om	407
Danfenona	352	Danilon	407
Danilon	359	Danol	342

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Dansida	359	Dantrium	326
Danylen	321	Daopar	386
Dapaz	367	Dapecfuran	353
Dapex	390	Daprisal	384
Dap-test	396	Daritran	367
Darkene	353	Darkeyfenac	320
Darmol	389	Darmoletten	381
Daromid	405	Darostrep	402
Dartranol	391	Darvocomp-n	384
Darvon compound	384	Darvon compuesto 65	384
Darvon n compuesto	384	Daserd	366
Daserol	366	Dasikon	384
Dasin	384	Dasin	332
Dasin ch	384	Dasten	365
Dastonil	398	Daturmed	399
Davimycin	375	Davosin	404
Davosin suspension	404	Davuron sedante	334
Day nurse	392	Db comb.	386
Db retard	386	Dbi	386
Dbnf	384	Db-retard	386
D-chloramphenicol	334	Ddd	332
De be	386	Deandros	398
Deba	326	Debej	386
Debendox	344	Debeon	386
Debinyl	386	Debnal m	403
Debutazon	391	Decabis	342
Decabolin	374	Deca-durabol	374
Deca-durabol	375	Decadurabolin	375
Deca-durabolin	375	Deca-durabolin	374
Deca-durabolin decanoate	374	Deca-hybolin	374
Deca-noralone	374	Decidex	392
Decomine	392	Decontractyl	366
Decontractyl	366	Decontractyl-baum	366
Dectamicina	334	Dectolin	353
Dectuss	336	Decycline	409
Defolgin	380	Defonamid	405
Degonon	365	Degoran	379
Degramycin	375	Degripol	399
Dehydrobenzperidol	348	Dehydrostilboestrol	344
Deililax	381	Dejo	346
Deladine	403	Delagil	336
Delgamer	321	Delipid	339
Deliva	339	Delmofluvina	355
Delmofluvina	355	Delphimix	343
Delta optil	334	Delta pimafucort	356
Delta-butazolidin	391	Delta-demoplas	391
Delta-myogit	391	Delta-tomanol	391

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Deltavagin	404	Deltawaukobuzon	391
Deltricin	369	Delvex	346
Delvinal	413	Delvinal sodium	413
Demazine	392	Demolpas	322
Demoplas	391	Demosa casi penicilina	328
Demovermil	394	Dentigoa	322
Dentigoa	359	Dentigoa forte	359
Dento-caine	348	Dentocaps	384
Dentocaps a	399	Deoxymykoïn	347
Dep0-clinover	342	Dep0-map	342
Depcorlutin	342	Dependal	338
Dephimixn	391	D-epifrin	348
Depinefrin	348	Depiral c	322
Depo-prodasone	342	Depo-progevera	342
Depo-promone	342	Depo-provera	342
Deporone	342	Depovernil	404
Deprax	411	Deprecstop	392
Deprelio	324	Deprestal	324
Deprex	343	Deptavac hvt	356
Deptran	347	Dequacaine	342
Dequafungan	342	Dequin	342
Deramix	321	Derbitan antibiotico	375
Derbitan antibiotico	402	Dereuma	322
Derfon	321	Derivative	356
Derivatives	410	Derl	356
Derma 10	356	Derma cas	389
Derma leaf	356	Dermacid	356
Dermacytostat	396	Dermadex	338
Dermaïrol	411	Dermalex	356
Dermaspray	327	Dermicema	375
Dermo sonerge	375	Dermobion	378
Dermoclar	411	Dermoface	375
Dermohex	356	Dermojuventas	411
Dermolle	356	Dermoplast	356
Dermo-quinol	338	Dermosa cusipenicilina	328
Dermosan	375	Dermovate-nn	375
Dermozolan	338	Derobion	375
Derugin	411	Descresepet	325
Deselmine	346	Desinflam	320
Desoblit	326	Desopimon	336
Desoxyn	368	Desphen	334
Desqyam-x	350	Desulfon	404
Desuric	327	Desyrel	411
Detal	328	Detaril	395
Detensitral	367	Detreomycin	334
Dettuso	379	Devaguanil	403
Devalgin	369	Devamycetin	334

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Devegan	319	Deverol	401
Devidone	411	Dewitt's pills for backache and joint pains	398
Dexa butarin	369	Dexa escopyrin	322
Dexa tomanol	391	Dexaamisolone-n	375
Dexa-atritin	391	Dexa-biofinicol	334
Dexabiotan	375	Dexabolin	351
Dexacidin	375	Dexadrine	343
Dexa-escopyrin	391	Dexalocal	338
Dexamed	343	Dexamed	391
Dexamin	343	Dexamin	321
Dexamist	375	Dexampex	343
Dexapirilene	371	Dexaspan	324
Dexa-tavegil	338	Dexatrim	392
Dexatrine	321	Dexatrzone	391
Dex-a-vet	327	Dexavetaderm	375
Dexedrina	343	Dexedrine	343
Dexinca	382	Dexital	324
Dexolan	356	Dexophrine	368
Dexoval	368	Dexten	343
Dextophan	343	Dextromycetin	334
Dextrophen	343	Dextro-profetamine	343
Dey-dose	361	d-Fenfluramine	343
Dha 51	322	Dha-s (prasterone)	398
Dhsm	345	Diaban	338
Diabis	386	Diabrin	330
Diacalm	382	Diacin	375
Diacolin	393	Diacta	403
Diadin	374	Diadril	365
Diaformin	386	Diafuron	353
Diagnorenol	372	Diaguard	382
Diaguard forte	362	Diaguard forte	382
Dia-ject	375	Dial toilet soap	356
Dialidene	353	Dialose plus	381
Dialpyrin	322	Diandron	398
Diandrone	398	Diapatal	324
Diapenin 3	345	Diapenin balsamico	345
Diaperidol	348	Diaphylline	323
Di-ap-trol	386	Dia-quel	380
Diarest	375	Diarexin	353
Diareze	382	Diareze	364
Diarin	353	Diarphem	346
Diarrest	344	Diarrest	341
Diarrestival	345	Diarrhosan d	382
Diarsed	346	Diarsed-neomycin	346
Diasatin	381	Diastat	382
Diastat	362	Diastat	402
Diatensec	401	Diatesurico	394

C. INDEX TO PHARMACUETICALS BY AVAILABLE TRADE NAMES

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Diatro	346	Di-bal-rone	369
Diban	400	Diban	382
Diban diet complex 1500	382	Di-barbs	383
Dibein	386	Dibein retard	386
Dibenide	386	Dibenylene	390
Dibenzylene	390	Dibenzylan	390
Dibetos	330	Dibinyl	386
Dibiraf	386	Dibolin	386
Dibophen	386	Dibotin	386
Dibromoksin	330	Dibromoquin	330
Dibromoxin	330	Dibromoxine	330
Dibun	386	Dibuzon	391
Dicandiol	367	Dicevermin	394
Dichinalex	336	Dichloronic	343
Dichronic	343	Diclo attritin	343
Diclo spondril	343	Diclo-atritin	343
Diclo-burg	343	Diclofur	353
Diclophen	344	Diclo-phlohont	343
Diclo-puren	343	Diclo-recip	343
Dicloream	343	Diclo-spondryl	343
Diclo-wolf	343	Dicortineff	375
Dicton-retard	348	Dicyclomine	344
Dicycloverin	344	Didromycin	345
Didrothenate	345	Diebin	386
Diebin retard	386	Diemal	326
Dienoestrol	344	Dienol	344
Dienostrol cream	344	Dienstrogen	344
Dienterol	375	Dietec	321
Dietelmin	394	Dietene	332
Dietil retard	321	Dietil-retard	321
Dietrol	386	Diet-trim	382
Diffu-k	397	Diffusin	358
Difimetus	379	Difimetus compositum	379
Diflarex	410	Diflurex	410
Difmedol	380	Digenol	337
Digesan	394	Digesept	330
Digi-aldopur	401	Digibutina	391
Digi-pulsnorma	387	Digisab	322
Digiseb	319	Dignoflex	359
Diguabet	386	Dihydrocidan sulfato	345
Dihydrodiethylstilbestrol	357	Dihydrostreptofar	345
Dihydrostreptom	345	Diidro-pantostrept	345
Dilakton	401	Dilangio	326
Dilangio caposium	326	Dilapres	326
Dilaurazine	394	Dilectus	339
Dilombrine	346	Diloxol	366
Dimametten	322	Dim-antos	399

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Dimapyrin	322	Dimetane	392
Dimetap sinus	359	Dimethedon	369
Dimezathine	403	Dimicina	375
Dimidin	403	Dimidon	359
Diminal	413	Dimopyrin	322
Dimotane	392	Dinestrol	344
Dinol	344	Dinopirina	369
Dinovex	344	Diocimex	347
Dioclin	345	Diocyl	344
Dioderm	338	Dioderm c	338
Dioderm c-c	338	Diodotracin	338
Dioloxol	366	Diomeride	343
Dioquinol	338	DioSSIDone	391
Dioxadol	369	Dipar	386
Dipental	383	Dipirin	322
Dipiron	369	Dipirona	369
Dipirone	369	Diprin	322
Diprivan	399	Diprofarm	369
Diproform	338	Dipyrin	322
Dipyrine	322	DipyriVO	369
Dipyrone	369	Dira	401
Direstop	391	Direver	402
Direver	393	Dirkan	403
Diromo	330	Diron	367
Dirorno	330	Disenterol	393
Disipan	354	Dismenodl n	359
Disoprivan	399	Dispalgine	369
Disparicida	319	Dispermin	394
Disphex	396	Dispos-a-med	361
Disprofol	399	Dissenten	364
Dissenter	364	Dissol	329
Distaval	409	Distilbene	345
Distocid	356	Distonocalm	383
Distraneurin	340	Distraneurine	340
Distreptopab	345	Dital	386
Dithene-r	387	Dithiazine (dye)	346
Ditinil	381	Ditmedol	381
Ditrone	391	Diudorm	372
Diurazina	394	Divalvon-d	400
Divarin	369	Divarmin	369
Divermex	394	Divinoctal	372
Dizan	346	Dizenterol	338
Dk 2	356	Do-ba-rone	369
Dobeom	386	Dobesin	321
Dobetin	369	Doboiosol	349
Docabolin	374	Docabolin	375
Docostyl	347	Doctamicina	334

C. INDEX TO PHARMACUETICALS BY AVAILABLE TRADE NAMES

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Doctofril	391	Doctus	339
Doksapan	347	Dolafort	384
Dolaren	343	Dolaren	369
Dolat	347	Dolatets	369
Dolazon	369	Dolemicin	369
Dolene	384	Doleron novum	385
Dolgenal	414	Dolgirit	359
Dolgit	359	Dolibral	399
Dolibrax	399	Doline	327
Dolispan	369	Dolispasmo	369
Dolkwal tartrazine	407	Dolo adamon	369
Dolo baralgine	369	Dolo buscopan	369
Dolo nerv	369	Dolo neurobion	369
Dolo neurobion forte	369	Dolo pangavit	369
Dolo raptalgin	369	Dolo spasuret	370
Dolo-attirin	322	Dolobasan	343
Dolocyl	359	Dolo-dolgit	359
Dolo-eupaco	387	Dologesic	359
Dolojudolor	370	Dolo-med-much	385
Dolo-mineuron	399	Dolomo	384
Dolo-neos	359	Dolo-neurobion	370
Dolo-optineural	322	Dolo-phlogase	380
Dolopirina	370	Dolo-prolixan	326
Dolo-puren	359	Dolorphen	322
Doloscopin	370	Dolosin dexta	391
Dolostop	384	Dolo-tandril	380
Dolotrem	343	Dolovisano	367
Dolovosano	322	Doloxene comp forte, capsules	384
Dolpirina	391	Dol-stop	385
Doltibil	359	Dolven	359
Dolviron	384	Dolwas	414
Domeform	338	Domical	324
Dona 200-s	355	Dona compositum	355
Donibin	387	Donjust-b	359
Donna 200	355	Donnage	382
Donnagel	382	Donnagel	362
Donnagel	400	Donnagel pg capsule	382
Donnagel pg liquid	362	Donnagel-mb	382
Donnagel-mb	362	Donnagel-pg	362
Donnagel-pg	382	Donnagel-pg	400
Donna-lix	387	Donnaplex	387
Donnatal	387	Donnatal	400
Donobin	322	Dopiral	370
Doragon	343	Doredin	322
Doregrippin	384	Doreplaston/doser/f	375
Doreplston	353	Dorflex merrell	370
Dorico	357	Dorico soluble	357

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Doriden	355	Doridene	355
Doriden-sed	355	Doridine	355
Dorimid	355	Dorimide	355
Dorithicin	376	Dorival	359
Dorlisin	370	Dorlotyn	324
Dormabrol	367	Dormigoa	372
Dormigoa-schlafmittel	372	Dormileno	326
Dormilfo n	367	Dormin	371
Dorminal	324	Dormir	372
Dormiral	387	Dormisedilal	372
Dormogen	372	Dormol	389
Dormon	326	Dormonal	326
Dormutil	372	Dormytal	324
Doron	370	Dorscopena	370
Dorsec	403	Dorsec	334
Dorsec	405	Dorsedin	370
Doryx	347	Doryxas	379
Dosberotec	352	Doscafis	384
Doscalun	387	Dosil	347
Doss	342	Dotur	347
Double-t	409	Dovaso	357
Dovenix	379	Doviron	384
Dowmicyn	349	Dowzene	394
Doxal	347	Doxatet	347
Doxedyn	347	Doxepin hcl	347
Doxi sergo	347	Doxicento	347
Doxidan	389	Doxifin	347
Doxilen	347	Doximycin	347
Doxin	347	Doxina	347
Doxinate	347	Doxiten bio	347
Doxivis	347	Doxy	347
Doxy-100	347	Doxy-basan	347
Doxybiocin	347	Doxychel	347
Doxycyl	347	Doxy-diolan	347
Doxydyn	347	Doxyfed	368
Doxyfim	347	Doxygram	347
Doxylag	347	Doxylan	347
Doxylar	347	Doxylets	347
Doxylin	347	Doxymycin	347
Doxyn	368	Doxy-p	347
Doxytem	347	Doxy-wolff	347
D-pron	370	Dradril	365
Dreiciclina balsamica	345	Dreimicina	349
Drenoliver	337	Drinacet	384
Drinalfa	368	Drinamyl	343
Dristan	399	Dristan sinus	359
Dropenzil	394	Droxan	330

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Droxarol	330	Droxaryl	330
Droxaryl zalf 50 mg	330	D-sinus	392
Dst	345	Dtdc	346
D-threo-chloramphenicol	334	Duerin	322
Dufemine	344	Dugen	342
Dulasi	406	Dulcicortine	376
Duloctil	406	Dumalgin	370
Dumoxin	347	Duneryl	387
Duo-autohaler	361	Duohist	371
Duo-medihaler	361	Duonale-e	350
Duo-tussin	371	Duivent	387
Duivent	352	Duozplin vitaminado	349
Duphacerate	376	Duphaspasmin	327
Duphenicol	334	Duplibiot	364
Duplinal	339	Durabol	374
Durabolin	374	Durabolin	375
Durabolin phenpropionate	375	Durabolin-o	351
Duraboral	351	Duraclofibrate	339
Duradermal	330	Duradoxal	347
Duradyne	359	Dura-ibu	359
Duralbuprofen	359	Duralnordin	370
Duraphyllin	323	Duraspiron	401
Durasul	404	Durasul jarabe	404
Durateston v	408	Duravolten	343
Duremesan	365	Durium	327
Duromin	390	Duromine m 40	372
Durophet	343	Durophet	321
Durophet-m	343	Durox	404
Durules-k	397	Dushel	353
Dutformin	330	Duvavotten	344
Duvium	327	Dv	344
Dv 201	376	Dya-tran	370
Dye yellow lake	407	Dylhista	371
Dymazone	378	Dynabalon	375
Dynabiotal	349	Dynarsan	319
Dyrex	394	Dyrexan-od	386
Dysdolen	359	Dysentrocym	330
Dysmalgin	399	Dysmensan	322
Dysne-inhal	348	Dyspas	344
Dyspnoesan	361	Dystoid	367
E 102	407	E 102 (dye)	407
E.e.s	349	E-217	409
Ear-dry	329	Eastman 7663	346
Eatan	372	Eatongel	344
Ebufac	359	E-caprine	348
Ecatrol	343	Eclipse	327
Ecobutazone	391	Econoclor	334

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Ecoprofen	359	Ecosan	394
Ecto pellicur	357	Ectobutazone	391
Ectofum	357	Ectofural	378
Ecuamil	367	Eczeceidin	338
Edental	367	Edgartet	370
Edicol supra tartrazine n	407	Edifeno	405
Ediluna	359	Edoiacolo	319
Edrisal	384	Ees-200	349
Ees-400	349	Eeskabarb span	387
Eespanal	370	Efamast	354
Efatin	350	Efed ii	392
Effederm	411	Effekton	344
Effox	337	Eficol	392
Ef-micin	393	Efo-dine	396
Efroxine	368	Egg yellow a	407
Eggobesin	399	Ego psoryl	389
Egomycol	389	Egosol-bs	329
Ehrlich 594	319	Eiproheptadine	341
Ejcopyrin	399	Ejificol	334
Ejificol strept	334	Ejificol sulfa	334
Ejor	362	Ekluton	396
Elaste chloromycel	334	Elastonon	321
Elatrol	324	Elatrolet	324
Elavil	324	Elavil plus	324
Elcoman	364	Eldopaque	358
Eldopaque forte	358	Eldoquin	358
Eldoquin forte 4% cream	358	Eldox	346
Eleudron	405	Elibese	387
Elipten	322	Elix	404
Elkosin	406	Ellemger	340
Elmedal	391	Elmigrin	387
Elmizin	346	Elphemet	386
Elpi	340	Elrodorm	355
Eludril	336	Emaform	338
Emagrin	387	Embacetin	334
Embutal	383	Embutol	350
Emcortina	376	Emd 15700	377
Emedrin	348	Emerin	403
Emetin	348	Emetina	348
Emetocamphrol	348	Emetren	334
Emineurina	340	Emitrip	324
Emlab	357	Emodin	359
Emorex k berna	376	Empiral	384
Empirin compound	384	Emprazil	384
Emprazil-c	384	E-mycin	349
E-mycine	349	Enarmon	408
Enarmon-oil	408	Enbacin	376

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Enbol	400	Enbrel	350
Encefabol	400	Encefort	400
Encephabol	400	Encerbrovit	400
Encerebron	400	Encilcort	408
Endal	392	Endamal	336
Endecon	392	Endep	324
Endex	392	Endocorion	396
Endoeritrina	349	Endometril	365
Endomixin	376	Endorid	394
Endrine	332	Endyne	360
Enerbol	400	Energital	375
Enerzer	361	Enicol	334
Enosept	330	Enovil	324
Ensobarb	387	Ensulfa	404
Entacyl	394	Entazin	394
Enteral	338	Enteramida	393
Enterar	353	Entera-strept	345
Entercol	379	Enteritan	338
Ente-rivo	338	Ente-rivo simplex	403
Enterocalme	393	Enterocol	379
Entero-hermes	393	Enterokin	338
Enterokvin	330	Enterolyte	382
Enteromac	376	Enteromycetin	334
Enteropast	376	Entero-red	393
Enterosan	362	Enterosan	338
Enterosept	338	Enteroseptol	338
Enterosintex	376	Enterosteril	393
Entero-sulfina	393	Entero-toxan	393
Entero-valodon	338	Entero-vioform	338
Entero-vioformio	338	Entero-vioformo	338
Enteroxon	353	Enterozol	338
Enterquinol	338	Entexidina	393
Entox	338	Entrafon-210	324
Entrafon-2-10	324	Entrafon-2-25	324
Entrafon-a	324	Entrafon-forte	324
Entrasorb	338	Entrokin	338
Entrokinol	338	Entromone	396
Enttocetrin	334	Enzipan combinado	370
Ephedrobarbital-t	387	Ephestmin	387
Epi-aberel	411	Epib	340
Epiboran ofteno	348	Epidormb	387
Epifrin	348	Epiglauftrin	348
Epikur	367	Epilantin	387
Epinal	320	Epinephrine hcl	348
Epinephrine pediatric	348	Epineramine	348
Epipen	348	Epirenan	348
Epitrate	348	Epivetol	389

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Epizon	399	Epobron	359
Epocan	400	Epocler	358
Epogam	354	Epragen	384
Epsylone	387	Equanil	367
Equi bute	391	Equiner	367
Equinil	367	Equipalazone	391
Equipur	413	Equithesin	350
Equizole-a	394	Equqtrqte	367
Eraldin	398	Eraldina	398
Eramid	340	Eraverm	394
Erbaplast	334	Erdol	406
Erestol	336	Ergobel plus	383
Ergojuvan	387	Ergo-lonarid	324
Eributazone	391	Erimec	349
Erio tartrazine	407	Erio yellow t supra	407
Eriobios	349	Eriscel	349
Eritrazol	349	Eritrobios	349
Eritrobiotic	349	Eritrocin	349
Eritrodes	349	Eritroger	349
Eritronicol	349	Eritropan	349
Eritroveinte	349	Eritrovienite	349
Eritrowolf	349	Eritro-wolf	349
Erittronicol	334	Ermysin	349
Eromycin	349	Erteilen	334
Ery dermat	349	Eryc	349
Erydin	361	Erymycin	349
Erypar	349	Eryped	349
Erysan	336	Ery-tar	349
Erythrocin	349	Erythromictine	349
Erythromid	349	Erythro-prat	349
Ery-toxinal	349	Erytrarco	349
Erytrodol	349	Erytro-prot	349
Eryt-toxinal	349	Esadoxi	347
Escoderm	326	Escofuran	378
Escofuron	378	Escomen	399
Escophylline	323	Escopon	380
Escopyrin	391	Escopyrinus	322
Escovermin	394	Esentil	344
Eskabarb	387	E-son	392
Esoterica	358	Esoterica facial	358
Esoterica regular	358	Esoterica sensitive skin	358
Esoterica sunscreen	358	Espafren	387
Espasfher	370	Espasmir	370
Espasmo-cibalgina	370	Espasmo-giliganan	354
Espasmoqual	370	Espasmotex	370
Espasmoviral	370	Espasnatex	322
Espimina	349	Espornade spansule	392

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Espotabs	381	Espotabs	389
Esprenit	359	Espril	377
Espyre	370	Estelapar	411
Esteraplidin mag	393	Esterofenil	334
Esteropipate	394	Estesina	399
Estevecicina cloranfenico	334	Estialim	341
Estimal	324	Estimina	349
Estomicina	350	Estomiicina	350
Estomycin	350	Estraguard	344
Estrepromade	402	Estrepromicina	402
Estrepto e	402	Estrepto level	402
Estrepto ph	402	Estrepto wolner	402
Estreptopectil	382	Estreptoluy	346
Estreptomicina normon	402	Estreptonetrol	382
Estreptoral	382	Estreptosirup	346
Estreptosirup	382	Estrifen	384
Estrodienol	344	Estroral	344
Etamyl	324	Etaphylline (acetyllinate)	394
E-tapp 3	392	Etarfon	324
Etbutol	350	Ethaminal	383
Ethibute	391	Ethophylline	323
Ethril	350	Ethylmandrol	351
Etrafon-a	324	Etrafon-forte	324
Etrein	319	Eubetal	334
Euchessina	389	Euchessinia	389
Euciton	347	Eudiamine	323
Eudyna	411	Eufibran	322
Eufibron	399	Eufilina	323
Eufilavin	320	Eugeniteed	393
Eulaxin	381	Eumatol	331
Eunalgit	322	Eunoctal	324
Euphozid	361	Euphrodinal	368
Euphyllin	323	Euphyllin 0.48	323
Euphyllin retard	323	Euphyllin cr	323
Euphyllina	323	Euplit	324
Euprogan	322	Eurocert tartrazine	407
Europan	399	Euspiran	361
Eustoporin	376	Eusulfa	404
Euteberol	401	Euvasal	406
Evac-q-tabs	389	Evac-qwik tablets	389
Evactil	389	Evac-u-gen	381
Evac-u-gen	389	Evac-u-lax	381
Evasprin	359	Evazol	342
Eventin	399	Evercil	329
Eviderm	357	Evipal	357
Evipal sodium	357	Evipan	357
Evipanl	357	Evixub	347

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Ex-adipos	390	Exadrin	349
Exazol	404	Exazole	404
Excedrin ib	359	Exelmin	394
Exidol	354	Exidol	359
Ex-lax	381	Ex-lax	389
Ex-lax pills	381	Exlutena	365
Exlution	365	Exluton	365
Exluton (a)	365	Exlutona	365
Exneural	359	Exofene	357
Exolise	331	Exopin	394
Exoseptoplix	405	Expec-c	336
Expect-blacken-pastillen n	401	Exponcit	332
Expseptoplix	405	Extraheudon	391
Exrheudon	391	Extracilina	334
Extracort	376	Extrovent	387
Exyphen	392	E-z scrub	357
F 190	319	F 650	391
Factorate	351	Factus	392
Faderma	405	Fadfilina	323
Fadormir	372	Fagolipo	365
Fago-paraxin	325	Fago-praxin	334
Falaper	328	Famet	403
Famodil	351	Farbinol	370
Farectil	406	Faredina	332
Farinffnicol	404	Faringina	342
Farlurin	342	Farlupal	342
Farlutale	342	Farmacyrol	345
Farmicetina	334	Farmodoxi	347
Farmolisina	370	Fas-cile 200	367
Fasconal	388	Fast yellow 5g	407
Fastin	390	Faverin	353
Faw 76	327	Fd 8	399
Fd and c yellow no. 5	407	Febral	399
Febren	322	Febrinina	322
Febrizene	376	Febron	322
Febrosolvin	322	Febutolo	381
Feclan	352	Fedrilum	388
Fedrinal	388	Feen-a-mint	389
Feguanide	386	Feloran	344
Felsol	385	Femafen	359
Femagest	366	Femakzem	405
Femapirin	359	Femcaps	384
Femidol	359	Fenacetina	384
Fenadin	408	Fenalgic	359
Fenalgin	388	Fenartril	374
Fenascor	384	Fenasprate	327
Fenazo yellow t 4	407	Fenazone	385

C. INDEX TO PHARMACUETICALS BY AVAILABLE TRADE NAMES

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Fenbid	359	Fenbutal	384
Fenemal	388	Fenfoduron	386
Fenformin	386	Fenguanide	386
Fenibutasan	391	Fenibutina	391
Fenibutol	391	Fenicado	389
Fenicol	334	Fenidina	384
Fenilcal	388	Fenilor	330
Fenina	384	Fenint	360
Feniprenazone	352	Fenisan	381
Fenlong	359	Fennosan h 30	356
Fenobolin	375	Fenodon	322
Fenodone	322	Fenofan	337
Fenoflam	344	Fenormin	386
Fenosed	388	Fenosed bitabs	388
Fenotone	391	Fenox	392
Fensol	352	Fepramole	352
Fercasulf	404	Fermakzem	329
Ferndex	343	Fertabolin	351
Fertagyl	327	Ferti-cept	396
Fesmicina	350	Festamoxin	363
Fetonal	363	Fevarin	353
Fever	322	Feverall	370
Fevonil	370	Fherbolico	375
Fherbolico	374	Fiblet	382
Fibramid	340	Fibrolynt	340
Fibutrox	380	Fibutrox	381
Filon	387	Fim-a-mint	381
Final step	396	Finam	321
Fin-a-mint gum	381	Finedal	339
Finibron	331	Finigripp	399
Finipect	379	Fiorinal	384
Fipexitum	352	Fipexium	352
Firtasec	364	Fisiolax	381
Fisioquens	365	Fisohen	357
Fisohexx	357	Fissan	362
Fissan	376	Fitazil	393
Fitty dermat	357	Fk-tussex	336
Fl 6321 n	376	Flamilon	407
Flanaril	380	Flavoquin	325
Flavoquine	325	Flebosil	391
Flecaine	352	Flenac	352
Flenaphthol	357	Flexalgit	384
Flexazone	391	Flex-care	329
Flib 518	381	Flivalgin	322
Flofos	407	Floghene	380
Flogacid	330	Flogistin	380
Flogistin	381	Flogitolo	380

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Flogitolo	381	Flogocid	376
Flogocid	330	Flogocid gel n.n	330
Flogocid sable	330	Flogodin	381
Flogodin	380	Flogofenac	344
Flogogenac	344	Flogolisin	370
Flogoril	380	Flogos	407
Flogosan	360	Florital	384
Flosin	360	Flosine	360
Flosint	360	Flosyn	360
Floxizam	362	Flubenil	359
Fludilat	326	Fludilat (r)-dti	326
Fludilat amp 50 mg	326	Fludilat drag 100 mg	326
Fludilat dragee	326	Fludilat retard	326
Fludilat tropfen	326	Flugolin	355
Flumamine	405	Flumil	322
Flumipam	353	Flunipam	353
Fluocinova	325	Fluonid	376
Fluorobioptal	334	Fluorobioptal	378
Flurofen	355	Fluryl	319
Flussema	326	Fluversin	406
Fluvisco	406	Fluxema	326
Fml-neo-liquifilm	376	Focus	359
Foille	376	Follidiene	345
Follormon	345	Follutein	396
Fomulex	344	Fonal	384
Food dye yellow 4	407	Food orange 8	332
Food yellow 4	407	Food yellow no. 4	407
Foragynol	345	Forbesotic	376
Forgenac	344	Formatrix	370
Formosa camphor	389	Formotablin antidiarreico	405
Formula 888	376	Formulex	344
Fornagest	392	Foroxon	353
Foroxone	353	Fortabolin	374
Fortacyl	384	Fortagesic	382
Fortal	382	Fortalgesic	382
Fortalidon	322	Fortasec	364
Forte	376	Forte	386
Forte	392	Forte	366
Forticillin	376	Fortral	382
Fortralin	382	Fortwin	382
Fourneau 190	319	Fr 3068	410
Fractines vichy	389	Fractine-vichy	389
Fractolon	396	Fradyl	376
Fragivix	327	Fragivix (r) forte	327
Frakidex	376	Frakitacine	376
Framenterol	353	Framidone	322
Fraquinol	338	Frein	345

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Frekentine	321	Frenal composium	361
Frenapyl	340	Frepp	396
Frepp/sepp	396	Fricton	405
Fridol	384	Fringanor	386
Friocellin	384	Froben	355
Fructines-vichy	389	Ft 15	353
Ftalazon	322	Ftalil-esteve	393
Ftalil-septol	393	Ftalil-tiazol	393
Ftalysept	393	Fts	375
Fugoa n	392	Fulcin	355
Fulcine	355	Fulcine-125	355
Fulcine-s	355	Fulneurina	400
Fultrexin	378	Fuluminol	338
Fulvicin	355	Fulvicin p/g	355
Fulvicin u/f	355	Fulvicina	355
Fumarsutin	338	Funapann	384
Funapon	322	Funed	409
Fungarest	363	Fungarol	363
Fungistat	408	Fungivin	355
Fungo-hubber	363	Fura	378
Furaberin	353	Furacilinum	378
Furacin	378	Furacinas	378
Furacine	378	Furacinethin	378
Furacinetten	378	Furacin-sol	378
Furacin-streusol	378	Furacoccid	378
Furacocid	378	Furacol	378
Furacol I	334	Furacol I.	353
Furacort	353	Furaderm	378
Furalatin p.	353	Furaldon	378
Furalidan	353	Furaliqua	353
Furall	353	Furalone	378
Furamecetil alpha magna	334	Furamecetil magna	334
Furan	378	Furan	378
Furan-ofteno	378	Furaplast	378
Furaseptin	378	Fura-septin	378
Furaskin	378	Furatone	346
Furatrimon	334	Fura-vet	378
Furazin	378	Furazina	378
Furazol	353	Furazol w	378
Furazon	353	Furea	378
Furesan	378	Furesol	378
Furokatin	334	Furosem	378
Furotalgin	378	Furovag	353
Furovol	378	Furox	353
Furoxal	353	Furoxane	353
Furoxon	353	Furoxona	353
Furoxona-cp	353	Furoxone	353

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Furoxone swine mix	353	Fusalar-yodocloro	338
Fuvitan	353	Fuxol	353
Fuzatyl	353	Fyloxxal	338
Fysiognens	365	Fysionorm	365
Fysioquens	365	G.r. ulix compuesto	370
G-11	357	Gabaphore	398
Gabbroral	382	Gabren	398
Gabrene	398	Gadexyl	367
Gagaril sulfamida	405	Galacid	353
Galanrent	408	Galenopyrin	322
Galinid	407	Gamafin	402
Gamafur s.	353	Gamex	364
Gamma benzene	364	Gammachetone	362
Gammaphenicol	334	Gamophen	357
Gamophen surgical soap	357	Ganda	349
Ganex p 804	396	Ganidan	403
Ga-pvp-101	396	Gardax	392
Gardenal	388	Gardenale	388
Gardepanyl	388	Gardstat	368
Gargilon	342	Gastromycin	376
Gastrop	388	Gastrosilane	344
Gebriazol	340	Gefulvine	355
Gelonida	384	Gene-bamate	367
Geno-sal	366	Genpril	359
Genservet	370	Gentarol	388
Gentiazina	394	Gentil	370
Geralgine	370	Geri-70	340
Geribolina	400	Germex	378
Germex	378	Germibon	357
Gerobit	368	Gerodryl	395
Geromid	340	Gerontabol comp.	400
Geronyl	368	Gerostop	340
Gesic	384	Gesinal	342
Gesta plan	379	Gestafortin	335
Gestapuran	342	Gestapuran	342
Gestrol	365	Gevilon	354
Gewodin	384	G-farlutal	342
Ghimadox	347	Giardil	353
Giarlam	353	Giarlin	353
Gidalon	352	Gifaril	370
Gillex	347	Gill soap	357
Ginarsol	319	Ginejuvent	378
Ginetriz	334	Gino-dectacil	334
Ginsopan	392	Ginvel	353
Giolate	388	Glafezon	354
Glaucadrin	349	Glaucadrine	329
Glaucadrine	349	Glaucoaicon	349

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Glaucon	349	Glauconin	349
Glaucosan	349	Glaucotahil	349
Glifadex	354	Glifan	354
Glifanan	354	Glifarelux	354
Glimid	355	Gliporal	330
Gliscol	334	Globenicol	334
Globveticol	334	Glorous	334
Gluciferne	386	Glucifrene	386
Glucocalcium	329	Glucopirina	322
Glucopitina	322	Glucopostin	386
Glucopstin	386	Gludorm	355
Glukopostin	386	Glupan	409
Glusac super	341	Glutanon	409
Glutisal	370	Glyanphen	388
Glybigid	330	Glycerinated skin testing solutions	320
Glycirenan	349	Glycopiparsol	394
Glycyl	391	Glykresinum	366
Glytol	366	Glyphen	386
Glyptol	366	Glyuferal	388
Gmd	338	Godafilin	323
Golaman	352	Gonabion	396
Gonadex	396	Gonadoplex	396
Gonafollin	396	Gonagestrol	396
Gonault	396	Gondrone	408
Gonoper	328	Gontochin	336
Goticas	334	Gotimycetin	334
Gourmase	388	Goyl	319
Gp 40705	380	Gram-val	347
Granidan	403	Granudoxy	347
Gratsidin	387	Gratusminal	388
Gravimun	396	Gregoderm	376
Greosin	355	Greplicina belsa	370
Grfulvin v	355	Gricin	355
Grifulin	355	Grifulvin	355
Grifulvin v	355	Gripanidan	384
Grippocaps	399	Grisactin	355
Grisaltin	355	Grisefalin	355
Grisefulin	355	Grisefulvin	355
Griseo	355	Griseomed	355
Griseostatin	355	Grisol	355
Grisona	352	Grisovin	355
Grisovina	355	Grisovina fp	355
Grisovine	355	Grisovin-fp	355
Grisowen	355	Gris-peg	355
Grocreme	342	Grom hgh	396
Gorm	401	Grysio	355
Gt-250	409	Guamide	403

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Guanicil	403	Guanidan	403
Guanimycin	403	Guanor	336
Guanosept	338	Guanowept	403
Guasept	403	Guildprofen	359
Gum camphor	389	Gustibon	376
Gynaedron	405	Gynedron	329
Gynedron	406	Gynefollin	345
Gyne-sulf	405	Gyno-bidex	396
Gynodian	398	Gynoplix	319
Gyno-terazol	408	Gyno-terazol	408
Gyn-sulf	405	H 116	370
H 117	370	H 118	370
H plus n	376	H.e.c	382
Haelan-c	338	Haemostasin	349
Haemovin	357	Hagalgin	370
Hagrosept	376	Haimaplex	351
Haitmin	330	Halcion	412
Halicomb	376	Halidor	326
Halog	376	Halogabide	398
Halprin	359	Haltran	359
Harbureta	384	Harmonin	367
Hartol	367	Hasain	370
Hasp	388	Hava-span	403
Hcg	396	Hcg standard tablets	396
Hcp	357	Hd tartrazine	407
Hd tartrazine supra	407	Headway	392
Healthstyle	340	Heaven	399
Hederix	379	Heksaden	357
Heksapar	394	Hektalin	349
Heliomycort	376	Helle-strep-forte	346
Helmacid	394	Helmezin	394
Helmicide	394	Helmifren	394
Helmipar	394	Helmirazine (adipate)	394
Helmirazine (citrate)	394	Helmitin	394
Helmizin	394	Helvagit	384
Helvagit-f	322	Helvedoclyn	347
Hemagene taylor	384	Hemicraneal	322
Hemineurin	340	Hemineurine	340
Heminevrin	340	Hemisine	349
Hemoantin	406	Hemodesis	396
Hemodez	396	Hemofil	351
Hemometina	348	Hemostatin	349
Hepabuzon	391	Hepadist	357
Hepa-obaton	375	Heptadorm	356
Herb royal round worm treatment	394	Heriat	356
Hermo m	408	Herpevac	356
Herpevax	356	Herpevax hvt	356

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Herphonal	412	Hesse-sulfon	404
Hexabalm	357	Hexacert yellow no 5	407
Hexachloride	364	Hexacol tartrazine	407
Hexadespon	357	Hexal	357
Hexalacton	401	Hexanal	357
Hexanastab	357	Hexanastab oral	357
Hexanthelin	394	Hexaph	357
Hexaphenyl	357	Hexaphenyl(1&b)	357
Hexascrub	357	Hexatrol	357
Hexenal	357	Hexidol	356
Hexocreme	357	Hexosan	357
Hex-o-san	357	Hf 1927	343
Hgh	401	Hichillos	362
Hi-enterol	338	Hiliopar	336
Hilomid	356	Hipnosedon	353
Hipolixan	354	Hiposedon	353
Hippuzon	409	Hiroval	363
Hisense-p	322	Hismanal	325
Hispacid fast yellow t	407	Histabid	392
Histade	392	Histadyl	371
Histadyl ec	371	Histalix	336
Histamanal	325	Histatapp	392
Histatets	341	Hitalones	371
Hizeneck-d	350	Hjorton's powder	384
Hocacorten-vioform	338	Hocophen	384
Hoe 15239	330	Hoe 984	379
Hokulaton	401	Hokuraton	401
Holbamate	367	Holodorm	372
Homandren	408	Homosterone	408
Honkon-n	350	Hormocillin forte	328
Hormofemin	345	Hormoteston	408
Hosta-500	409	Hostalival	379
Hourbese	386	Hp 48	346
Hsp 540	392	Humafac	351
Humagel	382	Humagel	382
Human groth hormone	401	Human growth hormon	401
Humanate	351	Humatin	382
Humatrope	401	Hyasorb	328
Hyate:c	351	Hybolin decabiate	375
Hybolin improved	375	Hybolin-decanoate	374
Hyclorate	340	Hydraplex	327
Hydrazine yellow	407	Hydril	336
Hydrocortiderm	376	Hydroform	338
Hydro-neo oculos	376	Hydrospiron	401
Hydroxine yellow l	407	Hydroxybenoxypyridine	356
Hydroxybenzene	389	Hylase	358
Hyminal	372	Hyonol	388

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Hyparon	322	Hypnaletten	388
Hypnodorm	353	Hypnogene	326
Hypnol	383	Hypnolone	388
Hypnomidat	351	Hypnomidate	351
Hypnomidate concentrate	351	Hypnomidate injection	351
Hypnosedon	353	Hypnotal	383
Hypnox	326	Hypocol	372
Hypromidate	351	Hyptonal	383
Hyptor	372	Hyptor base	372
Hyrex	386	Hyrex-105	386
Hysone	338	Hysron	342
Hysteps	388	I formula	378
Ia-but	391	Iangene	406
Iap	385	Ibenon	359
Ibisul	406	Ibol	359
Ibosure	359	Ibruthalal	359
Ibu-atritin	359	Ibucasen	359
Ibu-cream	359	Ibufac	359
Ibufen tablets	359	Ibufen-I	359
Ibufug	359	Ibugel	359
Ibugesic	359	Ibuhexal	359
Ibular	359	Ibulav	359
Ibuleve	359	Ibulgan	359
Ibumetin	359	Ibuphlogont	359
Ibupirac	359	Ibuprin	359
Ibuprocin	359	Ibuprofen 200	359
Ibuprohm	359	Ibu-slo	359
Ibu-slow	359	Ibusure	359
Ibu-tab	359	Ibutad	359
Ibutid	359	Ibutop	359
Ibuvivimed	359	Ibux	359
I-caps	376	Ichthosseptal	334
Ici 28257nt	340	Icladox	347
Icn 65	384	Icramin	344
Idemin	367	Idepa	376
Idocyklin	347	Ido-op	376
Idrolatton	401	Idrolattone	401
Iebolan	374	Ifenin	324
IfrasarI	341	Ii formula	378
Ila-med	388	Ilococillin	328
Ilentazol	393	Ilgon	341
Iloramina	326	Iloson	350
Ilosone	350	Ilosone pulvules	350
Ilosone ready-mix	350	Ilothycin	350
Ilotycin	350	Iltazon	380
Iltaxon	380	Ilvin	392
Imagon	336	Imben	359

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Imbun	381	Imbun	380
Imbun	359	Imidan	409
Immenoctal	400	Imodium	364
Imosec	364	Impremial	352
Impromin	341	Imuprel	361
Inabrin	359	Inbestan	338
Incefal	359	Incramin	344
Incron	344	Inctacol-c	344
Indemin	367	Indextron	370
Infantex	399	Inflam	359
Inflamac	344	Inflamid	327
Inflamil	380	Inflazone	391
Influbene	370	Influenza tabs	384
Influnal depot	322	Influvit	399
Ingalipt	405	Ingamid	402
Ingamid ophtal	402	Ingelan	361
Injectin	402	Injecur	353
Inlax	381	Inonamin	390
Inophylline	323	Inopsin	348
Inorgan	403	Inoven	359
Inrestibla strepto	393	Insacial	332
Insom rapido	383	Insoral	386
Inst	322	Instana	336
Instilin	405	Insulamin	330
Intal compositum	361	Intalbut	391
Intefuran	353	Inter-con	341
Intestiazol	393	Intestopan	330
Intestopan-q	330	Intestovet	403
Intex	342	Intrabutazone	391
Intrabuzone	391	Intradermo caf	376
Intradin	403	Intramycetin	334
Intranefrin	349	Intrazone	391
Inza	359	Iodentero0neomicina	376
Iodenterol	338	Iodentero-neomicina	393
Iodochlorhydroxyquinol	338	Iodo-cortifair	338
Iodocortindon	338	Iodoenterol	338
Iodo-max	338	Iodopiron	397
Ionakraft	390	Ionamin	390
Ionamine	390	Ipebutona	381
Ipercron	392	Ipnofil	372
Ipolipid	354	Ipolipid	340
Ipren	359	Iprenol	361
Iproben	359	Ipropran	361
Iprox	341	Irfen	359
Irgamid	402	Irgapyrine	322
Iridil	381	Iridil	380
Iriphan	337	Irs 109 a	367

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Irs 109a	388	Iruzol	334
Iruxolum	334	Isaaxan	381
Isacen	381	Isaphen	381
Isaphenyn	381	Isdol	359
Isicetina	334	Isindone	360
Isinok	379	Isisfen	359
Ismicetina	334	Ismiverm	394
Isoamtil sedante	324	Isoamyn	321
Isoamytal	383	Iso-autohaler	361
Isobarb	383	Isobec	324
Isobutil	380	Isobutil	381
Isocrin	381	Isoderm	338
Isodienestrol	345	Isodine	397
Isoftal	322	Isoline	397
Isollyl	384	Isom rapido	383
Isomenyl	361	Isomidon	384
Isomin	409	Isomyl	324
Isomyn	321	Isomytal	324
Isonal	325	Isonal	324
Isonorin	361	Isonox	372
Isopap	371	Isoplasma	397
Isoprel	361	Isoprel-neomistometer	361
Isopronazon	399	Isoprop	361
Isopto epinefrina	349	Isopto fenicol	334
Isopto frin	392	Isorenin	361
Isospamex	344	Isosulf	406
Isotamine	361	Isotretinoin	362
Isovon	361	Isuprel	361
Itamidone	322	Iterco	367
Itinerol	365	Itro	376
Iturate	383	Izal	389
Izal germicide	389	Izaman	381
Jaa aminophylline	323	Jabon antiseptico	357
Jacosulfon	405	Jalonac	324
Janes liquid permifu	394	Japan camphor	389
Japan yellow no. 4	407	Jarabe neox	394
Jatrosom	411	Jaun tartrique	407
Jeifer-old	408	Jenomycin	376
Jetsan supp. (adipate)	394	Jodoplex	397
Jovapyrin	374	Junifen	359
Juniormen	400	Jurmun	372
Justalmin	394	Juвамidon	367
Juвамycetin	334	Juванesta	328
K 115	397	K 15	397
K 25	397	K 30	397
K 4277	360	K 60	397
K 90	397	Kabolin	375

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Kabolin	374	Kadalex	397
Kadiur	397	Kadol	391
Kafa	384	Kako tartrazine	407
Kalacid	357	Kalimalterin	389
Kalinorm	397	Kalipor	397
Kalitabs	397	Kalium durules	397
Kalma	359	Kalma	364
Kalmin	384	Kalmine	322
Kalopsis	385	Kalopsisi	329
Kalpec-f	353	Kamaver	334
Kamfomen	378	Kanrenol	397
Kantrexil	382	Kaodinnon-narcotic	362
Kaolin w/pectin	362	Kaolgeais	367
Kaomagma	382	Kaomagma with pectin	362
Kaomagma with pectin	382	Kaomycin	376
Kaomycin	362	Kaomycin	382
Kaon-cl	397	Kaoneo	362
Kaoneo	382	Kaopectate	362
Kaopectate	382	Kaopectate n	382
Kaopectate n	362	Kaopectate n	376
Kaopectin	382	Kaoprompt-h	382
Kaoprompt-h	362	Kao-spen	362
Kao-spen	382	Kaostaten	382
Kapetolin	362	Kapron	384
Kapsitrin	350	Kataglicina	386
Katagrip	384	Katareuma	322
Ka-thal-pec	380	Kato	397
Katwilon n	361	Kavapyret	399
Kavipe	334	Kayaku food colour yellow no. 4	407
Kayaku tartrazine	407	Kay-cee-l	398
Kb-502	370	Kc	362
Kca foodcol tartrazine pf	407	Kca tartrazine pf	407
K-contin	398	K-dur	398
Kefren	370	Kemicetine	334
Kencaps	366	Kenedes	388
Kenmin-s	328	Kennel-maid	394
Kentan	362	Kentan-s	362
Kenta-s	362	Kentuss	336
Kenzon r	362	Keralyt	350
Kerapos	329	Keratyl	375
Keratyl	374	Kesan	370
Kesso-bamate	367	Kesso-mycin	350
Kest	389	Kesten	346
Ketanol	362	Ketazon	362
Ketazone	362	Ketiak	404
Ketobutane-jade	362	Ketocidin	363
Ketoderm	363	Ketofen	362

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Ketoisdin	363	Ketonan	363
Ketoral	363	Kevadon	409
Kevadone	409	Keypyrone	370
Kharophen	319	Kharophene	319
Khlorkinkotsin	338	Kidoline	349
Kihomato	394	Killgrip	370
Kinavosyl	366	Kindrog	378
Kinosin s	328	Kinotomin	338
Kipyrone	370	Kiron	404
Kitax alpha	370	Kitax n	370
Kiton yellow t	407	Klast	344
K-lease	398	Klianyi forte	345
Klianyl	345	Klinicin	338
Klinomycin	374	Kln	362
Kln	382	Klodin	410
Klofibrat	340	Klofiran	340
K-long	398	K-lor	398
Kloramfex	334	Klor-con	398
Klorita	334	Klorocid s	334
Kloromicin	334	Klort	367
Klorvess	398	Klotrix	398
K-lyte/cl	398	K-norm	398
Koate	351	Kodomo smarin	329
Kolanticon	344	Kolantyl	344
Kollidon	397	Kollidon 12pf	397
Kollidon 17	397	Kollidon 25	397
Kollidon 30	397	Kollidon 90	397
Kollidon ce 50/50	397	Kollidon k 25	397
Kollidon k 30	397	Kol-tac	392
Kombiquens	366	Kometileneamin	341
Komex	329	Kompleteron	375
Kondremul with phenolphtalein	389	Konitan	370
Kontalipide	340	Kontexin	392
Kontipar	394	Kontrast	372
Kontrast u	341	Koprol	389
Koronar	388	Kortikiod mepha	376
Koryza	392	Kos	359
Krebon	330	Kriplex	344
Kryobulin	351	K-tab	398
Kubarsol	319	Kuronde	399
Kw 5338	347	Kymalzone	380
Kynex	404	Kynex acetyl	404
L yellow z 1020	407	La 96	381
Labamicol	334	Labamicol-bismuth	334
Labosept	342	Labymetacincpo	370
Lacalmin	402	Lacdene	402
Lacilactone	402	Lacolysat	353

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Lacondan	359	Lacretin	338
Lactismine	329	Lactmicina	370
Lagaflex	322	Lagalgin	370
Lagalgine	370	Lagaquin	336
Lagasediv	344	Lagaspasm	388
Lake yellow	407	Lallamin	371
Lamboxil	394	Lamidon	359
Lamoryl	355	Lamoryl-novum	355
Lamoyl	355	Lamprcsnum	370
Lanbiotic	376	Lanceotic	385
Lan-dol	367	Laniazid	361
Lantanon	373	Lapalgine	370
Laractone	402	Laralmin	402
Lardet	388	Larmicin	376
Larodon	399	Laroxal	324
Laroxyl	324	Larozyl	324
Larq 731	370	Larten	367
Lasacilina	328	Lasain	370
Lasilacton	402	Lasiren	397
Lasitone	402	Latepyrine	322
Latodurin	376	Latorex	332
Latoxacet	363	Laucetin	350
Laurel camphor	389	Lauridin	332
Laurilin	350	Lauritran	350
Lauroanginol	322	Lauromicina	350
Lavaciclina	370	Lavema	381
Laveman	381	Lavylgan	385
Laxante yer	389	Laxan-vomoxin	381
Laxaseptol	381	Laxatabs	389
Laxatone	389	Laxem	381
Laxen busto	389	Laxin	389
Laxnormal	381	Laxocol	381
Laxocoleva	381	Laxogen	389
Laxo-isatin	381	Laxon	381
Laxos	381	Laxyl	381
L-caine	349	Lecortin	338
Leder	392	Lederderm	374
Lederform-d	338	Lederkyn	404
Legatin	388	Lekasin	384
Lekosept	338	Lemobese	368
Lemoderm	338	Lemon yellow a	407
Lemon yellow a geigy	407	Lenicor	367
Lennacol	334	Lenoprel	361
Lentac	404	Lentizol	324
Lentobetic	386	Lento-kalium	398
Lentosulfa	404	Leo k	398
Leonal	359	Leonar	400

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Lepetown	367	Lepinal	388
Lepinaletten	388	L-epinephrine	349
Leponex	341	Leponox	341
Leptidrol	395	Lerivon	373
Letaquine	336	Leuchlon	334
Leukamycetin	334	Leukomyan	334
Leukomycin	334	Leutrophin	401
Levacide-c	341	Levapa	370
Levat	324	Levate	324
Levatram	340	Levatrom	340
Levismon	370	Levocycline	334
Levomanilin	334	Levomethadylacetate	363
Levomicetina	334	Levomycin	334
Levomitsetin	334	Levomycetin	334
Levomycetina	334	Levoninizol	334
Levopa	334	Levophed	364
Levorenine	349	Levoreninl-adrenaline	349
Levosin	334	Levovetin	334
Levovinizol	350	Levum	390
Lf 530	357	Lg 335	379
Lh 5000	396	Liademycin	328
Liapten	340	Libelins	353
Libiolan	367	Librofem	359
Librofen	359	Licasol	338
Licothionil	349	Lidazon	327
Lidifen	359	Lidoacton	349
Lidor	326	Lifabiotico	334
Life	400	Liferitrin	350
Lifuzol	378	Likuden	355
Likuden m	355	Lilly 3794	327
Lilly 90459	327	Lilo	389
Limarsol	319	Limbatarail	324
Limbatral	324	Limbitryl	324
Limit	386	Limitrol	324
Linarol	384	Linctuss	336
Lindemil	329	Linder	404
Lindiol 2.5	365	Lineal-plus	321
Lineal-rivo	321	Lineal-valeas	321
Linea-valeas	321	Linitut	376
Linola	338	Linyl	390
Lipamone	345	Liparil	340
Lipaten	340	Lipavil	340
Lipavlon	340	Lipavlon 500	340
Lipese	365	Lipicidon	340
Lipidicon	340	Liple	320
Lipobay	332	Lipociden	340
Lipofacton	340	Lipomid	340

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Lipomin	321	Liponorm	340
Lipopill	390	Liporan	340
Liporeduct	340	Liporil	340
Liposan	364	Liposid	340
Lipo-sinahist	392	Liposlim	321
Liprin	340	Liprinal	340
Liptan	359	Liptrinal	340
Lipur	354	Liquichlor	334
Liquital	388	Lircapil	388
Lisador	370	Lisagal	381
Lisalgil	370	Lisi-budol	359
Lisoprecol	334	Lissephen	366
Liticon	382	Lixophen	388
Lm 5008	360	Lobetrin	340
Locacid	411	Locacorten-vioform	338
Locomycetine	334	Locorten	376
Locorten	338	Locorten-vioform	338
Loctidon	406	Locton	406
Loderm	350	Loftyzon	357
Logen	346	Logical	393
Logisul jarabe	404	Logos	400
Lokalin	327	Lom	394
Lomanate	346	Lomax	346
Lombricida tropico	394	Lombrifher	394
Lombrikal	394	Lombrimade	394
Lomecetina	334	Lomine	344
Lomotil	346	Lomotil liquid	346
Lonarid n	324	Longamid	404
Longevital 5000	398	Longisul	404
Longopax	324	Lonox	346
Lopemid	364	Lopemin	364
Loperam	364	Loperan	364
Loperin	364	Lopermid	364
Loperyl	364	Lopid	354
Loractone	402	Loromisin	334
Lorothidol	328	Lorothiodol	328
Lostat	340	Loxaryl	324
Lrcl 3794	327	Ls 6030	386
Lu	403	Lubergal	388
Lubomycina	350	Lubomycine	350
Lucatyl	403	Lucofen	337
Lucofen retard	337	Lucofen sa	337
Lucosil	403	Ludilat	326
Ludilat dti	326	Luf-iso	361
Lullamin	371	Lumbrical	394
Lumcalcio	388	Luminal	388
Lunadon	388	Lunerin	392

C. INDEX TO PHARMACUETICALS BY AVAILABLE TRADE NAMES

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Luteocrin orale	342	Luteodione	342
Luteos	342	Luteovet	396
Luteran	335	Lutoporal	342
Lutoral	342	Luvion	397
Luvion	332	Luviskol	397
Luviskol k 17	397	Luviskol k 25	397
Luviskol k 30	397	Luviskol k 90	397
Luvisteol	397	Lyabex retard	379
Lyman tabs	320	Lyn_ratiopharm	365
Lyn_ratiophram_sequenz	365	Lyndeol	365
Lyndile tt	365	Lyndiol	365
Lyndiol e	365	Lyndiol e.	365
Lyndiolett	365	Lynoenstrenol	365
Lyn-ratiopharm	365	Lyobex	379
Lyodrin	349	Lyophrin	349
Lysadestalt	388	Lysadestat	399
Lyspafen	345	Lyspofen	345
Lyspofenac	345	M.a.s.	367
M.p.	371	M.p. trantabs	367
Macaldex	329	Macmiror	378
Mactam	363	Madinex	327
Madrine	368	Magdor	370
Magic herb	348	Magnalsa	370
Magnemidon	370	Magnol	370
Magnopyrol	370	Magrene	321
Magrilan	365	Maikohist	338
Maind	400	Makatussin	401
Makatussin	332	Makrocyklina	350
Malaraqin	336	Malarex (diphosphate)	336
Malariron (diphosphate)	336	Maldocil	406
Malex	384	Malgesic	391
Malipurán	330	Mallermin	338
Malogen	408	Malogen in oil	408
Malonal	326	Malotrone	408
Malquin	336	Maltyl	342
Mamallet-a	322	Mamaslu	399
Mamex	357	Mamiesan	344
Mammanopen	376	Mammex	378
Mammiject	378	Mammphenicol	334
Mammyl	391	Mamomit	322
Manasul	384	Mandrax	372
Manegan	411	Manilina	350
Manslu	322	Mantacido	357
Maoa	372	Mapiprin	394
Mapir	370	Maple tartrazol yellow	407
Mar-bate	367	Marcaom	349
Marcoeritrex	350	Mardon	384

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Mardram	392	Mareline	324
Marevan	413	Margaris	367
Marimune	356	Marocid	350
Marplan	361	Marplon	361
Marsilid	361	Marsin	387
Marsthine	338	Masenate	408
Maskito	394	Masletine	338
Massotalil	393	Masterfen	406
Mastidol	378	Mastigun	346
Mastiphen	334	Mastisept	353
Mastofuran	378	Mastrinal	376
Maxepa	398	Maxibolin	351
Maxicam	362	Maxiton	343
Mazanor	365	Mazanor tablets	365
Mazeldene	365	Mazinil	365
Maznor	365	Mazur-a	388
Mc 3	336	M-cillin b	328
Mc n 2783	414	Mc n 2783-21-98	414
Mc n 742	323	Md 1020	388
Mebacid	403	Mebubarbital	383
Mecazine	365	Mecodrin	321
Mecoten	370	Med liquide san t	357
Medapan	356	Medaron	353
Medeyol	405	Mediamycetin	334
Mediatric	368	Medichol	334
Medicol	334	Medicon	379
Medicone derma-hc	356	Medicort	397
Medicycline	409	Medifenac	320
Medihaler-duo	361	Medihaler-epi	349
Medihaler-iso	361	Medipect	362
Medipect	382	Mediphen	388
Medipren	359	Mediprofen	359
Medisec neo	376	Medisec-cloxa	376
Medispanmin	322	Meditran	367
Medi-trol	324	Med-laxan	381
Medomin	356	Medomina	356
Medomine	356	Medri-biotic	376
Mefentil	366	Megace	366
Megacillin	328	Megal	326
Megal	370	Megazone	391
Megecat	366	Megeron	366
Megestat	366	Meimyd	376
Melabon	319	Melabon	384
Melaforte	322	Melanex	358
Melanex topical sollution	358	Melfen	359
Melfiat	386	Meliplus	334
Meloda	368	Meloka	322

C. INDEX TO PHARMACUETICALS BY AVAILABLE TRADE NAMES

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Melpaque hp	358	Melpen	370
Melqui hp	358	Melsed	372
Melsedin	372	Melsedine base	372
Melsomin	372	Meltrol	386
Memphenesin	366	Menabil complex	381
Menaderm antiacne	376	Menado ibuprofen usp	359
Menalgine	370	Menidrabol	375
Menocil	323	Menonorm	379
Menophase	379	Menoquens	366
Menospasm	344	Mentalormon	398
Mentol sedans sulfamididad	329	Mentol sedans sulfamididad	405
Mentol sedans sulfamididad	332	Menutil	321
Mepalgic	372	Mepantin	367
Mepavlon	367	Mep-e	367
Mephabutazon	391	Mepha-butazone	391
Mephadexamine-r	343	Mephadexamin-r	343
Mepha-gesic	366	Mephenicol powder	334
Mepherol	366	Mephesin	366
Mephesol	366	Mephson	366
Meposed	367	Meptrate	342
Meptrate	367	Mepriam	367
Meprin	367	Meprindon	367
Mepro	367	Meprobadal	367
Meprobamat	367	Meproban	367
Meprobil	367	Meprobit	388
Meprocompren	367	Meprocon cmc	367
Meprodil	367	Meprogesic q	367
Meprol	367	Meproliin	367
Mepron	367	Mepronel	367
Mepronil	367	Mepropon	388
Mepropyrin	391	Meprosoa	367
Mepro-secergan 400	367	Meproserpina	367
Meprospan	367	Meprospan 400	367
Meprotabs	367	Meproten	367
Meprotil	367	Meproyrin	367
Meprozone	367	Meptran	367
Mequal	372	Mequelon	372
Mequin	372	Merastat	389
Meratonic	395	Meratran	395
Meravil	324	Merbantal	344
Merbentyl	344	Merck skin testin solutions	320
Mercurio clinico	368	Mercurocol	368
Meridil	373	Meriprobate	367
Merital	379	Merival	379
Merizone	391	Mertestate	408
Mervan	320	Mervan	413
Mescomine	358	Mesconit	358

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Mesmar	367	Mespafin	347
Mesylith	336	Metabolite i	380
Metactiv	406	Metadin	395
Metadorm	372	Metakualon	372
Metakvalon	372	Metamit	404
Metamsustac	368	Metanephrine	349
Metapirazone	322	Metapyrin	370
Metaqualon	372	Metazina	404
Meterdos-iso	361	Methadorm	372
Methampex	368	Methampyrone	370
Methaquaion	372	Methaqualoneinone	372
Methased	372	Methasedil	372
Methazol	403	Methedrinal	368
Methedrine	368	Methexenyl sodium	357
Methidate	373	Methistaline	371
Methisul	403	Methoxyverapamil	354
Methozin	385	Methrazone	352
Methril spansul	371	Methybol	374
Methybol-depot	375	Methybol-depot	374
Methylaminoethanolcatechol	349	Methylarterenol	349
Methylmorphin	341	Metigestene	342
Metigestrona	342	Metilon	370
Metisept	334	Metodril	372
Metodril 2	372	Metodril napa	372
Metolquizolone	372	Metranquil	367
Metrazone	352	Metrijet	338
Metrityl	338	Metrojen	388
Metuzina	404	Mevan	320
Mexafermento	338	Mexafom	338
Mexaform	338	Mexnex	368
Mf 218d	402	Mi 540	391
Mialgan	370	Mialgone	388
Miansan	373	Miantor	360
Micloreтин	334	Micoclorina	334
Micoclorine	334	Micodry	334
Micofilina	334	Micogamma	357
Miconor	379	Micoral	363
Micotek	363	Micoticum	363
Micrainin	367	Microbamat	367
Microcetina	334	Microcid	404
Microcidal	355	Micro-sterandryl	408
Microsul	403	Mictrol	408
Micturin	408	Mictrol ampilina seda	403
Midicel	404	Midikel	404
Midisalb-m	366	Midixin	367
Midol	360	Midol 200 advanced pain formula	360
Midol ib	360	Mifegyne	373

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Mig-antos	385	Migen	320
Migesic	384	Migrafen	360
Migrane-dolviran	388	Migranin	385
Mikrozid	350	Milneuron	399
Milspan	367	Miltaun	367
Miltown	367	Miltown s-r	367
Minadol	360	Minalgin	370
Minalgine	370	Mindaril	334
Mindaril	380	Minette	365
Mini pregnon	365	Minifol	365
Minikel	404	Minilax	389
Minilip	337	Mini-lix	323
Minilyn	365	Minims	334
Minims	392	Minims chloramphenicol	334
Miniquine	336	Miniscap	332
Ministat	365	Mino-50	374
Minobese	390	Minobese forte	390
Minocin	374	Minomycin	374
Minoval	370	Minprog	320
Minprog pad	320	Minprostin	346
Mintal	383	Minus	386
Minusin depot	332	Minus-x	392
Miocitalgan	370	Miopotasio	398
Miraclin	347	Miranil	414
Mirapront	390	Mirapront n	332
Mironal	384	Mirsol	413
Mirvan	320	Mirvan a	320
Miscleron	340	Misedant	367
Misetin	334	Mistabron	368
Mistabron co	368	Mistabronco	368
Mistalon	368	Mistral	350
Mitrol	408	Mitsui tartrazine	407
Miucurin	408	Mixtencillin	346
Miyadril	380	Mobilat	360
Mobutazone	374	Mobuzon	374
Modane	389	Modane plus	389
Moderatan	321	Moderatan diffucap	321
Modicon	379	Modirit	388
Mofasal	374	Mofenar	330
Mofesal	374	Molipaxin	411
Mollinox	372	Molycu	397
Moment	360	Monacet	384
Monargan	319	Monatuss	392
Monazan	374	Monazone	374
Monbutina	374	Monobutina	374
Monobutyl	374	Monocillin	328
Monocline	347	Monodox	347

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Monodoxin	347	Monofen	374
Monoflam	344	Monomil	374
Monomycin	350	Monophenol	389
Monoprine	374	Monorheumetten	374
Monosan	352	Monozon	374
Monydrin	392	Moperidona	347
Morbam	367	Mornidine	394
Motilium	347	Motilix	364
Motofen	345	Motolon	372
Motrin	360	Motrin ib	360
Moxacef	363	Moxalactam	363
Moxam	363	Moxatres	363
Mozambin	372	Mozol	374
M-p	371	Mtq	372
Muaban d	324	Mucidrina	349
Mucinum	389	Mucofluid	368
Mucolene	368	Mucolyt-expecto	392
Mucorama	392	Mudeka	324
Mudrane	323	Mudrane gg	323
Muflin	336	Muldacin	378
Multifuge	394	Multifuj	394
Multi-med 2	353	Multi-med 3	353
Multi-med 6	354	Mundidon	397
Mundiphyllin	323	Muracin	334
Muracine	409	Musa	400
Musettamycin	379	Musilaks	389
Mutaban a/d/f	324	Mutabase	324
Muxol	381	My 101	320
Myacyne	376	Myanesin	366
Myasul	404	Mycerin	376
Mycetin	334	Mycetobis	334
Mychel	334	Mychel-s	334
Mychel-vet	334	Mycidex	376
Mycifradin	376	Myciguent	376
Mycimist	376	Mycinol	334
Mycipo	376	Myci-spray	371
Myclocin	334	Mycochlorin	334
Mycoquin	338	Mycotol	346
Mydfrin	392	Mydocalm	344
Mydriaticum	394	Myelotrast	372
Mylis	398	Mylodorm	324
Mylodorm sustrel	324	Mylofanol	337
Mylophanol	337	Mylosul	404
Mynocine	374	Myocalm	366
Myocardon	388	Myocardon	323
Myocuran	366	Myo-europan	399
Myogit	344	Myolate	384

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Myolisysin	366	Myoxane	366
Myprodol	360	Mysite	380
Mysteclin-f	409	My-trans	367
Mytrex	376	N 8	324
Nabac	357	Nadalgine	370
Nadigest	342	Nadozone	391
Naftalgin	370	Nafticlorina	336
Nagalyn	336	Naidoretico	341
Nalador	406	Naleran	381
Nalgot	351	Naloven	352
Naltrium	370	Nandrobolic	375
Nandrolin	375	Nandrolone decanoate	374
Nanormin	401	Nanormon	401
Naoven	352	Napasone	370
Napental	383	Naphthylamine mustard	336
Naphtocard yellow o	407	Napionate	408
Narcoren	383	Narcosan soluble	358
Narcotussin	379	Narcozep	353
Narfen	360	Naron	370
Nartate	370	Nasdol	408
Nasello	338	Nasello	332
Nasomixin	376	Naso-neomicin	376
Nasopomada	409	Nasopomada	405
Nasydrin	376	Natralgin	370
Natric	370	Natricilin	328
Natt-lunedon	385	Naupax	391
Nausidol	394	Nauzelin	347
Navicalm	365	Naxogin compositum	334
Nazona	352	Nci-c01741	386
Nd-hist	392	Nea-vermiol	394
Nectatussin	392	Nefco	378
Nefluan	376	Neforox	354
Neforox alpha cpto	354	Neftin	354
Neftivit	354	Nefurofan	402
Nefurox	338	Negalip	340
Neimicina roger	376	Nekel	346
Neklacid yellow t	407	Neko	368
Nemadital	394	Nemafugan	394
Nemasin	394	Nematocton	394
Nematorazine	394	Nembudeine	383
Nembutal	383	Neo decaderm	376
Neo epinine	361	Neo fulcin	355
Neo lyndiol	365	Neo-analsona	376
Neoaristovet	376	Neotromid	340
Neo-atromid	340	Neobacimyx-h	376
Neobes	321	Neobicin	376
Neobiotic	376	Neobrettin	376

C. INDEX TO PHARMACUETICALS BY AVAILABLE TRADE NAMES

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Neobristan	376	Neobrofen	360
Neobrufen	360	Neo-cantil	376
Neocervulax	381	Neocetin	334
Neocidin	376	Neocillin	376
Neoclox	376	Neocon	379
Neocones	376	Neodalit	343
Neodecasona	376	Neo-delpregnin	366
Neo-delta-cortef	376	Neo-dexoclin	334
Neodistreptotab	402	Neodit	343
Neodorm	383	Neodrine	368
Neodrine-triple	368	Neodualtrepto	402
Neo-durabolic	375	Neodurabolin	351
Neo-erycinum	350	Neo-farmadol	380
Neo-favmadol	381	Neo-felsol	385
Neo-filcin	355	Neofluid	376
Neogonadil	396	Neo-hombreol	408
Neo-hydro	376	Neo-ifusa	394
Neo-ilolycina	350	Neo-iloticina	350
Neointestin	376	Neo-istafenc	365
Neo-istafene	365	Neojodin	397
Neolate	376	Neo-lindiol	365
Neo-lynobol	365	Neo-m	376
Neomac	376	Neo-mantle	376
Neo-mastitar	376	Neo-melubrim	370
Neo-melubrin	370	Neo-melubrina	370
Neo-melubrine	370	Neomin	376
Neomix	376	Neomycane	376
Neo-myx	376	Neo-nervostal	367
Neo-nervostat	388	Neo-nilorex	386
Neo-oestrogenine	345	Neo-otosol-hc	376
Neo-oxipen	370	Neo-panalgyl	362
Neopec	382	Neopec	376
Neopellis	328	Neopenol	376
Neoprunex	389	Neopt	376
Neopurghes	389	Neopyrine	384
Neoquess	344	Neo-remusin	376
Neo-rybarex	349	Neosal-n	370
Neo-smarin dia	329	Neosoldana	392
Neo-soldana	381	Neo-soldana	332
Neosoldana	370	Neo-sombraven	372
Neosten	320	Neoston	320
Neostrata aha gel	358	Neostrata hq	358
Neostrep	376	Neosule	376
Neosulf	376	Neo-sulfazon	393
Neosutrin	405	Neo-synephrine	392
Neo-tetrine	409	Neotigason	319
Neotigason (r) 10	319	Neotigason roche 10 mg	319

C. INDEX TO PHARMACUETICALS BY AVAILABLE TRADE NAMES

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Neotigason sauter kapsein 25 mg	319	Neotizol	350
Neoton	321	Neo-tran	367
Neotrizine	403	Neotrizine	403
Neo-vagex	319	Neo-vagipurin	329
Neovagon	378	Neovamin a acid	362
Neovitamin a acid	362	Neox	394
Neo-xoline-m	366	Neo-zine	387
Neo-zoline	391	Nephenalin	361
Nephridine	349	Nerfactor	361
Neriodin	344	Nerobil	375
Nerobolil	375	Nerobolin	375
Nerofen	360	Nerufatin	409
Nervisal	325	Nervonus	367
Nessazona	352	Nestosyl	357
Neta662	347	Netocyd	346
Netsusarin	322	Netto-longcaps	390
Neufenil	362	Neuphenyl	362
Neuramate	367	Neuramin	399
Neur-amyl	324	Neuridal	399
Neuro	367	Neuro a2	372
Neurobarb	388	Neurocalm	367
Neurocotex	398	Neuro-demoplas	391
Neuro-demoplast	322	Neuro-effekton	344
Neuro-elmedal	391	Neurofenac	344
Neuro-fortamin	370	Neurolene	379
Neurosedyn	409	Neuro-spondryl	399
Neuro-voltaren	344	Neuroxin	400
Neurosteron	375	Neuzoline m	391
Nevimune	377	Neviodin	344
Nevral vit b1 b6	384	Nevralgin	370
Nevralgina	370	New isomidon	330
Nexaam	392	Nf 180	354
Nfs	378	Nfz 1	378
Nfz mix	378	Nia	366
Niaestine	366	Niagestin	366
Niagestine	366	Nialamid	377
Niamid	377	Niamidal	377
Niamide	377	Niamycetin	334
Niapren	360	Niaquital	377
Niaquital	377	Niazin	377
Nibiol	379	Nibratal	340
Nibratol	340	Nicaphlogyl	383
Nicene	379	Nicene	403
Nicolen	354	Nicolen r	354
Nidaxin	342	Nieraline	349
Nifedon	322	Nifucin	378
Nifulidone	354	Nifulin	354

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Nifuramicin	376	Nifuran	354
Nifuzon	378	Nikartrone	322
Nikinol	379	Nikopet	379
Nilacid	319	Nilatin	352
Nilspasm	388	Nimulid	377
Nioform	338	Nipaxan	379
Nipaxon	379	Niphridine	349
Nisidina	370	Nisocla	376
Nisoclyn	376	Nisodyn	376
Nitepax	379	Nitocetin	378
Nitrocetin	334	Nitrocol	334
Nitrocol plus	378	Nitrofan	378
Nitro-rea	378	Nitro-tromacardin	372
Nitrozone	378	Niux	350
Nivaquine	336	Nivaquine b'	336
Nivembin	336	Nivemycin	376
Nizcrem	363	Nizoral	363
Nizoral 2% shampoo	363	Nizoral 20% cream	363
Nizovules	363	Nizshampoo	363
Nlo conicilina balsamica	370	Nnormet	340
Nobacter	328	Nobadorm	372
Nobadorm compostium	372	Nobedorm	372
Nobelgin	370	Nobensin-75	321
Nobensine	321	Nobese	392
Nobesine	321	Nobesine-25	321
Nobfelon	360	Nobfen	360
Nobret	340	Nobrital	324
Nochyrol	366	Noctilene	372
Noctivane	358	Noctivane sodium	358
Noctulon	372	Noctynol	366
Nodiras	399	Nodryl	376
Nofenan	399	Nofenon	399
Nogest	342	Noidouble	402
Nokamycin	376	Nolotil	370
Nolotil composirum	370	Noludar	373
Nolurate	373	Nometan	394
Nomival	379	Nomocramp	344
Nomorytmin	399	Nonovulet	365
Noperil	376	Noptil	388
Nor 50	379	Norabol	375
Noracyclin	365	Noracyclin 22	365
Noracycline	365	Noradrec	364
Noralone	375	Norandrol	375
Norandros	375	Norane	371
Norbum	334	Nordecon	374
Nordox	347	Norephedrine	392
Norfemac	330	Norgesic	384

C. INDEX TO PHARMACUETICALS BY AVAILABLE TRADE NAMES

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Noric	399	Noriday	379
Norigest	379	Norimin	379
Norinolipol	340	Norisen	320
Norisen grass	320	Norisodrin aerotol	361
Norisodrin with calcium idodide	361	Noristerat	379
Norlutate acetate	379	Normalip	340
Normaln	324	Normax	342
Normet	340	Normet richter	340
Normetine	394	Normid	413
Normimycin v	334	Normi-nox	372
Normoc	376	Normoglucina	386
Normol	329	Normolipol	340
Normophasic	365	Normorest	372
Normotrytmin	399	Normotrytmin (r) 10 mg	399
Normud	413	Nornatane	392
Norodin	368	Norofluvin	355
Norolon	336	Noromon	375
Noroquinol	330	Norosodrine	361
Norphedrane	321	Nor-q-d	379
Norquentiel	379	Norquest fe	379
Norquinol	382	Norstenol	375
Nortesto	375	Nor-tet	409
Norval	373	Nosaclin	379
Noscalin	379	Noscapal	379
Noscapect	379	Noscarex	379
Noscatuss	379	Nosterolin	340
Nostress	322	Nostril	392
Notaba	378	Notensyl	344
Notermin	370	Notose	336
No-tripramine	412	Nourilax	381
Novacetol	384	Novacetol	341
Novacid	370	Novalcina	370
Novaldin	370	Novalgetol	370
Novalgin	370	Novalgin quinine	370
Novalgina	370	Novalgine	370
Nova-lyseen	370	Novambobarb	325
Novamidazofen	370	Novamidazophen	370
Novamideazophene	370	Novamidon	322
Novamina	370	Novaminophenazone	370
Novaminsulfon	370	Novaminsulfon ratiopharm	370
Novaminsulfone sodium	370	Novaminsulfonium	370
Novaminsulfonum	370	Novaminsulton	370
Nova-phenicol	334	Nova-pheno	388
Novapirina	344	Novaprin	360
Novaquin	366	Novarectal	383
Nova-rectal	383	Novazid	377
Novazolon dexametasona	370	Novelciclina	347

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Noveltex	370	Novemida	370
Novemina	370	Noventerol	382
Noventerol	362	Noveril	343
Novese	332	Novidorm	412
Noviel	353	Novil	370
Novo card-fludilat	326	Novobutazone	391
Novoclorocap	334	Novoderm	412
Novodon	388	Novodorm	412
Novo-doxepin	347	Novodrin	361
Novofibrate	340	Novogen	325
Novogent	360	Novokvens	366
Novolina	366	Novomato	367
Novomepro	367	Novomycetin	334
Novo-nastizol	325	Novopen	328
Novopentobarb	383	Novo-pentobarb	383
Novophenyl	391	Novoprofen	360
Novopuren	389	Novoquens	366
Novorythro	350	Novosephalgin	384
Novospasmin	388	Novospiroton	402
Novospirozine	402	Novosprioton	402
Novospriozine	402	Novostat	365
Novostrep	402	Novo-strep	402
Novosulfin	404	Novosulfina	393
Novotetra	409	Novo-tripramine	412
Novotriptyn	324	Novotryptin	324
Novo-tryptin	324	Novoxapin	347
Novulon	379	Novydrine	321
Novydrinene	321	Noxibiol	379
Noxine	379	Noxiurotan	394
Noxybel	372	Noxyron	355
Npa	376	Npp	375
Ntpp	375	Nuctane	412
Nu-ibuprofen	360	Nu-k	398
Nulobes	321	Numal	325
Nunol	388	Nuprin	360
Nuquin hp	358	Nuran	341
Nurdelin	341	Nuredal	377
Nurilaksi	381	Nur-isterate	379
Nurofen	360	Nuttriben	341
Nyazin	377	Nydrazid	361
Nyktogen	367	Nymfalon	396
Oasil	367	Oasil	388
Oasil procalmadiol	367	Obe_slim	325
Obe-del	386	Obedrin-la	368
Obelones	368	Obepar	386
Oberex	340	Obesan	386
Obesan-x	386	Obesin	321

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Obesine	321	Obesitab	321
Obesitex	321	Obe-slim	368
Obestat	392	Obestin 30	390
Obetrol	321	Obetrol	343
Obex la	386	Obex-la	386
Obezine	386	O-biol	329
Oblioser	372	Obotan	343
Obstecrim	338	Obstilax	381
Oby-trim	390	Octacaine	349
Octamet	406	Ocufen	355
Oculocidon	411	Ocu-vinc	413
Odamida	405	Odsil 10	367
Oestrasid	345	Oestrodien	345
Oestrodiene	345	Oestrodienol	345
Oestro-gyneadron	405	Oestro-gynedron	406
Oestro-gynedron	345	Oestro-gynedron	329
Oestroral	345	Oestrovis	345
Offitril	380	Oflamin	380
Oftalent	335	Oftan	335
Oftan flurekain	397	Oftlamin	370
Ogen	394	Ogyline	413
Oil of calamus	331	Okasa-mascul	408
Oktadrin	321	Okuside	394
Older	361	Oleomycetin	335
Olfano	384	Olfen	344
Oluprin	391	Omelip	340
Omnadren	327	Omiadol	384
Omnibex	390	Omni-passin	346
Omnyl	372	Ona-mast	390
Onco-provera	342	Opclor	335
Ophtalmin	329	Ophthaphenicol	335
Ophthlmycin	376	Ophthochlor	335
Opinsul	404	Oppazoen	391
Opren	327	Oprenal	327
Optairosol	348	Optalgin	370
Optalidon	322	Optalidon	360
Optazol	354	Opteron	410
Ophthalon	335	Optifen	360
Optimal	380	Optimax	364
Optimil	372	Optineural(analgesic)	322
Optinoxan	372	Optipax	322
Optiprime ophthcoat	376	Optison	376
Optisone	376	Optiverm	395
Optrin	335	Opturem	360
Orabilex	331	Orabilix	331
Orabolin	351	Oracolnal	366
Oractine	341	Oraflex	327

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Oragest	342	Orahesive	382
Oralcer	338	Oralcid	319
Oraleo	386	Oralmisetin	335
Oranixon	366	Orarsan	319
Orchiol	408	Orchisterone-p	408
Orchistin	408	Ordenol	403
Orecil	385	Oreton	408
Oreton-f	408	Orexigen	341
Org 485-50	365	Org gb 94	373
Orgabolin	375	Orgabolin	351
Orgaboral	351	Orgaguanidon	403
Orgaluton	365	Orgametil	365
Orgametril	365	Orgametrol	365
Oribiotic	376	Orimeten	322
Orkomin	341	Orlaam	363
Orlestrin	379	Ormeten	322
Ornacol	392	Ornatos	392
Ornex	392	Oromycosal	363
Oronazol	363	Orostat	327
Orostat	349	Orotenol	361
Orozl	404	Orphalginen	370
Ortedrine	321	Ortho	345
Ortho (cream)	345	Ortho dienestrol cream	345
Orthonal	372	Ortho-novum	379
Orthos kavident	336	Ortonal	372
Ortopirona	370	Or-trin	383
Or-tyl	344	Orulop	364
Osadrine	322	Osadrinim	391
Osarsal	319	Osarsol	319
Osarsole	319	Osiren	397
Osiren	402	Osirenol	397
Osmotipax	322	Osodent	354
Ossiurene	346	Osvarsan	319
Osyrol	397	Osyrol	402
Osyrol-lasix	397	Otachron	335
Oterna	376	Oticair	376
Otiprin	335	Otipyrin	320
Otipyrin	385	Oto vitna	376
Otobacid	399	Otocaina	405
Otocaina	329	Otocortison	376
Oto-flunal	376	Otomycin	376
Otonasal	405	Otone	380
Otone	381	Otophen	335
Otopred ear drops	335	Otorrilan	405
Otosan-sulfan	385	Oto-sinerbe	376
Otothricinol	385	Ovaban	366
Ovamezzo	365	Ovanon	365

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Ovanone	365	Ovanon-e	365
Ovarid	366	Ovariostat	365
Ovcon-50	379	Ovismen	379
Ovol	344	Ovoresta	365
Ovoresta m	365	Ovoresta micro	365
Ovosiston	379	Ovosiston	335
Ovosta	365	Ovostat	365
Ovostat-28	365	Ovostat-micro	365
Ovuthricinol	405	Ovysmen	379
Oxabar	388	Oxacef	363
Oxalid	380	Oxalid	381
Oxanal yellow t	407	Oxaprost	374
Oxazimedrine	387	Oxibutol	381
Oxidermiol	405	Oxin	356
Oxine	356	Oxiquiunazine	370
Oxiril syrup (hydrate)	395	Oxiuran (hydrate)	395
Oxiurasin	395	Oxiustip	395
Oxiustip elix	395	Oxivermin	395
Oxizin	395	Oxoids	388
Oxucid	395	Oxurasin	395
Oxuril	395	Oxybutazone	381
Oxybutazone	380	Oxybutol	380
Oxybuton	380	Oxygeron	413
Oxykin	356	Oxypaat	395
Oxyperol	380	Oxyphenbutone	380
Oxyphentamin	380	Oxypip	395
Oxyquin	338	Oxyquinoline-rhp	356
Oxytocin	381	Oxyzin	395
P 47	357	P.c. (citrate)	395
P.g.a.	328	P.s.b.p.	322
P-1-n forte	361	P2e1	349
P-50	328	Pabron gold	370
Pabron nose	392	Pacifan	383
Pacifene	360	Paclia g	328
Pacy	362	Pacyl	362
Padrax	395	Padudent	360
Palacaine	385	Palaprin forte	320
Palaran	323	Palaron	323
Paldona	372	Pallace	366
Pallacid	319	Pallidan	372
Paloxin	320	Palpent	383
Palprin	320	Pamin	344
Pamprin	384	Pamprin	360
Panacorn	392	Panacur	341
Panadyl	392	Panakiron	344
Panaldine	410	Panalvon	370
Panamor	344	Panax	370

C. INDEX TO PHARMACUETICALS BY AVAILABLE TRADE NAMES

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Panazone	391	Panbesy	390
Panformin	330	Panfungol	363
Panfuran	319	Panfuran s	346
Panfuran-s	346	Panfuran-troche	319
Pangul	409	Panmycin	409
Panosoma	336	Panotile	376
Panoxy	350	Panquil	367
Panrexin-m	386	Panshape	390
Pantesin	408	Pantofenicol	335
Pantopon	380	Pantosedive	409
Pantovernil	335	Pantrop	324
Pantrop	360	Panzon	345
Pao sole	389	Paoscle	389
Papatral	372	Papette	350
Papnin	384	Paradeines	389
Paradentol	357	Paraderm	330
Para-dien	345	Paradormalene	371
Parafenac	330	Parafenac (r) milch	330
Parafenac 5% creme	330	Parafenac basishad	330
Parafenac sable	330	Parafenal	330
Para-grip	384	Paralen	376
Paralgin	322	Paramette	384
Parametten	384	Paramiba	330
Paramibe	330	Paramibrodiar	330
Paramid supra	404	Paranephrine	349
Paraseptol	405	Paratodol	384
Paravermin	395	Paraxin	335
Parazine	395	Parazolidin	391
Paracyclin	335	Parenzyme	412
Parepectolin	362	Parepectolin	382
Parest	372	Parfenac	330
Parfenal	330	Parfenal creme derm	330
Pargestic compound	384	Parhist	392
Pariamate	395	Parid	395
Parilac	329	Parkeole	376
Parkestaf	327	Parkesteron	376
Parkestress forte	354	Parks-plus	324
Parlodel	329	Parmilene	372
Parmine	390	Parnate	411
Parnate tylciprine	411	Parnetene	411
Parodyne	385	Paroxyl	319
Parsal	344	Parsal	360
Parstelazin	411	Parstelin	411
Partapp	392	Par-tega	395
Partel	346	Partusisten	352
Partuss	392	Parzolidon	391
Pasadex	384	Pasirheuman	391

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Pasta antisola	385	Pastillas koki	401
Pat	380	Patalgin	370
Patosica	328	Pavadel	388
Paxidorm	372	Paxin	367
Paxofen	360	Payzone	345
Pbi	386	Pbz	391
Pcr 5332	410	Pe	349
Peba	388	Peccocode	403
Pecnon	362	Pecram	323
Pecran	323	Pectigels	382
Pectinfant	348	Pectolin	382
Pectolin	362	Pectrolyte	362
Pectrolyte	382	Pedg	386
Pediamycin	350	Pediaprofen	360
Pedi-cort	338	Pedigel	384
Pedimycetin	335	Pedivol	356
Pedoz	329	Pedroacal	394
Pels	350	Pembul	383
Penantin	402	Penbar	383
Penbon	383	Pencardin	388
Penetradol	391	Penibiot	328
Penicilina klari	328	Penilevel	328
Penimiluy	328	Peniroger	328
Penitasa "450" simple	328	Pen-nitrate	388
Pensive	367	Pentafen	382
Pental	405	Pental	383
Pental forte	405	Pentalgin	383
Pentalgina	382	Pentalmicina	376
Pentalmicina	405	Pentamycetin	335
Pentanca	383	Pentaneural	367
Penta-zine	336	Pentids	328
Pentobarb	383	Pentocetina	335
Pentodorm	383	Pentodormol	383
Pentogen	383	Pentolos	383
Penton	383	Pentone	383
Pentosol	326	Pentran	388
Pentrodin	370	Pentymal	325
Peplax	389	Pepsidac	351
Peragal st	397	Peral	371
Perandern	408	Peratran	395
Perborate	329	Percobarb	384
Percodan	384	Percomon	321
Percural	338	Percutacrine androgenique	408
Perduretas anfetamina	321	Peremesin	365
Perequil	367	Perfamone	321
Periactin	341	Periactine	341
Periactinol	341	Periactol	341

C. INDEX TO PHARMACUETICALS BY AVAILABLE TRADE NAMES

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Perideca	341	Peridon	347
Peridys	347	Perin	395
Periston	397	Periston-n	397
Periston-n-toxobin	397	Peritol	341
Perlutest	342	Perlutex	342
Permatrim	392	Permucal	357
Pernomol	389	Perphyllon	388
Persantinat	340	Pertaril	335
Pertesin	408	Pertonal	384
Pertranquil	367	Pervet	376
Pervincamine	413	Pervitin	368
Petab	383	Peterpect	362
Peterpect	382	Peterphylin	323
Petogen	342	Petonel	383
Petrisul	404	Petrolaglar emulsion	389
Petro-mul-phen	389	Pevidine	397
Peviston	397	Pexaqualone	372
Pf 185	364	Pfeil	399
Pfeil	360	Pfizer-e	350
Pfizerpen	325	Pfizerpen	328
Pfizerquin	336	Phaisohex	357
Phanalgin	370	Phanurane	397
Pharmalgen	320	Pharmalgine	370
Phasca	357	Phasicon	365
Phebuzin	391	Phedrisox	368
Phelantin	368	Phelloverin a	328
Phen bar	388	Phenacet	384
Phenacetine powder	384	Phenacetinum	384
Phenacitin	384	Phenacol-dm	336
Phenacon	384	Phenacon	337
Phenacon	400	Phenaemal	388
Phenalgin	319	Phenapap	392
Phenaphen	384	Phenaphen plus	384
Phenatuss	336	Phenazetin	384
Phenazetina	384	Phenazine	386
Phenazo	385	Phenazon	385
Phen-bel	388	Phenbuff	391
Phenbutazol	391	Phenbutazone	391
Phenedina	384	Phenedrine	321
Phenemal	388	Phenformine	386
Phenformix	386	Phenicarbazide	385
Phenidin	384	Phenin	384
Phenipan	330	Phenlaxine	381
Phenmetrazine	387	Phenobar	388
Phenobarbyl	388	Phenobolin	375
Phenodyne	384	Phenogen	388
Pheno-gesic	388	Phenolax	389

C. INDEX TO PHARMACUETICALS BY AVAILABLE TRADE NAMES

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Phenolax	381	Phenonyl	388
Phenopromin	321	Phenopyridine	356
Phenoquin	337	Phenorial	384
Phenoro	332	Phen-ortis	338
Phental	388	Phentermyl	390
Phentral cratecil	388	Phenylarthrite	391
Phenylbetazone	391	Phenylic acid	389
Phenylon	385	Phenylon plus	391
Phenylone	391	Phenyzone	391
Phiaquin	358	Philcociclina	347
Phillips laxcaps	389	Philopon	368
Phiso scrub	357	Phisodan	357
Phisohex	357	Phisohex(winthrop)	357
Phiso-med	357	Phisocrub	357
Phlebodine	357	Phlebolan	391
Phlogarol	336	Phlogase	380
Phlogase	381	Phlogistol	381
Phlogistol	380	Phlogont	380
Phlogont	381	Phloguran	380
Phloguron	362	Phob	388
Pholcolix	392	Pholcolix spansule	392
Phor pain	360	Phorac	357
Phoscanol	329	Phosohex	357
Phtalazol	393	Phtazol	393
Phylleten	342	Phyllocontin	323
Phyllotemp	323	Phynatol	401
Phyol	401	Phyoneon	401
Physiostat	365	Physistat	365
Phytacorcinc	376	Phyteia schlankheitsdragees	332
Phytex	329	Piadam	350
Piaverm	395	Piavermit	395
Piermap	342	Pigmanorm	358
Pigmanorm	411	Pilabutina	380
Piladren	349	Piloral	338
Pimabicion	335	Pincet	395
Pincide	395	Pinimentac	335
Pinozan	395	Pinrou	395
Pinsirup	395	Pin-tega	395
Pipadox	395	Pipan	395
Pip-a-ray	395	Pipenin	395
Pipenzolate mb san	394	Piper	394
Piperacid	395	Piperamicin	395
Piperascat	395	Piperaskat	395
Piperasol	395	Piperate	395
Piperaverm	395	Piperazate	395
Piperazinal	395	Piperazine (adipate)	395
Pipercrean	395	Piperex	395

C. INDEX TO PHARMACUETICALS BY AVAILABLE TRADE NAMES

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Piperidol	395	Piperital od	395
Piperitol	395	Piper-jodina	395
Piperol fort	395	Piperone	395
Piperoverm	395	Pipertox	395
Piperver	395	Piperzinal	395
Pipeverm	395	Pipezol	395
Pipizan	395	Pipizan citrate	395
Pipracid	395	Piprazid	395
Piprazyl	395	Pipricide	395
Piptal	394	Piptal pediatrico	394
Piptal pediatrique	394	Piptalin	394
Piptelate	395	Pirabutit	391
Piracodid	322	Piradenil	322
Piradol	322	Piraflogin	381
Piraflogin	380	Piramidon	322
Piramidone	322	Piraminal	388
Pirarreumol-b	391	Pirarreumol-p	391
Pirasco	322	Piraseptolo	322
Pirasulfon	404	Piriditol	400
Piridol	322	Piridrol	395
Piririomin	400	Piritinol	400
Piritiomin	400	Piro rectal	322
Pirolacton	402	Pirolcaton	402
Piromidina	322	Piروهeumal	322
Pituitrin	381	Pivalone	376
Piverma	395	Placidel	325
Placitabs	371	Placitate	367
Planphylline	323	Plarenil	402
Plasdone	397	Plasmadone	397
Plasmoid	397	Plasmosan	397
Plassint	397	Plastoderma	335
Plegine	386	Plegline	386
Plenish-k	398	Plenumil	400
Plexonal	326	Plivalgin	388
Pm 2	367	Pmb 4000	367
Pms isoniazid	361	Pms levazine	324
P-m-z	336	Pneumidex	392
Pneumol	323	Podiodine	397
Podofilm	396	Polcicut	393
Polemycin	376	Poliflogil	381
Polinalin	323	Polislerol	350
Polivasal	406	Pollinex	320
Polo-verm	395	Polvo sulfamida leti	405
Polvo sulfamida orrvan	405	Polvos wilfe	405
Polvos wilfe	405	Polybactrin-g	376
Polyclar at	397	Polyclar h	397
Polyclar l	397	Polydexa	376

C. INDEX TO PHARMACUETICALS BY AVAILABLE TRADE NAMES

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Polygris	355	Polygynax	376
Poly-gynedron	406	Poly-gynedron	329
Poly-karaya	397	Polyplasdone xl	397
Poly-pred	376	Polypyrrine	384
Polyquil	395	Polyspecrin	376
Polyvidone-escupient	397	Polyvidonum	397
Polyvinyl pyrrolidone	397	Pomada heridas	405
Pomada heridas	385	Pomada wilfe	405
Pomada wilfe	405	Pomana a	382
Pona	355	Porbiot	370
Porcelana	358	Porcijec	376
Portaderm	372	Poscle	389
Posodolor	360	Postafen	365
Postafene	365	Postivas	320
Potasion	398	Potsilo	381
Povadyne	397	Povera	342
Povidone k 29-32	397	Poxy	384
Pplan 2500	371	Practon	402
Practon 50	402	Praecicalm	383
Praecirheumin	391	Praelutin forate	396
Pragmarel	411	Pragmazone	411
Praktol	398	Pralon	398
Pranzo	341	Praxis	360
Prebutex	391	Precirhemin	391
Preconativ	351	Preconsol	356
Predekzem	357	Prednefrin	385
Prednicidin	376	Prednirheumin	391
Predno-facilus haemota	325	Prednomycetine	335
Prefamone	321	Preferal	329
Prefin	331	Prefrin	392
Prefrin	385	Prefrin liquifilm	385
Prefrin z	385	Pregine	389
Pregnesin	396	Pregnon	365
Pregnon-28	365	Prelazine	387
Prelu-2	386	Preludin	387
Premesin	365	Preminal	388
Premineat	323	Prenakes	352
Prenazon	352	Prenazone	352
Prenomiser	361	Prenoxan	388
Pre-op	357	Prequil	367
Pre-sate	337	Presocyl	336
Pretulon	357	Prevenol	328
Prevotec	376	Priatan	385
Pribetal	388	Pricilone	364
Pricort cream	338	Prifunal	389
Primatene mist	349	Primolut	379
Primotest	408	Primotestone	408

C. INDEX TO PHARMACUETICALS BY AVAILABLE TRADE NAMES

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Primun	353	Prinalgin	320
Prinel	344	Priollat	363
Pripsen	395	Privadol	354
Privenal	358	Pro dorm	372
Probal	367	Pro-ban	409
Probaphen	371	Probasan	367
Probese-p	387	Probocon	393
Probromato	367	Procadolor	328
Procalmidol	367	Procijec	404
Procomp-65	384	Proct anex	357
Proculin	329	Procusulf	335
Procyclomin	344	Prodasone	342
Prodermopur	357	Prodigestan	384
Prodisan	326	Prodol	371
Prodolor	384	Prodormol	383
Profamina	321	Profasi hp	396
Profenade	393	Profilate	351
Profilnine	351	Proflavin	320
Proflex	360	Progesic	384
Progestalfa	342	Progevera	342
Proklar-m	404	Prolax	366
Prolekofen	399	Prolix	326
Prolixan	326	Prolixana	326
Promassolax	381	Promassoletten	381
Promate	367	Promex	336
Promone-e	342	Pronidin	390
Pronone	342	Prontablin	405
Prontalgin	360	Prontoformin	386
Prontylin	323	Propaderm-c	339
Propaderm-n	376	Propadrin	393
Propadrine	393	Propagest	393
Prophenatin	344	Prophyllen	385
Propiocrine enfant	350	Propiokan	408
Propion	321	Propisamine	321
Proplex	351	Propriocin enfante	350
Proptan	343	Propynalin	361
Prospiocine	350	Prostadin	320
Prostaglandin E2	346	Prostalgin	374
Prostalgin	320	Prostandin	320
Prostarmon e	346	Prostavasin	320
Prostenon	346	Prostin e2	346
Prostin vr pediatric	346	Prostin vr pediatric	320
Prostin-vr	320	Prostivas	320
Protagent	397	Protaphane hm insulin	389
Protasma	325	Protectaderm	350
Protector	346	Protenol	361
Protension	384	Protercicline	335

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Proterytrin	350	Prothiazol	405
Prothromplex	351	Protopin	401
Protran	367	Protropin	401
Protylol	344	Prouvil	324
Provasa	340	Provera	342
Proverone	342	Provest	342
Provioline	397	Provtovermil	395
Proxyfezone	391	Proydynam	391
Prulet	389	Prulet	381
Prulet liquitab	381	Prunetta	389
Prurivet	335	Prusol	381
Prydonnal	371	Psico-retard	367
Psicosterone	398	Psicronizer	379
Psychamine a 66	387	Psyco-retard	377
Psyton	379	Pt-1-5	386
Puberogen	396	Pugrante el aleman	389
Pulmo vinco	335	Pulmomas	350
Pulveodil	377	Pulvex	395
Pulvi bacteramide	405	Puradin	354
Puragaceen	381	Purex	389
Purga	389	Purgaceen	381
Purganol	389	Purganos-daguin	389
Purgant aleman	389	Purgante	389
Purgante orravan	389	Purgen	389
Purgenum	389	Purgestol	389
Purgoids	389	Purgophen	381
Purgyl	389	Purjen sahap	389
Purmycin	350	Purphen	388
Pvp 40	397	Pvp 50	397
Pvp0	397	Pvp-k 15	397
Pvp-k 25	397	Pvp-k 3	397
Pvp-k 30	397	Pvp-k 60	397
Pvp-k 90	397	Pvp-macrose	397
Pvp-macrox	397	Pvpp	397
Pydirone	371	Pyocidin hc	377
Pyodental	405	Pyodron	405
Pyradon	323	Pyraelmedal	323
Pyralgin	371	Pyralgine	371
Pyramidon	323	Pyramidone	323
Pyraphen	384	Pyrathyn	371
Pyrazophyl	385	Pyrbotal	391
Pyretin	371	Pyridiate	385
Pyridium	385	Pyril	371
Pyrilgin	371	Pyriligin	371
Pyrinistab	371	Pyrinistol	371
Pyrisan	371	Pyrodin	323
Pyrojec	371	Pyronium	385

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Pyroxate	384	Quaalude	372
Quadrex	377	Quadri-derm	339
Quadrochin	384	Quadronal	384
Quad-sed	388	Quaname	368
Quanil	368	Quarelin	371
Quemeticina	335	Quetimid	409
Quietidon	368	Quimpeamida	405
Quin	339	Quin iii	339
Quina band	339	Quinachlor	336
Quinambicide	339	Quinercyl	336
Quinexin	327	Quiniodochlor	339
Quinoderm	356	Quinoped	356
Quinophenol	356	Quinoseptyl	404
Quitaxon	347	Quitrase	335
Quitrase antibiotico	335	Qz 2	372
R 20	336	R 33812	347
R 4-1778/1	373	R0 22-6595	411
R-18553	364	Radenarcon	351
Radiographol	372	Radox	347
Rafen	360	Ralenta	404
Rangozona	352	Ranocor	391
Ranphenicol	335	Ranstrepcol	335
Raphetamine	321	Rapifen	320
Rapinovet	399	Rapostan	380
Rapostan	381	Rastenil	368
Raucherstop 5 ht	390	Raudazida	402
Rau-fridetten	388	Ravelon	365
Razinol	395	Realin	380
Reamine	337	Reasec	346
Reatos	379	Rebugen	360
Rebuso	372	Recade	340
Recheton	362	Reclor	335
Recolip	340	Recta medicone-hc	356
Recthormone	408	Recthormone testosterone	408
Rectofasa	391	Rectolmin bronquial	379
Rectoral	384	Rectulon	372
Recudik	360	Redicres	321
Redidropsol	335	Redomex	324
Reducto	386	Reducyl	390
Reduform	332	Reduform	332
Reduzin	393	Refagan	384
Reflex rectal	371	Reflex-spray	328
Reformin	384	Regal	381
Regelan	340	Regelan n 500	340
Regenon	321	Regenon retard	321
Regibon	321	Regitol	323
Regium	368	Regulan	364

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Regulane	364	Regulex-d	342
Regulin	390	Reiderma	411
Rejam	371	Rekawan	398
Relaxar	366	Relaxil	366
Relaxil-g	366	Relaxin	368
Relcofen	360	Relexal compuesto	371
Remlomed	323	Remolmed	385
Renagladin	349	Renaglandin	349
Renaglandulin	349	Renaleptine	349
Renalina	349	Renarcol	366
Renasul	404	Renegen	335
Renoform	349	Renokab	377
Renostypticin	349	Renostyptin	349
Reocetin	335	Reomin	399
Reopin	391	Reostop	335
Reostrat	368	Reparal carnitina	341
Repocal	383	Represil	352
Repriman	371	Repro	384
Repromix	342	Resichin	336
Resirol	388	Resochin (diphosphate)	336
Resol	332	Resoquine	336
Respilene	414	Respirase	414
Respirex	414	Respisane	388
Respritin	384	Resquim	371
Restenil	368	Rest-on	371
Restovar	365	Restrol	345
Restryl	371	Resulfon	403
Retabolil	374	Retalon	345
Retamex	399	Retard	386
Retardo	386	Retasulfin	404
Retens	347	Retet	409
Reticus	339	Retin a	411
Retin-a	411	Retmonorm	399
Reton	386	Retromyopen	346
Reu-bon	323	Reuchetal	362
Reufenac	320	Reumachlor	336
Reumanova	323	Reumasedina	323
Reumasyl	391	Reumatox	374
Reumazin	391	Reumilene	391
Reumo	362	Reumo termina	323
Reumofene	360	Reumoftal	323
Reumotranc	323	Reumuzol	391
Reupolar	391	Revonal	372
Revulex	323	Rewodina	344
Rexahisine	336	Rezulin	412
Rheaform	339	Rhematan	337
Rheofin	335	Rheopyrin	391

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Rheosolon	391	Rheufen	360
Rheuma	374	Rheuma-cur	374
Rheumalgen	344	Rheumanol	399
Rheumanoln	391	Rheumaorctat	374
Rheumapax	381	Rheumapax	380
Rheumaphen	391	Rheuma-spalt	371
Rheumatol	331	Rheumavincin	344
Rheumavincin-n	344	Rheumin	337
Rheumox	326	Rheumycalm	391
Rhex	366	Rhex "hobein"	366
Rhinalator	321	Rhinamide	405
Rhinazol	384	Rhindecon	393
Rhinergal	338	Rhinergal	393
Rhinergal tavegil	338	Rhinervet	393
Rhinicept	393	Rhinidrin	393
Rhinivict	399	Rhinocap	393
Rhinophenazol	329	Rhomex	395
Rhotrimine	412	Rhotromine	412
Rhumalgan	391	Ribelfan	379
Ribo-azauracil	326	Ric 272	372
Ridol	371	Rifamate	361
Rigenox	355	Rigesol	403
Rilan	384	Rilax	368
Rimactane	361	Rimafen	360
Rimifon	361	Rinexin	393
Ringl-s	330	Rini c	323
Rino	377	Rino glucol sulf	405
Rino vitna	377	Rinofilax	377
Rinojet	377	Rinomar	337
Rinomar	393	Rinoplex	323
Rinotussal	393	Rinurel	393
Rinurel	384	Rinurel lictus	393
Rinurel tablets	393	Rinutan	384
Rinutan	393	Riogon	396
Riopnol	353	Riporest	372
Risicordin	402	Ritalin	373
Ritalin sr	373	Ritaline	373
Ritromin	350	Rivadorm	383
Rivafurazon	378	Rivastatin	332
Rivodin	403	Rivodol	374
Rivolax	381	Rivomycin	335
Rivomycin sulfa	335	Rivoquin	336
Rm 526	372	Ro 10-9359	351
Ro 1-5488	411	Ro 4-3780	362
Ro 5-0831/1	361	Ro 66827	398
Ro 7-1554	361	Roaccutan	362
Roaccutane	362	Roaccutane	411

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Roacutan	362	Robamate	368
Robarb	325	Robaxisal-ph	384
Robaxisan-pm	384	Robese	343
Robimycin	350	Robitet	409
Robizone-v	391	Rocmuth	397
Rocopenstrep	346	Rofen	360
Rofenid	363	Rohipnol	353
Rohpinol	353	Rohpnol	353
Rohypnol	353	Roidenin	360
Roipnol	353	Rolactone	402
Rolactone microfine	402	Rolintrex	335
Rometin	339	Romphenil	335
Roncovita	335	Rondelim	395
Rondoxy	395	Ron-drive	384
Ronglitazone	412	Ronphenil	335
Root bark oil	332	Roptazol	354
Rorer 148	372	Rorer 714	372
Roscomycin	335	Rotabromophen	393
Rotardon	404	Roulone	372
Rouqualone	372	Rovert-m	365
Rovicine	377	Rovictor	335
Rovonal	372	Roximycin	348
Roxo chemil	350	Roxochemil	350
Roxyne	348	Roychlor	398
Rp 2145	404	Rp 3602	366
Rp-mycin	350	Ru-486	373
Rubibacter	350	Rubifen	373
Rufen	360	Rufol	404
Rumalisine	371	Rumapax	380
Rumapax	381	Rumatral	320
Rumicine	384	Rumicine	319
Rum-k	398	Ruocil	403
Rupalgin	371	Rupton	393
Ru-tuss	400	Ru-tuss	393
Ru-vert-m	365	Rvc	319
Rx 099916	401	Rx 67408nac	352
Ryhmonorma	399	Rynatapp	393
Rynex	393	Rythmole	399
Rytmonorm	399	Ryza-gesic	393
S 611-3	388	S 7	386
S antineuralgic	384	S fc	384
S.d.l.	320	S.d.m.	404
Sabari	365	Sabril	413
Sabril	412	Sabrillex	412
Sacadol	384	Sacietyl	393
Sadaspir	384	Saddle mate	329
Safersan	395	Sagisal	402

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Salestol	336	Saleto	360
Saleto-600	360	Saleton	346
Saleton	354	Saleton	377
Salgydal	384	Salicopil	385
Salicylin-p	396	Salimed compound	366
Salimol	404	Salinidol	356
Salipran	327	Salipran	319
Sali-spiroctan	402	Saluretin	402
Salvacolina nn	382	Salvacolina nn	377
Salviton	388	Salzone	391
Samaphenicol	335	Samecin	348
San ei tartrazine	407	Sanalgin	384
Sanalgine	384	Sanalgin-p	399
Sanapert	381	Sanasthmyl	385
Sanbosten	410	Sancilin	328
Sandocycline	330	Sandoin	330
Sandosten	410	Sandostene	410
Sanepil	388	Sanglin	323
Sanibiovit	377	Saniciline	328
Sanifur	378	Sanimix	377
Sanistress	377	Sanodormin	409
Sanoquin	336	Sanorex	365
Sansdolor	366	Sanstrepto	346
Santeprednisan a	371	Santoban	395
Santus	414	Sapilant	412
Sapo-chlor	357	Sapoderm	357
Sapos	388	Sapotera	323
Saratem	324	Saridon	385
Saridon neu	399	Saridone	399
Sarna	389	Sarodormin	355
Sarolax	389	Saroten	324
Sarotena	324	Sarotex	324
Sas 1060	402	Savedorm	372
Saventrine	361	Sawamin	344
Sawaxin	400	Sc 9420	402
Scandantin	378	Scanicol	335
Scanicoline	335	Scaniquine (diphosphate)	336
Scantrimon	354	Schemergen	391
Schiwanox	325	Schlafen	383
Schlakforte	411	Schokilax	381
Scieramycetin	335	Scintidin	400
Sclaventerol	354	Sclerovasal	340
Scopoderm tts	400	Scotatal	388
Scotuss	393	Scurenaline	349
Sd 13	397	S-dimidine	403
Sdv specific desentistising caccine	320	Sea-leg	365
Sebbafon	357	Sebo-cds	357

C. INDEX TO PHARMACUETICALS BY AVAILABLE TRADE NAMES

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Sebon	371	Sebo-psor	411
Sebryl	339	Secantol	377
Seclodin	360	Seconal	400
Seconal sodium	400	Secophen-c	388
Secron	393	Sectam	363
Seda baxacor	368	Sedabel	371
Sedacol	339	Sedacoral	388
Sedafamen	386	Sedafen	323
Seda-intestain	388	Seda-ko	388
Sedalgin	388	Sedalis	409
Sedalmerck	385	Sedalone	372
Sedanoc	372	Sedanoc	364
Sedanox	383	Sedans	324
Sedantosol	361	Sedanyl	368
Sedapar	388	Sedarel	371
Sedarene	341	Sedarene	371
Sedaspray	360	Seda-tablinen	388
Sedatin	385	Sedatine	385
Sedatyl	372	Sedaural	389
Sedaural	385	Sedavier	368
Sedazepane	371	Sedazil	368
Sedeval	326	Sedistal	346
Sednotic	325	Sedo corodil	388
Sedo-asmol	349	Sedobex	401
Sedonal	388	Sedonan	385
Sedophen	388	Sedopsic	388
Sedo-rythmodan	325	Sedospin	399
Sedoval	409	Sedragesic	388
Sedural	385	Seecoren	344
Segosin	372	Segudol	380
Segurex	400	Selacryn	410
Selbon-a	323	Selcryn	410
Seldiar	364	Selene	368
Selodorm	368	Selpiran	371
Selvicin	350	Semelcyclina	348
Semenen	400	Semikon	371
Semori	356	Sensi-t	396
Sepp	397	Septa	377
Septex cream no. 2	405	Septicol	335
Septifalil	393	Septo-canulase	339
Septomixine forte	377	Septoplax	405
Septosil	403	Septotryl	404
Septozol	405	Seranex	385
Serenade	368	Sergi-cen	357
Sergo-amigdalar	335	Sergozin	373
Serial 28	366	Seril	368
Serohinol	356	Serolipid	340

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Serorhinol	356	Serotinex	340
Sertalanalgesico	371	Servalgin	399
Serviclofen	335	Servilactone	402
Servipan	328	Serviprofen	360
Serviquin	336	Servistrep	402
Servizolidin	391	Serzone	375
Sestron	340	Setran	368
Sevenal	388	Severen	371
Severin	371	Sexadien	345
Sexadieno	345	Sgd	403
S-guanidan	403	S-guanidine	403
Sh 833	398	Shalvaton	368
Shhe 21	385	Shield	378
Shigatox	403	Shignol	344
Shigrodim	391	Shinaito	409
Shinnibrol	409	Shin-rheufen	320
Shiomalin	363	Shiomarin	363
Sibren	354	Sibul	351
Sicol	350	Sificetina	335
Sigadoxin	348	Siglatan	341
Sigloton	341	Sigma-elmedal	391
Sigmaticilina	335	Silbesan	336
Silderm	377	Silic c	339
Silino	344	Silternum	372
Silubin	330	Silubin retard	330
Simpamina	321	Simpamina d	343
Simpatedrin	321	Simpatina	321
Simplene	349	Sinac	393
Sinacin	393	Sinalgex	371
Sinalgin	327	Sinan	366
Sinapet	321	Sincomen	402
Sincomen	397	Sincomen pro injectione	397
Sindesvel	372	Sindiatil	330
Sindomens	342	Sine-aid ib	360
Sinedal	385	Sinequan	347
Sinfat	337	Sinnamin	326
Sinosid	382	Sinquan	347
Sinquan concentrate	347	Sinquane	347
Sinquin	358	Sintabolin	375
Sintaverin	371	Sinteroid	340
Sintobutina	391	Sintomicetin	335
Sintomicetina	335	Sintomicetine r	335
Sintomitsin	335	Sintown	368
Sinubid	393	Sinudan	393
Sinu-lets	393	Sinus	393
Sinutab	385	Sinutab cough I	393
Sinutab ii	385	Sinviril	371

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Sipraktin	341	Siprodin	341
Siquent neomycin	377	Siragon	336
Sirben	354	Siropar	395
Sirprogen	342	Sistalgin	371
Sk 65 compound	385	Sk 65 compound caps.	385
Sk-amitriptyline	324	Sk-bamate	368
Sk-erythromycin	350	Skf-62698	410
Skiodan sodium	373	Sklero	340
Sklerocip	340	Sklerolip	340
Skleromex	340	Skleromexe	340
Sklero-tablinen	340	Sklerovasal	340
Skopolate	358	Skopyl	358
Skopyle	358	Sk-penicillin g	328
Skrub kreme	357	Sk-tetracycline	409
SI 76 002	398	Sladycin	341
Sleepan	409	Sleepinal	372
Sleepwell	358	Slim-plus	321
Slipro	409	Slow-k	398
Sly-II	386	Slyn-II	386
S-methizole	404	Smokerette	401
Smop	404	Snophenicol	335
Sobril	413	Sobril tab 25 mg	413
Sodaphilline	350	Sodelut	342
Sodelut "g"	342	Sodepyrine b 1	374
Sodiopen	328	Sodipen	328
Sodium narcosate	358	Sofan	377
Sofarin	344	Sofarin	413
Sofracaps	341	Softa man	350
Soft-care	397	Softenil	409
Softenon	409	Solaquin	358
Solaquin forte	358	Solaquin forte sun bleaching	358
Soldactone	397	Solielin	352
Solmycin	346	Solofoton	388
Soludactone	397	Soludectancil	335
Solufen	360	Solu-heks	357
Solupen	348	Solurol	407
Solustrep	402	Solvidont	328
Solvo-strep-s	402	Solvo-strept	346
Solvo-strept-s	402	Solvotest	408
Soma	385	Soma compound	385
Soma compuesto	385	Somacton	401
Somatonorm	401	Somatormone	401
Somatotrope choay	401	Somatrofin	401
Somatropin	401	Somberol	372
Sombucaps	358	Sombulex	358
Sombutol	383	Somid	355
Somnafac	372	Somnal	325

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Somnalert	358	Somnevrin	340
Somnex	372	Somnibel	372
Somnipron	325	Somnium	372
Somnofac	372	Somnomed	372
Somnopentyl	383	Somnophyt	383
Somnopyrin	323	Somnosan	372
Somnotol	383	Somnotropon	372
Somnytic tablets	326	Somonal	388
Somophyllin	323	Somophyllin-12	323
Somvit	325	Sonal	372
Sonalgin	385	Songar	412
Songarn	412	Soniphen	388
Sonistan	383	Sonotryl	399
Sooner	361	Soor-gel	342
Sopamycetin	335	Sopanil	368
Sopental	383	Sopor	372
Sorbitoxin	382	Sorbitoxin	377
Sorelmon	344	Soriatane	319
Sorot	342	Sosegon	382
Sotracarix	350	Soval	372
Sovelin	372	Soverin	372
Sovinal	372	Sowell	368
Soxypamine	368	Soy-dome	357
Spacin	385	Spactil	344
Spalt	319	Spalt	399
Spalt	385	Spalt n	385
Span r/d	390	Spanbolet	403
Spanbolet ii	403	Spandecon	393
Span-k	398	Spanor	348
Spantran	368	Spartoloxyn	366
Spascol	388	Spasdel	388
Spasdolsom	371	Spaslar	371
Spasmalgon	371	Spasmalones	388
Spasmin	371	Spasmindon	385
Spasmiium-comp.	371	Spasmizol	371
Spasmobamat	368	Spasmoban	344
Spasmo-barbanub	323	Spasmo-compragyl	388
Spasmo-compralgyl	385	Spasmo-deterex	323
Spasmo-dimonil	323	Spasmodor	371
Spasmofen	379	Spasmofen	400
Spasmogentarol	388	Spasmo-harnosal	404
Spasmolyn	366	Spasmo-paraxin	335
Spasmoprnt	372	Spasmopyralgin	371
Spasmotal	388	Spasmothil	371
Spasmo-tropax	323	Spasmovalin	323
Spasmo-van	388	Spasmoveragin	388
Spasmoverlgin	323	Spasmus	323

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Spastil	344	Spastyl	388
Specilline	328	Specilline g	328
Spectralgen	320	Spectralgen pollens	320
Spedifen	360	Speroctan-m	397
Spersanicol	335	Spersapolymyxin dispersa	377
Spetrasone	350	Spierifex	327
Spike	363	Spiractin	402
Spirexis	402	Spiretic	402
Spiridazide	402	Spiridon	402
Spirit of camphor	332	Spirix	402
Spiro	402	Spiro comp	402
Spiro50-d	402	Spiroctan	397
Spiroctan	402	Spirodigital	402
Spiro-f	402	Spirolang	402
Spirom	402	Spiromazine	402
Spiromocompren	402	Spiromone	402
Spiromothiazide	402	Spiropal	402
Spiroprop	402	Spirostada	402
Spiro-tablinen	402	Spirotone	402
Spirozid	319	Sporadazine	404
Spondyneuron	388	Spondyryl	391
Spongamed	399	Sprx 105	386
Spulmako-lax	389	Srda	393
S-spac	383	Stabilat	391
Stablon	410	Stadadorm	325
Stadasan	360	Stamicina	348
Stangyl	412	Stanomycetin	335
Starisil	404	Starogyn	330
Statobex	386	Statobex-d	386
Steclin	409	Steladex	343
Stelapar	411	Stella micina	350
Stellacyl	385	Stellamicina	350
Stenabolin	374	Stenabolin	375
Stensolo	368	Stental extentabs	388
Steraskin	357	Steridermis	357
Steridermis washing cream	357	Sterobolin	374
Steroderm	339	Steros-anal	377
Sterotest	408	Ster-zac	357
Ster-zac antibacterial shaving foam	357	Ster-zac antibacterial soap	357
Ster-zac dc skin cleanser	357	Ster-zac powder	357
Sth	401	S-thalamic	377
Stie vaa	411	Stiedex	377
Stievaa	411	Stil-2	343
Stilalgin	366	Stilco	379
Stilphostrol	345	Stimolag fortis	395
Sto-caps	393	Stodex	386
Stodinox	358	Stollerine	388

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Stona	399	Stopayne	368
Stopp-15	383	Stovarsol	319
Stovarsolan	319	Strabolene	375
Strep-diva	402	Strepolin	402
Streptacillin	405	Streptamin	405
Streptan	402	Streptaquine	402
Strepticine	335	Streptocal	402
Streptoduocin	346	Strepto-fatal	402
Streptoglobenicol	335	Streptomagma	362
Streptomagma	382	Streptomycin	402
Streptophenicol	335	Streptosol 25	402
Streptothemat	402	Streptotriad	405
Stretobretin	402	Strycin	402
Styptirenal	349	Subital supp.	335
Subtosan	397	Sucaryl	341
Sucaryl calcium	341	Sucaryl sodium	341
Sucrum	341	Sucrum 7	341
Sudil	406	Sudocrem	328
Sufenid	406	Sufonovin	371
Sugai tartrazine	407	Suganril	380
Suganyl	403	Sugracillin	328
Suigonan	396	Suismycetin	335
Suladyne	404	Sulamin	404
Sulc	406	Sulfa gram	404
Sulfa spirig	404	Sulfabon	404
Sulfacarbon	403	Sulfacetil	393
Sulfacromo	405	Sulfadazina	404
Sulfadepot	404	Sulfadin	404
Sulfadurazin	404	Sulfaglobenicol	335
Sulfaintensa	404	Sulfakeyn	404
Sulfalex	404	Sulfamethine	406
Sulfametin	404	Sulfametopyridazin	404
Sulfamizina	404	Sulfamul	405
Sulfamycetin	335	Sulfamyd	404
Sulfamyton-n	378	Sulfa-orzon	405
Sulfa-probocon	393	Sulfapyelon	404
Sulfapyrazin	404	Sulfatar	404
Sulfathalidine	393	Sulfavitina	405
Sulfazol	405	Sulfdurazin	404
Sulfentidine	403	Sulfex	405
Sulfhatose	405	Sulfintestin	405
Sulfix-6	377	Sulfocidan	404
Sulfogua	403	Sulfonamid	404
Sulfonamid spuman	405	Sulfonamide-spuman-style	405
Sulfonanilamid	405	Sulfonovin	371
Sulfopyrol	405	Sulforetent	404
Sulfo-rit	404	Sulfosellan-salbe	405

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Sulfour	405	Sulfstat	404
Sulftalyl	393	Sulfurine	404
Sulfzol	405	Sulgin	403
Sulka-s	403	Sul-mycin ii	402
Sulnac	405	Sulocton	406
Sulodene	406	Suloktil	406
Sulphamezathine	403	Sulphatriad	405
Sulphmezatine	403	Sulpin	371
Sulpyrin	371	Sulpyrine	371
Sultirene	404	Sultrin	405
Sulvina	355	Sulzol	405
Sumasept	357	Sumital	325
Sumycin	409	Supadol	371
Supamidal	388	Super anahist	385
Super emegrin	321	Super koki	401
Super masticort	377	Super mastitare	377
Super sat	357	Superanabolon	375
Superbolin	375	Superfade age spot	358
Supergine	371	Superior pain medicine	360
Supermesin	365	Superminal	365
Superol	356	Superpyrin	320
Superseptyl	403	Suppnon	323
Supoptanox	413	Supprestal	342
Suprabolin	375	Supracapsulin	349
Supracyclin	348	Supralgin	385
Supranephrene	349	Supranephrine	349
Supranol	406	Supraoxid	340
Suprapuren	402	Supra-puren	402
Suprarenaline	349	Suprarenine	349
Suprasec	364	Supraverm	395
Suprel	349	Supreme pain medicine	360
Supren	360	Suprexon	349
Suprexon 5	349	Suprimal	365
Suprol	406	Suracton	402
Surfex	406	Surg salve	357
Surge vet	357	Surgexl	377
Surgi-cen	357	Surmantil	412
Surmontil	412	Surofene	357
Surpyrine	371	Surrenine	349
Susano	400	Susano	388
Suscardia	361	Susiform ad is vet	330
Suspal	320	Susphrine	349
Sus-phrine	349	Suspren	360
Sustain iii	403	Sutanone	408
Sutidil	406	Svc	319
Sweet flag root	331	Swim-ear	329
Swim-eye	329	Swiss-kal sr	398

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Sy-dexam	325	Sylvemid	324
Symetra	386	Sympamine	321
Sympatedrin	321	Sympathin i	349
Sympatina	321	Symptrol	393
Synalar polyvalent	377	Synalar-c	339
Synalgos	385	Synalogos-dc	385
Synandrol	408	Synatan	321
Synatan	343	Syndian	381
Syndrox	368	Syneron	408
Synestrol	345	Synoestrol	345
Synoestrolum	357	Synovex-h	408
Synpyrin	399	Syntaverin	371
Synthomycetin	335	Synthomycetina	335
Synthomycetine	335	Synthophtone	335
Syntophyllin	323	Syntospon	388
Synureticum	402	Syptan	393
Syralbina	377	Syralbuna	354
Syrtussar	393	T h	385
T-712	321	Tabalon	360
Tabillin	328	Tabmint	401
Tabrien	352	Tacol	385
Taenifigin	395	Taf test	356
Taguinol	364	Taimoxin	350
Taizerl	365	Takamina	349
Talacen	382	Talamo	325
Talasa	414	Taleudron	393
Talidine	393	Talimol	409
Talisulfazol	393	Taloudron	393
Talwin	382	Talwin nx	382
Tamate	368	Tambocor	353
Tametil	347	Tamid	406
Tamil	393	Tampovagan	377
Tampovagan pss	405	Tanakan	336
Tanakan	354	Tanal	380
Tandacot	380	Tandacote	381
Tandalgesic	380	Tandalgesic	381
Tandearil	381	Tandearil	380
Tanderil	380	Tanderil	381
Tanderil-alka	381	Tanercept	350
Tangenin	328	Tanper	371
Tapal	371	Tapal	319
Taquadil	410	Tardilat	326
Tardolyt	325	Tardomyocel	335
Tardyl	355	Tarestin	344
Tariston	377	Taristop	378
Tartar yellow fs	407	Tartar yellow n	407
Tartar yellow pf	407	Tartar yellow s	407

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Tartran yellow	407	Tartraphenine	407
Tartrayellow	407	Tartrazin	407
Tartrazine a export	407	Tartrazine b	407
Tartrazine b.p.c.	407	Tartrazine c	407
Tartrazine extra pure a	407	Tartrazine fq	407
Tartrazine g	407	Tartrazine lake	407
Tartrazine lake yellow n	407	Tartrazine m	407
Tartrazine mcgl	407	Tartrazine n	407
Tartrazine ns	407	Tartrazine o	407
Tartrazine o specially pure	407	Tartrazine t	407
Tartrazine xx	407	Tartrazine xx especially pure	407
Tartrazine xxx	407	Tartrazine yellow	407
Tartrazol bpc	407	Tartrazol yellow	407
Tartrine yellow o	407	Tasnon	395
Tasvite	341	Tavegil	338
Tavegyl	338	Ta-verm	395
Taviset	393	Tavist	338
Tavist 1	338	Tavist tablets	338
Tavist-1	338	Tavist-d	338
Tavist-syrup	338	Taxagon	411
Tbp	328	Tbrien	352
Tcm 200	368	Tcm 400	368
Tcp	332	Tcp	410
Tears plus	397	Tebloc	364
Tedralan	388	Teebaconin	361
Tefamin	323	Tega-cetin	335
Tega-pyrone	371	Tegison	351
Telboc	364	Telestyl	377
Teletux	379	Telgin-g	338
Telidal	380	Telipex	408
Telmicid	346	Telmid	346
Telmide	346	Temagesic	331
Temasept	356	Temgesic	331
Temp	371	Tempil	371
Tempil	360	Tenalin	371
Tendar	360	Tendearil	380
Teneral	380	Teniver	395
Ten-k	398	Tenorac	354
Tenorac	365	Tensilence	326
Tensin	402	Tensoflex	402
Tensophoril	329	Tensophoril	325
Tensorelax	324	Tenuate	321
Tenuate dospan	321	Tenucap	321
Teofedrin	388	Teolaxin	388
Teophyllamin	323	Tepal	371
Tepanil	393	Tepanil	321
Tepcycline	409	Teperin	324

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Tepincal	340	Tepingal	340
Tequinophil	339	Teramine	390
Teramine	337	Teranol	398
Terazol	408	Terazol	408
Terazol 3	408	Tercospor	408
Terenac	365	Termonil	371
Terolin	408	Teronac	365
Teropicycline	409	Terracydin	385
Terramycin	355	Terrastatom	355
Tersaseptic	357	Tersulpha	403
Tersulpha	403	Tervalon	337
Teserene	345	Teslen	408
Tesrina	408	Testaform	408
Testanderogen	408	Testenat	408
Testex	408	Testigrmon	408
Testilen	408	Testirene	408
Testobase	408	Testodet	408
Testodrin	408	Testogen	409
Testoici	409	Testoidral	409
Testolets	409	Testonate	409
Testonique	409	Testopin	409
Testopinate	409	Testopropon	409
Testoral	409	Testo-retard	409
Testormol	409	Testosid	409
Testoviron	409	Testoviron (ampule)	409
Testoviron-10/-25/-50	409	Testoviron-depot-50/-100	409
Testovis	409	Testoxyl	409
Testrex	409	Testron	409
Tete-lax	381	Tetesept	332
Tetesept	342	Tetnor	391
Tetrabal-hosbon	371	Tetrabotic	409
Tetra-c	409	Tetracap	409
Tetracaps	409	Tetrachlorasone	335
Tetracid	404	Tetracol	335
Tetracyn	355	Tetracyn	409
Tetradox	348	Tetrafur	354
Tetralan	409	Tetram	409
Tetranfen	335	Tetraphenicol	335
Tetra-phenicol oculos	335	Tetrasan	348
Tetraspasmil	371	Tetrawest	403
Tetrex	409	Tetrex-apc	385
Tetrpsol	409	Tetracydin	385
Tevcocin	335	Tevocodyn	391
Thalazole	393	Thalinil	393
Thalinol	389	Thalinol mrt	389
Thalistanin	393	Thalostatyl	393
Thalsin	328	Thefedral	388

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Thelmin	395	Thenatol	395
Thenylene	371	Theodrine	388
Theotabs	388	Thephorin a-c	385
Therapen-na	328	Therazone	391
Thiadyl	405	Thiazamid	405
Thiazamide	405	Thiazole	393
Thicataren	344	Thidicur	404
Thinz	332	Thioactacid	364
Thiobactal	410	Thiocondramine	355
Thionylan	371	Thiosulfil	404
Thiosulfil a	404	Thioxidil	366
Thittico	411	Thiuramide	405
Thodrox	323	Thombran	411
Thromban	411	Tiadexol	371
Tiadyl	405	Tiartan	371
Tiatral	320	Tibased	400
Tibutazone	391	Ticinil	391
Ticinil calcio	391	Ticinil calico	391
Ticlid	410	Ticlidan	410
Ticlobran	340	Ticlodix	410
Ticlodone	410	Ticlopedine	410
Ticlosan	410	Ticrex	410
Ticrynafen	410	Ticrynapen	410
Tidemol retard	330	Tifomycine	335
Tiframild	377	Tiframilk	335
Tigasan	351	Tigason	351
Tiiomapirina	385	Tiklid	410
Tiklyd	410	Tikofuran	354
Tilcid	410	Timazincum	329
Tinaroc	393	Tiosulfan	404
Tipolin	329	Tiqualone	372
Tiromycetin	335	Tivazine	395
Tkb	362	Tlargan	409
Tobinal	358	Tobispray	377
Todalgil	360	Todalgil	391
Togerin	350	Togiren	350
Togrien	350	Tolansin	366
Tolax	366	Tolbrtaphen	386
Tolcil	366	Toleran	358
Tolhart	366	Tolllluan	347
Tolosate	366	Toloxin andromaco	371
Toloxyn	366	Tolseram	366
Tolserol	366	Tolseron	366
Tolsin	366	Tolulexin	366
Tolulox	366	Tolvin	373
Tolvon	373	Tolyprin	326
Tolyprina	326	Tolyspaz	366

C. INDEX TO PHARMACUETICALS BY AVAILABLE TRADE NAMES

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Tomapiena	385	Tombran	411
Tomevit	400	Tonedron	368
Tonobrein	400	Tonocard	410
Tonomentis	400	Tonosan	323
Topazone	354	Tophol	337
Topic	332	Topic	328
Topicon	377	Topitasico	377
Topral	406	Toptic	339
Toquidil	410	Toquilone	372
Toracsol	357	Torafon	372
Toramin	335	Torbetol lotion	357
Toriador	372	Torinal	372
Torofof	339	Toryxil	344
Tosinova	350	Tostrina	409
Totolin	393	Totrtasec	364
Touristic	347	Toxocan	395
Tr 1736	325	Tr 495	372
Trabar	391	Trabar	410
Trabit	391	Tracherine	356
Tramal	410	Tramensan	411
Tranatogen-ova	354	Trankilin	368
Trankvilan	368	Tranlisant	368
Tranmep	368	Tranoxa	378
Tranquil	368	Tranquilan	368
Tranquilax	368	Tranquiline	368
Transamin	411	Transaminase	411
Transaminase sgo	411	Transaminase sgp	411
Transamine	411	Transcop	400
Transepar	337	Transicetina	335
Transital	325	Transpulmycin	335
Traubofan	337	Trauma-dolgit	360
Traumasept	397	Trelenium	341
Trelmar	368	Trenteron	371
Trepiline	324	Trepulin	324
Tresaderm	377	Tresochin	336
Tretin m	411	Treupel	385
Triadapin	347	Triadol	327
Triartan	371	Triavil	324
Triazure	326	Tribiotic	377
Tribiotic	335	Tri-bow	377
Trichofuron	354	Tricho-gynedron	406
Tricho-gynedron	329	Trichovan	319
Tricilone	377	Tricofuron	354
Tricon	393	Tri-congestic	393
Tricoron	354	Tridezibarbitur	388
Trifurox	354	Trilax	389
Trimanyl	345	Trimcaps	386

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Trimeto	405	Trimo-san	356
Trimstat	386	Trimtabs	386
Trinalgen	371	Triniad	361
Tri-norinyl	379	Triofan	328
Triogesic elixir	393	Triomonic	393
Triomone	409	Tri-optics	377
Triotussic	393	Triphenatol	388
Tripin	385	Triplex	385
Triplopen	328	Triptizol	324
Triptonal	324	Triptpane	324
Tri-reumo-campil	368	Trisulfaminic	403
Trisulfaminic	403	Trisulfaminie	403
Trisulpha	405	Trisulpha	403
Trisulvet	403	Tritane	393
Tritico	411	Trittico	411
Triva douch powder	356	Triva jel	356
Trivial	324	Trivial-4-10	324
Trivial-4-50	324	Troc	377
Trochin	336	Trodax	379
Trofodermin	377	Trogal	323
Tropax	388	Tropax	323
Tropax	400	Trophen	335
Tropoxin	350	Troymycetin	335
Truphylline	323	Trypsillin	412
Tryptan	364	Trysul	405
Tsefokon	323	Tsudohmin	344
Tsudomin	344	Tualone	372
Tuazole	372	Tuazolona	372
Tuazolone	372	Tucotin	379
Tuinal	400	Tuinal	325
Tumex	356	Tumisan globulina	371
Tuocurine	378	Turbispan	393
Turinabol	375	Turinabol-depot	374
Tuscapin	379	Tusolone	335
Tussamine plus	379	Tussanil n	379
Tusscalman	380	Tussicure	380
Tussilene-dm	393	Tussisedal	380
Tussoretard	380	Tweenal	377
Tycloran	335	Tydamine	412
Tylasul	405	Tylciprine	411
Tylenol	382	Tylinal	321
Tympagesic	323	Tympagesic	385
Tyrivac	320	Ubrocelan	377
Ucb 5062	365	Ucb 630	377
Ufa 902-duo	405	Ufa-cfo-400	354
Uga-no	385	Ultradine	397
Ultragim	371	Ultragin	371

C. INDEX TO PHARMACUETICALS BY AVAILABLE TRADE NAMES

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Ultra-k-chlor	398	Ultrapla	398
Ultraprin	360	Ultraquin	358
Ultraquin plaine	358	Ultrasul	404
Ultratiazol	393	Umbellatin	328
Umbellatine	328	Umprel	329
Unacil	348	Unagen	371
Unalgen hc	371	Ung. vemleigh	405
Uniad	361	Unicilina	328
Unicilina sodia	328	Unidiarea	339
Unidox	363	Unidox	348
Unimycetin	335	Uniprofen	327
Uniriod	377	Unisol	329
Unisulfa	404	Unisulfa dulcis	404
Unisvelt	389	Unitertracid yellow te	407
Uniteston	409	Uno	368
Upstene	360	Ura	389
Uractone	402	Urafadyn	378
Uratrac	404	Urbil	368
Urbilat	368	Urem	360
Uricida	395	Uridina	395
Uritrol	379	Uro-beniktol	377
Urobotic	404	Uroclear (hexamine)	395
Urocoli	379	Uro-coli	379
Urocydal	404	Urodan (phosphate)	395
Urodiaton	404	Uro-gliscal	335
Uro-gliscal 500	335	Uroletten	378
Uroletten-s	335	Urolex	404
Urolucosil	404	Uroluxcosil	404
Urombal	373	Uromitexan	368
Uronal	326	Uro-nebactin	404
Uro-nebctin	377	Uronexitan	368
Uropeutic	404	Uroplex	404
Uroplex 4	335	Urosolvina	395
Urosonine	402	Urotrex	404
Uroz	404	Urusonin	402
Usacert yellow no 5	407	Ut forte	335
Uteroject	339	Uterojekt	354
Utovlar	379	Ultrasul	404
Uvilon syrup (hydrate)	395	Uvomycin	335
Uzone	391	V cold	393
Vabrocid	378	Vadicate	413
Vagifurona	354	Vagipurin	319
Vagisep	319	Vagisept	335
Vagitrol	405	Vagival	319
Vagoflor	319	Valcophen	385
Valetan	344	Valetan	404
Validil	381	Valpin	388

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Valprin	360	Valproine	412
Valsera	353	Valseram	353
Vanadian	320	Vancid	328
Vancide bl	328	Vandar-65	385
Vanital	388	Vanpar (hydrate)	395
Vanseb	357	Vantal	388
Vantostol-p	409	Vantyl	337
Vaopin	389	Vapesin	352
Vapo-iso	361	Vaponefrin	349
Vaponephrine	349	Vapo-n-iso	361
Variaphylline	323	Varicella-rit	377
Varihesive	382	Variolan	335
Vas dexa	411	Vasco	327
Vascudil	406	Vasoc	327
Vasocalm	368	Vasoconstrictine	349
Vasoconstrictor	349	Vasodarkey	326
Vasodrine	349	Vasogesic	385
Vasotonin	349	V-cline	365
V-cortanmycetine	377	V-crayolan	335
Vectren	362	Vederon	412
Vefren	380	Veganine	385
Velaten	404	Veltane	393
Veltap	393	Venactone	397
Venagil	327	Venostasin retard	397
Ventribex	339	Veracolate	389
Verafen	342	Veramix	342
Veramix plus v	342	Verban	326
Verfactor	361	Vericap	396
Verinogen	326	Veripaque	381
Veripar	395	Veritab	366
Vermago	395	Vermazine	395
Vermenter	395	Vermicompren	395
Vermidol	395	Vermifug	395
Vermilass	395	Vermipan	395
Vermipharmette	395	Vermiquimpe	395
Vermiquimyc	395	Vermisit	395
Vermisol	395	Vermisol	364
Vermitox	395	Vermofrik	395
Vernate	393	Verocid	395
Verodon	326	Veroletten	326
Verolitten	326	Veronal	326
Veronigen	326	Verospiron	402
Verospirone	402	Veroxil	395
Verra-med	411	Versidyne	373
Versomnal	388	Vertizine	366
Verucid	350	Vetacalin-m	329
Vetalderm	357	Vetalgin	371

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Vetedine	397	Vetedol	327
Vetical	335	Veticar	346
Vetophenicol	335	Vetoprim	354
Vetoprim mi	405	Vetoryl	393
Vetroyl	377	Vetsovate	377
Vevesca	373	Veycil-as	346
Viadol	323	Viafen	330
Viafen u est.crema 40 g	330	Viagra	400
Viartril	355	Vibolin	351
Vibracina	348	Vibramicina	348
Vibramycin	348	Vibramycin hyclate	348
Vibramycine	348	Vibra-tab	348
Vibra-tabs	348	Vibraveineuse	348
Vibravenos	348	Vibravenosa	348
Vibriomycin	346	Viceton	335
Vicks action 500	385	Victoril	343
Viden	385	Vidipon	340
Viform	339	Vigilor	352
Vigilor 200 mg cpr msfp	352	Viklorin	335
Vimedel	340	Vimicon	341
Vinbarbiton	413	Vinca	413
Vinca minor	413	Vincacen	413
Vincapront	413	Vincavix	413
Vinces	404	Vincimax	413
Vini	397	Vinisol	397
Vintab	362	Vintop	362
Vio-bamate	368	Vioform	339
Vioform bolus	339	Vioform hydrocortisan	339
Vioform hydrocortisone	339	Vioforme	339
Viofuragyn	354	Viophan	337
Viosept	339	Viperone	371
Viramune	377	Viridite	398
Viridite k	398	Virogin	335
Viromon	409	Viropulver	378
Virormone	409	Virosterone	409
Visadron	392	Visano cor	368
Visceralgine forte	371	Viscerol	344
Viscope	358	Vistabamate	368
Vista-methasone n	377	Vistaminic	393
Visublefarite	385	Visubutina	380
Vitacid a	411	Vitaklorin	335
Vitalone	372	Vitamin a acid	411
Vivcet	399	Vk 53	404
Vocaline	340	Volidan	366
Volocid	404	Volplan	366
Voltaren	344	Voltarene	344
Voltarol	344	Vomaxine	366

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Vomisseis	366	Vondacid tartrazine	407
Voxin-pg	393	Vsf-medical g 15	354
Vsmpozim	335	V-softa	377
Vtg 44	404	Vulnusol spray	357
W 32	386	W 58	393
W 66	393	W7320	320
W-7320	320	W83	371
Wairmex	395	Walconesin	366
Wans	383	Waran	413
Warfilone	413	Wartec	396
Warticon	396	Wartkil	396
Wart-off	396	Wauco-sin	399
Waudobuzon	323	Waukobuzon	391
Wecontrin	399	Wehless	386
Weighttrol	386	Weingeist	350
Wekamine	321	Wesco hex	357
Wescohex	357	Wescomep	368
Wescozone	391	Westasept	357
Wigraine	385	Wigraine-pb	383
Willnestrol	345	Win 11450	327
Winolate	327	Winorlate	327
Winorylate	327	Winrolate	327
Wintetil	335	Wintracin	409
Wintrazol	405	Wiolate	327
Wndomethasone	363	Wofapyrin	391
Wood yellow	407	Worm-away	395
Wurmex	395	Wurmirazin	395
Wurmsirup siegfried	395	Wyamycin	350
Wyamycin e	350	Wyamycin s	350
Wyovin	344	X 112 antiadipo	393
Xani	326	Xaril	385
Xenalmine	413	Xenalone	402
Xenovis	413	Xerac	357
Xeracin	350	Xeualon	402
Ximicina	348	XI 7	328
Xolamin	338	X-trozine	386
Xyduril	340	Xylene fast yellow gt	407
Xylestesin a	349	Xylotocan	410
Xylotox	364	Xylotox	349
Yalrocin	378	Yastyl	383
Yatrocin	378	Yellow lake 69	407
Yermonil	365	yhu TNFR: Fc	350
Yoclo	340	Yodiplexin	397
Yodomin	409	Zactirin compound-100	385
Zadorin	348	Zalpon	357
Zalpon antibacterial washing cream	357	Zedrine	321
Zeisin	340	Zelmid	413

**C. INDEX TO PHARMACUETICALS
BY AVAILABLE TRADE NAMES**

TRADE AND BRAND NAMES	PAGE	TRADE AND BRAND NAMES	PAGE
Zelmidine	413	Zepelin	352
Zerinol	393	Ziavetine	330
Zimovane	414	Zirkonorm	388
Zitoxil	414	Zolapelin	392
Zolidinium	392	Zomax	414
Zomaxin	414	Zonalon	347
Zontal	352	Zoontal	352
Zopirac	414	Zoppib spray blu	335
Zoppin spray blu	378	Zorprin	319
Zubirol	320	Zumaril	320
1 yellow	407	1409 yellow	407
16038	322	17-chetovis	398
17-hormoforin	398	190 f	319
22krl	401	292-comprimes	383
3 p maid	328	369, pulvules	383
3p bamte	367	3p bugesic	383
3p maid	389	3p methazol	403
3p pane	371	3p spas	387
4311 ciba	373	4-c-32	410
53-32-c	410	539 grippe-dragees	399
5-nitrok	379	8Omniflox	407
8Teflox	407	8Temac	407
90459 compound	327	99 armour formula	356

Annex I

Relevant resolutions of the General Assembly And the Economic and Social Council

General Assembly resolution 37/137

Protection against products harmful to health and the environment

The General Assembly,

Aware of the damage to health and the environment that the continued production and export of products that have been banned and/or permanently withdrawn on grounds of human health and safety from domestic markets is causing in the importing countries,

Aware that some products, although they present a certain usefulness in specific cases and/or under certain conditions, have been severely restricted in their consumption and/or sale owing to their toxic effects on health and the environment,

Aware of the harm to health being caused in importing countries by the export of pharmaceutical products ultimately intended also for consumption and/or sale in the home market of the exporting country, but which have not yet been approved there,

Considering that many developing countries lack the necessary information and expertise to keep up with developments in this field,

Considering the need for countries that have been exporting the above-mentioned products to make available the necessary information and assistance to enable the importing countries to protect themselves adequately,

Cognizant of the fact that almost all of these products are at present manufactured and exported from a limited number of countries,

Taking into account that the primary responsibility for consumer protection rests with each State,

Recalling its resolution 36/166 of 16 December 1981 and the report on transnational corporations in the pharmaceutical industry of developing countries,¹ and acting in pursuance of Economic and Social Council resolution 1981/62 of 23 July 1981,

Bearing in mind in this context the work of the Food and Agriculture Organization of the United Nations, the World Health Organization, the International Labour Organisation, the United Nations Environment Programme, the General Agreement on Tariffs and Trade, the United Nations Centre on

¹ E/C.10/85.

Transnational Corporations and other relevant intergovernmental organizations,

1. **Agrees** that products that have been banned from domestic consumption and/or sale because they have been judged to endanger health and the environment should be sold abroad by companies, corporations or individuals only when a request for such products is received from an importing country or when the consumption of such products is officially permitted in the importing country;
2. **Agrees** that all countries that have severely restricted or have not approved the domestic consumption and/or sale of specific products, in particular pharmaceuticals and pesticides, should make available full information on these products with a view to safeguarding the health and environment of the importing country, including clear labelling in a language acceptable to the importing country;
3. **Requests** the Secretary-General to continue to ensure the provision of the necessary information and assistance by the United Nations system in order to strengthen the national capacities of developing countries to protect themselves from the consumption and/or sale of banned, withdrawn, severely restricted or, in the case of pharmaceuticals, non-approved products;
4. **Requests** the Secretary-General, based upon the work already being done within the Food and Agriculture Organization of the United Nations, the World Health Organization, the International Labour Organisation, the United Nations Environment Programme, the General Agreement on Tariffs and Trade, the United Nations Centre on Transnational Corporations and other relevant intergovernmental organizations, to the maximum extent possible within existing resources, to prepare and regularly update a consolidated list of products whose consumption and/or sale have been banned, withdrawn, severely restricted or, in the case of pharmaceuticals, not approved by Governments, and to make this list available as early as possible and, in any case, not later than December 1983;
5. **Agrees** that the consolidated list referred to in paragraph 4 above should be easy to read and understand and should contain both generic/chemical and brand names in alphabetical order, as well as the names of all manufacturers and a short reference to the grounds and decisions taken by Governments that have led to the banning, withdrawal or severe restriction of such products;
6. **Decides**, on the basis of the above-agreed criteria, to keep under review the format of the consolidated list with a view to its possible improvements;
7. **Requests** Governments and the relevant organs, organizations and bodies of the United Nations system to provide all the information and assistance necessary for the prompt and effective fulfillment of the task entrusted to the Secretary-General.

109th plenary meeting
17 December 1982

General Assembly resolution 38/149

Protection against products harmful to health and the environment

The General Assembly,

Recalling its resolutions 36/166 of 16 December 1981 and 37/137 of 17 December 1982,

Bearing in mind the oral report presented by the Secretariat with regard to progress made in the implementation of resolution 37/137²

1. **Takes note** of the report of the Secretary-General on the exchange of information on banned hazardous chemicals and unsafe pharmaceutical products,³ and of the work being carried out by the United Nations system of organizations;

2. **Notes** with satisfaction that the work carried out in consultation with organizations of the United Nations system on the consolidated list of products whose consumption and/or sale have been banned, withdrawn, severely restricted or, in the case of pharmaceuticals, not approved by Governments, is in the process of being completed;

3. **Requests** the Secretary-General to make available the consolidated list, as established on the basis of information supplied up to now in accordance with the objectives of General Assembly resolution 37/137, and to bring it up-to-date on a regular basis;

4. **Urges** the relevant organs, organizations and bodies of the United Nations system, particularly the Food and Agriculture Organization of the United Nations, the World Health Organization, the International Labour Organisation, the United Nations Environment Programme, the General Agreement on Tariffs and Trade and the United Nations Centre on Transnational Corporations and other intergovernmental organizations, to continue to co-operate fully in providing information for the consolidated list and for its updated versions;

5. **Appreciates** the co-operation extended by Governments and urges all Governments, in particular those that have not yet done so, to provide the necessary information for inclusion in the consolidated list and its updated versions, as well as comments and views that they deem relevant;

6. **Urges** non-governmental organizations to extend co-operation to the Secretary-General regarding the preparation of the consolidated list, particularly in the identification of potential sources of information among national Governments and in obtaining governmental information on relevant regulatory actions;

7. **Requests** the Secretary-General, for purposes of review by the General Assembly at its thirty-ninth session, to submit a report on the implementation of Assembly resolution 37/137, including the consolidated list, taking into account the latest information and comments collected for possible improvement of the list, as envisaged in paragraph 6 of resolution 37/137;

² Official Records of the General Assembly, Thirty-eighth Session, Second Committee, 27th meeting, paras. 1-7.

³ A/38/190-E/1983/67.

8. Requests the Secretary-General to submit to the General Assembly at its thirty-ninth session, through the Economic and Social Council, a report on the exchange of information on banned hazardous chemicals and unsafe pharmaceutical products identifying elements for possible further work in this area in regard to the needs and capabilities of developing countries to monitor and control those substances in the light of the relevant observations in the report of the Secretary-General;

9. Requests the Secretary-General and the organs, organizations and other competent bodies of the United Nations system to continue to provide, within available resources, the necessary technical assistance to the developing countries, at their request, for the establishment or strengthening of national systems for better use by those countries of the information provided with regard to banned hazardous chemicals and unsafe products, as well as for an adequate monitoring of the importation of those products.

102nd plenary meeting
19 December 1983

General Assembly resolution 39/229

Protection against products harmful to health and the environment

The General Assembly,

Reaffirming its resolutions 37/137 of 17 December 1982 and 38/149 of 19 December 1983,

Taking note with satisfaction of the report of the Secretary-General on products harmful to health and the environment,⁴

Bearing in mind the report of the Secretary-General on the exchange of information on banned hazardous chemicals and unsafe pharmaceutical products,⁵ and welcoming the effort being made in various international forums with regard to the exchange of information on such products,

1. Expresses its appreciation to the Secretary-General and commends him for the distribution of the first issue of the consolidated list of products whose consumption and/or sale have been banned, withdrawn, severely restricted or, in the case of pharmaceuticals, not approved by Governments;

2. Reiterates its appreciation for the co-operation extended by Governments in the preparation of the consolidated list, and urges all Governments that have not yet done so to provide the necessary information for inclusion in the updated versions of the list;

3. Notes with satisfaction the co-operation provided by the appropriate organs, organizations and bodies of the United Nations system and other intergovernmental organizations in the issuance of the list and urges them, particularly the Food and Agriculture Organization of the United Nations, the World Health Organization, the International Labour Organization, the United Nations Environment Programme, the General Agreement on Tariffs and Trade and

⁴ A/39/452.

⁵ A/39/290-E/1984/120.

the United Nations Centre on Transnational Corporations, to continue to co-operate fully in the preparation of the updated versions of the list;

4. Expresses its appreciation for the co-operation provided by non-governmental organizations in this regard, and urges them to continue to extend co-operation to the Secretary-General in the preparation of the consolidated list, particularly in the identification of potential sources of information among national Governments and in obtaining governmental information on relevant regulatory actions;

5. Decides that:

(a) An updated consolidated list should be issued annually and that the data should be made available to Governments and other users in such a form as to permit direct computer access to it;

(b) In order to keep costs to a minimum, the consolidated list should be published and made available in all the official languages of the United Nations in sets of alternating languages each year, with no more than three languages per year and with the same frequency for each language;

(c) The format of the consolidated list should be kept under continuing review with a view to its improvement, in accordance with General Assembly resolution 37/137, in co-operation with the relevant organs, organizations and bodies of the United Nations system, taking into account the complementary nature of the list, the experiences obtained and the views expressed by Governments on this matter, and that the next review should be submitted by the Secretary-General to the General Assembly at its forty-first session;

(d) The review of the consolidated list should cover particularly the advantages and disadvantages of introducing to the list such information as the legal, public health and commercial context of the regulatory actions, as well as complementary information on safe uses of the products;

6. Urges importing countries, bearing in mind the extensive legal, public health and safety information already provided to the United Nations Centre on Transnational Corporations, the United Nations Environment Programme, the International Labour Organisation, the Food and Agriculture Organization of the United Nations, the World Health Organization and the General Agreement on Tariffs and Trade, to avail themselves of the information provision facilities of those organizations, which include, in some cases, direct computer access;

7. Requests the Secretary-General, with the assistance of the appropriate specialized agencies, to submit to the General Assembly at its forty-first session a report on a review of the various information exchange schemes now in operation within the United Nations system;

8. Requests the Secretary-General and the competent organs, organizations and bodies of the United Nations system to continue to provide the necessary technical assistance to the developing countries, at their request, for the establishment or strengthening of national systems for managing hazardous chemicals and pharmaceutical products, as well as for an adequate monitoring of the importation, manufacture and use of those products;

9. Also requests the Secretary-General, through the Economic and Social Council, to inform the General Assembly at its forty-first session and every three years thereafter about the implementation of resolutions 37/137 and 38/149 and of the present resolution;

10. **Further requests** the Secretary-General to take the necessary measures for the implementation of the present resolution.

104th plenary meeting
18 December 1984

General Assembly resolution 44/226

Traffic in and disposal, control and transboundary movements of Toxic and dangerous products and wastes

The General Assembly,

Recalling its resolutions 37/137 of 17 December 1982, 38/149 of 19 December 1983 and 39/229 of 18 December 1984, as well as its decision 41/450 of 8 December 1986,

Recalling also its resolution 42/183 of 11 December 1987 on traffic in toxic and dangerous products and wastes,

Recalling further its resolution 43/212 of 20 December 1988, entitled "Responsibility of States for the protection of the environment: prevention of the illegal international traffic in, and the dumping and resulting accumulation of, toxic and dangerous products and wastes affecting the developing countries in particular",

Recalling Economic and Social Council resolutions 1988/70 and 1988/71 of 28 July 1988 and taking note of Council resolution 1989/104 of 27 July 1989,

Taking note of the report of the Secretary-General on products harmful to health and the environment⁶ and Economic and Social Council decision 1989/177 of 27 July 1989,

Taking note also of decisions 15/28 and 15/30 of 25 May 1989 of the Governing Council of the United Nations Environment Programme,⁷

Welcoming the report of the Secretary-General on illegal traffic in toxic and dangerous products and wastes,⁸

Taking note of the conclusion of the Basel Convention on the Control of Transboundary Movements of Hazardous Wastes and their Disposal,⁹

Inviting all States to consider signing the Basel Convention without prejudice to the final positions to be taken by regional intergovernmental organizations in this regard,

⁶ A/44/276-E/1989/78.

⁷ See Official Records of the General Assembly, Forty-fourth Session, Supplement No. 25 (A/44/25), annex I.

⁸ A/44/362 and Corr.1.

⁹ See UNEP/IG.80/3.

Mindful of the growing threat to the environment and to human health and safety posed by the improper management and the increased generation, complexity and transboundary movement of hazardous wastes,

Convinced that illegal traffic in toxic and dangerous products and wastes poses a severe threat to the environment and to human health and safety,

Also convinced that these problems cannot be resolved without adequate co-operation among members of the international community,

Deeply concerned by the fact that cases of illegal transboundary movement and dumping of dangerous products and wastes particularly harmful for the environment and human health continue to occur, affecting, in particular, developing countries,

Convinced of the need to assist all countries, particularly developing countries, in obtaining all appropriate information concerning toxic and dangerous products and wastes and in reinforcing their capacity to detect and halt any illegal attempt to introduce toxic and dangerous products and wastes into the territory of any State in contravention of national legislation and relevant international legal instruments, as well as traffic not carried out in compliance with internationally accepted guidelines and principles in this field,

I

TRAFFIC IN TOXIC AND DANGEROUS PRODUCTS AND WASTES

1. Requests each regional commission, within existing resources, to contribute to the prevention of the illegal traffic in toxic and dangerous products and wastes by monitoring and making regional assessments of this illegal traffic and its environmental and health implications, on a continuing basis, in each region, and, in this context, in co-operation with and relying upon expert support and advice from the United Nations Environment Programme and other relevant bodies of the United Nations, including the International Register of Potentially Toxic Chemicals, and Ad Hoc Working Group of Experts on Prior Informed Consent and Other Modalities to Supplement the London Guidelines for the Exchange of Information on Chemicals in International Trade, and the Interim Secretariat of the Basel Convention on the Control of Transboundary Movements of Hazardous Wastes and their Disposal, without prejudice to the final position to be taken by regional intergovernmental organizations on the Convention, and to report to the Economic and Social Council at its second regular session starting in 1990;

2. Also requests the regional commissions to interact among themselves and co-operate with the United Nations Environment Programme, with a view to maintaining efficient and co-ordinated monitoring and assessment of the illegal traffic in toxic and dangerous products and wastes;

3. Requests the Economic and Social Council to submit recommendations to the General Assembly on the findings and conclusions of the regional commissions, in their consideration of environmental issues;

4. Calls upon all countries to co-operate with their respective regional commissions with the aim of preventing the illegal traffic in toxic and dangerous products and wastes;

PROTECTION AGAINST PRODUCTS HARMFUL TO HEALTH AND THE ENVIRONMENT

1. **Expresses** its appreciation to the Secretary-General for his report on products harmful to health and the environment, which contains a review of the Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or Not Approved by Governments;
2. **Notes** with appreciation the co-operative relationship established between the United Nations, the World Health Organization and the United Nations Environment Programme International Register of Potentially Toxic Chemicals for the preparation of the Consolidated List;
3. **Notes**, in this context, the need to utilize also the work being done by the Working Group on Export of Domestically Prohibited Goods and Other Hazardous Substances established by the General Agreement on Tariffs and Trade and those activities which are currently under way within the framework of the United Nations Environment Programme and the Food and Agriculture Organization of the United Nations in connection with implementation of prior informed consent schemes for chemicals and pesticides in international trade and which implement the system of information exchange envisaged by the developers of the Consolidated List, as well as the work being done under international agreements and conventions in related areas;
4. **Expresses** its appreciation for the growing co-operation by Governments in the preparation of the Consolidated List, and urges all Governments that have not yet done so to provide the necessary information for inclusion in updated versions of the Consolidated List;
5. **Requests** the Secretary-General to ensure, within existing resources, publication of the Consolidated List in English, French and Spanish, in accordance with demand, bearing in mind its resolution 39/229;
6. **Also requests** the Secretary-General to undertake a special effort to ensure effective and wider dissemination of the Consolidated List in all appropriate circles;
7. **Further requests** the Secretary-General, in this context, to consider ways and means of ensuring more effective involvement of non-governmental organizations in promoting the dissemination and utilization of the Consolidated List;
8. **Requests** the Secretary-General, in the context of the preparation of his next scheduled report on the question:
 - (a) To make specific suggestions on ways and means of providing technical co-operation, including through appropriate United Nations organizations, to countries, in particular developing countries, to create and strengthen their capacity to utilize the Consolidated List;
 - (b) To study all the pending issues, such as sustainable alternatives to banned and severely restricted products and unregistered pesticides, with a focus on improving the usefulness of the Consolidated List;

III

CONTROL OF TRANSBOUNDARY MOVEMENTS OF HAZARDOUS WASTES AND THEIR DISPOSAL

1. Recognizes the necessity of developing rules of international law, as early as practicable, on liability and compensation for damage resulting from the transboundary movement and disposal of hazardous wastes;

2. Requests the Executive Director of the United Nations Environment Programme, in accordance with the resolutions adopted at the Conference of Plenipotentiaries on the Global Convention on the Control of Transboundary Movements of Hazardous Wastes, held at Basel, Switzerland, from 20 to 22 March 1989, to establish, on the basis of equitable geographical representation and in consultation with Governments, an ad hoc working group of legal and technical experts to develop, as early as practicable, elements that might be included in a protocol on liability and compensation for damage resulting from the transboundary movement and disposal of hazardous wastes and to report to the preparatory committee of the United Nations conference on environment and development and to the Governing Council of the United Nations Environment Programme, in accordance with its mandate in this regard;

3. Invites the Executive Director of the United Nations Environment Programme and the Secretary-General of the International Maritime Organization, in consultation, as appropriate, with other relevant international organizations, to review the existing rules, regulations and practices with respect to the disposal of hazardous wastes at sea, in order to harmonize the provisions of the relevant conventions as adopted in this regard;

4. Requests the Secretary-General, in co-operation with the Executive Director of the United Nations Environment Programme, to report to the General Assembly at its forty-sixth session, through the Economic and Social Council, on the progress achieved in the implementation of the provisions of the Basel Convention on the Control of Transboundary Movements of Hazardous Wastes and their Disposal and of the present resolution.

85th plenary meeting
22 December 1989

Economic and Social Council resolution 1998/41

Protection against products harmful to health and the environment

The Economic and Social Council,

Recalling General Assembly resolutions 37/137 of 17 December 1982, 38/149 of 19 December 1983, 39/229 of 18 December 1984 and 44/226 of 22 December 1989, as well as Assembly decisions 47/439 of 22 December 1992 and 50/431 of 20 December 1995,

Taking note of the report of the Secretary-General on products harmful to health and the environment,¹⁰ which contains a review of the Consolidated List of Products Whose Consumption and/or Sale have been Banned, Withdrawn, Severely Restricted or not Approved by Governments,

Noting with satisfaction the continued close collaboration between the United Nations, the Food and Agriculture Organization of the United Nations, the World Health Organization and the United Nations Environment Programme in the preparation of the Consolidated List,

Taking note of the successful conclusion of the negotiations to develop a legally binding instrument for the application of the prior informed consent procedure for certain hazardous chemicals and pesticides in international trade (Rotterdam Convention),

1. Welcomes the report of the Secretary-General on products harmful to health and the environment and notes the progress being achieved in increasing the number of countries that participate in the preparation of the Consolidated List of Products Whose Consumption and/or Sale have been Banned, Withdrawn, Severely Restricted or not Approved by Governments;

2. Expresses its appreciation for the cooperation extended by Governments in the preparation of the Consolidated List and urges all Governments, in particular those that have not yet done so, to provide the necessary information to relevant organizations for inclusion in future issues of the Consolidated List;

3. Requests the Secretary-General to continue to prepare the Consolidated List focusing on chemicals and pharmaceutical products in alternate years, with the same frequency for each official language in publishing the Consolidated List as was envisioned in General Assembly resolutions 39/229 and 44/226;

4. Also requests the Secretary-General to continue to provide the necessary technical assistance to developing countries, at their request, for the establishment and/or strengthening of national capacity for managing hazardous chemicals and pharmaceutical products;

5. Urges the adoption of the agreed text of the Rotterdam Convention at the diplomatic conference to be held in Rotterdam, the Netherlands, on 10 and 11 September 1998 and calls for a speedy ratification by the signatories of the Convention, aimed at its early entry into force;

6. Emphasizes the need to continue to utilize the work being undertaken by relevant organizations of the United Nations system and other

¹⁰ A/53/156-E/1998/78.

intergovernmental organizations in this area, as well as that being carried out under international agreements and conventions in related areas in updating the Consolidated List;

7. Requests the Secretary-General to continue to report every three years, in accordance with General Assembly resolution 39/229, on the implementation of the present resolution and of previous Assembly resolutions on the same subject.

46th plenary meeting
30 July 1998

Economic and Social Council resolution 2001/33

Protection against products harmful to health and the environment

The Economic and Social Council,

Recalling General Assembly resolutions 37/137 of 17 December 1982, 38/149 of 19 December 1983, 39/229 of 18 December 1984 and 44/226 of 22 December 1989, General Assembly decisions 47/439 of 22 December 1992 and 50/431 of 20 December 1995, and Council resolution 1998/41 of 30 July 1998,

Having considered the report of the Secretary-General on products harmful to health and the environment,¹¹ which contains a review of the Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or Not Approved by Governments,¹²

Taking note of the fact that an increasing number of countries participate in the preparation of the Consolidated List,

Noting with satisfaction the continued close collaboration between the United Nations, the Food and Agriculture Organization of the United Nations, the World Health Organization, the United Nations Environment Programme and the World Trade Organization in the preparation and dissemination of the Consolidated List,

1. Expresses its appreciation for the cooperation extended by Governments in the preparation of the Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or Not Approved by Governments,¹³ and urges all Governments, in particular those that have not yet done so, to provide the necessary information to relevant organizations for inclusion in future issues of the Consolidated List;

2. Requests the Secretary-General to prepare each of the two issuances of the Consolidated List, pharmaceuticals and chemicals, in all official languages – the English version in the already established format, and the versions in

¹¹ A/56/115-E/2001/92.

¹² For previous issues of the Consolidated List, see United Nations publications, Sales Nos. E.84.IV.8, E.87.IV.a, E.91.IV.4, E.94.IV.3 and E.97.IV.2.

¹³ UNEP/FAO/PIC/CONF/5, annex III.

the other languages as a text file. In this connection, the Consolidated List should continue to include previously collected data, while at the same time making distinct entries for

those products covered in the interim prior informed consent procedure, in line with the Rotterdam Convention on the Prior Informed Consent Procedure for Certain Hazardous Chemicals and Pesticides in International Trade, and should consequently keep updating the information contained therein, in accordance with relevant action being taken by the Convention;

3. Invites multilateral and bilateral agencies to continue to strengthen and coordinate their activities for improving the capacity-building of developing countries, particularly least developed countries, including innovative methodologies for earmarking, assessing and monitoring technical assistance in the area of the sound management of hazardous chemicals and dangerous pharmaceutical products;

4. Emphasizes the need to continue to utilize the work being undertaken by relevant organizations of the United Nations system and other intergovernmental organizations in this area, as well as that being carried out under international agreements and conventions in related areas in updating the Consolidated List;

5. Requests the Secretary-General to continue to report every three years, in accordance with General Assembly resolution 39/229, on the implementation of the present resolution and of previous Assembly resolutions on the same subject;

6. Requests the Secretary-General, within existing resources, to continue to disseminate the list as widely as possible and to look at the possibility of using online dissemination in collaboration with the World Trade Organization, the Food and Agriculture Organization of the United Nations, the World Health Organization and the United Nations Environment Programme.

43rd plenary meeting
26 July 2001

Economic and Social Council resolution 2004/55

Protection against products harmful to health and the environment

The Economic and Social Council,

Recalling General Assembly resolutions 37/137 of 17 December 1982, 38/149 of 19 December 1983, 39/229 of 18 December 1984 and 44/226 of 22 December 1989, Assembly decisions 47/439 of 22 December 1992 and 50/431 of 20 December 1995, and Economic and Social Council resolutions 1998/41 of 30 July 1998 and 2001/33 of 26 July 2001,

Having considered the report of the Secretary-General on products harmful to health and the environment,¹⁴ which contains a review¹⁵ of the Consolidated

¹⁴ A/59/81-E/2004/63.

¹⁵ Ibid., sect. II.

List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or Not Approved by Governments,¹⁶

Taking note of the fact that an increasing number of countries participate in the preparation of the Consolidated List,

Noting with satisfaction the continued close collaboration among the United Nations, the Food and Agriculture Organization of the United Nations, the World Health Organization and the United Nations Environment Programme in the preparation and dissemination of the Consolidated List,

Taking note of commitments made and targets established regarding environmentally sound management of chemicals in the Plan of Implementation of the World Summit on Sustainable Development ("Johannesburg Plan of Implementation"),¹⁷ adopted by the Summit on 4 September 2002,

Noting the coming into force, in early 2004, of the Rotterdam Convention on the Prior Informed Consent Procedure for Certain Hazardous Chemicals and Pesticides in International Trade¹⁸ and the Stockholm Convention on Persistent Organic Pollutants,¹⁹

1. **Takes note** of the report of the Secretary-General on products harmful to health and the environment and notes the online availability²⁰ of the Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or Not Approved by Governments;

2. **Expresses its appreciation** for the cooperation extended by Governments in the preparation of the Consolidated List, and urges all Governments, in particular those that have not yet done so, to provide the necessary information to relevant organizations for inclusion in future issues of the Consolidated List;

3. **Requests** the Secretary-General to continue to update the electronic version of the Consolidated List, alternating between chemicals and pharmaceuticals every year, while printing only new data to complement previously printed issues for the benefit of those, particularly in developing countries, who may not have easy access to the electronic version;

4. **Urges** all Governments to participate fully in the process of developing a strategic approach to international chemicals management by 2005, in order to achieve the 2020 target of the World Summit on Sustainable Development, as set out in paragraph 23 of the Plan of Implementation of the World Summit on Sustainable Development ("Johannesburg Plan of Implementation"), pursuant to which chemicals would be used and produced in ways that lead to the minimization of significant adverse effects on human health and the environment, using transparent science-based risk assessment procedures and science-based risk management procedures, taking into account the precautionary approach, as set out in principle 15 of the Rio Declaration on

¹⁶ United Nations publications, Sales Nos. E.03.IV.9 and E.04.IV.2. For previous issues of the Consolidated List, see United Nations publications, Sales Nos. E.84.IV.8, E.87.IV.1, E.91.IV.4, E.94.IV.3, E.97.IV.2, E.02.IV.3 and E.03.IV.3.

¹⁷ Report of the World Summit on Sustainable Development, Johannesburg, South Africa, 26 August - 4 September 2002 (United Nations publication, Sales No. E.03.II.A.1 and corrigendum), chap. I, resolution 1, annex. 5 Text available from <http://www.pic.int/en/ViewPage.asp?id=104> (accessed 22 July 2004).

¹⁸ Text available from <http://www.pic.int/en/ViewPage.asp?id=104> (accessed 22 July 2004).

¹⁹ Text available from <http://www.pops.int/>. (accessed 22 July 2004).

²⁰ Available from www.un.org/esa/coordination/ecosoc/Path:Publications (accessed 22 July 2004).

Environment and Development,²¹ and support developing countries in strengthening their capacity for the sound management of chemicals and hazardous wastes by providing technical and financial assistance, and calls for a more coordinated use of existing international instruments in this field, taking into account the work undertaken by the United Nations system in this regard;

5. **Encourages** countries to implement the new Globally Harmonized System of Classification and Labeling of Chemicals²² as agreed in paragraph 23 (c) of the Johannesburg Plan of Implementation as soon as possible, with a view to having the system fully operational by 2008;

6. **Urges** all Governments that have not yet done so to consider ratifying the Rotterdam Convention on the Prior Informed Consent Procedure for Certain Hazardous Chemicals and Pesticides in International Trade and the Stockholm Convention on Persistent Organic Pollutants and to fully implement them;

7. **Invites** multilateral and bilateral agencies to continue to strengthen and coordinate their activities for improving the capacity-building of developing countries, particularly least developed countries, as well as countries with economies in transition, inter alia, through technical assistance in the area of the sound management of hazardous chemicals and dangerous pharmaceutical products;

8. **Emphasizes** the need to continue to utilize the work being undertaken by relevant organizations of the United Nations system and other intergovernmental organizations in this area, as well as that being carried out under international agreements and conventions in related areas, in updating the Consolidated List;

9. **Requests** the Secretary-General to continue to report every three years, in accordance with General Assembly resolution 39/229 of 18 December 1984, on the implementation of the present resolution, taking into account previous Assembly resolutions on the same subject, as appropriate.

*50th plenary meeting
23 July 2004*

²¹ Report of the United Nations Conference on Environment and Development, Rio de Janeiro, 3-14 June 1992, vol. I, Resolutions Adopted by the Conference (United Nations publication, Sales No. E.93.I.8 and corrigendum), resolution 1, annex I.

²² United Nations publication, Sales No. E.03.II.E.25.

Annex II

Criteria for the inclusion of pharmaceutical and chemical products in the Consolidated List

A. Pharmaceutical products^a

a) "Banned product"

A product that has been withdrawn from use and/or sale nationally in one or more countries by order of the competent national authority, having regard to its safety in relation to its intended use.

b) "Voluntary product"

A product that has been withdrawn from use and/or sale nationally in one or more countries by voluntary action of the manufacturer, having regard to its safety in relation to its intended use.

c) "Severely restricted"

A product containing:

(a) A substance that is controlled more rigorously than is provided for under the 1961 Single Convention on Narcotic Drugs or the 1971 Convention on Psychotropic Substances or that is subjected to analogous control at the national level before it has been considered for international scheduling,

(b) A substance that may be incorporated in pharmaceutical dosage forms only within the specific limits determined by statute;

(c) A substance that is approved by a competent national authority and is subsequently subjected to restrictions that exclude its use in a substantial proportion of the potential target population of patients having regard to its safety. A substance which from the outset has been severely restricted in its indications having regard to the known balance of safety and efficacy is excluded.

d) "Non-approved"

A product that has been formally submitted for registration by a manufacturer to a national competent authority and which has been rejected on grounds of safety.

B. Chemical products

a) "Banned"

A product that has been prohibited for all uses nationally in one or more countries by final government regulatory action because of health or environmental reasons.

b) "Withdrawn"

A product formerly in commerce that has been withdrawn for all uses nationally in one or more countries by final voluntary action of the manufacturer because of health or environmental reasons.

c) "Severely restricted"

A product for which virtually all uses have been prohibited nationally in one or more countries by final government regulatory action because of health or environmental reasons, but for which certain specific uses remain authorized.

^a Products, which are in illicit trade only, would not be considered.

Annex III

List of references cited in the regulatory text

AARNO	MINISTRY OF HEALTH LAGOS, NIGERIA
ARGANM	ADMINISTRACIÓN NACIONAL DE MEDICAMENTOS Y TECNOLOGIA MEDICA MINISTERIO DE SALUD BUENOS AIRES, ARGENTINA
ARGBO	ADMINISTRACIÓN NACIONAL DE MEDICAMENTOS Y TECNOLOGIA MEDICA TECNOLOGIA MEDICA, MINISTERIO DE SALUD BUENOS AIRES, ARGENTINA
ARGFDM	FOOD, DRUG AND MEDICAL DEVICES AGENCY (ANMAT) MINISTRY OF HEALTH BUENOS AIRES, ARGENTINA www.anmat.gov.ar
ARMCW	ARMENIAM DRUG AND MEDICAL TECHNOLOGY AGENCY MINISTRY OF HEALTH YEREVAN, ARMENIA
ASTRA	ASTRA-ZENECA 15 STANHOPE GATE LONDON W1K 1LN UNITED KINGDOM
AUDEC	REPORT OF THE AUSTRALIAN DRUG EVALUATION COMMITTEE COMMONWEALTH DEPARTMENT OF HEALTH WODEN, P. O. BOX 200, ACT, 2606 AUSTRALIA
AUSADR	ADVERSE DRUG REACTIONS UNIT THERAPEUTIC GOODS ADMINISTRATION, DEPARTMENT OF COMMUNITY SERVICES AND HEALTH WODEN, AUSTRALIA
AUSMDR	THERAPEUTIC GOODS ADMINISTRATION, DEPARTMENT OF COMMUNITY SERVICES AND HEALTH WODEN, AUSTRALIA www.health.gov.au
AUSPRE	AUSTRALIAN PRESCRIBER DEAKIN ACT 2600 AUSTRALIA www.australianprescriber.com
AUSTGA	THERAPEUTIC GOODS ADMINISTRATION, DEPARTMENT OF COMMUNITY SERVICES AND HEALTH WODEN, AUSTRALIA
AUTMH	MINISTRY OF HEALTH

List of references cited in the regulatory text

VIENNA, AUSTRIA

AUTGB	BUNDESGESETZBLATT FUR DIE REPUBLIK OESTERREICH DIRECTORATE GENERAL OF PUBLIC HEALTH FEDERAL CHANCERY DEPT VI (PUBLIC HEALTH) 2, RADETKYSTRASSE VIENNA, 1031 AUSTRIA
BDSMHS	MEDICAL AND HEALTH SERVICES HEADQUARTERS MINISTRY OF HEALTH BRUNEI DARUSSALAM
BDSOL	MINISTRY OF HEALTH BRUNEI DARUSSALAM
BELAP	ANNALES PHARMACEUTIQUES BELGES BRUXELLES, BELGIQUE
BELAR	ARRETE ROYAL INSPECTION GENERALE DE LA PHARMACIE, MINISTERE DE LA SANTE ET DE LA FAMILLE CITE ADMINISTRATIVE DE L'ETAT QUARTIER VERSALE 1010 BRUXELLES, BELGIUM
BELARD	BELGIAN CENTRE FOR MONITORING OF ADVERSE REACTION TO DRUGS BRUSSELS, BELGIUM
BELGPI	GENERAL PHARMACEUTICAL INSPECTOR ATE MINISTRY OF PUBLIC HEALTH AND ENVIRONMENT BRUSSELS, BELGIUM
BELMD	MINISTERIAL DECREE MINISTERE DE LA SANTE PUBLIQUE ET DE L'ENVIRONNEMENT BRUSSELS, BELGIUM
BFOLP	"FOLIA PHARMACOTHERAPEUTICA" CENTRE BELGE D'INFORMATION PHARMACOTHERAPEUTIQUE MINISTERE DE LA SANTE PUBLIQUE ET DE LA FAMILLE ADMINISTRATION DE L'HYGIENE 1010 BRUXELLES, BELGIUM
BGDCO	"THE DRUGS (CONTROL) ORDINANCE 1982, ORDINANCE NO. VIII" OFFICE OF THE DIRECTOR HEALTH MANPOWER DEVELOPMENT 105/106 MOTIJHEEL COMMERCIAL AREA DACCA 2, BANGLADESH
BGDDDA	DIRECTORATE OF DRUG ADMINISTRATION MINISTRY OF HEALTH AND FAMILY WELFARE DACCA, BANGLADESH

List of references cited in the regulatory text

BGHBL	BUNDESGESUNDHEITSBLATT BONN, GERMANY
BGNDI	MINISTRY OF HEALTH DACCA, BANGLADESH
BGRBDA	BULGARIAN DRUG AGENCY MINISTRY OF HEALTH SOFIA, BULGARIA
BHRCW	PHARMACY AND DRUG CONTROL DEPARTMENT MINISTRY OF HEALTH P. O. BOX 12 BAHRAIN
BIFTI	BOLLETTINO D'INFORMAZIONE SUI FARMACI GENERAL DIRECTOR PHARMACEUTICAL DIVISION VIALE DELLA CIVILTA ROMANA 7 00144 ROMA, ITALY
BMCHL	DEPARTAMENTO CONTROL NACIONAL INSTITUTO SALUD PUBLICA DE CHILE MINISTERIO DE SALUD MARATHON 100, SANTIAGO CHILE
BMJOAE	BRITISH MEDICAL JOURNAL BRITISH MEDICAL ASSOCIATION TAVISTOCK SQUARE LONDON WC1H 9JR, ENGLAND
BNIPH	BULLETIN OF THE NATIONAL INSTITUTE OF PHARMACY 1984 NATIONAL INSTITUTE OF PHARMACY ZRINYI U.3 H-1051, BUDAPEST, HUNGARY
BRACVS	CENTRO DE VIGILANCIA SANITARIA MINISTRY OF HEALTH RIO DE JANEIRO, 21 040 BRAZIL
BRADMS	DIARIO OFICIAL MINISTERIO DA SAUDE RIO DE JANEIRO 21 040 BRAZIL
BRAPT	PORTARIA DO SERVICO PUBLICO FEDERAL MINISTRY OF HEALTH RIO DE JANEIRO, 21 040 BRAZIL
BRARES	NATIONAL HEALTH SURVEILLANCE AGENCY MINISTRY OF HEALTH BRASILIA, BRAZIL

List of references cited in the regulatory text

BRASVS	MINISTERIO DA SAUDE RIO DE JANEIRO 21 040 BRAZIL
CANBMS	BRISTOL-MYERS SQUIBB CANADA www.hc-sc.gc.ca
CANDHP	BAYER PHARMACEUTICAL DIVISION www.hc-sc.gc.ca/
CANGZ	CANADA GAZETTE CANADIAN GOVERNMENT PUBLISHING CENTER OTTAWA, ONTARIO K1A OS9 CANADA
CANHW	CANADA HEALTH AND WELFARE OTTAWA, ONTARIO CANADA
CANPR	HEALTH CANADA OTTAWA, ONTARIO K1A 0K9 CANADA
CANWHC	HEALTH CANADA OTTAWA, ONTARIO K1A 0K9 CANADA www.hc-sc.gc.ca
CECC	COMMISSION OF THE EUROPEAN COMMUNITIES 200, RUE DE LA LOI BE - 1049 BRUXELLES, BELGIUM
CFRUS	CODE OF FEDERAL REGULATIONS OFFICE OF THE FEDERAL REGISTER NATIONAL ARCHIVES AND RECORDS SERVICE US GOVERNMENT PRINTING OFFICE GENERAL SERVICES ADMINISTRATION WASHINGTON, DC 20402, USA
CGPR	PRESS RELEASE FROM CIBA-GEIGY
CHBCM	BULLETIN MENSUEL ORGANISATION INTERCANTONALE DE CONTROLE DES MEDICAMENTS BERNE, SWITZERLAND
CHEAZ	SCHWEIZER APOTHEKER ZEITUNG SWITZERLAND
CHEOCM	INTERCANTONAL OFFICE FOR THE CONTROL OF MEDICINES BERNE, SWITZERLAND

List of references cited in the regulatory text

CHEPR	SWISS AGENCY FOR THERAPEUTIC PRODUCTS FEDERAL DEPARTMENT OF HOME AFFAIRS BERNE, SWITZERLAND www.swissmedic.ch
CHLCW	PUBLIC HEALTH INSTITUTE OF CHILE MINISTRY OF HEALTH SANTIAGO, CHILE
CHLMS	MINISTERIO DE SALUD SANTIAGO, CHILE
CHLRS	INSTITUTE OF PUBLIC HEALTH AVDA MARATHON 1000 SANTIAGO, CASILLA 48 CHILE
COECI	COUNCIL OF EUROPE STRASBOURG FRANCE
COLVMA	INSTITUTO NACIONAL DE VIGILANCIA DE MEDICAMENTOS Y ALIMENTOS MINISTERIO DE SALUD BOGOTA, COLOMBIA
CPMPAR	COMMITTEE ON PROPRIETARY MEDICINAL PRODUCTS EUROPEAN COMMISSION BRUSSELS
CPMPDP	COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS COMMISSION OF THE EUROPEAN COMMUNITIES LUXEMBOURG
CPMPPO	COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS COMMISSION OF THE EUROPEAN COMMUNITIES LUXEMBOURG
CPMPPP	COMMITTEE ON PROPRIETARY MEDICINAL PRODUCTS EUROPEAN COMMISSION BRUSSELS
CPMPPS	COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS COMMISSION OF THE EUROPEAN COMMUNITIES LUXEMBOURG
CRDDL	COMMUNICATION FROM ROUSSEL ENCLOSING "DEAR DOCTOR LETTER" UNITED KINGDOM
CRU	COMMUNICATION TO WHO ROUSEL UCLOF PARIS, FRANCE
CUBCDQ	CENTRE FOR STATE CONTROL OF DRUG QUALITY (CECMED)

List of references cited in the regulatory text

	MINISTRY OF HEALTH HAVANA, CUBA
CYPPS	MINISTRY OF HEALTH NICOSIA, CYPRUS
DAZ	DEUTSCHE APOTHEKER ZEITUNG GERMANY
DCCKB	DRUG COMPANY COMMUNICATION KABI PHARMACIA
DCCSKB	DRUG COMPANY COMMUNICATION SMITH KLINE BEECHAM BRENTFORD, UNITED KINGDOM
DCCUJC	NEWS RELEASE THE UPJOHN COMPANY KALAMAZO, MI 49001 UNITED STATES
DENBH	DANISH NATIONAL BOARD OF HEALTH COPENHAGEN, DENMARK
DEUAB	DEUTSCHES AERTZTEBLATT GERMANY
DEUCDC	DRUG COMMISSION OF THE GERMAN MEDICAL PROFESSION BERLIN, GERMANY
DEUCFI	FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES BERLIN, GERMANY
DEUCW	FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES BERLIN, GERMANY
DEUFHO	FEDERAL HEALTH OFFICE BERLIN, GERMANY
DEUNFI	FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES BERLIN, GERMANY
DEUPD	BGA PRESSEDIENST BUNDESGESUNDHEITSAMT (FEDERAL HEALTH OFFICE) BERLIN (WEST) 65, POSTFACH 33 00 13, D-1000 GERMANY
DEUPM	BERLIN, GERMANY
DEUPZ	PHARMAZEUTISCHE ZEITUNG BERLIN, GERMANY

List of references cited in the regulatory text

DEURFI	FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES BERLIN, GERMANY
DWM	DEUTSCHES WICHTIGE MITTEILUNGEN BERLIN, GERMANY
EGYDC	EGYPTION TECHNICAL COMMITTEE FOR DRUG CONTROL MINISTRY OF HEALTH CAIRO, EGYPT
EGYDI	EGYPTION PHARMACOPOEIAL INFORMATION CENTRE MINISTRY OF HEALTH CAIRO, EGYPT
EMEAPR	EUROPEAN AGENCY FOR THE EVALUATION OF MEDICINES LONDON, UNITED KINGDOM
EMEAPS	EUROPEAN AGENCY FOR THE EVALUATION OF MEDICINES LONDON, UNITED KINGDOM www.emea.eu.int
ESPAES	AGENCIA ESPAÑOLA DE MEDICAMENTO MINISTERIO DE SANIDAD Y CONSUMO MADRID, SPAIN
ESPCDR	EUROPEAN AGENCY FOR THE EVALUATION OF MEDICINAL PRODUCTS LONDON, UNITED KINGDOM www.msc.es/agemed
ESPCR	MINISTRY OF HEALTH AND CONSUMER PRODUCTS MADRID, SPAIN
ESPINS	INFORMACION TERAPEUTICA DE LA SEGURIDAD SOCIAL INSTITUTO NACIONAL DE LA SALUD MADRID SPAIN
ESPITS	INFORMACION DE LA TERAPEUTICA DEL SISTEMA NACIONAL DE SALUD MADRID SPAIN
ESPMAD	SPANISH MEDICINES AGENCY MINISTRY OF HEALTH MADRID, SPAIN
ESPMC	PROGRAMA SELECTIVO DE REVISION DE MEDICAMENTOS MINISTERIO DE SANIDAD Y CONSUMO MADRID SPAIN
ESPOR	MINISTERIO DE SANIDAD Y CONSUMO DIRECCION GENERAL DE INSPECCION DEL CONSUMO MADRID, SPAIN

List of references cited in the regulatory text

ESPSMA	SPANISH AGENCY FOR MEDICINES AND MEDICAL DEVICES MINISTRY OF HEALTH AND CONSUMER PRODUCTS MADRID, SPAIN www.agemed.es
ESPPS	SPANISH PHARMACOVIGILANCE SYSTEM MINISTRY OF HEALTH AND CONSUMER PRODUCTS MADRID, SPAIN
FDADB	US DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL CENTRE FOR DRUGS & BIOLOGICS FOOD AND DRUG ADMINISTRATION 5600 FISHERS LANE ROCKVILLE, MD, 20857, USA
FDAMB	FOOD AND DRUG ADMINISTRATION WASHINGTON D.C. USA
FDATP	FOOD AND DRUG ADMINISTRATION WASHINGTON, D.C. USA www.fda.gov
FDATPW	FOOD AND DRUG ADMINISTRATION WASHINGTON, D.C. USA
FDAWWW	FOOD AND DRUG ADMINISTRATION WASHINGTON, D.C. USA
FEREAC	US GOVERNMENT PRINTING OFFICE SUPERINTENDENT OF DOCUMENTS WASHINGTON, D.C. 20402 USA
FINAWH	NATIONAL AGENCY FOR WELFARE AND HEALTH HELSINKI, FINLAND
FINNAM	NATIONAL AGENCY FOR MEDICINES HELSINKI, FINLAND
FMOPL	LE MONITEUR DES PHARMACIES ET DES LABORATOIRES 15 RUE GODEFROY-CAVAIGNAC 75011 PARIS, FRANCE
FRAAM	JOURNAL OFFICIEL DE LA REPUBLIQUE FRANCAISE PARIS, FRANCE
FRAAMA	AGENCE DU MÉDICAMENT SAINT-DENIS, FRANCE
FRAAMC	AGENCE DU MÉDICAMENT

List of references cited in the regulatory text

	SAINT-DENIS, FRANCE
FRAAMI	AGENCE DU MÉDICAMENT SAINT-DENIS, FRANCE
FRAAMN	AGENCE DU MÉDICAMENT SAINT-DENIS, FRANCE
FRAAMP	AGENCE DU MÉDICAMENT SAINT-DENIS, FRANCE www.agmed.sante.gouv.fr
FRAAMR	AGENCE DU MÉDICAMENT SAINT-DENIS, FRANCE
FRAARN	PARIS, FRANCE
FRACCE	COMMISSION DES COMMUNAUTÉS EUROPÉENNES LUXEMBOURG
FRACW	AGENCE DU MÉDICAMENT SAINT-DENIS, FRANCE
FRADRA	PARIS, FRANCE.
FRAMH	MINISTRY OF SOLIDARITY, HEALTH AND SOCIAL PROTECTION PARIS, FRANCE
FRAMHH	MINISTRY OF HEALTH AND HUMANITARIAN ACTION PARIS, FRANCE
FRAMHS	MINISTRY OF HEALTH AND SOCIAL AFFAIRS PARIS, FRANCE
FRAMS	MINISTRY OF SOCIAL AFFAIRS AND INTEGRATION PARIS, FRANCE
FRAMSS	MINISTRY OF SOCIAL AFFAIRS AND SOLIDARITY PARIS, FRANCE
FRAPC	MINISTRY OF HEALTH AND FAMILY AFFAIRS 1, PLACE DE FONTENOY PARIS 75700 FRANCE
FRARP	LA REVUE PRESCRIRE PARIS FRANCE
FRGGH	BUNDESGESUNDHEITSAMT BERLIN (WEST) GERMANY

List of references cited in the regulatory text

GAZIE	CONTROLLER OF PUBLICATIONS MINISTRY OF HEALTH AND FAMILY WELFARE NEW DELHI, 110054 INDIA
GBCHL	MEDICINES DIVISION DEPARTMENT OF HEATH AND SOCIAL SECURITY, MARKET TOWERS 1 NINE ELMS LANE LONDON SW8 5NQ UNITED KINGDOM
GBMIL	DEPARTMENT OF HEALTH AND SOCIAL SECURITY MARKET TOWERS, 1 NINE ELMS LANE LONDON SW8 5NQ UNITED KINGDOM
GBPHA	MEDICINES DIVISION DEPARTMENT OF HEALTH AND SOCIAL SECURITY, MARKET TOWERS 1 NINE ELMS LANE LONDON SW8 5NQ UNITED KINGDOM
GBRCPP	COMMITTEE ON SAFETY OF MEDICINES MEDICINES CONTROL AGENCY DEPARTMENT OF HEALTH LONDON, SW1A 2NL, UNITED KINGDOM
GBRCSM	COMMITTEE ON SAFETY OF MEDICINES MEDICINES CONTROL AGENCY DEPARTMENT OF HEALTH LONDON, SW1A 2NL, UNITED KINGDOM
GBRCW	COMMITTEE ON SAFETY OF MEDICINES MEDICINES CONTROL AGENCY DEPARTMENT OF HEALTH LONDON, SW1A 2NL, UNITED KINGDOM www.mhra.gov.uk
GBRDPR	LONDON, UNITED KINGDOM
GBRDSI	COMMITTEE ON SAFETY OF MEDICINES MEDICINES CONTROL AGENCY DEPARTMENT OF HEALTH LONDON, SW1A 2NL, UNITED KINGDOM www.mca.gov.uk
GBRISM	MEDICINES CONTROL AGENCY DEPARTMENT OF HEALTH LONDON, SW1A 2NL, UNITED KINGDOM www.open.gov.uk
GBRKPR	MEDICINES CONTROL AGENCY

List of references cited in the regulatory text

	DEPARTMENT OF HEALTH LONDON, SW1A 2NL, UNITED KINGDOM
GBRLFC	COMMITTEE ON SAFETY OF MEDICINES, LONDON, UNITED KINGDOM www.mhra.gov.uk
GBRMCA	MEDICINES CONTROL AGENCY DEPARTMENT OF HEALTH LONDON, SW1A 2NL, UNITED KINGDOM
GBRMI	UK MEDICINES INFORMATION (UKMi) NATIONAL HEALTH SERVICES (NHS) LONDON, UNITED KINGDOM www.medicines.mhra.gov.uk
GBRMRS	MEDICINES CONTROL AGENCY DEPARTMENT OF HEALTH LONDON, SW1A 2NL, UNITED KINGDOM www.mca.gov.uk
GBRNBA	NATIONAL BLOOD AUTHORITY LONDON, UNITED KINGDOM
GBRNUP	MEDICINES CONTROL AGENCY DEPARTMENT OF HEALTH LONDON, SW1A 2NL, UNITED KINGDOM www.mca.gov.uk/whatsnew
GBRPHJ	THE PHARMACEUTICAL JOURNAL UNITED KINGDOM
GBRPR	HOME OFFICE LONDON, UNITED KINGDOM
GBRSIN	MEDICINES CONTROL AGENCY DEPARTMENT OF HEALTH LONDON, SW1A 2NL, UNITED KINGDOM
GBRSKB	SMITHKLINE BEECHAM BRENTFORD, UNITED KINGDOM
GBRSMU	COMMITTEE ON SAFETY OF MEDICINES MEDICINES CONTROL AGENCY DEPARTMENT OF HEALTH LONDON, SW1A 2NL, UNITED KINGDOM www.mca.gov.uk
GBRSTE	MEDICINES CONTROL AGENCY DEPARTMENT OF HEALTH LONDON, SW1A 2NL, UNITED KINGDOM www.mca.gov.uk

List of references cited in the regulatory text

GENMB	"GENEESMIDDELENBULLETIN" (DRUG INFORMATION BULLETIN) MINISTRY OF WELFARE, HEALTH & CULTURE POSTBUS 439 2260 AK LEIDSCHENDAM, NETHERLANDS
GHAPDR	PHARMACY AND DRUGS (BANNED DRUGS) REGULATIONS, LEGISLATIVE INSTRUMENTS ACCRA, GHANA
GLAXO	GLAXO RESEARCH AND DEVELOPMENT LTD GREENFORD, MIDDLESEX UNITED KINGDOM
GRAGA	MINISTRY OF HEALTH ATHENS, GREECE
GRANDO	NATIONAL DRUG ORGANIZATION ATHENS, GREECE
HHSNS	DEPT. OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION ROCKVILLE, MARYLAND 20857 USA
HINDU	THE HINDU INDIA
HNDSP	SECRETARIA DE ESTADO EN LOS DESPACHOS DE SALUD PUBLICA DIRECCION GENERAL DE SALUD TEGUCIGALPA, HONDURAS
HUNIH	NATIONAL INSTITUTE OF OCCUPATIONAL HEALTH BUDAPEST, HUNGARY
HUNIP	NATIONAL INSTITUTE OF PHARMACY BUDAPEST, HUNGARY
IARCCD	INTERNATIONAL AGENCY FOR RESEARCH ON CANCER 150, COURS ALBERT THOMAS F-69372 LYON CEDEX 08 FRANCE
IDMH	MINISTRY OF HEALTH JAKARTA, INDONESIA
IDMHD	MINISTERIAL DECREE MINISTRY OF HEALTH JAKARTA, INDONESIA
IDNCW	NATIONAL AGENCY FOR DRUG AND FOOD CONTROL (NADFC) MINISTRY OF HEALTH JAKARTA, INDONESIA

List of references cited in the regulatory text

INDC	DIRECTOR GENERAL OF HEALTH SERVICES MINISTRY OF HEALTH AND FAMILY WELFARE NEW DELHI 100 011, INDIA
INDDHS	DIRECTORATE OF HEALTH SERVICES MINISTRY OF HEALTH AND FAMILY WELFARE NEW DELHI 100 011, INDIA
INDEPH	THE EASTERN PHARMACIST INDIA
IRDAB	NATIONAL DRUGS ADVISORY BOARD 63-64 ADELAIDE ROAD DUBLIN 2, IRELAND
IRDAP	ANIMAL PHARM DUBLIN, IRELAND
IRDDS	THE IRISH MEDICINES BOARD DUBLIN, IRELAND
IRLCN	THE IRISH MEDICINES BOARD DUBLIN, IRELAND www.imb.ie
IRLPSI	PHARMACEUTICAL SOCIETY OF IRELAND DUBLIN, IRELAND www.pharmaceuticalsociety.ie
IRQMH	STATE COOPERATION FOR DRUGS AND MEDICAL EQUIPMENT MINISTRY OF HEALTH BAGHDAD, IRAQ
ISLCP	COMMITTEE ON PHARMACEUTICALS REYKJAVIK ICELAND
ISLSCP	STATE COMMITTEE ON PHARMACEUTICALS REYKJAVIK, ICELAND
ISRDB	MINISTRY OF HEALTH JERUSALEM ISRAEL
ISRMDR	MINISTRY OF HEALTH JERUSALEM, ISRAEL www.ogs.com
ITADMS	DECREE OF THE MINISTERO DELLA SANITA ROME, ITALY
ITAMD	MINISTRY OF HEALTH

List of references cited in the regulatory text

VIALE DELLA CIVILTA ROMANA, 7
ROME, I - 00144
ITALY

JAMMHS	MINISTRY OF HEALTH STANDARDS AND REGULATION KINGSTON, JAMAICA
JORF	JOURNAL OFFICIEL DE LA REPUBLIQUE FRANCAISE PARIS, FRANCE
JORMH	MINISTRY OF HEALTH P.O. BOX 86 AMMAN, JORDAN
JORPCC	PHARMACOVIGILANCE CENTRE FOOD AND DRUG ADMINISTRATION MINISTRY OF HEALTH AMMAN, JORDAN
JPNARD	PHARMACEUTICAL AFFAIRS BUREAU MINISTRY OF HEALTH AND WELFARE TOKYO, JAPAN
JPNMHC	MINISTRY OF HEALTH AND WELFARE TOKYO, JAPAN
JPNPAC	MINISTRY OF HEALTH AND WELFARE TOKYO, JAPAN
JPNPH	PHARMA JAPAN TOKYO, JAPAN
JPNPMB	PHARMACEUTICAL AND MEDICAL SAFETY BUREAU MINISTRY OF HEALTH AND WELFARE TOKYO, JAPAN
JPNSWP	SCRIP WORLD PHARMACEUTICAL NEWS LONDON, UNITED KINGDOM www.pjpubs.com/scrip
KRMHSA	MINISTRY OF HEALTH AND SOCIAL AFFAIRS SEOUL, REPUBLIC OF KOREA
KTMD	MINISTRY OF HEALTH P. O. BOX 5 SAFAT, KUWAIT
LANCET	THE LANCET 32 JAMESTOWN ROAD LONDON, NW1 7BY UNITED KINGDOM
LBNMHD	MINISTRY OF HEALTH AND SOCIAL AFFAIRS BEIRUT, LEBANON

List of references cited in the regulatory text

LIYRL	GENERAL PEOPLE'S HEALTH COMMITTEE TRIPOLI, LIBYA
LJJ	JOHNSON & JOHNSON NEW BRUNSWICK, NJ 08902 UNITED STATES
LKADES	MINISTRY OF HEALTH COLOMBO, SRI LANKA
LKADIB	UNIVERSITY OF PERADENIYA MINISTRY OF HEALTH COLOMBO, SRI LANKA
LKAGAZ	THE GAZETTE OF THE DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA (EXTRAORDINARY) COLOMBO, SRI LANKA
LTHCW	DECISION OF MEDICINE REGISTRATION CENTRE MINISTRY OF HEALTH VILNIUS 2600, LITHUANIA
LTHMCA	STATE MEDICINES CONTROL AGENCY GEDIMINO AVE. 27 VILNIUS 2600, LITHUANIA
LTHPHB	STATE MEDICINES CONTROL AGENCY GEDIMINO AVE. 27 VILNIUS 2600, LITHUANIA
MARDMP	DIRECTORATE OF MEDICINES AND PHARMACY MINISTRY OF HEALTH RABAT, MOROCCO
MEXMH	MINISTRY OF HEALTH MEXICO CITY, MEXICO
MPPHD	PHARMACY & POISONS (PROHIBITIONS OF HARMFUL DRUGS) REGULATIONS MINISTRY OF HEALTH PORT LOUIS, MAURITIUS
MUSCW	MINISTRY OF HEALTH PORT LOUIS, MAURITIUS
MUSMHQ	MINISTRY OF HEALTH AND QUALITY OF LIFE PORT LOUIS, MAURITIUS
MYSCW	DRUG CONTROL AUTHORITY MINISTRY OF HEALTH KUALA LUMPUR, MAYLAYSIA

List of references cited in the regulatory text

MYSDC	MALAYSIAN DRUG CONTROL AUTHORITY MINISTRY OF HEALTH KUALA LUMPUR 5300 MALAYSIA
MYSDI	DRUG CONTROL AUTHORITY MINISTRY OF HEALTH KUALA LUMPUR, MALAYSIA
MYSDN	BERITA UBAT-UBATAN (DRUG NEWSLETTER) DRUG CONTROL AUTHORITY PETALING JAYA MALAYSIA
MYSNL	DRUG CONTROL AUTHORITY MINISTRY OF HEALTH KUALA LUMPUR, MALAYSIA
MYSR	MINISTRY OF HEALTH PAHANG ROAD KUALA LUMPUR 5300 MALAYSIA
NEJOM	NEW ENGLAND JOURNAL OF MEDICINE WALTHAM, MA 02451-1411 UNITED STATES
NETJAN	NEDERLANDS TIJDSCHRIFT VOOR GENEESKUNDE POSTBUS 13079 3507 LB UTRECHT, NETHERLANDS
NGAPN	PHARMANEWS LAGOS, NIGERIA
NLDMEB	MEDICINES EVALUATION BOARD MINISTRY OF HEALTH AMSTERDAM, NETHERLANDS www.cbg-meb.nl/uk/nieuws
NNSLM	"NYTT FRA STATENS LEGEMIDDELKONTROLL" (NEWS FROM THE NATIONAL CENTRE FOR MEDICINAL PRODUCTS CONTROL) STATENS LEGEMIDDELKONTROLL SVEN OFTEDALS VEI 6 OSLO 9, NORWAY
NORMCA	NORWEGIAN MEDICINES CONTROL AUTHORITY OSLO, NORWAY
NORN	OSLO, NORWAY
NPHWB	PHARMACEUTISCH WEEKBLAD DE ERVEN BOHN B.V. AMSTERDAM, POSTBUS 10697 NETHERLANDS

List of references cited in the regulatory text

NPLDDA	DEPARTMENT OF DRUG ADMINISTRATION KATHMANDU, NEPAL
NPLGZ	KATHMANDU, NEPAL
NZCSL	"CLINICAL SERVICES LETTER" DEPARTMENT OF HEALTH P.O. BOX 5013 WELLINGTON, NEW ZEALAND
NZLPU	MINISTRY OF HEALTH WELLINGTON, NEW ZEALAND
NZLTN	MINISTRY OF HEALTH WELLINGTON, NEW ZEALAND
OMNCR	MINISTRY OF HEALTH MUSCAT, OMAN
OMNDGP	DIRECTORATE GENERAL OF PHAMACEUTICAL AFFAIRS MINISTRY OF HEALTH MUSCAT, OMAN
OMNDI	DRUG INFORMATION MINISTRY OF HEALTH MUSCAT, OMAN
OMNMH	OMAN MINISTRY OF HEALTH P.O. BOX 393 MUSCAT, SULTANATE OF OMAN
OMNPN	MINISTRY OF HEALTH MUSCAT, OMAN
PAKDI	MINISTRY OF HEALTH ISLAMABAD, PAKISTAN
PAKMH	MINISTRY OF HEALTH, SPECIAL EDUCATION AND SOCIAL WELFARE ISLAMABAD, PAKISTAN
PANMR	MINISTRY OF HEALTH PANAMA
PERDGM	DIRECCIÒN GENERAL DE MEDICAMENTOS, INSUMOS Y DROGAS MINISTRY OF HEALTH LIMA, PERU
PERMH	MINISTRY OF HEALTH LIMA, PERU
PHADO	FOOD AND DRUG ADMINISTRATION MINISTRY OF HEALTH MANILA, PHILIPPINES

List of references cited in the regulatory text

PHLCTW	DEPARTMENT OF HEALTH AND BUREAU OF FOOD AND DRUGS MANILA, PHILIPPINES
PRTIFM	MINISTERIO DA SAUDE INSTITUTO NACIONAL DA FARMACIA E DO MEDICAMENTO (INFARMED) LISBON, PORTUGAL
PRTMH	MINISTRY OF HEALTH LISBON, PORTUGAL
PRTOC	MINISTERIO DA SAUDE INSTITUTO NACIONAL DA FARMACIA E DO MEDICAMENTO LISBON, PORTUGAL
PRTRAC	PURTUGUESE REGULATORY AGENCY (INRARMED) LISBON, PORTUGAL
SANOFI	LETTER TO REGULATORY AGENCIES SANOFI-SYNTHELABO PARIS, FRANCE
SAUCW	MINISTRY OF HEALTH SAUDI ARABIA
SGPCW	NATIONAL PHARMACEUTICAL ADMINISTRATION MINISTRY OF HEALTH SINGAPORE
SGPHSA	HEALTH SCIENCES AUTHORITY SINGAPOR
SGPMA	THE MEDICINES ACT (CHAPTER 176) THE MEDICINES (LABELLING OF ASPIRIN PRODUCTS) REGULATIONS 1987 VOL.MH.(HQ) 36:26/1 VOL.3, AG/SL/31/84 PT. SINGAPORE NATIONAL PRINTERS LTD (GOVERNMENT PRINTERS) SINGAPORE
SGPPR	HEALTH SCIENCES AUTHORITY SINGAPORE
SGPRD	THE SALE OF DRUGS (PROHIBITED DRUGS) REGULATIONS SINGAPORE
SLVCW	MINISTRY OF HEALTH BRATISLAVA, SLOVAK REPUBLIC
SPCNR	NEW RELEASE SCHERING-PLOUGH CORPORATION KENILWORTH, NJ 07033-0530 UNITED STATES
SSLMS	INFORMATION FRAN SOCIALSTYRELESENS LAKEMEDELSAVDELNING STOCKHOLM, SWEDEN

List of references cited in the regulatory text

SWEFSL	FARMACEUTISKA SPECIALITETER I SVERIGE. LKEMEDELSINFORMATION AB STOCKHOLM, SWEDEN
SWEILS	INFORMATION FRN LKEMEDELSVERKET STOCKHOLM, SWEDEN
SWEMPA	LÄKEMEDELSVERKET (MEDICAL PRODUCTS AGENCY) STOCKHOLM, SWEDEN
SYRAFD	SUPRIM TECHNICAL COMMITTEE MINISTRY OF HEALTH DAMASCUS, SYRIA
THACW	MINISTRY OF PUBLIC HEALTH TIWANOND ROAD NONTHAMBURI 11000, THAILAND
THAFDA	FOOD AND DRUG ADMINISTRATION MINISTRY OF HEALTH TIWANOND ROAD NONTHAMBURI 11000, THAILAND
THAMH	MINISTRY OF PUBLIC HEALTH TIWANOND ROAD NONTHAMBURI 11000, THAILAND
TURCW	GENERAL DIRECTORATE OF PHARMACEUTICALS AND PHARMACY MINISTRY OF HEALTH ANKARA, TURKEY
TURDPC	DIVISION OF PAHARMACOVIGILANCE MINISTRY OF HEALTH ANKARA, TURKEY
TURMH	MINISTRY OF HEALTH ANKARA, TURKEY
UAECW	MINISTRY OF HEALTH ABU DHABI UNITED ARAB EMIRATES
UAEDIB	MINISTRY OF HEALTH ABU DHABI UNITED ARAB EMIRATES
UAEMD	MINISTRY OF HEALTH ABU DHABI UNITED ARAB EMIRATES
UGLAAD	UGESKRIFT FOR LAEGER UDGIVET AF DEN ALMINDELIGE DANSKE LAEGEFORENING KRISTIANIAGADE 12A COPENHAGEN DK-2100, DENMARK

List of references cited in the regulatory text

UNCPS	UNITED NATIONS TREATY SERIES UNITED NATIONS SECRETARIAT NEW YORK, NY. 10017, USA
UNSDN	SINGLE CONVENTION ON NARCOTIC DRUGS 1961 (UNITED NATIONS TREATY SERIES VOL. 520, E/CONF.34/22) AS AMENDED BY THE 1972 PROTOCOL (E/CONF.63/7-8, E.77.XI.3) UNITED NATIONS SECRETARIAT NEW YORK, NY 10017, USA
URTMH	PHARMACY BOARD MINISTRY OF HEALTH DAR-ES-SALAM, TANZANIA
USADAC	FOOD AND DRUG ADMINISTRATION WASHINGTON D.C., USA
USADDL	(www.fda.gov/medwatch/safety/1998) FOOD AND DRUG ADMINISTRATION WASHINGTON D.C., USA
USADHP	BAYER PHARMACEUTICAL DIVISION www.fda.gov/medwatch
USADIZ	DRUG INFO ZONE www.druginfozone.nhs.uk
USAMDR	FOOD AND DRUG ADMINISTRATION WASHINGTON D.C. USA www.fda.gov
USAMSA	MEDWATCH SAFETY ALERT www.fda.gov/medwatch
USAOPA	OFFICE OF PUBLIC AFFAIRS CALIFORNIA DEPARTMENT OF HEALTH SERVICES www.fda.gov
USAPHA	FOOD AND DRUG ADMINISTRATION WASHINGTON, D.C. USA www.fda.gov
USARLI	ROXANE LABORATORIES INC. www.fda.gov
VTNMHD	MINISTRY OF HEALTH DRUG ADMINISTRATION VIET NAM
WHOCON	WORLD HEALTH ORGANIZATION 1211 GENEVA 27, SWITZERLAND

List of references cited in the regulatory text

WHODI	WORLD HEALTH ORGANIZATION 1211 GENEVA 27, SWITZERLAND
WHODIB	WORLD HEALTH ORGANIZATION 1211, GENEVA 27, SWITZERLAND
WHORUD	THE RATIONAL USE OF DRUGS WORLD HEALTH ORGANIZATION 1211 GENEVA 27, SWITZERLAND
WHTAC	TECHNICAL REPORT SERIES WORLD HEALTH ORGANIZATION 1211 GENEVA 27, SWITZERLAND
WIMAM	WICHTIGE MITTEILUNG UBER ARZNEIMITTEL 1984 BUNDESMINISTERIUM FUR GESUNDHEIT UND UMWELTSCHUTZ GRUPPE PHARMAZIE LANDSTRASSE HAUPTSTRASSE 55-57 1030 WIEN, AUSTRIA
YEMCW	MINISTRY OF PUBLIC HEALTH SANA'A, REPUBLIC OF YEMEN
ZAFMCC	MEDICINES CONTROL COUNCIL MINISTRY OF HEALTH PRETORIA 0001, SOUTH AFRICA
ZAFPS	MINISTRY OF HEALTH PRETORIA 0001, SOUTH AFRICA
ZMBSI	STATUTORY INSTRUMENT MINISTRY OF HEALTH LUSAKA, ZAMBIA
ZWDCC	NEWS BULLETIN DRUGS CONTROL COUNCIL HARARE, ZIMBABWE
ZWEDIB	MINISTRY OF HEALTH HARARE, ZIMBABWE
ZWESI	STATUTORY INSTRUMENT MINISTRY OF HEALTH HARARE, ZIMBABWE

Annex IV

Questionnaire

Dear Reader,

Both the Economic and Social Council and the General Assembly of the United Nations have expressed interest in ascertaining the use which is being made of the Consolidated List. They have also requested that the Secretariat keep the format of the List under continuing review. The present questionnaire has been prepared with a view to obtaining this information, which will be reported to the Economic and Social Council and the General Assembly; comments regarding the format of the List will be taken into account in the preparation of future editions.

Please mail the questionnaire as soon as possible to: United Nations Secretariat, DESA/DESC/EICB, One United Nations Plaza, Room DC1-1438, New York, NY 10017, United States of America.

Name and address of ministry/organization/institution/company/university:

A. In what capacity do you use the Consolidated List?

Government:

Regulator Customs enforcement Policy maker

Other:

Academic Media
 International organization NGO/public intersecretariat group
 Manufacturer Other: _____

B. For which category of products have you used the List?

Agricultural chemicals Industrial chemicals
 Consumer products

C. 1. Has the information provided in the List prompted any action on your part?

Yes No

If "yes" please describe the nature of this action either in general terms or in relation to specific products.

2. What is the nature of this action? (Information on the following points is particularly requested from national regulatory authorities)

- Review of licensing provisions for chemical products
- Review of regulations for already regulated products
- Review of enforcement of laws and regulations
- Regulation of previously unregulated products
- Meeting with manufacturers/distributors
- Other actions (please describe)

D. Are you aware of any additional products or restrictive regulatory actions that should be included in the List?

Yes **No**

If "yes" please specify or attach a copy of any such regulation.

E. Are you aware of any additional trade and manufacturing data that should be included in the List?

Yes **No**

If "yes" please specify.

F. Do you find the following items of information useful?

	Yes	No
Product category listing	___	___
CAS numbers	___	___
Synonyms	___	___
Date of decision	___	___
Citation of national regulations/decisions	___	___
Trade names/manufacturer information	___	___
WHO comment	___	___
Bibliographic references	___	___

G. Which other sources do you use to obtain information on banned and severely restricted products?

H. Would you be interested in and have the facilities to obtain on-line access to the List?

___ Yes ___ No

I. What are your suggestions regarding the use of the List?

J. What are your suggestions regarding the preparation of the List?

K. Do you have any other comments?



Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or Not Approved by Governments

A unique list of restrictive regulatory actions taken by one hundred fifteen Governments on over eleven hundred pharmaceuticals and agricultural and industrial chemicals, as well as consumer products.

This comprehensive and informative book was produced in response to General Assembly resolutions aimed at protecting the world against products harmful to health and the environment.

Now updated and printed annually with an ever-expanding coverage of countries and products.

According to the previously determined schedule, yearly focus alternates between pharmaceuticals and chemicals. The current issue is entirely devoted to chemicals.